<SEC-DOCUMENT>0001372514-25-000044.txt : 20250509
<SEC-HEADER>0001372514-25-000044.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250509065955
ACCESSION NUMBER:		0001372514-25-000044
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		25928305

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>kprx-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0167d6af-99d4-4c6f-8900-ecd7455d4d35,g:cf0f15d1-3949-48fc-a909-df68c07a7e6e,d:358c170041ff4839b1853882b3d8afd1-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:kprx="http://www.eyegatepharma.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-27">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-57" decimals="7" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-330">0.1111111</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-169" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-653">33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-654">33</ix:nonFraction><ix:nonNumeric contextRef="c-199" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-700">3.25</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="performance_obligation"><xbrli:measure>kprx:performance_obligation</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>kprx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="count"><xbrli:measure>kprx:count</xbrli:measure></xbrli:unit><xbrli:unit id="day"><xbrli:measure>kprx:day</xbrli:measure></xbrli:unit><xbrli:unit id="operatinglease"><xbrli:measure>kprx:operatingLease</xbrli:measure></xbrli:unit><xbrli:unit id="aud"><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="licenseagreement"><xbrli:measure>kprx:licenseAgreement</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:EquityLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:EquityLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-11</xbrli:startDate><xbrli:endDate>2024-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO301Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO301Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO301Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoncumulativePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoncumulativePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A18MonthLeaseEncinitasCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A18MonthLeaseEncinitasCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A12MonthLeaseAdelaideAustraliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A12MonthLeaseAdelaideAustraliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-15</xbrli:startDate><xbrli:endDate>2023-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A2YearLeasePerthAndBrisbaneAustraliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A2YearLeasePerthAndBrisbaneAustraliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A3Year3MonthLeaseEncinitasCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A3Year3MonthLeaseEncinitasCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">kprx:UBSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">kprx:UBSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A3Year3MonthLeaseEncinitasCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO104NetOfAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO104NetOfAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO301Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO301Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i358c170041ff4839b1853882b3d8afd1_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.798%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #242424;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #242424;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #242424;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:174%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #242424;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #242424;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #242424;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2025</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36672</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><img src="kprx-20250331_g1.jpg" alt="Kiora Pharma Logo_RGB_Color.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-1"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>Incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">169 Saxony Rd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 212</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Encinitas</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices, including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:31.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #242424;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #242424;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">KPRX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #242424;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"/><td style="width:30.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On May&#160;7, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">3,043,857</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.798%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;margin-top:24pt"><span><br/></span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended March&#160;31, 2025</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_16">4</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_19">Condensed Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_19">4</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_22">Condensed Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_22">(Loss</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_22">) </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_22">Income</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_22"> (unaudited) for the Three Months Ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_22">5</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited) for the Three Months Ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_25">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_28">Condensed Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_28">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_31">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_70">26</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_103">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_103">30</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_106">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_106">31</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_109">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_112">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_112">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_112">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_115">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_115">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_115">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_118">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_118">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_118">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_121">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_121">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_121">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_124">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_124">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_124">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_127">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_127">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_127">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_130">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_130">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_130">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_133">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i358c170041ff4839b1853882b3d8afd1_133">33</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The forward-looking statements are principally, but not exclusively, contained in &#8220;Item 2: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management&#8217;s confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;goal,&#8221; "foreseeable," &#8220;see,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intends,&#8221; &#8220;think,&#8221; &#8220;potential,&#8221; &#8220;objective,&#8221; &#8220;optimistic,&#8221; &#8220;strategy,&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and success of preclinical studies and clinical trials conducted by us and our development partners;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain and maintain regulatory approval of our product candidates, and the labeling for any approved products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, expansion, and costs of developing and commercializing our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of the potential markets for our product candidates and the ability to serve those markets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of any approved products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding competition;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated growth strategies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract or retain key personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain development partnerships;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding federal, state and foreign regulatory requirements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated trends and challenges in our business and the market in which we operate; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to assess the probability of achievement of milestones and other advances in our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discuss many of these risks in detail under the heading &#8220;Item 1A. Risk Factors&#8221; beginning on page 17 of our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on March 25, 2025, or the Annual Report. You should carefully review all these factors, as well as other risks described in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals, Inc. is referred to herein as &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and &#8220;the Company.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i358c170041ff4839b1853882b3d8afd1_16"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i358c170041ff4839b1853882b3d8afd1_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:70.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.860%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025 (unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-31">3,771,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-32">3,792,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-Term Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-33">20,334,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-34">22,999,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Expenses and Other Current Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-35">941,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-36">2,042,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration Receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-37">1,337,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-38">601,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-39">722,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-40">270,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-41">27,107,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-42">29,706,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and Equipment, Net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-43">4,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-44">5,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-45">4,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-46">4,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Assets and In-Process R&amp;D, Net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="f-47">6,687,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="f-48">6,687,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Right-of-Use Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-49">152,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-50">57,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-51">64,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-52">24,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-53">34,019,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-54">36,484,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">942,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">415,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-57">3,522,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-58">4,588,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Collaboration Credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="kprx:CollaborationCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">738,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="kprx:CollaborationCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">981,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-61">71,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-62">23,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-63">5,274,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-64">6,008,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-65">4,466,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-66">4,191,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="f-67">490,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="f-68">490,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Current Operating Lease Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-69">87,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-70">33,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-71">5,044,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-72">4,715,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-73">10,319,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-74">10,724,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-75"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-76"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-77"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-78">0.01</ix:nonFraction></ix:nonFraction> Par Value: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-80">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-82">3,750</ix:nonFraction></ix:nonFraction> designated Series A, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-86">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-88">10,000</ix:nonFraction></ix:nonFraction> designated Series B, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-89"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-92">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding; <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-94">10,000</ix:nonFraction></ix:nonFraction> shares designated Series C, <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-95"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-97"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-98">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding; <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-100">20,000</ix:nonFraction></ix:nonFraction> shares designated Series D, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-104">7</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding; <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-106">1,280</ix:nonFraction></ix:nonFraction> shares designated Series E, <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-110">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding; <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="kprx:PreferredStockDesignatedShares" format="ixt:num-dot-decimal" scale="0" id="f-112">3,908</ix:nonFraction></ix:nonFraction> shares designated Series F, <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-113"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-116">420</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="f-117">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="f-118">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-119"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-120">0.01</ix:nonFraction></ix:nonFraction> Par Value: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-121"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-122">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-123"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-126">3,000,788</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-127">267,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-128">267,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-129">169,304,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-130">169,156,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-131">145,575,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-132">143,382,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-133">297,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-134">282,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-135">23,700,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-136">25,759,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-137">34,019,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-138">36,484,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:90%">See Accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="0" id="f-140">16,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="f-142">16,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-143">1,489,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-144">1,296,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-145">2,531,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-146">1,684,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and Research Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="kprx:CollaborationCreditOperatingExpense" format="ixt:num-dot-decimal" scale="0" id="f-147">1,966,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="kprx:CollaborationCreditOperatingExpense" format="ixt:num-dot-decimal" scale="0" id="f-148">190,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.96pt;text-align:left;text-indent:-5.77pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-149">275,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-150">12,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-151">2,330,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-152">2,777,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating (Loss) Income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-153">2,330,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-154">13,222,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense), Net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Income, Net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="0" id="f-155">276,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="0" id="f-156">223,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Expense) Income, Net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-157">16,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-158">8,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Income, Net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-159">260,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-160">231,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Income Before Income Tax Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-161">2,069,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-162">13,453,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-163">123,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (Loss) Income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-165">2,192,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-166">13,453,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income Attributable to Common Shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-167"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" format="ixt:num-dot-decimal" scale="0" id="f-168">2,192,980</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" format="ixt:num-dot-decimal" scale="0" id="f-169"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-170">13,453,207</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income per Common Share - Basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">0.52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-172">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Shares Outstanding - Basic</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-173">4,217,007</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-174">2,881,796</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income per Common Share - Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-175">0.52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-176">3.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Shares Outstanding - Diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-177">4,217,007</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-178">3,891,722</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Comprehensive (Loss) Income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-179">2,192,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-180">13,453,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.96pt;text-align:left;text-indent:-5.77pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Marketable Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-181">16,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="0" id="f-182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.96pt;text-align:left;text-indent:-5.77pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-183">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-184">81,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive (Loss) Income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-185">2,208,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-186">13,371,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2025 and 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.555%"><tr><td style="width:1.0%"/><td style="width:24.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.615%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="f-187">427</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-188">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-189">3,000,788</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-190">267,679</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-191">169,156,374</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-192">143,382,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-193">282,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-194">25,759,776</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-195">148,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-196">148,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.21pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss on Marketable Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-197">16,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-198">16,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.21pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-199">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-200">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-201">2,192,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-202">2,192,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="f-203">427</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-204">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-205">3,000,788</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-206">267,679</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-207">169,304,991</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-208">145,575,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-209">297,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-210">23,700,387</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"/><td style="width:24.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.632%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="f-211">427</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-212">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-213">856,182</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-214">77,078</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-215">153,192,228</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-216">146,976,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-217">182,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-218">6,109,654</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-219">175,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-220">175,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Common Stock and Warrants from Private Placement, Net of Offering Costs of $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="f-221">1.2</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-222">1,755,556</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-223">158,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-224">1,516,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-225">1,674,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Common Stock from Warrant Exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="kprx:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-226">305,617</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-227">27,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-228">156,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="kprx:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-229">184,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.21pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-230">81,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-231">81,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-232">13,453,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-233">13,453,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:SharesOutstanding" scale="0" id="f-234">427</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-235">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-236">2,917,355</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-237">262,584</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-238">155,041,241</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-239">133,523,648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-240">264,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-241">21,515,807</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"/><td style="width:71.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-242">2,192,980</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-243">13,453,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net (Loss) Income to Net Cash (Used in) Provided by Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and Amortization of Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="f-244">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-245">4,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Operating Lease Right-of-Use Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="kprx:IncreaseDecreaseInRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="f-246">19,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="kprx:IncreaseDecreaseInRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="f-247">11,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-Based Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-248">148,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-249">175,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-250">275,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-251">12,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment Income and Fair Value Adjustments on Marketable Securities and Cash Equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="kprx:FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-252">23,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="kprx:FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" format="ixt:fixed-zero" scale="0" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in Operating Assets and Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Expenses and Other Current Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-254">454,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-255">12,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-256">736,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-257">189,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research Credit Receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="kprx:IncreaseDecreaseResearchTaxCreditsReceivables" format="ixt:num-dot-decimal" scale="0" id="f-258">668,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="kprx:IncreaseDecreaseResearchTaxCreditsReceivables" format="ixt:num-dot-decimal" scale="0" id="f-259">165,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-260">225,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-261">13,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-262">39,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-263">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-264">1,171,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-265">124,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-266">1,084,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-267">124,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Collaboration Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="kprx:IncreaseDecreaseInAccruedCollaborationCredit" format="ixt:num-dot-decimal" scale="0" id="f-268">241,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="kprx:IncreaseDecreaseInAccruedCollaborationCredit" format="ixt:fixed-zero" scale="0" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-270">12,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-271">11,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash (Used in) Provided by Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-272">2,704,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-273">13,624,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of Marketable Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="f-274">3,619,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of Marketable Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="f-276">80,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of Marketable Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-278">6,212,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="0" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-280">2,672,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="0" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Proceeds from Private Placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="0" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="0" id="f-283">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance Costs for Private Placement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="0" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-285">1,191,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="0" id="f-286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-287">1,438,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="0" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-289">15,247,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-290">10,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-291">51,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-292">21,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-293">28,821,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash, Beginning of Period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-294">3,796,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-295">2,458,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash, End of Period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-296">3,775,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-297">31,280,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Noncash Operating and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Creation of Right-of-Use Assets and Related Lease Liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-298">114,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div id="i358c170041ff4839b1853882b3d8afd1_34"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-300" continuedAt="f-300-1" escape="true">Business, Presentation and Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="f-300-1" continuedAt="f-300-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals, Inc. (&#8220;Kiora&#8221; or the &#8220;Company&#8221;) was formed as a Delaware corporation on December 28, 2004. Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, Kiora has devoted substantially all its efforts to business planning, research and development, and raising capital.</span></div><ix:nonNumeric contextRef="c-1" name="kprx:UnauditedInterimFinancialInformationPolicyPolicyTextBlock" id="f-301" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company&#8217;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes previously included in the Company&#8217;s 2024 Annual Report on Form 10-K dated March 25, 2025. The balance sheet as of December&#160;31, 2024 was derived from audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-302" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Accounting Standards</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for us beginning in fiscal year 2025 for the annual reporting period ending December 31, 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company adopted ASU 2023-09 on January 1, 2025. The adoption of ASU 2023-09 did not have a material effect on the condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The guidance in ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying any relevant income statement expense captions. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. Upon adoption, ASU 2024-03 may be applied prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of ASU 2024-03 may have on its disclosures in its condensed consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="kprx:LiquidityAndCapitalResourcesPolicyTextBlock" id="f-303" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, the Company had unrestricted Cash and Cash Equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-304">3.8</ix:nonFraction> million and Short-term Investments of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="f-305">20.3</ix:nonFraction> million, and an Accumulated Deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-306">145.6</ix:nonFraction> million. Kiora has incurred annual losses and negative cash flows since inception, and future losses are anticipated. However, Management believes that the Company's capital resources as of March&#160;31, 2025 will be sufficient to fund the Company's planned operations for at least 12 months after the date that these unaudited condensed consolidated financial statements are issued.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-300-2" continuedAt="f-300-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-307" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, savings accounts, money market funds, and marketable securities with maturities of 3 months or less when acquired. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-308" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Short-Term Investments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term investments primarily consist of treasuries, corporate debt securities, and government and agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive (loss) income as a component of stockholders' equity until realized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-309" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Allowance for Credit Losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive (loss) income on the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on investment securities is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-310" continuedAt="f-310-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with FASB&#8217;s ASC 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-310-1" continuedAt="f-310-2"><ix:continuation id="f-300-3" continuedAt="f-300-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s balance sheet. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as deferred revenue, net of current portion. As of March&#160;31, 2025 and 2024, the Company did not have a deferred revenue balance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within the Company's or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company's estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a strategic development and commercialization agreement ("License Agreement") with Th&#233;a Open Innovation ("TOI"), a sister company of the global ophthalmic specialty company Laboratoires Th&#233;a ("Th&#233;a"). Under the agreement, the Company granted TOI exclusive worldwide development and commercialization rights, excluding certain countries in Asia, to KIO-301 for the treatment of degenerative retinal diseases (the "License"). The Company concluded that the Licensing Agreement contains <ix:nonFraction unitRef="performance_obligation" contextRef="c-52" decimals="INF" name="kprx:CollaborativeArrangementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-311">one</ix:nonFraction> material performance obligation, the License. The transaction price includes the upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="f-312">16.0</ix:nonFraction>&#160;million (the "License Access Fee"). The Company did not include any development or </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-300-4" continuedAt="f-300-5"><ix:continuation id="f-310-2" continuedAt="f-310-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regulatory milestones in the transaction price because it is probable that changes in the estimate of receiving those milestones would result in significant reversals of cumulative revenue in future periods, due to the inherent risks and uncertainties in the drug development process. The sales-based milestones and royalties are not included in the transaction price per ASC 606-10-32-11 and ASC 606-10-55-65. There is no financing component in the License Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The initial transaction price will be allocated to the <ix:nonFraction unitRef="performance_obligation" contextRef="c-52" decimals="INF" name="kprx:CollaborativeArrangementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-313">one</ix:nonFraction> performance obligation identified (i.e., the License), which was transferred to TOI at the execution of the License Agreement and the entire $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="f-314">16.0</ix:nonFraction>&#160;million transaction price was recognized in the first quarter of 2024 upon the satisfaction of the license performance obligations. Variable components of consideration related to development and regulatory milestones, commercial milestones, and royalties will be allocated to the transaction price if and when they occur. When it is probable that including milestones in the transaction price will not result in significant reversals of cumulative revenue in future periods, the Company will recognize the revenue for the milestones immediately since the license performance obligation to which the milestones relate has already been fully satisfied when the change in estimate of the variable consideration occurs. Since the reimbursement for the development activities clearly relates to those activities and are accounted for under ASC 808, the Company will recognize those amounts that are due from TOI as contra-R&amp;D expense.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-310-3">The License Access Fee was earned at a point in time (first quarter of 2024) and, as a result, the associated contract costs specifically, sublicense fees, were expensed at the same point in time (first quarter of 2024). All further revenue sources that may lead to sublicense fee payments will not be recognized until earned. As such, sublicense fees will be expensed in the same period as the revenue of the respective milestone or royalties are earned.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 8 to the condensed consolidated financial statements for additional information.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-315" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into a research agreement that falls under the scope of ASC 808, Collaborative Arrangements. Reimbursements from a collaboration partner are recorded as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income. Similarly, amounts that are owed to a collaboration partner are recognized as research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-316" continuedAt="f-316-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research and Development</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-316-1">The Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset at least annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. The Company performed an annual evaluation of its indefinite-lived intangible assets for impairment as of August 31, 2024 with a quantitative analysis using the Income Approach.</ix:continuation> At March&#160;31, 2025 and December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-317"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-318">6.7</ix:nonFraction></ix:nonFraction> million of in-process R&amp;D as part of intangible assets and in-process R&amp;D, net on the condensed consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="kprx:AccruedClinicalExpensesPolicyTextBlock" id="f-319" continuedAt="f-319-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s process of preparing the condensed consolidated financial statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-300-5" continuedAt="f-300-6"><ix:continuation id="f-319-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-320" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segment and Geographical Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-321">one</ix:nonFraction> business segment and <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="kprx:NumberOfGeographicSegments" format="ixt-sec:numwordsen" scale="0" id="f-322">three</ix:nonFraction> geographic areas. The Company's singular focus is developing innovative ophthalmic pharmaceutical products.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="kprx:ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" id="f-323" continuedAt="f-323-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refunds for Research and Development</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-323-1">The Company through its subsidiaries, Kiora Pharmaceuticals GmbH and Kiora Pharmaceuticals Pty Ltd., is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the eligible incurred research and development expenses. Following the approval of a research finding by the tax authority, the Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. In situations where a new research application has not yet been approved by the tax authority, the Company records the tax receivable and reduction of expense in the period following approval.</ix:continuation> As of March&#160;31, 2025 and December&#160;31, 2024, the Company has a research and development tax receivable of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="f-324">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="f-325">0.3</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-326" continuedAt="f-326-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2024, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to effect a one-for-nine ("1-for-9") reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#8217;s stockholders at the Company&#8217;s 2024 Annual Meeting of Stockholders held on May 1, 2024, and by the Company&#8217;s board of directors. The amendment became effective on June&#160;11, 2024, the effective date of the reverse stock split.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reverse stock split proportionally adjusted all shares of the Company&#8217;s common stock outstanding and shares of common stock underlying outstanding options and warrants immediately prior to the effective date of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all warrants, stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective date of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such warrants, stock options, and restricted stock awards, and, in the case of warrants and stock options, a proportionate increase in the exercise price of all such warrants and stock options. In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plans immediately prior to the effective date of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#8217;s Restated Certificate of Incorporation, which remained at <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-327">150,000,000</ix:nonFraction> shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the reverse stock split results in stockholders owning fractional shares). As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock as of June&#160;11, 2024 decreased from <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-328">26,735,116</ix:nonFraction> (pre-split) shares to <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-329">2,970,545</ix:nonFraction> (post-split) shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-326-1"><ix:continuation id="f-300-6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">presented reflecting the split. The Company&#8217;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on June&#160;11, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div id="i358c170041ff4839b1853882b3d8afd1_40"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-331" continuedAt="f-331-1" escape="true">Balance Sheet Information </ix:nonNumeric></span></div><ix:continuation id="f-331-1" continuedAt="f-331-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-333" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-332" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of cash and cash equivalents and restricted cash is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-334">3,771,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-335">3,792,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Cash, Non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-336">4,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-337">4,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-338">3,775,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-339">3,796,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current restricted cash consists of deposits with financial institutions for corporate credit cards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term Investments</span></div><ix:nonNumeric contextRef="c-1" name="kprx:ScheduleOfShortTermInvestmentsTableTextBlock" id="f-340" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes short-term investments as of March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-341">395,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-343">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-344">395,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-345">15,295,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-346">10,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-347">2,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-348">15,303,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-349">4,405,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-350">5,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-351">801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-352">4,410,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-353">224,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="f-354">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-356">224,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-357">20,321,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-358">16,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-359">3,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-360">20,334,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-361">92,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="f-362">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-364">92,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-365">18,517,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-366">28,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-367">4,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-368">18,540,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-369">4,058,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-370">5,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-371">2,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-372">4,062,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-373">301,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-374">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-376">304,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-377">22,970,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-378">36,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-379">6,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-380">22,999,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-331-2" continuedAt="f-331-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-381" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's short-term investments at March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-382">18,877,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="f-383">18,889,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-384">1,444,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="0" id="f-385">1,445,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-386">20,321,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-387">20,334,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-388">21,659,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="f-389">21,688,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-390">1,310,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="0" id="f-391">1,311,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-392">22,970,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-393">22,999,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-394" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the Company's available-for-sale investments' gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"/><td style="width:60.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.536%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Count</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="count" contextRef="c-59" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-395">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="f-396">1,943,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="f-397">2,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="count" contextRef="c-60" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-398">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="f-399">713,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="0" id="f-400">801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="count" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-401">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="f-402">3,052,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="f-403">3,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"/><td style="width:60.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.536%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Count</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="count" contextRef="c-63" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-404">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="f-405">3,369,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="f-406">4,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="count" contextRef="c-64" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-407">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="f-408">801,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="f-409">2,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="count" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-410">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="f-411">4,171,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="f-412">6,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its investments each quarter to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. The unrealized losses in the Company&#8217;s investments were caused by changes in interest rates resulting from changing economic conditions, and not from a decline in credit of their underlying issuers. The Company may be required to sell these investments prior to maturity to implement management strategies, however, it is not likely that the Company will sell these investments before recovery of their amortized cost basis. As such, the Company has classified these losses as temporary in nature.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-331-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="kprx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="f-413" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="kprx:PrepaidResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-414">728,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="kprx:PrepaidResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-415">1,181,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="kprx:PrepaidGeneralAndAdministrative" format="ixt:num-dot-decimal" scale="0" id="f-416">178,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="kprx:PrepaidGeneralAndAdministrative" format="ixt:num-dot-decimal" scale="0" id="f-417">118,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="f-418">34,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="f-419">96,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:fixed-zero" scale="0" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-421">646,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Prepaid Expenses and Other Current Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-422">941,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-423">2,042,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax and Other Receivables</span></div><ix:nonNumeric contextRef="c-1" name="kprx:ScheduleOfTaxAndOtherReceivablesTableTextBlock" id="f-424" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax and other receivables consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research Tax Credits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="kprx:ResearchTaxCreditsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-425">668,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="kprx:ResearchTaxCreditsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-426">223,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tax Receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="kprx:OtherTaxReceivablesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-427">53,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="kprx:OtherTaxReceivablesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-428">47,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Receivables</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-429">722,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="0" id="f-430">270,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-431" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and Benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-432">653,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-433">1,169,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-434">112,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-435">55,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="kprx:ClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-436">243,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="kprx:ClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-437">875,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-438">2,456,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-439">2,328,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-440">55,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-441">160,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-442">3,522,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-443">4,588,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i358c170041ff4839b1853882b3d8afd1_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-444" continuedAt="f-444-1" escape="true">Fair Value Disclosures</ix:nonNumeric></span></div><ix:continuation id="f-444-1" continuedAt="f-444-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-444-2" continuedAt="f-444-3"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-445" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:34.581%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-446">1,796,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-447">1,796,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-450">174,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-452">174,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Equivalents Measured at Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-454">1,970,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-455">1,796,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-456">174,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-458">395,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-460">395,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-462">15,303,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-464">15,303,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-466">4,410,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-468">4,410,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-470">224,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-472">224,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-474">20,334,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-476">20,334,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-478">22,305,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-479">1,796,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-480">20,509,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:34.581%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-482">562,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-483">562,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-486">691,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-488">691,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Equivalents Measured at Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-490">1,254,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-491">562,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-492">691,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-494">92,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-496">92,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-498">18,540,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-500">18,540,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-502">4,062,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-504">4,062,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-506">304,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-508">304,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-510">22,999,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-512">22,999,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-514">24,254,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-515">562,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-516">23,691,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><div style="text-align:center"><span><br/></span></div><ix:continuation id="f-444-3" continuedAt="f-444-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with historical acquisitions, additional consideration may be owed by the Company related to the achievement of certain milestones and such contingent consideration payments are required by U.S. GAAP to be presented at fair value. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="f-518" continuedAt="f-518-1" escape="true">The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:</ix:nonNumeric></span></div><ix:continuation id="f-518-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-519">4,466,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-520">4,191,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Contingent Consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-521">4,466,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-522">4,191,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific milestones. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-523" continuedAt="f-523-1" escape="true">After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:</ix:nonNumeric></span></div><ix:continuation id="f-523-1" continuedAt="f-523-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-524">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-525">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-526">48</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-125" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-527">77</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-528">42</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-127" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-529">77</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-530">30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-129" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-531">33</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-532">30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-131" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-533">33</ix:nonFraction>%</span></div></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the above table is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. The change in fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="kprx:ChangeInContingentConsiderationFairValue" scale="6" id="f-534">0.3</ix:nonFraction> million for the three months ended March&#160;31, 2025, was primarily driven by a decrease in the discount rate. The change in fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-2" sign="-" name="kprx:ChangeInContingentConsiderationFairValue" scale="3" id="f-535">12.2</ix:nonFraction> thousand for the three months ended March&#160;31, 2024 was primarily driven by an increase in the discount rate. The change in fair value of contingent consideration is recorded within operating expenses on the accompanying condensed consolidated statements of operations and comprehensive (loss) income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use at estimated fair value. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 350 allows an entity to first assess qualitative factors to determine whether events and circumstances indicate that it is more likely than not (that is, a likelihood of more than 50 percent) that an indefinite-lived intangible asset is impaired. If it is more likely than not that the asset is impaired, the entity must calculate the fair value of the asset and record an impairment charge if the carrying amount exceeds fair value. If an entity concludes that there is a less than 50 percent likelihood that the asset is impaired, no further action is required. An indefinite-lived intangible asset should be tested for impairment if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If such events or changes have occurred, a quantitative assessment is required.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-444-4"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity bypasses the qualitative assessment or determines from its qualitative assessment that an indefinite-lived intangible asset is more likely than not impaired, a quantitative impairment test should be performed. The quantitative impairment test compares the fair value of an indefinite-lived intangible asset with the asset&#8217;s carrying amount. If the fair value of the indefinite-lived intangible asset is less than the carrying amount, an impairment loss should be recognized in an amount equal to the difference in accordance with ASC 350-30-35-19.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values in-process R&amp;D related to asset acquisitions using the Income Approach which measures the value of an asset by the present value of its future economic benefits. These benefits can include interest and principal payments, earnings, cost savings, tax deductions, or proceeds from its disposition. Value indications are developed by discounting expected cash flows at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation, and risks associated with the particular investment. The selected discount rate is generally based on rates of return available from alternative investments of similar type and quality.</span></div><ix:continuation id="f-523-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company engaged a third-party valuation firm to complete a quantitative assessment of in-process R&amp;D as of August 31, 2024, which includes the following unobservable Level 3 inputs:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:12.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-104</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Period Excess Earnings Method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for next development phase</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="2" name="kprx:InProcessResearchAndDevelopmentMeasurementInput" scale="-2" id="f-536">17</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-133" decimals="2" name="kprx:InProcessResearchAndDevelopmentMeasurementInput" scale="-2" id="f-537">36</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="2" name="kprx:InProcessResearchAndDevelopmentMeasurementInput" scale="-2" id="f-538">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Period Excess Earnings Method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for next development phase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="2" name="kprx:InProcessResearchAndDevelopmentMeasurementInput" scale="-2" id="f-539">23</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="kprx:InProcessResearchAndDevelopmentMeasurementInput" scale="-2" id="f-540">43</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="kprx:InProcessResearchAndDevelopmentMeasurementInput" scale="-2" id="f-541">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company assessed qualitative factors to determine whether events and circumstances indicate impairment, and concluded that it is not more likely than not that any assets are impaired.</span></div></ix:continuation><div id="i358c170041ff4839b1853882b3d8afd1_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-542" continuedAt="f-542-1" escape="true">Capital Stock</ix:nonNumeric></span></div><ix:continuation id="f-542-1" continuedAt="f-542-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts of shares of common stock in the transactions described below have been adjusted to reflect post Amendment adjusted shares of common stock of the Company. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") where the Company's stockholders voted to approve various proposals including (i) adoption of a new Equity Incentive Plan, the "2024 Equity Incentive Plan", (ii) an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-543">150,000,000</ix:nonFraction>, which the Company filed with the Secretary of State for the State of Delaware on May 1, 2024 and (iii) the approval, as contemplated by Nasdaq Listing Rule 5635, of the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-544">5,486,066</ix:nonFraction> shares of Common Stock upon the exercise of Tranche A Warrants and Tranche B Warrants issued in the private placement that closed on February 5, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2024, the Company entered into a private placement agreement with Maxim Group LLC serving as placement agent for <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-545">1,755,556</ix:nonFraction> shares of common stock, pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-546">1,261,582</ix:nonFraction> shares of common stock, and accompanying Tranche A and Tranche B warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-547">5,486,066</ix:nonFraction> shares of common stock. The total net proceeds from the private placement were approximately $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-548">13.8</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tranche A warrants are exercisable for up to <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-549">2,743,033</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-550">5.4684</ix:nonFraction> per share for an aggregate of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-551">15.0</ix:nonFraction> million and will expire at the earlier of (i) <ix:nonFraction unitRef="day" contextRef="c-143" decimals="INF" name="kprx:ClassOfWarrantOrRightThresholdTradingDays" scale="0" id="f-552">30</ix:nonFraction> days following the announcement of full data (expected in 2026) from the Company's Phase 2 clinical trial (ABACUS-2) of KIO-301 in patients with retinitis pigmentosa and the daily Volume Weighted Average Price "VWAP" of the Company's common stock equaling or exceeding $<ix:nonFraction unitRef="usdPerShare" contextRef="c-143" decimals="INF" name="kprx:ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" scale="0" id="f-553">9.9432</ix:nonFraction> per share for <ix:nonFraction unitRef="day" contextRef="c-143" decimals="INF" name="kprx:ClassOfWarrantOrRightThresholdConsecutiveTradingDays" scale="0" id="f-554">30</ix:nonFraction> consecutive trading days following the announcement and (ii) <ix:nonNumeric contextRef="c-142" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-555">five years</ix:nonNumeric> from the date of shareholder approval of the warrants.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-542-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tranche B warrants are exercisable for up to <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-556">2,743,033</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-144" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-557">5.4684</ix:nonFraction> per share for an aggregate of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-558">15.0</ix:nonFraction> million and will expire at the earlier of (i) <ix:nonFraction unitRef="day" contextRef="c-145" decimals="INF" name="kprx:ClassOfWarrantOrRightThresholdTradingDays" scale="0" id="f-559">30</ix:nonFraction> days following the announcement of topline data (expected in 2026) from the planned Phase 2 trial of KIO-104 in retinal inflammation and the daily VWAP of the Company's common stock equaling or exceeding $<ix:nonFraction unitRef="usdPerShare" contextRef="c-145" decimals="INF" name="kprx:ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" scale="0" id="f-560">12.4290</ix:nonFraction> per share for <ix:nonFraction unitRef="day" contextRef="c-145" decimals="INF" name="kprx:ClassOfWarrantOrRightThresholdConsecutiveTradingDays" scale="0" id="f-561">30</ix:nonFraction> consecutive trading days following the announcement and (ii) <ix:nonNumeric contextRef="c-144" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-562">five years</ix:nonNumeric> from the date of shareholder approval of the warrants.</span></div></ix:continuation><div id="i358c170041ff4839b1853882b3d8afd1_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="kprx:WarrantsDisclosureTextBlock" id="f-563" continuedAt="f-563-1" escape="true">Warrants</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-564" escape="true"><ix:continuation id="f-563-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity for the Company&#8217;s equity-classified warrants for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common Shares<br/>Issuable Upon Exercise<br/>of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-565">7,389,523</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-146" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" scale="0" id="f-566">7.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-147" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-567">5.06</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-568">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-570">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" scale="0" id="f-572">69</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-573">4,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-574">7,389,454</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" scale="0" id="f-575">7.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-148" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-576">4.81</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i358c170041ff4839b1853882b3d8afd1_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-577" continuedAt="f-577-1" escape="true">Net (Loss) Income per Share - Basic and Diluted</ix:nonNumeric></span></div><ix:continuation id="f-577-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net (loss) income per share is computed by dividing net (loss) income available to common shareholders by the weighted-average number of common shares outstanding for the time period, which for basic net (loss) income per share, does not include the weighted-average unvested restricted common stock that has been issued and is subject to forfeiture totaling <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="f-578">45,363</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="f-579">24,094</ix:nonFraction> shares for the three months ended March&#160;31, 2025 and 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net (loss) income per share as their effect would be anti-dilutive. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-580" continuedAt="f-580-1" escape="true">The following is a summary of potentially dilutive securities excluded from the calculation of diluted net (loss) income per share as of March&#160;31, 2025 and 2024:</ix:nonNumeric></span></div><ix:continuation id="f-580-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Warrants, Excluding Pre-funded Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-581">6,127,872</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-582">5,661,699</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-583">161,276</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-153" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-584">89,338</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-585">45,363</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-586">24,094</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, as Converted into Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-587">42,426</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-157" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-588">42,426</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Reserved for Future Issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-589">570,846</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-590">54,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-591">6,947,783</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-592">5,872,252</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="f-593" continuedAt="f-593-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-593-1" continuedAt="f-593-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors (the "Board") adopted the 2014 Equity Incentive Plan (the "2014 Plan") and the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and the Company's Stockholders approved the 2014 Plan and ESPP in February 2015. The Board subsequently adopted the 2024 Equity Incentive Plan (the "2024 Plan") and the Company's Stockholders approved the Plan in May 2024. Following adoption of the 2024 Plan, no further grants were made under the 2014 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the 2014 Plan, the 2024 Plan provides for the granting of stock options (incentive and nonqualified), restricted stock or other stock-based awards to employees, officers, directors, consultants, and advisors. The Board is responsible for administration of the 2024 Plan. The Company&#8217;s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than <ix:nonFraction unitRef="number" contextRef="c-160" decimals="2" name="kprx:PercentageOfExercisePrice" scale="-2" id="f-594">110</ix:nonFraction>% of fair value in the case of holders of more than 10% of the Company&#8217;s voting stock) and with a term not to exceed <ix:nonNumeric contextRef="c-161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-595">ten years</ix:nonNumeric> from the date of the grant (<ix:nonNumeric contextRef="c-162" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-596">five years</ix:nonNumeric> for incentive stock options granted to holders of more than 10% of the Company&#8217;s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant, or director at an exercise price per share of not less than the par value per share. In January 2025, the number of shares of common stock issuable under the 2024 Plan automatically increased by <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-597">120,031</ix:nonFraction> shares pursuant to the terms of the 2024 Plan. As of March&#160;31, 2025, the maximum number of shares of Common Stock that may be issued pursuant to the 2024 Plan was <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-598">853,133</ix:nonFraction> of which <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-599">570,846</ix:nonFraction> shares were available for awards.</span></div><ix:nonNumeric contextRef="c-1" name="kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" id="f-600" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is presented in the same expense line items as cash compensation paid and for the three months ended March&#160;31, 2025 and 2024 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"/><td style="width:68.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-601">84,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-602">94,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-603">63,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-604">80,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stock-Based Compensation Expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-605">148,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="0" id="f-606">175,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants time-based stock options which generally vest one-third of the underlying shares on the <ix:nonNumeric contextRef="c-169" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-607">one-year</ix:nonNumeric> anniversary of the grant date and the remainder ratably over a <ix:nonNumeric contextRef="c-170" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-608">24-month</ix:nonNumeric> period. The fair value of time-based stock options is determined using the Black-Scholes Option Pricing Model, with such value recognized as expense over the service period, which is typically <ix:nonNumeric contextRef="c-171" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-609">three years</ix:nonNumeric>, net of actual forfeitures. There were no grants made during the three months ended March&#160;31, 2025 and 2024, and therefore no assumptions used to determine the fair value.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.689%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options outstanding as of March&#160;31, 2025 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-610">6.77</ix:nonFraction>. The expected term of the options granted is based on management's estimate. Expected volatility is based on the historical volatility of the Company&#8217;s common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-593-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized compensation expense related to the options amounted to $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-611">0.4</ix:nonFraction> million as of March&#160;31, 2025 and is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-612">3.44</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-613" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of stock option activity for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-614">161,303</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-615">21.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-172" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-616">9.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-617">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="f-619">27</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-620">23,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-621">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-623">161,276</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-624">17.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-625">8.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and vested at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-626">58,397</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-627">37.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-628">8.28</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options outstanding and exercisable as of March&#160;31, 2025 had <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-629"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-630">no</ix:nonFraction></ix:nonFraction> aggregate intrinsic value. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#8217;s common stock for options that had exercise prices lower than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-631">3.01</ix:nonFraction>, the closing price of the Company&#8217;s stock on March&#160;31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock compensation expense is recognized over the vesting period, which is typically one-third of the underlying shares on the <ix:nonNumeric contextRef="c-173" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-632">one-year</ix:nonNumeric> anniversary of the grant date and the remainder ratably over a <ix:nonNumeric contextRef="c-174" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-633">24-month</ix:nonNumeric> period. Unamortized compensation expense related to the restricted stock awards amounted to $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-634">0.2</ix:nonFraction> million as of March&#160;31, 2025 and is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="c-176" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-635">3.53</ix:nonNumeric> years. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-636" continuedAt="f-636-1" escape="true">The following is a summary of restricted stock activity for the three months ended March&#160;31, 2025:</ix:nonNumeric></span></div><ix:continuation id="f-636-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-637">46,697</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-638">7.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-178" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-639">2.19</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-640">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-642">1,334</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-643">34.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-644">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-646">45,363</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-175" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-647">6.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-176" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-648">1.97</ix:nonNumeric></span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-qualified ESPP, which provides for the issuance of shares of the Company&#8217;s common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of common stock through payroll deductions at a discounted price. <ix:nonNumeric contextRef="c-179" name="kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="f-649">Six month</ix:nonNumeric> offering periods are made at the Board&#8217;s discretion. The ESPP provides for <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="f-650">32</ix:nonFraction> aggregate shares of the Company&#8217;s common stock for participants to purchase. As of March&#160;31, 2025 and 2024, the remaining shares reserved for future offerings was <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="f-651"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="f-652">23</ix:nonFraction></ix:nonFraction>. Subsequent to the reporting period, in May 2025 the Company terminated the ESPP (Note 10).</span></div></ix:continuation><div id="i358c170041ff4839b1853882b3d8afd1_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-655" continuedAt="f-655-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-655-1" continuedAt="f-655-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to <ix:nonFraction unitRef="operatinglease" contextRef="c-1" decimals="INF" name="kprx:LesseeNumberOfOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="f-656">five</ix:nonFraction> real property operating leases for the rental of office and clinical trial space. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-655-2" continuedAt="f-655-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into an <ix:nonNumeric contextRef="c-182" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-657">18-month</ix:nonNumeric> lease for an office facility in Encinitas, California (the "Encinitas Lease"), which is now used for its corporate headquarters. The Encinitas Lease commenced in May 2022 and was amended to extend its lease term through April 30, 2025. The Company recorded a right-of use ("ROU") asset and lease liability upon lease commencement and lease amendment in May 2022 and November 2023, respectively. Monthly rent payments are approximately $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-2" name="kprx:LesseeOperatingLeaseMonthlyRentPayment" scale="3" id="f-658">3.3</ix:nonFraction> thousand, and the security deposit is $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="kprx:LesseeOperatingLeaseSecurityDeposit" scale="3" id="f-659">12</ix:nonFraction> thousand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into a <ix:nonNumeric contextRef="c-184" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-660">12-month</ix:nonNumeric> lease for office space in Adelaide, Australia (the "Adelaide Lease") which expired in May 2023. Following expiration, the landlord agreed to extend the Adelaide Lease on a month-month basis, whereby the Company must provide <ix:nonNumeric contextRef="c-185" name="kprx:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:durwordsen" id="f-661">90-day</ix:nonNumeric> notice of termination. The Adelaide Lease is a short-term lease which is exempt for ROU asset and lease liability reporting. Monthly rent payments are approximately A$<ix:nonFraction unitRef="aud" contextRef="c-185" decimals="-2" name="kprx:LesseeOperatingLeaseMonthlyRentPayment" scale="3" id="f-662">2.2</ix:nonFraction> thousand. The Adelaide lease is being used was a clinical trial site for ABACUS-2, with rent costs fully reimbursed by TOI.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into a lease for <ix:nonFraction unitRef="sqft" contextRef="c-186" decimals="INF" name="us-gaap:AreaOfLand" scale="0" id="f-663">910</ix:nonFraction> square feet of office space in Vienna, Austria (the "Vienna Lease"). The Vienna Lease commenced on October 15, 2023 with a term of <ix:nonNumeric contextRef="c-186" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-664">5</ix:nonNumeric> years through October 14, 2028. The Company recorded a ROU asset and lease liability upon lease commencement in October 2023. Monthly rent payments are approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-2" name="kprx:LesseeOperatingLeaseMonthlyRentPayment" scale="3" id="f-665">1.3</ix:nonFraction> thousand, and the security deposit is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-2" name="kprx:LesseeOperatingLeaseSecurityDeposit" scale="3" id="f-666">4.5</ix:nonFraction> thousand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company entered into a lease in Perth, Australia (the "Perth Lease") and another in Brisbane, Australia (the "Brisbane Lease"). Both leases commenced in February 2025, at which time the Company recorded a ROU asset and lease liability, with a term of <ix:nonNumeric contextRef="c-188" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-667">2</ix:nonNumeric> years through January 2027. Monthly rent payments are approximately A$<ix:nonFraction unitRef="aud" contextRef="c-189" decimals="-2" name="kprx:LesseeOperatingLeaseMonthlyRentPayment" scale="3" id="f-668">8.9</ix:nonFraction> thousand, and the total security deposit is A$<ix:nonFraction unitRef="aud" contextRef="c-188" decimals="-2" name="kprx:LesseeOperatingLeaseSecurityDeposit" scale="3" id="f-669">44.0</ix:nonFraction> thousand. The Company has rent abatement for the first 2 months of the Brisbane Lease and for the first 3 months of the Perth Lease. The Brisbane and Perth leases are for ABACUS-2 clinical trial sites, with rent costs fully reimbursed by TOI. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company entered into a new lease in Encinitas, California (the "New Encinitas Lease"). The New Encinitas Lease will commence in June 2025 with a term of 3 years and 3 months through August 31, 2028. Monthly rent payments will be approximately $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="0" name="kprx:LesseeOperatingLeaseMonthlyRentPayment" scale="3" id="f-670">8.4</ix:nonFraction> thousand per month and will increase by approximately 4% each year on the anniversary of the commencement, starting in 2026. The Company has rent abatement for the first 2 months of the lease and maintains a security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="kprx:LesseeOperatingLeaseSecurityDeposit" scale="3" id="f-671">9.4</ix:nonFraction> thousand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense, consisting of the reduction of the right-of-use asset and the imputed interest on the lease liability, totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-672">13,845</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-673">20,231</ix:nonFraction> for the three months ended March&#160;31, 2025 and 2024, respectively.The remaining lease terms range from less than <ix:nonNumeric contextRef="c-192" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durday" id="f-674">30</ix:nonNumeric> days to <ix:nonNumeric contextRef="c-193" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-675">3.5</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="c-1" name="kprx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" id="f-676" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leases is as follows as of March&#160;31, 2025:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-677">2.27</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Discount Rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-678">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-679" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under non-cancellable operating leases as of March&#160;31, 2025 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (remaining months)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="f-680">59,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-681">81,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-682">19,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-683">11,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-684">171,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Amounts Representing Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-685">12,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-686">159,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Current Portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-687">71,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-688">87,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><ix:continuation id="f-655-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Exclusive Rights Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to <ix:nonFraction unitRef="licenseagreement" contextRef="c-1" decimals="INF" name="kprx:NumberOfLicenseAgreements" format="ixt-sec:numwordsen" scale="0" id="f-689">six</ix:nonFraction> license agreements as previously disclosed in Note 12 to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes to the terms of these agreements during the three months ended March&#160;31, 2025. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Funding</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company received grant funding of $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="f-690">20,000</ix:nonFraction> from the Choroideremia Research Foundation in support of validating functional vision assessments for patients with profound blindness. This grant funding will aid in further validation of a suite of tests expected to be used in the upcoming ABACUS-2 Phase 2 clinical trial assessing KIO-301.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of various acquisitions in prior periods included contingent consideration, which consisted of various cash earn-out payments upon the achievement of certain milestones. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="f-691" continuedAt="f-691-1" escape="true">Below are the maximum obligation payments per the respective agreements and estimated fair value of contingent consideration payments remaining as of March&#160;31, 2025.</ix:nonNumeric></span></div><ix:continuation id="f-691-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Obligation<br/>per Agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Fair<br/>Value Estimated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-692">7,135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="0" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-693">2,355,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-694">9,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="0" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-695">2,111,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="f-696">16,635,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-697">4,466,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Line Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company entered into a credit line with UBS (the &#8220;Credit Line&#8221;) providing for a $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-698">10.0</ix:nonFraction>&#160;million revolving line of credit. The Credit Line bears interest at the 30-day Secured Overnight Financing Rate ("SOFR") average, plus <ix:nonFraction unitRef="number" contextRef="c-198" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-699">1.5</ix:nonFraction>%. The SOFR rate is variable. The Credit Line is secured by a first priority lien and security interest in the Company&#8217;s marketable securities held in its managed investment accounts with UBS. As of March&#160;31, 2025 the line was unused.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, as well as governmental proceedings and investigations that are incidental to the business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_480"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-701" continuedAt="f-701-1" escape="true">Segment Information</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-701-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in and reports as a single reportable segment, focused on the development of innovative ophthalmic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Operating Decision Maker "CODM" is our President and Chief Executive Officer. The CODM does not evaluate profitability nor evaluate performance or allocate resources below the level of the consolidated Company. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM reviews operating expenses and net (loss) income presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. These metrics serve as benchmarks to evaluate the business, measure performance, identify trends, prepare financial projections, and make strategic decisions. The CODM does not evaluate performance or allocate resources based on segment assets data; therefore, total segment assets are not presented. As part of the adoption of ASU 2023-07, the comparative prior period segment information has been disclosed herein to align with the current year&#8217;s presentation.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-702" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue, significant expenses, and net (loss) income for the Company&#8217;s single reportable segment:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="f-704">16,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Less: Significant and Other Segment Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-705">1,489,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-706">1,296,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-101</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-707">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-708">10,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-104<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">1</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="0" sign="-" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-709">149,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-710">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-201</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="f-711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-712">30,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-713">2,101,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-714">1,018,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301 Collaboration Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="kprx:CollaborationCreditOperatingExpense" format="ixt:num-dot-decimal" scale="0" id="f-715">1,966,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="kprx:CollaborationCreditOperatingExpense" format="ixt:num-dot-decimal" scale="0" id="f-716">190,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Research and Development Expenses<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">2</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-717">576,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-718">622,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-719">275,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="f-720">12,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest Income, Net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-721">277,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-722">223,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Segment Expenses<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">3</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="0" id="f-723">16,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="0" id="f-724">7,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-725">123,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net (Loss) Income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-727">2,192,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-728">13,453,207</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net of research tax credit offset, including a cumulative catch-up for the 2024 expense credit that was recorded in Q1 2025 upon confirmation of approval.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Unallocated research and development expenses primarily include personnel costs, research consulting and scientific advisory expenses.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Other segment expenses primarily include interest expense, other income, net, and loss on disposal of fixed assets.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2025</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-729" continuedAt="f-729-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-729-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, the Company and D&#244;mes Pharma, successor to SentrX Animal Care Inc., agreed to terminate the license agreement dated June 7, 2023 given the Company's decision to cease continued development of KIO-201 in combination with an antibiotic, and thereby to cease continued maintenance of all related licensed IP. D&#244;mes Pharma elected not to resume the prosecution and maintenance of the licensed IP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, the Company terminated the ESPP effective as of April 30, 2025. The Company has provided notice of the ESPP's termination to the Company's employees and ESPP participants, and there are no employee funds currently held for purchasing shares of Common Stock under the ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following section of this Quarterly Report on Form 10-Q entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains statements that are not statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Factors that may cause our actual results to differ materially from those in the forward-looking statements include those factors described in &#8220;Item 1A. Risk Factors&#8221; beginning on page 17 of our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 25, 2025. You should carefully review all of these factors, as well as the comprehensive discussion of forward-looking statements on page 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals, Inc. is referred to herein as &#8220;Kiora&#8221;, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and &#8220;the Company&#8221;. </span></div><div id="i358c170041ff4839b1853882b3d8afd1_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a specialty clinical-stage pharmaceutical company developing and commercializing products for the treatment of ophthalmic diseases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-301 is initially focused on patients with later stages of disease progression due to Retinitis Pigmentosa (any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a &#8220;photoswitch&#8221; specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is specifically designed to restore the eyes&#8217; ability to perceive and interpret light in visually impaired patients. It selectively enters viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the presence or absence of light. On March 17, 2022, we were granted Orphan Drug Designation by the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) for the Active Pharmaceutical Ingredient (&#8220;API&#8221;) in KIO-301. In July 2024, we were granted Orphan Medicinal Product Designation by the European Medicines Agency for KIO-301 for the treatment of non-syndromic, rod-dominant retinal dystrophies, which includes diseases like retinitis pigmentosa, choroideremia, Stargardt disease and others. In September 2024, the European Medicines Agency expanded our Orphan Medicinal Product Designation to also include syndromic, rod-dominant retinal dystrophies that includes diseases like Usher's syndrome, which has non-ocular aspects of diseases in addition to retinal involvement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. ("Bayon") transaction that closed October 21, 2021. We initiated a Phase 1b clinical trial (ABACUS-1) in the third quarter of 2022. Topline data from this trial was presented at the American Academy of Ophthalmology annual meeting in November 2023. The complete data set was presented at the Association for Research in Vision and Ophthalmology ("ARVO") annual conference in May 2024 highlighting improvements in visual acuity, visual field and functional vision among clinical trial participants relative to baseline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we entered into a strategic development and commercialization agreement ("License Agreement") with Th&#233;a Open Innovation ("TOI"), a sister company of the global ophthalmic specialty company Laboratoires Th&#233;a ("Th&#233;a"). Under the agreement, Kiora granted TOI exclusive worldwide development and commercialization rights, excluding Asia, to KIO-301 for the treatment of degenerative retinal diseases. In exchange, Kiora received an upfront, payment of $16 million; up to $285 million upon achievement of pre-specified clinical development, regulatory and commercial milestones; tiered royalties of up to low 20% on net sales; and reimbursement of all KIO-301 research and development expenses moving forward from the date of the execution of the License Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we, in collaboration with our partner TOI, announced that we received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 for vision restoration in patients with retinitis pigmentosa. The ABACUS-2 trial is expected be a 36 patient, multi-center, double-masked, randomized, controlled, multiple dose study enrolling patients </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ultra-low vision or no light perception regardless of their underlying gene mutation associated with retinitis pigmentosa. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment is expected to begin in Q2 2025 following validation of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">novel functional vision endpoints. These functional assessments may serve as approvable primary endpoints in subsequent registration studies in the United States, Europe and other major regions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on results of ABACUS-1, we have the opportunity to expand development of KIO-301 to treat patients with late stages of Choroideremia and Stargardt disease. These diseases have a similar underlying late-stage pathology as Retinitis Pigmentosa, hence the mechanism of action of KIO-301 could potentially provide a similar benefit to these patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also planning to develop </span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-104 for the treatment of retinal inflammatory diseases including Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease and diabetic macular edema. KIO-104 is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a novel and potent small molecule inhibitor of dihydroorotate dehydrogenase ("DHODH"), </span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">formulated for intravitreal delivery and ideally suited to suppress overactive T-cell activity to treat the underlying condition.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from a previous Phase 1/2a study in patients with Posterior Non-Infectious Uveitis, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported in October 2022, </span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">showed that a single injection of KIO-104 decreased intraocular inflammation and improved visual acuity significantly for the duration of the study. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, KIO-104 reduced macular edema (swelling) which if unchecked, can lead to permanent vision loss. The drug was well tolerated, with no serious side effects on intraocular tissues or other serious adverse events observed. We are currently approved to start enrolling patients in a Phase 2 trial for KIO-104 in retinal inflammation and expect enrollment to commence in Q2 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an additional asset, KIO-101, that we are currently seeking to partner. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-101 is based on the same molecule as KIO-104, however formulated for topical, eye drop delivery. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout our history we have not generated significant revenue; however, in January 2024 we entered into the License Agreement with TOI, whereby we recognized $16 million in collaboration revenue related to the upfront payment. We have never been profitable and from inception through March&#160;31, 2025, our losses from operations have aggregated $145.6 million. We expect to incur significant expenses and increasing operating losses for the foreseeable future as we continue the development and clinical trials of and seek regulatory approval for our product candidates. If we obtain regulatory approval for our product candidates, we expect to incur significant expenses in order to create an infrastructure to support their commercialization including sales, marketing, and distribution functions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need additional financing to support our continuing operations. We will seek to fund our operations through a combination of public or private sales of equity, debt financings, license and development agreements, non-dilutive grants and other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. Although historically we have been successful at raising capital, including raising net proceeds of approximately $13.8 million in a private placement offering that closed on February&#160;5, 2024, additional capital may not be available on terms favorable to Kiora, if at all. We do not know if any future offerings will succeed. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. Kiora has incurred losses and negative cash flows since inception, and future losses are anticipated. However, based on the cash on hand and short-term investments at March&#160;31, 2025 of approximately $3.8 million and $20.3 million, respectively, we anticipate having sufficient cash to fund currently planned operations into late 2027.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None noted.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Components of Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of three months ended, March&#160;31, 2025 and 2024</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration Revenue</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,000,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,000,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and Research Credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,966,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,775,570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,777,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,552)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Income, Net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Income Before Income Tax Expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,069,974)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,453,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,523,181)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax Expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,192,980)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,453,207&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,646,187)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease of $16.0 million was attributable to the revenue recognized from the upfront payment pursuant the strategic development and commercialization agreement with TOI.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $0.2 million was driven primarily by personnel related costs of related to higher salary and bonus expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $0.8 million was primarily due to increased preclinical, CMC and clinical trial related expenses of $1.8 million, partially offset by a reduction in licensing fees of $0.8 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and Research Credits.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase of $1.8 million is related to increased research and development expenses for the KIO-301 program which are fully reimbursed by TOI.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase of $0.3 million was primarily driven by the timing of expected milestone payments and fluctuations in the weighted average cost of capital.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase of $29.3 thousand was primarily due to additional estimated interest income resulting from accrued interest on short-term marketable securities.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal liquidity needs have historically been for acquisitions, working capital, research and development, and capital expenditures. While we anticipate having sufficient cash to fund currently planned operations into late 2027, we will need additional financing to support our future operations as we develop and work toward the commercialization of new products. We will seek to fund our operations through a combination of public or private sales of equity, debt financings, license and development agreements, non-dilutive grants and other sources, which may include collaborations with third parties. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds by issuing equity securities or convertible debt, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, or making capital expenditures. If we raise additional funds through collaboration and licensing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements with third parties, it may be necessary to relinquish valuable rights to our products, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to us. Although historically we have been successful at raising capital, most recently raising net proceeds of approximately $13.8 million in a private placement offering that closed on February&#160;5, 2024, additional capital may not be available on terms favorable to us, if at all. We do not know if any future offerings will succeed. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We have incurred losses and negative cash flows since inception, and future losses are anticipated. However, based on the cash on hand and short-term investments at March&#160;31, 2025 of approximately $3.8 million and $20.3 million, respectively, we anticipate having sufficient cash to fund currently planned operations into late 2027.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Regarding Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had unrestricted cash and cash equivalents totaling $3.8 million and restricted cash totaling $4.1 thousand for a total of $3.8 million compared to $3.8 million at December&#160;31, 2024. The following table sets forth the primary uses of cash for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash (Used in) Provided by Operating Activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,704,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,624,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Investing Activities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672,782&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,247,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net cash provided by operating activities decreased $16.3 million primarily due to an increase in net cash provided by operating activities of $13.6 million in first quarter of 2024 which was driven by the collaboration revenue recognized from the TOI agreement and the timing of research and development activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net cash provided by investing activities increased $2.7 million primarily due to the maturities of marketable securities. There were no marketable securities fin the first quarter of 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no financing activities for the first quarter of 2025, compared to an increase in net cash provided by financing activities during the first quarter of 2024 due to receiving net proceeds of approximately $13.8 million in a private offering that closed on February&#160;5, 2024 and proceeds of $1.7 million from warrant exercises.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements and Other Liquidity Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product pipeline is still in various stages of preclinical and clinical development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek partnerships for our KIO-101 product to continue its development activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approval for our KIO-301 product outside of the territory already partnered with TOI;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approval for our KIO-104 product or any other products that we successfully develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales and marketing infrastructure to commercialize our KIO-301 product outside of the territory already partnered with TOI;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales and marketing infrastructure to commercialize our KIO-104 product, if approved; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, grants and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, including our KIO-301 (outside of the territory already partnered with TOI), KIO-101, and KIO-104 products, on terms that may not be favorable to us. We have currently paused development work on KIO-101 and are seeking partnership for any further development of those programs. For our active programs, if we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market KIO-301 outside of the territory already partnered with TOI and KIO-104 products, or any other products that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our cash on hand and short-term investments at March&#160;31, 2025, we believe that we will have sufficient cash to fund planned operations into late 2027. However, the acceleration or reduction of cash outflows by management can significantly impact the timing for raising additional capital to complete development of our products. To continue development, we will need to raise additional capital through debt and/or equity financing, grants and other arrangements. Although historically we have been successful at raising capital, additional capital may not be available on terms favorable to us, if at all. We do not know if any future offerings will succeed. Accordingly, no assurances can be given that management will be successful in these endeavors. Our Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding Commitments and Contingencies, refer to Note 8. Commitments and Contingencies to the Notes to the Condensed Consolidated Financial Statements of Part 1, Item 1. Financial Statements of this Form 10-Q.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion of operating results is based upon the Unaudited Condensed Consolidated Financial Statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting policies and significant judgement and estimates are detailed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we have no material changes from such disclosures.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding new accounting pronouncements is included in Note 1 - Business, Presentation and Recent Accounting Pronouncements to the current period&#8217;s unaudited condensed consolidated financial statements.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Report includes the certifications of our Chief Executive Officer (who is our principal executive officer) and our Chief Financial Officer (who is our principal financial and accounting officer) required by Rule 13a-14 of the Exchange Act. See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Quarterly Report on the Form 10-Q, the Company&#8217;s Management, under the supervision of, and with the participation of, our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March&#160;31, 2025. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and our management necessarily was required to apply its judgment in evaluating and implementing our disclosure controls and procedures. Based upon the evaluation described above, our Chief Executive Officer and Chief Financial Officer have concluded that they believe that our disclosure controls and procedures were effective as of the end of the period covered by this report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Accounting and Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no changes in the Company&#8217;s internal control over financial reporting during the three months ended March&#160;31, 2025 that were identified in connection with management&#8217;s evaluation required by Rules 13a-15(d) and 15d-15(d) under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i358c170041ff4839b1853882b3d8afd1_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are not currently a party to any legal proceedings as of March&#160;31, 2025, from time to time we may be a party to a variety of legal proceedings that arise in the normal course of our business.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2024, each of which is incorporated herein by reference and which could materially affect our business, financial condition or future results. The risks described herein and in those filings are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. We do not believe that there have been any material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_118"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not purchase any of our registered equity securities during the period covered by this Quarterly Report on Form 10-Q.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_124"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_127"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No officers or directors, as defined in Rule 16a-1(f), <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-730"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-731">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-732"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-733">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement as defined in item 408 of Regulation S-K, during the period ended March&#160;31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, the Company terminated the ESPP effective as of April 30, 2025. The Company has provided notice of the ESPP's termination to the Company's employees and ESPP participants, and there are no employee funds currently held for purchasing shares of Common Stock under the ESPP.</span></div><div id="i358c170041ff4839b1853882b3d8afd1_130"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index immediately preceding such exhibits and are incorporated herein by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;9, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br/>(Principal executive officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;9, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i358c170041ff4839b1853882b3d8afd1_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i358c170041ff4839b1853882b3d8afd1_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this Quarterly Report on Form 10-Q. Where such filing is made by incorporation by reference to a previously filed document, such document is identified.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="kprx-20250331xexx311.htm">Certification of principal executive officer pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="kprx-20250331xexx312.htm">Certification of principal financial and accounting officer pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="kprx-20250331xexx321.htm">Certification of principal executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="kprx-20250331xexx322.htm">Certification of principal financial and accounting officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>kprx-20250331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9119cda4839341e894b710e9b3c17edb_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian M. Strem, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Kiora Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2025</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian M. Strem, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D.<br>President and Chief Executive Officer<br>(Principal executive officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>kprx-20250331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib3655ab3a44546c9b85ad83f4414351b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Melissa Tosca, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Kiora Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2025</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Melissa Tosca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa Tosca<br>Chief Financial Officer<br>(Principal financial and accounting officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>kprx-20250331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic26ddacfa4424e279da536bd13a61439_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC FINANCIAL REPORT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned officer of Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) hereby certifies to his knowledge that the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2025 (the &#8220;Report&#8221;) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (&#8220;Item 601(b)(32)&#8221;) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2025</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian M. Strem, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D.<br>President and Chief Executive Officer<br>(Principal executive officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>kprx-20250331xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i02568540dc094f2b999f2c9f569b618b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC FINANCIAL REPORT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned officer of Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) hereby certifies to her knowledge that the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2025 (the &#8220;Report&#8221;) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (&#8220;Item 601(b)(32)&#8221;) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2025</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Melissa Tosca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa Tosca<br>Chief Financial Officer<br>(Principal financial and accounting officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>kprx-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0167d6af-99d4-4c6f-8900-ecd7455d4d35,g:cf0f15d1-3949-48fc-a909-df68c07a7e6e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited">
        <link:definition>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessPresentationandRecentAccountingPronouncements" roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements">
        <link:definition>9952157 - Disclosure - Business, Presentation and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformation" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformation">
        <link:definition>9952158 - Disclosure - Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDisclosures" roleURI="http://www.eyegatepharma.com/role/FairValueDisclosures">
        <link:definition>9952159 - Disclosure - Fair Value Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStock" roleURI="http://www.eyegatepharma.com/role/CapitalStock">
        <link:definition>9952160 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.eyegatepharma.com/role/Warrants">
        <link:definition>9952161 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareBasicandDiluted" roleURI="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDiluted">
        <link:definition>9952162 - Disclosure - Net (Loss) Income per Share - Basic and Diluted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.eyegatepharma.com/role/StockBasedCompensation">
        <link:definition>9952163 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingencies">
        <link:definition>9952164 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.eyegatepharma.com/role/SegmentInformation">
        <link:definition>9952165 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.eyegatepharma.com/role/SubsequentEvents">
        <link:definition>9952166 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessPresentationandRecentAccountingPronouncementsPolicies" roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies">
        <link:definition>9955511 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationTables" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationTables">
        <link:definition>9955512 - Disclosure - Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDisclosuresTables" roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresTables">
        <link:definition>9955513 - Disclosure - Fair Value Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.eyegatepharma.com/role/WarrantsTables">
        <link:definition>9955514 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareBasicandDilutedTables" roleURI="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedTables">
        <link:definition>9955515 - Disclosure - Net (Loss) Income per Share - Basic and Diluted (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationTables">
        <link:definition>9955516 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955517 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.eyegatepharma.com/role/SegmentInformationTables">
        <link:definition>9955518 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessPresentationandRecentAccountingPronouncementsDetails" roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails">
        <link:definition>9955519 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9955520 - Disclosure - Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationShorttermInvestmentsDetails" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails">
        <link:definition>9955521 - Disclosure - Balance Sheet Information - Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails">
        <link:definition>9955522 - Disclosure - Balance Sheet Information - Maturities of Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails">
        <link:definition>9955523 - Disclosure - Balance Sheet Information - Available-for-Sale Investments Gross Unrealized Losses and Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9955524 - Disclosure - Balance Sheet Information - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails">
        <link:definition>9955525 - Disclosure - Balance Sheet Information - Schedule of Tax and Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetInformationAccruedExpensesDetails" roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails">
        <link:definition>9955526 - Disclosure - Balance Sheet Information - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDisclosuresAssetsatFairValueDetails" roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails">
        <link:definition>9955527 - Disclosure - Fair Value Disclosures - Assets at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDisclosuresLiabilitiesatFairValueDetails" roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails">
        <link:definition>9955528 - Disclosure - Fair Value Disclosures - Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDisclosuresUnobservableLevel3InputsDetails" roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails">
        <link:definition>9955529 - Disclosure - Fair Value Disclosures - Unobservable Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDisclosuresNarrativeDetails" roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresNarrativeDetails">
        <link:definition>9955530 - Disclosure - Fair Value Disclosures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails" roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails">
        <link:definition>9955531 - Disclosure - Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&amp;D (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockDetails" roleURI="http://www.eyegatepharma.com/role/CapitalStockDetails">
        <link:definition>9955532 - Disclosure - Capital Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsScheduleofWarrantActivityDetails" roleURI="http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails">
        <link:definition>9955533 - Disclosure - Warrants - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareBasicandDilutedDetails" roleURI="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails">
        <link:definition>9955534 - Disclosure - Net (Loss) Income per Share - Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9955535 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockbasedCompensationDetails" roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails">
        <link:definition>9955536 - Disclosure - Stock-Based Compensation - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofstockoptionactivityDetails" roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails">
        <link:definition>9955537 - Disclosure - Stock-Based Compensation - Schedule of stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockActivityDetails" roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails">
        <link:definition>9955538 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9955539 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails">
        <link:definition>9955540 - Disclosure - Commitments and Contingencies - Supplemental balance sheet information related to the leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails">
        <link:definition>9955541 - Disclosure - Commitments and Contingencies - Future annual minimum lease payments under non-cancellable operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails" roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails">
        <link:definition>9955542 - Disclosure - Commitments and Contingencies - Maximum obligation payments per respective agreements and estimated fair value of contingent consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.eyegatepharma.com/role/SegmentInformationDetails">
        <link:definition>9955543 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="kprx_CollaborationCreditReceivableCurrent" abstract="false" name="CollaborationCreditReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_PreferredStockDesignatedShares" abstract="false" name="PreferredStockDesignatedShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_CollaborationCreditOperatingExpense" abstract="false" name="CollaborationCreditOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_EquityLineOfCreditMember" abstract="true" name="EquityLineOfCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_IncreaseDecreaseInRightOfUseAssets" abstract="false" name="IncreaseDecreaseInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" abstract="false" name="FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_IncreaseDecreaseResearchTaxCreditsReceivables" abstract="false" name="IncreaseDecreaseResearchTaxCreditsReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_IncreaseDecreaseInAccruedCollaborationCredit" abstract="false" name="IncreaseDecreaseInAccruedCollaborationCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_WarrantsAbstract" abstract="true" name="WarrantsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_WarrantsDisclosureTextBlock" abstract="false" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_LiquidityAndCapitalResourcesPolicyTextBlock" abstract="false" name="LiquidityAndCapitalResourcesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_AccruedClinicalExpensesPolicyTextBlock" abstract="false" name="AccruedClinicalExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ScheduleOfShortTermInvestmentsTableTextBlock" abstract="false" name="ScheduleOfShortTermInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock" abstract="false" name="ScheduleOfTaxAndOtherReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" abstract="false" name="EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kprx_CollaborativeArrangementNumberOfPerformanceObligations" abstract="false" name="CollaborativeArrangementNumberOfPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_NumberOfGeographicSegments" abstract="false" name="NumberOfGeographicSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_PrepaidResearchAndDevelopment" abstract="false" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_PrepaidGeneralAndAdministrative" abstract="false" name="PrepaidGeneralAndAdministrative" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ResearchTaxCreditsReceivableCurrent" abstract="false" name="ResearchTaxCreditsReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_OtherTaxReceivablesCurrent" abstract="false" name="OtherTaxReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ClinicalTrialsCurrent" abstract="false" name="ClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ProbabilityOfSuccessForPaymentMember" abstract="true" name="ProbabilityOfSuccessForPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_BayonMember" abstract="true" name="BayonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_PanoptesMember" abstract="true" name="PanoptesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ChangeInContingentConsiderationFairValue" abstract="false" name="ChangeInContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_ProbabilityOfSuccessForDevelopmentPhaseMember" abstract="true" name="ProbabilityOfSuccessForDevelopmentPhaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_MultiPeriodExcessEarningsMethodMember" abstract="true" name="MultiPeriodExcessEarningsMethodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_KIO104Member" abstract="true" name="KIO104Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_KIO301Member" abstract="true" name="KIO301Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_InProcessResearchAndDevelopmentMeasurementInput" abstract="false" name="InProcessResearchAndDevelopmentMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="kprx_MaximGroupLLCMember" abstract="true" name="MaximGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_TrancheAWarrantsMember" abstract="true" name="TrancheAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_TrancheBWarrantsMember" abstract="true" name="TrancheBWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightThresholdTradingDays" abstract="false" name="ClassOfWarrantOrRightThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" abstract="false" name="ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" abstract="false" name="ClassOfWarrantOrRightThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" abstract="true" name="ClassOfWarrantOrRightNumberOfAwardsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" abstract="true" name="HoldersOwingMoreThanTenPercentageVotingRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_EquityIncentivePlan2014Member" abstract="true" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_PercentageOfExercisePrice" abstract="false" name="PercentageOfExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_A18MonthLeaseEncinitasCAMember" abstract="true" name="A18MonthLeaseEncinitasCAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_A12MonthLeaseAdelaideAustraliaMember" abstract="true" name="A12MonthLeaseAdelaideAustraliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_A5YearLeaseViennaAustriaMember" abstract="true" name="A5YearLeaseViennaAustriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_A2YearLeasePerthAndBrisbaneAustraliaMember" abstract="true" name="A2YearLeasePerthAndBrisbaneAustraliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_A3Year3MonthLeaseEncinitasCaliforniaMember" abstract="true" name="A3Year3MonthLeaseEncinitasCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_UBSMember" abstract="true" name="UBSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kprx_LesseeNumberOfOperatingLeases" abstract="false" name="LesseeNumberOfOperatingLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_LesseeOperatingLeaseMonthlyRentPayment" abstract="false" name="LesseeOperatingLeaseMonthlyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_LesseeOperatingLeaseSecurityDeposit" abstract="false" name="LesseeOperatingLeaseSecurityDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kprx_LesseeOperatingLeaseTerminationPeriod" abstract="false" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kprx_NumberOfLicenseAgreements" abstract="false" name="NumberOfLicenseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kprx_ResearchAndDevelopmentAllocationAxis" abstract="true" name="ResearchAndDevelopmentAllocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="kprx_ResearchAndDevelopmentAllocationDomain" abstract="true" name="ResearchAndDevelopmentAllocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_KIO101Member" abstract="true" name="KIO101Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_KIO104NetOfAdjustmentMember" abstract="true" name="KIO104NetOfAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_KIO201Member" abstract="true" name="KIO201Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kprx_UnallocatedResearchAndDevelopmentMember" abstract="true" name="UnallocatedResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>kprx-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0167d6af-99d4-4c6f-8900-ecd7455d4d35,g:cf0f15d1-3949-48fc-a909-df68c07a7e6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19d32302-51a3-4653-86fe-f5db43183914" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e7f13964-b932-4266-95a3-44a232ecc46f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19d32302-51a3-4653-86fe-f5db43183914" xlink:to="loc_us-gaap_PreferredStockValue_e7f13964-b932-4266-95a3-44a232ecc46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f19c283d-51cb-4d4d-b837-8db7839b24fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19d32302-51a3-4653-86fe-f5db43183914" xlink:to="loc_us-gaap_CommonStockValue_f19c283d-51cb-4d4d-b837-8db7839b24fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fa7909b3-a016-44ca-8cb5-7c071d930244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19d32302-51a3-4653-86fe-f5db43183914" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fa7909b3-a016-44ca-8cb5-7c071d930244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bc23e225-e521-4c27-a153-a65a8672dba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19d32302-51a3-4653-86fe-f5db43183914" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bc23e225-e521-4c27-a153-a65a8672dba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_864c7bad-aff3-4e94-940d-6d00834b32f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19d32302-51a3-4653-86fe-f5db43183914" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_864c7bad-aff3-4e94-940d-6d00834b32f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b2d1524-71ac-4eae-8ecd-90f5846fa948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_36b734e4-7cdb-4e59-8232-8f4bc8594a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7b2d1524-71ac-4eae-8ecd-90f5846fa948" xlink:to="loc_us-gaap_AccountsPayableCurrent_36b734e4-7cdb-4e59-8232-8f4bc8594a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b15ef9ba-89a8-41c1-ae40-088d60367571" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7b2d1524-71ac-4eae-8ecd-90f5846fa948" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b15ef9ba-89a8-41c1-ae40-088d60367571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditReceivableCurrent_9eb664e1-3ccf-4d69-a1a2-dcdcc001d05b" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7b2d1524-71ac-4eae-8ecd-90f5846fa948" xlink:to="loc_kprx_CollaborationCreditReceivableCurrent_9eb664e1-3ccf-4d69-a1a2-dcdcc001d05b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_86babd16-b7ca-40b9-9d0f-2926f1e331bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7b2d1524-71ac-4eae-8ecd-90f5846fa948" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_86babd16-b7ca-40b9-9d0f-2926f1e331bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8353bd9c-6f4b-4301-b08d-d0fd8a1c92c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b76bc246-a141-4697-9f12-e0a7662797cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8353bd9c-6f4b-4301-b08d-d0fd8a1c92c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b76bc246-a141-4697-9f12-e0a7662797cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aadfe001-0610-4dff-99e3-18964e50575c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8353bd9c-6f4b-4301-b08d-d0fd8a1c92c2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aadfe001-0610-4dff-99e3-18964e50575c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a56de74b-834c-42f3-9186-8533b5023e85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8353bd9c-6f4b-4301-b08d-d0fd8a1c92c2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a56de74b-834c-42f3-9186-8533b5023e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_67974d9a-edde-4670-9195-7a68800fe923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8353bd9c-6f4b-4301-b08d-d0fd8a1c92c2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_67974d9a-edde-4670-9195-7a68800fe923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_10aa14e4-a838-4502-8bb3-1ed6db8e831b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8353bd9c-6f4b-4301-b08d-d0fd8a1c92c2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_10aa14e4-a838-4502-8bb3-1ed6db8e831b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6b5be8fb-1f6a-4917-8eae-27bd5dfba161" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8353bd9c-6f4b-4301-b08d-d0fd8a1c92c2" xlink:to="loc_us-gaap_AssetsCurrent_6b5be8fb-1f6a-4917-8eae-27bd5dfba161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_faeacdb7-bcf7-471f-91c6-009bc3826a19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3f509733-e0c0-492e-9dde-e2404a584d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_faeacdb7-bcf7-471f-91c6-009bc3826a19" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3f509733-e0c0-492e-9dde-e2404a584d8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_655b326a-83ce-4c7b-98d9-f6b50410ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_faeacdb7-bcf7-471f-91c6-009bc3826a19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_655b326a-83ce-4c7b-98d9-f6b50410ccb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3ba1e8ee-524c-44dc-aa89-bc08da9a250f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_faeacdb7-bcf7-471f-91c6-009bc3826a19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3ba1e8ee-524c-44dc-aa89-bc08da9a250f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_40b5907c-e8ee-4566-9dc4-b74c61e37d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a9cff3dd-4345-484b-85e5-3a1d6234bc33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_40b5907c-e8ee-4566-9dc4-b74c61e37d6b" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a9cff3dd-4345-484b-85e5-3a1d6234bc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_05f96e51-79df-4c04-ae72-76f2ddbf1cad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_40b5907c-e8ee-4566-9dc4-b74c61e37d6b" xlink:to="loc_us-gaap_ShortTermInvestments_05f96e51-79df-4c04-ae72-76f2ddbf1cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b13b8489-1ed9-457d-893e-95aef985279b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_40b5907c-e8ee-4566-9dc4-b74c61e37d6b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b13b8489-1ed9-457d-893e-95aef985279b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dbfb8cae-8533-44af-b442-53430b15389d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_40b5907c-e8ee-4566-9dc4-b74c61e37d6b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dbfb8cae-8533-44af-b442-53430b15389d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c48cf07-ca3a-4e03-9916-4f4ae42ab8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_40b5907c-e8ee-4566-9dc4-b74c61e37d6b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c48cf07-ca3a-4e03-9916-4f4ae42ab8f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37e948a0-b128-4078-9d15-7ab24f659948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7e3d6fcd-ba41-47e3-b046-39f1ab9eb1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_37e948a0-b128-4078-9d15-7ab24f659948" xlink:to="loc_us-gaap_Liabilities_7e3d6fcd-ba41-47e3-b046-39f1ab9eb1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43423aa8-119e-4630-95d1-8ef91235aa75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_37e948a0-b128-4078-9d15-7ab24f659948" xlink:to="loc_us-gaap_StockholdersEquity_43423aa8-119e-4630-95d1-8ef91235aa75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ad359426-4dd8-48d9-a723-c93969ab4365" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_37e948a0-b128-4078-9d15-7ab24f659948" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ad359426-4dd8-48d9-a723-c93969ab4365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e22a636d-ed8a-43a7-8de2-dc494811ee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_90ca4e83-0d94-4c65-b62f-019e04d5101c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e22a636d-ed8a-43a7-8de2-dc494811ee1a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_90ca4e83-0d94-4c65-b62f-019e04d5101c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f17b1f19-c4bb-4b94-b4b4-c071325be958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e22a636d-ed8a-43a7-8de2-dc494811ee1a" xlink:to="loc_us-gaap_LiabilitiesCurrent_f17b1f19-c4bb-4b94-b4b4-c071325be958" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_597c5291-1a2e-4800-8524-a564357f220b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditOperatingExpense_bed82d37-5f37-4ad0-90be-3e30b9f30b75" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_597c5291-1a2e-4800-8524-a564357f220b" xlink:to="loc_kprx_CollaborationCreditOperatingExpense_bed82d37-5f37-4ad0-90be-3e30b9f30b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9ce6821e-1aea-4db1-b51d-a0617c28c84c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_597c5291-1a2e-4800-8524-a564357f220b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9ce6821e-1aea-4db1-b51d-a0617c28c84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ec4290db-21d3-4157-bc1c-8c74d1b5b294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_597c5291-1a2e-4800-8524-a564357f220b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ec4290db-21d3-4157-bc1c-8c74d1b5b294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b277e5dc-72ae-4a61-a4f1-c853b22a5e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_597c5291-1a2e-4800-8524-a564357f220b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b277e5dc-72ae-4a61-a4f1-c853b22a5e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a146626f-e7d8-4242-a491-ac5c03b669a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6c146ed0-caa5-4270-8738-f86dfd02a008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a146626f-e7d8-4242-a491-ac5c03b669a8" xlink:to="loc_us-gaap_NetIncomeLoss_6c146ed0-caa5-4270-8738-f86dfd02a008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2a23c701-b61c-413e-9904-7e16514ad3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a146626f-e7d8-4242-a491-ac5c03b669a8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2a23c701-b61c-413e-9904-7e16514ad3e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ebbc8126-2b6f-447b-a77b-4aedd03c5468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a146626f-e7d8-4242-a491-ac5c03b669a8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ebbc8126-2b6f-447b-a77b-4aedd03c5468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_5e9d9c37-00b6-48c3-a4da-4fd7fde2542a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b4cb83c6-9904-4d7e-96a7-f17e9c59f869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_5e9d9c37-00b6-48c3-a4da-4fd7fde2542a" xlink:to="loc_us-gaap_NetIncomeLoss_b4cb83c6-9904-4d7e-96a7-f17e9c59f869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a352441f-296f-44dd-8799-60c96862cd87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bd5fce42-7ab8-4cb3-8ac4-546db5414872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a352441f-296f-44dd-8799-60c96862cd87" xlink:to="loc_us-gaap_Revenues_bd5fce42-7ab8-4cb3-8ac4-546db5414872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_121a10f9-22c9-4df9-a7bd-8a40badb9648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a352441f-296f-44dd-8799-60c96862cd87" xlink:to="loc_us-gaap_OperatingExpenses_121a10f9-22c9-4df9-a7bd-8a40badb9648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_93da04e2-7704-4f1e-b8b8-f2bfae023a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d99fbed8-f2ea-4610-b5cc-ec77ed71c15f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_93da04e2-7704-4f1e-b8b8-f2bfae023a5a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d99fbed8-f2ea-4610-b5cc-ec77ed71c15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8d968acb-6ad6-4598-9adb-b01b6dcb7623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_93da04e2-7704-4f1e-b8b8-f2bfae023a5a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8d968acb-6ad6-4598-9adb-b01b6dcb7623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ab7a3967-2cec-4da7-8912-156927681b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_09da9a9a-4c39-45df-9f76-888980961ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ab7a3967-2cec-4da7-8912-156927681b9d" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_09da9a9a-4c39-45df-9f76-888980961ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_90a8066f-1c1b-4a29-a1b1-bb561f2a693a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4531d12-422d-42d2-a119-b910e539c925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_90a8066f-1c1b-4a29-a1b1-bb561f2a693a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b4531d12-422d-42d2-a119-b910e539c925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a175325b-8761-4a96-8d75-957c48f0f9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_90a8066f-1c1b-4a29-a1b1-bb561f2a693a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a175325b-8761-4a96-8d75-957c48f0f9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56934507-cead-43bd-b541-51d971ef3e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9ef305f8-6073-4f76-830f-cde9b57e50ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56934507-cead-43bd-b541-51d971ef3e63" xlink:to="loc_us-gaap_OperatingIncomeLoss_9ef305f8-6073-4f76-830f-cde9b57e50ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7cb0e001-fda4-429b-af59-4424345aa7df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56934507-cead-43bd-b541-51d971ef3e63" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7cb0e001-fda4-429b-af59-4424345aa7df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_2fd8eace-bb7a-4f22-bfb5-bf880c158f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_a728b11e-e091-48d8-99f7-461062b94fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_2fd8eace-bb7a-4f22-bfb5-bf880c158f4e" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_a728b11e-e091-48d8-99f7-461062b94fc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_adc36077-06bb-4398-bd18-1cffa3880728" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseResearchTaxCreditsReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_adc36077-06bb-4398-bd18-1cffa3880728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e347a24c-b978-479a-88c5-dbd575bee32d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e347a24c-b978-479a-88c5-dbd575bee32d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f9d8fd57-640d-4421-91ad-e717c1d18e01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f9d8fd57-640d-4421-91ad-e717c1d18e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_3746e86f-9ebf-4937-a0a6-aa2e312dded4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_3746e86f-9ebf-4937-a0a6-aa2e312dded4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_39f04bcd-a088-4b78-80fd-d884a167c8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_39f04bcd-a088-4b78-80fd-d884a167c8ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit_af8a0e16-7da9-4b52-b9ad-906af69c9991" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInAccruedCollaborationCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit_af8a0e16-7da9-4b52-b9ad-906af69c9991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f0015ecd-814b-4cd5-9898-9d8a26d78ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f0015ecd-814b-4cd5-9898-9d8a26d78ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets_cd72dab4-e2a4-406c-ac01-71712845df8b" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_kprx_IncreaseDecreaseInRightOfUseAssets_cd72dab4-e2a4-406c-ac01-71712845df8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7851d717-200b-428c-b96d-b73ae75ccef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7851d717-200b-428c-b96d-b73ae75ccef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_f94377ae-43c2-436d-b462-59982f811f86" xlink:href="kprx-20250331.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_f94377ae-43c2-436d-b462-59982f811f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d8699994-9371-4194-b36a-dcf9a13ea33d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d8699994-9371-4194-b36a-dcf9a13ea33d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_856cc999-05e4-4acc-9197-4476da9a4498" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_ShareBasedCompensation_856cc999-05e4-4acc-9197-4476da9a4498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be2c4e3c-06a6-447d-9b29-a4e8f8be61b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_NetIncomeLoss_be2c4e3c-06a6-447d-9b29-a4e8f8be61b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_851dd3e1-7f1b-4936-8d9f-55b92d965b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_851dd3e1-7f1b-4936-8d9f-55b92d965b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_375ed804-a10d-47b6-b149-35388545af99" xlink:href="kprx-20250331.xsd#kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a576555-487f-4e61-9aa8-9beae3658b8d" xlink:to="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_375ed804-a10d-47b6-b149-35388545af99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721be4a6-1abc-422a-a7d6-c581324f52c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c1c47c81-d568-40d8-bc3a-41c61b0c888a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721be4a6-1abc-422a-a7d6-c581324f52c2" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c1c47c81-d568-40d8-bc3a-41c61b0c888a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_16eafe02-e43e-4067-b8a4-40a7f57f5ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721be4a6-1abc-422a-a7d6-c581324f52c2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_16eafe02-e43e-4067-b8a4-40a7f57f5ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9ac8b874-df84-482d-a7ce-3cb5377ad157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_721be4a6-1abc-422a-a7d6-c581324f52c2" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9ac8b874-df84-482d-a7ce-3cb5377ad157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a028881-9e69-43c1-a99d-a44de11967d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34a0e22a-b8ec-44a8-9a77-e8f89efd7053" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a028881-9e69-43c1-a99d-a44de11967d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34a0e22a-b8ec-44a8-9a77-e8f89efd7053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_690527fa-fbcb-4897-aa7e-2497a375edeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a028881-9e69-43c1-a99d-a44de11967d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_690527fa-fbcb-4897-aa7e-2497a375edeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b40738fe-4720-446e-9913-ca99b6f4b0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a028881-9e69-43c1-a99d-a44de11967d2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b40738fe-4720-446e-9913-ca99b6f4b0e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d99a0d6-2075-4dde-a7a8-644f6a91e257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2a028881-9e69-43c1-a99d-a44de11967d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d99a0d6-2075-4dde-a7a8-644f6a91e257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_224cf32e-ac4b-491b-8868-ad1987d02b35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c54d01c7-4727-4cfe-892e-0b8761e5410d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_224cf32e-ac4b-491b-8868-ad1987d02b35" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c54d01c7-4727-4cfe-892e-0b8761e5410d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_f596d5e8-4076-4b77-acf5-0be30ea088ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_224cf32e-ac4b-491b-8868-ad1987d02b35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_f596d5e8-4076-4b77-acf5-0be30ea088ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_e5d22185-a6ea-4248-b9f7-e01faaa5507b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_224cf32e-ac4b-491b-8868-ad1987d02b35" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_e5d22185-a6ea-4248-b9f7-e01faaa5507b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e02d9c6-e203-42c7-a3e1-94d31a2fc7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20c260ef-ac1c-4a82-92ee-21e7ef1d83b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e02d9c6-e203-42c7-a3e1-94d31a2fc7fa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20c260ef-ac1c-4a82-92ee-21e7ef1d83b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_21a72ce2-8f20-4f9e-80c3-7bf81ea6f723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e02d9c6-e203-42c7-a3e1-94d31a2fc7fa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_21a72ce2-8f20-4f9e-80c3-7bf81ea6f723" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_43e1caf1-2978-406e-8adb-582eb3e02103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2417ddf2-e8c7-4e8f-a47c-34ffbb90d5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_43e1caf1-2978-406e-8adb-582eb3e02103" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2417ddf2-e8c7-4e8f-a47c-34ffbb90d5a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d5aa638d-8ce6-4d75-a512-587665b43831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_43e1caf1-2978-406e-8adb-582eb3e02103" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d5aa638d-8ce6-4d75-a512-587665b43831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f63d880-f8eb-47b1-b3ce-01ba8b88efa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_43e1caf1-2978-406e-8adb-582eb3e02103" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f63d880-f8eb-47b1-b3ce-01ba8b88efa8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b166572a-5efc-4ef2-97ba-d52c8be81e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2eaeded5-cd0f-4557-b4ca-bd7fae4cbbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b166572a-5efc-4ef2-97ba-d52c8be81e2c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2eaeded5-cd0f-4557-b4ca-bd7fae4cbbaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_51d7e02d-1f69-4751-b2b0-551535fd2a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b166572a-5efc-4ef2-97ba-d52c8be81e2c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_51d7e02d-1f69-4751-b2b0-551535fd2a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8026d29-b0cc-403a-bbbb-771c85269b58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9fd260e7-40c7-475a-9dcd-9bf48d37b297" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8026d29-b0cc-403a-bbbb-771c85269b58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9fd260e7-40c7-475a-9dcd-9bf48d37b297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8680dac6-c931-4865-bd3a-6e874175fb83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8026d29-b0cc-403a-bbbb-771c85269b58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8680dac6-c931-4865-bd3a-6e874175fb83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea8900f9-110e-4fb9-aa22-00e21a91955b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrepaidResearchAndDevelopment_9831fe17-4ef4-4932-87c4-76745686b399" xlink:href="kprx-20250331.xsd#kprx_PrepaidResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea8900f9-110e-4fb9-aa22-00e21a91955b" xlink:to="loc_kprx_PrepaidResearchAndDevelopment_9831fe17-4ef4-4932-87c4-76745686b399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_2acd6770-4940-4976-b5fe-a832c100677d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea8900f9-110e-4fb9-aa22-00e21a91955b" xlink:to="loc_us-gaap_PrepaidInsurance_2acd6770-4940-4976-b5fe-a832c100677d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_85424317-0520-4e9c-afc9-22d68370a08c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea8900f9-110e-4fb9-aa22-00e21a91955b" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_85424317-0520-4e9c-afc9-22d68370a08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrepaidGeneralAndAdministrative_b33a7034-0746-4fac-a6fc-d29ef3fcbc11" xlink:href="kprx-20250331.xsd#kprx_PrepaidGeneralAndAdministrative"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea8900f9-110e-4fb9-aa22-00e21a91955b" xlink:to="loc_kprx_PrepaidGeneralAndAdministrative_b33a7034-0746-4fac-a6fc-d29ef3fcbc11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a3826794-7348-41a6-86b5-b0564f58ccd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_OtherTaxReceivablesCurrent_74286ef6-d738-43d6-aa7f-f999926160c9" xlink:href="kprx-20250331.xsd#kprx_OtherTaxReceivablesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesReceivable_a3826794-7348-41a6-86b5-b0564f58ccd6" xlink:to="loc_kprx_OtherTaxReceivablesCurrent_74286ef6-d738-43d6-aa7f-f999926160c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchTaxCreditsReceivableCurrent_9c157107-bd4e-4013-83f9-f01a28187cf6" xlink:href="kprx-20250331.xsd#kprx_ResearchTaxCreditsReceivableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesReceivable_a3826794-7348-41a6-86b5-b0564f58ccd6" xlink:to="loc_kprx_ResearchTaxCreditsReceivableCurrent_9c157107-bd4e-4013-83f9-f01a28187cf6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f027ca2c-bf36-49c3-812d-9135322c43cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3259eef-fe66-4e49-a97f-10d05c40c0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f027ca2c-bf36-49c3-812d-9135322c43cf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3259eef-fe66-4e49-a97f-10d05c40c0fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3bf12dd4-4dc5-4d53-ae5e-f53831a3a761" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f027ca2c-bf36-49c3-812d-9135322c43cf" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3bf12dd4-4dc5-4d53-ae5e-f53831a3a761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_dcbce2d2-36fa-470f-95e1-68bec0d2c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f027ca2c-bf36-49c3-812d-9135322c43cf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_dcbce2d2-36fa-470f-95e1-68bec0d2c2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_035981ec-6962-43b7-b604-8b73efc74e31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f027ca2c-bf36-49c3-812d-9135322c43cf" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_035981ec-6962-43b7-b604-8b73efc74e31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalTrialsCurrent_2973e5c2-79d8-4e56-b701-18603f813c56" xlink:href="kprx-20250331.xsd#kprx_ClinicalTrialsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f027ca2c-bf36-49c3-812d-9135322c43cf" xlink:to="loc_kprx_ClinicalTrialsCurrent_2973e5c2-79d8-4e56-b701-18603f813c56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresAssetsatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3f937cd8-da2d-44d3-a6a6-6fb8fab7b256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8ecf3bb2-2ac2-4522-9064-d72be8a0f474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3f937cd8-da2d-44d3-a6a6-6fb8fab7b256" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8ecf3bb2-2ac2-4522-9064-d72be8a0f474" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_32a0aab4-b6e5-4ebd-8e97-7f88ef13d72b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3f937cd8-da2d-44d3-a6a6-6fb8fab7b256" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_32a0aab4-b6e5-4ebd-8e97-7f88ef13d72b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c1365b24-abd6-418c-be8b-db276458b2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bf63ebef-fdbf-45b0-bea0-87a35bb35051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c1365b24-abd6-418c-be8b-db276458b2f4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bf63ebef-fdbf-45b0-bea0-87a35bb35051" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"/>
  <link:calculationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f03211ba-8e86-433e-bf2a-4c7b1f6b34b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a9f6b595-5738-452e-8a81-0c24545d6bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f03211ba-8e86-433e-bf2a-4c7b1f6b34b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a9f6b595-5738-452e-8a81-0c24545d6bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2fa9f96-0e34-4f0c-b70e-b1bdaab1d587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f03211ba-8e86-433e-bf2a-4c7b1f6b34b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2fa9f96-0e34-4f0c-b70e-b1bdaab1d587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61d87ae2-e14e-42b4-b130-921e49cddaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2c206057-2cfa-4f94-9161-9d1ca0fe2e20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61d87ae2-e14e-42b4-b130-921e49cddaa9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2c206057-2cfa-4f94-9161-9d1ca0fe2e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7a41b5f-2ac2-4800-ad5a-f93be4196430" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61d87ae2-e14e-42b4-b130-921e49cddaa9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7a41b5f-2ac2-4800-ad5a-f93be4196430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8fc1541d-e71f-404f-963c-21473e486ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61d87ae2-e14e-42b4-b130-921e49cddaa9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8fc1541d-e71f-404f-963c-21473e486ba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e59e3df6-d856-48e0-930c-957c868e18bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61d87ae2-e14e-42b4-b130-921e49cddaa9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e59e3df6-d856-48e0-930c-957c868e18bc" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>kprx-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0167d6af-99d4-4c6f-8900-ecd7455d4d35,g:cf0f15d1-3949-48fc-a909-df68c07a7e6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f619eb9-7c66-45cd-a504-5185bf3766a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_StatementTable_1f619eb9-7c66-45cd-a504-5185bf3766a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8d99456b-06ad-4479-970b-ed3c0dddf487" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1f619eb9-7c66-45cd-a504-5185bf3766a7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8d99456b-06ad-4479-970b-ed3c0dddf487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d99456b-06ad-4479-970b-ed3c0dddf487_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8d99456b-06ad-4479-970b-ed3c0dddf487" xlink:to="loc_us-gaap_ClassOfStockDomain_8d99456b-06ad-4479-970b-ed3c0dddf487_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8d99456b-06ad-4479-970b-ed3c0dddf487" xlink:to="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2056f41d-d1b3-4bfa-82cb-8402a59eaad4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2056f41d-d1b3-4bfa-82cb-8402a59eaad4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_50b4dd30-13e8-410f-a9bb-3b97845d20bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_50b4dd30-13e8-410f-a9bb-3b97845d20bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_fd8d1661-6fb5-4539-b582-e67aa0fbca7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_fd8d1661-6fb5-4539-b582-e67aa0fbca7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_da031fe2-0bd0-44f3-9ca4-7824a828f7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_da031fe2-0bd0-44f3-9ca4-7824a828f7a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_39fd5c00-ed54-4533-a698-134ca0356d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_39fd5c00-ed54-4533-a698-134ca0356d4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_aef3d88a-b10e-4256-b9a1-362b9c572118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_aef3d88a-b10e-4256-b9a1-362b9c572118" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d23b5be-cb5c-4a4f-b2fb-f684a1572134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d23b5be-cb5c-4a4f-b2fb-f684a1572134" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b6834c56-81ec-4953-8671-d93f61ad9a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b6834c56-81ec-4953-8671-d93f61ad9a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreferredStockDesignatedShares_b6b3144c-8e7c-4591-a0d1-22f210509345" xlink:href="kprx-20250331.xsd#kprx_PreferredStockDesignatedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_kprx_PreferredStockDesignatedShares_b6b3144c-8e7c-4591-a0d1-22f210509345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_04107e4f-74bb-4d5f-99c1-1e8a5d58f499" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_04107e4f-74bb-4d5f-99c1-1e8a5d58f499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7b56d383-3beb-4eb6-b1bc-c2cd2c9eef35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7b56d383-3beb-4eb6-b1bc-c2cd2c9eef35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_85f5d74d-b90f-44a3-a0d5-8906cbde0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_85f5d74d-b90f-44a3-a0d5-8906cbde0d3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ed3b8bd3-aa29-4cb9-8245-4280d5450e05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ed3b8bd3-aa29-4cb9-8245-4280d5450e05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d6940082-5cb8-48e6-b9c6-1093f9d32ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockSharesIssued_d6940082-5cb8-48e6-b9c6-1093f9d32ea9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f2f7c218-65fa-49f0-a249-a4f1cd727919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f2f7c218-65fa-49f0-a249-a4f1cd727919" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6f9267e-1cdc-4597-baa0-857a73df6b72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c6f9267e-1cdc-4597-baa0-857a73df6b72" xlink:to="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b4b6b04c-c21a-492f-b52d-404cffa4d8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b4b6b04c-c21a-492f-b52d-404cffa4d8d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b4b6b04c-c21a-492f-b52d-404cffa4d8d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b4b6b04c-c21a-492f-b52d-404cffa4d8d9" xlink:to="loc_us-gaap_EquityComponentDomain_b4b6b04c-c21a-492f-b52d-404cffa4d8d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b4b6b04c-c21a-492f-b52d-404cffa4d8d9" xlink:to="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9c8f62e6-5fc2-4d8c-8638-a04a24d9d374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_PreferredStockMember_9c8f62e6-5fc2-4d8c-8638-a04a24d9d374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1ca52792-759e-44f7-bf57-13c44ee9269d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_CommonStockMember_1ca52792-759e-44f7-bf57-13c44ee9269d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0c493800-eddc-445e-b68e-3441968e5f20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0c493800-eddc-445e-b68e-3441968e5f20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9329ee05-df71-4c5b-845d-ca96453b90e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_RetainedEarningsMember_9329ee05-df71-4c5b-845d-ca96453b90e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed2b191d-ee75-4b39-8dec-8bed1c57515a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed2b191d-ee75-4b39-8dec-8bed1c57515a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bbb086cf-216c-4634-9f49-a8fe52bc656a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bbb086cf-216c-4634-9f49-a8fe52bc656a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bbb086cf-216c-4634-9f49-a8fe52bc656a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bbb086cf-216c-4634-9f49-a8fe52bc656a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bbb086cf-216c-4634-9f49-a8fe52bc656a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a677b6a-6746-4d49-a12a-20ad2dfc6d86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bbb086cf-216c-4634-9f49-a8fe52bc656a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a677b6a-6746-4d49-a12a-20ad2dfc6d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ec84e09d-32b3-497a-9b0c-6f938dc6bda5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a677b6a-6746-4d49-a12a-20ad2dfc6d86" xlink:to="loc_us-gaap_PrivatePlacementMember_ec84e09d-32b3-497a-9b0c-6f938dc6bda5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6f9267e-1cdc-4597-baa0-857a73df6b72" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7ea55e18-8ac2-453c-b0c3-0c3f5e7aced8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_SharesOutstanding_7ea55e18-8ac2-453c-b0c3-0c3f5e7aced8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d5ebe40-01b9-4ceb-8fdb-c2a2460b7823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_StockholdersEquity_6d5ebe40-01b9-4ceb-8fdb-c2a2460b7823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a11389e-e418-459d-8962-b2603be5c210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a11389e-e418-459d-8962-b2603be5c210" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_424790fb-92c6-4241-a550-8182e48191f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_424790fb-92c6-4241-a550-8182e48191f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_fc98476e-e326-4f9d-94e0-abebf0e19e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_fc98476e-e326-4f9d-94e0-abebf0e19e02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d3a1b44-1d3d-42ff-9274-6a370a76ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_NetIncomeLoss_5d3a1b44-1d3d-42ff-9274-6a370a76ccaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c77fc598-9ad2-4218-97b0-74f095025a93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c77fc598-9ad2-4218-97b0-74f095025a93" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a76fb12-4875-4c3e-92ef-bcd319880f79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a76fb12-4875-4c3e-92ef-bcd319880f79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_76d279c3-b3e9-4097-992a-9212f1f05b0d" xlink:href="kprx-20250331.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_76d279c3-b3e9-4097-992a-9212f1f05b0d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_81a86283-46cf-4206-a16f-18e0c450bece" xlink:href="kprx-20250331.xsd#kprx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_81a86283-46cf-4206-a16f-18e0c450bece" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_92ff5dcb-3c36-4484-867f-2039b7580482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98bd80d9-25b7-4a75-b9ae-000277f8333e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6e78cb9d-35f5-4c39-a292-3e82f5943d52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b1651b1c-13e3-4ff0-96fd-e56d96882887" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6e78cb9d-35f5-4c39-a292-3e82f5943d52" xlink:to="loc_us-gaap_StatementTable_b1651b1c-13e3-4ff0-96fd-e56d96882887" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b1651b1c-13e3-4ff0-96fd-e56d96882887" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40f52565-bf3e-4b9a-9a9d-ea191cffbe94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40f52565-bf3e-4b9a-9a9d-ea191cffbe94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_abd370da-bee5-4d53-af04-ff4ca47c25e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40f52565-bf3e-4b9a-9a9d-ea191cffbe94" xlink:to="loc_us-gaap_PrivatePlacementMember_abd370da-bee5-4d53-af04-ff4ca47c25e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_6b7c9c59-44ca-49a6-9f28-07e3abbb888a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6e78cb9d-35f5-4c39-a292-3e82f5943d52" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_6b7c9c59-44ca-49a6-9f28-07e3abbb888a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3b26344c-d16c-4895-a7fb-b6a708d34285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_StatementTable_3b26344c-d16c-4895-a7fb-b6a708d34285" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_318059f3-d1dd-407e-ae37-393d48e81657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3b26344c-d16c-4895-a7fb-b6a708d34285" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_318059f3-d1dd-407e-ae37-393d48e81657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_318059f3-d1dd-407e-ae37-393d48e81657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_318059f3-d1dd-407e-ae37-393d48e81657" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_318059f3-d1dd-407e-ae37-393d48e81657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b193e52-d3b1-4eb6-b0fa-bd3ed1f6b534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_318059f3-d1dd-407e-ae37-393d48e81657" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b193e52-d3b1-4eb6-b0fa-bd3ed1f6b534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityLineOfCreditMember_5625596a-8cb8-4075-90cd-e31916038f32" xlink:href="kprx-20250331.xsd#kprx_EquityLineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b193e52-d3b1-4eb6-b0fa-bd3ed1f6b534" xlink:to="loc_kprx_EquityLineOfCreditMember_5625596a-8cb8-4075-90cd-e31916038f32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aff93310-91fb-4fac-b105-3ca8007fcc63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:to="loc_us-gaap_NetIncomeLoss_aff93310-91fb-4fac-b105-3ca8007fcc63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f028361d-398f-4342-a089-00ac3b173a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f028361d-398f-4342-a089-00ac3b173a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets_bba446a3-f253-4721-ae0a-9c905fc83437" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_kprx_IncreaseDecreaseInRightOfUseAssets_bba446a3-f253-4721-ae0a-9c905fc83437" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3ddfe15b-7e6d-4033-90b4-de01e772bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_us-gaap_ShareBasedCompensation_3ddfe15b-7e6d-4033-90b4-de01e772bb96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_a4484ab8-2918-4423-a0a6-d9d971b9225d" xlink:href="kprx-20250331.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_a4484ab8-2918-4423-a0a6-d9d971b9225d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_32517d1d-83c8-4eca-b5b5-c59e32f8797e" xlink:href="kprx-20250331.xsd#kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_32517d1d-83c8-4eca-b5b5-c59e32f8797e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e08d9062-5985-495c-ae17-585ff6282022" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e08d9062-5985-495c-ae17-585ff6282022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce9ca1f5-7f90-4b4e-b5e6-852075e696d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce9ca1f5-7f90-4b4e-b5e6-852075e696d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_99510b60-3a53-4ef3-8b53-7ba621f10ded" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseResearchTaxCreditsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_99510b60-3a53-4ef3-8b53-7ba621f10ded" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_aecbbe4c-f68b-4137-bfe0-cde04b9f2f28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_aecbbe4c-f68b-4137-bfe0-cde04b9f2f28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a3891ea7-25c2-4f85-9ee0-31db762eb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a3891ea7-25c2-4f85-9ee0-31db762eb2c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c79c5ba2-37a5-4dfa-a070-a7ccd227ef11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c79c5ba2-37a5-4dfa-a070-a7ccd227ef11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82fca795-356c-4495-abf3-4095266ca1db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82fca795-356c-4495-abf3-4095266ca1db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit_ba0b4a4c-9c45-4b8e-b642-32ceda402083" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInAccruedCollaborationCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit_ba0b4a4c-9c45-4b8e-b642-32ceda402083" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f8b92da5-3133-460c-9af5-3db25d55aaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f8b92da5-3133-460c-9af5-3db25d55aaa3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a33caa6-2cc5-4119-8159-3791c1670580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a33caa6-2cc5-4119-8159-3791c1670580" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9b7ab5d2-8a3c-489a-980b-9229762e378d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9b7ab5d2-8a3c-489a-980b-9229762e378d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8c886725-672c-4cbd-8e41-3e643e46bda6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8c886725-672c-4cbd-8e41-3e643e46bda6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7a51fcfa-d34c-4c10-aefd-4e570914be06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7a51fcfa-d34c-4c10-aefd-4e570914be06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34390586-14e0-41f2-8525-a4db72b506c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34390586-14e0-41f2-8525-a4db72b506c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b8a0930b-a6ce-46bf-9e47-f9ef9362f362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b8a0930b-a6ce-46bf-9e47-f9ef9362f362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_19ce37f6-e815-4510-895a-a6e708e63da8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_19ce37f6-e815-4510-895a-a6e708e63da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0f5fb657-7a1b-43d1-91e0-71d84ccbf072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0f5fb657-7a1b-43d1-91e0-71d84ccbf072" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb7152f2-4317-45db-9973-688f8129e719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb7152f2-4317-45db-9973-688f8129e719" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a5b2c77-bbaa-4b50-abc0-bde729b899bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a5b2c77-bbaa-4b50-abc0-bde729b899bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19ea5264-5100-4897-b7f3-19adf03ed930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19ea5264-5100-4897-b7f3-19adf03ed930" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16795d21-72b8-4de5-bb7b-eec61294279a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16795d21-72b8-4de5-bb7b-eec61294279a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec88bd56-f5bc-4a6f-94ca-c3159c24cff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_865cc3a3-e810-4564-b257-983804a626d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_865cc3a3-e810-4564-b257-983804a626d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35c02a23-92a0-404a-91b1-36e434732629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_865cc3a3-e810-4564-b257-983804a626d3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35c02a23-92a0-404a-91b1-36e434732629" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BusinessPresentationandRecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_62f06a6f-2a70-4f37-9f89-29599775224b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_62f06a6f-2a70-4f37-9f89-29599775224b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0395885c-e333-44c0-b849-05e6400ee203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_62f06a6f-2a70-4f37-9f89-29599775224b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0395885c-e333-44c0-b849-05e6400ee203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0395885c-e333-44c0-b849-05e6400ee203_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0395885c-e333-44c0-b849-05e6400ee203" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0395885c-e333-44c0-b849-05e6400ee203_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3fa7bc01-751f-4970-8c87-2c80b832899b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0395885c-e333-44c0-b849-05e6400ee203" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3fa7bc01-751f-4970-8c87-2c80b832899b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7bbd5c99-5786-4ca6-992e-c66056f3712b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3fa7bc01-751f-4970-8c87-2c80b832899b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7bbd5c99-5786-4ca6-992e-c66056f3712b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cdf23d1-c726-4e07-9694-2ca245a1fac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cdf23d1-c726-4e07-9694-2ca245a1fac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ce03f01e-41bd-4ab8-ac2e-e5db95bc8ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_ShortTermInvestments_ce03f01e-41bd-4ab8-ac2e-e5db95bc8ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b74bdd-33ad-42dc-989d-c0617b8a36ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b74bdd-33ad-42dc-989d-c0617b8a36ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborativeArrangementNumberOfPerformanceObligations_e27ec87a-7c3e-444b-99c2-2f02cc29bbbe" xlink:href="kprx-20250331.xsd#kprx_CollaborativeArrangementNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_kprx_CollaborativeArrangementNumberOfPerformanceObligations_e27ec87a-7c3e-444b-99c2-2f02cc29bbbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_939430ff-5c95-4282-a77f-a7d45200f818" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_ProceedsFromCollaborators_939430ff-5c95-4282-a77f-a7d45200f818" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_16bf87ca-66a2-4ab4-afb9-18940794f0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_16bf87ca-66a2-4ab4-afb9-18940794f0e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a30eda46-1e08-4505-af6c-192d036b4459" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a30eda46-1e08-4505-af6c-192d036b4459" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfGeographicSegments_bfff6677-6f21-4e88-8750-4c2ec41d23db" xlink:href="kprx-20250331.xsd#kprx_NumberOfGeographicSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_kprx_NumberOfGeographicSegments_bfff6677-6f21-4e88-8750-4c2ec41d23db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_9ecaec8b-1317-4972-a44c-cbdebe49f25c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_IncomeTaxReceivable_9ecaec8b-1317-4972-a44c-cbdebe49f25c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_eed7449a-d4b1-45ce-b74c-aef33310b6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_eed7449a-d4b1-45ce-b74c-aef33310b6f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_998dd5dc-5a1d-4642-9404-d3ef9e9103c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_998dd5dc-5a1d-4642-9404-d3ef9e9103c9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6620cee-4333-4d5c-b7b1-362e8dda30f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6620cee-4333-4d5c-b7b1-362e8dda30f4" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32d445ed-7ac8-4b56-9451-6232ce621d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32d445ed-7ac8-4b56-9451-6232ce621d9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c84930e-499a-4159-b034-3ec145449962" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32d445ed-7ac8-4b56-9451-6232ce621d9e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c84930e-499a-4159-b034-3ec145449962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c84930e-499a-4159-b034-3ec145449962_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c84930e-499a-4159-b034-3ec145449962" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c84930e-499a-4159-b034-3ec145449962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c84930e-499a-4159-b034-3ec145449962" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_60a2797d-b6ed-46d2-8dfc-2fab5fde166c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_60a2797d-b6ed-46d2-8dfc-2fab5fde166c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_056e681c-adaa-4332-b20a-6dce8ee04eac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_056e681c-adaa-4332-b20a-6dce8ee04eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0da28af5-be70-4493-8af5-e8115221559c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0da28af5-be70-4493-8af5-e8115221559c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_41891d07-c243-4dde-b252-79bf0b4d5849" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_41891d07-c243-4dde-b252-79bf0b4d5849" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a150969-fef9-4dcb-9e45-4edd71a7c1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a150969-fef9-4dcb-9e45-4edd71a7c1d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b41a27e6-a7a8-43c1-beb0-17716f874463" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b41a27e6-a7a8-43c1-beb0-17716f874463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aa7bf5f3-a001-4106-ab8a-c936264f41a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aa7bf5f3-a001-4106-ab8a-c936264f41a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8208176-c87f-4d06-91a5-7d9173a588da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8208176-c87f-4d06-91a5-7d9173a588da" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4f29ba91-727f-4146-aa06-e7918794e996" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4f29ba91-727f-4146-aa06-e7918794e996" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4b8aef26-0380-4fe7-bb1a-bfb2b3837845" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4f29ba91-727f-4146-aa06-e7918794e996" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4b8aef26-0380-4fe7-bb1a-bfb2b3837845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b8aef26-0380-4fe7-bb1a-bfb2b3837845_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b8aef26-0380-4fe7-bb1a-bfb2b3837845" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b8aef26-0380-4fe7-bb1a-bfb2b3837845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b8aef26-0380-4fe7-bb1a-bfb2b3837845" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b5a92589-2dfc-4ded-a2f5-4a1a40fe43bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b5a92589-2dfc-4ded-a2f5-4a1a40fe43bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3ffb170c-fdf0-44c0-8c8a-73d01753d026" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3ffb170c-fdf0-44c0-8c8a-73d01753d026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_9544150b-a897-4d4f-bcff-9c47a741effe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_9544150b-a897-4d4f-bcff-9c47a741effe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2b7881cc-441a-4ff2-a748-d72b51345459" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_9544150b-a897-4d4f-bcff-9c47a741effe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2b7881cc-441a-4ff2-a748-d72b51345459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_6e267423-57ac-4f7e-836f-2ab85157a6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_6e267423-57ac-4f7e-836f-2ab85157a6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d4b959fb-9aae-4cbb-8969-2631380f28d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_6e267423-57ac-4f7e-836f-2ab85157a6fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d4b959fb-9aae-4cbb-8969-2631380f28d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_a43bdde2-b34b-4111-be8b-b3c3a6252744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_a43bdde2-b34b-4111-be8b-b3c3a6252744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1973b3d3-79ac-4a0e-8ca7-3a8d782cd7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_a43bdde2-b34b-4111-be8b-b3c3a6252744" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1973b3d3-79ac-4a0e-8ca7-3a8d782cd7b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresAssetsatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc5ac154-bcd9-45b9-a5ec-c89c32a395af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc5ac154-bcd9-45b9-a5ec-c89c32a395af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc5ac154-bcd9-45b9-a5ec-c89c32a395af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc5ac154-bcd9-45b9-a5ec-c89c32a395af" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dc5ac154-bcd9-45b9-a5ec-c89c32a395af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1e11e4e-1833-42dd-9bd3-991da0919431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc5ac154-bcd9-45b9-a5ec-c89c32a395af" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1e11e4e-1833-42dd-9bd3-991da0919431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3107d4d1-e9c4-4782-8b63-7f2237027f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1e11e4e-1833-42dd-9bd3-991da0919431" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3107d4d1-e9c4-4782-8b63-7f2237027f4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_075f002d-144c-4159-af65-c0cc2af84b97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_075f002d-144c-4159-af65-c0cc2af84b97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_075f002d-144c-4159-af65-c0cc2af84b97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_075f002d-144c-4159-af65-c0cc2af84b97" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_075f002d-144c-4159-af65-c0cc2af84b97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_075f002d-144c-4159-af65-c0cc2af84b97" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc009baa-1977-4e65-b7ba-9125adb78c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc009baa-1977-4e65-b7ba-9125adb78c55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a9f5a97-046c-4b65-a9e3-ca73d35f620c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a9f5a97-046c-4b65-a9e3-ca73d35f620c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_95728a20-1da0-423f-a158-ed796292b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_95728a20-1da0-423f-a158-ed796292b50c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_43d063ba-e6eb-407c-9c10-27f5f9f91f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_43d063ba-e6eb-407c-9c10-27f5f9f91f2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_43d063ba-e6eb-407c-9c10-27f5f9f91f2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_43d063ba-e6eb-407c-9c10-27f5f9f91f2c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_43d063ba-e6eb-407c-9c10-27f5f9f91f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_43d063ba-e6eb-407c-9c10-27f5f9f91f2c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_11d75d14-3f0d-4363-a938-72fad0021164" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_11d75d14-3f0d-4363-a938-72fad0021164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d5b98428-be9a-49c0-bb9f-98d504161905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d5b98428-be9a-49c0-bb9f-98d504161905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5477503d-66b6-48fa-9316-9857eeaa9ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5477503d-66b6-48fa-9316-9857eeaa9ed2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5477503d-66b6-48fa-9316-9857eeaa9ed2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5477503d-66b6-48fa-9316-9857eeaa9ed2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5477503d-66b6-48fa-9316-9857eeaa9ed2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5477503d-66b6-48fa-9316-9857eeaa9ed2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_be7679ef-4913-4d96-b2de-9c50b19e5a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_be7679ef-4913-4d96-b2de-9c50b19e5a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29138b89-5444-4e63-917f-8b5bc3221073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29138b89-5444-4e63-917f-8b5bc3221073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c1b2f80c-9383-4810-891f-9fc889929cae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c1b2f80c-9383-4810-891f-9fc889929cae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_0f350cf3-3f92-43e9-928c-f4695eea3db1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_0f350cf3-3f92-43e9-928c-f4695eea3db1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e326cdc-5c73-4b09-acb6-45a48dc0c070" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e326cdc-5c73-4b09-acb6-45a48dc0c070" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9e2164fb-dfc4-4ccc-bac8-f7c45ebe96d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9e2164fb-dfc4-4ccc-bac8-f7c45ebe96d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_78ee2704-b757-42bf-89d5-7d07ef3ab14f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_78ee2704-b757-42bf-89d5-7d07ef3ab14f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7946d132-53fc-4538-bdcd-5bde06949a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7946d132-53fc-4538-bdcd-5bde06949a2f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c4737c75-adc7-4217-95be-50c8d88e4dac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c4737c75-adc7-4217-95be-50c8d88e4dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c4737c75-adc7-4217-95be-50c8d88e4dac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c4737c75-adc7-4217-95be-50c8d88e4dac" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c4737c75-adc7-4217-95be-50c8d88e4dac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7319ac1-a91f-4612-b14a-86c576ccb194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c4737c75-adc7-4217-95be-50c8d88e4dac" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7319ac1-a91f-4612-b14a-86c576ccb194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1acf9da0-f201-4504-9155-7896aab501c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7319ac1-a91f-4612-b14a-86c576ccb194" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1acf9da0-f201-4504-9155-7896aab501c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_696b4938-35b8-42b1-863d-d14764618231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_696b4938-35b8-42b1-863d-d14764618231" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696b4938-35b8-42b1-863d-d14764618231_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_696b4938-35b8-42b1-863d-d14764618231" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_696b4938-35b8-42b1-863d-d14764618231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fccfd5c-9cfd-4d73-9247-a12c4dc4e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_696b4938-35b8-42b1-863d-d14764618231" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fccfd5c-9cfd-4d73-9247-a12c4dc4e85d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ddbcf8c4-8b32-4800-84c8-2f485dd95900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fccfd5c-9cfd-4d73-9247-a12c4dc4e85d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ddbcf8c4-8b32-4800-84c8-2f485dd95900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7946d132-53fc-4538-bdcd-5bde06949a2f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4c6949dc-5c53-4a93-a2d2-4a3d96c57e04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4c6949dc-5c53-4a93-a2d2-4a3d96c57e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fb05a44f-29e2-4070-8e37-5fec93e44dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fb05a44f-29e2-4070-8e37-5fec93e44dbf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresUnobservableLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8c629443-6078-426e-85df-8d6415ec4dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8c629443-6078-426e-85df-8d6415ec4dcc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_66a73028-33c8-4b3c-892c-7d77b785c60c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_us-gaap_ValuationTechniqueAxis_66a73028-33c8-4b3c-892c-7d77b785c60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_66a73028-33c8-4b3c-892c-7d77b785c60c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_66a73028-33c8-4b3c-892c-7d77b785c60c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_66a73028-33c8-4b3c-892c-7d77b785c60c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f3fbe5fb-82e4-4b16-9bb0-121907721a43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_66a73028-33c8-4b3c-892c-7d77b785c60c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f3fbe5fb-82e4-4b16-9bb0-121907721a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_9e8fb53a-1e56-4dfe-b38e-233821037550" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f3fbe5fb-82e4-4b16-9bb0-121907721a43" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_9e8fb53a-1e56-4dfe-b38e-233821037550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3e6d487c-4667-44d8-b5ab-7002ed7239a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3e6d487c-4667-44d8-b5ab-7002ed7239a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3e6d487c-4667-44d8-b5ab-7002ed7239a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3e6d487c-4667-44d8-b5ab-7002ed7239a5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3e6d487c-4667-44d8-b5ab-7002ed7239a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3e6d487c-4667-44d8-b5ab-7002ed7239a5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2ec593b8-5beb-417c-8c9b-2c89b82f1260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2ec593b8-5beb-417c-8c9b-2c89b82f1260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProbabilityOfSuccessForPaymentMember_046a847c-2a30-40a5-a796-891cd54e244c" xlink:href="kprx-20250331.xsd#kprx_ProbabilityOfSuccessForPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:to="loc_kprx_ProbabilityOfSuccessForPaymentMember_046a847c-2a30-40a5-a796-891cd54e244c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_49e45abf-9b68-4f5e-b895-5d8e4d574958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_49e45abf-9b68-4f5e-b895-5d8e4d574958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_49e45abf-9b68-4f5e-b895-5d8e4d574958_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_49e45abf-9b68-4f5e-b895-5d8e4d574958" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_49e45abf-9b68-4f5e-b895-5d8e4d574958_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_49e45abf-9b68-4f5e-b895-5d8e4d574958" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_e242a480-6ba7-4934-b923-cbbadec75de1" xlink:href="kprx-20250331.xsd#kprx_BayonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:to="loc_kprx_BayonMember_e242a480-6ba7-4934-b923-cbbadec75de1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesMember_3f65acbb-ae40-43c8-8d31-8be47fb67f2a" xlink:href="kprx-20250331.xsd#kprx_PanoptesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:to="loc_kprx_PanoptesMember_3f65acbb-ae40-43c8-8d31-8be47fb67f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f0b43d01-e6b0-4519-893c-cb6ed9094c81" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_srt_RangeAxis_f0b43d01-e6b0-4519-893c-cb6ed9094c81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f0b43d01-e6b0-4519-893c-cb6ed9094c81_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f0b43d01-e6b0-4519-893c-cb6ed9094c81" xlink:to="loc_srt_RangeMember_f0b43d01-e6b0-4519-893c-cb6ed9094c81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f0b43d01-e6b0-4519-893c-cb6ed9094c81" xlink:to="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_24d5201b-acd1-4beb-95a2-0c7a829b93e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:to="loc_srt_MinimumMember_24d5201b-acd1-4beb-95a2-0c7a829b93e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_101ded21-ea6e-4bb2-8f5b-f991f49b7184" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:to="loc_srt_MaximumMember_101ded21-ea6e-4bb2-8f5b-f991f49b7184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_9f6ef293-3db8-48d3-b5ea-f44735c7d097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8c629443-6078-426e-85df-8d6415ec4dcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_9f6ef293-3db8-48d3-b5ea-f44735c7d097" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9d13d14d-4221-4f81-8b06-6677684728ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9d13d14d-4221-4f81-8b06-6677684728ac" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6c927a89-651f-40fd-89bf-62750ce401aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6c927a89-651f-40fd-89bf-62750ce401aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6c927a89-651f-40fd-89bf-62750ce401aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6c927a89-651f-40fd-89bf-62750ce401aa" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6c927a89-651f-40fd-89bf-62750ce401aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6c927a89-651f-40fd-89bf-62750ce401aa" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember_908635a5-38c1-459d-89ff-50b33a82b90c" xlink:href="kprx-20250331.xsd#kprx_ProbabilityOfSuccessForDevelopmentPhaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:to="loc_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember_908635a5-38c1-459d-89ff-50b33a82b90c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_99a34904-670f-4533-bf22-b36642758b60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_99a34904-670f-4533-bf22-b36642758b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_eaab47c3-7933-4023-9b33-a66bbf1e9a35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_us-gaap_ValuationTechniqueAxis_eaab47c3-7933-4023-9b33-a66bbf1e9a35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_eaab47c3-7933-4023-9b33-a66bbf1e9a35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_eaab47c3-7933-4023-9b33-a66bbf1e9a35" xlink:to="loc_us-gaap_ValuationTechniqueDomain_eaab47c3-7933-4023-9b33-a66bbf1e9a35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_25c5e349-02d7-4ad3-9aed-7c8b0f5a208c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_eaab47c3-7933-4023-9b33-a66bbf1e9a35" xlink:to="loc_us-gaap_ValuationTechniqueDomain_25c5e349-02d7-4ad3-9aed-7c8b0f5a208c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MultiPeriodExcessEarningsMethodMember_7b98bb29-f6d5-4ea3-a834-b9cf8ab26d54" xlink:href="kprx-20250331.xsd#kprx_MultiPeriodExcessEarningsMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_25c5e349-02d7-4ad3-9aed-7c8b0f5a208c" xlink:to="loc_kprx_MultiPeriodExcessEarningsMethodMember_7b98bb29-f6d5-4ea3-a834-b9cf8ab26d54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87b49825-49d1-42c4-8ac9-afde1d9231f6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_srt_ProductOrServiceAxis_87b49825-49d1-42c4-8ac9-afde1d9231f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87b49825-49d1-42c4-8ac9-afde1d9231f6_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_87b49825-49d1-42c4-8ac9-afde1d9231f6" xlink:to="loc_srt_ProductsAndServicesDomain_87b49825-49d1-42c4-8ac9-afde1d9231f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_87b49825-49d1-42c4-8ac9-afde1d9231f6" xlink:to="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO104Member_6226600f-b455-4df2-9418-5618e745f602" xlink:href="kprx-20250331.xsd#kprx_KIO104Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:to="loc_kprx_KIO104Member_6226600f-b455-4df2-9418-5618e745f602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO301Member_27b1dafd-8d15-44c0-8115-3748f044f9d5" xlink:href="kprx-20250331.xsd#kprx_KIO301Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:to="loc_kprx_KIO301Member_27b1dafd-8d15-44c0-8115-3748f044f9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dbea0dcb-8830-4755-9e9c-8e96f29badcf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_srt_RangeAxis_dbea0dcb-8830-4755-9e9c-8e96f29badcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dbea0dcb-8830-4755-9e9c-8e96f29badcf_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dbea0dcb-8830-4755-9e9c-8e96f29badcf" xlink:to="loc_srt_RangeMember_dbea0dcb-8830-4755-9e9c-8e96f29badcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dbea0dcb-8830-4755-9e9c-8e96f29badcf" xlink:to="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8c3579b4-e0a9-4f6b-9ec3-663212a41055" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:to="loc_srt_MinimumMember_8c3579b4-e0a9-4f6b-9ec3-663212a41055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d934262-e627-4a5d-adf4-edcf27f4502e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:to="loc_srt_MaximumMember_5d934262-e627-4a5d-adf4-edcf27f4502e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_InProcessResearchAndDevelopmentMeasurementInput_9825bd70-1fa8-4142-ba62-0546701ab125" xlink:href="kprx-20250331.xsd#kprx_InProcessResearchAndDevelopmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9d13d14d-4221-4f81-8b06-6677684728ac" xlink:to="loc_kprx_InProcessResearchAndDevelopmentMeasurementInput_9825bd70-1fa8-4142-ba62-0546701ab125" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CapitalStockDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7f2af116-e82a-42ad-bc61-9eb40331a878" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:to="loc_srt_CounterpartyNameAxis_7f2af116-e82a-42ad-bc61-9eb40331a878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7f2af116-e82a-42ad-bc61-9eb40331a878_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7f2af116-e82a-42ad-bc61-9eb40331a878" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7f2af116-e82a-42ad-bc61-9eb40331a878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65cde7ac-21ce-4ada-8456-4d73447b6ff0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7f2af116-e82a-42ad-bc61-9eb40331a878" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65cde7ac-21ce-4ada-8456-4d73447b6ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MaximGroupLLCMember_cfc598b3-76b4-4320-b2fc-68066c257449" xlink:href="kprx-20250331.xsd#kprx_MaximGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65cde7ac-21ce-4ada-8456-4d73447b6ff0" xlink:to="loc_kprx_MaximGroupLLCMember_cfc598b3-76b4-4320-b2fc-68066c257449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e43c408e-ea37-45f6-8803-bd904ead0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e43c408e-ea37-45f6-8803-bd904ead0de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e43c408e-ea37-45f6-8803-bd904ead0de7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e43c408e-ea37-45f6-8803-bd904ead0de7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e43c408e-ea37-45f6-8803-bd904ead0de7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e43c408e-ea37-45f6-8803-bd904ead0de7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreFundedWarrantsMember_dbc7d4e3-c755-499b-a522-c48c1ca15f42" xlink:href="kprx-20250331.xsd#kprx_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:to="loc_kprx_PreFundedWarrantsMember_dbc7d4e3-c755-499b-a522-c48c1ca15f42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_TrancheAWarrantsMember_f5010aca-32dd-4e74-981a-922df51b59d4" xlink:href="kprx-20250331.xsd#kprx_TrancheAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:to="loc_kprx_TrancheAWarrantsMember_f5010aca-32dd-4e74-981a-922df51b59d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_TrancheBWarrantsMember_bbc897a5-2e50-4c84-b638-eab39904fb71" xlink:href="kprx-20250331.xsd#kprx_TrancheBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:to="loc_kprx_TrancheBWarrantsMember_bbc897a5-2e50-4c84-b638-eab39904fb71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c10386f8-4f33-45d8-9058-4d3f8b0aa0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c10386f8-4f33-45d8-9058-4d3f8b0aa0f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_971f27b8-b052-467f-b77e-12e3f48c0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_971f27b8-b052-467f-b77e-12e3f48c0fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f6dadf1b-a82e-402a-8daa-f6260467f358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f6dadf1b-a82e-402a-8daa-f6260467f358" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f2abe262-4b77-42c1-af5c-5d999e5729fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f2abe262-4b77-42c1-af5c-5d999e5729fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c98a8eab-8eda-46d3-91fd-d00ac6f95c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c98a8eab-8eda-46d3-91fd-d00ac6f95c7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_97f5dd4e-337a-4708-86af-728d42df4d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_97f5dd4e-337a-4708-86af-728d42df4d8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightThresholdTradingDays_07b09701-280a-456c-8efb-7fcdd2afce01" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_kprx_ClassOfWarrantOrRightThresholdTradingDays_07b09701-280a-456c-8efb-7fcdd2afce01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock_8d045542-c5dc-42df-b389-dfdf97340ed2" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock_8d045542-c5dc-42df-b389-dfdf97340ed2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_677a0e2e-48df-4841-9dab-577bfcdbd41e" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_677a0e2e-48df-4841-9dab-577bfcdbd41e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c35391e7-b2f5-4597-88ac-e2fe1c9d9cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c35391e7-b2f5-4597-88ac-e2fe1c9d9cd6" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#WarrantsScheduleofWarrantActivityDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6adcd96d-0c86-4c56-a197-ce304660366d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6adcd96d-0c86-4c56-a197-ce304660366d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e946b159-93fd-4f62-8d27-c91e45a15c86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6adcd96d-0c86-4c56-a197-ce304660366d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e946b159-93fd-4f62-8d27-c91e45a15c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e946b159-93fd-4f62-8d27-c91e45a15c86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e946b159-93fd-4f62-8d27-c91e45a15c86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e946b159-93fd-4f62-8d27-c91e45a15c86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ec62ec14-cef8-4a6e-a47e-5a4949665105" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e946b159-93fd-4f62-8d27-c91e45a15c86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ec62ec14-cef8-4a6e-a47e-5a4949665105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c1ce99fe-d34f-4875-94f0-e4bd966783c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ec62ec14-cef8-4a6e-a47e-5a4949665105" xlink:to="loc_us-gaap_WarrantMember_c1ce99fe-d34f-4875-94f0-e4bd966783c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:to="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_98aaa1c0-30c0-40fb-b5ae-c67cc4a43855" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_98aaa1c0-30c0-40fb-b5ae-c67cc4a43855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a849487-168d-4d69-afbc-c8cc3ad1fbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a849487-168d-4d69-afbc-c8cc3ad1fbf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9412079-ba1e-4cda-963e-e71ec34e499a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9412079-ba1e-4cda-963e-e71ec34e499a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_76d29329-c467-4efb-8156-ecaad6bffd5d" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_76d29329-c467-4efb-8156-ecaad6bffd5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef59c6e0-6949-409a-b70c-4fa451bd07f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_46469396-76ab-485d-80fb-bfbe1d133bdc" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_46469396-76ab-485d-80fb-bfbe1d133bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_dc1ac5fb-3379-4081-b6bb-60bef1c9d888" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_dc1ac5fb-3379-4081-b6bb-60bef1c9d888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice_db1d33e9-6e34-484b-b6e7-3554ad02ace7" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice_db1d33e9-6e34-484b-b6e7-3554ad02ace7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_d6121212-8643-40a4-990f-f62459d6d984" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_d6121212-8643-40a4-990f-f62459d6d984" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_b5230bc4-8e4f-45a6-a6bb-21307bce7823" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_a9710120-f04f-41c4-bcec-7f9c8e7a1a56" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_a9710120-f04f-41c4-bcec-7f9c8e7a1a56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7c924e58-712e-49df-9779-db6908d5b2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_a9710120-f04f-41c4-bcec-7f9c8e7a1a56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7c924e58-712e-49df-9779-db6908d5b2b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#NetLossIncomeperShareBasicandDilutedDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3484533-ddcd-4e5f-adc7-1d57614ccd42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3484533-ddcd-4e5f-adc7-1d57614ccd42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f029790-1653-43f6-9772-0521119b38ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3484533-ddcd-4e5f-adc7-1d57614ccd42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f029790-1653-43f6-9772-0521119b38ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f029790-1653-43f6-9772-0521119b38ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f029790-1653-43f6-9772-0521119b38ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f029790-1653-43f6-9772-0521119b38ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f029790-1653-43f6-9772-0521119b38ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cb7c2cc8-34d0-42b7-bc2c-e6c6063dd0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_WarrantMember_cb7c2cc8-34d0-42b7-bc2c-e6c6063dd0e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dbb98f78-f362-46d1-bd78-01cd4ca2292a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dbb98f78-f362-46d1-bd78-01cd4ca2292a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5b8e97d8-6b74-459f-b65e-8a435c9c98cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_RestrictedStockMember_5b8e97d8-6b74-459f-b65e-8a435c9c98cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncumulativePreferredStockMember_29a2cc70-2368-41df-a0f8-d8f98510090f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncumulativePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_NoncumulativePreferredStockMember_29a2cc70-2368-41df-a0f8-d8f98510090f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ae7666bd-9b8e-439f-bab0-e1e25ad1fa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_CommonStockMember_ae7666bd-9b8e-439f-bab0-e1e25ad1fa9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ad1e282c-a8b2-4722-ab2e-c9d7f5b74e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ad1e282c-a8b2-4722-ab2e-c9d7f5b74e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a732e879-9888-43d4-add3-eb29d6f1703a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a732e879-9888-43d4-add3-eb29d6f1703a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ff3f13d-e092-402a-bf78-cfe5a80b61be" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_srt_RangeAxis_4ff3f13d-e092-402a-bf78-cfe5a80b61be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ff3f13d-e092-402a-bf78-cfe5a80b61be_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4ff3f13d-e092-402a-bf78-cfe5a80b61be" xlink:to="loc_srt_RangeMember_4ff3f13d-e092-402a-bf78-cfe5a80b61be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4ff3f13d-e092-402a-bf78-cfe5a80b61be" xlink:to="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3be816f-4edc-4c26-9bf9-6c1f0587bb05" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:to="loc_srt_MinimumMember_d3be816f-4edc-4c26-9bf9-6c1f0587bb05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_245280c8-6652-4618-b1b1-cdbced5b8638" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:to="loc_srt_MaximumMember_245280c8-6652-4618-b1b1-cdbced5b8638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f087ae74-657d-4c08-8df9-50dba2478144" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_srt_TitleOfIndividualAxis_f087ae74-657d-4c08-8df9-50dba2478144" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f087ae74-657d-4c08-8df9-50dba2478144_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_f087ae74-657d-4c08-8df9-50dba2478144" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f087ae74-657d-4c08-8df9-50dba2478144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_020386a0-29a6-495b-8593-7cd1a4f020cd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_f087ae74-657d-4c08-8df9-50dba2478144" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_020386a0-29a6-495b-8593-7cd1a4f020cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_d7b021b5-1281-4010-9aed-c1c7529566ee" xlink:href="kprx-20250331.xsd#kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_020386a0-29a6-495b-8593-7cd1a4f020cd" xlink:to="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_d7b021b5-1281-4010-9aed-c1c7529566ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2adf53e2-45b5-4a15-8323-229a7ce589d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_us-gaap_PlanNameAxis_2adf53e2-45b5-4a15-8323-229a7ce589d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2adf53e2-45b5-4a15-8323-229a7ce589d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2adf53e2-45b5-4a15-8323-229a7ce589d8" xlink:to="loc_us-gaap_PlanNameDomain_2adf53e2-45b5-4a15-8323-229a7ce589d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2adf53e2-45b5-4a15-8323-229a7ce589d8" xlink:to="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityIncentivePlan2014Member_103e7b8c-68b9-4e98-9e03-b7c0172aebbe" xlink:href="kprx-20250331.xsd#kprx_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:to="loc_kprx_EquityIncentivePlan2014Member_103e7b8c-68b9-4e98-9e03-b7c0172aebbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeStockPurchasePlanMember_81d3fa8e-55da-4c95-895f-b8b7bd6b5bed" xlink:href="kprx-20250331.xsd#kprx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:to="loc_kprx_EmployeeStockPurchasePlanMember_81d3fa8e-55da-4c95-895f-b8b7bd6b5bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd0c0fc9-d193-40e7-8730-ad6923618e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_us-gaap_AwardTypeAxis_cd0c0fc9-d193-40e7-8730-ad6923618e29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd0c0fc9-d193-40e7-8730-ad6923618e29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cd0c0fc9-d193-40e7-8730-ad6923618e29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd0c0fc9-d193-40e7-8730-ad6923618e29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cd0c0fc9-d193-40e7-8730-ad6923618e29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10274435-1385-48d5-ab38-3c72e1aeba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10274435-1385-48d5-ab38-3c72e1aeba5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5e8eeced-f2bc-44ea-ab23-a7cae5350b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:to="loc_us-gaap_RestrictedStockMember_5e8eeced-f2bc-44ea-ab23-a7cae5350b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7134ce7e-ab2e-418d-a1da-2eeecef43ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_us-gaap_VestingAxis_7134ce7e-ab2e-418d-a1da-2eeecef43ab1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7134ce7e-ab2e-418d-a1da-2eeecef43ab1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7134ce7e-ab2e-418d-a1da-2eeecef43ab1" xlink:to="loc_us-gaap_VestingDomain_7134ce7e-ab2e-418d-a1da-2eeecef43ab1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7134ce7e-ab2e-418d-a1da-2eeecef43ab1" xlink:to="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a712b11-242b-420b-a299-1820b2a3cde8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a712b11-242b-420b-a299-1820b2a3cde8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7ddc191-7160-4bdd-a09c-f1c7621fd3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7ddc191-7160-4bdd-a09c-f1c7621fd3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfExercisePrice_99a6d023-b7f3-4555-909b-8e667af782f7" xlink:href="kprx-20250331.xsd#kprx_PercentageOfExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_kprx_PercentageOfExercisePrice_99a6d023-b7f3-4555-909b-8e667af782f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f765fcf9-ce25-4316-9b5b-20e66172dcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f765fcf9-ce25-4316-9b5b-20e66172dcb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_95aab066-be0a-4774-8641-5d674f447287" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_95aab066-be0a-4774-8641-5d674f447287" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7477729e-8270-494c-8548-f2fcaf695555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7477729e-8270-494c-8548-f2fcaf695555" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fa9069fc-9d14-47fe-87ca-2ecfb9fccc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fa9069fc-9d14-47fe-87ca-2ecfb9fccc9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0e1d6369-ca0f-459f-9380-02288eecbe65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0e1d6369-ca0f-459f-9380-02288eecbe65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af905ee8-dd79-41c4-a1a1-d752cf6cea85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af905ee8-dd79-41c4-a1a1-d752cf6cea85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2ffc1635-a082-4b97-919b-8cd6a127cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2ffc1635-a082-4b97-919b-8cd6a127cb85" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2547bfdb-d01e-4b18-80b2-3c56d0125306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2547bfdb-d01e-4b18-80b2-3c56d0125306" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_10bbb69c-6800-4768-abfd-34d7a39577dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_10bbb69c-6800-4768-abfd-34d7a39577dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a169b6ac-4a5d-47af-9823-00a28e958d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a169b6ac-4a5d-47af-9823-00a28e958d2a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e621e15b-8589-4a80-a33a-016d313a7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_SharePrice_e621e15b-8589-4a80-a33a-016d313a7a1e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d45fb423-7bdc-4c65-b939-cbda80931c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d45fb423-7bdc-4c65-b939-cbda80931c57" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_71caad54-23aa-4df9-a54e-49a0ecc0f142" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_71caad54-23aa-4df9-a54e-49a0ecc0f142" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_569b8f86-4c64-472b-b600-140c849dba59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6951e39-1986-4e76-bb72-958a60926dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_569b8f86-4c64-472b-b600-140c849dba59" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6951e39-1986-4e76-bb72-958a60926dbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9a05b9db-6664-4724-be88-6080cb71dccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6951e39-1986-4e76-bb72-958a60926dbb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9a05b9db-6664-4724-be88-6080cb71dccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9a05b9db-6664-4724-be88-6080cb71dccc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9a05b9db-6664-4724-be88-6080cb71dccc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9a05b9db-6664-4724-be88-6080cb71dccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9a05b9db-6664-4724-be88-6080cb71dccc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f8109cf-1b00-4fe5-a9f6-0d6614ef6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f8109cf-1b00-4fe5-a9f6-0d6614ef6b04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c10f3fe-6c53-449b-84b7-2a94839bd7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c10f3fe-6c53-449b-84b7-2a94839bd7f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_5ec5d489-f384-4c17-9dde-f39b9dbab6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_569b8f86-4c64-472b-b600-140c849dba59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_5ec5d489-f384-4c17-9dde-f39b9dbab6fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3af20b6a-c2c2-40d2-81b5-727b4b148097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:to="loc_us-gaap_StatementTable_3af20b6a-c2c2-40d2-81b5-727b4b148097" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f25bf170-e5c3-4e62-9aae-5b332a26cef0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3af20b6a-c2c2-40d2-81b5-727b4b148097" xlink:to="loc_us-gaap_AwardTypeAxis_f25bf170-e5c3-4e62-9aae-5b332a26cef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f25bf170-e5c3-4e62-9aae-5b332a26cef0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f25bf170-e5c3-4e62-9aae-5b332a26cef0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f25bf170-e5c3-4e62-9aae-5b332a26cef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_978ccff5-2f20-4b6e-83d0-4daca1f701fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f25bf170-e5c3-4e62-9aae-5b332a26cef0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_978ccff5-2f20-4b6e-83d0-4daca1f701fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_05d446a7-0d0a-40ed-a627-b1c9eb7d3186" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_978ccff5-2f20-4b6e-83d0-4daca1f701fc" xlink:to="loc_us-gaap_RestrictedStockMember_05d446a7-0d0a-40ed-a627-b1c9eb7d3186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63ff793f-a648-40fe-a498-fbcf0c807f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63ff793f-a648-40fe-a498-fbcf0c807f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4f34bfb-4dce-48fd-8544-fc9a04bac6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4f34bfb-4dce-48fd-8544-fc9a04bac6e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3a516abf-86ce-4d9a-b2e1-ac3c2b035241" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3a516abf-86ce-4d9a-b2e1-ac3c2b035241" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_713790f1-a682-4233-b91f-b3b0091c3a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_713790f1-a682-4233-b91f-b3b0091c3a4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_260fb563-c49f-4bfd-8b4a-9e2db95d047f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad1eb71-00ff-4cf3-a218-1f6f3dc73e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad1eb71-00ff-4cf3-a218-1f6f3dc73e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_377f3587-8b41-48e8-af45-74b6c6581402" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_377f3587-8b41-48e8-af45-74b6c6581402" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14fc355c-50ce-43ef-b9f0-c412236d476a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14fc355c-50ce-43ef-b9f0-c412236d476a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39c46ea5-740d-426e-94f6-52e56d7fd95c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39c46ea5-740d-426e-94f6-52e56d7fd95c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f8f80cc-eb29-4d66-955c-dd5320b97cec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a24d8641-9810-4291-9ebf-4a7d37a86ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a24d8641-9810-4291-9ebf-4a7d37a86ba5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_65bf0a57-ad40-4f6e-af81-4835171cad7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a24d8641-9810-4291-9ebf-4a7d37a86ba5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_65bf0a57-ad40-4f6e-af81-4835171cad7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4aa0ee93-2145-41be-8934-76e8d6c3ed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:href="kprx-20250331.xsd#kprx_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:href="kprx-20250331.xsd#kprx_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a" xlink:to="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A18MonthLeaseEncinitasCAMember_a39b95a0-aa1e-4b6c-95c7-ae0798a82232" xlink:href="kprx-20250331.xsd#kprx_A18MonthLeaseEncinitasCAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A18MonthLeaseEncinitasCAMember_a39b95a0-aa1e-4b6c-95c7-ae0798a82232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A12MonthLeaseAdelaideAustraliaMember_a1840ded-01d4-4fd2-93b2-ca17b6742327" xlink:href="kprx-20250331.xsd#kprx_A12MonthLeaseAdelaideAustraliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A12MonthLeaseAdelaideAustraliaMember_a1840ded-01d4-4fd2-93b2-ca17b6742327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A5YearLeaseViennaAustriaMember_27454c30-5430-4a95-b4e1-63415a11c102" xlink:href="kprx-20250331.xsd#kprx_A5YearLeaseViennaAustriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A5YearLeaseViennaAustriaMember_27454c30-5430-4a95-b4e1-63415a11c102" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember_f6856bdb-ab8c-49bb-81d0-05d036c16d85" xlink:href="kprx-20250331.xsd#kprx_A2YearLeasePerthAndBrisbaneAustraliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember_f6856bdb-ab8c-49bb-81d0-05d036c16d85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember_e6337598-1e98-4729-b2d0-b546d5a139d2" xlink:href="kprx-20250331.xsd#kprx_A3Year3MonthLeaseEncinitasCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember_e6337598-1e98-4729-b2d0-b546d5a139d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_deaba134-cf15-4c00-a8ca-cbee10a200fc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_srt_RangeAxis_deaba134-cf15-4c00-a8ca-cbee10a200fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deaba134-cf15-4c00-a8ca-cbee10a200fc_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_deaba134-cf15-4c00-a8ca-cbee10a200fc" xlink:to="loc_srt_RangeMember_deaba134-cf15-4c00-a8ca-cbee10a200fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_deaba134-cf15-4c00-a8ca-cbee10a200fc" xlink:to="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4591882d-f2ce-4ae7-9c0f-769ab083ce69" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:to="loc_srt_MinimumMember_4591882d-f2ce-4ae7-9c0f-769ab083ce69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b984cbb-a8dd-41b2-b63a-28778c318065" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:to="loc_srt_MaximumMember_0b984cbb-a8dd-41b2-b63a-28778c318065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb5e0b17-4949-4100-be58-2357c7867373" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_srt_ProductOrServiceAxis_fb5e0b17-4949-4100-be58-2357c7867373" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb5e0b17-4949-4100-be58-2357c7867373_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fb5e0b17-4949-4100-be58-2357c7867373" xlink:to="loc_srt_ProductsAndServicesDomain_fb5e0b17-4949-4100-be58-2357c7867373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_992eb177-f7f1-4578-811f-aa8acbf817e1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fb5e0b17-4949-4100-be58-2357c7867373" xlink:to="loc_srt_ProductsAndServicesDomain_992eb177-f7f1-4578-811f-aa8acbf817e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_8967b238-ea07-4f8d-88f1-50b70bc21fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_992eb177-f7f1-4578-811f-aa8acbf817e1" xlink:to="loc_us-gaap_GrantMember_8967b238-ea07-4f8d-88f1-50b70bc21fcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4a00cc61-a9f5-46a9-a96c-4d75cd523193" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_us-gaap_CreditFacilityAxis_4a00cc61-a9f5-46a9-a96c-4d75cd523193" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4a00cc61-a9f5-46a9-a96c-4d75cd523193_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4a00cc61-a9f5-46a9-a96c-4d75cd523193" xlink:to="loc_us-gaap_CreditFacilityDomain_4a00cc61-a9f5-46a9-a96c-4d75cd523193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ef475abd-7a4f-40bf-bfb2-17beca19bbac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4a00cc61-a9f5-46a9-a96c-4d75cd523193" xlink:to="loc_us-gaap_CreditFacilityDomain_ef475abd-7a4f-40bf-bfb2-17beca19bbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a4ba1ea5-3aa4-405f-a2ad-e5414fa70242" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ef475abd-7a4f-40bf-bfb2-17beca19bbac" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a4ba1ea5-3aa4-405f-a2ad-e5414fa70242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c393eddb-26eb-4f75-a05f-2885112f1b78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c393eddb-26eb-4f75-a05f-2885112f1b78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c393eddb-26eb-4f75-a05f-2885112f1b78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c393eddb-26eb-4f75-a05f-2885112f1b78" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c393eddb-26eb-4f75-a05f-2885112f1b78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0be27328-6320-41bf-ab7a-745c3cf84776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c393eddb-26eb-4f75-a05f-2885112f1b78" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0be27328-6320-41bf-ab7a-745c3cf84776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UBSMember_1f84d61f-da64-4fb7-b017-09e422e603d4" xlink:href="kprx-20250331.xsd#kprx_UBSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0be27328-6320-41bf-ab7a-745c3cf84776" xlink:to="loc_kprx_UBSMember_1f84d61f-da64-4fb7-b017-09e422e603d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeNumberOfOperatingLeases_5649fdac-3c21-4596-a37c-49c45e9353ed" xlink:href="kprx-20250331.xsd#kprx_LesseeNumberOfOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeNumberOfOperatingLeases_5649fdac-3c21-4596-a37c-49c45e9353ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3aef8b0a-8993-4be2-bb95-8c056dd0feff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3aef8b0a-8993-4be2-bb95-8c056dd0feff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseMonthlyRentPayment_eb75d6f1-a822-46c1-8318-7b9d2978531b" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeOperatingLeaseMonthlyRentPayment_eb75d6f1-a822-46c1-8318-7b9d2978531b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseSecurityDeposit_612ac08e-788c-49cc-9707-8237054c80c1" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseSecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeOperatingLeaseSecurityDeposit_612ac08e-788c-49cc-9707-8237054c80c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseTerminationPeriod_a9ad5bf3-03f9-43cf-bd12-5c3c2ed7437d" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeOperatingLeaseTerminationPeriod_a9ad5bf3-03f9-43cf-bd12-5c3c2ed7437d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_680b15fa-3a4f-49d2-a4b2-46580a25d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_AreaOfLand_680b15fa-3a4f-49d2-a4b2-46580a25d4da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c78f6b65-5e94-4140-87e7-44e5843f5e68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LeaseCost_c78f6b65-5e94-4140-87e7-44e5843f5e68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a48af980-078c-4690-a9f8-7888cf84c08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a48af980-078c-4690-a9f8-7888cf84c08e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfLicenseAgreements_9ecfac8b-daf2-45ac-acfa-62530fda6e0d" xlink:href="kprx-20250331.xsd#kprx_NumberOfLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_NumberOfLicenseAgreements_9ecfac8b-daf2-45ac-acfa-62530fda6e0d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_070bda9f-b90c-4a29-9d3e-af99563ab1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_Revenues_070bda9f-b90c-4a29-9d3e-af99563ab1a2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_8b42eedd-906a-41a6-8287-02a232f92d28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LineOfCredit_8b42eedd-906a-41a6-8287-02a232f92d28" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2c7c2bc2-1602-494b-8a8f-8f7e7ae9fbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2c7c2bc2-1602-494b-8a8f-8f7e7ae9fbd1" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_83c8a86d-ed68-485f-ab81-c3a03bb318df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_83c8a86d-ed68-485f-ab81-c3a03bb318df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_981733bf-d598-4382-88ba-6f5e2a67ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_83c8a86d-ed68-485f-ab81-c3a03bb318df" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_981733bf-d598-4382-88ba-6f5e2a67ca74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981733bf-d598-4382-88ba-6f5e2a67ca74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_981733bf-d598-4382-88ba-6f5e2a67ca74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981733bf-d598-4382-88ba-6f5e2a67ca74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_981733bf-d598-4382-88ba-6f5e2a67ca74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_51f2a5c2-0673-48af-bebe-689a4459eaa4" xlink:href="kprx-20250331.xsd#kprx_BayonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:to="loc_kprx_BayonMember_51f2a5c2-0673-48af-bebe-689a4459eaa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesMember_18a11533-71b2-49a2-8791-b6ca5cf9068d" xlink:href="kprx-20250331.xsd#kprx_PanoptesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:to="loc_kprx_PanoptesMember_18a11533-71b2-49a2-8791-b6ca5cf9068d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2d6d16d5-d120-4758-a409-efa20cd1b597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2d6d16d5-d120-4758-a409-efa20cd1b597" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_3a2fec12-4d97-43b5-9261-dd0f0f4e16b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_3a2fec12-4d97-43b5-9261-dd0f0f4e16b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eyegatepharma.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_03d0a419-e4a4-45e1-b8ff-725a5e3c4eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_03d0a419-e4a4-45e1-b8ff-725a5e3c4eeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentAllocationAxis_404070b0-69d1-41c3-be4e-26c5a49a81d1" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentAllocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_03d0a419-e4a4-45e1-b8ff-725a5e3c4eeb" xlink:to="loc_kprx_ResearchAndDevelopmentAllocationAxis_404070b0-69d1-41c3-be4e-26c5a49a81d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentAllocationDomain_404070b0-69d1-41c3-be4e-26c5a49a81d1_default" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentAllocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationAxis_404070b0-69d1-41c3-be4e-26c5a49a81d1" xlink:to="loc_kprx_ResearchAndDevelopmentAllocationDomain_404070b0-69d1-41c3-be4e-26c5a49a81d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentAllocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationAxis_404070b0-69d1-41c3-be4e-26c5a49a81d1" xlink:to="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO101Member_f19d6028-aaad-4ba5-9216-a64ee7f7c93c" xlink:href="kprx-20250331.xsd#kprx_KIO101Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO101Member_f19d6028-aaad-4ba5-9216-a64ee7f7c93c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO104NetOfAdjustmentMember_d1a2944f-e68a-4b4f-82b2-a7e98ff0380e" xlink:href="kprx-20250331.xsd#kprx_KIO104NetOfAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO104NetOfAdjustmentMember_d1a2944f-e68a-4b4f-82b2-a7e98ff0380e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO201Member_18c2fc16-dd29-40cf-adb2-b50e0ac187ca" xlink:href="kprx-20250331.xsd#kprx_KIO201Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO201Member_18c2fc16-dd29-40cf-adb2-b50e0ac187ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO301Member_dfb52a1f-375c-4503-8773-73adeb79b124" xlink:href="kprx-20250331.xsd#kprx_KIO301Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO301Member_dfb52a1f-375c-4503-8773-73adeb79b124" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnallocatedResearchAndDevelopmentMember_36b50a02-0208-4fc9-b152-4e6b2ea1d423" xlink:href="kprx-20250331.xsd#kprx_UnallocatedResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_UnallocatedResearchAndDevelopmentMember_36b50a02-0208-4fc9-b152-4e6b2ea1d423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7c046e12-834f-4191-9be0-febea196ff93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:to="loc_us-gaap_Revenues_7c046e12-834f-4191-9be0-febea196ff93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:to="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d9712f7f-4d12-4447-9115-ce4964625af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d9712f7f-4d12-4447-9115-ce4964625af1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58187d36-cb9d-4480-ac66-4169674b0fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58187d36-cb9d-4480-ac66-4169674b0fb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditOperatingExpense_f201a9c9-fe7e-4f8e-89fa-cdff543357d8" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_kprx_CollaborationCreditOperatingExpense_f201a9c9-fe7e-4f8e-89fa-cdff543357d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c3c055eb-7d3c-483f-b1cf-98e96be62268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c3c055eb-7d3c-483f-b1cf-98e96be62268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9cda0669-96ee-4f52-b5d5-8619665852a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9cda0669-96ee-4f52-b5d5-8619665852a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_39156cde-de71-4545-883f-bc5fcc05b522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_39156cde-de71-4545-883f-bc5fcc05b522" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_30192dc1-6d78-4036-93c0-05b1a2830988" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_30192dc1-6d78-4036-93c0-05b1a2830988" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f3dd5e5-a1e9-4901-a78b-2e4e940b5542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_NetIncomeLoss_7f3dd5e5-a1e9-4901-a78b-2e4e940b5542" xlink:type="arc" order="8"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>kprx-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0167d6af-99d4-4c6f-8900-ecd7455d4d35,g:cf0f15d1-3949-48fc-a909-df68c07a7e6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RangeMember_3e711b8e-4669-4fe6-bdfb-9cbf987d9648_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_3e884f5a-ad3c-41f8-85ca-e5207a2334db_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c4d40c6f-ded3-46e6-853b-8a36553528c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9eb9996d-8160-4433-b64e-b56ce7db3284_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (remaining months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CommitmentsAndContingenciesTable_edefc7bd-d87f-4683-8cb8-106f6d7aa0df_terseLabel_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesTable" xlink:href="kprx-20250331.xsd#kprx_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CommitmentsAndContingenciesTable" xlink:to="lab_kprx_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04df1ea2-7170-4b9c-99e6-1d91d169b637_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_46202763-b69a-4a7b-b0d9-e44bd416e9cd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_80c59c06-173f-4d2a-b4e7-3194242d85c3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_edbb6c72-1215-4a98-a7c3-42a25ac346c2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average unvested restricted common stock that has been issued and is subject to forfeiture (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_616a2653-76b9-4755-9fdb-2b9d806a9bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d9575199-9e04-4cb2-b92f-41bd1d86cb51_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of Accounting Standards and Accounting Standards Pending Adoption</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_LesseeOperatingLeaseSecurityDeposit_7e24166b-dce1-42d9-84b7-fb80e185d7da_terseLabel_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_kprx_LesseeOperatingLeaseSecurityDeposit_label_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Security Deposit</link:label>
    <link:label id="lab_kprx_LesseeOperatingLeaseSecurityDeposit_documentation_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseSecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseSecurityDeposit" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseSecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_LesseeOperatingLeaseSecurityDeposit" xlink:to="lab_kprx_LesseeOperatingLeaseSecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PercentageOfExercisePrice_f464c296-5ab0-4171-a4c6-5c22d5e02b6d_terseLabel_en-US" xlink:label="lab_kprx_PercentageOfExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of exercise price</link:label>
    <link:label id="lab_kprx_PercentageOfExercisePrice_label_en-US" xlink:label="lab_kprx_PercentageOfExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Exercise Price</link:label>
    <link:label id="lab_kprx_PercentageOfExercisePrice_documentation_en-US" xlink:label="lab_kprx_PercentageOfExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfExercisePrice" xlink:href="kprx-20250331.xsd#kprx_PercentageOfExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PercentageOfExercisePrice" xlink:to="lab_kprx_PercentageOfExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_82f11558-f3cf-454a-90a6-a7a9cf7037d6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_7bf3e91e-9460-4e5e-b5b6-ceff3dcc026d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Income, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5bd954f3-5a35-4c65-a1d4-0e7ffb4c1bab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ProbabilityOfSuccessForPaymentMember_0fa902fd-d22d-484c-91a5-45aec1403db6_terseLabel_en-US" xlink:label="lab_kprx_ProbabilityOfSuccessForPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of success for payment</link:label>
    <link:label id="lab_kprx_ProbabilityOfSuccessForPaymentMember_label_en-US" xlink:label="lab_kprx_ProbabilityOfSuccessForPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability of Success for Payment [Member]</link:label>
    <link:label id="lab_kprx_ProbabilityOfSuccessForPaymentMember_documentation_en-US" xlink:label="lab_kprx_ProbabilityOfSuccessForPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probability of Success for Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProbabilityOfSuccessForPaymentMember" xlink:href="kprx-20250331.xsd#kprx_ProbabilityOfSuccessForPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ProbabilityOfSuccessForPaymentMember" xlink:to="lab_kprx_ProbabilityOfSuccessForPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_41eb5fc4-5ae1-4587-9e53-f9bd86d50b0c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income per Common Share - Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dd3b262c-9713-403d-bba6-8f2c489d5284_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ad5bcd4b-a3c9-41c4-a5e9-8d5d1b7fb693_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cecebb1a-357c-41ba-a91f-575350c2ae5c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_52a402c3-2976-497c-86df-f7319ef32a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9e0094c3-eb89-48f0-8a65-20c5eca816fa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_0c069bbf-1680-46ba-a657-f29b3cdafad8_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a79d64cc-66a4-40e8-96c9-8409f093cafb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_3ac4bec6-ca90-4f2e-a18e-a666c5db64fa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_238f7190-6aec-48d5-82f8-dfb9b15d43fd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_44582368-e97b-4cb1-8d47-8f4f04032683_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_20facd0d-f5de-491d-bf8c-a92c36aa4881_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_2b023e15-82c9-4f9a-9a83-f4ad6baee957_terseLabel_en-US" xlink:label="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Holders Owing More Than Ten Percentage Voting Rights</link:label>
    <link:label id="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_label_en-US" xlink:label="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Holders Owing More Than Ten Percentage Voting Rights [Member]</link:label>
    <link:label id="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_documentation_en-US" xlink:label="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">n/a.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:href="kprx-20250331.xsd#kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:to="lab_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_952eb8a4-7c95-4a93-8d23-ca6055b92c8a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_59158e60-ac5f-4e4d-b3bd-1f0cdb52f7d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_31d83321-8391-43bf-895b-8a259cbbd7c9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_01ddc145-86d3-44e2-aa95-dfca8db19013_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e2f675d1-d21b-4156-b46b-24fd4c657260_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f93dc16d-16d8-46c4-afc2-57c65c50a94d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_73d2dfb0-0b14-4497-b2eb-0568d9d0d546_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_773bb659-3713-44c2-b832-ca7345006ad7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_db9f292a-236a-49fe-822f-21f7c65dfc1e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4ae5ce45-294c-4f81-b303-ed61e284ffc7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_33326ca7-33f0-45f0-b256-b8b3c4662ed3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_12770a7b-7880-433e-8483-525517cbac7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_05e1bfd0-7e4e-434c-8afd-46a3fe49fda9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_423ae310-56ab-4951-8c16-0cf7d0bd33dd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_533967c6-d158-421d-9aa1-133e02a38cf9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cfc30144-038c-4dd0-bc9a-f71fb11544e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EmployeeStockPurchasePlanMember_a54413f8-994f-416e-b66a-52af77ce3619_terseLabel_en-US" xlink:label="lab_kprx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_kprx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_kprx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_kprx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_kprx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeStockPurchasePlanMember" xlink:href="kprx-20250331.xsd#kprx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EmployeeStockPurchasePlanMember" xlink:to="lab_kprx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b212d353-5570-42a5-960e-5b0de8aebf57_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b5afaf6e-befc-4313-995e-cebdd04831b5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_6c7992ec-23e7-45c3-8bca-c85b12227f8d_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="lab_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bc25c117-b32b-44a2-85e5-c7d82a619bf3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Cash Equivalents Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8b104262-65dd-4312-8ab9-5727613699f4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c192faee-f5a2-47c5-8d65-ea71f416c5ed_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f1226671-1700-46ad-be9a-37eae8710590_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Annual Minimum Lease Payments Under Non-Cancellable Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_bab54593-72eb-4c3c-abfb-312a388dd64b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e25db4fb-27ee-41b8-bad0-8172d6d00bab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_cd665e2f-47e9-4148-bb22-c5eb91789a02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_76938a65-1bad-42d1-8324-5bf7600cdb47_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9e6a493d-0683-45a6-b7fe-1d563ed94c81_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_508bf81b-838e-494e-89ff-3f628abd6739_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Agency Securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fbb656d6-959c-42f1-987e-d716dff5fc1a_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government Agency Securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_fa958495-2488-449a-9774-3145b2d751bf_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_197fb6eb-f438-4ca5-b9c4-e564f0c08fb5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cdc1496f-4bda-4e29-96f6-6b72044debf2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) Income Before Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_71e3f512-43be-4f64-9851-d24c3ceb7884_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_25aeca97-d467-4b78-800e-1ea260168d64_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClinicalTrialsCurrent_637e6a37-9114-485e-8506-5a01293c8015_terseLabel_en-US" xlink:label="lab_kprx_ClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trials</link:label>
    <link:label id="lab_kprx_ClinicalTrialsCurrent_label_en-US" xlink:label="lab_kprx_ClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trials Current</link:label>
    <link:label id="lab_kprx_ClinicalTrialsCurrent_documentation_en-US" xlink:label="lab_kprx_ClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalTrialsCurrent" xlink:href="kprx-20250331.xsd#kprx_ClinicalTrialsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClinicalTrialsCurrent" xlink:to="lab_kprx_ClinicalTrialsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_caa07f84-4719-48c0-bf64-575eb20d9268_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f5d16f12-357e-457d-930d-1608b8243e0d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_627e54c6-a00a-48ae-ac48-083ff2424a37_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4d41c789-7000-4946-938d-dcf21c94048b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_49d410cb-a96b-40eb-a3db-2637c524da0b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_563c9f33-65d9-4b0a-acf1-c2e5ccb79df1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_16982fcb-99ce-42a8-babb-2278a2b2eda5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a4b95a9a-72db-4972-9ce9-81f26406a225_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less Current Portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ae2a059b-1621-4d5f-9629-9445bfc8551b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d1636ec7-6e89-47a7-b0d5-54aaf21da7fb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_336f827f-bdb8-4b40-befa-61b835b81369_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c386f584-1e9e-4973-96e3-67ead99205af_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ResearchAndDevelopmentAllocationAxis_b80eeb7c-01b1-404b-81ba-4e151b9c142f_terseLabel_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentAllocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Allocation [Axis]</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentAllocationAxis_label_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentAllocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Allocation [Axis]</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentAllocationAxis_documentation_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentAllocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentAllocationAxis" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentAllocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationAxis" xlink:to="lab_kprx_ResearchAndDevelopmentAllocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_a77cb7da-18b5-4a7f-baa0-1519c69aea72_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_89c127d6-07e2-4562-a0fa-4aa8426912ef_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_01cdc72f-af9a-4d9e-b020-30bd4e39f37b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f07d0a4c-0aae-4c81-bfd1-2155c9ecee29_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ffeba9bf-1cc6-46cb-aae5-71fd3c6fa268_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Released (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IncreaseDecreaseInRightOfUseAssets_b584827f-429f-477c-8f8f-b5cfd719df1d_terseLabel_en-US" xlink:label="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseInRightOfUseAssets_label_en-US" xlink:label="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Right-Of-Use Assets</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseInRightOfUseAssets_documentation_en-US" xlink:label="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents increase decrease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:to="lab_kprx_IncreaseDecreaseInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_40e447a7-3cf1-4c03-861b-2899b3026374_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_467a850d-42de-43ee-94a5-e24f81d5ceb3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d667ddb-e06c-4029-9e7c-4259a4d25960_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_5d761eb8-d1e7-4904-97b9-c60eead7978d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment Expenses</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_KIO201Member_ac928cbc-6cb1-40c7-a166-ecde2508c997_terseLabel_en-US" xlink:label="lab_kprx_KIO201Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KIO-201</link:label>
    <link:label id="lab_kprx_KIO201Member_label_en-US" xlink:label="lab_kprx_KIO201Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KIO-201 [Member]</link:label>
    <link:label id="lab_kprx_KIO201Member_documentation_en-US" xlink:label="lab_kprx_KIO201Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KIO-201</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO201Member" xlink:href="kprx-20250331.xsd#kprx_KIO201Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_KIO201Member" xlink:to="lab_kprx_KIO201Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29f49d35-eb46-473b-88b9-ec4b58bfc9ae_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_InProcessResearchAndDevelopmentMeasurementInput_10712cc3-8f28-4002-8976-57c72741eaa7_terseLabel_en-US" xlink:label="lab_kprx_InProcessResearchAndDevelopmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process R&amp;D</link:label>
    <link:label id="lab_kprx_InProcessResearchAndDevelopmentMeasurementInput_label_en-US" xlink:label="lab_kprx_InProcessResearchAndDevelopmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development, Measurement Input</link:label>
    <link:label id="lab_kprx_InProcessResearchAndDevelopmentMeasurementInput_documentation_en-US" xlink:label="lab_kprx_InProcessResearchAndDevelopmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In Process Research And Development, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_InProcessResearchAndDevelopmentMeasurementInput" xlink:href="kprx-20250331.xsd#kprx_InProcessResearchAndDevelopmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_InProcessResearchAndDevelopmentMeasurementInput" xlink:to="lab_kprx_InProcessResearchAndDevelopmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d87a992c-b336-4923-b8a8-891aaf6671e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_df56add5-f077-47ad-8b8b-e4ea8e1d6202_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6e61a556-3227-4a41-8319-fb263f8e8d42_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_1f822b63-8b04-4798-a55f-81483920f51d_terseLabel_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_label_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liabilities</link:label>
    <link:label id="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_documentation_en-US" xlink:label="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:href="kprx-20250331.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:to="lab_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_65861a4c-c48d-447e-a060-5cff4bf85ee6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_95df36d5-a163-4f6b-8020-55f2b88a47b9_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Excluding Pre-funded Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fd9466ee-c6f7-4fe1-afaa-7626772659d9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9367a445-719b-4990-acf9-b41dc300bec1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Creation of Right-of-Use Assets and Related Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d5d608f7-55df-42cb-8732-d0fe043ce066_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5652cf0a-f272-4b11-b1d5-fb8b41bfd846_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31b73ce0-1ce9-459e-b08e-6ed5d7b5117d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7fdf4e2e-fbc8-4ddf-b1c2-22ee4c36d76d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_BayonMember_135af92e-f9f4-48e1-bfd1-a9ba31331478_terseLabel_en-US" xlink:label="lab_kprx_BayonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayon</link:label>
    <link:label id="lab_kprx_BayonMember_label_en-US" xlink:label="lab_kprx_BayonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayon [Member]</link:label>
    <link:label id="lab_kprx_BayonMember_documentation_en-US" xlink:label="lab_kprx_BayonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Bayon.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember" xlink:href="kprx-20250331.xsd#kprx_BayonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_BayonMember" xlink:to="lab_kprx_BayonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_aa1d6c1e-909c-4743-b37b-1f77756a4468_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e7840fae-8723-4163-a702-19327ea38564_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-Process R&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9adc7247-fa25-4e4c-be6e-336842afbf46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bbc1117e-f708-4c63-a456-b5ce7590588c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_f76f6ca9-d566-4642-99ff-0d47ca19fcf8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock_7c47d4a8-41e6-4f9d-ae37-a36560236132_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, volume weighted average price of common stock (in usd per share)</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Volume Weighted Average Price Of Common Stock</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Volume Weighted Average Price Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" xlink:to="lab_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_87c6beb2-27f1-42bc-b5ab-19a8233902c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest Income, Net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_aeb91952-a7f9-46f5-b553-2153f3cf9de8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Disclosures of Noncash Operating and Financing Activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_934f16bc-8eb4-406d-8145-76de2dd87616_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e9daf1f2-1caa-407e-9f83-2c141a443005_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in Operating Assets and Liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightThresholdTradingDays_d49d1e41-41e2-4b45-9352-da8119e28408_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, threshold trading days</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightThresholdTradingDays_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Threshold Trading Days</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightThresholdTradingDays_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightThresholdTradingDays" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightThresholdTradingDays" xlink:to="lab_kprx_ClassOfWarrantOrRightThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_LesseeOperatingLeaseMonthlyRentPayment_4b3664dd-0bac-47dd-bc09-025ab4711d39_terseLabel_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for rent</link:label>
    <link:label id="lab_kprx_LesseeOperatingLeaseMonthlyRentPayment_label_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:label id="lab_kprx_LesseeOperatingLeaseMonthlyRentPayment_documentation_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseMonthlyRentPayment" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_LesseeOperatingLeaseMonthlyRentPayment" xlink:to="lab_kprx_LesseeOperatingLeaseMonthlyRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6b5e4da6-42f9-4446-940b-71acb1f8b6ac_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f4af5f73-4742-4bca-9892-fe7fb2c9b518_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_004ba3e9-d6b5-4851-bcfb-f7793e930753_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94a28084-c637-4713-8b52-bac96cefc601_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3407bf72-3a47-4ca9-af24-e17a30488749_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9dee1be4-7eb6-49a6-9f7a-5dee0a081ac0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bfef772-f474-4141-841f-02fd63ac6cfb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75e005da-319d-44cc-a9b6-eb81e8b0379f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a525909f-4347-480e-a9c0-6995aae93341_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash, End of Period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_917d26ed-b1e3-48ad-9371-61a2c790daf1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a527ed90-21de-445f-84ee-1136e8ff77e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c5ecd9ca-1ff2-4d3d-9ae2-1df190f232c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c6e1c1d1-28e1-4835-83db-bb34627f33da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_72e4f2be-e836-4791-be7d-71c032317dbe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_f38e9abd-3d4d-4a37-acaa-f2e8a8a652fb_terseLabel_en-US" xlink:label="lab_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Information</link:label>
    <link:label id="lab_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Information Policy [Policy Text Block]</link:label>
    <link:label id="lab_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for interim financial information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="kprx-20250331.xsd#kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_89fafb74-38f9-4e6d-8f86-74e6fee5efd7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_f9ce7bff-91d6-4ab7-be43-8fb5af62f821_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Short-term Investments Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_10fd7a91-0d30-4d9f-bb1e-b34ac383bf01_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_eddd7746-87f2-40cc-80c8-1929dfdabaf7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and In-Process R&amp;D, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4d8a2bfd-7ef0-4851-b935-f430650e375a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9f20ad-3709-4896-96b2-909e3d3e87d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_593f1fce-d73f-484b-804b-9a42b0c09b85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maximum Obligation Payments Per Respective Agreements and Estimated Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_fab7b446-6e13-42a7-a09b-5097185dbe73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable and vested at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c51971ff-7982-4bba-8f81-16d3271e0f8a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0cc90c3-42af-4f1f-95c7-7d5986d243ed_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CommitmentsAndContingenciesLineItems_3dd5303e-d50d-4cd7-863e-3a10e12e5753_terseLabel_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_kprx_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesLineItems" xlink:href="kprx-20250331.xsd#kprx_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems" xlink:to="lab_kprx_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_044124c8-2486-4e9b-9004-9e354cf95fc9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Stock Split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised_a34d3da3-d194-4b0f-be66-421e4901468d_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock from Warrant Exercises</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="kprx-20250331.xsd#kprx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_kprx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_OtherTaxReceivablesCurrent_2e041a98-7487-4183-bb99-f391a81500eb_terseLabel_en-US" xlink:label="lab_kprx_OtherTaxReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Tax Receivables</link:label>
    <link:label id="lab_kprx_OtherTaxReceivablesCurrent_label_en-US" xlink:label="lab_kprx_OtherTaxReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Receivables, Current</link:label>
    <link:label id="lab_kprx_OtherTaxReceivablesCurrent_documentation_en-US" xlink:label="lab_kprx_OtherTaxReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Tax Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_OtherTaxReceivablesCurrent" xlink:href="kprx-20250331.xsd#kprx_OtherTaxReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_OtherTaxReceivablesCurrent" xlink:to="lab_kprx_OtherTaxReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_a9a7f52e-bdea-4425-8f53-38c52751b33f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Proceeds from Private Placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_65e8aaab-75a1-412b-b545-147a01bd8511_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_738494e2-ad04-488e-978f-be3f4547cad0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d6f02724-c01d-4490-88ed-db2da621f3b9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bf2ed011-a699-479e-9511-5f4e81c88824_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_790dbc0e-0ed2-4242-99c0-d370c242e97d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c89dfb49-af2f-48e5-9a59-54355d833618_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_d974d6ff-451a-4228-823e-bb80744c7c00_periodStartLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_b28a42ca-ec9a-4395-aefc-a8cee8dd90de_periodEndLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average exercise price of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_efd85533-0782-4a4d-a2fb-25d75bf2408d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_146759aa-5537-4f3a-9fff-da789dc3c9aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fff13cd1-9a6e-4f64-8ed0-6e5a06985a3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ee83e87-352c-47c4-95ea-ebad9fe661f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c283989e-0c15-45a3-bd13-05bdfa23098e_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bca15216-871c-431f-b797-952a2ba4eb87_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_b884b9b0-e6b0-4198-8bd3-613031a3ccb6_terseLabel_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refunds for Research and Development</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Refunds, Policy [Policy Text Block]</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for refunds assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:to="lab_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_627afbc1-6fdb-4684-aaa6-0ab7f7412114_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized compensation expense related to options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0515521-6178-4931-b906-49abf1cdec36_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash (Used in) Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_54a96dca-e0db-4631-96b8-a908b10d0fc0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CollaborationCreditOperatingExpense_3a1d65cd-3806-484f-818c-99058bc65fec_negatedLabel_en-US" xlink:label="lab_kprx_CollaborationCreditOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Research Credits</link:label>
    <link:label id="lab_kprx_CollaborationCreditOperatingExpense_175260c9-4962-4440-bbff-9ead9c6d73c9_negatedTerseLabel_en-US" xlink:label="lab_kprx_CollaborationCreditOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">KIO-301 Collaboration Credit</link:label>
    <link:label id="lab_kprx_CollaborationCreditOperatingExpense_label_en-US" xlink:label="lab_kprx_CollaborationCreditOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Credit, Operating Expense</link:label>
    <link:label id="lab_kprx_CollaborationCreditOperatingExpense_documentation_en-US" xlink:label="lab_kprx_CollaborationCreditOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Credit, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditOperatingExpense" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CollaborationCreditOperatingExpense" xlink:to="lab_kprx_CollaborationCreditOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_99159f1a-46fc-4494-a2b3-454e6cac1469_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_d860ac98-f4d6-46d6-abb8-dc59f408c00d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PreferredStockDesignatedShares_b72a5687-f3a6-457f-bffa-049b2934c924_terseLabel_en-US" xlink:label="lab_kprx_PreferredStockDesignatedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock designated shares (in shares)</link:label>
    <link:label id="lab_kprx_PreferredStockDesignatedShares_label_en-US" xlink:label="lab_kprx_PreferredStockDesignatedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Designated Shares</link:label>
    <link:label id="lab_kprx_PreferredStockDesignatedShares_documentation_en-US" xlink:label="lab_kprx_PreferredStockDesignatedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of designated preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreferredStockDesignatedShares" xlink:href="kprx-20250331.xsd#kprx_PreferredStockDesignatedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PreferredStockDesignatedShares" xlink:to="lab_kprx_PreferredStockDesignatedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e6cd9870-1fcf-4736-bcc3-e328036df13a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_4788fedd-a9dd-4c36-87ef-ba121845882f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_f17e3b3a-dfcc-40ba-8c8b-b3844e67f5db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fd01b8df-94a4-4e65-b9a6-f85e8a2b3d72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_86487d37-27e1-4731-8c9a-9d150172d485_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business, Presentation and Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_083ad4f9-ce95-47b0-896c-d11aa1d5cb7b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, measurement input, rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_81a4c3de-48bb-46a6-a308-2eaa4ac51235_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_430db5a7-fe10-4f06-a4ec-7142dc40c5ac_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0cd6fc17-638f-4e7d-8b43-37becd9f5481_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_94125657-5d85-4733-9060-eff57651c28c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_65fde5a1-9ec3-4502-89dd-1f7e376a40bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7caa6586-8d86-44e8-b9dd-a003f52475ff_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c7acfd1a-e97c-4ede-9194-7308d863ed1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_A12MonthLeaseAdelaideAustraliaMember_cb7edb83-5973-400c-bd99-b5027602fb5e_terseLabel_en-US" xlink:label="lab_kprx_A12MonthLeaseAdelaideAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adelaide Lease</link:label>
    <link:label id="lab_kprx_A12MonthLeaseAdelaideAustraliaMember_label_en-US" xlink:label="lab_kprx_A12MonthLeaseAdelaideAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">12 Month Lease, Adelaide Australia [Member]</link:label>
    <link:label id="lab_kprx_A12MonthLeaseAdelaideAustraliaMember_documentation_en-US" xlink:label="lab_kprx_A12MonthLeaseAdelaideAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">12 Month Lease, Adelaide Australia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A12MonthLeaseAdelaideAustraliaMember" xlink:href="kprx-20250331.xsd#kprx_A12MonthLeaseAdelaideAustraliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_A12MonthLeaseAdelaideAustraliaMember" xlink:to="lab_kprx_A12MonthLeaseAdelaideAustraliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_dc4a212a-dd21-4d4d-89d8-4f347f29f525_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c123730a-f7d8-4fb3-8590-93cab2378096_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d313ec9b-3227-4b40-beae-4ff5df0b1fdd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_KIO104NetOfAdjustmentMember_84372c0f-8b5e-45b7-9db9-6b06635adb31_terseLabel_en-US" xlink:label="lab_kprx_KIO104NetOfAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KIO-104</link:label>
    <link:label id="lab_kprx_KIO104NetOfAdjustmentMember_label_en-US" xlink:label="lab_kprx_KIO104NetOfAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KIO-104, Net Of Adjustment [Member]</link:label>
    <link:label id="lab_kprx_KIO104NetOfAdjustmentMember_documentation_en-US" xlink:label="lab_kprx_KIO104NetOfAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KIO-104, Net Of Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO104NetOfAdjustmentMember" xlink:href="kprx-20250331.xsd#kprx_KIO104NetOfAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_KIO104NetOfAdjustmentMember" xlink:to="lab_kprx_KIO104NetOfAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1c8f7a92-b169-4f0e-a208-bcc4e3b99f83_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a3a480b0-f6b7-4094-b936-cef699b5257c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_7a7ae0f3-fb08-455d-b776-aafe268d3976_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_a2ace671-f0f4-4307-b7d5-515ba9c927e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4c224540-d84a-4663-95ff-6bab3ab05284_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7e828155-0e09-47cb-8914-9e8ec9a9f36b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e9df6afa-33b4-4436-9f0e-be318494b4f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Term in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_fab2372e-1bea-4e56-8575-646e4857a805_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d05a94c9-1f87-46b0-a316-3a53253ddafc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_5fc5f745-4d65-43b3-a8a1-6e1164c3ebc5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_KIO101Member_25eb2f1a-9db3-4ba9-8d95-7947b80af9c4_terseLabel_en-US" xlink:label="lab_kprx_KIO101Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KIO-101</link:label>
    <link:label id="lab_kprx_KIO101Member_label_en-US" xlink:label="lab_kprx_KIO101Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KIO-101 [Member]</link:label>
    <link:label id="lab_kprx_KIO101Member_documentation_en-US" xlink:label="lab_kprx_KIO101Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KIO-101</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO101Member" xlink:href="kprx-20250331.xsd#kprx_KIO101Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_KIO101Member" xlink:to="lab_kprx_KIO101Member" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_75cafe15-3f99-447e-bcfd-0d1661ca4cf2_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Term in Years</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_e3d21dc5-4d17-4bf7-baa6-95aef3cd15a1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dc261c55-43e3-4e89-a767-76a612652d18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7a3b3e50-e6e2-4b1b-881f-2e82f7392191_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_cc162d63-f5f4-427f-bbe4-d167f32b77d2_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of land</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ChangeInContingentConsiderationFairValue_4ecac47c-67b1-44e8-9688-b7cb52b84596_terseLabel_en-US" xlink:label="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_kprx_ChangeInContingentConsiderationFairValue_label_en-US" xlink:label="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contingent Consideration Fair Value</link:label>
    <link:label id="lab_kprx_ChangeInContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of change in contingent consideration fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ChangeInContingentConsiderationFairValue" xlink:href="kprx-20250331.xsd#kprx_ChangeInContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ChangeInContingentConsiderationFairValue" xlink:to="lab_kprx_ChangeInContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd58dc0b-879e-486a-8a1c-d369c6168756_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_KIO104Member_93e84d25-d7fa-4f4d-8e7f-d50ed3f92b47_terseLabel_en-US" xlink:label="lab_kprx_KIO104Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KIO-104</link:label>
    <link:label id="lab_kprx_KIO104Member_label_en-US" xlink:label="lab_kprx_KIO104Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KIO-104 [Member]</link:label>
    <link:label id="lab_kprx_KIO104Member_documentation_en-US" xlink:label="lab_kprx_KIO104Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KIO-104</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO104Member" xlink:href="kprx-20250331.xsd#kprx_KIO104Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_KIO104Member" xlink:to="lab_kprx_KIO104Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7c28381c-1ef4-496d-8a8d-782a3660389f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum Obligation per Agreements</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_127c2392-c30f-44e6-a587-88336c073df5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_c6c3dbea-415e-4dc5-86be-aaa1efd2b211_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_us-gaap_SeriesDPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3f77df4d-fd07-457a-a364-eb78dbb852e6_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_aa8f3d6d-e408-44cd-a169-48ce665bba14_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income Attributable to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_AccruedClinicalExpensesPolicyTextBlock_5d784d2b-233f-45e4-adc6-95a228fc1db4_terseLabel_en-US" xlink:label="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Clinical Expenses</link:label>
    <link:label id="lab_kprx_AccruedClinicalExpensesPolicyTextBlock_label_en-US" xlink:label="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Expenses [Policy Text Block]</link:label>
    <link:label id="lab_kprx_AccruedClinicalExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for accrued clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:href="kprx-20250331.xsd#kprx_AccruedClinicalExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:to="lab_kprx_AccruedClinicalExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_8ce1e42f-c375-4718-b289-8487cca747ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_18c6f321-f4b4-466d-b1f2-a2e4c583db6f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_837783ea-e0bd-49f5-8263-2450e8313ed9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_00a98516-0b08-43fe-bf77-59bbe4b6b63b_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_0a797e6a-0995-4645-b6ba-e21f467f4c32_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_415e7ee4-ed95-4603-8755-58cb4ec7a059_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_NumberOfGeographicSegments_224a8e30-e3d8-47ba-9476-a04eb923ae62_terseLabel_en-US" xlink:label="lab_kprx_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic segments</link:label>
    <link:label id="lab_kprx_NumberOfGeographicSegments_label_en-US" xlink:label="lab_kprx_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Geographic Segments</link:label>
    <link:label id="lab_kprx_NumberOfGeographicSegments_documentation_en-US" xlink:label="lab_kprx_NumberOfGeographicSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Geographic Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfGeographicSegments" xlink:href="kprx-20250331.xsd#kprx_NumberOfGeographicSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_NumberOfGeographicSegments" xlink:to="lab_kprx_NumberOfGeographicSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_256b4eb9-e01a-4f9b-9300-bbf65c0e8efa_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_A18MonthLeaseEncinitasCAMember_27d19492-fcb1-4bc7-b0b5-ed7d5debb889_terseLabel_en-US" xlink:label="lab_kprx_A18MonthLeaseEncinitasCAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Encinitas Lease</link:label>
    <link:label id="lab_kprx_A18MonthLeaseEncinitasCAMember_label_en-US" xlink:label="lab_kprx_A18MonthLeaseEncinitasCAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">18 Month Lease, Encinitas, CA [Member]</link:label>
    <link:label id="lab_kprx_A18MonthLeaseEncinitasCAMember_documentation_en-US" xlink:label="lab_kprx_A18MonthLeaseEncinitasCAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">18 Month Lease, Encinitas, CA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A18MonthLeaseEncinitasCAMember" xlink:href="kprx-20250331.xsd#kprx_A18MonthLeaseEncinitasCAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_A18MonthLeaseEncinitasCAMember" xlink:to="lab_kprx_A18MonthLeaseEncinitasCAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_21470187-39df-4499-9339-0f79e7a9148a_terseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_242982df-fac1-418b-97c2-000370f8e695_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7e50b06e-60a0-4a50-8089-810a4c44087e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_534da7e3-9b95-4914-97ef-428f114e9002_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_0896b551-c567-4053-9e64-04c5f23cec98_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember_0de3ba8e-765b-4e82-891c-8d0719c4ec17_terseLabel_en-US" xlink:label="lab_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Perth and Brisbane Lease</link:label>
    <link:label id="lab_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember_label_en-US" xlink:label="lab_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2 Year Lease Perth and Brisbane Australia [Member]</link:label>
    <link:label id="lab_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember_documentation_en-US" xlink:label="lab_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2 Year Lease Perth, Australia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember" xlink:href="kprx-20250331.xsd#kprx_A2YearLeasePerthAndBrisbaneAustraliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember" xlink:to="lab_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ae3d1a7c-784c-4614-910c-b46386fbe156_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2a7aaa16-dd7f-41a8-9927-d961d564edec_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_f23234b8-4ec4-4b0b-aa55-68962318cb8d_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d98ba639-7bb4-4fc0-998d-5ffafde7a017_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6f005ad5-183f-467d-b585-b426e5e6b1f0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_78819042-ed87-474a-830d-ded60bdec413_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_88dd1853-5d37-4cbc-867a-00e2c470cbe2_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesFPreferredStockMember_b1e21578-d879-43a7-a60c-8bfc68ffe0ce_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesFPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series F Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesFPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesFPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series F Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember" xlink:to="lab_us-gaap_SeriesFPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c00f3c99-b8c5-4694-998e-3a06476c78bc_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_12411511-95e5-4794-afa1-44e9efde38b8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAbstract_1febb651-b2cf-4922-9074-2d280c83b6e3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_7c582022-3a53-4120-b8b9-dad0dd5e57d5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_7e5bda4c-bac0-4f00-81de-bac857035d24_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_266a4f61-2096-4d40-9e94-575ee0c73687_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cdc52446-dbfb-4cfc-b7f5-89d3a14fedad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0f079e1a-5aae-4c01-b410-144f837c0d2f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PrepaidResearchAndDevelopment_d9146a69-73be-438e-9a86-08ec0c0d19a8_terseLabel_en-US" xlink:label="lab_kprx_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Research and Development</link:label>
    <link:label id="lab_kprx_PrepaidResearchAndDevelopment_label_en-US" xlink:label="lab_kprx_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development</link:label>
    <link:label id="lab_kprx_PrepaidResearchAndDevelopment_documentation_en-US" xlink:label="lab_kprx_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrepaidResearchAndDevelopment" xlink:href="kprx-20250331.xsd#kprx_PrepaidResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PrepaidResearchAndDevelopment" xlink:to="lab_kprx_PrepaidResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fbf5f88d-0e5d-4c8e-906b-a7c8bb86244d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18507bd8-3a0d-4c0a-9c64-c946d6cec111_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_437cf519-1549-4f4d-acb8-233f1a7c6fdd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7735887c-5d6d-441f-af19-a299fd96a8cf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_be69c95d-9338-49e8-a4f2-d70a2f174f13_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fe77caa7-0cc5-4bc3-b369-f3294bd6fd1b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e68c66ac-811d-42a8-b35a-0e7ca22822f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_859c9014-6547-4820-a1c6-b4c485c5ebe2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3d10bdbd-2122-4720-8fee-29856e9ba787_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ScheduleOfShortTermInvestmentsTableTextBlock_94c0189f-5661-476e-904c-ea83389202f4_terseLabel_en-US" xlink:label="lab_kprx_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short term Investments</link:label>
    <link:label id="lab_kprx_ScheduleOfShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_kprx_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Short Term Investments [Table Text Block]</link:label>
    <link:label id="lab_kprx_ScheduleOfShortTermInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_kprx_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Short Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:to="lab_kprx_ScheduleOfShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4e686a4e-eab7-4f5c-9281-fca721ca8e77_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_UBSMember_731ba8f0-4f4f-41bc-b44a-5d3dd21781e2_terseLabel_en-US" xlink:label="lab_kprx_UBSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UBS</link:label>
    <link:label id="lab_kprx_UBSMember_label_en-US" xlink:label="lab_kprx_UBSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UBS [Member]</link:label>
    <link:label id="lab_kprx_UBSMember_documentation_en-US" xlink:label="lab_kprx_UBSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UBS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UBSMember" xlink:href="kprx-20250331.xsd#kprx_UBSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_UBSMember" xlink:to="lab_kprx_UBSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e3f12fde-c7b1-4df8-b488-053603d8e88e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_24928a6b-9de5-4760-a406-d4376decb2a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of Warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EquityLineOfCreditMember_b4e84b88-694a-4187-a186-13e8f141edc2_terseLabel_en-US" xlink:label="lab_kprx_EquityLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Line Of Credit</link:label>
    <link:label id="lab_kprx_EquityLineOfCreditMember_label_en-US" xlink:label="lab_kprx_EquityLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Line Of Credit [Member]</link:label>
    <link:label id="lab_kprx_EquityLineOfCreditMember_documentation_en-US" xlink:label="lab_kprx_EquityLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Line Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityLineOfCreditMember" xlink:href="kprx-20250331.xsd#kprx_EquityLineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EquityLineOfCreditMember" xlink:to="lab_kprx_EquityLineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PreFundedWarrantsMember_b562717c-3142-44e7-b08d-3dbd89443ada_terseLabel_en-US" xlink:label="lab_kprx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants</link:label>
    <link:label id="lab_kprx_PreFundedWarrantsMember_label_en-US" xlink:label="lab_kprx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
    <link:label id="lab_kprx_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_kprx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreFundedWarrantsMember" xlink:href="kprx-20250331.xsd#kprx_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PreFundedWarrantsMember" xlink:to="lab_kprx_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c1a7224-a26b-4a05-9690-f1c09145427c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e292e6ec-a267-4d6a-83df-e4e34d735bc6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_c73e8ece-465e-49a6-a458-77724950c119_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ResearchTaxCreditsReceivableCurrent_de5b46c4-783b-4532-8fac-bcf5f8545339_terseLabel_en-US" xlink:label="lab_kprx_ResearchTaxCreditsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credits</link:label>
    <link:label id="lab_kprx_ResearchTaxCreditsReceivableCurrent_label_en-US" xlink:label="lab_kprx_ResearchTaxCreditsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credits Receivable, Current</link:label>
    <link:label id="lab_kprx_ResearchTaxCreditsReceivableCurrent_documentation_en-US" xlink:label="lab_kprx_ResearchTaxCreditsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Tax Credits Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchTaxCreditsReceivableCurrent" xlink:href="kprx-20250331.xsd#kprx_ResearchTaxCreditsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ResearchTaxCreditsReceivableCurrent" xlink:to="lab_kprx_ResearchTaxCreditsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d5c60000-97a5-44a6-8d65-ee039d89fd15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e0ff305b-f7ee-45ae-bd2e-494f8e120a3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable and vested at the end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_529354ac-eaab-4026-9d2d-0a0b51e2a2a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized compensation expense related to restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_10a8472e-eb97-4a4d-9c5a-b8add33fe0b1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_3609b87a-79bf-4ca4-a7fe-58c2592fa727_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f7e9a4b3-5999-4514-b1ce-bf69f322b4e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_32e64f2b-bb6a-4cf6-84f7-b55402a70c29_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_MaximGroupLLCMember_6e17d23e-3e69-48e4-9871-55413dda9fdf_terseLabel_en-US" xlink:label="lab_kprx_MaximGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maxim Group LLC</link:label>
    <link:label id="lab_kprx_MaximGroupLLCMember_label_en-US" xlink:label="lab_kprx_MaximGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maxim Group LLC [Member]</link:label>
    <link:label id="lab_kprx_MaximGroupLLCMember_documentation_en-US" xlink:label="lab_kprx_MaximGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maxim Group LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MaximGroupLLCMember" xlink:href="kprx-20250331.xsd#kprx_MaximGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_MaximGroupLLCMember" xlink:to="lab_kprx_MaximGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1b11a7e9-dc75-48bb-bf0d-af2147b0e0fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unobservable Level 3 Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7683b952-72dd-4559-9958-78f9991ea36c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a40b026b-f319-47f5-862d-b7bd01c173bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b62d92c1-2857-4582-99d4-cd43784c3872_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1d7b4927-caf0-4213-99ef-7ce1fb52edf9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ff1f98f1-f942-4e52-8ee1-e2a7bf9e0570_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_f6831009-f2cd-4718-b995-0e9cd523a011_verboseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average exercise price of granted awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_98d1e12a-a1dd-4f9b-8f82-fd06e332d97b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in usd per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_LesseeNumberOfOperatingLeases_1bece580-6770-46cc-9f71-990b068ff020_terseLabel_en-US" xlink:label="lab_kprx_LesseeNumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating leases</link:label>
    <link:label id="lab_kprx_LesseeNumberOfOperatingLeases_label_en-US" xlink:label="lab_kprx_LesseeNumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Number Of Operating Leases</link:label>
    <link:label id="lab_kprx_LesseeNumberOfOperatingLeases_documentation_en-US" xlink:label="lab_kprx_LesseeNumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Number Of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeNumberOfOperatingLeases" xlink:href="kprx-20250331.xsd#kprx_LesseeNumberOfOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_LesseeNumberOfOperatingLeases" xlink:to="lab_kprx_LesseeNumberOfOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantsAbstract_3fc44e79-8a2c-4d23-83bd-f881bc2b76f9_terseLabel_en-US" xlink:label="lab_kprx_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_kprx_WarrantsAbstract_label_en-US" xlink:label="lab_kprx_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_kprx_WarrantsAbstract_documentation_en-US" xlink:label="lab_kprx_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract" xlink:href="kprx-20250331.xsd#kprx_WarrantsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantsAbstract" xlink:to="lab_kprx_WarrantsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_c1b4d70f-0270-43d3-b668-62a1a61b883a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_23dc0ebe-5b3b-4b72-87f9-bf91b9290c25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a65e0dee-a798-485f-bca4-a658e557bb12_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_9a7e8183-343d-4efb-ac83-5fc283b3723e_negatedTerseLabel_en-US" xlink:label="lab_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment Income and Fair Value Adjustments on Marketable Securities and Cash Equivalents</link:label>
    <link:label id="lab_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_label_en-US" xlink:label="lab_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment and Investment Income of Marketable Securities and Cash Equivalents</link:label>
    <link:label id="lab_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_documentation_en-US" xlink:label="lab_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment and Investment Income of Marketable Securities and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" xlink:href="kprx-20250331.xsd#kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" xlink:to="lab_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8630c489-455f-4ec4-acbf-d7dd723ca58b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38480ba3-d4b1-4217-bd34-fc1c160828d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_LiquidityAndCapitalResourcesPolicyTextBlock_01a17397-2133-4d45-92e8-952635b5ef1c_terseLabel_en-US" xlink:label="lab_kprx_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity And Capital Resources</link:label>
    <link:label id="lab_kprx_LiquidityAndCapitalResourcesPolicyTextBlock_label_en-US" xlink:label="lab_kprx_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity And Capital Resources [Policy Text Block]</link:label>
    <link:label id="lab_kprx_LiquidityAndCapitalResourcesPolicyTextBlock_documentation_en-US" xlink:label="lab_kprx_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liquidity And Capital Resources</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:href="kprx-20250331.xsd#kprx_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:to="lab_kprx_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_23432adf-9b86-4f4f-9736-e776171ecaf1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_TrancheBWarrantsMember_6c065a56-91db-4d14-96bc-ac80846691c8_terseLabel_en-US" xlink:label="lab_kprx_TrancheBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B Warrants</link:label>
    <link:label id="lab_kprx_TrancheBWarrantsMember_label_en-US" xlink:label="lab_kprx_TrancheBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B Warrants [Member]</link:label>
    <link:label id="lab_kprx_TrancheBWarrantsMember_documentation_en-US" xlink:label="lab_kprx_TrancheBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_TrancheBWarrantsMember" xlink:href="kprx-20250331.xsd#kprx_TrancheBWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_TrancheBWarrantsMember" xlink:to="lab_kprx_TrancheBWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_0ad0bc67-1341-4b71-a2d0-d030d642537d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_578443c3-45b3-42bf-bf48-2dee49de6c7f_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Common Shares Issuable Upon Exercise of Outstanding Warrants</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Awards [Roll Forward]</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:to="lab_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2789ce65-bb76-4ee2-a941-0e00873cd0dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one to five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_01d798b0-e16c-4870-a4e6-5b7a2cb4a836_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7cb95180-f0c9-43ba-934f-19681fe68f51_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_4f035078-ff5e-4177-9dba-782e8ce9539f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0959b6d7-7edd-4e4b-a887-b63d9b1725dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_22b4b59d-b0ce-45d5-a7ca-ec0b5a8fceef_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PrepaidGeneralAndAdministrative_5599fa12-ff2f-4314-ae2e-9042ac99d242_terseLabel_en-US" xlink:label="lab_kprx_PrepaidGeneralAndAdministrative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid General and Administrative</link:label>
    <link:label id="lab_kprx_PrepaidGeneralAndAdministrative_label_en-US" xlink:label="lab_kprx_PrepaidGeneralAndAdministrative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid General And Administrative</link:label>
    <link:label id="lab_kprx_PrepaidGeneralAndAdministrative_documentation_en-US" xlink:label="lab_kprx_PrepaidGeneralAndAdministrative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid General And Administrative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrepaidGeneralAndAdministrative" xlink:href="kprx-20250331.xsd#kprx_PrepaidGeneralAndAdministrative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PrepaidGeneralAndAdministrative" xlink:to="lab_kprx_PrepaidGeneralAndAdministrative" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_d737a51b-8e1d-49dd-bdbe-34c1ed7fb39c_negatedTerseLabel_en-US" xlink:label="lab_kprx_IncreaseDecreaseResearchTaxCreditsReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research Credit Receivables</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_label_en-US" xlink:label="lab_kprx_IncreaseDecreaseResearchTaxCreditsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Research Tax Credits Receivables</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_documentation_en-US" xlink:label="lab_kprx_IncreaseDecreaseResearchTaxCreditsReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Research Tax Credits Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseResearchTaxCreditsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables" xlink:to="lab_kprx_IncreaseDecreaseResearchTaxCreditsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_UnallocatedResearchAndDevelopmentMember_12043f0c-29cb-4c4d-a0cc-ff4317169a39_terseLabel_en-US" xlink:label="lab_kprx_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KIO-301 Collaboration Credit</link:label>
    <link:label id="lab_kprx_UnallocatedResearchAndDevelopmentMember_label_en-US" xlink:label="lab_kprx_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated Research and Development [Member]</link:label>
    <link:label id="lab_kprx_UnallocatedResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_kprx_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unallocated Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnallocatedResearchAndDevelopmentMember" xlink:href="kprx-20250331.xsd#kprx_UnallocatedResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_UnallocatedResearchAndDevelopmentMember" xlink:to="lab_kprx_UnallocatedResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_IncreaseDecreaseInAccruedCollaborationCredit_5a43fd96-5212-4714-816a-5fd4b66b9726_terseLabel_en-US" xlink:label="lab_kprx_IncreaseDecreaseInAccruedCollaborationCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Credit</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseInAccruedCollaborationCredit_label_en-US" xlink:label="lab_kprx_IncreaseDecreaseInAccruedCollaborationCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Credit</link:label>
    <link:label id="lab_kprx_IncreaseDecreaseInAccruedCollaborationCredit_documentation_en-US" xlink:label="lab_kprx_IncreaseDecreaseInAccruedCollaborationCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInAccruedCollaborationCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit" xlink:to="lab_kprx_IncreaseDecreaseInAccruedCollaborationCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_A5YearLeaseViennaAustriaMember_c4eb3787-970c-4b96-9144-85c350dce6f8_terseLabel_en-US" xlink:label="lab_kprx_A5YearLeaseViennaAustriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vienna Lease</link:label>
    <link:label id="lab_kprx_A5YearLeaseViennaAustriaMember_label_en-US" xlink:label="lab_kprx_A5YearLeaseViennaAustriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5 Year Lease, Vienna Austria [Member]</link:label>
    <link:label id="lab_kprx_A5YearLeaseViennaAustriaMember_documentation_en-US" xlink:label="lab_kprx_A5YearLeaseViennaAustriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5 Year Lease, Vienna Austria</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A5YearLeaseViennaAustriaMember" xlink:href="kprx-20250331.xsd#kprx_A5YearLeaseViennaAustriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_A5YearLeaseViennaAustriaMember" xlink:to="lab_kprx_A5YearLeaseViennaAustriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CollaborativeArrangementNumberOfPerformanceObligations_d79d925e-eaff-4fed-9545-7609f02b80fd_terseLabel_en-US" xlink:label="lab_kprx_CollaborativeArrangementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_kprx_CollaborativeArrangementNumberOfPerformanceObligations_label_en-US" xlink:label="lab_kprx_CollaborativeArrangementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Performance Obligations</link:label>
    <link:label id="lab_kprx_CollaborativeArrangementNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_kprx_CollaborativeArrangementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborativeArrangementNumberOfPerformanceObligations" xlink:href="kprx-20250331.xsd#kprx_CollaborativeArrangementNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CollaborativeArrangementNumberOfPerformanceObligations" xlink:to="lab_kprx_CollaborativeArrangementNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ea63bf4c-9bf6-4192-93fb-f4a70fa7e374_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_57e27d71-28eb-417a-94f9-97509a52c8d5_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_246a5348-b8e1-4744-80b4-8cbc11287a19_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_547523b9-edc9-43db-ba16-a9a6929d483f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e517ebcf-b4a0-4f37-b3c5-15862c3991da_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_145ceb13-ee20-43b8-9bc2-463b32a28142_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Marketable Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ea02b223-8e11-4548-9198-1e4e36a10587_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Marketable Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_cf3cd8f1-4959-484a-8d21-8c8446f3a0be_verboseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Fair Value Estimated</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock_43781d21-fcc9-4a25-9850-f9a6cfe5ce47_terseLabel_en-US" xlink:label="lab_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Tax and Other Receivables</link:label>
    <link:label id="lab_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock_label_en-US" xlink:label="lab_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Tax And Other Receivables [Table Text Block]</link:label>
    <link:label id="lab_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Tax And Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock" xlink:to="lab_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b6191da7-45d4-4acd-9a02-2dfbc078caee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00631496-c9ab-4d53-8dab-9c763f3c6f19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ef388b4f-b3cd-4bcf-8bf8-abd00c0aa1e5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants issued to purchase the shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1d6be8c5-3a35-4ea4-b799-ce2f5c1d2e4b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_ccd5b8d0-a3f9-4ad4-8cc5-5ee01a191e60_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_8e35736e-3542-458c-bbe7-5ee5d5f9245c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income Attributable to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_87a5e4e9-65fa-41d7-9bb1-a051ba3fb03c_terseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_a580a8d8-beb5-4916-93ef-f9371d6dbf96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2be568ad-d266-41f0-b5fe-79e41f6ec56e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_60256edf-d458-4e46-9f54-f991f462bbe9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember_077b601c-5bc3-4002-b106-14e82a4004ab_terseLabel_en-US" xlink:label="lab_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Encinitas Lease</link:label>
    <link:label id="lab_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember_label_en-US" xlink:label="lab_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3 Year 3 Month Lease, Encinitas California [Member]</link:label>
    <link:label id="lab_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember_documentation_en-US" xlink:label="lab_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3 Year 3 Month Lease, Encinitas California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember" xlink:href="kprx-20250331.xsd#kprx_A3Year3MonthLeaseEncinitasCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember" xlink:to="lab_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7c23526c-9278-4a12-b438-37cb6afba8a9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_f3675c3e-3e96-4a22-a354-d085e4d4accf_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5d656c01-56f3-4893-8b80-539380ba8d19_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, $0.01 Par Value: 150,000,000 shares authorized; 3,000,788 shares issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_e12b3800-373b-4da8-98fd-9cd8e47c0201_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_67a73ff7-7b30-456a-a6a1-005e37760a43_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_501ac7f9-7968-4d7e-b8d9-096e4926d211_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_23aecda3-1268-44a4-a35c-ef2a448fa209_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_08318859-93e5-4e13-9c83-3fd8c5fd7007_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed44fd74-f731-4df3-b71e-039e799582d8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Shares Outstanding - Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ee354767-2c16-416b-99e9-9231db854835_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5ed35642-ea95-4c79-998e-cb9e257c45bd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7829b55b-07b7-4099-8417-c0dd31492fde_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_8da31d4f-6491-4708-afe1-ec9189be4b5a_terseLabel_en-US" xlink:label="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_label_en-US" xlink:label="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee and Non Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table Text Block]</link:label>
    <link:label id="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_documentation_en-US" xlink:label="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of employee and non employee service share based compensation allocation of recognized period costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:href="kprx-20250331.xsd#kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:to="lab_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_TrancheAWarrantsMember_d69926bf-cbc7-4d84-a4c6-38b06fd6a4bc_terseLabel_en-US" xlink:label="lab_kprx_TrancheAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche A Warrants</link:label>
    <link:label id="lab_kprx_TrancheAWarrantsMember_label_en-US" xlink:label="lab_kprx_TrancheAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche A Warrants [Member]</link:label>
    <link:label id="lab_kprx_TrancheAWarrantsMember_documentation_en-US" xlink:label="lab_kprx_TrancheAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche A Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_TrancheAWarrantsMember" xlink:href="kprx-20250331.xsd#kprx_TrancheAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_TrancheAWarrantsMember" xlink:to="lab_kprx_TrancheAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1fef118d-10ba-4958-aab7-0cfb998a5711_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6f275ae3-7b7b-410c-8d48-20f843e08faf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_550ea435-3713-4c76-a1fb-d94c65d2b267_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_068e60f9-eb80-4aff-b706-86b5462a17e9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_d7548abf-f991-4aa9-be70-35a81887aa47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance Costs for Private Placement</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c330c464-69b6-4708-acf6-ceb2068feac8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0c190639-839a-4472-87d2-49b58b727a1d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ResearchAndDevelopmentAllocationDomain_380ce39e-2a41-4b68-a099-19c05a30d883_terseLabel_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentAllocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Allocation [Domain]</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentAllocationDomain_label_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentAllocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Allocation [Domain]</link:label>
    <link:label id="lab_kprx_ResearchAndDevelopmentAllocationDomain_documentation_en-US" xlink:label="lab_kprx_ResearchAndDevelopmentAllocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Allocation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentAllocationDomain" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentAllocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain" xlink:to="lab_kprx_ResearchAndDevelopmentAllocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_77fe86d2-a6b0-4777-b86b-b93a0918ab04_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one to five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_98ab90bc-57a0-4fe5-9b31-7033d7f0c405_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_250a3594-86c8-4aad-8cb3-1e757ef00ed4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_057bb7c1-1679-4331-a70b-79cf51df70cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9d89f03d-0fe1-4f3e-8a68-fc87d3e34de2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_88d00a07-f972-43a5-8a95-ce289a3c24c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_88f13b6a-8bcc-436f-ac99-d011644506dd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_cd0bb0ab-4c79-428c-91a4-4cb20fa83905_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2b653f40-e7f7-4404-b526-aba1fac2519f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_79c6a98d-a470-4b45-8c66-1517b191e57d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income per Share - Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_262ea280-4bff-42bf-943d-ab24ed12c1f7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e3db0f15-b17c-442a-994d-61d6bb590fc9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_NumberOfLicenseAgreements_bba18ea8-5632-4ec8-8a4e-ebdc7fbb3518_terseLabel_en-US" xlink:label="lab_kprx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of license agreements</link:label>
    <link:label id="lab_kprx_NumberOfLicenseAgreements_label_en-US" xlink:label="lab_kprx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:label id="lab_kprx_NumberOfLicenseAgreements_documentation_en-US" xlink:label="lab_kprx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfLicenseAgreements" xlink:href="kprx-20250331.xsd#kprx_NumberOfLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_NumberOfLicenseAgreements" xlink:to="lab_kprx_NumberOfLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5175d87c-3cc0-4d15-abee-da91ecdd5094_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_38a31109-f668-4df2-a2c0-a28f7639202b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a01e91e3-aae2-4683-b049-27e6d3b89b37_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8e6de2b2-60fe-4ec6-90f0-3ff9d0ed18aa_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_5f385d24-69cc-4762-9580-31d5851b0988_negatedTerseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired In Period</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e7499b57-369c-4bbb-9380-bcab86210a88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_5d5626e0-1dc2-4a29-b5c3-3561b88d9590_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_286bcb2d-8a7a-4aa6-8955-8a9ca4f1ec88_terseLabel_en-US" xlink:label="lab_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of Prepaid expenses and Other Current Assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ba482652-b815-4c87-a4ca-cd82ccbe1668_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_17245cc0-6c94-41a8-a353-ff651bc26487_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b5852f8c-9c8e-4ebb-916f-d07125d7202c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Term in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_84f5c463-4e6b-46b7-a03f-b3ca5aad7b3a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_1778508f-45ca-47f4-8d12-71a3f5d0d6ef_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_274c1ad3-540f-4086-8f77-a86f13edb270_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_a43e889b-b235-436a-8e30-729322e3496c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_82c9e2f8-1dca-4db8-9be5-f1b87235e1b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c9fb10d1-896a-4c95-80fc-7d8a829aec22_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_cb635b5a-e1da-42cf-9c1e-aa1ae0845dee_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cc236b83-a246-4740-80e5-ce3d4972bd71_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income per Common Share - Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1dda1202-b87f-474b-8f5d-e194bee470b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0702fa49-b2e3-4633-b1d1-4a3ae38eb40e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3e530631-0b6c-4d14-9618-efbdf000d408_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d91d8f22-ab8b-4d52-8470-f4dbbe90277c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_8a5c16e6-2a06-4fe9-ae6f-d4423232d1f2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_KIO301Member_7083fc89-dc52-408e-9183-66d2a923b494_terseLabel_en-US" xlink:label="lab_kprx_KIO301Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KIO-301</link:label>
    <link:label id="lab_kprx_KIO301Member_label_en-US" xlink:label="lab_kprx_KIO301Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KIO-301 [Member]</link:label>
    <link:label id="lab_kprx_KIO301Member_documentation_en-US" xlink:label="lab_kprx_KIO301Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KIO-301</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO301Member" xlink:href="kprx-20250331.xsd#kprx_KIO301Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_KIO301Member" xlink:to="lab_kprx_KIO301Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_676133c4-8c78-45d0-ba3f-e7982329b684_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_480c75a8-9a2f-4dcf-aa8b-242d16ba1194_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e7aa31b3-4ded-46af-bab3-42f8dd9bdbd4_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Other Income, Net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4a82d3a3-090b-4a5b-8c0b-39ff7c3c2460_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Potential Common Stock Equivalents are not Included in the Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_662c9fd8-70a6-4ff1-92ea-630cbf113410_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_54a0143a-84c4-441f-a2d5-0cd782960400_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c26c3423-f454-435a-94af-722f052f9741_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less Amounts Representing Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_MultiPeriodExcessEarningsMethodMember_64d02aad-d56a-41af-ab01-32cdc7587dec_terseLabel_en-US" xlink:label="lab_kprx_MultiPeriodExcessEarningsMethodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multi-Period Excess Earnings Method</link:label>
    <link:label id="lab_kprx_MultiPeriodExcessEarningsMethodMember_label_en-US" xlink:label="lab_kprx_MultiPeriodExcessEarningsMethodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Multi-Period Excess Earnings Method [Member]</link:label>
    <link:label id="lab_kprx_MultiPeriodExcessEarningsMethodMember_documentation_en-US" xlink:label="lab_kprx_MultiPeriodExcessEarningsMethodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Multi-Period Excess Earnings Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MultiPeriodExcessEarningsMethodMember" xlink:href="kprx-20250331.xsd#kprx_MultiPeriodExcessEarningsMethodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_MultiPeriodExcessEarningsMethodMember" xlink:to="lab_kprx_MultiPeriodExcessEarningsMethodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9d6e8dca-8ed5-4621-b2b8-3ac8ccc162fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8c090666-ec76-4bf2-9f5a-56671bf93122_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4222bd1c-c65f-44d8-a7dd-3ee2ec096383_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payroll and Benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fef541c-c0c8-4ce8-b27f-9c743bd2e0a2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4199dab2-7ed8-4cba-a74c-cceb18b1e344_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6f62b635-2b59-4a94-bdf6-74148b296423_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_50b3ef52-e06b-45fb-baf8-c0aea0f9af43_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1b9463f5-b01e-4bc3-a5c4-a42c3145db6c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_a92aecde-d231-4645-ab65-5ed7abe98881_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Investments Gross Unrealized Losses and Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncumulativePreferredStockMember_169f4c56-afd9-490e-9689-53f1588023d6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncumulativePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, as Converted into Common Stock</link:label>
    <link:label id="lab_us-gaap_NoncumulativePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_NoncumulativePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncumulative Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncumulativePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncumulativePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncumulativePreferredStockMember" xlink:to="lab_us-gaap_NoncumulativePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_53646b8a-27fe-4e70-88a3-8b0f3a0f1987_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_13847f39-8866-4357-a743-5670b11385cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db46d341-dc39-4caf-b0b3-233333467058_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4c976566-e7c1-4fa2-a9ed-32d0e59d0051_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f23a876f-8466-4caa-99d0-64791270ec29_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0f93dced-5d50-4687-9f65-8db63f209fa5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable and vested at the end of year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_PanoptesMember_6db4b5b1-a93e-4372-91e4-32411bcd6773_terseLabel_en-US" xlink:label="lab_kprx_PanoptesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Panoptes</link:label>
    <link:label id="lab_kprx_PanoptesMember_label_en-US" xlink:label="lab_kprx_PanoptesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Panoptes [Member]</link:label>
    <link:label id="lab_kprx_PanoptesMember_documentation_en-US" xlink:label="lab_kprx_PanoptesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to acquisition of Panoptes Pharma Ges.m.b.H.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesMember" xlink:href="kprx-20250331.xsd#kprx_PanoptesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_PanoptesMember" xlink:to="lab_kprx_PanoptesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4cdd976a-76fd-4b02-9f49-1443101fe2b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_95ea2ad2-4f52-4ff1-9685-77e50f52745f_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_46cf2bec-ba52-492f-bf6d-c77bfa581728_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b6cc75ab-34ea-4ea2-be4f-66278c9cd520_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c7b69493-5c91-49fa-822d-3a93028ce679_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating (Loss) Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_93a90823-dc62-4c0b-b8d4-97a1998ca990_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2925317e-5e90-4706-b5ea-cb54a4a1fa97_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5d1b27cd-7307-4a4c-b9b5-90d7840782a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_EquityIncentivePlan2014Member_c6a37656-e65c-4b90-8c74-7980f965f085_terseLabel_en-US" xlink:label="lab_kprx_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_kprx_EquityIncentivePlan2014Member_label_en-US" xlink:label="lab_kprx_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_kprx_EquityIncentivePlan2014Member_documentation_en-US" xlink:label="lab_kprx_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityIncentivePlan2014Member" xlink:href="kprx-20250331.xsd#kprx_EquityIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_EquityIncentivePlan2014Member" xlink:to="lab_kprx_EquityIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_3a593a64-d841-4b7e-9244-d7fd19583aed_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Count</link:label>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:to="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_16ef60aa-fe7f-4a09-9c14-b588e3e4cd92_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_634de126-48ad-4f28-b2f0-8f15e23dd3b2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_8fb684c3-52c6-4c3d-a3d9-e88c4aa848a3_terseLabel_en-US" xlink:label="lab_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases</link:label>
    <link:label id="lab_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:label id="lab_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_eaf1f7b2-070a-46d5-bbcd-05c29df9fc6e_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Loss) Income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_44d9a239-27f7-4ba4-9a75-26ee36f575de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Count</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a96c3568-67e6-46a2-939c-e18c95a7dbc2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c73c81c4-9c6f-424b-9fc3-c0a8d6b2b162_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1d07b703-cb86-4f54-a526-5b30448b856a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7c74b48-4dc1-4ff5-91fb-d48d0f6b4ae4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a6c49afb-da1e-43ee-bbd0-25de05b8bef3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_67052e1a-fdcf-4807-b6af-67384895fe51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Expense) Income, Net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_eeb390e8-a988-43e1-977d-e80c4bdfd816_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_WarrantsDisclosureTextBlock_1068aa71-f294-41cd-845d-b4e92631901f_terseLabel_en-US" xlink:label="lab_kprx_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_kprx_WarrantsDisclosureTextBlock_label_en-US" xlink:label="lab_kprx_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Disclosure [Text Block]</link:label>
    <link:label id="lab_kprx_WarrantsDisclosureTextBlock_documentation_en-US" xlink:label="lab_kprx_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsDisclosureTextBlock" xlink:href="kprx-20250331.xsd#kprx_WarrantsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_WarrantsDisclosureTextBlock" xlink:to="lab_kprx_WarrantsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_68c71991-2b21-4743-8cd6-95f00fe14985_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net (Loss) Income to Net Cash (Used in) Provided by Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0ac3b00b-8bcb-4395-9510-e2fce915bbcd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30ccc5d5-d071-43a5-b234-9d100bd20491_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_c9caf3d1-4206-4268-bbb6-31370d6ce625_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_14c08613-bbd4-452a-a564-bcea334bfb61_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive shares excluded from the calculation of net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_476c99e7-9937-4dfd-8626-1a1cd34fbd6d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_66e9adea-2fa2-48c8-aab2-b1b727ea0d64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_42002853-7793-4145-be4e-9a245d8547f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember_9b7dc19a-7183-47c2-8369-75d70dcb8fc7_terseLabel_en-US" xlink:label="lab_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of success for next development phase</link:label>
    <link:label id="lab_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember_label_en-US" xlink:label="lab_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability Of Success For Development Phase [Member]</link:label>
    <link:label id="lab_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember_documentation_en-US" xlink:label="lab_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probability Of Success For Development Phase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember" xlink:href="kprx-20250331.xsd#kprx_ProbabilityOfSuccessForDevelopmentPhaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember" xlink:to="lab_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_899998ff-54b8-4461-a009-e6d3474172a8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e258698-6f18-4d32-b3a8-ee79d8d0a7d0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Discount Rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_21376de5-4a17-4dc0-8205-3d44f728d680_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bab61963-6117-4fc0-b513-dbe0e3763be3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e7ab1597-781e-48b6-8a84-6bfef3b9faad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d3fe2eb8-5d56-4dd7-bd79-5f128542d7c9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Shares Outstanding - Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d28e6a94-c4b7-4bd2-903b-8d98663688fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_62530234-20fb-4e76-b4cd-f4e820ad9cdb_terseLabel_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, threshold consecutive trading days</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:to="lab_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1ba8bdb6-495c-47bf-9315-2471bad34a84_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_321d7de9-d781-4a54-b078-a90deb110652_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash, Non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a085f98e-73fa-4f0a-9e47-9bcfce71b1aa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_CollaborationCreditReceivableCurrent_ab454470-7d52-47e1-b18a-d6d54126becd_terseLabel_en-US" xlink:label="lab_kprx_CollaborationCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Credit</link:label>
    <link:label id="lab_kprx_CollaborationCreditReceivableCurrent_label_en-US" xlink:label="lab_kprx_CollaborationCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Credit Receivable, Current</link:label>
    <link:label id="lab_kprx_CollaborationCreditReceivableCurrent_documentation_en-US" xlink:label="lab_kprx_CollaborationCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Credit Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditReceivableCurrent" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_CollaborationCreditReceivableCurrent" xlink:to="lab_kprx_CollaborationCreditReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_7cb593be-a6e1-491a-8603-efe3a2254c49_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7b9d3cf4-4180-49e8-b864-cb2c5f72f31e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_5dff762f-b700-4530-9a1a-f2c43e4dcaa1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice_b5730be1-cba3-46c3-a99a-b26d5f11423d_terseLabel_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised Weighted Average Exercise Price</link:label>
    <link:label id="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average exercise price of Vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" xlink:to="lab_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e2ec55c0-411a-4d3d-a1fe-f7849f02effd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b76099d9-2455-4d11-9472-556b25464a85_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08f10205-5f8e-45c6-ad35-f06c083bdfe9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5e981972-6974-484e-8eef-a73290ff7509_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8d01d261-d18a-4ce1-921b-6370970781ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_78e0575d-1ea3-4203-9df9-47137864cc25_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax Receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_ea8af64c-d73a-4ef3-a00c-7d4b1398df26_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Tax Receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0a27f465-42cb-4754-b6dc-a3894c1344eb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6ba503d7-3844-4176-ba60-ee3bd8528316_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_29980952-4306-41c9-8831-06124df1f862_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_us-gaap_SeriesEPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_c563afd0-e746-49f6-b9db-8d684756d9cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2f05f2f5-3795-4a92-8fe5-fbc6d8f5fe14_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_LesseeOperatingLeaseTerminationPeriod_83cf2986-2187-4291-9872-b6df8b85f32e_terseLabel_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_kprx_LesseeOperatingLeaseTerminationPeriod_label_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_kprx_LesseeOperatingLeaseTerminationPeriod_documentation_en-US" xlink:label="lab_kprx_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseTerminationPeriod" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_LesseeOperatingLeaseTerminationPeriod" xlink:to="lab_kprx_LesseeOperatingLeaseTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_5de560a8-b2e9-45cf-bb2d-57b0bf84bd07_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2a696b49-9ba1-4a37-9863-f686f19e911c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f1864955-f7d4-49e3-b16f-3bcbf0358f51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_10712b96-825e-43b3-9dcd-bf59d7952bc8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_a76e3e85-b2dc-44a7-855c-3ef931904246_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Non-Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6db12845-25e9-40e6-8f8c-33e6d5732879_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_80ca1e3c-c4c1-4bd3-9241-276ed0f7b872_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_75d3739c-2689-4376-9299-e8443cc63c8d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_287d6219-94ac-487c-b490-b1e860f7f34a_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_1812b300-c436-430d-97f5-d11ad4c10acd_terseLabel_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock from Warrant Exercises (in shares)</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="kprx-20250331.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_kprx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_61145148-cec1-4c4a-a911-2526c958bb21_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_91062aa9-874e-4f18-948b-041d394fd46b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_042b4a09-0712-4edc-9a69-ad6f626db463_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0d01e7a-2568-4afd-83c6-06d1bb9a041b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e1aea024-02e6-4cbf-848b-a191cb50e754_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_680c8ff6-0d1e-4415-acea-c1c9a2361bcc_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_7538f8ad-69c0-4eea-afeb-4fd833f5b8c4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Backed Securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3e960fd0-4c18-446b-bcb9-9da8446bc85c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc4a7de6-d123-4af0-841e-c9368708343e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5bda20cb-15e4-468d-bf75-87648032756f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0827e93f-308b-4842-b6e8-04615be5a83b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_0a90b595-830f-43bd-a574-53d0f8dbad6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2b0f9159-17a3-4ac6-be6e-12ec14d88ebd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_61131db2-dd4a-4162-ae53-0ba94e41a1c6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ba2f31a2-e71e-455d-9574-1a2de3b2dfc4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_76341fca-10d3-4ca9-b568-bc0967214799_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f9a829bf-39eb-4829-bc54-87c0058e0fe8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_20d599a7-051e-4839-b83b-d780cc07c48e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_50d89ad8-666a-4a82-b139-c3e782335a26_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6b607b4c-1265-4f19-9497-ac836527eaf9_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_49733659-ee2a-4fd0-bcee-f84858bdb449_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_3a7debc6-342b-4c3e-83a6-6a887a39b262_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a0e59a6d-e958-4541-a41f-cacf978daa0c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7994cb77-11c6-459e-b32b-d1d02e64a73a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>kprx-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0167d6af-99d4-4c6f-8900-ecd7455d4d35,g:cf0f15d1-3949-48fc-a909-df68c07a7e6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d9fc7612-3d6b-4e90-993f-51ee3c8124f7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_DocumentType_d9fc7612-3d6b-4e90-993f-51ee3c8124f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5a6e28a4-d835-49ed-8bdb-fdda74d1b299" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_DocumentQuarterlyReport_5a6e28a4-d835-49ed-8bdb-fdda74d1b299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_30cff3e0-9bcc-4fc4-bc1f-c0cb8a4c49f4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_DocumentPeriodEndDate_30cff3e0-9bcc-4fc4-bc1f-c0cb8a4c49f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9e29509c-5510-48b1-9edb-da30318f1f33" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_DocumentTransitionReport_9e29509c-5510-48b1-9edb-da30318f1f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bba72bf5-4212-4d15-9709-ba445df7cd5e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityFileNumber_bba72bf5-4212-4d15-9709-ba445df7cd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_400356ad-23e8-4dac-9b8c-07c199e1d972" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityRegistrantName_400356ad-23e8-4dac-9b8c-07c199e1d972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1cef447c-6220-4baf-8d67-1cb32807897e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1cef447c-6220-4baf-8d67-1cb32807897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_73bd697d-e593-4fd5-b2d0-1a10a6c0dc5d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityTaxIdentificationNumber_73bd697d-e593-4fd5-b2d0-1a10a6c0dc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e60ad64d-d9a1-4670-895e-e15c3073a69e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityAddressAddressLine1_e60ad64d-d9a1-4670-895e-e15c3073a69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c6bc6b7d-e939-4047-a848-9abe26e412c3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityAddressAddressLine2_c6bc6b7d-e939-4047-a848-9abe26e412c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_74d73419-6d7f-49e3-9f5c-f2d5e59fe5f6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityAddressCityOrTown_74d73419-6d7f-49e3-9f5c-f2d5e59fe5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a5ec3474-81ff-427a-a06e-8717b28190da" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityAddressStateOrProvince_a5ec3474-81ff-427a-a06e-8717b28190da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_25d79877-ebe3-4be9-a18b-2f8f77752c88" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityAddressPostalZipCode_25d79877-ebe3-4be9-a18b-2f8f77752c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_231b0251-b3e6-4d7e-8aad-fa0b87f47635" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_CityAreaCode_231b0251-b3e6-4d7e-8aad-fa0b87f47635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bca9f15c-6821-465a-9cba-07f1190067d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_LocalPhoneNumber_bca9f15c-6821-465a-9cba-07f1190067d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4d7b9aa7-5596-4f0e-a034-a06e214365f1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_Security12bTitle_4d7b9aa7-5596-4f0e-a034-a06e214365f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_52f67df2-e343-470c-9f37-1a09d4d23292" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_TradingSymbol_52f67df2-e343-470c-9f37-1a09d4d23292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cc5b6e0f-67fe-4b2b-9646-df07996c708f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_SecurityExchangeName_cc5b6e0f-67fe-4b2b-9646-df07996c708f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0973bbfe-2d35-403b-91a2-bd7adc2196e9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityCurrentReportingStatus_0973bbfe-2d35-403b-91a2-bd7adc2196e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e50c0665-b4ee-411f-bf5a-9d6d38fdf7d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityInteractiveDataCurrent_e50c0665-b4ee-411f-bf5a-9d6d38fdf7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_192566f8-fae6-4745-b697-0ab14e671746" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityFilerCategory_192566f8-fae6-4745-b697-0ab14e671746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_722be3d2-501c-4fff-a91a-093f9747e4a6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntitySmallBusiness_722be3d2-501c-4fff-a91a-093f9747e4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2938c5cf-7bc3-4bbb-bf6a-1dba0964767f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityEmergingGrowthCompany_2938c5cf-7bc3-4bbb-bf6a-1dba0964767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_70ba423b-2e33-45ae-b768-96c9917a00b2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityShellCompany_70ba423b-2e33-45ae-b768-96c9917a00b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a6f4f4da-1ece-4dc9-b3b2-1d42dae18cc2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a6f4f4da-1ece-4dc9-b3b2-1d42dae18cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8ff7c0ba-a630-4044-9a84-069a0d0b0d71" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_EntityCentralIndexKey_8ff7c0ba-a630-4044-9a84-069a0d0b0d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a88848e5-8d45-4ff2-85a8-d88033391b8b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_CurrentFiscalYearEndDate_a88848e5-8d45-4ff2-85a8-d88033391b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e23b706b-5ae2-4e58-95a0-4e27f3bf3951" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_DocumentFiscalYearFocus_e23b706b-5ae2-4e58-95a0-4e27f3bf3951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4b4518ef-d947-4b31-aba0-c183b48b6e0d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4b4518ef-d947-4b31-aba0-c183b48b6e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e38f9e34-2474-46ff-aaab-e31bb0f75f8e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4156d33-a43c-4dde-9320-a9869c7a2618" xlink:to="loc_dei_AmendmentFlag_e38f9e34-2474-46ff-aaab-e31bb0f75f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_968d8366-0ea8-40b8-8cc0-2e07e888aa7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a0628803-cef8-439b-a8a8-39b2088af19b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_968d8366-0ea8-40b8-8cc0-2e07e888aa7e" xlink:to="loc_us-gaap_AssetsAbstract_a0628803-cef8-439b-a8a8-39b2088af19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a0628803-cef8-439b-a8a8-39b2088af19b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57d3295c-c608-48f8-96e0-322c8eabb77b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57d3295c-c608-48f8-96e0-322c8eabb77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c48b91da-cb8b-43d0-b561-e45b92d8b11c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:to="loc_us-gaap_ShortTermInvestments_c48b91da-cb8b-43d0-b561-e45b92d8b11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9477cfb0-8959-4cfe-b518-8a50e833aa05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9477cfb0-8959-4cfe-b518-8a50e833aa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a1df6f2d-a934-4279-8250-f6dc7fa2c3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a1df6f2d-a934-4279-8250-f6dc7fa2c3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_4bf7a0cb-3789-45bb-baa6-d39bd434d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:to="loc_us-gaap_IncomeTaxesReceivable_4bf7a0cb-3789-45bb-baa6-d39bd434d7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_09c87cc2-c489-4c7d-958d-cef91abcecc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_660c77c1-7fb5-4bdc-8af2-41d41844b1d7" xlink:to="loc_us-gaap_AssetsCurrent_09c87cc2-c489-4c7d-958d-cef91abcecc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_32edfe17-48fa-4450-8776-426b3ce7f1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a0628803-cef8-439b-a8a8-39b2088af19b" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_32edfe17-48fa-4450-8776-426b3ce7f1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c8b263eb-09c9-4cec-822b-d711bdd52e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_32edfe17-48fa-4450-8776-426b3ce7f1ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c8b263eb-09c9-4cec-822b-d711bdd52e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c3d8e751-4ca5-4fb0-9633-286bfe59c742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_32edfe17-48fa-4450-8776-426b3ce7f1ba" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c3d8e751-4ca5-4fb0-9633-286bfe59c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1c50cb5d-d3bc-4c22-b06b-91b10f3411d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_32edfe17-48fa-4450-8776-426b3ce7f1ba" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1c50cb5d-d3bc-4c22-b06b-91b10f3411d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_df952e22-af7e-431f-81c8-072264954749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_32edfe17-48fa-4450-8776-426b3ce7f1ba" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_df952e22-af7e-431f-81c8-072264954749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_40096075-816d-4638-ac4e-55fd46e05f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_32edfe17-48fa-4450-8776-426b3ce7f1ba" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_40096075-816d-4638-ac4e-55fd46e05f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2e05d432-59a2-4028-a380-a49385afe27d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a0628803-cef8-439b-a8a8-39b2088af19b" xlink:to="loc_us-gaap_Assets_2e05d432-59a2-4028-a380-a49385afe27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_968d8366-0ea8-40b8-8cc0-2e07e888aa7e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_321d5727-6bdd-46e6-b741-ef444c808d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_321d5727-6bdd-46e6-b741-ef444c808d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_28b412ac-8143-4f27-8057-eb0fdc16a44d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_321d5727-6bdd-46e6-b741-ef444c808d5b" xlink:to="loc_us-gaap_AccountsPayableCurrent_28b412ac-8143-4f27-8057-eb0fdc16a44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c3a53e62-20ba-454a-990c-d906156dee83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_321d5727-6bdd-46e6-b741-ef444c808d5b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c3a53e62-20ba-454a-990c-d906156dee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditReceivableCurrent_0ca27cf6-d772-4da8-acd2-f627c85d345e" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_321d5727-6bdd-46e6-b741-ef444c808d5b" xlink:to="loc_kprx_CollaborationCreditReceivableCurrent_0ca27cf6-d772-4da8-acd2-f627c85d345e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1740638-1b05-446d-98e7-ab278ab26f65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_321d5727-6bdd-46e6-b741-ef444c808d5b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1740638-1b05-446d-98e7-ab278ab26f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44e02baf-6d1b-4547-8288-8cd093bf76ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_321d5727-6bdd-46e6-b741-ef444c808d5b" xlink:to="loc_us-gaap_LiabilitiesCurrent_44e02baf-6d1b-4547-8288-8cd093bf76ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_d852ec22-d8a4-4a5e-abf3-bb842415476e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_d852ec22-d8a4-4a5e-abf3-bb842415476e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bace7d53-9076-40c1-ba71-c280e7fee07e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d852ec22-d8a4-4a5e-abf3-bb842415476e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bace7d53-9076-40c1-ba71-c280e7fee07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7ce75668-883c-4a83-9ba8-1c4ed7e94572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d852ec22-d8a4-4a5e-abf3-bb842415476e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7ce75668-883c-4a83-9ba8-1c4ed7e94572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36235cef-a6cc-4bb4-8592-5de3f8fd61a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d852ec22-d8a4-4a5e-abf3-bb842415476e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_36235cef-a6cc-4bb4-8592-5de3f8fd61a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_8fda53b0-515a-4a37-ae65-da9ef10a236d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d852ec22-d8a4-4a5e-abf3-bb842415476e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_8fda53b0-515a-4a37-ae65-da9ef10a236d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c052161e-f6f6-4479-8898-efc0202e85db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:to="loc_us-gaap_Liabilities_c052161e-f6f6-4479-8898-efc0202e85db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cb276175-e8d4-44dc-a615-360844291e03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cb276175-e8d4-44dc-a615-360844291e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b05d7d76-0e82-45b2-adcd-5dfa70675ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:to="loc_us-gaap_PreferredStockValue_b05d7d76-0e82-45b2-adcd-5dfa70675ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9a098fac-cfc3-4cc1-a2b9-c8b970e5cd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:to="loc_us-gaap_CommonStockValue_9a098fac-cfc3-4cc1-a2b9-c8b970e5cd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dfbafce1-b738-4db5-9dd9-65a1e751a9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dfbafce1-b738-4db5-9dd9-65a1e751a9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b744094-3f14-4f24-85ef-1a431c29a6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b744094-3f14-4f24-85ef-1a431c29a6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a74a0553-8f17-476d-a507-108e5aa1a49f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a74a0553-8f17-476d-a507-108e5aa1a49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7666a7b-3bce-4a61-a6b5-34671dcf7ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6c8bf200-9118-438e-a524-0ece0de69d2a" xlink:to="loc_us-gaap_StockholdersEquity_a7666a7b-3bce-4a61-a6b5-34671dcf7ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9dd3d712-7239-42f4-8e07-2ff619c728b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd7cb2c0-63f3-4fc3-b589-42874c87bcaf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9dd3d712-7239-42f4-8e07-2ff619c728b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fd237ab9-580d-414d-b2ae-286083bbfa96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f619eb9-7c66-45cd-a504-5185bf3766a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd237ab9-580d-414d-b2ae-286083bbfa96" xlink:to="loc_us-gaap_StatementTable_1f619eb9-7c66-45cd-a504-5185bf3766a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8d99456b-06ad-4479-970b-ed3c0dddf487" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f619eb9-7c66-45cd-a504-5185bf3766a7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8d99456b-06ad-4479-970b-ed3c0dddf487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8d99456b-06ad-4479-970b-ed3c0dddf487" xlink:to="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2056f41d-d1b3-4bfa-82cb-8402a59eaad4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2056f41d-d1b3-4bfa-82cb-8402a59eaad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_50b4dd30-13e8-410f-a9bb-3b97845d20bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_50b4dd30-13e8-410f-a9bb-3b97845d20bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_fd8d1661-6fb5-4539-b582-e67aa0fbca7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_fd8d1661-6fb5-4539-b582-e67aa0fbca7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_da031fe2-0bd0-44f3-9ca4-7824a828f7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_da031fe2-0bd0-44f3-9ca4-7824a828f7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_39fd5c00-ed54-4533-a698-134ca0356d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_39fd5c00-ed54-4533-a698-134ca0356d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_aef3d88a-b10e-4256-b9a1-362b9c572118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_794a8775-5cef-469d-994a-8cfd2f9e5741" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_aef3d88a-b10e-4256-b9a1-362b9c572118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f619eb9-7c66-45cd-a504-5185bf3766a7" xlink:to="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d23b5be-cb5c-4a4f-b2fb-f684a1572134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d23b5be-cb5c-4a4f-b2fb-f684a1572134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b6834c56-81ec-4953-8671-d93f61ad9a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b6834c56-81ec-4953-8671-d93f61ad9a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreferredStockDesignatedShares_b6b3144c-8e7c-4591-a0d1-22f210509345" xlink:href="kprx-20250331.xsd#kprx_PreferredStockDesignatedShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_kprx_PreferredStockDesignatedShares_b6b3144c-8e7c-4591-a0d1-22f210509345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_04107e4f-74bb-4d5f-99c1-1e8a5d58f499" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_04107e4f-74bb-4d5f-99c1-1e8a5d58f499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7b56d383-3beb-4eb6-b1bc-c2cd2c9eef35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7b56d383-3beb-4eb6-b1bc-c2cd2c9eef35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_85f5d74d-b90f-44a3-a0d5-8906cbde0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_85f5d74d-b90f-44a3-a0d5-8906cbde0d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ed3b8bd3-aa29-4cb9-8245-4280d5450e05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ed3b8bd3-aa29-4cb9-8245-4280d5450e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d6940082-5cb8-48e6-b9c6-1093f9d32ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockSharesIssued_d6940082-5cb8-48e6-b9c6-1093f9d32ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f2f7c218-65fa-49f0-a249-a4f1cd727919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f224f69-8e0a-46bb-b800-14f22d7a483e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f2f7c218-65fa-49f0-a249-a4f1cd727919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_715bd187-19c1-4392-867b-66e869ea3874" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_RevenuesAbstract_715bd187-19c1-4392-867b-66e869ea3874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_51ec0d41-9ff9-4b08-8d47-7b6d343fb227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_715bd187-19c1-4392-867b-66e869ea3874" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_51ec0d41-9ff9-4b08-8d47-7b6d343fb227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1665fcbc-3b2e-49cc-afc8-972c62cb3b48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_715bd187-19c1-4392-867b-66e869ea3874" xlink:to="loc_us-gaap_Revenues_1665fcbc-3b2e-49cc-afc8-972c62cb3b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_349a35df-0e1f-4ac5-9b72-b00740eb9556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_349a35df-0e1f-4ac5-9b72-b00740eb9556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e8f91a5d-b682-4166-a480-8a208aebc8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_349a35df-0e1f-4ac5-9b72-b00740eb9556" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e8f91a5d-b682-4166-a480-8a208aebc8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_57a09dbb-b638-45ef-9e26-2500a4889309" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_349a35df-0e1f-4ac5-9b72-b00740eb9556" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_57a09dbb-b638-45ef-9e26-2500a4889309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditOperatingExpense_13ccc2fa-34ef-4a5f-81a6-b9f4c2c26483" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditOperatingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_349a35df-0e1f-4ac5-9b72-b00740eb9556" xlink:to="loc_kprx_CollaborationCreditOperatingExpense_13ccc2fa-34ef-4a5f-81a6-b9f4c2c26483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f97755ad-0889-45c1-8f79-428ed92d2cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_349a35df-0e1f-4ac5-9b72-b00740eb9556" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f97755ad-0889-45c1-8f79-428ed92d2cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_29134abb-2442-4bc8-b602-9f2a841b1a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_349a35df-0e1f-4ac5-9b72-b00740eb9556" xlink:to="loc_us-gaap_OperatingExpenses_29134abb-2442-4bc8-b602-9f2a841b1a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ff907b1-3de6-4da1-aa08-22e44b83536f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ff907b1-3de6-4da1-aa08-22e44b83536f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e44fdd25-4adc-4329-9f37-77d5c776b374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e44fdd25-4adc-4329-9f37-77d5c776b374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_927e4306-34a2-48d4-a0ec-636931eddb14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e44fdd25-4adc-4329-9f37-77d5c776b374" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_927e4306-34a2-48d4-a0ec-636931eddb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_974692ca-77e1-4db0-9ca9-375b5f398913" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e44fdd25-4adc-4329-9f37-77d5c776b374" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_974692ca-77e1-4db0-9ca9-375b5f398913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4796add9-9a66-4242-b228-119ad3d0bf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e44fdd25-4adc-4329-9f37-77d5c776b374" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4796add9-9a66-4242-b228-119ad3d0bf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09c849a0-2954-4c39-8418-298b404e1baa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e44fdd25-4adc-4329-9f37-77d5c776b374" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_09c849a0-2954-4c39-8418-298b404e1baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f88ce5cf-da60-4e3c-8f17-40527743d904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e44fdd25-4adc-4329-9f37-77d5c776b374" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f88ce5cf-da60-4e3c-8f17-40527743d904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76fdb2ad-4f99-48fb-888e-8a37258381f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_NetIncomeLoss_76fdb2ad-4f99-48fb-888e-8a37258381f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_c53d02ad-2751-4874-a435-6ed4426eef18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_c53d02ad-2751-4874-a435-6ed4426eef18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_abcffed7-937c-4dd2-935c-5768748336dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_abcffed7-937c-4dd2-935c-5768748336dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fd85dbee-6a3b-4356-b3cf-2ec5e6ee3f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_EarningsPerShareBasic_fd85dbee-6a3b-4356-b3cf-2ec5e6ee3f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ccdb45c-9d7b-464f-943b-6f116ecd7bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ccdb45c-9d7b-464f-943b-6f116ecd7bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_153a9172-3d6b-46b3-a942-6d032a7107eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_153a9172-3d6b-46b3-a942-6d032a7107eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6f580e6-0ef8-407b-87f9-f7871b807272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6f580e6-0ef8-407b-87f9-f7871b807272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_4e55530d-d7a4-441f-b144-37087e5f1464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6f8e77bf-5b7d-4cae-851b-6e6297984b5c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_4e55530d-d7a4-441f-b144-37087e5f1464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11692355-2be1-4247-bd4b-e62e4663b3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_4e55530d-d7a4-441f-b144-37087e5f1464" xlink:to="loc_us-gaap_NetIncomeLoss_11692355-2be1-4247-bd4b-e62e4663b3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbb7b552-0a04-412d-b85f-52039ac9dcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_4e55530d-d7a4-441f-b144-37087e5f1464" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbb7b552-0a04-412d-b85f-52039ac9dcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1fe217e7-b38a-4a82-afef-844dc833ab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_4e55530d-d7a4-441f-b144-37087e5f1464" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1fe217e7-b38a-4a82-afef-844dc833ab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ce0af4ed-e9aa-44cf-8322-ce449901ce84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_4e55530d-d7a4-441f-b144-37087e5f1464" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ce0af4ed-e9aa-44cf-8322-ce449901ce84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8ebea83c-6a74-4c48-8f1d-78b8ec875390" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8ebea83c-6a74-4c48-8f1d-78b8ec875390" xlink:to="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b4b6b04c-c21a-492f-b52d-404cffa4d8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b4b6b04c-c21a-492f-b52d-404cffa4d8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b4b6b04c-c21a-492f-b52d-404cffa4d8d9" xlink:to="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9c8f62e6-5fc2-4d8c-8638-a04a24d9d374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_PreferredStockMember_9c8f62e6-5fc2-4d8c-8638-a04a24d9d374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1ca52792-759e-44f7-bf57-13c44ee9269d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_CommonStockMember_1ca52792-759e-44f7-bf57-13c44ee9269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0c493800-eddc-445e-b68e-3441968e5f20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0c493800-eddc-445e-b68e-3441968e5f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9329ee05-df71-4c5b-845d-ca96453b90e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_RetainedEarningsMember_9329ee05-df71-4c5b-845d-ca96453b90e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed2b191d-ee75-4b39-8dec-8bed1c57515a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8bc45ca-a98f-4437-933a-e94476d1c5ab" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed2b191d-ee75-4b39-8dec-8bed1c57515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bbb086cf-216c-4634-9f49-a8fe52bc656a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bbb086cf-216c-4634-9f49-a8fe52bc656a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a677b6a-6746-4d49-a12a-20ad2dfc6d86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bbb086cf-216c-4634-9f49-a8fe52bc656a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a677b6a-6746-4d49-a12a-20ad2dfc6d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ec84e09d-32b3-497a-9b0c-6f938dc6bda5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a677b6a-6746-4d49-a12a-20ad2dfc6d86" xlink:to="loc_us-gaap_PrivatePlacementMember_ec84e09d-32b3-497a-9b0c-6f938dc6bda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6f9267e-1cdc-4597-baa0-857a73df6b72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b6d9bb1-6710-4bcb-a67d-6a8adbbaaac2" xlink:to="loc_us-gaap_StatementLineItems_c6f9267e-1cdc-4597-baa0-857a73df6b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6f9267e-1cdc-4597-baa0-857a73df6b72" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7ea55e18-8ac2-453c-b0c3-0c3f5e7aced8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_SharesOutstanding_7ea55e18-8ac2-453c-b0c3-0c3f5e7aced8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d5ebe40-01b9-4ceb-8fdb-c2a2460b7823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_StockholdersEquity_6d5ebe40-01b9-4ceb-8fdb-c2a2460b7823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a11389e-e418-459d-8962-b2603be5c210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a11389e-e418-459d-8962-b2603be5c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_424790fb-92c6-4241-a550-8182e48191f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_424790fb-92c6-4241-a550-8182e48191f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_fc98476e-e326-4f9d-94e0-abebf0e19e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_fc98476e-e326-4f9d-94e0-abebf0e19e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d3a1b44-1d3d-42ff-9274-6a370a76ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_NetIncomeLoss_5d3a1b44-1d3d-42ff-9274-6a370a76ccaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c77fc598-9ad2-4218-97b0-74f095025a93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c77fc598-9ad2-4218-97b0-74f095025a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a76fb12-4875-4c3e-92ef-bcd319880f79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a76fb12-4875-4c3e-92ef-bcd319880f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_76d279c3-b3e9-4097-992a-9212f1f05b0d" xlink:href="kprx-20250331.xsd#kprx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_kprx_StockIssuedDuringPeriodSharesWarrantsExercised_76d279c3-b3e9-4097-992a-9212f1f05b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_81a86283-46cf-4206-a16f-18e0c450bece" xlink:href="kprx-20250331.xsd#kprx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_kprx_StockIssuedDuringPeriodValueWarrantsExercised_81a86283-46cf-4206-a16f-18e0c450bece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_92ff5dcb-3c36-4484-867f-2039b7580482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_SharesOutstanding_92ff5dcb-3c36-4484-867f-2039b7580482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98bd80d9-25b7-4a75-b9ae-000277f8333e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2a8b701-8568-41a6-bbce-b5dcccb15738" xlink:to="loc_us-gaap_StockholdersEquity_98bd80d9-25b7-4a75-b9ae-000277f8333e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_745096a2-1b8e-4d86-a242-764da5804716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b1651b1c-13e3-4ff0-96fd-e56d96882887" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_745096a2-1b8e-4d86-a242-764da5804716" xlink:to="loc_us-gaap_StatementTable_b1651b1c-13e3-4ff0-96fd-e56d96882887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1651b1c-13e3-4ff0-96fd-e56d96882887" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40f52565-bf3e-4b9a-9a9d-ea191cffbe94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_56dcbd2e-17ad-4da6-91c1-a7f0cabc1fbb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40f52565-bf3e-4b9a-9a9d-ea191cffbe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_abd370da-bee5-4d53-af04-ff4ca47c25e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_40f52565-bf3e-4b9a-9a9d-ea191cffbe94" xlink:to="loc_us-gaap_PrivatePlacementMember_abd370da-bee5-4d53-af04-ff4ca47c25e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6e78cb9d-35f5-4c39-a292-3e82f5943d52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b1651b1c-13e3-4ff0-96fd-e56d96882887" xlink:to="loc_us-gaap_StatementLineItems_6e78cb9d-35f5-4c39-a292-3e82f5943d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_6b7c9c59-44ca-49a6-9f28-07e3abbb888a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6e78cb9d-35f5-4c39-a292-3e82f5943d52" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_6b7c9c59-44ca-49a6-9f28-07e3abbb888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" xlink:type="simple" xlink:href="kprx-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b34981af-c028-433c-97bb-765a3e2c13e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3b26344c-d16c-4895-a7fb-b6a708d34285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b34981af-c028-433c-97bb-765a3e2c13e4" xlink:to="loc_us-gaap_StatementTable_3b26344c-d16c-4895-a7fb-b6a708d34285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_318059f3-d1dd-407e-ae37-393d48e81657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3b26344c-d16c-4895-a7fb-b6a708d34285" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_318059f3-d1dd-407e-ae37-393d48e81657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b193e52-d3b1-4eb6-b0fa-bd3ed1f6b534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_318059f3-d1dd-407e-ae37-393d48e81657" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b193e52-d3b1-4eb6-b0fa-bd3ed1f6b534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityLineOfCreditMember_5625596a-8cb8-4075-90cd-e31916038f32" xlink:href="kprx-20250331.xsd#kprx_EquityLineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b193e52-d3b1-4eb6-b0fa-bd3ed1f6b534" xlink:to="loc_kprx_EquityLineOfCreditMember_5625596a-8cb8-4075-90cd-e31916038f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3b26344c-d16c-4895-a7fb-b6a708d34285" xlink:to="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aff93310-91fb-4fac-b105-3ca8007fcc63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:to="loc_us-gaap_NetIncomeLoss_aff93310-91fb-4fac-b105-3ca8007fcc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f028361d-398f-4342-a089-00ac3b173a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f028361d-398f-4342-a089-00ac3b173a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInRightOfUseAssets_bba446a3-f253-4721-ae0a-9c905fc83437" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_kprx_IncreaseDecreaseInRightOfUseAssets_bba446a3-f253-4721-ae0a-9c905fc83437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3ddfe15b-7e6d-4033-90b4-de01e772bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_us-gaap_ShareBasedCompensation_3ddfe15b-7e6d-4033-90b4-de01e772bb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_a4484ab8-2918-4423-a0a6-d9d971b9225d" xlink:href="kprx-20250331.xsd#kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities_a4484ab8-2918-4423-a0a6-d9d971b9225d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_32517d1d-83c8-4eca-b5b5-c59e32f8797e" xlink:href="kprx-20250331.xsd#kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents_32517d1d-83c8-4eca-b5b5-c59e32f8797e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1af08195-60e4-4a1a-97ca-78ab768be8a2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e08d9062-5985-495c-ae17-585ff6282022" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e08d9062-5985-495c-ae17-585ff6282022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce9ca1f5-7f90-4b4e-b5e6-852075e696d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce9ca1f5-7f90-4b4e-b5e6-852075e696d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_99510b60-3a53-4ef3-8b53-7ba621f10ded" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseResearchTaxCreditsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_kprx_IncreaseDecreaseResearchTaxCreditsReceivables_99510b60-3a53-4ef3-8b53-7ba621f10ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_aecbbe4c-f68b-4137-bfe0-cde04b9f2f28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_aecbbe4c-f68b-4137-bfe0-cde04b9f2f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a3891ea7-25c2-4f85-9ee0-31db762eb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a3891ea7-25c2-4f85-9ee0-31db762eb2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c79c5ba2-37a5-4dfa-a070-a7ccd227ef11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c79c5ba2-37a5-4dfa-a070-a7ccd227ef11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82fca795-356c-4495-abf3-4095266ca1db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82fca795-356c-4495-abf3-4095266ca1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit_ba0b4a4c-9c45-4b8e-b642-32ceda402083" xlink:href="kprx-20250331.xsd#kprx_IncreaseDecreaseInAccruedCollaborationCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_kprx_IncreaseDecreaseInAccruedCollaborationCredit_ba0b4a4c-9c45-4b8e-b642-32ceda402083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f8b92da5-3133-460c-9af5-3db25d55aaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e8ea0801-255b-441e-b990-214c10f983a1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f8b92da5-3133-460c-9af5-3db25d55aaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a33caa6-2cc5-4119-8159-3791c1670580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee94db6d-d0f2-4b7a-9893-cd10d5dc9446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a33caa6-2cc5-4119-8159-3791c1670580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9b7ab5d2-8a3c-489a-980b-9229762e378d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9b7ab5d2-8a3c-489a-980b-9229762e378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8c886725-672c-4cbd-8e41-3e643e46bda6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8c886725-672c-4cbd-8e41-3e643e46bda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7a51fcfa-d34c-4c10-aefd-4e570914be06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7a51fcfa-d34c-4c10-aefd-4e570914be06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34390586-14e0-41f2-8525-a4db72b506c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_383e1b13-8c97-43a8-9a9c-173319c72168" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34390586-14e0-41f2-8525-a4db72b506c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b8a0930b-a6ce-46bf-9e47-f9ef9362f362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b8a0930b-a6ce-46bf-9e47-f9ef9362f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_19ce37f6-e815-4510-895a-a6e708e63da8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_19ce37f6-e815-4510-895a-a6e708e63da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0f5fb657-7a1b-43d1-91e0-71d84ccbf072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0f5fb657-7a1b-43d1-91e0-71d84ccbf072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb7152f2-4317-45db-9973-688f8129e719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3d412102-5100-4e4c-a128-04a57ea01121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb7152f2-4317-45db-9973-688f8129e719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a5b2c77-bbaa-4b50-abc0-bde729b899bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a5b2c77-bbaa-4b50-abc0-bde729b899bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19ea5264-5100-4897-b7f3-19adf03ed930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19ea5264-5100-4897-b7f3-19adf03ed930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16795d21-72b8-4de5-bb7b-eec61294279a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16795d21-72b8-4de5-bb7b-eec61294279a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec88bd56-f5bc-4a6f-94ca-c3159c24cff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec88bd56-f5bc-4a6f-94ca-c3159c24cff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_865cc3a3-e810-4564-b257-983804a626d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7b1c7a4a-bca2-4e3a-a991-baacb8c31d5c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_865cc3a3-e810-4564-b257-983804a626d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35c02a23-92a0-404a-91b1-36e434732629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_865cc3a3-e810-4564-b257-983804a626d3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35c02a23-92a0-404a-91b1-36e434732629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements" xlink:type="simple" xlink:href="kprx-20250331.xsd#BusinessPresentationandRecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b02f5f20-b3cf-43db-a588-100d4ea482fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_e1b3e923-25e1-471a-b1ff-aa33326e0dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b02f5f20-b3cf-43db-a588-100d4ea482fb" xlink:to="loc_us-gaap_NatureOfOperations_e1b3e923-25e1-471a-b1ff-aa33326e0dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformation" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aeaa3444-8097-472d-818d-bfe151516e27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7b16c13b-f382-454e-a502-eb143aaed51b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aeaa3444-8097-472d-818d-bfe151516e27" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7b16c13b-f382-454e-a502-eb143aaed51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosures" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosures"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ccaaff78-3c4c-492d-a3fa-c3cd9811ae99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_fbbb7c33-b857-4374-8c10-aa84be4aa6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ccaaff78-3c4c-492d-a3fa-c3cd9811ae99" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_fbbb7c33-b857-4374-8c10-aa84be4aa6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CapitalStock" xlink:type="simple" xlink:href="kprx-20250331.xsd#CapitalStock"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CapitalStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c2ee652e-922c-4a4d-8383-7220fc6c2c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f52611d3-9a7c-4361-8811-f2dd312b8651" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2ee652e-922c-4a4d-8383-7220fc6c2c4a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f52611d3-9a7c-4361-8811-f2dd312b8651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Warrants" xlink:type="simple" xlink:href="kprx-20250331.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract_fb1918fa-a2b9-4d8d-a66b-ae7e6170dfd0" xlink:href="kprx-20250331.xsd#kprx_WarrantsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsDisclosureTextBlock_fdd27697-b3d3-4db8-b665-b396a475a378" xlink:href="kprx-20250331.xsd#kprx_WarrantsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_WarrantsAbstract_fb1918fa-a2b9-4d8d-a66b-ae7e6170dfd0" xlink:to="loc_kprx_WarrantsDisclosureTextBlock_fdd27697-b3d3-4db8-b665-b396a475a378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDiluted" xlink:type="simple" xlink:href="kprx-20250331.xsd#NetLossIncomeperShareBasicandDiluted"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDiluted" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_167c90bc-7d73-49c5-b1d6-7630328551d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1ab92517-485f-417d-ab4f-ba7a5626ccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_167c90bc-7d73-49c5-b1d6-7630328551d3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1ab92517-485f-417d-ab4f-ba7a5626ccd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_965cc0a1-ce08-4931-9a8d-499848eff81f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_615316b1-85e4-452b-814e-06b09d40920c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_965cc0a1-ce08-4931-9a8d-499848eff81f" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_615316b1-85e4-452b-814e-06b09d40920c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_951d3b34-527f-406d-9d6c-3f9191984c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c417db0e-068c-44a7-89e6-54b35399ab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_951d3b34-527f-406d-9d6c-3f9191984c64" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c417db0e-068c-44a7-89e6-54b35399ab2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SegmentInformation" xlink:type="simple" xlink:href="kprx-20250331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7352649f-dd89-4c51-8165-c9e66a5f2e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5895553b-d5e9-4efd-be2b-9f1631fe162e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7352649f-dd89-4c51-8165-c9e66a5f2e78" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5895553b-d5e9-4efd-be2b-9f1631fe162e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="kprx-20250331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d570fec9-6d50-48c6-9df8-92dedf5cb58b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_bf9ca4c5-538a-430c-ba38-2745e66f2e67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d570fec9-6d50-48c6-9df8-92dedf5cb58b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_bf9ca4c5-538a-430c-ba38-2745e66f2e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="kprx-20250331.xsd#BusinessPresentationandRecentAccountingPronouncementsPolicies"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_d84f1279-fb06-4576-9dae-c9b7e5912ec3" xlink:href="kprx-20250331.xsd#kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_d84f1279-fb06-4576-9dae-c9b7e5912ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f48f49ee-a709-485f-a551-1364669c2835" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f48f49ee-a709-485f-a551-1364669c2835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LiquidityAndCapitalResourcesPolicyTextBlock_7c21f006-5997-4825-9037-088140098c38" xlink:href="kprx-20250331.xsd#kprx_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_kprx_LiquidityAndCapitalResourcesPolicyTextBlock_7c21f006-5997-4825-9037-088140098c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_777ed90e-f3a4-4bee-ae3a-7fd95f8b9722" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_777ed90e-f3a4-4bee-ae3a-7fd95f8b9722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_c3b0b740-5c3e-4f1c-89d4-1eddb5ac2f50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_c3b0b740-5c3e-4f1c-89d4-1eddb5ac2f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_5f870306-8b7c-4a80-96b6-c75624d489cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_5f870306-8b7c-4a80-96b6-c75624d489cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_89a50fe7-0f51-4383-b060-c6d6a51c72ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_89a50fe7-0f51-4383-b060-c6d6a51c72ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1b63094e-83db-4f9d-82e6-3468ed2fc3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1b63094e-83db-4f9d-82e6-3468ed2fc3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_81d91044-481e-4640-8b9c-e54a05c9ce3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_81d91044-481e-4640-8b9c-e54a05c9ce3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_AccruedClinicalExpensesPolicyTextBlock_4ac66879-03e4-45da-9dd3-9fadb025187c" xlink:href="kprx-20250331.xsd#kprx_AccruedClinicalExpensesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_kprx_AccruedClinicalExpensesPolicyTextBlock_4ac66879-03e4-45da-9dd3-9fadb025187c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b2ee44b6-33d3-4cab-819e-f2c328c37651" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b2ee44b6-33d3-4cab-819e-f2c328c37651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_18c39b92-7bef-4024-ab1f-8de048086c33" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock_18c39b92-7bef-4024-ab1f-8de048086c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_8b942339-add7-4cf7-aca4-4a6d53377286" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f55f82c-45d7-4cbb-a8a9-a805dfec9a2f" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_8b942339-add7-4cf7-aca4-4a6d53377286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationTables" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_11992565-fedf-476d-b1fe-bc7d3eb964b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_11992565-fedf-476d-b1fe-bc7d3eb964b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_82fb32d3-d1e4-4860-b4b4-6fd89c0582d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_82fb32d3-d1e4-4860-b4b4-6fd89c0582d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfShortTermInvestmentsTableTextBlock_f7dc3c20-0c6b-4448-a051-1fb2b94a5224" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_kprx_ScheduleOfShortTermInvestmentsTableTextBlock_f7dc3c20-0c6b-4448-a051-1fb2b94a5224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6fcaf0c3-4bdb-4f51-82a1-c6f842837a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6fcaf0c3-4bdb-4f51-82a1-c6f842837a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_fb29066b-c383-4e16-adf7-a7af0bc0c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_fb29066b-c383-4e16-adf7-a7af0bc0c7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_72150f1b-2eed-4df7-bb8a-bc1b9fae30cf" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_72150f1b-2eed-4df7-bb8a-bc1b9fae30cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock_6993e9fe-8116-487a-bfa7-af5aea250c63" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock_6993e9fe-8116-487a-bfa7-af5aea250c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_43d88739-efb9-421b-b84a-ca8a3cc5fd41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_82d4b2db-6847-4bd9-af15-df5ef17fd906" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_43d88739-efb9-421b-b84a-ca8a3cc5fd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresTables" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0dec477-a47f-45a5-8fac-cf674f249e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_96fb265d-2919-462a-83fb-a1f3a79e453b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0dec477-a47f-45a5-8fac-cf674f249e4b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_96fb265d-2919-462a-83fb-a1f3a79e453b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_c10c6858-6fac-4205-a32b-a8d7f2c0b6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0dec477-a47f-45a5-8fac-cf674f249e4b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_c10c6858-6fac-4205-a32b-a8d7f2c0b6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_6e7ba33e-507d-4605-8d46-3b1ba6db2611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0dec477-a47f-45a5-8fac-cf674f249e4b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_6e7ba33e-507d-4605-8d46-3b1ba6db2611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/WarrantsTables" xlink:type="simple" xlink:href="kprx-20250331.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract_f3da1578-eb55-4652-9125-66e85b139af7" xlink:href="kprx-20250331.xsd#kprx_WarrantsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7564fbae-6328-44fa-bee0-a6d04267155a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_WarrantsAbstract_f3da1578-eb55-4652-9125-66e85b139af7" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_7564fbae-6328-44fa-bee0-a6d04267155a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedTables" xlink:type="simple" xlink:href="kprx-20250331.xsd#NetLossIncomeperShareBasicandDilutedTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_93ae9131-5f37-43bf-a83c-a3b1dc86a33b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_79bff9c5-ecfa-4176-baa4-5c8f1c91340e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_93ae9131-5f37-43bf-a83c-a3b1dc86a33b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_79bff9c5-ecfa-4176-baa4-5c8f1c91340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8975e931-4252-4760-81e2-a9eab273c461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_d209d017-00d2-4194-863d-f5f0f046d58e" xlink:href="kprx-20250331.xsd#kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8975e931-4252-4760-81e2-a9eab273c461" xlink:to="loc_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock_d209d017-00d2-4194-863d-f5f0f046d58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dc6dce74-2a53-4f8a-9ad9-37dbb6d5e408" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8975e931-4252-4760-81e2-a9eab273c461" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dc6dce74-2a53-4f8a-9ad9-37dbb6d5e408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1023db87-fd63-4012-99a1-0105ff63b641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8975e931-4252-4760-81e2-a9eab273c461" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1023db87-fd63-4012-99a1-0105ff63b641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4e4acaa-c311-448c-b978-dc895f5c1bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_13f959eb-7009-4c37-9758-7575d6b85296" xlink:href="kprx-20250331.xsd#kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4e4acaa-c311-448c-b978-dc895f5c1bfa" xlink:to="loc_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_13f959eb-7009-4c37-9758-7575d6b85296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ee9913e7-da7e-470d-aa43-07a22addaa35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4e4acaa-c311-448c-b978-dc895f5c1bfa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ee9913e7-da7e-470d-aa43-07a22addaa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_a69709d4-7cb8-4ba0-80df-8bdfb3527b76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4e4acaa-c311-448c-b978-dc895f5c1bfa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_a69709d4-7cb8-4ba0-80df-8bdfb3527b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="kprx-20250331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dd9d421c-3669-4128-99c2-1a7b47ffbbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b5aea1d9-c411-4072-9d8f-b39875dfe087" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dd9d421c-3669-4128-99c2-1a7b47ffbbe0" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b5aea1d9-c411-4072-9d8f-b39875dfe087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BusinessPresentationandRecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cee1eed-2fc6-4b4f-aa0d-ac7ca31a0b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_62f06a6f-2a70-4f37-9f89-29599775224b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cee1eed-2fc6-4b4f-aa0d-ac7ca31a0b70" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_62f06a6f-2a70-4f37-9f89-29599775224b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0395885c-e333-44c0-b849-05e6400ee203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_62f06a6f-2a70-4f37-9f89-29599775224b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0395885c-e333-44c0-b849-05e6400ee203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3fa7bc01-751f-4970-8c87-2c80b832899b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0395885c-e333-44c0-b849-05e6400ee203" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3fa7bc01-751f-4970-8c87-2c80b832899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7bbd5c99-5786-4ca6-992e-c66056f3712b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3fa7bc01-751f-4970-8c87-2c80b832899b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7bbd5c99-5786-4ca6-992e-c66056f3712b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_62f06a6f-2a70-4f37-9f89-29599775224b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cdf23d1-c726-4e07-9694-2ca245a1fac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cdf23d1-c726-4e07-9694-2ca245a1fac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ce03f01e-41bd-4ab8-ac2e-e5db95bc8ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_ShortTermInvestments_ce03f01e-41bd-4ab8-ac2e-e5db95bc8ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b74bdd-33ad-42dc-989d-c0617b8a36ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b74bdd-33ad-42dc-989d-c0617b8a36ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborativeArrangementNumberOfPerformanceObligations_e27ec87a-7c3e-444b-99c2-2f02cc29bbbe" xlink:href="kprx-20250331.xsd#kprx_CollaborativeArrangementNumberOfPerformanceObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_kprx_CollaborativeArrangementNumberOfPerformanceObligations_e27ec87a-7c3e-444b-99c2-2f02cc29bbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_939430ff-5c95-4282-a77f-a7d45200f818" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_ProceedsFromCollaborators_939430ff-5c95-4282-a77f-a7d45200f818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_16bf87ca-66a2-4ab4-afb9-18940794f0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_16bf87ca-66a2-4ab4-afb9-18940794f0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a30eda46-1e08-4505-af6c-192d036b4459" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a30eda46-1e08-4505-af6c-192d036b4459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfGeographicSegments_bfff6677-6f21-4e88-8750-4c2ec41d23db" xlink:href="kprx-20250331.xsd#kprx_NumberOfGeographicSegments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_kprx_NumberOfGeographicSegments_bfff6677-6f21-4e88-8750-4c2ec41d23db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_9ecaec8b-1317-4972-a44c-cbdebe49f25c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_IncomeTaxReceivable_9ecaec8b-1317-4972-a44c-cbdebe49f25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_eed7449a-d4b1-45ce-b74c-aef33310b6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_eed7449a-d4b1-45ce-b74c-aef33310b6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_998dd5dc-5a1d-4642-9404-d3ef9e9103c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_998dd5dc-5a1d-4642-9404-d3ef9e9103c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6620cee-4333-4d5c-b7b1-362e8dda30f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3c8a4dc3-ce2d-43c1-b28f-081eee154eb2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6620cee-4333-4d5c-b7b1-362e8dda30f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4bfc074a-4c04-484d-8d02-88a9a5ecbbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c8e87fe-8a45-4bae-96c4-773c8685e072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4bfc074a-4c04-484d-8d02-88a9a5ecbbe9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c8e87fe-8a45-4bae-96c4-773c8685e072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_060fe331-c6d8-4fac-9a1b-f192eec26799" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4bfc074a-4c04-484d-8d02-88a9a5ecbbe9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_060fe331-c6d8-4fac-9a1b-f192eec26799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80c84bde-7f87-4d17-923d-5ee00b2820ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4bfc074a-4c04-484d-8d02-88a9a5ecbbe9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80c84bde-7f87-4d17-923d-5ee00b2820ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e830dccf-f516-47f4-8355-71c3ec431152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32d445ed-7ac8-4b56-9451-6232ce621d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e830dccf-f516-47f4-8355-71c3ec431152" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32d445ed-7ac8-4b56-9451-6232ce621d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c84930e-499a-4159-b034-3ec145449962" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32d445ed-7ac8-4b56-9451-6232ce621d9e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c84930e-499a-4159-b034-3ec145449962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c84930e-499a-4159-b034-3ec145449962" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_60a2797d-b6ed-46d2-8dfc-2fab5fde166c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_60a2797d-b6ed-46d2-8dfc-2fab5fde166c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_056e681c-adaa-4332-b20a-6dce8ee04eac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_056e681c-adaa-4332-b20a-6dce8ee04eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0da28af5-be70-4493-8af5-e8115221559c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0da28af5-be70-4493-8af5-e8115221559c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_41891d07-c243-4dde-b252-79bf0b4d5849" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7f48bb8-7018-4e97-a593-33161921a571" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_41891d07-c243-4dde-b252-79bf0b4d5849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32d445ed-7ac8-4b56-9451-6232ce621d9e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a150969-fef9-4dcb-9e45-4edd71a7c1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a150969-fef9-4dcb-9e45-4edd71a7c1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b41a27e6-a7a8-43c1-beb0-17716f874463" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b41a27e6-a7a8-43c1-beb0-17716f874463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aa7bf5f3-a001-4106-ab8a-c936264f41a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aa7bf5f3-a001-4106-ab8a-c936264f41a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8208176-c87f-4d06-91a5-7d9173a588da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e08fa017-67a1-438b-89ab-0ead4d0b9d2d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8208176-c87f-4d06-91a5-7d9173a588da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9ca84647-57fa-4f5a-ae71-1dda1706bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cbd781ce-07e6-4264-8c1e-a5281022e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9ca84647-57fa-4f5a-ae71-1dda1706bc26" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cbd781ce-07e6-4264-8c1e-a5281022e0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_cc14703b-8dc0-49d3-a129-9b867f09f2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cbd781ce-07e6-4264-8c1e-a5281022e0d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_cc14703b-8dc0-49d3-a129-9b867f09f2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e711565f-236c-4689-ab3c-13bbe797370d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cbd781ce-07e6-4264-8c1e-a5281022e0d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e711565f-236c-4689-ab3c-13bbe797370d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a372d527-0044-412d-beae-60ab988ca6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cbd781ce-07e6-4264-8c1e-a5281022e0d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a372d527-0044-412d-beae-60ab988ca6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_10d3cf2b-f4ed-4bd9-9de3-28871ff77841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9ca84647-57fa-4f5a-ae71-1dda1706bc26" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_10d3cf2b-f4ed-4bd9-9de3-28871ff77841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_94623bc8-b53e-4e7a-ae1f-d21bcceab330" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_10d3cf2b-f4ed-4bd9-9de3-28871ff77841" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_94623bc8-b53e-4e7a-ae1f-d21bcceab330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3bb945a4-293c-40c8-92d3-24a35235886d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_10d3cf2b-f4ed-4bd9-9de3-28871ff77841" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3bb945a4-293c-40c8-92d3-24a35235886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bbf7ca24-431d-45ca-9849-b0ad0623b7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_10d3cf2b-f4ed-4bd9-9de3-28871ff77841" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bbf7ca24-431d-45ca-9849-b0ad0623b7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f7b9f084-40a2-40f4-97c5-06c2f8405143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4f29ba91-727f-4146-aa06-e7918794e996" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f7b9f084-40a2-40f4-97c5-06c2f8405143" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4f29ba91-727f-4146-aa06-e7918794e996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4b8aef26-0380-4fe7-bb1a-bfb2b3837845" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4f29ba91-727f-4146-aa06-e7918794e996" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4b8aef26-0380-4fe7-bb1a-bfb2b3837845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b8aef26-0380-4fe7-bb1a-bfb2b3837845" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b5a92589-2dfc-4ded-a2f5-4a1a40fe43bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b5a92589-2dfc-4ded-a2f5-4a1a40fe43bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3ffb170c-fdf0-44c0-8c8a-73d01753d026" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5e3635c-8b44-4656-a941-fc972913b307" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3ffb170c-fdf0-44c0-8c8a-73d01753d026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_4f29ba91-727f-4146-aa06-e7918794e996" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_9544150b-a897-4d4f-bcff-9c47a741effe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_9544150b-a897-4d4f-bcff-9c47a741effe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2b7881cc-441a-4ff2-a748-d72b51345459" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_9544150b-a897-4d4f-bcff-9c47a741effe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_2b7881cc-441a-4ff2-a748-d72b51345459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_6e267423-57ac-4f7e-836f-2ab85157a6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_6e267423-57ac-4f7e-836f-2ab85157a6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d4b959fb-9aae-4cbb-8969-2631380f28d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_6e267423-57ac-4f7e-836f-2ab85157a6fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d4b959fb-9aae-4cbb-8969-2631380f28d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_a43bdde2-b34b-4111-be8b-b3c3a6252744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6fdca624-d5a2-4852-8a7b-649f38ce109b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_a43bdde2-b34b-4111-be8b-b3c3a6252744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1973b3d3-79ac-4a0e-8ca7-3a8d782cd7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract_a43bdde2-b34b-4111-be8b-b3c3a6252744" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1973b3d3-79ac-4a0e-8ca7-3a8d782cd7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cb177e90-5196-4826-83e2-b7fd81ff5c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAbstract_2df4128b-b76b-4137-9634-a82075ba704c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cb177e90-5196-4826-83e2-b7fd81ff5c4d" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAbstract_2df4128b-b76b-4137-9634-a82075ba704c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrepaidResearchAndDevelopment_445d8e3a-899e-41d8-ac93-09ecc0887ae2" xlink:href="kprx-20250331.xsd#kprx_PrepaidResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_2df4128b-b76b-4137-9634-a82075ba704c" xlink:to="loc_kprx_PrepaidResearchAndDevelopment_445d8e3a-899e-41d8-ac93-09ecc0887ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PrepaidGeneralAndAdministrative_3d7d5a0f-8f40-4dec-a1af-b344843a7515" xlink:href="kprx-20250331.xsd#kprx_PrepaidGeneralAndAdministrative"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_2df4128b-b76b-4137-9634-a82075ba704c" xlink:to="loc_kprx_PrepaidGeneralAndAdministrative_3d7d5a0f-8f40-4dec-a1af-b344843a7515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_44bf76fc-e3dd-4df4-9d71-f75a4ae85b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_2df4128b-b76b-4137-9634-a82075ba704c" xlink:to="loc_us-gaap_PrepaidInsurance_44bf76fc-e3dd-4df4-9d71-f75a4ae85b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_bfa28e59-ca5a-44b4-8193-f51dc2708cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_2df4128b-b76b-4137-9634-a82075ba704c" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_bfa28e59-ca5a-44b4-8193-f51dc2708cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c7cc0274-84f3-42f5-a18e-9a95d8b3788c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAbstract_2df4128b-b76b-4137-9634-a82075ba704c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c7cc0274-84f3-42f5-a18e-9a95d8b3788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e1e7fdbb-c9f0-40fe-a9db-80ef38f42ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchTaxCreditsReceivableCurrent_d350dbe7-5123-4ee8-9077-cfb5d11fb19a" xlink:href="kprx-20250331.xsd#kprx_ResearchTaxCreditsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e1e7fdbb-c9f0-40fe-a9db-80ef38f42ab6" xlink:to="loc_kprx_ResearchTaxCreditsReceivableCurrent_d350dbe7-5123-4ee8-9077-cfb5d11fb19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_OtherTaxReceivablesCurrent_faae92b2-8d06-4288-a288-33460bfb9f90" xlink:href="kprx-20250331.xsd#kprx_OtherTaxReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e1e7fdbb-c9f0-40fe-a9db-80ef38f42ab6" xlink:to="loc_kprx_OtherTaxReceivablesCurrent_faae92b2-8d06-4288-a288-33460bfb9f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_1721651a-eae7-42dd-a27b-5ed5a6a7e330" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e1e7fdbb-c9f0-40fe-a9db-80ef38f42ab6" xlink:to="loc_us-gaap_IncomeTaxesReceivable_1721651a-eae7-42dd-a27b-5ed5a6a7e330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#BalanceSheetInformationAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdd85ca6-0e6d-4201-8c50-7845e0006793" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_deaf20a1-7d4a-4fb1-adab-2296d50e3712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdd85ca6-0e6d-4201-8c50-7845e0006793" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_deaf20a1-7d4a-4fb1-adab-2296d50e3712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3b57c25c-ae55-4878-a098-9c973f9c337d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdd85ca6-0e6d-4201-8c50-7845e0006793" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3b57c25c-ae55-4878-a098-9c973f9c337d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClinicalTrialsCurrent_85e75043-590f-4031-94b9-fcf1ee9b4819" xlink:href="kprx-20250331.xsd#kprx_ClinicalTrialsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdd85ca6-0e6d-4201-8c50-7845e0006793" xlink:to="loc_kprx_ClinicalTrialsCurrent_85e75043-590f-4031-94b9-fcf1ee9b4819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_de55f1ef-d03f-4bd8-8611-6b253069ac06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdd85ca6-0e6d-4201-8c50-7845e0006793" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_de55f1ef-d03f-4bd8-8611-6b253069ac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_76f41a1d-198a-4d8c-81d9-371b84d8f2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdd85ca6-0e6d-4201-8c50-7845e0006793" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_76f41a1d-198a-4d8c-81d9-371b84d8f2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c4de71db-ffdc-4b76-9267-ac300878c124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdd85ca6-0e6d-4201-8c50-7845e0006793" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c4de71db-ffdc-4b76-9267-ac300878c124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresAssetsatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2f79f3d3-ada2-4bac-b349-b2293df1c973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f79f3d3-ada2-4bac-b349-b2293df1c973" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc5ac154-bcd9-45b9-a5ec-c89c32a395af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc5ac154-bcd9-45b9-a5ec-c89c32a395af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1e11e4e-1833-42dd-9bd3-991da0919431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dc5ac154-bcd9-45b9-a5ec-c89c32a395af" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1e11e4e-1833-42dd-9bd3-991da0919431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3107d4d1-e9c4-4782-8b63-7f2237027f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1e11e4e-1833-42dd-9bd3-991da0919431" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3107d4d1-e9c4-4782-8b63-7f2237027f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_075f002d-144c-4159-af65-c0cc2af84b97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_075f002d-144c-4159-af65-c0cc2af84b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_075f002d-144c-4159-af65-c0cc2af84b97" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc009baa-1977-4e65-b7ba-9125adb78c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc009baa-1977-4e65-b7ba-9125adb78c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a9f5a97-046c-4b65-a9e3-ca73d35f620c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a9f5a97-046c-4b65-a9e3-ca73d35f620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_95728a20-1da0-423f-a158-ed796292b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76f6227-4884-491a-a051-1607bd2cf92a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_95728a20-1da0-423f-a158-ed796292b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_43d063ba-e6eb-407c-9c10-27f5f9f91f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_43d063ba-e6eb-407c-9c10-27f5f9f91f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_43d063ba-e6eb-407c-9c10-27f5f9f91f2c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_11d75d14-3f0d-4363-a938-72fad0021164" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_11d75d14-3f0d-4363-a938-72fad0021164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d5b98428-be9a-49c0-bb9f-98d504161905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c15d0f8a-a8ec-476e-b276-ea4a9db56e5e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d5b98428-be9a-49c0-bb9f-98d504161905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5477503d-66b6-48fa-9316-9857eeaa9ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5477503d-66b6-48fa-9316-9857eeaa9ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5477503d-66b6-48fa-9316-9857eeaa9ed2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_be7679ef-4913-4d96-b2de-9c50b19e5a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_be7679ef-4913-4d96-b2de-9c50b19e5a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29138b89-5444-4e63-917f-8b5bc3221073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_29138b89-5444-4e63-917f-8b5bc3221073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c1b2f80c-9383-4810-891f-9fc889929cae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c1b2f80c-9383-4810-891f-9fc889929cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_0f350cf3-3f92-43e9-928c-f4695eea3db1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_52c33e75-eca8-4a84-9ba6-66b667cb485c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_0f350cf3-3f92-43e9-928c-f4695eea3db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87978bd1-0768-4b4b-a8ab-4f5a741c0c59" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e326cdc-5c73-4b09-acb6-45a48dc0c070" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e326cdc-5c73-4b09-acb6-45a48dc0c070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9e2164fb-dfc4-4ccc-bac8-f7c45ebe96d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9e2164fb-dfc4-4ccc-bac8-f7c45ebe96d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_78ee2704-b757-42bf-89d5-7d07ef3ab14f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1a2572c-3d4a-4487-aa10-3d9132d95be7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_78ee2704-b757-42bf-89d5-7d07ef3ab14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a381c064-5ee5-4a72-b0a4-cdc9243e6e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a381c064-5ee5-4a72-b0a4-cdc9243e6e57" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c4737c75-adc7-4217-95be-50c8d88e4dac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c4737c75-adc7-4217-95be-50c8d88e4dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7319ac1-a91f-4612-b14a-86c576ccb194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c4737c75-adc7-4217-95be-50c8d88e4dac" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7319ac1-a91f-4612-b14a-86c576ccb194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1acf9da0-f201-4504-9155-7896aab501c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7319ac1-a91f-4612-b14a-86c576ccb194" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1acf9da0-f201-4504-9155-7896aab501c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_696b4938-35b8-42b1-863d-d14764618231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_696b4938-35b8-42b1-863d-d14764618231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fccfd5c-9cfd-4d73-9247-a12c4dc4e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_696b4938-35b8-42b1-863d-d14764618231" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fccfd5c-9cfd-4d73-9247-a12c4dc4e85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ddbcf8c4-8b32-4800-84c8-2f485dd95900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fccfd5c-9cfd-4d73-9247-a12c4dc4e85d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ddbcf8c4-8b32-4800-84c8-2f485dd95900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7946d132-53fc-4538-bdcd-5bde06949a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eef79c69-795a-426a-9fc3-60d7d23ed8f8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7946d132-53fc-4538-bdcd-5bde06949a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7946d132-53fc-4538-bdcd-5bde06949a2f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4c6949dc-5c53-4a93-a2d2-4a3d96c57e04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4c6949dc-5c53-4a93-a2d2-4a3d96c57e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fb05a44f-29e2-4070-8e37-5fec93e44dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_24c5b42f-7cfa-49d0-905e-9a28a207c8ce" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fb05a44f-29e2-4070-8e37-5fec93e44dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresUnobservableLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e6a7b377-7538-417d-aa92-5682952c458f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e6a7b377-7538-417d-aa92-5682952c458f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_66a73028-33c8-4b3c-892c-7d77b785c60c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_us-gaap_ValuationTechniqueAxis_66a73028-33c8-4b3c-892c-7d77b785c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f3fbe5fb-82e4-4b16-9bb0-121907721a43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_66a73028-33c8-4b3c-892c-7d77b785c60c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f3fbe5fb-82e4-4b16-9bb0-121907721a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_9e8fb53a-1e56-4dfe-b38e-233821037550" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f3fbe5fb-82e4-4b16-9bb0-121907721a43" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_9e8fb53a-1e56-4dfe-b38e-233821037550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3e6d487c-4667-44d8-b5ab-7002ed7239a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3e6d487c-4667-44d8-b5ab-7002ed7239a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3e6d487c-4667-44d8-b5ab-7002ed7239a5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2ec593b8-5beb-417c-8c9b-2c89b82f1260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2ec593b8-5beb-417c-8c9b-2c89b82f1260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProbabilityOfSuccessForPaymentMember_046a847c-2a30-40a5-a796-891cd54e244c" xlink:href="kprx-20250331.xsd#kprx_ProbabilityOfSuccessForPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbbdfef6-21a1-44ff-a50d-20c3b7b3d534" xlink:to="loc_kprx_ProbabilityOfSuccessForPaymentMember_046a847c-2a30-40a5-a796-891cd54e244c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_49e45abf-9b68-4f5e-b895-5d8e4d574958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_49e45abf-9b68-4f5e-b895-5d8e4d574958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_49e45abf-9b68-4f5e-b895-5d8e4d574958" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_e242a480-6ba7-4934-b923-cbbadec75de1" xlink:href="kprx-20250331.xsd#kprx_BayonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:to="loc_kprx_BayonMember_e242a480-6ba7-4934-b923-cbbadec75de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesMember_3f65acbb-ae40-43c8-8d31-8be47fb67f2a" xlink:href="kprx-20250331.xsd#kprx_PanoptesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c736333a-4911-4b86-a291-4af81b3ca6c5" xlink:to="loc_kprx_PanoptesMember_3f65acbb-ae40-43c8-8d31-8be47fb67f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f0b43d01-e6b0-4519-893c-cb6ed9094c81" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_srt_RangeAxis_f0b43d01-e6b0-4519-893c-cb6ed9094c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f0b43d01-e6b0-4519-893c-cb6ed9094c81" xlink:to="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_24d5201b-acd1-4beb-95a2-0c7a829b93e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:to="loc_srt_MinimumMember_24d5201b-acd1-4beb-95a2-0c7a829b93e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_101ded21-ea6e-4bb2-8f5b-f991f49b7184" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac14bd64-dda6-4ef6-9522-b2c3f8f009ce" xlink:to="loc_srt_MaximumMember_101ded21-ea6e-4bb2-8f5b-f991f49b7184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8c629443-6078-426e-85df-8d6415ec4dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_68f9d117-61fd-4b0a-b48b-6589bec2028f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8c629443-6078-426e-85df-8d6415ec4dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_9f6ef293-3db8-48d3-b5ea-f44735c7d097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8c629443-6078-426e-85df-8d6415ec4dcc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_9f6ef293-3db8-48d3-b5ea-f44735c7d097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresNarrativeDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83aff549-1d6b-4737-80ef-5a431110c933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ChangeInContingentConsiderationFairValue_b5369e33-8f05-4419-b5fa-b66f8af193b5" xlink:href="kprx-20250331.xsd#kprx_ChangeInContingentConsiderationFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83aff549-1d6b-4737-80ef-5a431110c933" xlink:to="loc_kprx_ChangeInContingentConsiderationFairValue_b5369e33-8f05-4419-b5fa-b66f8af193b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_986f976e-c45c-45f4-8566-c9f1f7b730ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_986f976e-c45c-45f4-8566-c9f1f7b730ce" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6c927a89-651f-40fd-89bf-62750ce401aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6c927a89-651f-40fd-89bf-62750ce401aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6c927a89-651f-40fd-89bf-62750ce401aa" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember_908635a5-38c1-459d-89ff-50b33a82b90c" xlink:href="kprx-20250331.xsd#kprx_ProbabilityOfSuccessForDevelopmentPhaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:to="loc_kprx_ProbabilityOfSuccessForDevelopmentPhaseMember_908635a5-38c1-459d-89ff-50b33a82b90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_99a34904-670f-4533-bf22-b36642758b60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a811518-5c46-4ed2-a368-a8a00f0b1a72" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_99a34904-670f-4533-bf22-b36642758b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_eaab47c3-7933-4023-9b33-a66bbf1e9a35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_us-gaap_ValuationTechniqueAxis_eaab47c3-7933-4023-9b33-a66bbf1e9a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_25c5e349-02d7-4ad3-9aed-7c8b0f5a208c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_eaab47c3-7933-4023-9b33-a66bbf1e9a35" xlink:to="loc_us-gaap_ValuationTechniqueDomain_25c5e349-02d7-4ad3-9aed-7c8b0f5a208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MultiPeriodExcessEarningsMethodMember_7b98bb29-f6d5-4ea3-a834-b9cf8ab26d54" xlink:href="kprx-20250331.xsd#kprx_MultiPeriodExcessEarningsMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_25c5e349-02d7-4ad3-9aed-7c8b0f5a208c" xlink:to="loc_kprx_MultiPeriodExcessEarningsMethodMember_7b98bb29-f6d5-4ea3-a834-b9cf8ab26d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87b49825-49d1-42c4-8ac9-afde1d9231f6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_srt_ProductOrServiceAxis_87b49825-49d1-42c4-8ac9-afde1d9231f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_87b49825-49d1-42c4-8ac9-afde1d9231f6" xlink:to="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO104Member_6226600f-b455-4df2-9418-5618e745f602" xlink:href="kprx-20250331.xsd#kprx_KIO104Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:to="loc_kprx_KIO104Member_6226600f-b455-4df2-9418-5618e745f602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO301Member_27b1dafd-8d15-44c0-8115-3748f044f9d5" xlink:href="kprx-20250331.xsd#kprx_KIO301Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_330abaf5-afb1-4cd7-97ea-e92d6c7e93f2" xlink:to="loc_kprx_KIO301Member_27b1dafd-8d15-44c0-8115-3748f044f9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dbea0dcb-8830-4755-9e9c-8e96f29badcf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_srt_RangeAxis_dbea0dcb-8830-4755-9e9c-8e96f29badcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dbea0dcb-8830-4755-9e9c-8e96f29badcf" xlink:to="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8c3579b4-e0a9-4f6b-9ec3-663212a41055" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:to="loc_srt_MinimumMember_8c3579b4-e0a9-4f6b-9ec3-663212a41055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d934262-e627-4a5d-adf4-edcf27f4502e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a8830c97-8404-4293-b848-483b4c2066fd" xlink:to="loc_srt_MaximumMember_5d934262-e627-4a5d-adf4-edcf27f4502e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9d13d14d-4221-4f81-8b06-6677684728ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c9078d0f-48ef-4889-9036-1a8ac770b719" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9d13d14d-4221-4f81-8b06-6677684728ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_InProcessResearchAndDevelopmentMeasurementInput_9825bd70-1fa8-4142-ba62-0546701ab125" xlink:href="kprx-20250331.xsd#kprx_InProcessResearchAndDevelopmentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9d13d14d-4221-4f81-8b06-6677684728ac" xlink:to="loc_kprx_InProcessResearchAndDevelopmentMeasurementInput_9825bd70-1fa8-4142-ba62-0546701ab125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CapitalStockDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CapitalStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9c2b1d3c-8201-4ef4-aad7-2b94bb5532c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9c2b1d3c-8201-4ef4-aad7-2b94bb5532c1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7f2af116-e82a-42ad-bc61-9eb40331a878" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:to="loc_srt_CounterpartyNameAxis_7f2af116-e82a-42ad-bc61-9eb40331a878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65cde7ac-21ce-4ada-8456-4d73447b6ff0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7f2af116-e82a-42ad-bc61-9eb40331a878" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65cde7ac-21ce-4ada-8456-4d73447b6ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_MaximGroupLLCMember_cfc598b3-76b4-4320-b2fc-68066c257449" xlink:href="kprx-20250331.xsd#kprx_MaximGroupLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65cde7ac-21ce-4ada-8456-4d73447b6ff0" xlink:to="loc_kprx_MaximGroupLLCMember_cfc598b3-76b4-4320-b2fc-68066c257449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e43c408e-ea37-45f6-8803-bd904ead0de7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e43c408e-ea37-45f6-8803-bd904ead0de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e43c408e-ea37-45f6-8803-bd904ead0de7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PreFundedWarrantsMember_dbc7d4e3-c755-499b-a522-c48c1ca15f42" xlink:href="kprx-20250331.xsd#kprx_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:to="loc_kprx_PreFundedWarrantsMember_dbc7d4e3-c755-499b-a522-c48c1ca15f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_TrancheAWarrantsMember_f5010aca-32dd-4e74-981a-922df51b59d4" xlink:href="kprx-20250331.xsd#kprx_TrancheAWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:to="loc_kprx_TrancheAWarrantsMember_f5010aca-32dd-4e74-981a-922df51b59d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_TrancheBWarrantsMember_bbc897a5-2e50-4c84-b638-eab39904fb71" xlink:href="kprx-20250331.xsd#kprx_TrancheBWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2f1a250-a392-4f24-8afd-969edbf540d8" xlink:to="loc_kprx_TrancheBWarrantsMember_bbc897a5-2e50-4c84-b638-eab39904fb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f9f4e908-fc30-44ba-9b92-5235afb0b0f2" xlink:to="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c10386f8-4f33-45d8-9058-4d3f8b0aa0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c10386f8-4f33-45d8-9058-4d3f8b0aa0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_971f27b8-b052-467f-b77e-12e3f48c0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_971f27b8-b052-467f-b77e-12e3f48c0fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f6dadf1b-a82e-402a-8daa-f6260467f358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f6dadf1b-a82e-402a-8daa-f6260467f358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f2abe262-4b77-42c1-af5c-5d999e5729fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f2abe262-4b77-42c1-af5c-5d999e5729fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c98a8eab-8eda-46d3-91fd-d00ac6f95c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c98a8eab-8eda-46d3-91fd-d00ac6f95c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_97f5dd4e-337a-4708-86af-728d42df4d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_97f5dd4e-337a-4708-86af-728d42df4d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightThresholdTradingDays_07b09701-280a-456c-8efb-7fcdd2afce01" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_kprx_ClassOfWarrantOrRightThresholdTradingDays_07b09701-280a-456c-8efb-7fcdd2afce01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock_8d045542-c5dc-42df-b389-dfdf97340ed2" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock_8d045542-c5dc-42df-b389-dfdf97340ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_677a0e2e-48df-4841-9dab-577bfcdbd41e" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_677a0e2e-48df-4841-9dab-577bfcdbd41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c35391e7-b2f5-4597-88ac-e2fe1c9d9cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_46f5d501-48e9-4f65-bf52-cf2f7d10b53e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c35391e7-b2f5-4597-88ac-e2fe1c9d9cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#WarrantsScheduleofWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kprx_WarrantsAbstract_1b05357b-88f3-4694-99ff-48b6029b44db" xlink:href="kprx-20250331.xsd#kprx_WarrantsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6adcd96d-0c86-4c56-a197-ce304660366d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_WarrantsAbstract_1b05357b-88f3-4694-99ff-48b6029b44db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6adcd96d-0c86-4c56-a197-ce304660366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e946b159-93fd-4f62-8d27-c91e45a15c86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6adcd96d-0c86-4c56-a197-ce304660366d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e946b159-93fd-4f62-8d27-c91e45a15c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ec62ec14-cef8-4a6e-a47e-5a4949665105" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e946b159-93fd-4f62-8d27-c91e45a15c86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ec62ec14-cef8-4a6e-a47e-5a4949665105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c1ce99fe-d34f-4875-94f0-e4bd966783c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ec62ec14-cef8-4a6e-a47e-5a4949665105" xlink:to="loc_us-gaap_WarrantMember_c1ce99fe-d34f-4875-94f0-e4bd966783c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6adcd96d-0c86-4c56-a197-ce304660366d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:to="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_98aaa1c0-30c0-40fb-b5ae-c67cc4a43855" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_98aaa1c0-30c0-40fb-b5ae-c67cc4a43855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a849487-168d-4d69-afbc-c8cc3ad1fbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a849487-168d-4d69-afbc-c8cc3ad1fbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9412079-ba1e-4cda-963e-e71ec34e499a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f9412079-ba1e-4cda-963e-e71ec34e499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_76d29329-c467-4efb-8156-ecaad6bffd5d" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_76d29329-c467-4efb-8156-ecaad6bffd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef59c6e0-6949-409a-b70c-4fa451bd07f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward_47f3d48a-1afc-44a2-8fe6-107758abeb87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef59c6e0-6949-409a-b70c-4fa451bd07f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_46469396-76ab-485d-80fb-bfbe1d133bdc" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_46469396-76ab-485d-80fb-bfbe1d133bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_dc1ac5fb-3379-4081-b6bb-60bef1c9d888" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_dc1ac5fb-3379-4081-b6bb-60bef1c9d888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice_db1d33e9-6e34-484b-b6e7-3554ad02ace7" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice_db1d33e9-6e34-484b-b6e7-3554ad02ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_d6121212-8643-40a4-990f-f62459d6d984" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice_d6121212-8643-40a4-990f-f62459d6d984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_b5230bc4-8e4f-45a6-a6bb-21307bce7823" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_2a2b7d8e-5588-4a99-a72f-1723d4fe6641" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_b5230bc4-8e4f-45a6-a6bb-21307bce7823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_a9710120-f04f-41c4-bcec-7f9c8e7a1a56" xlink:href="kprx-20250331.xsd#kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15954960-00cf-49ac-b8c3-60ae0783356e" xlink:to="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_a9710120-f04f-41c4-bcec-7f9c8e7a1a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7c924e58-712e-49df-9779-db6908d5b2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract_a9710120-f04f-41c4-bcec-7f9c8e7a1a56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7c924e58-712e-49df-9779-db6908d5b2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#NetLossIncomeperShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5de80cce-ee28-431e-bf54-67712631ef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3484533-ddcd-4e5f-adc7-1d57614ccd42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5de80cce-ee28-431e-bf54-67712631ef9a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3484533-ddcd-4e5f-adc7-1d57614ccd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f029790-1653-43f6-9772-0521119b38ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3484533-ddcd-4e5f-adc7-1d57614ccd42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f029790-1653-43f6-9772-0521119b38ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f029790-1653-43f6-9772-0521119b38ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cb7c2cc8-34d0-42b7-bc2c-e6c6063dd0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_WarrantMember_cb7c2cc8-34d0-42b7-bc2c-e6c6063dd0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dbb98f78-f362-46d1-bd78-01cd4ca2292a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dbb98f78-f362-46d1-bd78-01cd4ca2292a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5b8e97d8-6b74-459f-b65e-8a435c9c98cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_RestrictedStockMember_5b8e97d8-6b74-459f-b65e-8a435c9c98cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncumulativePreferredStockMember_29a2cc70-2368-41df-a0f8-d8f98510090f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncumulativePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_NoncumulativePreferredStockMember_29a2cc70-2368-41df-a0f8-d8f98510090f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ae7666bd-9b8e-439f-bab0-e1e25ad1fa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f1548ea-69bf-4081-9b56-25f268242a51" xlink:to="loc_us-gaap_CommonStockMember_ae7666bd-9b8e-439f-bab0-e1e25ad1fa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3484533-ddcd-4e5f-adc7-1d57614ccd42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ad1e282c-a8b2-4722-ab2e-c9d7f5b74e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ad1e282c-a8b2-4722-ab2e-c9d7f5b74e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a732e879-9888-43d4-add3-eb29d6f1703a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_873a83d2-dafa-45c8-883a-612079fc412d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a732e879-9888-43d4-add3-eb29d6f1703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a28ab911-5f9d-41b8-bcc4-fb4bd9c01d39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a28ab911-5f9d-41b8-bcc4-fb4bd9c01d39" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ff3f13d-e092-402a-bf78-cfe5a80b61be" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_srt_RangeAxis_4ff3f13d-e092-402a-bf78-cfe5a80b61be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4ff3f13d-e092-402a-bf78-cfe5a80b61be" xlink:to="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3be816f-4edc-4c26-9bf9-6c1f0587bb05" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:to="loc_srt_MinimumMember_d3be816f-4edc-4c26-9bf9-6c1f0587bb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_245280c8-6652-4618-b1b1-cdbced5b8638" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cf1e7d26-259d-49b8-8e98-6d1c39b4f9de" xlink:to="loc_srt_MaximumMember_245280c8-6652-4618-b1b1-cdbced5b8638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f087ae74-657d-4c08-8df9-50dba2478144" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_srt_TitleOfIndividualAxis_f087ae74-657d-4c08-8df9-50dba2478144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_020386a0-29a6-495b-8593-7cd1a4f020cd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_f087ae74-657d-4c08-8df9-50dba2478144" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_020386a0-29a6-495b-8593-7cd1a4f020cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_d7b021b5-1281-4010-9aed-c1c7529566ee" xlink:href="kprx-20250331.xsd#kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_020386a0-29a6-495b-8593-7cd1a4f020cd" xlink:to="loc_kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember_d7b021b5-1281-4010-9aed-c1c7529566ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2adf53e2-45b5-4a15-8323-229a7ce589d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_us-gaap_PlanNameAxis_2adf53e2-45b5-4a15-8323-229a7ce589d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2adf53e2-45b5-4a15-8323-229a7ce589d8" xlink:to="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EquityIncentivePlan2014Member_103e7b8c-68b9-4e98-9e03-b7c0172aebbe" xlink:href="kprx-20250331.xsd#kprx_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:to="loc_kprx_EquityIncentivePlan2014Member_103e7b8c-68b9-4e98-9e03-b7c0172aebbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_EmployeeStockPurchasePlanMember_81d3fa8e-55da-4c95-895f-b8b7bd6b5bed" xlink:href="kprx-20250331.xsd#kprx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f4fcbbfd-1f40-4278-a9c6-6c85c650484f" xlink:to="loc_kprx_EmployeeStockPurchasePlanMember_81d3fa8e-55da-4c95-895f-b8b7bd6b5bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd0c0fc9-d193-40e7-8730-ad6923618e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_us-gaap_AwardTypeAxis_cd0c0fc9-d193-40e7-8730-ad6923618e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cd0c0fc9-d193-40e7-8730-ad6923618e29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10274435-1385-48d5-ab38-3c72e1aeba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10274435-1385-48d5-ab38-3c72e1aeba5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5e8eeced-f2bc-44ea-ab23-a7cae5350b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71c6e92b-5f01-4480-9263-e0c114084050" xlink:to="loc_us-gaap_RestrictedStockMember_5e8eeced-f2bc-44ea-ab23-a7cae5350b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7134ce7e-ab2e-418d-a1da-2eeecef43ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_us-gaap_VestingAxis_7134ce7e-ab2e-418d-a1da-2eeecef43ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7134ce7e-ab2e-418d-a1da-2eeecef43ab1" xlink:to="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a712b11-242b-420b-a299-1820b2a3cde8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4a712b11-242b-420b-a299-1820b2a3cde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7ddc191-7160-4bdd-a09c-f1c7621fd3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_cb056cbc-6d02-4717-b0fd-0567804eedaa" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7ddc191-7160-4bdd-a09c-f1c7621fd3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d177cf2c-53b1-4611-b5f1-b31d39e8a542" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PercentageOfExercisePrice_99a6d023-b7f3-4555-909b-8e667af782f7" xlink:href="kprx-20250331.xsd#kprx_PercentageOfExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_kprx_PercentageOfExercisePrice_99a6d023-b7f3-4555-909b-8e667af782f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f765fcf9-ce25-4316-9b5b-20e66172dcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f765fcf9-ce25-4316-9b5b-20e66172dcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_95aab066-be0a-4774-8641-5d674f447287" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_95aab066-be0a-4774-8641-5d674f447287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7477729e-8270-494c-8548-f2fcaf695555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7477729e-8270-494c-8548-f2fcaf695555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fa9069fc-9d14-47fe-87ca-2ecfb9fccc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fa9069fc-9d14-47fe-87ca-2ecfb9fccc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0e1d6369-ca0f-459f-9380-02288eecbe65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0e1d6369-ca0f-459f-9380-02288eecbe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af905ee8-dd79-41c4-a1a1-d752cf6cea85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af905ee8-dd79-41c4-a1a1-d752cf6cea85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2ffc1635-a082-4b97-919b-8cd6a127cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2ffc1635-a082-4b97-919b-8cd6a127cb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2547bfdb-d01e-4b18-80b2-3c56d0125306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2547bfdb-d01e-4b18-80b2-3c56d0125306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_10bbb69c-6800-4768-abfd-34d7a39577dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_10bbb69c-6800-4768-abfd-34d7a39577dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a169b6ac-4a5d-47af-9823-00a28e958d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a169b6ac-4a5d-47af-9823-00a28e958d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e621e15b-8589-4a80-a33a-016d313a7a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_SharePrice_e621e15b-8589-4a80-a33a-016d313a7a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d45fb423-7bdc-4c65-b939-cbda80931c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d45fb423-7bdc-4c65-b939-cbda80931c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_71caad54-23aa-4df9-a54e-49a0ecc0f142" xlink:href="kprx-20250331.xsd#kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28ee1b7b-8fcf-4056-8887-0158f441e1c0" xlink:to="loc_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_71caad54-23aa-4df9-a54e-49a0ecc0f142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27d6d1a2-a97b-4193-bcda-85f2f90715df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6951e39-1986-4e76-bb72-958a60926dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27d6d1a2-a97b-4193-bcda-85f2f90715df" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6951e39-1986-4e76-bb72-958a60926dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9a05b9db-6664-4724-be88-6080cb71dccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6951e39-1986-4e76-bb72-958a60926dbb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9a05b9db-6664-4724-be88-6080cb71dccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9a05b9db-6664-4724-be88-6080cb71dccc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f8109cf-1b00-4fe5-a9f6-0d6614ef6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f8109cf-1b00-4fe5-a9f6-0d6614ef6b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c10f3fe-6c53-449b-84b7-2a94839bd7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a046f25-cdd2-4690-9405-a5ee37312c35" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c10f3fe-6c53-449b-84b7-2a94839bd7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_569b8f86-4c64-472b-b600-140c849dba59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6951e39-1986-4e76-bb72-958a60926dbb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_569b8f86-4c64-472b-b600-140c849dba59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_5ec5d489-f384-4c17-9dde-f39b9dbab6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_569b8f86-4c64-472b-b600-140c849dba59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_5ec5d489-f384-4c17-9dde-f39b9dbab6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationScheduleofstockoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed34746f-2499-406d-aee1-b0c63d42c1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afe67543-d9ad-4db3-be6c-88639b488b13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed34746f-2499-406d-aee1-b0c63d42c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afe67543-d9ad-4db3-be6c-88639b488b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2edc714-1673-4614-a315-00c9f2c641ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afe67543-d9ad-4db3-be6c-88639b488b13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2edc714-1673-4614-a315-00c9f2c641ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7556fc92-b331-448e-b3e9-83ee63c9284b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afe67543-d9ad-4db3-be6c-88639b488b13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7556fc92-b331-448e-b3e9-83ee63c9284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a2f0953d-2678-425d-8506-2056b4c20870" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afe67543-d9ad-4db3-be6c-88639b488b13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a2f0953d-2678-425d-8506-2056b4c20870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2c21099d-b2fc-4a74-8ce3-8191a741011d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afe67543-d9ad-4db3-be6c-88639b488b13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2c21099d-b2fc-4a74-8ce3-8191a741011d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bba9f2c4-45ba-4caf-a60a-ae657630a658" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afe67543-d9ad-4db3-be6c-88639b488b13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bba9f2c4-45ba-4caf-a60a-ae657630a658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_346d62a5-a111-4889-aa86-6e09b38a005d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed34746f-2499-406d-aee1-b0c63d42c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_346d62a5-a111-4889-aa86-6e09b38a005d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_961b0e5a-9d4e-4794-b850-c9e3f108a510" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed34746f-2499-406d-aee1-b0c63d42c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_961b0e5a-9d4e-4794-b850-c9e3f108a510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e20fa53d-ff0d-4b58-9ec0-45ae0606ea3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_961b0e5a-9d4e-4794-b850-c9e3f108a510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e20fa53d-ff0d-4b58-9ec0-45ae0606ea3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_df5541dc-7f46-4324-97ae-78c3aff112e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_961b0e5a-9d4e-4794-b850-c9e3f108a510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_df5541dc-7f46-4324-97ae-78c3aff112e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85ea6336-2aa2-4496-87af-4cae48742120" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_961b0e5a-9d4e-4794-b850-c9e3f108a510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85ea6336-2aa2-4496-87af-4cae48742120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_00035bf5-289c-46c4-9e2c-d13ef08761d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_961b0e5a-9d4e-4794-b850-c9e3f108a510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_00035bf5-289c-46c4-9e2c-d13ef08761d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa653bb7-4e7e-4cf6-a006-93899e9aafb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_961b0e5a-9d4e-4794-b850-c9e3f108a510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa653bb7-4e7e-4cf6-a006-93899e9aafb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_203f4aa1-77c8-40f6-af64-29e017b80cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed34746f-2499-406d-aee1-b0c63d42c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_203f4aa1-77c8-40f6-af64-29e017b80cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bdad1cca-a9c4-4012-9c28-6990f9294fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed34746f-2499-406d-aee1-b0c63d42c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bdad1cca-a9c4-4012-9c28-6990f9294fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c281eb98-81c2-473a-ba8b-1103d81568b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bdad1cca-a9c4-4012-9c28-6990f9294fc5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c281eb98-81c2-473a-ba8b-1103d81568b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dbb462c8-d4e5-4cec-9ceb-745f627aca08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bdad1cca-a9c4-4012-9c28-6990f9294fc5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dbb462c8-d4e5-4cec-9ceb-745f627aca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717392c8-2d6a-47b5-ae36-0f4302781368" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3af20b6a-c2c2-40d2-81b5-727b4b148097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717392c8-2d6a-47b5-ae36-0f4302781368" xlink:to="loc_us-gaap_StatementTable_3af20b6a-c2c2-40d2-81b5-727b4b148097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f25bf170-e5c3-4e62-9aae-5b332a26cef0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3af20b6a-c2c2-40d2-81b5-727b4b148097" xlink:to="loc_us-gaap_AwardTypeAxis_f25bf170-e5c3-4e62-9aae-5b332a26cef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_978ccff5-2f20-4b6e-83d0-4daca1f701fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f25bf170-e5c3-4e62-9aae-5b332a26cef0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_978ccff5-2f20-4b6e-83d0-4daca1f701fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_05d446a7-0d0a-40ed-a627-b1c9eb7d3186" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_978ccff5-2f20-4b6e-83d0-4daca1f701fc" xlink:to="loc_us-gaap_RestrictedStockMember_05d446a7-0d0a-40ed-a627-b1c9eb7d3186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3af20b6a-c2c2-40d2-81b5-727b4b148097" xlink:to="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63ff793f-a648-40fe-a498-fbcf0c807f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63ff793f-a648-40fe-a498-fbcf0c807f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4f34bfb-4dce-48fd-8544-fc9a04bac6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4f34bfb-4dce-48fd-8544-fc9a04bac6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3a516abf-86ce-4d9a-b2e1-ac3c2b035241" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3a516abf-86ce-4d9a-b2e1-ac3c2b035241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_713790f1-a682-4233-b91f-b3b0091c3a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_713790f1-a682-4233-b91f-b3b0091c3a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_260fb563-c49f-4bfd-8b4a-9e2db95d047f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e80c98b-7c4e-4392-8f34-c2d66a8bd507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_260fb563-c49f-4bfd-8b4a-9e2db95d047f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad1eb71-00ff-4cf3-a218-1f6f3dc73e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad1eb71-00ff-4cf3-a218-1f6f3dc73e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_377f3587-8b41-48e8-af45-74b6c6581402" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_377f3587-8b41-48e8-af45-74b6c6581402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14fc355c-50ce-43ef-b9f0-c412236d476a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_14fc355c-50ce-43ef-b9f0-c412236d476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39c46ea5-740d-426e-94f6-52e56d7fd95c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39c46ea5-740d-426e-94f6-52e56d7fd95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f8f80cc-eb29-4d66-955c-dd5320b97cec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de258203-f5f9-45aa-885c-2330575afacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f8f80cc-eb29-4d66-955c-dd5320b97cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a24d8641-9810-4291-9ebf-4a7d37a86ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e77fd549-58b3-417f-b71e-373a5946febb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a24d8641-9810-4291-9ebf-4a7d37a86ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_65bf0a57-ad40-4f6e-af81-4835171cad7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a24d8641-9810-4291-9ebf-4a7d37a86ba5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_65bf0a57-ad40-4f6e-af81-4835171cad7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4aa0ee93-2145-41be-8934-76e8d6c3ed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_a24d8641-9810-4291-9ebf-4a7d37a86ba5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4aa0ee93-2145-41be-8934-76e8d6c3ed3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18607597-8255-4bec-b971-f0a874ce0b55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:href="kprx-20250331.xsd#kprx_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18607597-8255-4bec-b971-f0a874ce0b55" xlink:to="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ecb6c487-0019-41ef-8dfe-aeeb4ab35a7a" xlink:to="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A18MonthLeaseEncinitasCAMember_a39b95a0-aa1e-4b6c-95c7-ae0798a82232" xlink:href="kprx-20250331.xsd#kprx_A18MonthLeaseEncinitasCAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A18MonthLeaseEncinitasCAMember_a39b95a0-aa1e-4b6c-95c7-ae0798a82232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A12MonthLeaseAdelaideAustraliaMember_a1840ded-01d4-4fd2-93b2-ca17b6742327" xlink:href="kprx-20250331.xsd#kprx_A12MonthLeaseAdelaideAustraliaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A12MonthLeaseAdelaideAustraliaMember_a1840ded-01d4-4fd2-93b2-ca17b6742327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A5YearLeaseViennaAustriaMember_27454c30-5430-4a95-b4e1-63415a11c102" xlink:href="kprx-20250331.xsd#kprx_A5YearLeaseViennaAustriaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A5YearLeaseViennaAustriaMember_27454c30-5430-4a95-b4e1-63415a11c102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember_f6856bdb-ab8c-49bb-81d0-05d036c16d85" xlink:href="kprx-20250331.xsd#kprx_A2YearLeasePerthAndBrisbaneAustraliaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A2YearLeasePerthAndBrisbaneAustraliaMember_f6856bdb-ab8c-49bb-81d0-05d036c16d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember_e6337598-1e98-4729-b2d0-b546d5a139d2" xlink:href="kprx-20250331.xsd#kprx_A3Year3MonthLeaseEncinitasCaliforniaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_e3a9fb18-6612-4562-bf0c-ee46d30677fc" xlink:to="loc_kprx_A3Year3MonthLeaseEncinitasCaliforniaMember_e6337598-1e98-4729-b2d0-b546d5a139d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_deaba134-cf15-4c00-a8ca-cbee10a200fc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_srt_RangeAxis_deaba134-cf15-4c00-a8ca-cbee10a200fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_deaba134-cf15-4c00-a8ca-cbee10a200fc" xlink:to="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4591882d-f2ce-4ae7-9c0f-769ab083ce69" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:to="loc_srt_MinimumMember_4591882d-f2ce-4ae7-9c0f-769ab083ce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b984cbb-a8dd-41b2-b63a-28778c318065" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d369d323-759a-475b-a412-e0a89ef2fed1" xlink:to="loc_srt_MaximumMember_0b984cbb-a8dd-41b2-b63a-28778c318065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb5e0b17-4949-4100-be58-2357c7867373" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_srt_ProductOrServiceAxis_fb5e0b17-4949-4100-be58-2357c7867373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_992eb177-f7f1-4578-811f-aa8acbf817e1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fb5e0b17-4949-4100-be58-2357c7867373" xlink:to="loc_srt_ProductsAndServicesDomain_992eb177-f7f1-4578-811f-aa8acbf817e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_8967b238-ea07-4f8d-88f1-50b70bc21fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_992eb177-f7f1-4578-811f-aa8acbf817e1" xlink:to="loc_us-gaap_GrantMember_8967b238-ea07-4f8d-88f1-50b70bc21fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4a00cc61-a9f5-46a9-a96c-4d75cd523193" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_us-gaap_CreditFacilityAxis_4a00cc61-a9f5-46a9-a96c-4d75cd523193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ef475abd-7a4f-40bf-bfb2-17beca19bbac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4a00cc61-a9f5-46a9-a96c-4d75cd523193" xlink:to="loc_us-gaap_CreditFacilityDomain_ef475abd-7a4f-40bf-bfb2-17beca19bbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a4ba1ea5-3aa4-405f-a2ad-e5414fa70242" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ef475abd-7a4f-40bf-bfb2-17beca19bbac" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a4ba1ea5-3aa4-405f-a2ad-e5414fa70242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c393eddb-26eb-4f75-a05f-2885112f1b78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c393eddb-26eb-4f75-a05f-2885112f1b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0be27328-6320-41bf-ab7a-745c3cf84776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c393eddb-26eb-4f75-a05f-2885112f1b78" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0be27328-6320-41bf-ab7a-745c3cf84776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UBSMember_1f84d61f-da64-4fb7-b017-09e422e603d4" xlink:href="kprx-20250331.xsd#kprx_UBSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0be27328-6320-41bf-ab7a-745c3cf84776" xlink:to="loc_kprx_UBSMember_1f84d61f-da64-4fb7-b017-09e422e603d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:href="kprx-20250331.xsd#kprx_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesTable_45e810df-f93d-4046-bc2f-8f81aeb1d932" xlink:to="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeNumberOfOperatingLeases_5649fdac-3c21-4596-a37c-49c45e9353ed" xlink:href="kprx-20250331.xsd#kprx_LesseeNumberOfOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeNumberOfOperatingLeases_5649fdac-3c21-4596-a37c-49c45e9353ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3aef8b0a-8993-4be2-bb95-8c056dd0feff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3aef8b0a-8993-4be2-bb95-8c056dd0feff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseMonthlyRentPayment_eb75d6f1-a822-46c1-8318-7b9d2978531b" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeOperatingLeaseMonthlyRentPayment_eb75d6f1-a822-46c1-8318-7b9d2978531b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseSecurityDeposit_612ac08e-788c-49cc-9707-8237054c80c1" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseSecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeOperatingLeaseSecurityDeposit_612ac08e-788c-49cc-9707-8237054c80c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_LesseeOperatingLeaseTerminationPeriod_a9ad5bf3-03f9-43cf-bd12-5c3c2ed7437d" xlink:href="kprx-20250331.xsd#kprx_LesseeOperatingLeaseTerminationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_LesseeOperatingLeaseTerminationPeriod_a9ad5bf3-03f9-43cf-bd12-5c3c2ed7437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_680b15fa-3a4f-49d2-a4b2-46580a25d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_AreaOfLand_680b15fa-3a4f-49d2-a4b2-46580a25d4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c78f6b65-5e94-4140-87e7-44e5843f5e68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LeaseCost_c78f6b65-5e94-4140-87e7-44e5843f5e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a48af980-078c-4690-a9f8-7888cf84c08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a48af980-078c-4690-a9f8-7888cf84c08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_NumberOfLicenseAgreements_9ecfac8b-daf2-45ac-acfa-62530fda6e0d" xlink:href="kprx-20250331.xsd#kprx_NumberOfLicenseAgreements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_kprx_NumberOfLicenseAgreements_9ecfac8b-daf2-45ac-acfa-62530fda6e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_070bda9f-b90c-4a29-9d3e-af99563ab1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_Revenues_070bda9f-b90c-4a29-9d3e-af99563ab1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_8b42eedd-906a-41a6-8287-02a232f92d28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_LineOfCredit_8b42eedd-906a-41a6-8287-02a232f92d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2c7c2bc2-1602-494b-8a8f-8f7e7ae9fbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_CommitmentsAndContingenciesLineItems_2b5c5a3c-e72b-41ac-98d3-a164d05096e8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2c7c2bc2-1602-494b-8a8f-8f7e7ae9fbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d978f03f-6374-417e-acc6-40d4f52aab5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7740666d-4e04-4ec9-a1d7-f893c8049ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d978f03f-6374-417e-acc6-40d4f52aab5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7740666d-4e04-4ec9-a1d7-f893c8049ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b2779ce-c712-448b-ba6d-82ffd87d0f92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d978f03f-6374-417e-acc6-40d4f52aab5d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b2779ce-c712-448b-ba6d-82ffd87d0f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_61e51be8-c8a2-477f-a412-c23eb7693cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_61e51be8-c8a2-477f-a412-c23eb7693cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5ce6157-3562-4343-874c-0baa63226f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5ce6157-3562-4343-874c-0baa63226f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_56aec78c-8cfb-4ccf-915f-e769d5b5f048" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_56aec78c-8cfb-4ccf-915f-e769d5b5f048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35812162-8466-4a2f-b02a-32216ee5db21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_35812162-8466-4a2f-b02a-32216ee5db21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0352cd0d-8e58-44c7-aff4-d25f8fda37b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0352cd0d-8e58-44c7-aff4-d25f8fda37b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e7138dd7-a94f-4cfd-9ab5-34b7fc56347f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e7138dd7-a94f-4cfd-9ab5-34b7fc56347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fdfd4c10-02e2-4425-85fa-fdaa0f239e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_OperatingLeaseLiability_fdfd4c10-02e2-4425-85fa-fdaa0f239e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bde21a91-cbbe-4196-a97b-8ab3449c6ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bde21a91-cbbe-4196-a97b-8ab3449c6ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2514567-9e69-4012-b358-9f11358b66d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0efe5366-4c84-42cf-9a2b-2099b56bdef2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2514567-9e69-4012-b358-9f11358b66d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9fed06b0-de2a-4402-bcfa-06b1d0018016" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_83c8a86d-ed68-485f-ab81-c3a03bb318df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9fed06b0-de2a-4402-bcfa-06b1d0018016" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_83c8a86d-ed68-485f-ab81-c3a03bb318df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_981733bf-d598-4382-88ba-6f5e2a67ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_83c8a86d-ed68-485f-ab81-c3a03bb318df" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_981733bf-d598-4382-88ba-6f5e2a67ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_981733bf-d598-4382-88ba-6f5e2a67ca74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_BayonMember_51f2a5c2-0673-48af-bebe-689a4459eaa4" xlink:href="kprx-20250331.xsd#kprx_BayonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:to="loc_kprx_BayonMember_51f2a5c2-0673-48af-bebe-689a4459eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_PanoptesMember_18a11533-71b2-49a2-8791-b6ca5cf9068d" xlink:href="kprx-20250331.xsd#kprx_PanoptesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_737be12c-bb87-4f9d-bc2f-0e7f03684f2d" xlink:to="loc_kprx_PanoptesMember_18a11533-71b2-49a2-8791-b6ca5cf9068d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_83c8a86d-ed68-485f-ab81-c3a03bb318df" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2d6d16d5-d120-4758-a409-efa20cd1b597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2d6d16d5-d120-4758-a409-efa20cd1b597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_3a2fec12-4d97-43b5-9261-dd0f0f4e16b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c8fffe1e-a0af-4963-acea-c67c5e38fc37" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_3a2fec12-4d97-43b5-9261-dd0f0f4e16b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="kprx-20250331.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4e4a183a-2552-4fa2-9948-f8bedc5e4418" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_03d0a419-e4a4-45e1-b8ff-725a5e3c4eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e4a183a-2552-4fa2-9948-f8bedc5e4418" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_03d0a419-e4a4-45e1-b8ff-725a5e3c4eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentAllocationAxis_404070b0-69d1-41c3-be4e-26c5a49a81d1" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentAllocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_03d0a419-e4a4-45e1-b8ff-725a5e3c4eeb" xlink:to="loc_kprx_ResearchAndDevelopmentAllocationAxis_404070b0-69d1-41c3-be4e-26c5a49a81d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:href="kprx-20250331.xsd#kprx_ResearchAndDevelopmentAllocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationAxis_404070b0-69d1-41c3-be4e-26c5a49a81d1" xlink:to="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO101Member_f19d6028-aaad-4ba5-9216-a64ee7f7c93c" xlink:href="kprx-20250331.xsd#kprx_KIO101Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO101Member_f19d6028-aaad-4ba5-9216-a64ee7f7c93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO104NetOfAdjustmentMember_d1a2944f-e68a-4b4f-82b2-a7e98ff0380e" xlink:href="kprx-20250331.xsd#kprx_KIO104NetOfAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO104NetOfAdjustmentMember_d1a2944f-e68a-4b4f-82b2-a7e98ff0380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO201Member_18c2fc16-dd29-40cf-adb2-b50e0ac187ca" xlink:href="kprx-20250331.xsd#kprx_KIO201Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO201Member_18c2fc16-dd29-40cf-adb2-b50e0ac187ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_KIO301Member_dfb52a1f-375c-4503-8773-73adeb79b124" xlink:href="kprx-20250331.xsd#kprx_KIO301Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_KIO301Member_dfb52a1f-375c-4503-8773-73adeb79b124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_UnallocatedResearchAndDevelopmentMember_36b50a02-0208-4fc9-b152-4e6b2ea1d423" xlink:href="kprx-20250331.xsd#kprx_UnallocatedResearchAndDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kprx_ResearchAndDevelopmentAllocationDomain_53ee5b14-4d39-4547-a9f4-b035b69facad" xlink:to="loc_kprx_UnallocatedResearchAndDevelopmentMember_36b50a02-0208-4fc9-b152-4e6b2ea1d423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable_03d0a419-e4a4-45e1-b8ff-725a5e3c4eeb" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7c046e12-834f-4191-9be0-febea196ff93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:to="loc_us-gaap_Revenues_7c046e12-834f-4191-9be0-febea196ff93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems_c7706a53-421b-4bcb-b635-370037047210" xlink:to="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d9712f7f-4d12-4447-9115-ce4964625af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d9712f7f-4d12-4447-9115-ce4964625af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58187d36-cb9d-4480-ac66-4169674b0fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58187d36-cb9d-4480-ac66-4169674b0fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kprx_CollaborationCreditOperatingExpense_f201a9c9-fe7e-4f8e-89fa-cdff543357d8" xlink:href="kprx-20250331.xsd#kprx_CollaborationCreditOperatingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_kprx_CollaborationCreditOperatingExpense_f201a9c9-fe7e-4f8e-89fa-cdff543357d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c3c055eb-7d3c-483f-b1cf-98e96be62268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c3c055eb-7d3c-483f-b1cf-98e96be62268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9cda0669-96ee-4f52-b5d5-8619665852a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9cda0669-96ee-4f52-b5d5-8619665852a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_39156cde-de71-4545-883f-bc5fcc05b522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_39156cde-de71-4545-883f-bc5fcc05b522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_30192dc1-6d78-4036-93c0-05b1a2830988" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_30192dc1-6d78-4036-93c0-05b1a2830988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f3dd5e5-a1e9-4901-a78b-2e4e940b5542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_64c3abeb-848e-4648-88ca-575666b19824" xlink:to="loc_us-gaap_NetIncomeLoss_7f3dd5e5-a1e9-4901-a78b-2e4e940b5542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>kprx-20250331_g1.jpg
<DESCRIPTION>KIORA LOGO
<TEXT>
begin 644 kprx-20250331_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M(W,T4/#!T8+"TC,4)'0&HD.CL^&3XR6 4Z05-7!C@^3#TQ:0\524M'4F_]H
M# ,!  (1 Q$   "?P
M
M
M                                >M]_/3,@U/2,CT_4&^U75VYUW7VU
MP>&Y^)Q_+\/C^_E^/U^?1\OO[&/Z\KP<KG.NS.Q]1G]K:39]T1[;][QK=<UU
MV6
M
M                                          .D)'I\0)Y%L3YQ&,7Y
ME'<>95H?C9'D       !VEI=EDK$)!E3"I+EO!I1EI!I/R+$]P
M
M
M                         /G>OGA=842P+LV%8-61#>G=_J@
M  !]/Q],N8+*,ZZUF>?M7S?NF/;<
M
M
M#^3$N<Q?6G;]?:^K2@_"=CA@              #R920N2;'ZEGVQRI9]SW69
MH
M
M                               ^!E>&MFW(!JONJM<=Y7H@
M         !]?P]=A-5SK:W25EY10R1@        >#1#T+5'36\U@   '+\+)
MD!\X6]]+R^P
M
M                      !Q/.QM5-V5IJCNVM. ;3!
M    S,K^6;AJ$M7,NOY8       /!$K[*Y[C3=3TD   !R_"R)S7\_NJ-LM.
M6"
M
M             !\;(\M5=UUKJ'O>K>#['#                       S+K
M^6;K>>+=REA<D      \$2OLKGN--U/20   '+\+(G-?S^ZHVRTY8(
M
M
M     & =GPC2)T93_3,@U(                        _3\_=D%23_ '6\
M\6[V9I]@    /!$K[*Y[C3=3TD   !R_"R)S7\_NJ-LM.6"
M
M                                                          .I
MMYK-%/2E,X(V7"P                         !GM64UD3\HWP   !X(E?
M97/<:;J>D@   .7X61.:_G]U1MEIRP0
M
M                                         !K6MZO]'71U.<0S\4
M                        9BP&5R->3;ZY'B9    \$2OLKGN--U/20
M'+\+(G-?S^ZHVRTY8(
M
M                            '%,W&T/=,4MKNM:"
M           9BP&5R->3;ZY'B9    \$2OLKGN--U/20   '+\+(G-?S^ZHV
MRTY8(
M
M               &/<JT4=[JNB>AY-I0                          ,Q
M8#*Y&O)M]<CQ,@   >")7V5SW&FZGI(   #E^%D3FOY_=4;9:<L$
M
M
M  #!6RH9'VZDH[BN;C                           9BP&5R->3;ZY'B9
M    \$2OLKGN--U/20   '+\+(G-?S^ZHVRTY8(          Q,VF#U=D^(
M ]C\_<_-'LP             /R_6 N[UGY?OX!VWB^^5.LS0!P;V\\--OKP
M .Z</(R;UV8              .KLGQZ6S,?@7MY>K]?G/_#V[HP_?MK%]P
M           ,=<_$Z%SL8      #DGG]\W\?3N7$R.Q,?U
M           Q>V6'TYEXXR4UV9WAAY                       U<W/7&C
M+I&F_5^_D                          #,6 RN1KR;?7(\3(   '@B5]E
M<]QINIZ2    Y?A9$YK^?W5&V6G+!           KAN@*JC[SJ+@ #FGCZ7)
MO)=\@            #U?W\@3W=6L6"RX:!E5K,VS7YUMW8!HMF -24HTE77T
ME3H  $J2LYG/=I&R@          !QCT^-24ITFH"5Z+5S)-/KXWVKPJV^OZS
MR?$  =E8WMG-IMCL>C^UVNQC=[G(CO\ 9G'=M^_Y^@          0BKCKR'G
M:\%        '86/ZY:ZO.SETVQV/1_:[5XQNMRD2WV3FNS
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MQO8                    #3'T%4VGZ^:K
M  &8L!E<C7DV^N1XF0   /!$K[*Y[C3=3TD   !R_"R)S7\_NJ-LM.6"
M       !7#= 55'WG47  '-/'TN3>2[Y            'Q_OYKY[UK&-=842
M S=TVQLS^=K<S5T^P  &I*4:2KKZ2IT  "5)6<SGNTC90        '2^9CQ/
MK.A<4FSH7B[LL(          ;8HONY?]53F0M Y1[7Y^@       "$5<=>0\
M[7@H     ^E\_7K?OYZW[^     #F'CZ2@:XF$SRHI]DIK\L
M      "OKO6L8R5BQ  6#5%6?)GKJ7                    #3Q?=5::>@
M*G                           &8L!E<C7DV^N1XF0   /!$K[*Y[C3=3
MTD   !R_"R)S7\_NJ-LM.6"            *X;H"JH^\ZBX  YIX^ER;R7?(
M           ''?3YKS;XJZ.E/HJ!GQH]G9C\[VWF%J<\  #4E*-)5U])4Z
M!*DK.9SW:1LH       #BWK\1+K0A,..V8'TIF8X ']_G[M&C>XWFPR1;7(Q
MN\]-)LLC]?E\D\_KB?I\8[;#%P:W.NU@233Z89=']/4LT?POOX   &SV-[B<
M[3%B[IXA(        (15QUY#SM>"@  #>_"9)*3K:9;/XWM\H=;F<O\ +T'6
M.3XXE;3"US;_ %6G66:&/Y.HQA/N->   !W7AY$\.E+(DIUY+0
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MO1[,    #'[.Q8U5AQ.)M9\)P=W6N   _O\ /V3'7<MG74M8_=N'D
M0BKCKR'G:\%   W\P:360?/]K_K^    /P_?S1W,H]"ZMZ :CI3HP   )>55
MSF<535B?K^                 (J]F0R!-=U:@ ?2^?JW!Y;N[*[5YH
M              &!EFPJ.[U91/K_ %\@                          9B
MP&5R->3;ZY'B9    \$2OLKGN--U/20    SGK^4V"7\W>ON:X&4
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MS54Y                  &.4LT$97L/GGC.9C@
M     9BP&5R->3;ZY'B9    \$2OLKGN--U/20     W:4-9\W7@CJ']?S]
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MY@                 .'9^)&![)YUZ1D>G
M  S%@,KD:\FWUR/$R   !X(E?97/<:;J>D@     !+ X[Z DW<I7B
M     *X;H"JH^\ZBX  YIX^ER;R7?(         '6V1Y5L70E3:9)=H -K48
MW5EYSQ;?=>'D     :DI1I*NOI*G0  )4E9S.>[2-E     #J7*\*UKH6IM/
MLKT0 '=>'D63G/=L[>HKO          /7_?R%_;L!ACVY ?   /U_/V<#3=A
MR^ZJG(     A%7'7D/.UX*  !:Y\QW3L.T.T       C5V'$J]*]ZO   &5.
MLS;93F"Z^Q,?U               $#R[*WB@V="@  !:I<SW-LOCNW
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M"*N.O(>=KP4  "U]YBNG8)HMH       *YV_:KCP3V+   "=A2MCRT:OFP
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MP           !#>MF!PG[AKX  #]OS]L,*(M"277LL    $(JXZ\AYVO!0
M+7WF*Z=@FBV@       P(WFLJ@NG*6]+Z_   -F<=V]J=S/<P
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M^JNC?6!$P  .;^/I:"\WW#M%C>X    A%7'7D/.UX*  !:^\Q73L$T6T
M    K0^AZDT=3..@  >2W-Y9O#+/5YH              K'NBZBTOR^/CD?G
M]\<]/@  "S YWMO>##9$               /Y(W77% 84V'$0
M              !F+ 97(UY-OKD>)D   #P1*^RN>XTW4])         #^OQ
M.T_GQU;MXI:Q           *X;H"JH^\ZBX  YIX^ER;R7?(       &->QQ
M*SCHBH];,AU(&^>$26Q?H.U.=^'H      !J2E&DJZ^DJ=   E25G,Y[M(V4
M   !H2F\:K<.@JH_+]_  ,VM-L;6?F6Y^P/#U             '563XU5?3-
M,83[C7@  9X:396I'-%S=DX_J   (15QUY#SM>"@  6OO,5T[!-%M
M (J5F0R!7=U:@  "QOH"U9"4$E              &!V[UM3KT]2OX_OX)LE/
M6#"FM^O_ %/K\  $F&NY=80439X               US6S H_?45'@
M                   #,6 RN1KR;?7(\3(   '@B5]E<]QINIZ2
M  &5\.W]BE_,SLKEN%D          "N&Z JJ/O.HN  .:>/I<F\EWR
M ,5-GA5G'1-2:\-]J@)!,%E%B50EI<N\OL       :DI1I*NOI*G0  )4E9S
M.>[2-E   #HO-QJH[INE\8]EA@ "Q>H*U)$<"E(              TAS*/5G
M?1%1^   "675\VG;4K8X   A%7'7D/.UX*  !:^\Q73L$T6T        UL2'
M4U4O3-,   "<135B2^:JG(             $(RXZ]AXVO!!V%C^MO9RM>5;3
MT'4^F>7:   =G8WM;U<K7CV3C^P              XWEX\5GM;FSJS=:T
M                      #,6 RN1KR;?7(\3(   '@B5]E<]QINIZ2
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M66'%#6C%7LR&0)KNK4  "PIHBT)+%>2T              :<;]JG3A?U4
M                       9BP&5R->3;ZY'B9    \$2OLKGN--U/20
M       '/-=E6.G\PNT._HYMP         *X;H"JH^\ZBX  YIX^ER;R7?(
M     PJW&OK,.B:CPBW.N DHU[+;!BBK.^Q\?0        U)2C25=?25.@
M2I*SF<]VD;*   UJR'4U7'2]-?/^OD  6#]$V?)BKN7               #7
M9O\ 5U3_ $S2_H_7X  !O#ADBLON>+;   A%7'7D/.UX*  !:^\Q73L$T6T
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ME3H  $J2LYG/=I&R@  *X;H"J8^\ZC   [MP\BW>Y7O'FWCZ
M    5Q-_U3'TG<8   %H)SA<.WV*;P  0BKCKR'G:\%   M?>8KIV":+:
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M2KKZ2IT  "5)6<SGNTC90  UU;_553?35,>O^_@  D_UQ,+ *C+-
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MKZ2IT  "5)6<SGNTC90  @3W=6L5:S(8  !8_P#/UKR H-)@
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M5U])4Z  !*DK.9SW:1LH #@?OY5#'5%'=0Y?@  /K?'U<(\I7IVUB^X
M           $'BY:[B"VK!@  !.CI>QI;U6S< "$5<=>0\[7@H  %K[S%=.P
M31;0       #AWKYTW76=#^I]?@  \ENURQ>.4VLS            !ZO[^5,
MW4%*80[G7#8+HMI:]<Q73_0 *YF_JKCR3R+   6L/,MT;((_M0
M !X-)O1-0:E;RK$                       #,6 RN1KR;?7(\3(   '@B
M5]E<]QINIZ2                ES<8]#R2.7+J         KAN@*JC[SJ+@
M #FGCZ7)O)=\@   :J9-IJT3H>I.C\W& F35+/9K-/V!_0          !J2E
M&DJZ^DJ=   E25G,Y[M(V4 !'<GL6KH;]JL  #9W'-Q:C<T7*
M      --LMT-8AT;4    W,1'?V=/.=O  0BKCKR'G:\%   M?>8KIV":+:
M       :R)'J*K7I>F0  -DT>VUJWS-<X            &DN8QZLRZ)J,":Y
M3]@S):EG@ $=R>Q:NAOVJP  )@54SJ;_ $W88            '@TF]$U!J5O
M*L0                      ,Q8#*Y&O)M]<CQ,@   >")7V5SW&FZGI(
M              9IP236+'\RNR_[_         KAN@*JC[SJ+@ #FGCZ7)O)
M=\@  #4/*M'6L]"U-TYEXX$U2H+ F6U)/0           -24HTE77TE3H  $
MJ2LYG/=I&R@ *]>]ZOC36'$@  )05;S"?_1MF@                #COI\4
M]/5U%];9'B  !]_S^[A#E*].TL;V $(JXZ\AYVO!0  +7WF*Z=@FBV@
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MG0  )4E9S.>[2-E #\OU4,=44;C5L<0  "<K3%BR[*LG
M  %9=T54>D^81X   67W.]M[PX;(@!"*N.O(>=KP4  "U]YBNG8)HMH
M  !66]%5%I0F$?  '9./[6VW+EVY!8&4            .AL[&J*>IJ/X;[>8
MW&1/?6>O.-O@  5[U[5A&?L2(@  69O.UN;M(=(0            !X-)O1-0
M:E;RK$                    #,6 RN1KR;?7(\3(   '@B5]E<]QINIZ2
M                 D9\Q7-+[XKZ+        %<-T!54?>=1<  <T\?2Y-Y+
MOD  :1)C'JX+H&J>MLCQ'Z_G[.EI>QI:]738            #4E*-)5U])4Z
M  !*DK.9SW:1LH :_P#>ZRI^Z=I4   6.% 6K(1@DH
MA"7'7D/FUX*   )ME.V%,5J>=@"$5<=>0\[7@H  %K[S%=.P31;0       :
MZ=_JJI[IJF/5_?P  3/JBG\T.HI\            !$MM&$P4+IK@"?-1]ERF
MZUF0  &AV;1NM@Z$J8  "3A7,OL$:+LX             #P:3>B:@U*WE6(
M                  &8L!E<C7DV^N1XF0   /!$K[*Y[C3=3TD
M         ,A(UN+*'^6W:_L_'T       !7#= 55'WG47  '-/'TN3>2[Y
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M#4K>58@                  9BP&5R->3;ZY'B9    \$2OLKGN--U/20
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M#:H   $""[ZUBNV7#   +#>AK1DE5]+              !X-)O1-0:E;RK$
M                #,6 RN1KR;?7(\3(   '@B5]E<]QINIZ2
M         E)\D7O*;Y%OH       "N&Z JJ/O.HN  .:>/I<F\EWR.M\CR@U
MW-745NS(9X !.+IJQ)>U53D             #4E*-)5U])4Z  !*DK.9SW:1
MLH 5T%^U7'=GL6   %O[RI>>0F!E                  8X[#$J#.JJ-
M&:&GV%MCR[=H A%7'7D/.UX*  !:^\Q73L$T6T      &A.;QJN/O^JN->GP
M !W#B9%E7SU;.W6*[P             0$KPK2+794- L;Z M60E!)0   !I@
MEV@K'>C*A   WNPJ264G/5L@         =0;[5<\UF;R/$R   !X-)O1-0:E
M;RK$                #,6 RN1KR;?7(\3(   '@B5]E<]QINIZ2
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MPLD       5PW0%51]YU%P !Y/U_/W\?W\    Y_X>MF]SI;NV2+[L
M      #4E*-)5U])4Z  !*DK.9SW:1LH 5-?3]*8);O6@  "XQY.O?M#&]@
M                !4+]4T=C-L<,  #E?E]W*W)5] "$5<=>0\[7@H  %K[S
M%=.P31;0    #%G984&&Z*ZCA6!%  /))0KV6SP*4LCO#"R
M (P%CP^O]O.L@)3]:3.?%2%E     08[GKJ(U:<'   G1TO8TMZK9N
M   ([_5E$X!6?",Q8#*Y&O)M]<CQ,@   >#2;T34&I6\JQ
M S%@,KD:\FWUR/$R   !X(E?97/<:;J>D@                     )^O\
M.7KC9S5$Y       %<-T!54?>=1<        9*Z[,M&.;KAS4T^P
M    &I*4:2KKZ2IT  "5)6<SGNTC90 J(.J*.Q=V6&   +A#E&]>\</(
M              %3=T_2F!^[UH  'T_CZN;N2+[ $(JXZ\AYVO!0  +7WF*Z
M=@FBV@   Z<R_#3Q+-#';GL6CBS^*<&]_, #;+%]W-RIVPMU4/D
M      %7KTA3VHB5:,"SYYQN#<1$]Z    !JCD^EJVNDZ<   VE1K<VF_-5R
M         ")[V_S-U)O-6,Q8#*Y&O)M]<CQ,@   >#2;T34&I6\JQ
M       S%@,KD:\FWUR/$R   !X(E?97/<:;J>D@
M !+IXPZ'DB\NW4       *X;H"JH^\ZBX  ^K\?4K.LIIAYML#1O,X[P+W\@
M   -B6@VMH1SA<'<^'D            :DI1I*NOI*G0  )4E9S.>[2-E "H:
MZHH[&/988   MR^6;ORVU><                  *JKIBF=:<BU   '.O#U
MN1^3+X $(JXZ\AYVO!0  )!\$E'<.)[@#C_I\=<^_ET#G8V'>VP,/]M@^O\
MOX !V#X>N_V#2:5#6DSW01#?_P!               &NK?ZJJ4Z;I?P#-C3[
M"VAY>NSV/S]     _@J:>H*4P7W6M   M;N9+HV)Z#:@       #A&QPXC7=
M7+W@ S%@,KD:\FWUR/$R   !X-)O1-0:E;RK$            #,6 RN1KR;?
M7(\3(   '@B5]E<]QINIZ2                       W]<Y6Y,TX;Z5
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M0   /!$K[*Y[C3=3TD                       -D-7S2P-_F]UZ
M *X;H"JH^\ZBX  YIX^ER;R7?('S_K\KY+UK"-38<2    E!5O,)_M&V;_0
M         !J2E&DJZ^DJ=   E25G,Y[M(V4 *FOI^E,$MWK0  !9A<[VWN_A
MLB                  %5MTO36L>1Z<  #/S1[.V%YANH 0BKCKR'G:\%
M        V!:+:6A'-]P=[X62               !Q7U^*BWJ:C\>L_%'DM@.
M8KJV :+9@     :Y]_JJI;INEP  ,O\ 4Y]MORY=OM_GZ       !K6MZO\
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M\%   FA5%/LF];F#B7K\:GI1I8[\\BW$/;S    W%Q/?68?.]M\S\?0
M          1T9]%:ZR_*L VL1C=6E/-EQ@      54W3-,:UY#J0  +-OG2W
M=TT0D        &G6_*ITV7_5   &8L!E<C7DV^N1XF0   /!I-Z)J#4K>58@
M         9BP&5R->3;ZY'B9    \$2OLKGN--U/20
M      %GA_)_N;GVNRP      *X;H"JH^\ZBX  YIX^ER;R7?( '2&9CU>W2
M%/:]M]JP  ![7Y^V'E#6C([K^5@         #4E*-)5U])4Z  !*DK.9SW:1
MLH 5TM^59'8GT5   $P^IYW-RIVP@                 !49=34AB7M,$
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MTE77TE3H  $J2LYG/=I&R@!"5N&OH=%LP,   ;\X/)K([GVUP
M      !3<=9T/P7W\@  )M].V%,2J>=@"$5<=>0\[7@H  %K[S%=.P31;0 #
MB'KYURU_57H6F\:    EY57.9Q],V(              ,,-O@5+74-)>E]?@
M            ';F)[V]/*]X\\\/4       1W^JZ)P"M"$    9BP&5R->3;
MZY'B9    \&DWHFH-2MY5B       !F+ 97(UY-OKD>)D   #P1*^RN>XTW4
M])                          3_/YQ]<[,JJG       %<-T!54?>=1<
M <T\?2Y-Y+OD  #43*M'64]%5%PKV\P  !D+@95HMS=<6<VEV(         U
M)2C25=?25.@  2I*SF<]VD;* $;ZP(I7?WU5H   RDUF;;N\L7@
M        !T_E^%.]U?1(   LI.>K9WNPJ2 "$5<=>0\[7@H  %K[S%=.P31;
M0  =<Y'E6-]&5#JHDVE    G>TI9$L2L)J             !"SMZ 0RK<@(
M            %B/0MI2.J_E8       C7==\_89V!$P   !F+ 97(UY-OKD>
M)D   #P:3>B:@U*WE6(      &8L!E<C7DV^N1XF0   /!$K[*Y[C3=3TD
M                        )TG\^^J=Q5)60      !7#= 55'WG47  '-/
M'TN3>2[Y   $<F?Q6N^OJK?5_?P   9^Z/9VA_-UP]ZX62        !J2E&D
MJZ^DJ=   E25G,Y[M(V4 ,'=SKJF#J&DP   +:CEV[<V=/L
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MI1I*NOI*G0  )4E9S.>[2-E  5'G4M(8@[7!   $_6CK,E&5M,0
M       !'CGD6KFK^JL  #97'=O:K<SW, !"*N.O(>=KP4  "U]YBNG8)HMH
M   , =[K*O;H^GNA<[&   '8/AZV:O.MN[:XMNP           !HAFL;K7.A
M:F [6Q?>8]4T[        'H?7Y"TMZ ?%^_D  ?=^/NW5Y8N_(_7Y8
M$7?LSG/&J7QX     9BP&5R->3;ZY'B9    \&DWHFH-2MY5B    !F+ 97(
MUY-OKD>)D   #P1*^RN>XTW4])                           ":#POTO
MOMYVMH      "N&Z JJ/O.HN  .:>/I<F\EWR   !_)7\WG648:QX>   !)>
MKN76#U%6?^OX        U)2C25=?25.@  2I*SF<]VD;*  @,7?6D66RX:
M )!L$E%CI0%J@                "&!;L!A>V[    )@E4SJ;[3=A@ 0BKC
MKR'G:\%   M?>8KIV":+:    :>I9HJSCHBH^%>WF   ,BM?EVB/-]PYS:78
M@           5RU_57'GGD6 DUUU+[!:BK.         K2NAJET9S2.   3L
MJ5L>6?5\V       B[]F<YXU2^/      9BP&5R->3;ZY'B9    \&DWHFH-
M2MY5B    )$?*=[Y]5A-@   ,997HZ\'^EW'/5.XP
M        !,]X8Z6WX\ZVV      !7#= 55'WG47  '-/'TN3>2[Y    ''?3
MYK4NA:ETFS&/    30ZBG\SZHI\       !J2E&DJZ^DJ=   E25G,Y[M(V4
M !HWF<=K1NAZD   '/\ P];>WE6\NU<;V                 K:>@ZGT*3>
M-   6CG-MQ;98ONP (15QUY#SM>"@  6OO,5T[!-%M    !'7GT6KL[ZJSTO
MK\   &>6DV5H7S?<.0F!E           8V;#$J,^IJ0X[Z? %F+SO;F[R&R$
M        ",'8\/K^KSK(  #:O&=U:5<UW&      !%W[,YSQJE\>      &8
ML!E<C7DV^N1XF0   /!I-Z)J#4K>58@   ?<QO:15RC?&:]=R\   #7?9D-@
M;_T-Y/ZIW&                           !-+X4Z9WQ\\VP      !7#=
M 55'WG47  '-/'TN3>2[Y     Z5S,>KUZ0I_7EOM4   /U_/VPBHFSY+5>2
MT       :DI1I*NOI*G0  )4E9S.>[2-E  ?*^OFI%ZDI+$W:8(   L"J,LZ
M3O7$O                'S?K\I^^K*+Z4S,<  9Y:396QG,%U_V  0BKCKR
M'G:\%   M?>8KIV":+:     1&;3A$&2YZY    V[Q7>6:/.MN\Y\?0
M     1 K5@T'NY:[ RNU>;;A\MW?]#Y_0        .E\S'J%>J*.XA[>8  \
MEKUS%=.P;1;0      1D>Q.>,4)O&0      ,Q8#*Y&O)M]<CQ,@   >#2;T
M34&I6\JQ    ^YC>TBKE&^,UZ[EX   &N^S(; W_ *&\G]4[C
M                $W;@GJ'=Q0EH       5PW0%51]YU%P !S3Q]+DWDN^0
M    !A+N-?5S])4[CAL,0   <J\ONS YWMS<O$M\      !J2E&DJZ^DJ=
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MR'G:\%   M?>8KIV":+:     #Y_U^5TU^59'GGD6    EL5=-YU-+6,
M     -.$MT-8;T;4  M3^9[FV91W;@         1U)]%:ZF_*L   S+U&?;7
M<NW;['Y^@     1[NIZ,UYVI!0       ,Q8#*Y&O)M]<CQ,@   >#2;T34&
MI6\JQ    ^YC>TBKE&^,UZ[EX   &N^S(; W_H;R?U3N,
M           6"'\WNO=CU7S0      "N&Z JJ/O.HN  .:>/I<F\EWR
M (Y\_BM=Q?56^K^_@   SJTNRM$^;KAR$P,H     #4E*-)5U])4Z  !*DK.
M9SW:1LH  "$%<E>0^[6@H   W>PV168G.]M@              #Y7U\U(_4E
M)8E[3!  $Q*IYW-OIVP@  (15QUY#SM>"@  6OO,5T[!-%M      .!^_G68
M]$U%J(E6C    G14O8TM^K9N        !7TWK6,92Q8@!LFCVVM6^9KG
M      '!O;SJ$NJJ-ZDRO   "SJYRM_<O$M\     !HSZ1IO5==5;
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MO!0  +7WF*Z=@FBV@      Q[S\6KWZ/I_ K>:P   >]\_MBK0EIR'H%*0
M     .G<OPJ(>J*.Z^]_(";]3=AS ZIG0          %??>E8QCK&B   $HR
MMIC/UHZS      -1%[5=I9Z%J,        #,6 RN1KR;?7(\3(   '@TF]$U
M!J5O*L0   /N8WM(JY1OC->NY>   !KOLR&P-_Z&\G]4[C
M           ]CY_;03^3/=7(L;V       KAN@*JC[SJ+@ #FGCZ7)O)=\@
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M9#4T\FP4]8(    &I*4:2KKZ2IT  "5)6<SGNTC90   _DK>^@:HT"3F,@
M"6M5TWG5TM8P             $=R>Q:NAOVJP !NXATALPN=[;_?\_0  !"*
MN.O(>=KP4  "U]YBNG8)HMH       -3,HTE9+T7477WOY   #(# RK0OF^X
M<]M)L@      *LOI6F]64ETP&["'R&S1YUMP           ?+^ORHYZEI#%C
M9X0  %BM0=IR*X#*@    !C%,8[%_P"RN=          ,Q8#*Y&O)M]<CQ,@
M   >#2;T34&I6\JQ    ^YC>TBKE&^,UZ[EX   &N^S(; W_ *&\G]4[C
M                     VH5%/9[W\Z^M       !7#= 55'WG47  '-/'TN
M3>2[Y        Z8S,>KWZ/I_7;O]4   /)8"T99TGNN)>    -24HTE77TE3
MH  $J2LYG/=I&R@   .@L[&JP^EJ:PWVV   !^WY^V,] VI(4@DH
M     ZDRO"J9Z:IC#_;8  &1>OR[4CFBY<KM9F@   0BKCKR'G:\%   M?>8
MKIV":+:        1_IS&:Y&_ZJ^;]?(   SBTVQM$>;KAR.U^6     !K#D>
MGJNNEZ: %@11EG2>:XEX           $&:YZZB+VG!P  -_,&DUD1S]:X
M  ^!E>$0CN_EO\/KY          S%@,KD:\FWUR/$R   !X-)O1-0:E;RK$
M  #[F-[2*N4;XS7KN7@   :[[,AL#?\ H;R?U3N,
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M<O    UWV9#8&_\ 0WD_JG<8                      $R7A_I*03S=;X
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MKKZ2IT  "5)6<SGNTC90     T-3:-USM^U7P7W\@  .Z\/(L9Z!M7=?#Y
M         (F-H0F"C=-<_E^_@ ^A\_L^&D++E(5M,0    !"*N.O(>=KP4
M"U]YBNG8)HMH        !ZO[^5X-\U='&L"*    2O*QFL\6D[(    $:>PX
ME7K7O5X LDN?+8WWPB2@            0Z+8@D)6XJ]   VRQ?=VCG-MQ
M  #5O<]<:*NE*9           &8L!E<C7DV^N1XF0   /!I-Z)J#4K>58@
M ?<QO:15RC?&:]=R\   #7?9D-@;_P!#>3^J=Q@                    #
ML?5YMFO_ "F[A^AY_8       KAN@*JC[SJ+@ #FGCZ7)O)=\@         0
M^;6@L(2Y*\    VSQ?=V;G.EN\^\/4  :DI1I*NOI*G0  )4E9S.>[2-E
M   :?Y7HJX7H"J<>,_%   ^W\?4U.H+ E_U3.OJ?/Z        ./>GS!]N2N
MXD5I0CP #G/AZV$%%6?(H@,I      A%7'7D/.UX*  !:^\Q73L$T6T
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M/J#7EOM4   /:_/VQ!H6TI&T E0  &!V[UM3KT]2OX_OX!+!K":SP*4L@
M          "L;Z,J'3%+M   !,LJ2>S5:@L     #^2)YW!S+U/N]8
M     !F+ 97(UY-OKD>)D   #P:3>B:@U*WE6(   'W,;VD5<HWQFO7<O
M UWV9#8&_P#0WD_JG<8                    ET\8=#R1>7;J        K
MAN@*JC[SJ+@ #FGCZ7)O)=\@         #X'I\UKG0E3:0)E'0   )?E53J<
M+35A@ :DI1I*NOI*G0  )4E9S.>[2-E       <>]/F&K;4"AW6Q!.->GP
M!_?Y^[U(7(Y8=837>?#)%]CX^@   !ZG[^:8Y=H(F%H0F/U.HS^/[^ #^_S]
MDRUW+9V5+6/W/AY       $(JXZ\AYVO!0  +7WF*Z=@FBV@          PM
MV^OJ[^D:>Q@V6&   .8^/I9@<\6WN0B6^  $(BXZ]AZVO! !:.<VW%MEB^[
M             B[61#H ]Y5F  !FQI]A;1<O79^_Y^@    :(>EZ7U@7)70
M           S%@,KD:\FWUR/$R   !X-)O1-0:E;RK$   #[F-[2*N4;XS7K
MN7@   :[[,AL#?\ H;R?U3N,                   "QM_F)V=F#"9&
M   !7#= 55'WG47  '-/'TN3>2[Y           Z<R_"KWZ0I[73O]4   /)
M/CI"RY3M:3( :DI1I*NOI*G0  )4E9S.>[2-E        :\M]JX-5S5UH@FT
M;    R#P,K>-#9%M[BF]V,:#:99ZO.[6Q?8=8Y/CBKL\/7QO=7J3E.DT8S2.
M8I[/"  &S&.[>=#2]C;KX?(        (15QUY#SM>"@  6OO,5T[!-%M
M       -6<ETU8QT94/6.3X@  #O7"R;03G"X-A&AV@ ^%]_-1UU+2&,&RPP
M,]='L[8GF&ZO[              .G<OPJ%>J:-X5[>8  %GSSC<&XB)[T
M #!NR(='&ZSH,            #,6 RN1KR;?7(\3(   '@TF]$U!J5O*L0
M /N8WM(JY1OC->NY>   !KOLR&P-_P"AO)_5.XP                  ,W8
M#*+%'^9G9(        KAN@*JC[SJ+@ #FGCZ7)O)=\@          #"W;Z^K
MEZ2I[&K8X8   ^W\?5DQSY;&\Z%R,#4E*-)5U])4Z  !*DK.9SW:1LH
M   #3Q+-%#TM:"Z&YM&O4^OP          ;2(UN9@=4SJ1/ I3[_ ,_H
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M36NS)"\#E$F6NY=MKBV[          A%7'7D/.UX*  !:^\Q73L$T6T
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ML]3]_   !F#J<^T<YMN+*36YFI*4:2KKZ2IT  "5)6<SGNTC90
M P;W.NTI3"/ZDI3H]9TBU.!&\UG4F5X   <P\?3.'3;'91'MMM<C&ZW01'?[
M08WN/;_/T          "$5<=>0\[7@H  %K[S%=.P31;0            0G[
MAKZ&];,#    WV0B2V/O/]K8R['$J1^HZ1^1]_(&WR*;VT%YPN
M      <>]/FHGZGH_'?/Q   +&.@;4D/0.4@    8KS6-QBNQN=@
M     ,Q8#*Y&O)M]<CQ,@   >#2;T34&I6\JQ    ^YC>TBKE&^,UZ[EX
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M<8                FS<&]/;R* M,
M
M                                #6O;M?Z"NGJ2              &8
ML!E<C7DV^N1XF0   /!I-Z)J#4K>58@   ?<QO:15RC?&:]=R\   #7?9D-@
M;_T-Y/ZIW&               ,CXON;(3^7W:?V\?U
M
M                                             ^7[><4WMKFGJC=Z
MP              9BP&5R->3;ZY'B9    \&DWHFH-2MY5B   !]S&]I%7*-
M\9KUW+P   -=]F0V!O\ T-Y/ZIW&              !+0XWZ#DO<K7<
M
M                                                          !J
MCNZL]'W1M/               9BP&5R->3;ZY'B9    \&DWHFH-2MY5B
M!]S&]I%7*-\9KUW+P   -=]F0V!O_0WD_JG<8             '=.BV=D+_+
MWM+L#6Y@
M
M           'Q,CQBJ=L<U]4;O6               9BP&5R->3;ZY'B9
M \&DWHFH-2MY5B   !]S&]I%7*-\9KUW+P   -=]F0V!O_0WD_JG<8
M       ED<<] R9N5+P
M
M                        UE7#7FA?IJE0              !F+ 97(UY-
MOKD>)D   #P:3>B:@U*WE6(   'W,;VD5<HWQFO7<O    UWV9#8&_\ 0WD_
MJG<8            R4BVZL:OYB=G<PPLD
M
M                                     #UOOYC!=D\ZXT2^/
M        #,6 RN1KR;?7(\3(   '@TF]$U!J5O*L0   /N8WM(JY1OC->NY>
M   !KOLR&P-_Z&\G]4[C            FI\)=-;V^>[7
M
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M(X5@137WO=9-!J*?   ?P:R)'I]5$FTV/&?B\G\_O,[49^XB)[W)O79@
M TQR[0:6I?H-G\;W$@*#28   1]YU&-8TCU$O.JYQV=C>P    X-[>>E681_
M7IOM7QW[^,L=9F[L8=(<KM9F@        :(NEJ7U?W+70
M&8L!E<C7DV^N1XF0   /!I-Z)J#4K>58@   ?<QO:15RC?&:]=R\   #7?9D
M-@;_ -#>3^J=Q@         <CQ?:PT_FIV)FO Y.          !7#= 55'WG
M47YIX^@ X=Z_'\?OYGAI-E/UHZS-SD1WX J@NG:6X7[>=MCRY=H   POV^OJ
M3NHZ2EL5;-YU-+V,   (<%LP.$[<-?"U*YHN;9O'-N   *D[J.DL0MK@]JXO
ML/2_?SK3)\?G_7YR+S^Y1];3&<Y3%B\T\?0 "KJZ1IW4G*=)-[INPY@U4SH
M   "#E<M=Q"[5@VZ"(;^SAYTMX   5B_1E0Z9I=H,I]9FVXO+5W?5^?H   8
MJ;/"A&7%7L<&P8IQKT^/;^?WZOS]<?\ 3X&7VJSYAE3SJ556<S]W\_0!'"L"
M*5W=]5;V#C^O)_/[  $\^DK)DE5]+!J2E&DJZ^DJ=G44M8\MFKIL   *AKJB
MCLT-1GVBO-UQ"'E:\%AYVO! !U/E>([8Q?8 3/:BGTMRKIN*X;H"JH^\ZB]T
M#R+?H  COSV+0JK?K_7GOM6.1>?W\7[^?7_?SWOG]WTPB2S>:<L/8CH=H
M *OKH^G]0<KT67VJS[;;ER[?=^?T  "ONO2L8Q]C1"WEY6O')S79@   $;*P
MHG!2NFN<>,_$Y/Y??L_G[P_V\_J_'U*5K:8SJ:6L?EWE]@       </S\6+=
MV?SAU'O=6               !F+ 97(UY-OKD>)D   #P:3>B:@U*WE6(
M'W,;VD5<HWQFO7<O    UWV9#8&_]#>3^J=Q@        "5MQ]?TGCD^\P
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MGZ9IC#G;8-P]RA>H%4%T[2W"_;SML>7+M   &%^WU]2=U'24MBK9O.II>Q@
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M*D_D?7S;<\N7=5N])4[K]WNKMYN5[Q[-QO8  5]UZ5C&/L:(6\O*UXY.:[,
M  ZBRO"G;ZPHF2A7LML,:'M   :E)3I-%,TCF_B#R7:3&MR        /4^_F
M-SUQ0&&=@1,                9BP&5R->3;ZY'B9    \&DWHFH-2MY5B
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MF0   /!I-Z)J#4K>58@   ?<QO:15RC?&:]=R\   #7?9D-@;_T-Y/ZIW&
M   !*IY"ON4+R7>P            %<-T!54?>=1>Z!Y%OT  >A]?E15U-1_+
M_+TMM>7+M J@NG:6X7[>=MCRY=H   POV^OJ3NHZ2EL5;-YU-+V,  (\$]BU
M<[?M5S@Z;L27]5,Y%7ITA3VL"2:>WEY6O'N7$R  !4G=1TEW1AY%J3S1<H
MKY+UK"-'8D2MM>7+MS"U.> *NKI&G=?>]UENSRQ>%1]U)2.WB+;RR)Y]M<
M"KNZ1I[&38X=LKS!==,KUO0FZ"(;^SAYTMX  0$[PK2+594-M3.:+FV:QS;]
M!YV-40]3T=MVBV\LY.<[> $(BXZ]AZVO!+1;FZXMM<6W8      $<*P(I7=W
MU5M@C1=G2<*YEX   &I*4:2KKZ2IV=12UCRV:NFP   J&NJ*.S0U&?:*\W7$
M  !5!=.TL+7WF*Z0  *X;H"JH^\ZB]T#R+?HXKZ_%//U=16TB-;FSZYQM\
M      "OXO.LHPMCP^UIYDNC8QH-KCAL,2HJZGI#<[$=]9C\[6X  *^Z]*QC
M'V-$+>7E:\<G-=F   "JTZ7IK7AOM59X\Y6_MIB^[             &/$JT4
M9GL+GGA^?B@               #,6 RN1KR;?7(\3(   '@TF]$U!J5O*L0
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MP1HNSI.%<R\   #4E*-)5U])4[.HI:QY;-738   5#75%'9H:C/M%>;KB
MJ@NG:6%K[S%=(  %<-T!54?>=1>Z!Y%OT:T)%J*JWIBF9?-53F<135B
M   #KO(\JACJBCL\M)LK3GFJY *VKH.I]$,UC=MQRY=V7>JS@ *^Z]*QC'V-
M$+>7E:\<G-=F   #2=,(_6M]"U-['XE65G-)-M<R[9C'=O\ V
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M]U<B6!2FPAHFT.=^'H !5U=(T[K[WNLN&>4;UQDV.'4D=1TE)ZKF7SV*1LH
M"N@OVJ]'TRCMN5RU>':V+[4OW75!;H(AO[.'G2W@ (XM@12NXOJK9Q=-6)+V
MJJ<@1Z)Y%ZY6_JJFJ5!8$RVI)Z!5>=+4UC%LL.W@Y7O$       1PK BE=W?
M56Y!8&5V=C^P &\>&2*?51]E@:DI1I*NOI*G9U%+6/+9JZ;   "H:ZHH[-#4
M9]HKS=<0  %4%T[2PM?>8KI   KAN@*JC[SJ+W0/(M^C1[,H[6@=$5).8IBQ
M9=-63@        1JK#B5>G>]7SJ*6L:6S5TW CF3^*UV-]U9-QIVPIB%3SL
M"ONO2L8Q]C1"WEY6O')S79@   &JZ3::$9<5>Z2IC'O7_?S+?59V]&%R.1#
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M3..Z,9G'.H\OPV3Q[;V&]#VALCCVV           & 5H0B/?U-1GS_7X
M            &8L!E<C7DV^N1XF0   /!I-Z)J#4K>58@   ?<QO:15RC?&:
M]=R\   #7?9D-@;_ -#>3^J=Q@    ;Z>=[8F<<-=+^[Y_0           KA
MN@*JC[SJ+V\O*UX@#M;&]^QL?U   J@NG:6X7[>=MCRY=H   POV^OJ3NHZ2
MEL5;-YU-+V, !5A]+4W@-N]9;T<KWCV;C>P CXSN,5QE_P!4S0JBG\S^HI\
M!4G=1TEW1AY%J3S1<HTCS&/5IO0U2[N8=(;)_GNV?I?/Z  !5U=(T[K[WNLN
M&>4;U&N*0:JJAZ9IB:I4%@3)ZEG@$%&Z:YBCV="K:+EZ[,Q-3GBE^ZZH+=!$
M-_9P\Z6\ ,8=EAU&G4M(;LH?(;+?GBV@ ($]W5K%6LR&6A?-]P[=HKO!7#=
M53H G,9N*.3[V[0QO8      ".%8$4KN[ZJVP1HNSI.%<R\   #4E*-)5U])
M4[.HI:QY;-738   5#75%'9H:C/M%>;KB   J@NG:6%K[S%=(  %<-T!54?>
M=1>Z!Y%OT8(;O6U-O3]*2KJRFD].DK)        Q,VF%4@]24CO7A4CLFN?+
M8  @%7C6<7.R8=:4\UW'M8C.Z %?=>E8QC[&B%O+RM>.3FNS      !U_P"_
ME%2LV&0E[AK[NC#][7GF.Z>],+)           &#5D0V/+U517P<GQ
M          &8L!E<C7DV^N1XF0   /!I-Z)J#4K>58@   ?<QO:15RC?&:]=
MR\   #7?9D-@;_T-Y/ZIW&    !OIYWMB9QPUTO[OG]           5PW0%5
M1]YU%[H'D6_0    !5!=.TMPOV\[;'ER[0  !A?M]?4G=1TE+8JV;SJ:7L8
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M            8F3B,1T^L*&X#L\(                9BP&5R->3;ZY'B9
M   \&DWHFH-2MY5B   !]S&]I%7*-\9KUW+P   -=]F0V!O_ $-Y/ZIW&
M !OIYWMB9QPUTO[OG]          "N&Z JJ/O.HO= \BWZ     *H+IVEN%^
MWG;8\N7:   ,+]OKZD[J.DI;%6S>=32]C "#K<M=Q"+5@P    L]^<;@W%1/
M>@"I.ZCI+NC#R+4GFBY0/R_5=K?561TI]%K%N@[3D0P*4@ "KJZ1IW7WO=9<
M,\HWJ!HYF<=K1.AZDL"Z+LZ3M7,OB!6K!H/=RUW:2\V7'M<C&Z I?NNJ"W01
M#?V</.EO "JJZ8IG6G(M0   !WAA9-O%RO>'+_+TPRV^!4R]04GNSATALM.>
M;:    &B&:QN)A:$)WV0F2RP:PFHCA6!%*[N^JML$:+LZ3A7,O    QAV6'4
M.=44=* K>86 -&V:  !T_E^%//U=14CBOY58@4-:0  %4%T[2PM?>8KI   K
MAN@*JC[SJ+W0/(M^@05KIKF)/:,(LQN=K<W=PZ0@   ?P0![RK/$[9X-@31E
MG91ZW,'\E4CTW2^N[?ZH   #(/ RK=CEB\.3>?V!7W7I6,8^QHA;R\K7CDYK
MLP  #KO(\L"MWK<C-?E96ZS-  &!>[UM3ET_2DN*K)Q.?IBQ0
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M7  &IF4:2KDZ2IV:14,_F<U'/@            .*9N-H,Z>I+ "T(0
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M_P"?H &%NWU]=+?M6:JI-I9P]-6)+ZJJ<@1PK BE=W?56V"-%V=)PKF7@
M"*[9<-@07?6DI6M9E/=I&RO?^?T 85;C7U>_1]/^E]?ELES!=?;&+[   507
M3M+"U]YBND  "N&Z JJ/O.HO= \BWZ (Z<^BM=K?=6[-XYM[%B@[4SGTNQ
M_@BWV5#H&=V5MD9K\JTEYLN/*[69H$#^ZZWB?6?"K.3G.WMSL1WX  & F\UE
M3YT[2TA*"2>QLH&U0*^Z]*QC'V-$+>7E:\<G-=F   "K!Z6IK6?(M39J\ZVY
MN9B._ 'S_K\KCK_JK03.(S:E<T7+LMCNW             '\_K51=E::4>AZ
MB^3[^0               &8L!E<C7DV^N1XF0   /!I-Z)J#4K>58@   ?<Q
MO:15RC?&:]=R\   #7?9D-@;_P!#>3^J=Q@    ;Z>=[8F<<-=+^[Y_0
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M.H*1QJE\?                S%@,KD:\FWUR/$R   !X-)O1-0:E;RK$
M#[F-[2*N4;XS7KN7@   :[[,AL#?^AO)_5.XP    -]/.]L3..&NE_=\_H
M      5PW0%51]YU%[H'D6_0    !5!=.TMPOV\[;'ER[0  !A?M]?4G=1TE
M+8JV;SJ:7L8=/Y?A4-=44=L'T6TM/N:;D    PKW&OJ6NH:3WO0J263?/=L
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MWKW1AY &$&YUT):X:^C]3J,<+]O,#/+2;*9+4L]DT5U+OZ
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M*0ZGO["R<[])L@ !U%E>&%&XU_&/7XR&P,K,K49_M_GZ  !T%G8V!^ZUH
MSDTVQR)P,H  #$K:8./>?C?;^/K-G3[#L7']0    -9<BU V:1W;@  8";S6
M=&YF/MMB^[   'X?OYASML'&[88G+/+[S+U&?W/B9   &'6VP,5]EA[ ]'L^
MZL/(    Z[R/+6M(-3D-@Y6<^EV(P;W.NQVS\4  #:M&MS]?X^@ .&>WG@ON
MM=UY[^64&MS,OM5G                  =-2#4Z1^BJ@P M&#^
M      #,6 RN1KR;?7(\3(   '@TF]$U!J5O*L0   /N8WM(JY1OC->NY>
M !KOLR&P-_Z&\G]4[C     WT\[VQ,XX:Z7]WS^@
M
M                                                    ,0YW%M+G
M0E28@SR+               9BP&5R->3;ZY'B9    \&DWHFH-2MY5B   !]
MS&]I%7*-\9KUW+P   -=]F0V!O\ T-Y/ZIW&    !OIYWMB9QPUTO[OG]
M
M
M          #"ZPHEJ&O>K<+;"B/@              S%@,KD:\FWUR/$R
M!X-)O1-0:E;RK$   #[F-[2*N4;XS7KN7@   :[[,AL#?^AO)_5.XP    -]
M/.]L3..&NE_=\_H
M
M                            #&V71_5?=5;:Z;7@?&LS'
M  &8L!E<C7DV^N1XF0   /!I-Z)J#4K>58@   ?<QO:15RC?&:]=R\   #7?
M9D-@;_T-Y/ZIW&    !OIYWMB9QPUTO[OG]
M
M                                                 #B^;C:^K2@^
MN:V(%AM8$3]'T^            !F+ 97(UY-OKD>)D   #P:3>B:@U*WE6(
M  'W,;VD5<HWQFO7<O    UWV9#8&_\ 0WD_JG<8    &^GG>V)G'#72_N^?
MT
M
M                .";+"P9LF&X.6/#L,K!B76>XUX           S.KZ6R0
M.2K]]_R^P  !X-)O1-0:E;RK$   #[F-[2*N4;XS7KN7@   :[[,AL#?^AO)
M_5.XP    -]/.]L3..&NE_=\_H
M
M                                          ?R=%2;2XG3>,XP3*.8
MX2[08_RC1]<;;       'TO'T[PCFXR%BN]R9A\AREA<DRMA,FY7@Y(    \
M&DWHFH-2MY5B   !]S&]I%7*-\9KUW+P   -=]F0V!O_ $-Y/ZIW&    !OI
MYWMB9QPUTO[OG]
M
M                                 <7S<;J#?:OK#<Z[K[:8/#-AA\>R
M_#U/OY_#Z^?W^?K[./Z\IPLGG.MS>Q]3G]L:/9]IZ79>S\?0       \&L.Y
M*ZZMW6M    ^YC>^UZD;+^KX>H   &ORR(AIKO"M0  /W_/WD6+[#<+2=CYT
MU]*P
M
M
M
M                                                 !__V@ ( 0(
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M0C>\QG:ZY7(1)!!PX69B]!C/;B2\E^[MR6J1+5NGCXC,4V<;Q+KRUF$?3[F
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M=5 0A% !,2\45#.P8$&((C%8"&6%VU2F?>YWJI<S[I/<YX7.FQ2\Z\Z]N,F
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MY:S"/I]T12L:2QW7F/,T#PE"'H T+!9..SHOS1GF?RG42*NC$,4,)@#(&<>
M"&853I 8GXF[(Q$O"WF,8QF1]]UQU9K1IDW4E9\C.I_,.YNO-=:BE:PY@Z*Y
M2/'.Z4N"KC#C(OS/CS_>Y8&?NQ<ZQ+.]4_J25,?@'6\+E#!%:$' 198+T9<3
M'XO2& PI@%7B#%)05HRTF6:R\-2$^*E,5=E'9G")2:-&BB(VX2Z\M9A'T^ZH
M-7?!;HJE-0%""$AHX,1F1?FC/,_E.JF56,3L8M,P1L%SQ(<.-#4TO'X>'W'X
M;^Y0H46/$2J!<"MRB!$ ) 5JTC'3=65GR,ZG\P[I CQ@T9)J>"H0>BNTC\!N
MBB"KNL@VF@^&6%T6(_&B[V1&+2DW=>=>=S-9[<*0L[H.M-$F;"A5;RN4,$5H
M0<!%E@O1EQ,?B](8#"F 5>(,4E!6C+299K+PU(3XJ4Q5V3/\[842YW&77EK,
M(^GW9#*WO*'HK1)NG0=YUYU[*B_-&>9_*=8F.S B%)U5%R@A:!\DRH_=/$@<
M$;=P(DD;'KQ EBQ/P\IR>%Q$&42I,%#&UI6?(SJ?S#NI>8"BL8GC\*H &@\Z
MQYBU232:-G3I6TX.6,8QFV9IG\$!OJ(,^\T]GF>6>UW38UK&IHT8<D&\KE#!
M%:$' 198+T9<3'XO2& PI@%7B#%)05HRTF6:R\-2$^*E,5=D5.GO$'>XRZ\M
M9A'T^[0HL2!$2"HAGX317B2^.S*B_-&>9_*=>%%BP(B<F*SV0HT*/#SM9[<'
M"$)#7!H@3XN;$AQ(3^DZZ\\\5(<_,\$R )BW#&,8S(UOLPHU^"+F#AXPR$Z\
MK/D9U/YAW8D.A9$/*34(<@M"/ @BH*L3$9/#,TL2KW(.18F?>B@WV6IGPQKG
M/RUAN3M8UC=.3!MQ)'O2Y0P16A!P$66"]&7$Q^+TA@,*8!5X@Q24%:,M)EFL
MO#4A/BI3%78\QE Q4+?<9=>6LPCZ?=P(X46BTZ?A5" T5TDN[XF1%^:,\S^4
M[B2J0U(8A$N2@XTAI67&3@Z6Y$(P*E@9.-CH13P,1$TH(3>YS;'<YMB&FU!%
MQ 0RHCX"RQ-HF 4M":!@ 3%16S,=JDH(G3]:&IYN4K/D9U/YAW=,*,0GAP06
M''!M Q+PIH#4) +3X[)#AOQHA07PRHLVJ,R84$K6^W?@ R(7C0\>$*#YUJ6=
MV*#3E6<=UJW>URA@BM"#@(LL%Z,N)C\7I# 84P"KQ!BDH*T9:3+-9>&I"?%2
MF*NQ9GJ%J70FY2Z\M9A'T^\$AT+(AY4:!#@#H1(<.-#6"6B$ K:B_-&>9_*=
MS)5D=$N"=?$9FQUYUYW=C=6DA-@YF$;F+'GGGWMRE9\C.I_,.\(Y5/D(F'$<
MBN:!X2A#T :E8LF';9?%7>![DF>9^UN_R[,^-(\\RRSB"S3@1XH:.3F4(X*M
M[7*&"*T(. BRP7HRXF/Q>D,!A3 *O$&*2@K1EI,LUEX:D)\5*8J[$J=4GM>W
M*77EK,(^GWE+*2.GAP83 &!] :"#&(52)\2GA^Q%^:,\S^4[J6* X)VEDSW6
MX+E,1&FY#C<L+'3*9A=!8:K$_-MVE9\C.I_,.\H=7=W1-%3IL.H@0L(( "=B
M!*N[B':UK&,4)DTW.=_E^9\ ?YS %#,0,>#$#1].3)UQ1/OBY0P16A!P$66"
M]&7$Q^+TA@,*8!5X@Q24%:,M)EFLO#4A/BI3%7836L=9,)3-5RRW*77EK,(^
MGWI%JQXECNO.O.Z!T3A#P ;E0LE'81?FC/,_E.\ %$=EF <S3>#@),PFBX#+
M%-"L0!P(5H11$" P0J4Z%P*F0GX&!DT!C^!RO49AAYYYY[=Y6?(SJ?S#O2$5
MWOLT5BE'#T-$AOPGR4N?-C6&XY"<VK0S[K3_ &!"BQ($4K'PS,NSS#+.!/=.
M7QYW"J=]7*&"*T(. BRP7HRXF/Q>D,!A3 *O$&*2@K1EI,LUEX:D)\5*8J[!
MG8J?"Z!W, I#LL#^-%1CQHJ,>-%1CQHJ,>-%1CQHJ,/+-3/.[V$52@ A_&BH
MQXT5&/&BHQXT5&/&BHQXT5&/&BHQXT5&/&BHP9'1F;[ 8P2 $^-%1CQHJ,>-
M%1CQHJ,>-%1CQHJ,>-%1@Q/S@VA;[",!\##BD4$/#JO4KK?&BHP\L5,_B(IU
M%$Q%-32/AKS7F[X6GAJ4.^-%1CQHJ,>-%1CQHJ,>-%1CQHJ,>-%1@2(C"X^]
M,:UC75FIW7?&BHQXT5&/&BHQXT5&/&BHQXT5&/&BHQXT5&/&BHP,&B3 0 ,1
MI6(\:*C'C148\:*C'C148,CTV-W.P0*F/2T-XT5&/&BHQXT5&/&BHQXT5&/&
MBHQXT5&#(\-3=W401]XA3&^KE#!%:$' 198+T9<3'XO2& PI@%7B#%)05HRT
MF6:R\-2$^*E,5=@5#JQAZL?_ +O*!0=W'F_+E#!%:$' 198+T9<3'XO2& PI
M@%7B#%)05HRTF6:R\-2$^*E,5;\LU*'2"8%BA X5_P#=PXB,$$)PZ@J$EWY<
MH8(K0@X"++!>C+B8_%Z0P&%, J\08I*"M&6DRS67AJ0GQ4IBK?:E5CQ(_P#^
M\R;4?##=_7*&"*T(. BRP7HRXF/Q>D,!A3 *O$&*2@K1EI,LUEX:D)\5*8JW
MM3'X-+$!P:C#PU_^\A!8@ *3AW 41+OZY0P16A!P$66"]&7$Q^+TA@,*8!5X
M@Q24%:,M)EFLO#4A/BI3%6]5)+=@D7_][E$J.[33L!<H8(K0@X"++!>C+B8_
M%Z0P&%, J\08I*"M&6DRS67AJ0GQ4IBK>%HJ0:,31D8BS<P_^]PXC\*(AU,X
MJ2'L!<H8(K0@X"++!>C+B8_%Z0P&%, J\08I*"M&6DRS67AJ0GQ4IBK=Z@5[
MXB4/_P!]E^JFI<]=>=>=[ 7*&"*T(. BRP7HRXF/Q>D,!A3 *O$&*2@K1EI,
MLUEX:D)\5*8JW6<*^=0J6>>>?>W9.H7O\M^U>/M7C[5X^U>'Y61&8CRO-'6#
MD4I #'G7G'LI7+CO(N,):\  T"\)QX_[5X5"0\-!] G+(IP9_:O N6$4.%T2
M^6O'@/M7C[5X^U>'Y5OL9$E<-8P5+I1AV#2PQ+7LY++WO@K^U># #&+1VF3%
M<8Y,OM7@^0'<A5H)9*Q5*_\ :O"E0\5/ -,$6F!B^$ETHQ#')6C&L;*R-[8\
ML3AQ@U&J0"QYUYQ[,FB+Q"8_:O'VKQ]J\?:O'VKQ]J\?:O'VKPIT_P"'!^PE
M+>^#3[5X5":\-"- '+/BPAU+WN<KV)5*^)L?:O'VKQ]J\?:O'VKQ]J\?:O'V
MKQ]J\?:O"I3'AJ)L3J%[_+?M7H,9[< $DH3%@>6)P^QDK(V'Y6C&,$RX44!@
MXH-"QNHEDG%4K?M7A3(F*G06@F$5XC ?:O P/P@O2#AA N*"E^I!;(<K1C77
MI61V8%2T/8+# E-2I[<Y2J[O(!V"N4,$5H0<!%E@O1EQ,?B](8#"F 5>(,4E
M!6C+299K+PU(3XJ4Q5N8T:%+0<QUN*7JGW>77EK'$!\<0'QQ ?'$!\,;[=AN
MG2D[<4R1')Y_(F/+J@Y#H)_GV)H_0:$L2SWHFQ6%?=)]H)_D+[[D-WO !CO
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MA<Z;%+SKSCV>6/(<''-M%+H40;NEY67E4'$2-!@LAB($;8^XY$<4<O0@MV/
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MHP4""0@(-7&?=)!M0!GW@0/.NONG9<\4FV66/(<''-M!'J9J?'0(\$3!$!X
MJ"<2T"QFF*3/RO#6>S>T&MQ"3'!!0<<&["7*&"*T(. BRP7HRXF/Q>D,!A3
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MY=4'(=!/\^Q-'Z#*DBSNDA&"H0(*,%11HO)+TSX$^Q,XKS)_D*N\M;$>IXA
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MX46%%@1?^#@)B/+(Y+.,_!8)IH),WQ!C01$/>ERA@BM"#@(LL%Z,N)C\7I#
M84P"KQ!BDH*T9:3+-9>&I"?%2F*M&<DFX2KA1846!%_X0+3DV*(A5.)2 \%<
MXDP,P7*$C-V;PO44 4X&-!?#QM&7$Q^+TA@,*8!5X@Q24%:,M)EFLO#4A/BI
M3%6C.23<)5PHL*+ B_\ "3&M8TN62I*L )RJ4/@#.PIB,!S.18S 0_(QVO&$
M!PSHQ;)(#@;.!(AL#IW1VX,)IK(?@:9F)D_IRXF/Q>D,!A3 *O$&*2@K1EI,
MLUEX:D)\5*8JT9R2;A*N%%A18$7_ (7#&)@"P'7*O#8@346T'$*<BLAXASL/
M&-<G>.8S[X"L/3PC^S[X"L/SN-&XBSJ4KV(TW5C%Q'F2MA&!"H4@O#\2)%>W
M$@G$8E9=]\L??+'WRQ]\L??+'WRQ]\L??+'WRP,G,%, HE\.^(T9<S,.I=&'
M]I\?VGQ_:?']I\?VGQ_:?']I\/53O-=_M(/Q_:0?B8*U+UT9?_P^_]H " $#
M  $% /\ H=]]R&Z(4!&&Q&7::A8BS)*'<1)FX?F69-P],8^>PV8*B:UY>J1K
M?'BEPZOU&ZQV8:@=8Y,DZ9B',P4S$*9@5N(,Q"")B L$V(P',  O_D,:H"4O
MP,F,3P<"ID&L3 E6J(5B,(CB'MQ#'!L#P%7BC#X"3,9@&N4Z+P'%!A;G_',6
M+"@.&"Z( .!\R#&-@:>G!CO<*-&@/@5LH06 $R@K^"\^*#3_ (T_\P9K B*\
M&4QC,1@88#C!_L#_ ,P7*T^+,%LQP<7 (R &4/\ XN$"0X2$:S% !\&BE.3=
MO8T&/&#1"N81J#P4JLE.-U-YMD9:/^])7C[TE>/O25X^])7C[TE>/O25X^])
M7C[TE>/O25X"3>"CQ,)Y]Z'_ ,%"QH0!!.9C..X'F0\SB]EE"S.2K!,LB<W;
MN,Q)B<7I! @D>)0R&#)8-_P3'CP T(ZF)!A-'& TRC=GDJR-R?!*JBD[9K3$
MF)Q>D$""1XE#(8,E@W_!)\N"TJP:GAF<Q>TF-:ZTB7H\!@M-0!M TYB3$XO2
M"!!(\2AD,&2P;_@@T."\F#GZU,3?M=%DQF.'Z4Q)B<7I! @D>)0R&#)8-_P0
MHUT%+L#1PLP$=K)A,"#\0%"AP0?1F),3B](($$CQ*&0P9+!O^!Q@P* #J1;"
MC7MA,)@0?B H4."#Z,Q)B<7I! @D>)0R&#)8-_P.>*  0ASH^'GHCM=,)@0?
MB H4."#Z,Q)B<7I! @D>)0R&#)8-_P #J=7AB-T8,$CQ':Z83 @_$!0H<$'T
M9B3$XO2"!!(\2AD,&2P;=HYD7A8G?91COLHQWV48[[*,=]E&.^RC##HI:W??
M_,-.BEC>^RC'?91COLHP',0 M_)&C0H$/OLHQWV48[[*,=]E&.^RC'?91COL
MHP', 0M[?GQ >'AXS+7<-.2EUO?11AAH6/-<$AHF_"1P,&WOLHQWV48[[*,=
M]E&.^RC'?91COLHQWV48[[*,=]E&.^RC'?91COLHQWV48[[*,.FY4\QTR+G\
M.QX#_:@@P A'^^RC'?91@,+"C'>SE8M'0&'WWXC_ &NF$P(/Q 4*'!!]&8DQ
M.+T@@02/$H9#!DL&W=7<XS0OF[XUK&,4*D>%MV@  DR$E94&*@^11\DSHKZ_
M>(D2'"=$J8F#8CK>&S$98&\3$4].(V(@B/%SPQ$>#B$?'$'$!8FD/ =;!7L!
MCXI%X8UC6;NM_G;E#CQH6(1R:P<056=0L05O'9@.L"F+@,8 1G9QR-[P,MB/
M&\.8]FJY:>YVRF$P(/Q 4*'!!]&8DQ.+T@@02/$H9#!DL&WA7<XS0OF[V\\Z
MZZH5&\-;M+BX29B2PK"E0?*H^29T5]?NK\1R$X-5A8%P,5QH(Q&$B!+VX!3$
M<":#6@J'@"?E8_=EO\[=_P#S 0_-@> 2T@O8"#@8YSLE2#N!*ML",^'CAX[@
MF!V6L5C[_;*83 @_$!0H<$'T9B3$XO2"!!(\2AD,&2P;>5=SC-"^;O3SSKCJ
M@4;Y@W:6%@DT$EI:&*P^91\DSHKZ_<Q(L,#AF"S=9@68#1[^[%Z@,R[!<JR\
M9AC6-9N2W^=J,=>>:UC6-U(46+!?+5@)@X!C@@^%V.L!WQQ^1'#?CE_92T5W
MN]LIA,"#\0%"AP0?1F),3B](($$CQ*&0P9+!MZ5W.,T+YN\OON0G% HGS)[:
M5%0DU$EQ<&+ V=1\DSHKZ_<8D2'"<-%A#AX$BQ(R+F"$!L,8&1,1N(*1)X6(
M9&40L.@0+F.%"X>  7\1",GBXC)$FBX$(C I,G 7#[C\-[0+3PP*VE2B F>Y
M+?YV@5)D<9.ADD40&0BHL@X<A0H>U\.'B8BDI3&Q'2!1%P*10ES PJ,0&D%%
MB <4E5$ <WL44(<"!H\9\1&R)<;P9MV2M%9P3O;"83 @_$!0H<$'T9B3$XO2
M"!!(\2AD,&2P;>U=SC-"^;O$6+#@PS]0OF;VTJ*1)L(   Q<&T%'R3.BOK]P
M-CX$5.F1P--'\L*#%CQ"Y&B(N ).7%[-,2""#'1R,#Q,#BH>7/:!0JQ(/ 46
M'&P==;_.SI@J<,1G_FDUC&L,4P6CF&:?,"S23ZG>AM_][$60[X0/*Z\\Z\7"
MW1P'L=7JATD#O///O=KIA,"#\0%"AP0?1F),3B]-'*5J6.@0T*8A-[5W.,T+
MYN[QHT*!"/S^(:1-I23B3:."!!R\/HJ/DF=%?7ZS6L8P[5;'</OO1'LI0EQ9
MA@"6@BZ'KON.1'31(!H^!8,2!C9R\R%ED8G/0ILYK+?YV=(0&0BC4:QC6'24
MA1V1(<2$_H)<_:X]V&?CN/-,R+&^]![&41\'(0 L6('">UTPF!!^("A0X(/H
MS$F)Q>K+E;M3PQC6/,WI7<XS0OF[M&C0@\(^/HIK%VDY,(-HX,&' A])1\DS
MHKZ_5C1H0>$>J.,9-RPH46/$)$O!![H,!!1\$Z38DL;GAQ(D%\A4K@[66_SL
MZ>=8X2ZQZ0PC6%%A1($703)QWB&[!/1W=Y9G(QO &G8HX:'+@AX<B3P?VNF$
MP(/Q 4*'!!]&8DQ.+UY6+7XSF]*[G&:%\W=8\>"&@GAY&-HVTF)1!M'"A8 *
M!IJ/DF=%?7Z@@1!"03L\CFT;*%"QQL<E(PY1"W5K&-8?);V:'_F$ZI616:BW
M^=G)&,84:ZG)&#H.@7C8I<+@1H8F#V LQWQ!6@1C>/*^Q%HI.]Q?:Z83 @_$
M!0H<$'T9B3$XO<(46) BH-70U25;RKN<9H7S=T$"((2"=G<8WC;20DC&\8.'
M@A(.HH^29T5]?IQX\$+!.SN,;QLH>!&%1B4F@E ?>%&G.)Q_YH)I1?&U%O\
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M:83 @_$!0H<$'T9B3$XO?Y/*#AQVZ*[G&:%\W3-C8,4AQPX08"-J<3C1#?\
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M4Y!P[=%.'K2V*Z\Z\[NIP.[P,=J+!>_&W56 ^&-,Z*&^Q_673GNJ;<$PIQ!
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M9HD1S$*1,*+#CP]11\DSHKZ_.*#0A@8:#B@!6@F37O$#OZK'\(6Y@02*.%!
MT(&&SK?YV<DY1K# < >'-2R.5"M!UYKK4X?.F4+<10AP(&CQGQ$;:B@7NPMW
M6(/X)AG1HWX([5F;!]L#<TPIQ! ("B@XT/HK%'</I!Q$<)'2RI@'T#16*. J
MP"9E@XG'=HNNM>>#06!P^NKN<9H7S=P4Q#P;^BFSYI?$8UC6::CY)G17U^@J
MRCC V@4F,0K&P8T,1"WX_,F&1CF213PH?06_SLY)RC7-"R :!1H*.7B="#%B
M0(I&=0C8/N"R'?"";76->:6A&  &[J<%QA3G"B'P@F#%<CPM28D#XI!NB84X
M@@$!10<:'T5BCN'T@XB.$CI94P#Z!HK%' 58!,RP<3CNT$X&XQ0;@KN<9H7S
M=P?<<B.* D?*H^BES_W6Z:CY)G17U^BI29I:*T$F<_!B;ZJ37@069.D[306Q
MC&,T%O\ .SDG*-P.R:$;AH\&*'BZ ,9' B"HS@&H77/QW'FFU, N,-MX>==?
M=,0CP$=G2(WB2S45@?B4YNJ84X@@$!10<:'T5BCN'T@XB.$CI94P#Z!HK%'
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MHI<_^*S14H[C37:!"OC1;CCL-S>S0&P>7M8UUN<G&\>6Z:E!<>1;RF%.((!
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M%8H[A](.(CA(Z65, ^@:*Q1P%6 3,L'$X[?9.I_X(7_[S,4G^.&W],*<00"
MHH.-#Z*Q1W#Z0<1'"1TLJ8!] T5BC@*L F98.)QV]DQ4(.S0O ARP%_]Y$0(
M0J <%D4H,M_3"G$$ @**#C0^BL4=P^D'$1PD=+*F ?0-%8HX"K )F6#B<=O4
MGTVV# _^]S ).- ]@)A3B" 0%%!QH?16*.X?2#B(X2.EE3 /H&BL4<!5@$S+
M!Q..WA.D@A0G ,(' !/_ +V^X[$=4Q*\1FO8"84X@@$!10<:'T5BCN'T@XB.
M$CI94P#Z!HK%' 58!,RP<3CMWE4E^Z2G_P"^JPB8>%;6-=;V F%.((! 44'&
MA]%8H[A](.(CA(Z65, ^@:*Q1P%6 3,L'$X[=9?I9Y3';&,=9NQNI^ZAGCG'
MCG'CG'CG#JX<Q#6P)N JD)Q36/,>9E&K#@Q818\4*T!<?A0OCG!(H.^8N@8#
M7"\%XYP'6KD6/HBUCPHKQSCQSCQSAU<.^UQ;AFX@*XGBM##0@QW.8JSN\;XY
MP$$PQ@;3,1T,N!^.<%:J[R':!V>.$SOCG!,I7#85IB!@4(['5Q1"P\MP[&L7
M$/$-:E[S0RB)Q.&/,>9F.3/ND)XYQXYQXYQXYQXYQXYQXYQXYP2FO? 789#.
M[P7CG!(<]\PM 0L_@1RY6=X#=AX>=RX\<X\<X\<X\<X\<X\<X\<X\<X\<X\<
MX(SOOEW8;J?NH9XYT11\4A&Q5H7NM:N(>'5N':V"KRB+@*8 AK-0\/7";'CG
M!*I'#<3H'2C[G%>.<!XOQP^E%C0H#@E5DX=KZW#L:Q<0L0%D61&A#$".9N:^
M3_!BNP4PIQ! ("B@XT/HK%'</I!Q$<)'2RI@'T#16*. JP"9E@XG';F&#QQ8
MA(IN ER7=U=SC'PHN/A1<?"BX^%%V@#8>6O$Q^&-G<AUS8IYIH&W*\(GZK06
MHWV.;"(;QY7H&W-'77GWN$%XX07AH42ZQKKSK<.1'X3Y2K8\!Z%%A1X>51\[
MPC##WH>FLS#WXV$OSW04HWC3;!<+> C77G7W= <8!"Z"9*X:);$B1(K^&,:U
MKSC[K-@,S'%[Q6KX$=K&L>9D6/*<.0(\5G""\<(+QP@O'""\<(+QP@O".AQ(
M19L4?),(GZ30,/KTYSO8M8,6+CA!>.$%XX07CA!>'G7G6NNO/-X07CA!>.$%
MXX07A%PHL*%L5W.,YLJ08!H\Y,3)NQD-]YC6-8W#'FNM+E29 FEAP"-7-)1C
M>--<%@QH >QK'F9UIS3!?]!HG:GA%[18T6.B8<AQ(C7X46'L=>><>*%;'@/0
MHL.-#W$<##F 0Y*A!*8=@IA3B" 0%%!QH?16*.X?2#B(X2.EE3 /H&BL4<!5
M@$S+!Q..W*4Z0^$YO"NYQEBAP\=@])EHITQ+119'A18D"(2&CIJ"VG7-BGFF
M@;<KPB?JM X&]X&4*%$C/X18WW(^@;<T(.<[7W'(C!2>*!;#A+"0#N$L</ Q
M.51\[P6C'R\;#?<BN:(F/#"AQ0B(+$82_/<YJ,8 +VM:UK(41L/"6&\659SL
M[@%$$6,$CH\*%%CQ"]&QHC Q 4!6...0V8C%X$0P8CRV.PS(QY6W!&H8Y8_!
MC0A$+:L>4X1?*]%1\DPB?I- P^O3G.\YUS8EYMG5W.,KSSKKI\IH@IN"TE'F
MC02/+H#(( "&9A]QR(P20E IA@C(CC(T&,'B08T6!$3ZA<,V:!N-[O+L,A1&
MPL)@;QA3G6G-,%_T&@ICEI<'_P#<$Y&*-WP*=*@+&.L=8UC&L&$)4.=.4X)*
MV82YT\"$;DKD\Z> 'G7G'NP4PIQ! ("B@XT/HK%'</I!Q$<)'2RI@'T#16*.
M JP"9E@XG';@A$G$5)O"A0X,/>%=SC.<EKAH!:QKK4H-:%--IUS8IYIH&W*\
M(GZK.H1O E6$8!9$CFH-H P "G@(UQ]V(YG-N:$'.<RG*W2X<QK6-*Q7&EV1
M1\[V)$PXD!HK(P^' V)?GN=:C?\ \P7$OQ$QA(#>',<QJ90BL&*$QAD<O+Q!
MD)*B<(50LS[CL1U1)M@-W"8.V@(^U8\IPB^5Z*CY)A$_2:!A]>G.=YSKFQ+S
M;.KN<954>-?>PGTUQ;'''(;F8U* AM!'@!!<)AQ'X3Y";NFP/.M1OM;@$2^^
MEL(\;\ PSK3FF"_Z#0.1C1QF!"/CA@8-!"0,CSKK[I^5]UC\$0UH\KW)>IKW
M'NPDPIQ! ("B@XT/HK%'</I!Q$<)'2RI@'T#16*. JP"9E@XG':Q45C#HP3:
M?!IHJWE7<XT#V"R ;A8K8 K:=<V*>::!MRO")^JSK,;\49@A!< 5K4%[&X2H
MWBRK.;<T(.<YEG"8^682,1KY-D4?.PK&/"3@ TN,"$?W<9:#SSKCIH.>,1Z>
M+^\3/"7Y[F_\P;#6F!B7A'APUUUUQU0@N!-8$9\/&#1W!0?*HS1ID/APWXL0
ME*H92#T'G6/,4)3W6-PF#-I@7[%CRG"+Y7HJ/DF$3])H&'UZ<YWG.N;$O-LZ
MNYQD/C/NLO:UKS4V3L,Q3&,8S0/BETU!-8UUI*8O%@]C6/,RM:QC#08T>8%H
M-H\<ZQCK#\%P)J'COAHX>.X)@9EIS3!?]!G%/_"#81L-U\US'9*X<PO V"4I
M>)P^Y/N.17%8G'R(;V$F%.((! 44'&A]%8H[A](.(CA(Z65, ^@:*Q1P%6 3
M,L'$X[4==>?>EVBW4T WI7<XT%.UCQXQC6MVG7-BGFF@;<KPB?JLT6(Y!AC!
M+XP42 N/,\&X+O NPD1O#&6<VYH0<YS+*(QPJPD8;7";(H^=A/JUB7_&"X31
MAQY9G5AAPA=A)E_"%V$OSW,HQO!%.$6"]^/A9@OBA,(X;\8!D4 UH JPCB]D
M<5I'!7#-PG@;!,G(A0*V+'E.$7RO14?),(GZ30,/KTYSO.=<V)>;9U=SC(K1
MS1)DQC7FE !TM :1BD88X9X&P #1 8/*I1O!%.$6"]Z+A: OB!L(\;Q!?F6G
M-,%_T&>.XV) PDA#L XWPR+@IJ#.B<42#NPDPIQ! ("B@XT/HK%'</I!Q$<)
M'2RI@'T#16*. JP"9E@XG':<KT/[C-[5W.,[6L=88">,'%0=HHRVG7-BGFF@
M;<KPB?JLRM&\,6810+W86Q1 N"-H,5^!%"B'!8;,;<T(.<YE>8.BAK&-:TL"
M<"7Y%'SL)]7'@PQ$$:%B A:5,.#,LZA,.\3,K O&(]UUUQW"7Y[F60WXPW!$
M"X KP,#.# D2&_"B)H;P1MD6PEK8N$Z%8$*-=8\IPB^5Z*CY)A$_2:!A]>G.
M=YSKFQ+S;.KN<;8D1V%#C17X\9-A6"SC<UB-^./P2 N +,#@KHT&^X]#?3 W
M@S;,M.:8+_H- ]!/ 32'$?A1"4Z@&P??% 0AC\"-!"2X5V$F%.((! 44'&A]
M%8H[A](.(CA(Z65, ^@:*Q1P%6 3,L'$X[12KY(X?0WH;\/>U=SC.J#Z&Y"P
MC2YKT7:=<V*>::!MRO")^JS*L;Q1HZZ\\\7!'0 '8LP7Q0>$:-^,"S&W-"#G
M.1K6,8>JB% <:UK6I0H>%"<JCYV$^KPLR_V-8UK&DX]AD7Y5"8=WEF$:7_#@
M;$OSW+&BN0(0H0^+$D8+CS3:K 7"FC&M8TJ&,'E^U51?B'4-QL1]QQV&YKK'
ME.$7RO14?),(GZ30,/KTYSO.=<V)>;9U=SC:?1?@D^$1"8V/N4>,X'@B8[XH
M00 N/--JJ!<*:NM:ZTM&,'@,JTYI@O\ H-!0$S#8-$AQ(,2%%BP(A>LHT-@0
M]*AN^*E,P3\+'@1@L;L),*<00" HH.-#Z*Q1W#Z0<1'"1TLJ8!] T5BC@*L
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MQE_]P&)S,9@N1C&-@0((:%D.N; H#HD9X* 8\% ,>"@&/!0#'@H!CP4 QX*
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MR7Y[L50WA"K"*!>]$T5D"^,"PBQOQ VUK&/,,DB"%-&)TV!-:QKK=H<(*%/
M4>/CM+B8 5NY5CRG01?*\C6,>8:)"!':,*3$ W:XX_$> )4S%M+"8$5.:)US
M8EYMG5W.,XXN!F,,>C1,-HD",!MVL8UK0A$:C<%Z-#PFPH4.##R*P;PI7A%
MO:]HK,%\4)A&#?B!-BTYIG"_2[3$K!FD(P21@%;%A18+VT$4&(]I2E P-[L&
M)#AQH9_+YQ_ @/'"1NP$PIQ! ("B@XT/HK%'</I!Q$<)'2RI@'T#16*. JP"
M9E@XG':,OI@OD;[C[D5S<11.6C8OAPDU8Q"41XL(@*(,30BPW(T/PX28!E8
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M.D8[ J7)+&P*EH/<P(1*D#XCE1H%UX<&+&>#ID_%8#2]4$; 66<)F B&3@7
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MK6NP@D-TS]M.4X.7]N2@25KB=EZ@4@S8IY)296T.85J2VU-!V<'3'VS)BN5
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M])5)2DJ.4B12*;0:;T'GG77;O%WAY>/:EGVY9&I(F! CP!4#>NIG]4C-+?\
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M+$EHPOH1E)O74)V88)R$SAA(@&(L*7C':TD3I=7)_(F>U#Z:>X7-*,RBO*C
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M@G!1S/&WM7M*"XC3ONE]GTFL_2<?F9DZHF4#5[;FT*(9RPJ>:Q.Q:A5G]N9
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M7Q!400:-PZWC+2O*6D[))S+IXF7V38VDZ]-.OS<>IG]4C-+?^0]U>==?=O\
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MW132E/T<?T@U?$%1!!HW#K>,M*\I:3LDG,NGB9>_4C4]GE5%1R93A(CDW_\
M=SLF+%&33PE8:27FIOU)56JDIQ4B15R;7B;T&L8\RN*AUJ<;HII2GZ./Z0:O
MB"H@@T;AUO&6E>4M)V23F73Q,O?>GFI/\/HO_P"\W/)'M/DIO])56JDIQ4B1
M5R;7B;T&L8\RN*AUJ<;HII2GZ./Z0:OB"H@@T;AUO&6E>4M)V23F73Q,O>Z=
M9'*VI.=\J99I*3,M?_O*D3I,KD_.^5)Q)2:._P!)56JDIQ4B15R;7B;T&L8\
MRN*AUJ<;HII2GZ./Z0:OB"H@@T;AUO&6E>4M)V23F73Q,O>NGRHZ?($O_P#>
M[DT@6KF7W8%)56JDIQ4B15R;7B;T&L8\RN*AUJ<;HII2GZ./Z0:OB"H@@T;A
MUO&6E>4M)V23F73Q,O>*1*;%55M4-+Y!I:5R%_\ O8P&$, E6$AQ=/\ -_L"
MDJK524XJ1(JY-KQ-Z#6,>97%0ZU.-T4TI3]''](-7Q!400:-PZWC+2O*6D[)
M)S+IXF7N]BZB1LA)$?\ WVLVGJ'4!*2+"BP(O8%)56JDIQ4B15R;7B;T&L8\
MRN*AUJ<;HII2GZ./Z0:OB"H@@T;AUO&6E>4M)V23F73Q,O=;4-#XFM"I6! @
M!8&[7,^H'_715)_KRQ_KRQ_KRQ_KRP4=76FXSJ$ZLNDTSBT_WVK7]0PDK-"P
M[+LM5_4^_P!8:EJ;^J4_L'41H5(3>_KY3O\ Z\L6E+U/[29B:%;55*6HFI8_
MUY8DSU822F'-O1J0ZI3^OE1'^O+'^O+'^O+!3U=I-&$)OJV9$"HTINIIMA3&
M$R(JNIHJ?*L]=G4F_P!*:LO]>6*:Y](NJ*06G7#5JBZ&Z7/]>6+>G4;?WRK
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M#IR/VM(?U<NYIK"SM9L/"\1+1+!RL23_ , _84*Z-*I':36!T$'UF(N06G+
M1(_#:N2,]@.TFM:\P[IR+F46#=,2?A?LI6C-UU-7U<O(HN[29"T*#<+"Y$!
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MY\&/PQV4K1FZZFKZN7D47=I,A:%!N%A<B @ S+,KZ^8TVKFM%F-Y/( !8 (
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M@ N^&.RE:,W74U?5R\BB[M)D+0H-PL+D0$ &99E?7S&FU<UHLQO)Y  + !
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M5R\BB[M)D+0H-PL+D0$ &99E?7S&FU<UHLQO)Y  + !      8F OPE?N_\
M=\K_ '"QZ:F<?=95FS5/\W*B'[OI-ZR EXPZ^U*G_P#U%*G1 ]XE"),L_P#N
M+:91RVRS8RE"C@A@8$&P@C(=MK[:9RC9S.HW(=KK2TJ-,J', H$2?\!>3<!:
M;,.WGP?6KCG-D4>(FYG-['<@-AIS2'K&'JY8-K'.<RC*<MPB<'KJYR\]SP 9
M%49%&0<)B23BZ3KMZ#8BG_4_4;'+2TJ-,J', H$23\;S<!:;,%K:X+-UJ1OK
M+W%SMG?@6 B3L6J:EU20@BS$P &_\8W8-1:I+2J"XO<\P?54YND1>1:NU!5:
MOF-+FB^%S#,PN8;AWQ;;@M+5:,C6?BQYK]0G+Y!MS%K2-FTB>JO)<0*L(@@Y
M"#?@VL=5!GU=>RVEI><YV09[U\*(YV.K>O+Y'Q%8QO[0#B51\F/$BH+3-5.>
M<MY2/A)\JW-OP."5-,P>0Z@JPN(-WQR9<3^-I%AJZ>20!<CWE-P&]=R('1^
MI%,PC(5M-\V@EI!W&,%^EB*BE41G!=-.LG. &ZP!7A^!I6K*!-.KG-HJ,FZ2
M<BJ(ECD )P35M)!IE\QX0,QR+6.89%6/-4 1)B3\+]E*T9NNIJ^KEY%%W:3(
M6A0;A87(@( ,RS*^OF--JYK19C>3R  6 "      Q,!?A*_=_P"[Y7^X6/34
MSC[K*LV:I_FY40_=])O60$O'3/WYJ"7"G=HUDM1T78^\ #(Y@)L+G(F&.DY&
MVE]M,Y1LYG4;D.UDI*1"]0Y@JC+\P%Y)L M-F&F\'UFXY[YO(3,HRF]C:;(
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MF)]9LRCC8V#*0]96.7J',23R#,!< + +!C:3KMZ#8BG_ %/U&QB4E(A>H<P
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M+4;Q,ILZY0?*6,#P&P$8JMZ\OD?$5OZE_2.TI:.8SZ<F4=Y;4_@(&^#B:FB
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M-B*?]3]1L2=<U*_F9X@D?!EY]]R(]4"!M.SFU:&%2W,E]=KC]$1;@AA$VD_
M'X.H:-;304QO9/ ;@Z)W@3:V(,MP"C @@V@@W@C,<'I5!_"/SY9SH3='.IBI
MRF -Q&(K>O+Y'Q%;^I?TCM))R=)&##?!C@'7HD1'#B*.9"YY@COA#\G>VZLF
M4"TQV  SDF '"<)&KTA"5+ )&5KV/"Q)X>Z*%#";4O#Z"09N_HC>)[DW5CGF
M3TTEZZ1,.%2Q/5&(6O00E5*1/72"M_#H'=).WYG[HJUSRY$>*9,']L'V@S?"
MW92M&;KJ:OJY>11=VDR%H4&X6%R(" #,LROKYC3:N:T68WD\@ %@ @     ,
M3 7X2OW?^[Y7^X6/34SC[K*LV:I_FY40_=])O60$O;,_5&L4[2AJ932W7.K"
M!@<A%ZD6@@$6C"J_;U=;.IIA :$ Z'G2Y@W'0JT,D8&T':R^VF<HV<SJ-R''
MBDHENM9CT4&=CR 6DW98"CHQ;>[GI.V<_(+@.$GNMJ[5Q#:T(M:\2HY\[PN6
MX7MD!,V:2TQB223$DFTDDWD[3I.NWH-B*?\ 4_4;$2Z0@_AEY\PYD%XWV,%&
MZ8W X!$ " 0 %P N V:ZME&,BF6W=F- MQ#1&X=+X!E5L3V$=&8,Z-?OPL8;
MH& =""A$01<0;B,0TR4(UM/%TSD0YZ\*B(&5E48BMZ\OD?$5OZE_2.TZ6;XU
M/+/&BG$4OMF]';HJ9@C(I5TSFT[D&_&+#J[!Y*&,FF'9CK"USOZ1*[RCN2:^
M7TI4P-#. ;1PB(X<%FRS&6R@@YP1$'BV<R8@C/ISVHWA8XWM EM]1MZ1JFE^
M^GS L?%%[,=Q5!8[@PE:NHUT::3+"*-P"\YR;R<I))M/PKV4K1FZZFKZN7D4
M7=I,A:%!N%A<B @ S+,KZ^8TVKFM%F-Y/( !8 (     #$P%^$K]W_N^5_N%
MCTU,X^ZRK-FJ?YN5$/W?2;UD!+VW*_>5"D:RA'9SX7M3LW-;=[*8Q^A,=B8+
MM9?;3.4;.9U&Y#CA348Y@@7<]%%SG.<RBT[P)"T5$ME[,>D[968\@N L&P;5
MFJV#:R-C,+1*^=]RY<MMF!=R2Y,23:23>2<I.U*3KMZ#8BG_ %/U&Q JYPA5
MU4'.<)X X02WTH&[9SJZ;]W*ELQW8"(&^38-TX/4SC&=,<LQSEC$]\_ 0I9I
MC4TI"'/H'[L\0*_1Q,R7*$*2;ZR7F :]1U6B /%AGV=;UY?(^(K?U+^D=IT/
MZ.3_ &UQ%%+C>TTPW@@[T>_MU:AQ"?4GM#U;D&]H\X=8]V?K!X0E2RP!RMX(
M^DT!PX--F$F8Q)).4DQ)X3W9<MS&=3DRCO"U.#1(7Z)V9ES "C @@W$&P@[^
M$_5[Q]5,(&ZMZGA4@\.W9O[FJ5Y\R,J3'Q0?6.-]@$!O&BXN/PKV4K1FZZFK
MZN7D47=I,A:%!N%A<B @ S+,KZ^8TVKFM%F-Y/( !8 (     #$P%^$K]W_N
M^5_N%CTU,X^ZRK-FJ?YN5$/W?2;UD!+VY-H*Q!,I)TMI;J;F1P593N$$C"L_
M;T_2(D33H,?#E-SI3YN<A!,+FBMX.U5]M,Y1LYG4;D.-%/2B$D0TYA'-0;N=
MCX*WG< )"T5$L)8M)/29LK,<I/$!8(  ;!M5ZI8&O,0[BZ7G _\ <]#K7%F)
M+$Q).7:M)UV]!L13_J?J-LY-$P)D1TIG46UMZ-B@YV& 51!1LY>KT,'J)EO4
M2!/\13B/P'+5S"GJ/5-FBQYAX&@(Y 3B362Q&HI3I[N@8!QP"#?1V=;UY?(^
M(K?U+^D=IT/Z.3_;7$4E/'HRG;SF ^IWMN2-7I&$R8 2,BBUSP*"<%ERP!+4
M  9@+ . =V3JJ6>=.;3;JI<#OL8_0V#T#F$NIEV==(LO\.F-TPQ$C6TL<V8O
M9OUEM4G=*DC>3;DC5E*(SY\P(-R)M8[BB+'<!PDZMI!"FD2U1<\%$(G.3>3E
M))^%.RE:,W74U?5R\BB[M)D+0H-PL+D0$ &99E?7S&FU<UHLQO)Y  + !
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M6/3N//@7^"^RE:,W74U?5R\BB[M)D+0H-PL+D0$ &99E?7S&FU<UHLQO)Y
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M &39KJ&F;,TZ'&B?7/T=W;DW6\P>KDKH)UVZ1'56P]?82]6(?5TZ1;KO ]Y
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MEM*JY3093>#R$$6@B(((()!Q4O\ ;_[@F?F[%DSF/3R"7,)\/(K'IW'GP+_
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M4RK&*:JE [_;U+<C#:"^VF<HV<SJ-R'&)74;:%1+,0>4$90181E& JI,%GK
M3$C:C?9-I4Y1N@@8B!NP.M-7K_MDQN<H_E,<G48]$W*>;XL=H4G7;T&Q%/\
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M_B'(;#88@RIH*S%)!!$""+""#<1A(U>L83)@!(R*+7/ H)P67+ $M0 !F L
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M^:GV</>W\U/LX>]OYJ?9P][?S4^SA[V_FI]G!ZFH;2GS&+,;+2;S9 ;;B+\
MHJW@!F0]\K$\.'O;^:GV</>W\U/LX>]OYJ?9P][?S4^SA[V_FI]G#WM_-3[.
M'O;^:GV</>W\U/LX>]OYJ?9P:KJVTZAKV@!&%D3H@".[?A^*H',NHT2-( $P
M-]X(P][?S4^SA[V_FI]G#WM_-3[.'O;^:GV<%EZQGM-1"2 0H@39'F@=_P"
MA2450TNF4DA0%($3$WJ3:3'#WM_-3[.'O;^:GV</>W\U/LX>]OYJ?9P][?S4
M^SA[V_FI]G#WM_-3[.")K*<9JH25B%$(WW 7P&-IZMVTJN6.RFY]- !$[KKH
MO]+;W:RM&5KJ4OJYF1A?V<R%I4FXVE"8B(+*TR@KY;2JN4T&4W@\A!%H(B""
M""0<5+_;_P"X)GYNQ9,YCT\@ES"?#R*QZ=QY\"^)>BK4692S%*LK"((/QB"+
M08$$$8?B:;2F:CF-S'O*$_RYF[XK7,,Q!&*[65I3M1SF';R(V,+NTEQL6:HN
M-S#FM9 K*UUJ6:L[5\Y8JPO!RJPO5U-C*;0?@%=1TS1H=5H99A<9[P::?H@)
M+(-S(V?_ ->'U-/:%+6KS8W":D2N]I+I+NMH#;_:RM&5KJ4OJYF1A?V<R%I4
MFXVE"8B(+*TR@KY;2JN4T&4W@\A!%H(B""""0<5+_;_[@F?F[%DSF/3R"7,)
M\/(K'IW'GP+XEZ*M19E+,4JRL(@@_&((M!@001A^)IM*9J.8W,>\H3_+F;OB
MM<PS$$8KM96E.U'.8=O(C8PN[27&Q9JBXW,.:UD"LK76I9JSM7SEBK"\'*K"
M]74V,IM!V_6?N&H@?P\DE%/AS6YLI,\&F%087")R83*VK8O53IC.[&TL[DLS
M'=)))_\ 7A*JG8I42W#*PO#*8@C>(CA3ZVDP]:@TAXKBQUX&!AG$#EV_VLK1
ME:ZE+ZN9D87]G,A:5)N-I0F(B"RM,H*^6TJKE-!E-X/(01:"(@@@@D'%2_V_
M^X)GYNQ9,YCT\@ES"?#R*QZ=QY\"^)>BK4692S%*LK"((/QB"+08$$$8?B:;
M2F:CF-S'O*$_RYF[XK7,,Q!&*[65I3M1SF';R(V,+NTEQL6:HN-S#FM9 K*U
MUJ6:L[5\Y8JPO!RJPO5U-C*;0=O4W[*HV!DT\)]1#_FL")2'-H2V+D6@]HIO
M7_UZF_MNI;U-1&9*CDF*.>OTT$=],[? ':RM&5KJ4OJYF1A?V<R%I4FXVE"8
MB(+*TR@KY;2JN4T&4W@\A!%H(B""""0<5+_;_P"X)GYNQ9,YCT\@ES"?#R*Q
MZ=QY\"^)>BK4692S%*LK"((/QB"+08$$$8?B:;2F:CF-S'O*$_RYF[XK7,,Q
M!&*[65I3M1SF';R(V,+NTEQL6:HN-S#FM9 K*UUJ6:L[5\Y8JPO!RJPO5U-C
M*;0=N57[@KS^6I9)>$8%FN1!Y3N51=UAA4:XU@VG6U,YICG)%C& S*+E%P
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MB:;2F:CF-S'O*$_RYF[XK7,,Q!&*[65I3M1SF';R(V,+NTEQL6:HN-S#FM9
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MKC(<QN;) V#847Z9/1&%=^CG?VVQ-#^LD_W%[E+[9O1Q,_6\P6*.R3?,&<\
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MXP:IU*QGR!:99AV@'DFP/O6-D 8X%'!# P(-A!&0[$_IG]).YH3IDM&A&#,
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M8S;4E(3#.;E7Z3$#APF5M6VE43&B3\@S "P#( !L1-E$K,4@@@P((M!!%Q&
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MI =]=&&\=G0_HY/]M<*SV)Y1L8"TG!:_7:&71"T2S8[YM(7JN<&#', 8X!5
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MR1VJ[Z1TAPII"&>&SH?T<G^VN$[5VGV?:IHZ4-*&["(CQC#W_P#H?ZV'O_\
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MTR6(4502Z0N!)YZ?1)B!XI7%0%^$EM:RW:O9=)^>RP)M"P! YH@#N@X?<O\
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MHL-X'1(WSW#4H(2*E=,9M(6.-^,&/6V$[]8_]N5W*K]3-]-L125+&"+/2)S
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M)<PGP\BL>G<>? OB7HJU%F4LQ2K*PB"#\8@BT&!!!&'XFFTIFHYC<Q[RA/\
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M5U-C*;0<4_[E_;2*G[E18S)8@%JE XA. L5C8XYK6Z+!I$]62<C%65@0RL#
M@@V@@V$&T&P_\!JR&?\ %T _ES220,R3.DME@!TE&1<%DO,_"5QAS)I !.99
MG0:VP E6.1<(B[;W:RM&5KJ4OJYF1A?V<R%I4FXVE"8B(+*TR@KY;2JN4T&4
MW@\A!%H(B""""0<5+_;_ .X)GYNQ9,YCT\@ES"?#R*QZ=QY\"^)>BK4692S%
M*LK"((/QB"+08$$$8?B:;2F:CF-S'O*$_P N9N^*US#,01BNUE:4[4<YAV\B
M-C"[M)<;%FJ+C<PYK60*RM=:EFK.U?.6*L+P<JL+U=38RFT'%/\ N7]M(J?N
M5%C,EB 6J4#B$X"Q6-CCFM;HL&D3U9)R,596!#*P,""#:"#80;0;#_P'!*"H
M+4@_E3(O+AF )BOT&4X+)UW*>DGGPUC,E'B&FL<VBP&5L!5:OG2Y].?"1@PW
MC F!S@VC*-N]K*T96NI2^KF9&%_9S(6E2;C:4)B(@LK3*"OEM*JY3093>#R$
M$6@B(((()!Q4O]O_ +@F?F[%DSF/3R"7,)\/(K'IW'GP+XEZ*M19E+,4JRL(
M@@_&((M!@001A^)IM*9J.8W,>\H3_+F;OBM<PS$$8KM96E.U'.8=O(C8PN[2
M7&Q9JBXW,.:UD"LK76I9JSM7SEBK"\'*K"]74V,IM!Q3_N7]M(J?N5%C,EB
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M5U-C*;0<4_[E_;2*G[E18S)8@%JE XA. L5C8XYK6Z+!I$]62<C%65@0RL#
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M /7P_P#%_P#4_P#U\/\ Q?\ U/\ ]?#_ ,7_ -3_ /7P_P#%_P#4_P#U\/\
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M)><GDRD[@MP,O5J1/CO=P+?QD;V&G5S&<YB;!O 6#@&UPLM].2/!>T<&4<!
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M0 92?\3  G#M)O-DKT4%RCY3G/% 6;#MY\5H5-IRL?%7Y3DN%MRR9*A92B
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M'X6I/YY!YXSC='A#A&4#;E1U1Z2XB;['ZR[&>V9@.)5'R8F6#?V:\@^!H&[
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M:AY[Y_(3.QRFY1:;8 I2TJ!*=!  9/G)O)-I-IMQ3Z@U _Y6U9TY3T\A1"/
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M)HG/-.;R3NC(<HW088E=65K<X62V.7R#N^+GNOA':]1U1Z2XB;['ZR[&>,[
M\:J?EQ,R5E6<>(JOR@_ ]2;_ %S<N(DYETCQ*T._#8T_5?E7$2JIYLT/,0,0
M-&%HR68?>SOX?FP^]G?P_-AZN?,#;H!Y(<N!>F99R#-S6XC9Q,3@94Y668+P
M1 C@.*@T6HW//7-Y0W1FRBS,0LZ20TIA$$7$'X!_#J83)[0^B+6^0<.PE2R(
MRU.FV\MO?,!P[0FR (2]+27JM:.*,.#$2](QFRN8?H]'^&'#':5'(&>8Q_@
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MRK>Y$)WSD'"8#AP:8YB[$DG.3:=@C,/63>>=X]'^$ [Y.U%JU'/DM;U6L/\
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M=!OJGR3WC;G!:3.4K-4P(-X.)6IIFT9JGCS@YP<N J)5CBQERJ<VZ#D.7?!
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MG!R@X"6\$K0+5R'=7.,L+QNBW:[4&KVC47.X\'.%\K.?!R<[HQ-^Q"J"6)@
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M68"<D!.6QUS'YCD/!>#W:CJCTEQ$WV/UEVM^:E*SPZ5S><('@NP+4$WZ+_:
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M,1O3(_4&'K9,U=[1;E*X:*S@CYG!7OGF]_#24@J=E,I?P^EV;E8]I",#",-
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MU,\T_-A,68K*W;M801X"9^[4=4>DO<G^T')B9_MG](X4_6/HMW:;LE9H=I&
M)A]WFP^ZF>:?FP^ZF>:?FP^ZF>:?FP^ZF>:?FP*L"&&0X!5!+'(,/NIGFGYL
M/NIGFGYL/NIGFGYL/NIGFGYL*@359262\$9&S]T^S7$&33>NJ1F/-7?.4[@W
MB0<#^)F'LSX*V+Q9=\Q.[W8J"1O80-_<TE)## )//;R,S'G<#7\<1AI4[0F@
M6H;&'!E&Z(C>-F+F,IC+EG07>6_C:)[DJK%R-;U38PXB< RVJ<1+_3KZ;]R1
M[%/1&*-+1PF58L)\%-_.VX+LIR8=K5S&=]VX;PN WAW(2U+'<!.'K%9=\$<O
M<#(2&%Q%A& D:RC,D7:?AKO^,/XMTW8";*(:6PB"+B-I3**J72D3%@1R$9B#
M:#D(!P>@J+2IBK9&4]%AOY1D((R? 6@\7U:YYZ9O+3,PRBYA8;8$)54KAZ=Q
M$$9?F(N(-H-AMQ3:VU2OY>^9+'@YW0>+XR^#>.;T<2M33,4GH8JPO!^-XN(L
M-F'8SH)K-!SER,/'3<SB]3N0.*T'A+UE+![*;"[R6RE";Q>IYRY09FKM8RS+
MJI9@0<N8@W%2+0181M/_ /=&L%Y[ BG!R"YIOTK53R=(W,IVR?9KLH3T1QY2
M@\HP+4X,F=D*VKPJ<G5AAV%4(&\$7,,X/R7C*,%G225FJ8@B\$8"<8">O-<9
MCG&X;QPC)L*GVS<N%-^HE^F,34_IYGH'N3_9CEQ,VI'W9:"]5;!Q@1WR<.SE
M L\"8#, 2>( GN3*!SS7&DN^+#QB!^CB:G]1,],X4_M/D.PT7 9=T1P.G)56
MSIS3WK#P@X&HI29M*+3XRC.0+QG(NO( M[@H9Y_*S3 >2YNX&N.[ YX[&HZP
M]%>Y+JT\!K1G4V,.$1X<%F2S%& (.<&T'%/4S3"6BECP#E.3=P>IF_>.Q)X<
MF\+AN=R1]/\ MOB)M5X2KS>L;%[Y'!A$WX&< >R4@$Y 3$@<.B>+N*C&,V2=
M [PZ/\,!P'$9&JV'-7ZS9E'&38,I!J*IBTP\0&8"X#<& E25+3&N $2> 8"9
MK%]!?$6!;A:T#@TL!V<A&;.W./\ %$#@ PT4 5=P0[D)\F4V^HCQPB,"U*6D
MS-SG+Q$QXF&$9ZZ4C(ZVKPYCN'@CW!(G$O0DVC*NZORK<<D#@LZ2P:4PB"+B
M-@/;+R-W)GZAO03%5'5'I+W)_M!R8F?[9_2.%/UCZ+8BI]LW+A3>V7EQ!]FN
MR+,0% B2;@,&H]7DK37%Q87WLR]\[@L[D:=828VNUB_XG< .[# -5EITSS5X
M@8\;6YL(2),M-Y0#QPB>Y"8 PW1'#UDA <Z\P_PPCPQP,S5KZ8\1X \#6 \(
M&_@9,]62:MX(@<!.DL5FJ8@@P(P%+4P6N X' RC,<XX19$#$3:H=,+!>L;%X
MB8G<![AG 'L@P4G)$@D#B4\7<0,8S97,/!T?X8<(.(E_IU]-^Y(]BGHC$BFI
MS"LFB_Q5N+;YN7A.3")OPBG,I@><Y%F\!E.Y<,I%D01+$R;XS\X\ -@X!'=P
MT5 "C"!NP(FRE5SX2#1;?LL/T@<.WEGM*/QH6KUA\HLWH@=P4,\_E)A@(^ Q
MN(W";#P'/':6E( _[C)!*'QAE0[^3,T+@3@58$,# @V$$9#\!:#Q?5KGGIF\
MM,S#*+F%AM@0E52N'IW$01E^8BX@V@V&W%-K;5*_E[YDL>#G=!XOC+X-XYO1
MQ*U-,Q2>ABK"\'XWBXBPV8=C.@FLT'.7(P\=-S.+U.Y XK0>$O64L'LIL+O)
M;*4)O%ZGG+E!F:NUC+,NJEF!!RYB#<5(M!%A&T0DT$:JD0:<V<9)8/C/ [RA
MC> "LF2H64BA5 $  !  #( + -LGV:XAI! [8"*',PNX#<=PYP,"K6$8"23Z
MJ<-$[]ZG?C9](["I]LW+A3?J)?IC$U/Z>9Z![D_V8Y<1,=3":XT%WVL/$L3P
M=R;7.(H@T!OM?Q"SZ6$VE\%6YO5-J]XB.[A*JU\!P3NC*.$1& =#%& (.<&[
M$5/ZB9Z9PI_:?(=GIR1"FG L!D!'2 W+01N&&3"(OPDU1Z3H(]86-WP=C4=8
M>BO=-(Y];(,!NH;1Q&(W!#%)JZ6>=,.DW5!L'"UOT>[(^G_;?$2M7H?+;OA?
MK'B/<>21^8G@S!GB+4&\0!YQ[AIF/JYRP^DMH[T1P[-JF9:URKXS9!O93N8-
M4U!TIKF)/R#,!<!D& IJ8<\VDFY1E).;E-@MPT9(C.(YSF\_,,P'#$V[,HX!
M0B!!M!&8C UU #^&\)?$W1G7/E7>NP%'4'\G,-D? 8Y=XW-QYX]T>V7D;N3/
MU#>@F*J.J/27N3_:#DQ,_P!L_I'"GZQ]%L14^V;EPIO;+RX@^S79'5=(>8/O
M",I\3>'A9S9D,<!6ZP!%->JW%]TY0N;*V]>)<L!4 @ !  ;@V>A.$)P'-<7K
M\XSCD-N!IJD0<7'(PR$'*#WKC:#@)DLE9BF((O!%QPTV@*I+'&[D8;C=XQ&(
ME:O4W<]N^%^L>$=QI!'YF:O:C/&]!PJ /I'N-2.>9.6SK+:.,:0W3#$2_P!.
MOIOW)'L4]$8F;41BFE!>JM@XX1WR<)=)+Z3M".87D\ B>#!*:0(2D$ /E.Z;
MR<IMV)1P"A$"#:"#>",#+E^[.-)-P95^B;-Z!-_<E3W,9L-%M];(\-AX=IG7
MM$O,)]<HR'),&X;GW8-E8CX"T'B^K7//3-Y:9F&47,+#; A*JE</3N(@C+\Q
M%Q!M!L-N*;6VJ5_+WS)8\'.Z#Q?&7P;QS>CB5J:9BD]#%6%X/QO%Q%ALP[&=
M!-9H.<N1AXZ;F<7J=R!Q6@\)>LI8/9387>2V4H3>+U/.7*#,U=K&69=5+,"#
MES$&XJ1:"+",?*U90+I54UH#,,I8G(JB)8Y ,)>K*.W1M=X0+N>DYW[@+=%0
M!&S;1]FN)J)8$!VA/G0;Y<)<\7I,5N(@["I]LW+A3?J)?IC$U/Z>9Z![D_V8
MY<0E$IYLI8GK-\RPAOGN2I)$)A&DV^UMN\(+P82M8(+^8W?*_6'%W%EL8S9)
MT#O7KP0LX,14_J)GIG"G]I\AV:3?"2<.(AH]^'<5?%F,._I?+L:CK#T5PEJU
MH,Q>483*7^6#%>J;1Q7'=!PESF,)+'1?JMEX# \&)+L8*!$G,!A,JST6;FC,
MHL4<5^['!$<1D)SVS0%PX3 ;T<W<D?3_ +;[.)NPFU4>86@O5%B]X1W\)5(O
MAN =P7L>  G (@@H$ -P83440E.=-=YK3#<#1'!@D^79,1@PWP8C!*F7T)B!
MAPB,."X[(JA_*RHJN[XS<)[P&"RI8)F,0 !E)L P$H0-0T"[9SFWEN'"<N)*
ML 5(@0<N'JQ^4F1*;F=?HY-PC+W!+F&-1)@IW1X)X0('.03E[H]LO(W<F?J&
M]!,54=4>DO<G^T')B9_MG](X4_6/HMB*GVS<N%-[9>7$'V:[%IJ>\-S4WSE^
MB(G?@,N&DUI.':SQ^3E$%O*.1=[*VY9ECA 6 8DJH_-)$H=W*N\W>,#DP*L"
M&!M&"5'\D\UQG4W\(O&Z, RVJ=E$V 83:KP6:SJBQ>\!PX2J07.XCU1:QX #
M@%6Q0,)LH"$MCIKO-;WC$<&"5$O[Q&##?!C@E1+^[=0PWB([.7^G7TW[DCV*
M>B,1,F1AHHQX@3W&<WI)8C?)4<A.S1"_9NC$@Z.E81:(16^PQCDNP]Z_I_ZF
M#4YF]HK/I#FZ,+ #X39AM,RY@#2V!!!$00;"",H(O&&G)!.K9I)0WZ)RH3G&
M2-Z[H/P'H/%]6N>>F;RTS,,HN86&V!"55*X>G<1!&7YB+B#:#8;<4VMM4K^7
MOF2QX.=T'B^,O@WCF]'$K4TS%)Z&*L+P?C>+B+#9AV,Z":S0<Y<C#QTW,XO4
M[D#BM!X2]92P>RFPN\ELI0F\7J><N4&9J[6,LRZJ68$'+F(-Q4BT$6$8T(@)
M<F  M))N &4G#\;7*/\ O50HTO\ VTO$L;N5R+V@+0H)VT?9KB9Y%T4[TM1A
M 7G85/MFY<*;]1+],8FI_3S/0/<G^S'+LVFS#"6JDDY@!$]["95/TICD[T;A
MP"S"5((C+TM)NJMIX[N'N3:4=,K%>L+5XR(;Q[GX9CZN<L/I"U?E&^<14_J)
MGIG"G]I\AV:I&UYRCB#'Y!W%;QIC'OZ/R;&HZP]%<)7M%Y1@M?+'K)1@W4)^
M1O2)[BZ9C/E<QN#HGA$+<X.(_#(?73S#Z(Z7'8O">Y^)<>NGF/T1T>.UN$=R
M1]/^V^SF,IA-F<Q=]K^)8G?AW)M>XL0:"[YM/"! ?2[DNN0<Z4VBW5:[B: ^
MEW&HV//DM9U6M[S1XQL9DQ3":PT%WVR[X$2-[N-7S!S)5B]8Y?HCOD')B_PS
MMH.&!5H1@<MD1&(B+]W)A[U_3_U,#4+4::,I4KH0CE%NF;CN9QE[H]LO(W<F
M?J&]!,54=4>DO<G^T')B9_MG](X4_6/HMB*GVS<N%-[9>7$'V:['\,I]5($/
MI&UCR#@P"K:QPETHZ8$6W6-_S#< Q;U<N=V0<Q*Z&E;E,=(7FVZ\X>]?T_\
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MA.5D?,P(/$=@/PTIBA\(V+YQ@.*)P$^M(G5 N$.8IX>D=^ W,OP$94Y0TIA
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MHG%"7//95TO[N<%B5&56$1I(?%B(&T$6Q_\ )_\ 3?Z^'_D_^F_U\/\ R?\
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M_P"=5[&XWF%#% E1188PO&B:;X(B< 637R'U153C[1DO%?\ F[NW_P"/%/\
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MJ<;UYKS&[7+\VR^UCTN.8Y2QUE6-I8RE7D99#B+;3338DX\\X0,QV0-UTP;
MB0,QS$*K+^I++ZH&LNRYH$E5V%5TI&WG<%P5UYL7&H#3@BD^>@@]9O BJ@,
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M9F7Q[*7B\;8N8T^+/7\:G<ALVK]4W:26"F-5[M@P+JAQ0%=%%^5.WVYNF/\
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MVHFVZV8H0D*HJ*G%.U=#P7J9S/,,3KT!D<#W(X&V\5*"VH*%9$^F?O'(<=@
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MLH 3? E-<>9F0V8$B$*HGX+N-+Z7N/R+\?69WG=8_P#_ 'W^LS,QG&9C)?\
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M[/8QRIDV#-/#<5I]5LKN6RW#BBC;A.27P$1(E1%V/N+/)HV.:[3SG*M@Y7-
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MWJ3Z?X]OG.IG(K/&TS&E\L#V<:GYQ_Z\LLKX+<BL A54NX,5M#99D22(@,2
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MN1P&$M<BM48:=M[=UH)%E( ?99C,Q8L?X:OJ'ZB(UUA7210VX%5P &369)U
MV55-Y+"@QF6AQY=-KZ)(8./:WK/XUYU#A5Y)(&3*@8]@^#X]3XEAV)4]?CV,
M8QCU?&J:.@HZF,W"K:FIK83;,6# @Q61;;;;$1$11$3XEUE?F7A/UN:]]1U'
M?=C?^M77GJ8?0[JZ_%_573[<#9[;E5LELXF6;V&-)ANT+[C//XT'5%7-<A.-
M\XHEY+G-O-<\)@T]+5&H+BOD3-78Y(=VCNM]IMQ6&M983(AR;"HDO-\"C#FU
MY*@4 ."J&T5HCJ<?#7M'APX[$2)$8:C18L9IMB-&C,-BTQ'CL-"+3+#+0H(
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MM,0JZMKH3 -,,- #;38((HB(B?$^LK\R\)^MS7OJ.H[[L;_UJZ\]1L;<T67
M_:E?-)KO1=+-;22EKM/)XDP:JP>A+P&358961I5Y-!PFVWH]<L=#%U]I"L[V
M\L9MO=75A-MK>VLI+TVQM+2QDN3+"QGS)!N2)<V;+>-UUTR(W'"4B5555]/(
M.IS*:DHN?]5%^DRB=EL(W+K].8'*L*7$VF@=17XPY/DKEK9D0\@3()U[G D
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M=W; M5X-7C4X7K7#<8P+$:L5$DK\:Q"EA4%'#Y@!L3*-65[0*2"G,J<>'?\
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M>8U4T:"Y @.BA9*J(ZZGNKE&R9C1F6H\>.TVQ'CL-@TRPRT"-M,LM-H(---
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M)<N%E6Z]ZYS<;"V1F,M)5QD%PZ'L,LCX4"HJ8$<&:^DH*B,@LPX,1IF+%9%
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M'#(C,R55557T\@_WB6TZ$@!&KS7G3/&GM\%-7?,TFS-I10XH2(+2/8W7.*O
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MZYGBN/JO,[*R+'8K0\5H57B<N("?D/>XVGEN88_X)]X6'G*+5U%,;#)<E!M
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M'1!G:QQ"P%2574,;^:RH(X5>"R(CI&9$9F2D1$JD1$2\2(B7BJDJKWKZ.*]
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MJ ZC'Y,1F[P3 [%O HTQ&7&K/9F2$UC.N:XHKR'YR.]F-O#.4 @:C#;><45
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MHDAMV+,BN.,/MN,N&!-6<A:K$^HS7$"KK=WZSCO*VV,YQD([&P\,C2'794C
M,ME-F30$;K]3*YX4@W.5B5+^-9MA=!8^3V#U0V'["\?!HS22QAUQ!?G[7M%
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M;@S3^!='_,_M8N4W6SE$JW;@3#JHMAI.HB0)-D,=PH+$V6QLB4]%B/2D$77
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M-41$4C7T-6VUS7%!SOJ-ES.H3+/&$5D-U>9Q($/6T,'N*NI#_9G454[P"0?
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M8C#:(VQ%B160;; 41! 41/D^*;CT'EPA]'MOZWR[7\^030/'6+DM++K8=W%
MT)!L*&>\U-C'PXMR& -.\4[9OK/-(!568Z[R_)<%RRK(N8JW)<1N9M!>P")1
M%2*':5[K:KP3CR_)Z8F!$!@2$)"JB0D*\1(23@J$BIW+VZ=MY3K(;',Y^$QL
M.V@9R4D34V?K]P\0S.98 IN/17<CLZE;AAMTB<\G8LDJDA(2^NW VK*QU*XI
M9'(K?A<R2\3Q^4CW*HCQ22CWB(7]M#YN*\>/Q#W?8><O=77LQL\EQH'$-^N?
M- :+(\<%TQ:8MV&A1'6E4&IS0(VXHF+3K51EV(V\.]QR]AA.J[2":FQ(8-5$
MA(2076)+#HDV\RX(.LN@0&(F)"GJ%14145%145.**B]RHJ+W*BIVM]S:9J%7
M'55ZQSC!ZYGBN/JO,[*R+'8K0\5H57B<N("?D/>XVGEN88_J:G*,7MIE'D%'
M,:L*JUKW59E0Y3*KRF!<%$P,54'&S0FW6R(#$A)44:&^*'1[8HX8G=T@$C,7
M((K*"V>1XX#A*1QC)4\S&XDY$<+^TV0&OJ?=MEY+$]R8G"E'J_: 1>=^L?/G
M?7%\H1@%DVV$VTE?QS/M/0GB63&3G\5I_)]1[<QB;B><8G-6)8UTM.=B2P?M
MP;>HG!QC6U';1E%Z)+9(F7V20A7Y43\+%)=-HF[C=NQK&,C9&IML-5^*5! ^
MA  BZLFJ<)$%23D45X\544]?E?[E]/?,]AZ>!?GIBWSY!];DVB=L1 @S'0?N
M=;;"B0F9>0ZOS]B(\S3993";D<I<42=\&RKU>9;LJ]QU@C:,FWFLXZ>]WX^=
M'FF&31\&6SS/4>68Y-YGL?S/%+'E1NTQO(H*(ZPX/!QEQ'([X-2F'V6_48OL
M/7^26^'YQA5[69/B>4T,QVON:"_II;4ZLM*Z8RJ.,2HDID3%>]%X<%14545:
M[*7ZC&^J75U9#C[AP:*C4&-D$/G9A0]J81 *0\Z[B5[)<!N8R/$J>S-8[B(R
M[">D^OZROS+PGZW->^HZCONQO_6KKST]*]=6(U)EY8&=#[E>B-(H-L$[9Y#J
MK)9K;2HH_E#]O52I;@KQ4ZV.I)P:%?4:@SC(;8:K5NRI#FE-O//OFQ BX;G\
MJ#&@9#/-.8&H>&9I$JK>0:MN%Y.$^V/!7.9/P%U'W<2P&#E6U:"/H+"P\4V'
MY=KMLW,?R-(4AK\8Q/JM<)>6+)CP)#A)P45X$GI[FZX,MIR8L=DRSTMI^5+8
MY'2P?%["/:;)R"O<)LD>K<AS:+!K ,#$@DX[* A5%%?3Z'_S+WI\^:Q]1T,_
M=CU)^J5?ZW)>NGI3Q+EU%?6!V>_=78Y X-:LO[%YUR5LK%JN!&!F)K2ZE$/O
M2*'=23WO&;3W>^05WJ8N@MZW=A9](VRKUI'9,ER3/>T7F%K(1GZ;4+#LH6X^
M$6DE_FR.$T!$B(D^.*OMOLS:R^H;.ONZ.[KX5O37-1-C655;U5E&:F5UG66,
M-UZ'/KY\-X'67FC-MULQ(2451?BKCSS@-,M ;KKKIBVVTVV*D;CADJ"  **J
MJJHB(G;?N]V+ YV&V&72,1U8'B.%&C:LP5/HQA3L1DR)(GOZMK_>TEL5Y?/6
M+Y)_67T-^=9&0UPNUFMZ.+I/7$EX")LLSS)N+D6>6,0A44:GX]B$6OB+S<4)
MC(#X)Q3BGQ6WV?25Q1,*ZI,0K-K0WFFR&"UGM87T2V36-&0#SSWK"LB7<G@I
MHA7H]Z<>4?3ZA^B[(;+EC7\*'U :RB/R/#:"WJ/=>%;/@10<%1D3;6I?Q^6V
MT!"0LUDISE-.<F_7;'>YB+WA!P>9P4>5 Y,%QROY17BO.*^1YN/=WJJ?T?$?
M=]AYR]U=>S&SR7&@<0WZY\T!HLCQP73%IBW8:%$=:50:G- C;BB8M.M5&78C
M;P[W'+V&$ZKM()J;$A@U42$A)!=8DL.B3;S+@@ZRZ! 8B8D*>H5%1%145%14
MXHJ+W*BHO<J*G:WW-IFH5<=57K'.,'KF>*X^J\SLK(L=BM#Q6A5>)RX@)^0]
M[C:>6YAC^IJ<HQ>VF4>04<QJPJK6O=5F5#E,JO*8%P43 Q50<;-";=;(@,2$
ME11H;XH='MBCAB=W2 2,Q<@BLH+9Y'C@.$I'&,E3S,;B3D1PO[39 :^I]VV7
MDL3W)B<*4>K]H!%YWZQ\^=]<7RA& 63;83;25_',^T]">)9,9.?Q6G\GU'MS
M&)N)YQB<U8EC72TYV)+!^W!MZB<'&-;4=M&47HDMDB9?9)"%?E1/PKJ>=Y<V
M?I)EFU[KQ"<YTE^!L7(<=\PV/.7@@/N#PN7@/$FE+A[7%?7Y7^Y?3WS/8>G@
M7YZ8M\^0?7+6P1J,4ZCM;Q9]EI+9,L/+L>9>;)V;KS-9<>),F2,!RAX14U!L
MWZR<#<MA"%),>5EVK=GXM;X3L' [V?C678K>Q_+6E)=5KRLRHD@!)QIT%5$-
MIYHW&)#)"ZT9MF)KZC!]^Z-R=W%MAX'9>=KI*@4FKMH$@"C7&-9)6>(TW<8U
MD-<XY%FQB(5-EQ5 FW1!P*?<^N7&*/*:PXV/[<UA(GI,O-99TD0),BJDNG'A
M.VF/6C2K(J+0&08GQN8>#<EB5'8]=UE?F7A/UN:]]1U'?=C?^M77GI[DZ<,[
M;8]P;8PBVQH+!Z,DPL>OU 9^)9=$C*XUXMAA^50X=G''F%"?B"B]RKVV%IS9
M%2=%GFL,QR#!LMJS4C"+>8U9R*J?Y5\@;297OO1E<C2!3PY,<P=!5 Q5?4:\
ML<BM"G;AT:U#TEMU)4@W[*SM,4JH88GF\IR092IA9SAQ1)4F22(#EP$]L.*,
MK^ NGGH[H+$G(> 4=CO'8\5EQMR*649AYG%M>0)2":N1[7'\8KK>4H$*<8M^
MR2*O'N]+6>D-<UY6><;5S;'L&QN-RNDP%CD-DQ7A.GFT#A1JJK;>*3,?5.2/
M%9<=)4$%5-1]/6O6N3$=18)0X5623C,195R]5PP&VR6S9C?B$NLJNCD64XA[
MG)DMTOZ?3Z'_ ,R]Z?/FL?4=#/W8]2?JE7^MLZ&^K*^[H[NOFU%S36\*-955
MO5649V'8UEG73&GH<^OGPWC:>9= VW6S(2%154[2M^Z*I+"SZ1ME7KJM1HS<
MF>]HO,+60KWT)OGVHHMQ\(M)+_+CDUTR)$18$@E?;8>F^IQGH7ZK<NY-37<U
MJJT%M+);'@SK"[FF@1M;99<6D\&(6M[9Y$"H?5.6FG.^ :^1> H'Q3<,VGLA
M@[$WE'7I_P!=BU(1B>U,V)76,?,+N(3:K*CNX]KN);2&)+:)X%AY5.<"<!?1
MZ=]56M<==G-SBH;3V<S(!&Y[.?[/4<LM:BR$6V@\[B-?.B4:\$5.2K'VC7VR
M^*IN:E@%*S/I5S:OSULV(Y29C^NLR>@X7L2N8$23P8\=^3474EU>*!&I#XIP
M553T^GGJ,9D2&:C7^PZOZ;-11\1Z=K?) ?Q39%>VRHN ](E81=ST8XB7))\,
MT]H15(L^!*CS8,V.S+AS(CS<F)+B26Q>CRHLADC9D1Y#)H8&"J)BJ*BJB^N9
MDDCB);ZZQ:Q!3Y>4A:G7U2JM<$X^'SU:HO'OYT+^CA\2]WV'G+W5U[,;/)<:
M!Q#?KGS0&BR/'!=,6F+=AH41UI5!J<T"-N*)BTZU49=B-O#O<<O883JNT@FI
ML2&#51(2$D%UB2PZ)-O,N"#K+H$!B)B0IZA45$5%145%3BBHO<J*B]RHJ=K?
M<VF:A5QU5>L<XP>N9XKCZKS.RLBQV*T/%:%5XG+B GY#WN-IY;F&/ZFIRC%[
M:91Y!1S&K"JM:]U694.4RJ\I@7!1,#%5!QLT)MULB Q(25%&AOBAT>V*.&)W
M=(!(S%R"*R@MGD>. X2D<8R5/,QN).1'"_M-D!KZGW;9>2Q/<F)PI1ZOV@$7
MG?K'SYWUQ?*$8!9-MA-M)7\<S[3T)XEDQDY_%:?R?4>W,8FXGG&)S5B6-=+3
MG8DL'[<&WJ)P<8UM1VT91>B2V2)E]DD(5^5$_"G2[7BVVTDC$LEOE%IUUX5+
M*=B9CDYN*;RJ:..G;J9@GL-F2B/LHGQ#*_W+Z>^9[#T\"_/3%OGR#Z^7U(:
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M.4S)8BY#B]U'C65;()L_+3XC+J(J@G;:73CM2&3&6:RR:53^\ CN1Z_**%Y
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M)=$ %.\B)$3MT]].$1J.$W6>N:B!E+L7P?+S\^N5?R78EHR3"DV;5KG-U82
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MU) 8B8&*B0DB$)"2<"$A7BBBJ+P5%[%N/4U ;'2SO^]M+'%&:^+RUNJ=AO\
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MN>L>YDH'-61E.NCGP<FN2?5]#_YE[T^?-8^HZ&?NQZD_5*O^*9=U\]*6*_\
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M)5557BOHUE%15EA=7EU80JFFIJF%)LK6VM;*2W#KJRLKH;;TN?83Y;P-,LM
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MD3QU9;\W">!ZNL : 9+#O(VH2;+*:U_973]:6:1,,WWBU5+''72E.&E=0YY
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MNM\M8[R-K-<S=D9GF#!ND(N/)"R._DL-D2(O@M B(B(@I\1RO]R^GOF>P]/
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M.-HY'=< 'CI:1AAJOKD(07RD87#!'7757XOE?[E]/?,]A\'_ .(6:?HM>?\
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M)$^#K*_,O"?K<U[\'5O^^C"/U'>]3U<?><WW]:F5]NC7\],U^J38/P] _P!
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M\J)\0B0;Z'-BZ,UL[79'MZ^:61&&=#)\CJ, JYK/*;=[F;L5QM3 P.+7LR9
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M-*0#'@!_57B ZYV]@TP8&9ZNSG%-A8I,-")J/D.'7D'(*=Q]L# G8Z3Z]OQ
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M2:^[:%_?1J[]>*+MK_K-PVF&1F73M9-X9LM^(P*S+'3.=6C3-782W!0Y,IK
M=ARF? : 4!J-D,^0X2 UW=M>MY'<>\MM=/OEM';,25)!ZUGAB];%^@.6RQ5!
ME/ADV#G$%V6XBK*M(4[VS(#7U"Z%Q6U\ILOJVL)N"$$:0#<VMU#1!#G[1L5
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M6M,3X. D%!-!)%%/7T/WG-6_JEL[X-R_?0V)]1W3KZKK*_,O"?K<U[\'5O\
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M*[JB&3R<>851O^@OB>R=QYS,\AANJ\$RO8642T[W&J+#Z.=?V?@ B*3THXD
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MZG/X6XE_,[L#\/!NK"^=)X6BAU.LM<LR&P('#6297FY*:(K($""J"Z3G,:<
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MXG@=[L"[9)MMI":N\VM;"6'%%) >1%553BOPYIK?-*UJYP[8.)Y'A&65#_\
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MV7 -GV5A/Z3=R74&/L:N%9,W]F>4/ Q6UVWL?KF_$,O),-M1KZ.P*O3JIL3
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MASUG5U>1!A^O\2>B3\VS&50VS,ZMD'/DOPZ6$$QA6W?/27FE5R$O#_/IA?\
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MY NV+^OIP%DNK+5UD37P*V-339-!$[AY@QTNY512+X=-?<OUW]>/45\'2/\
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MG,<(C1C!"=9]]7=,W6OD"*2Q)KH\%0E17&7FS:=:,FW6G!('&W )1-MP"1"
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MJSU@V;K\5,4;C8QMVHB<2-&KK75M8N,7ALH0M Y13[&1))"<*'&'V$E8CM#
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M\@HYC5A56M>ZK,J'*95>4P+@HF!BJ@XV:$VZV1 8D)*BC0WQ0Z/;%'#$[ND
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M/+4P)2JA>40'6VG%+PU!M0:#_/\ _P#V5?\ B1V_S_\ _P!E7_B1V_S_ /\
M]E7_ (D=O\__ /\ 95_XD=O\_P#_ /95_P")';_/_P#_ &5?^)';_/\ _P#V
M5?\ B1V_S_\ _P!E7_B1V_S_ /\ ]E7_ (D=JG*,7ZE)E'D%',:L*JUK]7JS
M*ARF57E,"_:.HF!BJ@XV:$VZV1 8D)*BUD7(+.'=7<>%'9M;>!5'1P[*<VV(
MR)L>H.QMRKFY)HI>#YEY X\$)4X>J@5.4ROH+L[%^[ ]NU5*Q<7%!%>?1Z?1
M7%44^G^E&+3N8S\DY,CDQ)5'F'6B5U'?MI_ZN7_CQV^VG_JY?^/';[:?^KE_
MX\=OMI_ZN7_CQV^VG_JY?^/';[:?^KE_X\=OMI_ZN7_CQV9*7UG//Q1<%7V8
MW3T$5]QI%]L&9+N[YC;#A#\A$TXB+_97Y.WVL\I_A%4_]O\ M]K/*?X15/\
MV_[3=36?4/=;NUU%=&1@]-DV$L4%C@!NNNNV-=273&57;CV-SW'/%2O<:Y(T
.CF-@VT<= _\ ]Q]__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">169 Saxony Rd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,043,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Document Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 3,771,024<span></span>
</td>
<td class="nump">$ 3,792,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">20,334,831<span></span>
</td>
<td class="nump">22,999,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="nump">941,542<span></span>
</td>
<td class="nump">2,042,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Collaboration Receivables</a></td>
<td class="nump">1,337,604<span></span>
</td>
<td class="nump">601,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Tax Receivables</a></td>
<td class="nump">722,290<span></span>
</td>
<td class="nump">270,246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">27,107,291<span></span>
</td>
<td class="nump">29,706,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, Net</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="nump">5,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted Cash</a></td>
<td class="nump">4,081<span></span>
</td>
<td class="nump">4,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets and In-Process R&amp;D, Net</a></td>
<td class="nump">6,687,100<span></span>
</td>
<td class="nump">6,687,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease Right-of-Use Assets</a></td>
<td class="nump">152,083<span></span>
</td>
<td class="nump">57,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">64,323<span></span>
</td>
<td class="nump">24,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">34,019,862<span></span>
</td>
<td class="nump">36,484,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="nump">942,492<span></span>
</td>
<td class="nump">415,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
<td class="nump">3,522,003<span></span>
</td>
<td class="nump">4,588,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CollaborationCreditReceivableCurrent', window );">Accrued Collaboration Credit</a></td>
<td class="nump">738,584<span></span>
</td>
<td class="nump">981,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease Liabilities</a></td>
<td class="nump">71,554<span></span>
</td>
<td class="nump">23,355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">5,274,633<span></span>
</td>
<td class="nump">6,008,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent Consideration</a></td>
<td class="nump">4,466,682<span></span>
</td>
<td class="nump">4,191,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Tax Liability</a></td>
<td class="nump">490,690<span></span>
</td>
<td class="nump">490,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-Current Operating Lease Liabilities</a></td>
<td class="nump">87,470<span></span>
</td>
<td class="nump">33,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-Current Liabilities</a></td>
<td class="nump">5,044,842<span></span>
</td>
<td class="nump">4,715,995<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">10,319,475<span></span>
</td>
<td class="nump">10,724,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.01 Par Value: 150,000,000 shares authorized; 3,000,788 shares issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">267,679<span></span>
</td>
<td class="nump">267,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-In Capital</a></td>
<td class="nump">169,304,991<span></span>
</td>
<td class="nump">169,156,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(145,575,102)<span></span>
</td>
<td class="num">(143,382,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="num">(297,185)<span></span>
</td>
<td class="num">(282,159)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">23,700,387<span></span>
</td>
<td class="nump">25,759,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 34,019,862<span></span>
</td>
<td class="nump">$ 36,484,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CollaborationCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Credit Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CollaborationCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">3,000,788<span></span>
</td>
<td class="nump">3,000,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">3,000,788<span></span>
</td>
<td class="nump">3,000,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock designated shares (in shares)</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock designated shares (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock designated shares (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock designated shares (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock designated shares (in shares)</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PreferredStockDesignatedShares', window );">Preferred stock designated shares (in shares)</a></td>
<td class="nump">3,908<span></span>
</td>
<td class="nump">3,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PreferredStockDesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of designated preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PreferredStockDesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">1,489,398<span></span>
</td>
<td class="nump">1,296,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">2,531,887<span></span>
</td>
<td class="nump">1,684,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CollaborationCreditOperatingExpense', window );">Collaboration and Research Credits</a></td>
<td class="num">(1,966,123)<span></span>
</td>
<td class="num">(190,553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="nump">275,192<span></span>
</td>
<td class="num">(12,194)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">2,330,354<span></span>
</td>
<td class="nump">2,777,906<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (Loss) Income</a></td>
<td class="num">(2,330,354)<span></span>
</td>
<td class="nump">13,222,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense), Net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income, Net</a></td>
<td class="nump">276,633<span></span>
</td>
<td class="nump">223,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (Expense) Income, Net</a></td>
<td class="num">(16,253)<span></span>
</td>
<td class="nump">8,066<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income, Net</a></td>
<td class="nump">260,380<span></span>
</td>
<td class="nump">231,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) Income Before Income Tax Expense</a></td>
<td class="num">(2,069,974)<span></span>
</td>
<td class="nump">13,453,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense</a></td>
<td class="num">(123,006)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Income</a></td>
<td class="num">(2,192,980)<span></span>
</td>
<td class="nump">13,453,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net (Loss) Income Attributable to Common Shareholders</a></td>
<td class="num">(2,192,980)<span></span>
</td>
<td class="nump">13,453,207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted', window );">Net (Loss) Income Attributable to Common Shareholders</a></td>
<td class="num">$ (2,192,980)<span></span>
</td>
<td class="nump">$ 13,453,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (Loss) Income per Common Share - Basic (in usd per share)</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding - Basic (in shares)</a></td>
<td class="nump">4,217,007<span></span>
</td>
<td class="nump">2,881,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (Loss) Income per Common Share - Diluted (in usd per share)</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding - Diluted (in shares)</a></td>
<td class="nump">4,217,007<span></span>
</td>
<td class="nump">3,891,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Other Comprehensive (Loss) Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Income</a></td>
<td class="num">$ (2,192,980)<span></span>
</td>
<td class="nump">$ 13,453,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Marketable Securities</a></td>
<td class="num">(16,099)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency Translation Adjustments</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="num">(81,573)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive (Loss) Income</a></td>
<td class="num">$ (2,208,007)<span></span>
</td>
<td class="nump">$ 13,371,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CollaborationCreditOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Credit, Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CollaborationCreditOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Private Placement</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Private Placement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Private Placement</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">856,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 6,109,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 77,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,192,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (146,976,855)<span></span>
</td>
<td class="num">$ (182,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-Based Compensation</a></td>
<td class="nump">175,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign Currency Translation Adjustment</a></td>
<td class="num">(81,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Income</a></td>
<td class="nump">13,453,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,453,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,674,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,516,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of Common Stock from Warrant Exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of Common Stock from Warrant Exercises</a></td>
<td class="nump">184,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">2,917,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">21,515,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 262,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,041,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133,523,648)<span></span>
</td>
<td class="num">(264,374)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">3,000,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">25,759,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 267,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,156,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,382,122)<span></span>
</td>
<td class="num">(282,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-Based Compensation</a></td>
<td class="nump">148,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized Loss on Marketable Securities</a></td>
<td class="num">(16,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,099)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Income</a></td>
<td class="num">(2,192,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,192,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">3,000,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 23,700,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 267,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,304,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (145,575,102)<span></span>
</td>
<td class="num">$ (297,185)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Income</a></td>
<td class="num">$ (2,192,980)<span></span>
</td>
<td class="nump">$ 13,453,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net (Loss) Income to Net Cash (Used in) Provided by Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization of Intangible Assets</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">4,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncreaseDecreaseInRightOfUseAssets', window );">Reduction of Operating Lease Right-of-Use Assets</a></td>
<td class="nump">19,290<span></span>
</td>
<td class="nump">11,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-Based Compensation</a></td>
<td class="nump">148,616<span></span>
</td>
<td class="nump">175,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="nump">275,192<span></span>
</td>
<td class="num">(12,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents', window );">Investment Income and Fair Value Adjustments on Marketable Securities and Cash Equivalents</a></td>
<td class="num">(23,953)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Operating Assets and Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="nump">454,932<span></span>
</td>
<td class="nump">12,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Collaboration Receivables</a></td>
<td class="num">(736,407)<span></span>
</td>
<td class="num">(189,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncreaseDecreaseResearchTaxCreditsReceivables', window );">Research Credit Receivables</a></td>
<td class="num">(668,916)<span></span>
</td>
<td class="nump">165,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Tax Receivables</a></td>
<td class="nump">225,794<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other Assets</a></td>
<td class="num">(39,226)<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts Payable</a></td>
<td class="nump">1,171,627<span></span>
</td>
<td class="nump">124,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="num">(1,084,242)<span></span>
</td>
<td class="num">(124,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_IncreaseDecreaseInAccruedCollaborationCredit', window );">Accrued Collaboration Credit</a></td>
<td class="num">(241,894)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating Lease Liabilities</a></td>
<td class="num">(12,350)<span></span>
</td>
<td class="num">(11,343)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash (Used in) Provided by Operating Activities</a></td>
<td class="num">(2,704,199)<span></span>
</td>
<td class="nump">13,624,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of Marketable Securities</a></td>
<td class="num">(3,619,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of Marketable Securities</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of Marketable Securities</a></td>
<td class="nump">6,212,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by Investing Activities</a></td>
<td class="nump">2,672,782<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross Proceeds from Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,438,817<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,247,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">10,143<span></span>
</td>
<td class="num">(51,024)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(21,274)<span></span>
</td>
<td class="nump">28,821,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash, Beginning of Period</a></td>
<td class="nump">3,796,379<span></span>
</td>
<td class="nump">2,458,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash, End of Period</a></td>
<td class="nump">3,775,105<span></span>
</td>
<td class="nump">31,280,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Noncash Operating and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Creation of Right-of-Use Assets and Related Lease Liabilities</a></td>
<td class="nump">114,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_EquityLineOfCreditMember', window );">Equity Line Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance Costs for Private Placement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,191,185)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment and Investment Income of Marketable Securities and Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IncreaseDecreaseInAccruedCollaborationCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Collaboration Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IncreaseDecreaseInAccruedCollaborationCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IncreaseDecreaseInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents increase decrease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IncreaseDecreaseInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_IncreaseDecreaseResearchTaxCreditsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Research Tax Credits Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_IncreaseDecreaseResearchTaxCreditsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kprx_EquityLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kprx_EquityLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Presentation and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business, Presentation and Recent Accounting Pronouncements</a></td>
<td class="text">Business, Presentation and Recent Accounting Pronouncements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals, Inc. (&#8220;Kiora&#8221; or the &#8220;Company&#8221;) was formed as a Delaware corporation on December 28, 2004. Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, Kiora has devoted substantially all its efforts to business planning, research and development, and raising capital.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company&#8217;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes previously included in the Company&#8217;s 2024 Annual Report on Form 10-K dated March 25, 2025. The balance sheet as of December&#160;31, 2024 was derived from audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Accounting Standards</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for us beginning in fiscal year 2025 for the annual reporting period ending December 31, 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company adopted ASU 2023-09 on January 1, 2025. The adoption of ASU 2023-09 did not have a material effect on the condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The guidance in ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying any relevant income statement expense captions. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. Upon adoption, ASU 2024-03 may be applied prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of ASU 2024-03 may have on its disclosures in its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, the Company had unrestricted Cash and Cash Equivalents of $3.8 million and Short-term Investments of $20.3 million, and an Accumulated Deficit of $145.6 million. Kiora has incurred annual losses and negative cash flows since inception, and future losses are anticipated. However, Management believes that the Company's capital resources as of March&#160;31, 2025 will be sufficient to fund the Company's planned operations for at least 12 months after the date that these unaudited condensed consolidated financial statements are issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, savings accounts, money market funds, and marketable securities with maturities of 3 months or less when acquired. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Short-Term Investments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term investments primarily consist of treasuries, corporate debt securities, and government and agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive (loss) income as a component of stockholders' equity until realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Allowance for Credit Losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive (loss) income on the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on investment securities is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with FASB&#8217;s ASC 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s balance sheet. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as deferred revenue, net of current portion. As of March&#160;31, 2025 and 2024, the Company did not have a deferred revenue balance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within the Company's or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company's estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a strategic development and commercialization agreement ("License Agreement") with Th&#233;a Open Innovation ("TOI"), a sister company of the global ophthalmic specialty company Laboratoires Th&#233;a ("Th&#233;a"). Under the agreement, the Company granted TOI exclusive worldwide development and commercialization rights, excluding certain countries in Asia, to KIO-301 for the treatment of degenerative retinal diseases (the "License"). The Company concluded that the Licensing Agreement contains one material performance obligation, the License. The transaction price includes the upfront, non-refundable payment of $16.0&#160;million (the "License Access Fee"). The Company did not include any development or </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regulatory milestones in the transaction price because it is probable that changes in the estimate of receiving those milestones would result in significant reversals of cumulative revenue in future periods, due to the inherent risks and uncertainties in the drug development process. The sales-based milestones and royalties are not included in the transaction price per ASC 606-10-32-11 and ASC 606-10-55-65. There is no financing component in the License Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The initial transaction price will be allocated to the one performance obligation identified (i.e., the License), which was transferred to TOI at the execution of the License Agreement and the entire $16.0&#160;million transaction price was recognized in the first quarter of 2024 upon the satisfaction of the license performance obligations. Variable components of consideration related to development and regulatory milestones, commercial milestones, and royalties will be allocated to the transaction price if and when they occur. When it is probable that including milestones in the transaction price will not result in significant reversals of cumulative revenue in future periods, the Company will recognize the revenue for the milestones immediately since the license performance obligation to which the milestones relate has already been fully satisfied when the change in estimate of the variable consideration occurs. Since the reimbursement for the development activities clearly relates to those activities and are accounted for under ASC 808, the Company will recognize those amounts that are due from TOI as contra-R&amp;D expense.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The License Access Fee was earned at a point in time (first quarter of 2024) and, as a result, the associated contract costs specifically, sublicense fees, were expensed at the same point in time (first quarter of 2024). All further revenue sources that may lead to sublicense fee payments will not be recognized until earned. As such, sublicense fees will be expensed in the same period as the revenue of the respective milestone or royalties are earned. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 8 to the condensed consolidated financial statements for additional information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into a research agreement that falls under the scope of ASC 808, Collaborative Arrangements. Reimbursements from a collaboration partner are recorded as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income. Similarly, amounts that are owed to a collaboration partner are recognized as research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset at least annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. The Company performed an annual evaluation of its indefinite-lived intangible assets for impairment as of August 31, 2024 with a quantitative analysis using the Income Approach. At March&#160;31, 2025 and December&#160;31, 2024, there was $6.7 million of in-process R&amp;D as part of intangible assets and in-process R&amp;D, net on the condensed consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s process of preparing the condensed consolidated financial statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segment and Geographical Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment and three geographic areas. The Company's singular focus is developing innovative ophthalmic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refunds for Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company through its subsidiaries, Kiora Pharmaceuticals GmbH and Kiora Pharmaceuticals Pty Ltd., is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the eligible incurred research and development expenses. Following the approval of a research finding by the tax authority, the Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. In situations where a new research application has not yet been approved by the tax authority, the Company records the tax receivable and reduction of expense in the period following approval. As of March&#160;31, 2025 and December&#160;31, 2024, the Company has a research and development tax receivable of $0.7&#160;million and $0.3&#160;million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2024, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to effect a one-for-nine ("1-for-9") reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#8217;s stockholders at the Company&#8217;s 2024 Annual Meeting of Stockholders held on May 1, 2024, and by the Company&#8217;s board of directors. The amendment became effective on June&#160;11, 2024, the effective date of the reverse stock split.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reverse stock split proportionally adjusted all shares of the Company&#8217;s common stock outstanding and shares of common stock underlying outstanding options and warrants immediately prior to the effective date of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all warrants, stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective date of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such warrants, stock options, and restricted stock awards, and, in the case of warrants and stock options, a proportionate increase in the exercise price of all such warrants and stock options. In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plans immediately prior to the effective date of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#8217;s Restated Certificate of Incorporation, which remained at 150,000,000 shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the reverse stock split results in stockholders owning fractional shares). As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock as of June&#160;11, 2024 decreased from 26,735,116 (pre-split) shares to 2,970,545 (post-split) shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">presented reflecting the split. The Company&#8217;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on June&#160;11, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Information</a></td>
<td class="text">Balance Sheet Information <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of cash and cash equivalents and restricted cash is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,792,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Cash, Non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current restricted cash consists of deposits with financial institutions for corporate credit cards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes short-term investments as of March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,295,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,303,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,405,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,321,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,104)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,517,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,540,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,970,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's short-term investments at March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,877,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,889,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,321,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,659,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,688,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,970,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the Company's available-for-sale investments' gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:60.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.536%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Count</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,104)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:60.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.536%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Count</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its investments each quarter to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. The unrealized losses in the Company&#8217;s investments were caused by changes in interest rates resulting from changing economic conditions, and not from a decline in credit of their underlying issuers. The Company may be required to sell these investments prior to maturity to implement management strategies, however, it is not likely that the Company will sell these investments before recovery of their amortized cost basis. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Prepaid Expenses and Other Current Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax and Other Receivables</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax and other receivables consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research Tax Credits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tax Receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Receivables</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and Benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text">Fair Value Disclosures<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Equivalents Measured at Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,970,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,303,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,303,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,305,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,509,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Equivalents Measured at Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,540,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,540,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,254,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,691,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with historical acquisitions, additional consideration may be owed by the Company related to the achievement of certain milestones and such contingent consideration payments are required by U.S. GAAP to be presented at fair value. The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Contingent Consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific milestones. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48% - 77%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42% - 77%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30% - 33%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30% - 33%</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the above table is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. The change in fair value of contingent consideration of $0.3 million for the three months ended March&#160;31, 2025, was primarily driven by a decrease in the discount rate. The change in fair value of contingent consideration of $12.2 thousand for the three months ended March&#160;31, 2024 was primarily driven by an increase in the discount rate. The change in fair value of contingent consideration is recorded within operating expenses on the accompanying condensed consolidated statements of operations and comprehensive (loss) income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use at estimated fair value. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 350 allows an entity to first assess qualitative factors to determine whether events and circumstances indicate that it is more likely than not (that is, a likelihood of more than 50 percent) that an indefinite-lived intangible asset is impaired. If it is more likely than not that the asset is impaired, the entity must calculate the fair value of the asset and record an impairment charge if the carrying amount exceeds fair value. If an entity concludes that there is a less than 50 percent likelihood that the asset is impaired, no further action is required. An indefinite-lived intangible asset should be tested for impairment if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If such events or changes have occurred, a quantitative assessment is required.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity bypasses the qualitative assessment or determines from its qualitative assessment that an indefinite-lived intangible asset is more likely than not impaired, a quantitative impairment test should be performed. The quantitative impairment test compares the fair value of an indefinite-lived intangible asset with the asset&#8217;s carrying amount. If the fair value of the indefinite-lived intangible asset is less than the carrying amount, an impairment loss should be recognized in an amount equal to the difference in accordance with ASC 350-30-35-19.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values in-process R&amp;D related to asset acquisitions using the Income Approach which measures the value of an asset by the present value of its future economic benefits. These benefits can include interest and principal payments, earnings, cost savings, tax deductions, or proceeds from its disposition. Value indications are developed by discounting expected cash flows at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation, and risks associated with the particular investment. The selected discount rate is generally based on rates of return available from alternative investments of similar type and quality.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company engaged a third-party valuation firm to complete a quantitative assessment of in-process R&amp;D as of August 31, 2024, which includes the following unobservable Level 3 inputs:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:12.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-104</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Period Excess Earnings Method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for next development phase</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17% to 36%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Period Excess Earnings Method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for next development phase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23% to 43%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company assessed qualitative factors to determine whether events and circumstances indicate impairment, and concluded that it is not more likely than not that any assets are impaired.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text">Capital Stock<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts of shares of common stock in the transactions described below have been adjusted to reflect post Amendment adjusted shares of common stock of the Company. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") where the Company's stockholders voted to approve various proposals including (i) adoption of a new Equity Incentive Plan, the "2024 Equity Incentive Plan", (ii) an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to 150,000,000, which the Company filed with the Secretary of State for the State of Delaware on May 1, 2024 and (iii) the approval, as contemplated by Nasdaq Listing Rule 5635, of the issuance of up to 5,486,066 shares of Common Stock upon the exercise of Tranche A Warrants and Tranche B Warrants issued in the private placement that closed on February 5, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2024, the Company entered into a private placement agreement with Maxim Group LLC serving as placement agent for 1,755,556 shares of common stock, pre-funded warrants to purchase up to 1,261,582 shares of common stock, and accompanying Tranche A and Tranche B warrants to purchase up to an aggregate of 5,486,066 shares of common stock. The total net proceeds from the private placement were approximately $13.8 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tranche A warrants are exercisable for up to 2,743,033 shares of common stock at an exercise price of $5.4684 per share for an aggregate of up to approximately $15.0 million and will expire at the earlier of (i) 30 days following the announcement of full data (expected in 2026) from the Company's Phase 2 clinical trial (ABACUS-2) of KIO-301 in patients with retinitis pigmentosa and the daily Volume Weighted Average Price "VWAP" of the Company's common stock equaling or exceeding $9.9432 per share for 30 consecutive trading days following the announcement and (ii) five years from the date of shareholder approval of the warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tranche B warrants are exercisable for up to 2,743,033 shares of common stock at an exercise price of $5.4684 per share for an aggregate of up to approximately $15.0 million and will expire at the earlier of (i) 30 days following the announcement of topline data (expected in 2026) from the planned Phase 2 trial of KIO-104 in retinal inflammation and the daily VWAP of the Company's common stock equaling or exceeding $12.4290 per share for 30 consecutive trading days following the announcement and (ii) five years from the date of shareholder approval of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity for the Company&#8217;s equity-classified warrants for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common Shares<br/>Issuable Upon Exercise<br/>of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389,523</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389,454</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.81</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Basic and Diluted<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income per Share - Basic and Diluted</a></td>
<td class="text">Net (Loss) Income per Share - Basic and Diluted<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net (loss) income per share is computed by dividing net (loss) income available to common shareholders by the weighted-average number of common shares outstanding for the time period, which for basic net (loss) income per share, does not include the weighted-average unvested restricted common stock that has been issued and is subject to forfeiture totaling 45,363 and 24,094 shares for the three months ended March&#160;31, 2025 and 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net (loss) income per share as their effect would be anti-dilutive. The following is a summary of potentially dilutive securities excluded from the calculation of diluted net (loss) income per share as of March&#160;31, 2025 and 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Warrants, Excluding Pre-funded Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,872</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661,699</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,276</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,338</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,363</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,094</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, as Converted into Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,426</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Reserved for Future Issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,846</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947,783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872,252</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors (the "Board") adopted the 2014 Equity Incentive Plan (the "2014 Plan") and the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and the Company's Stockholders approved the 2014 Plan and ESPP in February 2015. The Board subsequently adopted the 2024 Equity Incentive Plan (the "2024 Plan") and the Company's Stockholders approved the Plan in May 2024. Following adoption of the 2024 Plan, no further grants were made under the 2014 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the 2014 Plan, the 2024 Plan provides for the granting of stock options (incentive and nonqualified), restricted stock or other stock-based awards to employees, officers, directors, consultants, and advisors. The Board is responsible for administration of the 2024 Plan. The Company&#8217;s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company&#8217;s voting stock) and with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more than 10% of the Company&#8217;s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant, or director at an exercise price per share of not less than the par value per share. In January 2025, the number of shares of common stock issuable under the 2024 Plan automatically increased by 120,031 shares pursuant to the terms of the 2024 Plan. As of March&#160;31, 2025, the maximum number of shares of Common Stock that may be issued pursuant to the 2024 Plan was 853,133 of which 570,846 shares were available for awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is presented in the same expense line items as cash compensation paid and for the three months ended March&#160;31, 2025 and 2024 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"></td><td style="width:68.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stock-Based Compensation Expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants time-based stock options which generally vest one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period. The fair value of time-based stock options is determined using the Black-Scholes Option Pricing Model, with such value recognized as expense over the service period, which is typically three years, net of actual forfeitures. There were no grants made during the three months ended March&#160;31, 2025 and 2024, and therefore no assumptions used to determine the fair value.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.689%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options outstanding as of March&#160;31, 2025 was $6.77. The expected term of the options granted is based on management's estimate. Expected volatility is based on the historical volatility of the Company&#8217;s common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized compensation expense related to the options amounted to $0.4 million as of March&#160;31, 2025 and is expected to be recognized over a weighted average period of approximately 3.44 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of stock option activity for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,303</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,276</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and vested at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,397</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.28</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options outstanding and exercisable as of March&#160;31, 2025 had no aggregate intrinsic value. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#8217;s common stock for options that had exercise prices lower than $3.01, the closing price of the Company&#8217;s stock on March&#160;31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock compensation expense is recognized over the vesting period, which is typically one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period. Unamortized compensation expense related to the restricted stock awards amounted to $0.2 million as of March&#160;31, 2025 and is expected to be recognized over a weighted average period of approximately 3.53 years. The following is a summary of restricted stock activity for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,697</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,363</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-qualified ESPP, which provides for the issuance of shares of the Company&#8217;s common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of common stock through payroll deductions at a discounted price. Six month offering periods are made at the Board&#8217;s discretion. The ESPP provides for 32 aggregate shares of the Company&#8217;s common stock for participants to purchase. As of March&#160;31, 2025 and 2024, the remaining shares reserved for future offerings was 23. Subsequent to the reporting period, in May 2025 the Company terminated the ESPP (Note 10).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to five real property operating leases for the rental of office and clinical trial space. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into an 18-month lease for an office facility in Encinitas, California (the "Encinitas Lease"), which is now used for its corporate headquarters. The Encinitas Lease commenced in May 2022 and was amended to extend its lease term through April 30, 2025. The Company recorded a right-of use ("ROU") asset and lease liability upon lease commencement and lease amendment in May 2022 and November 2023, respectively. Monthly rent payments are approximately $3.3 thousand, and the security deposit is $12 thousand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into a 12-month lease for office space in Adelaide, Australia (the "Adelaide Lease") which expired in May 2023. Following expiration, the landlord agreed to extend the Adelaide Lease on a month-month basis, whereby the Company must provide 90-day notice of termination. The Adelaide Lease is a short-term lease which is exempt for ROU asset and lease liability reporting. Monthly rent payments are approximately A$2.2 thousand. The Adelaide lease is being used was a clinical trial site for ABACUS-2, with rent costs fully reimbursed by TOI.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into a lease for 910 square feet of office space in Vienna, Austria (the "Vienna Lease"). The Vienna Lease commenced on October 15, 2023 with a term of 5 years through October 14, 2028. The Company recorded a ROU asset and lease liability upon lease commencement in October 2023. Monthly rent payments are approximately &#8364;1.3 thousand, and the security deposit is &#8364;4.5 thousand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company entered into a lease in Perth, Australia (the "Perth Lease") and another in Brisbane, Australia (the "Brisbane Lease"). Both leases commenced in February 2025, at which time the Company recorded a ROU asset and lease liability, with a term of 2 years through January 2027. Monthly rent payments are approximately A$8.9 thousand, and the total security deposit is A$44.0 thousand. The Company has rent abatement for the first 2 months of the Brisbane Lease and for the first 3 months of the Perth Lease. The Brisbane and Perth leases are for ABACUS-2 clinical trial sites, with rent costs fully reimbursed by TOI. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company entered into a new lease in Encinitas, California (the "New Encinitas Lease"). The New Encinitas Lease will commence in June 2025 with a term of 3 years and 3 months through August 31, 2028. Monthly rent payments will be approximately $8.4 thousand per month and will increase by approximately 4% each year on the anniversary of the commencement, starting in 2026. The Company has rent abatement for the first 2 months of the lease and maintains a security deposit of $9.4 thousand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense, consisting of the reduction of the right-of-use asset and the imputed interest on the lease liability, totaled $13,845 and $20,231 for the three months ended March&#160;31, 2025 and 2024, respectively.The remaining lease terms range from less than 30 days to 3.5 years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leases is as follows as of March&#160;31, 2025:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Discount Rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under non-cancellable operating leases as of March&#160;31, 2025 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (remaining months)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Amounts Representing Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Current Portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Exclusive Rights Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to six license agreements as previously disclosed in Note 12 to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes to the terms of these agreements during the three months ended March&#160;31, 2025. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Funding</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company received grant funding of $20,000 from the Choroideremia Research Foundation in support of validating functional vision assessments for patients with profound blindness. This grant funding will aid in further validation of a suite of tests expected to be used in the upcoming ABACUS-2 Phase 2 clinical trial assessing KIO-301.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of various acquisitions in prior periods included contingent consideration, which consisted of various cash earn-out payments upon the achievement of certain milestones. Below are the maximum obligation payments per the respective agreements and estimated fair value of contingent consideration payments remaining as of March&#160;31, 2025.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Obligation<br/>per Agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Fair<br/>Value Estimated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,135,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,635,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Line Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company entered into a credit line with UBS (the &#8220;Credit Line&#8221;) providing for a $10.0&#160;million revolving line of credit. The Credit Line bears interest at the 30-day Secured Overnight Financing Rate ("SOFR") average, plus 1.5%. The SOFR rate is variable. The Credit Line is secured by a first priority lien and security interest in the Company&#8217;s marketable securities held in its managed investment accounts with UBS. As of March&#160;31, 2025 the line was unused.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, as well as governmental proceedings and investigations that are incidental to the business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in and reports as a single reportable segment, focused on the development of innovative ophthalmic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Operating Decision Maker "CODM" is our President and Chief Executive Officer. The CODM does not evaluate profitability nor evaluate performance or allocate resources below the level of the consolidated Company. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM reviews operating expenses and net (loss) income presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. These metrics serve as benchmarks to evaluate the business, measure performance, identify trends, prepare financial projections, and make strategic decisions. The CODM does not evaluate performance or allocate resources based on segment assets data; therefore, total segment assets are not presented. As part of the adoption of ASU 2023-07, the comparative prior period segment information has been disclosed herein to align with the current year&#8217;s presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue, significant expenses, and net (loss) income for the Company&#8217;s single reportable segment:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Less: Significant and Other Segment Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,489,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,296,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-101</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-104<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">1</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(149,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-201</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,101,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,018,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301 Collaboration Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,966,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(190,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Research and Development Expenses<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">2</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">576,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">622,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">275,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest Income, Net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(277,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(223,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Segment Expenses<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">3</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">123,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net (Loss) Income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(2,192,980)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">13,453,207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, the Company and D&#244;mes Pharma, successor to SentrX Animal Care Inc., agreed to terminate the license agreement dated June 7, 2023 given the Company's decision to cease continued development of KIO-201 in combination with an antibiotic, and thereby to cease continued maintenance of all related licensed IP. D&#244;mes Pharma elected not to resume the prosecution and maintenance of the licensed IP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, the Company terminated the ESPP effective as of April 30, 2025. The Company has provided notice of the ESPP's termination to the Company's employees and ESPP participants, and there are no employee funds currently held for purchasing shares of Common Stock under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Income</a></td>
<td class="num">$ (2,192,980)<span></span>
</td>
<td class="nump">$ 13,453,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Presentation and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company&#8217;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes previously included in the Company&#8217;s 2024 Annual Report on Form 10-K dated March 25, 2025. The balance sheet as of December&#160;31, 2024 was derived from audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of Accounting Standards and Accounting Standards Pending Adoption</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Accounting Standards</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for us beginning in fiscal year 2025 for the annual reporting period ending December 31, 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company adopted ASU 2023-09 on January 1, 2025. The adoption of ASU 2023-09 did not have a material effect on the condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The guidance in ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying any relevant income statement expense captions. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. Upon adoption, ASU 2024-03 may be applied prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of ASU 2024-03 may have on its disclosures in its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LiquidityAndCapitalResourcesPolicyTextBlock', window );">Liquidity And Capital Resources</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, the Company had unrestricted Cash and Cash Equivalents of $3.8 million and Short-term Investments of $20.3 million, and an Accumulated Deficit of $145.6 million. Kiora has incurred annual losses and negative cash flows since inception, and future losses are anticipated. However, Management believes that the Company's capital resources as of March&#160;31, 2025 will be sufficient to fund the Company's planned operations for at least 12 months after the date that these unaudited condensed consolidated financial statements are issued.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, savings accounts, money market funds, and marketable securities with maturities of 3 months or less when acquired. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Short-Term Investments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term investments primarily consist of treasuries, corporate debt securities, and government and agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive (loss) income as a component of stockholders' equity until realized.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Allowance for Credit Losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive (loss) income on the condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on investment securities is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with FASB&#8217;s ASC 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s balance sheet. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as deferred revenue, net of current portion. As of March&#160;31, 2025 and 2024, the Company did not have a deferred revenue balance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within the Company's or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company's estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a strategic development and commercialization agreement ("License Agreement") with Th&#233;a Open Innovation ("TOI"), a sister company of the global ophthalmic specialty company Laboratoires Th&#233;a ("Th&#233;a"). Under the agreement, the Company granted TOI exclusive worldwide development and commercialization rights, excluding certain countries in Asia, to KIO-301 for the treatment of degenerative retinal diseases (the "License"). The Company concluded that the Licensing Agreement contains one material performance obligation, the License. The transaction price includes the upfront, non-refundable payment of $16.0&#160;million (the "License Access Fee"). The Company did not include any development or </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regulatory milestones in the transaction price because it is probable that changes in the estimate of receiving those milestones would result in significant reversals of cumulative revenue in future periods, due to the inherent risks and uncertainties in the drug development process. The sales-based milestones and royalties are not included in the transaction price per ASC 606-10-32-11 and ASC 606-10-55-65. There is no financing component in the License Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The initial transaction price will be allocated to the one performance obligation identified (i.e., the License), which was transferred to TOI at the execution of the License Agreement and the entire $16.0&#160;million transaction price was recognized in the first quarter of 2024 upon the satisfaction of the license performance obligations. Variable components of consideration related to development and regulatory milestones, commercial milestones, and royalties will be allocated to the transaction price if and when they occur. When it is probable that including milestones in the transaction price will not result in significant reversals of cumulative revenue in future periods, the Company will recognize the revenue for the milestones immediately since the license performance obligation to which the milestones relate has already been fully satisfied when the change in estimate of the variable consideration occurs. Since the reimbursement for the development activities clearly relates to those activities and are accounted for under ASC 808, the Company will recognize those amounts that are due from TOI as contra-R&amp;D expense.</span></div>The License Access Fee was earned at a point in time (first quarter of 2024) and, as a result, the associated contract costs specifically, sublicense fees, were expensed at the same point in time (first quarter of 2024). All further revenue sources that may lead to sublicense fee payments will not be recognized until earned. As such, sublicense fees will be expensed in the same period as the revenue of the respective milestone or royalties are earned.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Agreements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into a research agreement that falls under the scope of ASC 808, Collaborative Arrangements. Reimbursements from a collaboration partner are recorded as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income. Similarly, amounts that are owed to a collaboration partner are recognized as research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research and Development</span></div>The Company records in-process R&amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;D project as an indefinite-lived intangible asset and evaluates this asset at least annually for impairment until the R&amp;D process has been completed. Once the R&amp;D process is complete, the Company amortizes the R&amp;D asset over its remaining useful life. The Company performed an annual evaluation of its indefinite-lived intangible assets for impairment as of August 31, 2024 with a quantitative analysis using the Income Approach.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_AccruedClinicalExpensesPolicyTextBlock', window );">Accrued Clinical Expenses</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s process of preparing the condensed consolidated financial statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#8217;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business Segment and Geographical Information</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segment and Geographical Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment and three geographic areas. The Company's singular focus is developing innovative ophthalmic pharmaceutical products.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock', window );">Refunds for Research and Development</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refunds for Research and Development</span></div>The Company through its subsidiaries, Kiora Pharmaceuticals GmbH and Kiora Pharmaceuticals Pty Ltd., is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the eligible incurred research and development expenses. Following the approval of a research finding by the tax authority, the Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. In situations where a new research application has not yet been approved by the tax authority, the Company records the tax receivable and reduction of expense in the period following approval.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2024, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to effect a one-for-nine ("1-for-9") reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#8217;s stockholders at the Company&#8217;s 2024 Annual Meeting of Stockholders held on May 1, 2024, and by the Company&#8217;s board of directors. The amendment became effective on June&#160;11, 2024, the effective date of the reverse stock split.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reverse stock split proportionally adjusted all shares of the Company&#8217;s common stock outstanding and shares of common stock underlying outstanding options and warrants immediately prior to the effective date of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all warrants, stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective date of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such warrants, stock options, and restricted stock awards, and, in the case of warrants and stock options, a proportionate increase in the exercise price of all such warrants and stock options. In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plans immediately prior to the effective date of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#8217;s Restated Certificate of Incorporation, which remained at 150,000,000 shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the reverse stock split results in stockholders owning fractional shares). As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock as of June&#160;11, 2024 decreased from 26,735,116 (pre-split) shares to 2,970,545 (post-split) shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">presented reflecting the split. The Company&#8217;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on June&#160;11, 2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_AccruedClinicalExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_AccruedClinicalExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_LiquidityAndCapitalResourcesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity And Capital Resources</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_LiquidityAndCapitalResourcesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for refunds assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interim financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of cash and cash equivalents and restricted cash is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,792,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Cash, Non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of cash and cash equivalents and restricted cash is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,792,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Cash, Non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ScheduleOfShortTermInvestmentsTableTextBlock', window );">Schedule of Short term Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes short-term investments as of March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,295,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,303,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,405,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,321,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,104)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,517,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,540,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,970,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-Sale</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company's short-term investments at March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,877,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,889,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,321,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,659,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,688,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one to five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,970,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Investments Gross Unrealized Losses and Fair Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the Company's available-for-sale investments' gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:60.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.536%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Count</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,104)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:60.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.536%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Count</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Prepaid Expenses and Other Current Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock', window );">Schedule of Tax and Other Receivables</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax and other receivables consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research Tax Credits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Tax Receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Receivables</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and Benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,588,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of Prepaid expenses and Other Current Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ScheduleOfShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Short Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ScheduleOfShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Tax And Other Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Equivalents Measured at Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,970,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,303,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,303,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,334,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,305,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,509,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cash Equivalents Measured at Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Agency Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,540,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,540,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Short-term Investments Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,999,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets Measured at Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,254,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,691,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Liabilities Measured on Recurring Basis</a></td>
<td class="text">The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Contingent Consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Unobservable Level 3 Inputs</a></td>
<td class="text">After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 - 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48% - 77%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42% - 77%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30% - 33%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30% - 33%</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company engaged a third-party valuation firm to complete a quantitative assessment of in-process R&amp;D as of August 31, 2024, which includes the following unobservable Level 3 inputs:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:12.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-104</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Period Excess Earnings Method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for next development phase</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17% to 36%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-Period Excess Earnings Method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success for next development phase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23% to 43%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_WarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of warrant activity for the Company&#8217;s equity-classified warrants for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common Shares<br/>Issuable Upon Exercise<br/>of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389,523</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389,454</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.81</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potential Common Stock Equivalents are not Included in the Calculation of Diluted Net Loss Per Share</a></td>
<td class="text">The following is a summary of potentially dilutive securities excluded from the calculation of diluted net (loss) income per share as of March&#160;31, 2025 and 2024:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Warrants, Excluding Pre-funded Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,872</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661,699</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,276</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,338</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,363</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,094</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, as Converted into Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,426</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Reserved for Future Issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,846</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947,783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872,252</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is presented in the same expense line items as cash compensation paid and for the three months ended March&#160;31, 2025 and 2024 is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"></td><td style="width:68.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stock-Based Compensation Expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of stock option activity for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,303</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,276</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and vested at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,397</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.28</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text">The following is a summary of restricted stock activity for the three months ended March&#160;31, 2025:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average<br/>Remaining<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,697</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,363</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee and non employee service share based compensation allocation of recognized period costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule Of Supplemental Balance Sheet Information Related To Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leases is as follows as of March&#160;31, 2025:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average Discount Rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Annual Minimum Lease Payments Under Non-Cancellable Operating Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under non-cancellable operating leases as of March&#160;31, 2025 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (remaining months)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Amounts Representing Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Current Portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Maximum Obligation Payments Per Respective Agreements and Estimated Fair Value of Contingent Consideration</a></td>
<td class="text">Below are the maximum obligation payments per the respective agreements and estimated fair value of contingent consideration payments remaining as of March&#160;31, 2025.<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Obligation<br/>per Agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Fair<br/>Value Estimated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayon</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,135,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panoptes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,635,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Supplemental Balance Sheet Information Related To Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue, significant expenses, and net (loss) income for the Company&#8217;s single reportable segment:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Less: Significant and Other Segment Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,489,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,296,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-101</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-104<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">1</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(149,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-201</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,101,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,018,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIO-301 Collaboration Credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,966,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(190,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Research and Development Expenses<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">2</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">576,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">622,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Contingent Consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">275,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest Income, Net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(277,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(223,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other Segment Expenses<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">3</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">123,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net (Loss) Income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(2,192,980)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">13,453,207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Presentation and Recent Accounting Pronouncements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 10, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,771,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,792,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,334,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,999,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (145,575,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,382,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CollaborativeArrangementNumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Business segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_NumberOfGeographicSegments', window );">Geographic segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.1111111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares) | shares</a></td>
<td class="nump">2,970,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,788<span></span>
</td>
<td class="nump">26,735,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">In-Process R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CollaborativeArrangementNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CollaborativeArrangementNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_NumberOfGeographicSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Geographic Segments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_NumberOfGeographicSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 3,771,024<span></span>
</td>
<td class="nump">$ 3,792,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted Cash, Non-current</a></td>
<td class="nump">4,081<span></span>
</td>
<td class="nump">4,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">$ 3,775,105<span></span>
</td>
<td class="nump">$ 3,796,379<span></span>
</td>
<td class="nump">$ 31,280,414<span></span>
</td>
<td class="nump">$ 2,458,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Information - Short-term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 20,321,209<span></span>
</td>
<td class="nump">$ 22,970,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">16,726<span></span>
</td>
<td class="nump">36,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3,104)<span></span>
</td>
<td class="num">(6,728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">20,334,831<span></span>
</td>
<td class="nump">22,999,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">395,150<span></span>
</td>
<td class="nump">92,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">395,139<span></span>
</td>
<td class="nump">92,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,295,366<span></span>
</td>
<td class="nump">18,517,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">10,762<span></span>
</td>
<td class="nump">28,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(2,292)<span></span>
</td>
<td class="num">(4,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">15,303,836<span></span>
</td>
<td class="nump">18,540,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,405,847<span></span>
</td>
<td class="nump">4,058,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">5,812<span></span>
</td>
<td class="nump">5,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(801)<span></span>
</td>
<td class="num">(2,107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">4,410,858<span></span>
</td>
<td class="nump">4,062,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">224,846<span></span>
</td>
<td class="nump">301,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 224,998<span></span>
</td>
<td class="nump">$ 304,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Information - Maturities of Short-term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 18,877,094<span></span>
</td>
<td class="nump">$ 21,659,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due in one to five years</a></td>
<td class="nump">1,444,115<span></span>
</td>
<td class="nump">1,310,580<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,321,209<span></span>
</td>
<td class="nump">22,970,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">18,889,213<span></span>
</td>
<td class="nump">21,688,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in one to five years</a></td>
<td class="nump">1,445,618<span></span>
</td>
<td class="nump">1,311,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 20,334,831<span></span>
</td>
<td class="nump">$ 22,999,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Information - Available-for-Sale Investments Gross Unrealized Losses and Fair Value (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>count</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>count</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Count</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Count | count</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">$ 3,052,913<span></span>
</td>
<td class="nump">$ 4,171,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (3,104)<span></span>
</td>
<td class="num">$ (6,728)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Count</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Count | count</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">$ 1,943,922<span></span>
</td>
<td class="nump">$ 3,369,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (2,292)<span></span>
</td>
<td class="num">$ (4,621)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Count</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Count | count</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">$ 713,852<span></span>
</td>
<td class="nump">$ 801,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (801)<span></span>
</td>
<td class="num">$ (2,107)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Information - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Prepaid Expense, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PrepaidResearchAndDevelopment', window );">Prepaid Research and Development</a></td>
<td class="nump">$ 728,555<span></span>
</td>
<td class="nump">$ 1,181,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PrepaidGeneralAndAdministrative', window );">Prepaid General and Administrative</a></td>
<td class="nump">178,431<span></span>
</td>
<td class="nump">118,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid Insurance</a></td>
<td class="nump">34,556<span></span>
</td>
<td class="nump">96,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">646,276<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total Prepaid Expenses and Other Current Assets</a></td>
<td class="nump">$ 941,542<span></span>
</td>
<td class="nump">$ 2,042,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PrepaidGeneralAndAdministrative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid General And Administrative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PrepaidGeneralAndAdministrative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Information - Schedule of Tax and Other Receivables (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchTaxCreditsReceivableCurrent', window );">Research Tax Credits</a></td>
<td class="nump">$ 668,916<span></span>
</td>
<td class="nump">$ 223,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_OtherTaxReceivablesCurrent', window );">Other Tax Receivables</a></td>
<td class="nump">53,374<span></span>
</td>
<td class="nump">47,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Total Tax Receivables</a></td>
<td class="nump">$ 722,290<span></span>
</td>
<td class="nump">$ 270,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_OtherTaxReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Tax Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_OtherTaxReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchTaxCreditsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Tax Credits Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchTaxCreditsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Information - Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and Benefits</a></td>
<td class="nump">$ 653,201<span></span>
</td>
<td class="nump">$ 1,169,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional Fees</a></td>
<td class="nump">112,556<span></span>
</td>
<td class="nump">55,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClinicalTrialsCurrent', window );">Clinical Trials</a></td>
<td class="nump">243,556<span></span>
</td>
<td class="nump">875,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income Tax</a></td>
<td class="nump">2,456,920<span></span>
</td>
<td class="nump">2,328,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">55,770<span></span>
</td>
<td class="nump">160,893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 3,522,003<span></span>
</td>
<td class="nump">$ 4,588,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClinicalTrialsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClinicalTrialsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Disclosures - Assets at Fair Value (Details) - Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">$ 1,970,782<span></span>
</td>
<td class="nump">$ 1,254,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">20,334,831<span></span>
</td>
<td class="nump">22,999,760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets Measured at Fair Value</a></td>
<td class="nump">22,305,613<span></span>
</td>
<td class="nump">24,254,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">395,139<span></span>
</td>
<td class="nump">92,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">15,303,836<span></span>
</td>
<td class="nump">18,540,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">4,410,858<span></span>
</td>
<td class="nump">4,062,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">224,998<span></span>
</td>
<td class="nump">304,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">1,796,171<span></span>
</td>
<td class="nump">562,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">174,611<span></span>
</td>
<td class="nump">691,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">1,796,171<span></span>
</td>
<td class="nump">562,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets Measured at Fair Value</a></td>
<td class="nump">1,796,171<span></span>
</td>
<td class="nump">562,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets | Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">1,796,171<span></span>
</td>
<td class="nump">562,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">174,611<span></span>
</td>
<td class="nump">691,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">20,334,831<span></span>
</td>
<td class="nump">22,999,760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets Measured at Fair Value</a></td>
<td class="nump">20,509,442<span></span>
</td>
<td class="nump">23,691,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">395,139<span></span>
</td>
<td class="nump">92,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">15,303,836<span></span>
</td>
<td class="nump">18,540,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">4,410,858<span></span>
</td>
<td class="nump">4,062,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs | Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">224,998<span></span>
</td>
<td class="nump">304,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">174,611<span></span>
</td>
<td class="nump">691,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs | Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Short-term Investments Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents Measured at Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Disclosures - Liabilities at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">$ 4,466,682<span></span>
</td>
<td class="nump">$ 4,191,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">4,466,682<span></span>
</td>
<td class="nump">4,191,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Contingent Consideration</a></td>
<td class="nump">$ 4,466,682<span></span>
</td>
<td class="nump">$ 4,191,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Disclosures - Unobservable Level 3 Inputs (Details) - Discounted cash flow<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Payment discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, measurement input, rate</a></td>
<td class="nump">0.140<span></span>
</td>
<td class="nump">0.151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Probability of success for payment | Bayon | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, measurement input, rate</a></td>
<td class="nump">0.48<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Probability of success for payment | Bayon | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, measurement input, rate</a></td>
<td class="nump">0.77<span></span>
</td>
<td class="nump">0.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Probability of success for payment | Panoptes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, measurement input, rate</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Probability of success for payment | Panoptes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, measurement input, rate</a></td>
<td class="nump">0.33<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure liability in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_PanoptesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Disclosures - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ChangeInContingentConsiderationFairValue', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="num">$ (12,200)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ChangeInContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in contingent consideration fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ChangeInContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&amp;D (Details) - Multi-Period Excess Earnings Method<br></strong></div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForDevelopmentPhaseMember', window );">Probability of success for next development phase | KIO-104 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_InProcessResearchAndDevelopmentMeasurementInput', window );">In-process R&amp;D</a></td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForDevelopmentPhaseMember', window );">Probability of success for next development phase | KIO-104 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_InProcessResearchAndDevelopmentMeasurementInput', window );">In-process R&amp;D</a></td>
<td class="nump">0.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForDevelopmentPhaseMember', window );">Probability of success for next development phase | KIO-301 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_InProcessResearchAndDevelopmentMeasurementInput', window );">In-process R&amp;D</a></td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForDevelopmentPhaseMember', window );">Probability of success for next development phase | KIO-301 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_InProcessResearchAndDevelopmentMeasurementInput', window );">In-process R&amp;D</a></td>
<td class="nump">0.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | KIO-104</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_InProcessResearchAndDevelopmentMeasurementInput', window );">In-process R&amp;D</a></td>
<td class="nump">0.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | KIO-301</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_InProcessResearchAndDevelopmentMeasurementInput', window );">In-process R&amp;D</a></td>
<td class="nump">0.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_InProcessResearchAndDevelopmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In Process Research And Development, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_InProcessResearchAndDevelopmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForDevelopmentPhaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=kprx_ProbabilityOfSuccessForDevelopmentPhaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=kprx_MultiPeriodExcessEarningsMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=kprx_MultiPeriodExcessEarningsMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kprx_KIO104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kprx_KIO104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kprx_KIO301Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kprx_KIO301Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 11, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="nump">5,486,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,486,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kprx_MaximGroupLLCMember', window );">Maxim Group LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">1,755,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kprx_MaximGroupLLCMember', window );">Maxim Group LLC | Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="nump">1,261,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kprx_MaximGroupLLCMember', window );">Maxim Group LLC | Tranche A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="nump">2,743,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 5.4684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightThresholdTradingDays', window );">Class of warrant or right, threshold trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock', window );">Class of warrant or right, volume weighted average price of common stock (in usd per share) | $ / shares</a></td>
<td class="nump">$ 9.9432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays', window );">Class of warrant or right, threshold consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kprx_MaximGroupLLCMember', window );">Maxim Group LLC | Tranche B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase the shares (in shares)</a></td>
<td class="nump">2,743,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 5.4684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightThresholdTradingDays', window );">Class of warrant or right, threshold trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock', window );">Class of warrant or right, volume weighted average price of common stock (in usd per share) | $ / shares</a></td>
<td class="nump">$ 12.4290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays', window );">Class of warrant or right, threshold consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Volume Weighted Average Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=kprx_MaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=kprx_MaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_TrancheAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_TrancheAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=kprx_TrancheBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=kprx_TrancheBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Schedule of Warrant Activity (Details) - Common Stock Warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward', window );"><strong>Number of Common Shares Issuable Upon Exercise of Outstanding Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">7,389,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year (in shares)</a></td>
<td class="nump">7,389,454<span></span>
</td>
<td class="nump">7,389,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share)</a></td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice', window );">Issued (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice', window );">Expired (in usd per share)</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share)</a></td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding</a></td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">5 years 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of Vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of granted awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Basic and Diluted (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Weighted-average unvested restricted common stock that has been issued and is subject to forfeiture (in shares)</a></td>
<td class="nump">45,363<span></span>
</td>
<td class="nump">24,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">6,947,783<span></span>
</td>
<td class="nump">5,872,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common Stock Warrants, Excluding Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">6,127,872<span></span>
</td>
<td class="nump">5,661,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">161,276<span></span>
</td>
<td class="nump">89,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">45,363<span></span>
</td>
<td class="nump">24,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_NoncumulativePreferredStockMember', window );">Preferred Stock, as Converted into Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">42,426<span></span>
</td>
<td class="nump">42,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation of net loss per share (in shares)</a></td>
<td class="nump">570,846<span></span>
</td>
<td class="nump">54,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_NoncumulativePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_NoncumulativePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in usd per share)</a></td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized compensation expense related to options</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, period for recognition</a></td>
<td class="text">3 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in usd per share)</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award service period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, period for recognition</a></td>
<td class="text">3 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized compensation expense related to restricted stock</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kprx_EquityIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares issuable (in shares)</a></td>
<td class="nump">853,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for grant (in shares)</a></td>
<td class="nump">570,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kprx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares issuable (in shares)</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for grant (in shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember', window );">Holders Owing More Than Ten Percentage Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Holders Owing More Than Ten Percentage Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_PercentageOfExercisePrice', window );">Percentage of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Holders Owing More Than Ten Percentage Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_PercentageOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_PercentageOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kprx_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kprx_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kprx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kprx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total Stock-Based Compensation Expense</a></td>
<td class="nump">$ 148,616<span></span>
</td>
<td class="nump">$ 175,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total Stock-Based Compensation Expense</a></td>
<td class="nump">84,944<span></span>
</td>
<td class="nump">94,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total Stock-Based Compensation Expense</a></td>
<td class="nump">$ 63,672<span></span>
</td>
<td class="nump">$ 80,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of stock option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">161,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year (in shares)</a></td>
<td class="nump">161,276<span></span>
</td>
<td class="nump">161,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable and vested at the end of year (in shares)</a></td>
<td class="nump">58,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share)</a></td>
<td class="nump">$ 21.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share)</a></td>
<td class="nump">23,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share)</a></td>
<td class="nump">17.22<span></span>
</td>
<td class="nump">$ 21.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable and vested at end of year (in usd per share)</a></td>
<td class="nump">$ 37.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 9 months<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable and vested at the end of year</a></td>
<td class="text">8 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">46,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(1,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of year (in shares)</a></td>
<td class="nump">45,363<span></span>
</td>
<td class="nump">46,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of year (in usd per share)</a></td>
<td class="nump">$ 7.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in usd per shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in usd per share)</a></td>
<td class="nump">34.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of year (in usd per share)</a></td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="nump">$ 7.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Beginning of year</a></td>
<td class="text">1 year 11 months 19 days<span></span>
</td>
<td class="text">2 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">End of year</a></td>
<td class="text">1 year 11 months 19 days<span></span>
</td>
<td class="text">2 years 2 months 8 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2023 </div>
<div>EUR (&#8364;) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>licenseAgreement </div>
<div>operatingLease</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeNumberOfOperatingLeases', window );">Number of operating leases | operatingLease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,845<span></span>
</td>
<td class="nump">$ 20,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_NumberOfLicenseAgreements', window );">Number of license agreements | licenseAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | UBS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kprx_A18MonthLeaseEncinitasCAMember', window );">Encinitas Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseMonthlyRentPayment', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseSecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kprx_A12MonthLeaseAdelaideAustraliaMember', window );">Adelaide Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseMonthlyRentPayment', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseTerminationPeriod', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kprx_A5YearLeaseViennaAustriaMember', window );">Vienna Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseMonthlyRentPayment', window );">Payments for rent | &#8364;</a></td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseSecurityDeposit', window );">Security deposit | &#8364;</a></td>
<td class="nump">&#8364; 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kprx_A5YearLeaseViennaAustriaMember', window );">Vienna Lease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kprx_A5YearLeaseViennaAustriaMember', window );">Vienna Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kprx_A2YearLeasePerthAndBrisbaneAustraliaMember', window );">Perth and Brisbane Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseMonthlyRentPayment', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseSecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kprx_A3Year3MonthLeaseEncinitasCaliforniaMember', window );">New Encinitas Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseMonthlyRentPayment', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_LesseeOperatingLeaseSecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_LesseeNumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Number Of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_LesseeNumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_LesseeOperatingLeaseMonthlyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_LesseeOperatingLeaseMonthlyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_LesseeOperatingLeaseSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Security Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_LesseeOperatingLeaseSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=kprx_UBSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=kprx_UBSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=kprx_A18MonthLeaseEncinitasCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=kprx_A18MonthLeaseEncinitasCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=kprx_A12MonthLeaseAdelaideAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=kprx_A12MonthLeaseAdelaideAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=kprx_A5YearLeaseViennaAustriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=kprx_A5YearLeaseViennaAustriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=kprx_A2YearLeasePerthAndBrisbaneAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=kprx_A2YearLeasePerthAndBrisbaneAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=kprx_A3Year3MonthLeaseEncinitasCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=kprx_A3Year3MonthLeaseEncinitasCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Supplemental balance sheet information related to the leases (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-Average Remaining Lease Term</a></td>
<td class="text">2 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-Average Discount Rate</a></td>
<td class="nump">6.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future annual minimum lease payments under non-cancellable operating leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (remaining months)</a></td>
<td class="nump">$ 59,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">81,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">19,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">11,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Lease Liabilities</a></td>
<td class="nump">171,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Amounts Representing Interest</a></td>
<td class="num">(12,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">159,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less Current Portion</a></td>
<td class="num">(71,554)<span></span>
</td>
<td class="num">$ (23,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total</a></td>
<td class="nump">$ 87,470<span></span>
</td>
<td class="nump">$ 33,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maximum obligation payments per respective agreements and estimated fair value of contingent consideration (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Maximum Obligation per Agreements</a></td>
<td class="nump">$ 16,635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Current Fair Value Estimated</a></td>
<td class="nump">4,466,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember', window );">Bayon</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Maximum Obligation per Agreements</a></td>
<td class="nump">7,135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Current Fair Value Estimated</a></td>
<td class="nump">2,355,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesMember', window );">Panoptes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Maximum Obligation per Agreements</a></td>
<td class="nump">9,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Current Fair Value Estimated</a></td>
<td class="nump">$ 2,111,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_BayonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_BayonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=kprx_PanoptesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=kprx_PanoptesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems', window );"><strong>Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">1,489,398<span></span>
</td>
<td class="nump">1,296,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">2,531,887<span></span>
</td>
<td class="nump">1,684,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_CollaborationCreditOperatingExpense', window );">KIO-301 Collaboration Credit</a></td>
<td class="num">(1,966,123)<span></span>
</td>
<td class="num">(190,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="nump">275,192<span></span>
</td>
<td class="num">(12,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest Income, Net</a></td>
<td class="num">(277,321)<span></span>
</td>
<td class="num">(223,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other Segment Expenses</a></td>
<td class="nump">16,941<span></span>
</td>
<td class="num">(7,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense</a></td>
<td class="nump">123,006<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss) Income</a></td>
<td class="num">(2,192,980)<span></span>
</td>
<td class="nump">13,453,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO101Member', window );">KIO-101</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">3,014<span></span>
</td>
<td class="nump">10,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO104NetOfAdjustmentMember', window );">KIO-104</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="num">(149,326)<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO201Member', window );">KIO-201</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO301Member', window );">KIO-301</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">2,101,850<span></span>
</td>
<td class="nump">1,018,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_UnallocatedResearchAndDevelopmentMember', window );">KIO-301 Collaboration Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">$ 576,349<span></span>
</td>
<td class="nump">$ 622,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_CollaborationCreditOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Credit, Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_CollaborationCreditOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO104NetOfAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO104NetOfAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO201Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO201Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO301Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchAndDevelopmentAllocationAxis=kprx_KIO301Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kprx_ResearchAndDevelopmentAllocationAxis=kprx_UnallocatedResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kprx_ResearchAndDevelopmentAllocationAxis=kprx_UnallocatedResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( 'DWJ5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( 'DWJ5H1_7VR\P   "L"   1
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MGDZ]*[BH:K&NWR;7'WY78>NTV9O_95P5WXPO@FT#O_Y%^PE02P,$%     @
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M3@H\W/[O#;#"Q([A[8N_ 5!+ P04    " !Y-ZE:(O?"!.$%  "K'P  &
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M+Q(I5(O[Q_2"<H>.V4%WPW?)AGKLNJ7Z6<+$EK5&/_V >_:O)KKO9/8*ME/
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MXU0LX1S7-.^#1.?9KTP%,V@!M\*OW<:D[6#CIL(YTH]3IA\'#BU&TGMUT3C
M5IB=6IZ&94T9R_SCP&GE+>-A0?XT)6SWV5R/Y\@^SHN],#BIC!6@GT.&U#C&
M5!B<'%5AW?\%LUYLA^H)+]LE3I"GEUSSG='B:K$3/<[V7ZWR\7P;^X'J^3)!
M(5LJJ7W95P.>R'>&\Q/)-]GFZH)+R:/L<,VHSX1^0-U?<BZ/)_H?%/OSH_\
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M;MVZ.\?."1?+XC1>HGFV255Y2EL_+4_\K_'EJ#@8/W@^Q)?#XOR[VX0I?T:
M6;2,4HEB_@(AG0L?!E*4)_/EC<K6Q>'V<Z94EA27*\Z@+\@-X/N7+%/O-_D+
MZM]'!O\!4$L#!!0    ( 'DWJ5JK'7*V]@<  .)#   8    >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&ULO9QMDYNZ%<>_BL:]TR8SUS$2B(=T=V>R-H]-LMMX
MTSN=3E\06U[38-@+>#?IIZ_ Q#9"EDWNF>9%%FR=WQ'XKX/@#UR]Y,77<LU8
MA;YMTJR\'JVKZNGM9%(NUFP3EV_R)Y;Q;U9YL8DKOEH\3LJG@L7+)FB33HBF
MF9--G&2CFZOFL_OBYBK?5FF2L?L"E=O-)BZ^W[(T?[D>X=&/#SXEC^NJ_F!R
M<_44/[(YJSX_W1=\;;*G+),-R\HDSU#!5M>C=_AM1/0ZH&GQCX2]E$?+J-Z4
M+WG^M5X)E]<CK>X12]FBJA$Q__/,IBQ-:Q+OQ^\M=+3/60<>+_^@>\W&\XWY
M$I=LFJ>_)<MJ?3VR1VC)5O$VK3[E+P%K-XC6O$6>ELW_Z&77UN2-%]NRRC=M
M,._!)LEV?^-O[8XX"L#ZB0#2!A QX%0&O0W0Q0#S1(#1!AB7=HFV 50(T/&)
M +,-,(4 8IT(L-H 2P@PZ(D NPVPQ0S:B0"G#7#$;3C5):S]^.6T1D&[G[S1
MRRRNXINK(G]!1=V>\^J%1G1-/)=)DM7C8UX5_-N$QU4WT[N/,_?CW)TAOC2_
M>Q_.WCWPE?D#__/!_?@P1W<>7[N;_BVX>S]S/\W_@MR_?PX?_HG&Z/-\AE[]
M\OIJ4O&.U+C)HDUZNTM*3B1]R*LXE81-U6'W1?(<5PS=I_&"\3%:21"S<PBV
M8D7!EFA>Y8NO$H"K!DSSS88/ZU/1WN71Z)+-\=6\=\ME4I>9.$7W<;(<AQF:
MQD^)?.\&/\NZJ*?A&?IBL=UL4TY9HAE;)8M$!HDNA]Q5:U8@OD/Y86%=U^MG
MAM[G9=FE3OAPV(\)LA\3I$ECG$ASRQZ3+$NR1UYYTSA;,/0JR5"YC@M6OD9Q
MQ3=@\0;I^%=$-*++Y*_DUX>\M^43WY77(][YDA7/;'3SYS]A4_NK;%! PF8[
M&&U@];'S^<8@UM7D^7@$]-O8U,0VZ3;S(/OE0\("2%@("8N 8!U9ZWM9ZP-E
M?8F4=TSS2 PFUAR3&ETU3)6YAZJTGU1(Y_9;6)9FV8)$(3OE]U-BJF.'$"*D
M#2#3AOVT8VR8CF7:E';S1K*F-K$UO&_7$8ZQ%X[1!.HGA!-F"S[U+GD9Y&II
MEEZCI#V*K?-TR8J2SPI^WR;5=_2O3WF:(CYU?8F+Y;]E@C(@:R,D; 8)<R%A
M'B3,AX0%D+ 0$A8!P3HCANY'#%66VF9HC&_Y2%DV4Q0^/XGKN95L/-#>T19;
MU#!TH;XJ$PY5.B3,A81YD##_LET;0.8,(6$1$*RC87.O85.IX<\9+_5I\E\N
MX7I>C?AYRX>X^,JJ^$O*T)PMM@4_7V"E3--F;\=K@IR5N8?*&1+F0L(\2)@/
M"0L@82$D+ *"=41O[45O*47/)RXL>>1GOMNB8-GB.WHHXJQ,F^*-WBW_LRVK
M$^>_MU9/\V,;4TNLX\K\0X4/"7,A81XDS(>$!9"P$!(6G5501]+V7M*V4M(?
M685>U17\->(3^7S#9.*U^T=*W: ZT81K U-EKJ'RA82YD# /$N9#P@)(6'CI
MSQX!9>T(V-D+V%$*."S+;7.Y(E^AS@74HZMR,DTKJ4-/-"%A,TB8"PGS'-F,
MF?\SNWKP(9,&D+ 0$A8!P3JRQ]K!FM%^2OA2PT6)&JKVEM:YUF5:AD6%NC #
M3>N"TCS91E!;TX13$1\T:R#-RG>>N.M"T+01%*TKU2,7$?]<C5X5^0;]%A=\
M&ETA]QLK%DG)RG.E6YUML)HA:3-0FMO2CBNNKE$3"VKQ0+/ZH+0 E!:"TB(H
M6G=<')Q$K+82!XX+Z5CHVW'8-G0LF Y3=4\&JQR2YK:TXZ)(+*J9HLA!+479
MCJ.FC04?,P#-&H+2(BA:5[X'QQ"K+4,W6RIL\ ]QL?<.#:ET(8VP*2AMUM+4
M3KBD$7&PI8O.FP?:-Q^4%H#20E!:!$7KZOM@;&*E"R3J^R)-&WU)\ D>GUB*
METK4N0?KU3CKB4N:$)-0VQ#%"FHG2G8(IE0S,#&P6&E!W4))XC'6=4ITTQ .
MCI&L+3$-W3+D%]?PP>G#:JMOT,U"<D5!6D934-H,]RTT297L-]+Y:99EB[=C
M@/;-!Z4%H+00E!9!T;H2/QB!6.T$GKUQ2"[KO@E(J$4=RS+%0@EJ!K8T9:'L
M-R&F95J.J%=0^TZR0[#I\"GI<15JQ0CJSDD2C[&AZS;!A(B%4M*6\(;4.5$H
M#\X:WOD7_Y^[B#"D\S(%I<U :2XHS0.E^:"T )06@M(B*%IW\!P\/*PV\8;<
M4(0EKHYAF[A7=D&]/%":"TKS0&G^A?LW ,T:@M(B*%I7S@='#ZLMO3]R;Q'N
M>U1CWC''$>4-:MF!TEQ0F@=*\T%I 2@M!*5%YY74?7SD8-P1M7'W!^XB:LF=
MXJ)9PBQMJLX_^)D04!,/E.:!TGQ06@!*"T%IT3D==95]\/F(VN>[Z&8BTO>T
MQ@0[Q+'%NT#5V0;K&-29 Z5YH#0?E!: TL*+?_T(*F]7RP=OCJB]N<O-#2I5
M.>Q#?K!/^5WTF%^_D?RR'6C??%!: $H+06D1%*VK[X-Y1P:9=Q=INO\$&=$M
M3=-MT=Q0YQZLU_,/_,FZ)KMF!]HQ7Y(5FXZN&8XCFAN@B4-)XC$V*+4HUL1K
M=K*VQ+&P387#_>3H/0'UVR^X'AZ3K$0I6_%([8W%:T&Q>Z'$;J7*GYI7!WS)
MJRK?-(MK%B]943?@WZ_RO/JQ4K^-8/]:CYO_ 5!+ P04    " !Y-ZE:1\P*
M/T8"  "^!   &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;'U4;4_;,!#^
M*Y:'-I"F)DT+0RR-1%\0:)1VI&S:1Y-<&@O'SFRW9?]^9R?-.@GZ);ZS[WGN
M.?LN\4[I%U,"6/):"6E&M+2VO@H"DY50,=-3-4@\*92NF$57KP-3:V"Y!U4B
MB,+P(J@8ES2)_=Y2)[':6,$E+#4QFZIB^L\8A-J-:)_N-Q[YNK1N(TCBFJTA
M!?M4+S5Z0<>2\PJDX4H2#<6(7O>OQD,7[P-^<-B9 YNX2IZ5>G'.73ZBH1,$
M C+K&!@N6YB $(X(9?QN.6F7T@$/[3W[C:\=:WEF!B9*_.2Y+4?TDI(<"K81
M]E'M;J&MY]SQ94H8_R6[-C:D)-L8JZH6C HJ+IN5O;;W< "(HG< 40N(O.XF
MD5<Y998EL58[HETTLCG#E^K1*(Y+]RBIU7C*$6>3R>)A.GM(9U."5KJXOYM>
MK]!)5[C,9P^KE"QNT%M,OMTN[J>SQ_03F7U_NEO](J=+ID':$BS/F#@C)X1+
M,N="X&6;.+ HSJ4(LE;(N!$2O2-D0.8*V0R9R1SR__$!%M55%NTK&T='">=,
M]\B@_YE$830D3^F4G)Z<'>$==#<V\+S#=WB7FF^9!;(4+ -L3_M6K4<IW*!=
MF1KA(XJ39$!O@28?/_0OPJ]'! X[@<.C A=% 9K+-<F4L6^^1(._]'@WM=ND
MWXOB8'N8-#CHJ0KTVD^.0<Z-M$U[=;O=<%XW/?DOO)EL?(DUEX8(*! :]KZ<
M4Z*;:6D<JVK?H<_*8K][L\0?#&@7@.>%4G;ON 3=+ROY"U!+ P04    " !Y
M-ZE:+(O">9H'  !O(0  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;+5:
M;6_;.!+^*X1O<6B!NA9)O>82 X[C[ 9(DR!NMY\9F8YUE44O22?I_?H;2HYE
MFQ2;[/D^M)'EX>B9X<P\,Y1/GX7\H1:<:_2R+"MUUEMHO3H9#%2^X$NF/HL5
MK^";N9!+IN&C?!RHE>1L5B]:E@,2!/%@R8JJ-SRM[]W)X:E8Z[*H^)U$:KU<
M,OGSG)?B^:R'>Z\W[HO'A38W!L/3%7OD4ZZ_K>XD?!ILM<R*):]4(2HD^?RL
M-\(G8YJ9!;7$GP5_5CO7R)CR(,0/\^%J=M8+#")>\EP;%0S^//$Q+TNC"7#\
MM5':VS[3+-R]?M5^61L/QCPPQ<>B_%[,].*LE_;0C,_9NM3WXOD/OC$H,OIR
M4:KZ?_2\D0UZ*%\K+9:;Q8!@653-7_:R<<3. M#C7D V"\CA@K!C =TLH+6A
M#;+:K NFV?!4BF<DC31H,Q>U;^K58$U1F6V<:@G?%K!.#\>W-Q>3F^GD L'5
M]/;ZZF+T%3Y,O\*?+Y.;KU-T>XG&H^D?Z/+Z]OL4?5A7;#TK-)]]1'WT;7J!
M/OSV\72@ 8I1.,@WCSUO'DLZ'DO1%U'IA4*3:L9G^^L'8,+6#O)JQSGQ*OS"
MY&=$\2=$ A(Y\(S?OCSTP*%;M]):'^W0=[OBDNFB>D0C$Z>%+K@Z<;FI41.Z
MU9@</E$KEO.S'B2IXO*)]X;__ >.@W^Y;#R2LCV+PZW%H4_[\ 9*SH=KH=1'
M=%7E8LE=UC8JXEJ%*3!/PS[!&<G2X'3PM&N)+8AI&%$2)%O!/931%F7DW9?1
M[-^04U"&M$):H'N>BRHO2HXL^.9K<W/,U )]^*;X#!751W0GQ5,!(8L>?J(W
M;W)TS$T^DK(]]\5;]\7>3;[@H#0O6%.!JQD:+874Q7^:&V(.OM.L>BP>P*,C
MI;A6+G<TSXAV-I?B]"  ;)DPC3/WYB=;](D7_3V?K?-7I.WF77.@ 5036%_,
M^[#5'NR)A<O$[V'X.J0@?JD;?KJ%GWKA3[7(?_3/F0G%L5@"D:O:[RZ8J0T
M_(?C YP.L20*NX!F6Z"9%^AX 3' (5W0)2LD^I.5:VY</H:2#PZ'Y#.7"M)(
M=AJ06<A($H&K#PRPQ?H8*DKH-@ '+2L&7A.NJB?>U(G7<F"B?<><W4(" 07\
M\8-K9N)^RO.UK&M!O::N'Y._UL43*XVTDRL#VPQ"LX@>6.N0"SHLW>%_[*V(
MS68ILUL[]:R._QK_=<$>BK*[MFW4'ZFX'4O;OC-(ZPSBW?8[R5>LF*')B\FN
MS0[>Z@67:+R6TH1#=VG8Z-ZK65&8T<.8=<AA$D>X8R?;E@-[^7T(G6S)'D23
M4X;:.,0<1*0;++5#+J%QN$.P&[0.09QF6="58VW#@/T=PSUL()/Y HTEAX[R
MEXA#&T@<IYE5U!R".([BM*-UP&WO@+W<.OS*7GX),K+K%HF2G8*TP6C+ 4$$
M7=G<\C/V$W03JYX8M7FU3S-"+!_:<AACT@&O)6#L9^!1GHNU*9EW[*?QH1.B
MBSP3'!,K,AV"),R2J -ER[/83[2 4JYY6P6<*&WJ[.,@#4EHI;M+DH0TZTKX
MEF:QGV=?<>XG?I--3LP.MB0A)+,5G;9@1V22EE&)GU$/^ZT=7G%A)0Y*Q(1&
MAYV64ZZ[UR(M+Q(OU0S_1N_OM ,[?)X$(<ZR0TML24QC$J911T"3EM8(\7)\
MT\V\85 A7GI\+YD?2]N^U2T?$C\?WJV!7)AA<>@]G0V:TP4.OJ,Q=)[6B.*0
M[,J2EA.)GQ.GT"2^$Z_-=FD0!%:>V&)=8%L^)'X^_,+T:Z?[+L0V]\4$$P=F
M6[ +<TN0Q$^0V[3>3697?CB1VZQ(XH0DZ6'-=PAV(6^YDR3>)+XL*E;E;TEB
M+P>_.XF/I&W?ZI:+B9^+?Y="*;-9.><SA>92+.$3=&":H[L2GFM&,*<7;-JU
MXLLQ_D9!L)<]^[!;:B9^:IZ\<)D7JAY[OS,I6<?D1WQ,NT%IB^"0IBGNZ&=I
M2\G43\G.7'"%F?/@TC>+;HXC;1$<D3"):4<C25MVIGYVGLSG/-?&NY.7O#EN
MN#<A\3K-FCX(+/MDC=_U1 >3AY9%KGDSGCO-<[!Q@,/#B=PAUH]P?8;L-+"E
M;.J?1.OSR N>2],LU6>2]949T_]'P^SILP_5-SGL 1UR)$T)#N..UHKNG(W_
M8E!]LP&?T#E_+*K*A"/L]1V7A9@YK;*YF"99#/\.S;(%21BE6=?X35OJIG[J
M?H]5$[CIM\>F:YHD$%G1H3T.04Q2:#"[0K"E=^H_*Y^N5ZNRKJ^L1!>%RDNA
MUK(A^QM1Y<;2M@VNS\?>6CN.>B!^+&W[;FH["NKO*&#>VAY_.PZ1-P%0,K/[
M;QI]J&OV#NW#6X=<!V_1MLF@_@'=1*[^"0@KCF[GGEG2K^?=6_C_:#)HVV30
M]#BM%?4V*^^V^DC:]JUN>Q3J[U&NE%J#V4":0D&<SH5\6V>U41O[F-\6@:D\
MPS@]G&4'.Z^NEUP^UF_T%:J/B9JWO]N[S:\&SO')N'ZY?G!_A$]&]3OT0:NF
M^2D"#"; (0J5? XJ@\\)9(QLWNXW'[18U2_('X368EE?+CB;<6D$X/NY$/KU
M@WG ]C<6P_\"4$L#!!0    ( 'DWJ5I$<&I4Z1T  +5=   8    >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&ULQ3QID]O&E7^E:^)R9JI(:B[)BF6K:BS'B1++
MUFJD9*NV]D,3:))M 6@:#0Q%__J\JP^ X,S(F]W]8&M( MWOOKN_V;GVH]\8
MTZE/==7X;T\V7;?]^LD37VQ,K?W";4T#OZQ<6^L./K;K)W[;&EW22W7UY/+\
M_-F36MOFY.4W]-W;]N4WKN\JVYBWK?)]7>MV_YVIW.[;DXN3\,4[N]YT^,63
ME]]L]=K<FN[#]FT+GY[$54I;F\9;UZC6K+X]N;GX^KMK?)X>^(<U.Y_]K1"3
MI7,?\</K\MN3<P3(5*;H< 4-_]R95Z:J<"$ XU=9\R1NB2_F?X?5?R#< 9>E
M]N:5J_YIRV[S[<GS$U6:E>ZK[IW;_=4(/D]QO<)5GOZO=O+L^8DJ>M^Y6EX&
M"&K;\+_ZD]#A,2]<R@N7!#=O1%!^KSO]\IO6[52+3\-J^ >A2F\#<+9!IMQV
M+?QJX;WNY7>]AV^\GZFWK?&FZ303JRG5.U/ 9W53%*YO.MNLX1'7P-^% :YT
M_ILG'0" RSPI9+/O>+/+(YM=J3>NZ39>_;DI33E\_PD 'J&_#-!_=WGO@F]T
MNU!7%S-U>7[Y])[UKB(UKFB]JR/K_=RN=6-_(QK,U"O7>%?9,I%D0".W4C_8
M1C>%U96ZA2^9+.J_;I:^:T'<_GN*0@S ]30 J()?^ZTNS+<G6]RKO3,G+[_\
MP\6S\Q?WH'<=T;N^;_5_-[/_US93/]\!YJC2?[>NU>KM1H,"%J;O;*$K6/%U
M4RS4Z9=_>'YY>?Z"GJ&_+UXHUZIN8Y3\],K56]WLY<<SM=->H2$SI8*_M/K>
M5'JG6Z,*UVYA%>9K ]\#)$O3JLOG*%OGUPN!Q.);!:"*@,Q]!W9+^:U!$>CV
M:CN $Q:EW<%(W('QVR*>B#U\79L67[&_X7< ;ZNWUA!H!'T'YK5#2J",N>VF
MV^BJMH4JK3=@@?Q"W5J@E;) *OQCR_+*(&X ,]C1=8"D[T$4-9!85]5>P?_H
M%;."C>#?SJFE,$EM*]TT ,U,(;-T6VP(5@$=89G1%ZVV'H$N .).5POUH=%]
M:7&SUTUG6EMG2O&Z8:^!5'T/>.E"2((K]/'%PH$Y:#S_)1H''U9Q'9^4"PB"
M%!+& K)W1BV-:12HRQ8X60)!:)^VU$BBG>TV]%D$;=L"P>RV FJO30.$)\(4
M2$-^%U?_T!!<I-,^RMF'Q>U"_>7FYFT4)^27%:P3M#;#&DE&(."RM@&[T),W
M(N*C6U$7Y_/_8*7H*Z.>S\^O$,=W9MU7O,3M_#\7ZFW?^AX8B:_!4MZHMD<<
MB"7Q6= ,^!$$SJG&=2@:55\:YOL(*/@=7F_-K[U%HBWW*J)':"&C*M.922XL
M@+.$$0JUF,):-Z ,(BBPH2Y_ >_%3#M%OEI/#(!'&X2D@LV+OFU)*]*S9R0#
MMC0(50-JZ#W$"@225BMM6[4=V>!,') Q%U^]\!G0*%LV8@VO@K?VK%:&]=UG
M0B04*Q?J9_X9@ OO!.6$'ZPK?8 #30D8$*1W ->"2%G8MM 8<008PSJ@S!U0
M:P\[*O,); ?)NBR^ZH%T>X-N[9\(4V5! ?D5_!D,0%$YW\-:L+^[ SJ5"LR'
M0:$'*'0)# 4NH9C4^J,1L4NL3T CP+7U%01RB.5N8QJ1K*280;8_1T$1#(P.
M49?@Z5_ J-/.40LRK7]HJ2BG /:==;TGPC*+@JZ.60^1P+6Z:9H>UGIGP*AW
M:-"#JOU=\7YOR,)=/N7(84'6::DK,AD<#&N2DN@(),BX)A<"T@F,!:A;5W\&
M/B/;M>P[T%3 ;JRK8TY/:NE"W91N&Y0@<Z5@M9I2MR"AKW-'=GYY1=9!_7!S
M^QWX,=_#@C>W'^B7^?F?R*FZVJCW^A,:O?>@VX7ZZOK\3,W5ZQJE3=  V4J/
MJN\3H$S&!MRV%Q@"Z.0U!6UX'<0>>4N^Z)/8!<M+=K!DAON,O>L*_2DPOP5_
MC>1E*PC.J$-A \H7MK+)N*6U4':T+1FR")4E'V@H(2#5ZSWHVMJ2!T3!6@$$
MFA61!"3JIV;!:DFPR)^0-5"F(2T:B\O3"9+@YD'MT0/#HMLMZ'F)&HW8(E35
M?D;RT9HN?<D/%HPG+ -[U[;KC* 7Y$JC7 R9BRKP-PV@@RD=0*9S&<J>+RU;
M"#*-&FP)&@) G,F&RR$U/LLND/EE]I6YS$R*[ELA:)1QD.6?4 )%EJ^/RO(U
M>- 92J5>K\$S1C<A(AOC=/5G8 + GOQ[MD#P\$RD=6\YF #)R!Y*PHW\G4!Z
MH,1HKO02''6KV!S/\.<(),E=YJ*7D$"3M2Y:NT0"PYIKUV*4V /1VVK/X23I
MA+G#T$"D/FUO&$.,U<C1/:0%F=3G^J!7P/PDVA=L-)^)IK&'"$X1K?Q0?QY>
MZ:L9.P=XN-HGB<RD^\,622(_S 8\$$<ZJ4*8# P4J-H/-04H@"$(T H>!B)6
M/7."O"8\4G3)]4YH2@2 M 1U$N1\Q'/\ZC/49*%^M"!4X%'V1-]7'&:#)_.N
M;R&\4#>=.*]@8F:C@+@$ 8'-N]:2B7FE_4:6@C_^#(L#GL$=?7&U> Y10%4%
MRWF[ ;LV!R[5H#!W)@1P^.CE^>(J/,NY@&Y0>?NZ9ZW^WH"9MI2S?'%Q_73Q
M+#R]R#(3$%*D>!DL*9#*2QS;D"+<H;P"I*O*[;SRG.>D' <?7/4=D#>^BG$/
MV ^(ZC5)RU_=#H*F=@9T"B%IB*1\XJ<0[(\^I#(8H F-V?</R0PR"JX91,WW
M*\33<#"^ FT<K4>I%&"819@4OG8*@BW?J8M+57,9A/6!W#T%;0+;( ;[W-B+
MK2%FB.N&_.8HT885"K0BQ^4BUY 0C'L*3#9VO0%-J4A$@2M)0$B!P3R!I@-(
M8,3Z%J)N(S%/:TQ &0A18;Y)\>86R U"$1TA,=XD4!8)RO%/,6"B'VQ#,2<&
MWOI.VTHO(9<J-J;X2&:'T<=@0M_!%S[[!L""A*G6[4>(^9"9GF6,OZ%U/.8I
MC VA.<3N:A(S77#(QO:FT&W+]KJF;25^2$'L%+L'X2B+4'&4&LAYM%^H6!TL
MXL&][#86L_@MV,1/MJ94EA(H>FXAJOY^K.J9!<@9#'ESS9F-Y'+$62 Z6#J+
M<5JHH( LFV67$8WIN0;GW3:DBV0Z(/DN]ME30\.,EJ*HM/<@P:84G<C!P>I-
M8/0<2#/W>L"I&3Z!E*7O 53?%YO!"N(X8FP-"&*,YP)[*5"UF 03T"F]55C<
M V<<4</ZC0$8S!ALSKM'2A*7+XDC2[-WM$:F(R'90V("Z$%+$"5Q5_"G-YT/
MXO-Y=96A8$$ !@2'2*.V?8U"C X,I11DBDL] $X$ >M?-8:^OY$)+Y^@82L*
M\+*LQ!0/ ,(A&$$^-5E^C\_LK:G 2?G@:9&>6#N?8P51U:;;0$"-XD*_5G85
M4V@NH. ZBX',<LXI*L74 SF'GTGLRX'8?P#GB)4W^'JM84%B8>9*\OQ29][-
M(9LIB6G-!IL2X*A.\;VS'%=Z $P*E^Y\YXJ/&U>A ?TCZ2OP'0TQ.AL& LA?
M@:<CAJ"*OP)9!!_Z(P/T Y+W/CDG*!OR^((4@J2VSEOVEWELL+*M9]&AQ<%0
M$4ZV([:!Z4/N>%-5,Y0#NZ)?0%-0M"O[$2,J<%$-)0;DJ^#WX!6C'L4EB+4,
M*&H:*0CF:L#8/1('(Z,D2VBRL+UBL;BT4L82:,)WB($I_\!2%T2N'"QW1.0V
M[!RD"S<GJ$TWA"%6"*8VQ3=V+8:;#>3DNX9<>Y0:5$_7KRE$Q4 68'R8,T0A
MJ<356%$@344R(*C ' 1 $!OR22+1C$5D#DQ!"H+A=8(,30Y7ED(]HF )$I$&
M,%ER5Q#-NI9+=[7^R,J'ZDSBP'6[;M+S,Q&!;<C(H(GPD&U#61B>!KE82\0;
M3 !:2?2P[%MC(0Y]A3PM:7R6T CP7'ICW42*@;]#_(+XS)"'6$L<8D:NEA:8
MATR3TG0.VD<Z$JPW0H]E<I BE"";53IF8EBPF,P&86S>@ER@C8MJ+,$%&]9$
M*!8(Y!=*!)4;X]*3ZY#''S#3^H%Y>M@DW9^GCQU![H'-)]J'N2]U!PR&T-CW
MH32(E""96SHI[F622<2=4C7@Q?V:@XB#QP$CQB$6B"$HS&H?&B@U1QWT*2,P
ME1*&P &!#<1("#BF9]%E#"RH3WR0])5Z"1#AFE BP%V%VD,'_+L)G*Q1UIO
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MN:^8_4.K=^[+X4JWK:[=<BL%,BL=P/Y:ZW9\H NF3\GG?P-02P,$%     @
M>3>I6AR$%+B$#0  &B@  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
MW5I9<]RX$?XK*,7>V%74:"Y=OJKD:Z/:.%8L>_.0R@.&Q&BP)@D: "7-_OI\
MW0"OT8Q6WMV\I,IE\0 :?7Q]<E[<&/O5K93RXK;(2_=R;^5]]>S@P*4K54@W
M,I4J\69I;"$];NW5@:NLDAEO*O*#Z7A\=%!(7>Z]>L'/+NRK%Z;VN2[5A16N
M+@IIUZ]5;FY>[DWVF@>?]-7*TX.#5R\J>:4NE?]275C<';14,EVHTFE3"JN6
M+_?.)L]>SVD]+_A9JQO7NQ8DR<*8KW1SGKW<&Q-#*E>I)PH2?Z[5&Y7G1 AL
M?(LT]]HC:6/_NJ'^GF6'+ OIU!N3_TMG?O5R[V1/9&HIZ]Q_,C=_4U&>0Z*7
MFMSQ_^(FK)W-]T1:.V^*N!D<%+H,?^5MU$-OP\EXQX9IW#!EOL-!S.5;Z>6K
M%];<"$NK08TN6%3>#>9T24:Y]!9O-?;Y5^^EMN)GF==*O-4NS8VKK7(O#CQH
MTXJ#--)Y'>A,=]"9B0^F]"LGWI69RH;[#\!3R]BT8>SU]%Z"'Z0=B=DD$=/Q
M]/ >>K-6T!G3FWV7H.+?9POG+;#QGVTR!Y+S[23)7YZY2J;JY1X<PBE[K?9>
M_?"7R='X^3T,SUN&Y_=1_P[+_!XZXO-*P2524Y=>EU?BJM:9+%-%B 8!)Y:T
M[9JV)4(Y+Q>Y!LJ<D"(U<$GG5>G%TLI"D=L)A =1* G:1*V_69:94+<5_CB1
MM0SP!B73%<#\"RZE<XA M#;7<J%S[=<BE5Y=&;N.A%4FI.^1%G!JI?U*83?B
M0UI;/AO$2E-V]_!9[4;B?;=/NR@E"#H! N O7<GR2HG*:NC KW#0C:GS3"P4
MD5:('!FS+,O(*JXKJ3/AC0!^2K=D-CKFGV"ENM4^D'PJ=,DGX:Y,=25S(E 8
M!YFS:UEZ!$!3.RC#?@5Q.HE6MT=U=$$'E(W-E,W7X6@9 MQ"^1NERH9&):W7
M=%3I':F*Z$5%%F2[#-H=B3.'>)RNDKY>-5DY4-FGB)<-]K%RW*K13J:\L@4K
M,ZPUK*&ZJ(@I%Y9O8RGHMW:*1"(ED;'ZZFUE9BYE,"2KAA$(!= .XKY_8!(4
MMP790Q3[E55JWVN8K2?Z"O?2IJMU(FY6&I3!F+':ZU]50(HNJQK,UR0I^-X&
M>0+5TN1(=^Z9^+NZ5KF8B'WQI939+PCHV/BM-O2'D>'8HIR;HIJBSJ1E,91S
M>I$K@OXV"[(^H O(FLH\$360CX"F4\_H=D2NITNMX J!IREX^N> $2+E=*%S
M:9NM?8?4VWA-[@IS1XK2^+@K(5ZB"H-^Z;U94.R$;2C4!(?.-+S. ^"\OKE+
M HLU0C8@I&5.'@"E+.L\%P1#898[_*:1>@:I+P*K)MA+LO-XE:Y*_:U6D6^K
MOM4XM6&VE65A_ I*NBKU$@HG=S"!A<[\?1.1_NJR$U \T2,U2B!#51E+>ENL
MP:3W>,6!JW$5UA?X?CKB2!WP1#CS3";44"TJWY@"3K7^*VRH2X =J@'GP$%-
M7+A[ F@_<@8' WJAQ0_D!6W^93G>(@X6"Q@G/IW'H!IRRX=.:D?'?%(D()%]
M2S#]XN@RXNVBQ<I9 -.'"!DR[WD#9G@]8_"RI^V/C(Z/G3[/@WWZ:[[T]1W?
M?S8>!)]$;WS:7$W;J]E3"C)W!7\CW4J\ Q:@,1+M&=4Y:ATY%N]K2FN/Q"0Y
M/CU*)L>3C>L?_G(RG4R?]ZZ^7(K/EG6U%I>D^N!8D^-Y<C29M,LV[X, F]PT
M6F?#]HQ!3)P>CY/CD^DF<Y%NQ]#E"G;:9^\Y+Z\1/(H@YPY&'XG9Z6$RF9T.
MI+O[[$=SK6S)3G!VI<IT*.UA,AO/DI/942?PW4=OC 6&"#UOU<+W]\^3^62<
MG!R>M&OO/F'TB-<R_0KU]/9.I_/D]+1;MWD?-+U=*[OU/1TGL]D<[ ^MOO5Q
M."&B>S?%*11R"&/--DP(FH?CTV0^G_9H_A]ZXIUX\U!G/#R:)D?C^>#JP8YX
M= K7F1RWRS;OO]\1IX?SY' Z&;#34/T#;G@*?$R&HMUY=+\3GB2'<V#I<-PY
MX=U']SGAF.0YGO6<<//)+B><C>?)=-JMV[S_G4XXA2>?)L='XZ$3;GO\0"><
ML_FF)T/S36<)6?#HN&_!\Y(*TS*.&VY0R*"<1 -OV85D"K0X'6M4F65\B1=-
M,1OJD$*NJ:HV-Z$TZ"5W).I<DL_&B@.]DX;#L''A+:FR7E+UI7,HRE +1TF;
MRV,<0?Y/*X>G57(=PX153<G#YWX978[$CV=G%W3:@MH6]+>EWZP@MA<GE377
M.(/"2I@:T5'+817Z725)S2&K*>!"2?9L,U-O"1>=V&_Z8C\3_S#E/AU!KQY1
M[C@Z2HXX5\Z3"0P[/QTWCKZ#QNYM/8OI4L<JE85SNPW1L^V"I$75CQ7% M5<
M:*.""B3I=A%+VOT;'CEA%_"5UGF@!"A4AIISJ@&C?85+58ERT80.G#JCH'CR
M:T>S-1Z2(?S'^MEJ]Y4J06=02M):1G/HE"O%O<6R]M3&IQ0(E]3KA,[L#@I'
MXB=$Z'Y'R+T3!,4"75!@V:B?"<R[](3F.:\SAM@OD8]>P=NB+6G*:+1(DOT@
M]-ZM[L(S]#HT,%A&7V($8YV#B)3"!E*<+1&'8@O(5NV:AV3@IN :W)+1(2A\
M -ZU )6>N*8!_VXY81L>CE"O [>D!;9-XQ4Z7Y-%2/B! PYZC4V'^;GM=CXW
MW<[6%/V;CO6V U%K?W$1L=8@C,$E)O/16#Q&=3>:X,]KN<;IS<HH!T@>HRO#
MG]/!]84L347XW+G^9' =B?>,#,LB_E$+S>!LO&%^\AA[CH\?B_FTN>H.^^W]
MLS'MFLT>]Z[Z94^8);DX\G%J@/Z4QQX(IW7NN9WN=Y, S0H^#5U3M$02L'>"
M[3TA)':4<=(D%TC^,2)36]<-'R26T? HS&OJ*@Z'*K IKT(,T 7WHTRG##,;
MVMMHPS!?.4%XX#W;W)^9#M,UO'F@G^/=H_%H1H3R)GL0,SRU$448-2L:-6^@
M-1$W:& KJZD]AHR915@K*:5)D:F4*BG5:&B U#_ Z&0ZFH*@J1U%E8>R.M_-
M*<>Y/YU539$^I<EAB.?8:2I^"<M17"\I7D4PT "-XQF;U8#]DL!"%$VNLX &
MCS^A?L"YD19AG-1 VZU:T><;P/!);IRC(2@>1_Z[LH9X(F_91X!F>'WZ01;5
M\[=-E'>A>+(!VW%2W"NGPG1F):_#J,E2Y*040T'.Y.:*ZZ\EU*E[P3^,G^(F
M(7.X!.7::]5D-II,RBYL9P-/?,]SJ8<QO#6A#W-&*BN-:J,W9=Q%FL8SC ^>
M8&NO]G.>3>O2 PYA4MB.TE5(44R4)SOA15ES>N+)(<[7EJ,:C4MS/KUW)+.P
MDI3"5,DVS15T,1(?RU1M7:Q=NVPHHRPH?342-MOBI YM"F=*M*V('YS)G%K6
M.4K&)4VI+]^(&9H2R5-54@ 5.+ D<NE26YJB@PY.1W"#A:,=98KBV]&:=D@-
MLRMN7)$:RSC?3+5-ZX)&BJ$5SG0:JA)87WL2")PK</)5\;P1IQ/,GH0%5,R'
M=WIED)W@";R<UX%E> 6*+_\TCA ?8CJ<&.Q"BCY?WL<$$^TFGKV=0?E1305"
M?ULE;BNX.A*DD>"2S&R'#\0;2_$F+$ZEM1P;8%:*2^HV52IS R<!ZYVE$#FX
M=',MSS9^:<C)<!OJZFOT/AGANLO:AF] :1?E@O,!-P]1=_<M Y[BXW>>GN"0
M.**%"MPNM_].W.P6AS7&#=O=\SA0F92;EHP@!Z238@/4 _H#MWWY!Q98K"M>
MQX?W':6W&R>VO@)C6E.P6^Y8_5V0WJJ,SI(;$O7T3U;I&0D(H3J?Q/L<!-F]
MBW.8C2(/$?\@MMNVAV^YT3]^[C;!SWK>[E,/TDSG %L\*]EP0TJD/6V0JZ)\
M_#7FQK+U1S)9,RK(]'()=Z.0S1]PR+OYDQC+%X/K_@S_#O<GI\/T'#O7+1FI
MU[-NR<E==W+.25^<52! /4W(O+$%"J;I6R70BK./.'?H%A :8X*&Y*4IT*8M
MT'$M\8(91]9N[J'*KF.$XA5]&N, UWV%;28@"?HM2XD'5RE]EG7R.MQY>0N?
MR.HTYFUJ!$@3'.T:!T%]5ID@^B@.CV) " 61I0^EZ,90)/%\I:GGFM(K'?12
M/+:5H8&"S%9!WC(&%B@S#N1<VZKO+ZG4M,WG0'I,U0NV+FDDF@P[]X8L^N4\
M]J\<]'?V_.&S;4V?!74[A@LH"3^OP>)AUP=0=VUP^UDX,-T))*_10W!_PGKL
MUV"Z-^ZC+BQ^E?3K2C&S(2"MAU!5Y17ZEXP_[FJ;[1/?Z]XW/E0*!:&UJ4_N
MB:*LGCN(#Y_&SNHK2J=-&=]\*=9=?OO3._*FX1:?2+L_G7_<GXSGX@-:2+U_
M$;KB=[?,ZKN(8O$!=8[)[FMG2W7K&U2&_GI%'<<$W3"4-#M">SQ#STZGS<:3
M_]%ITQF?-I_%T[9]A-NH(]E**OLS:[TNOB:Q>0G&S/K9G/+5[HS>L!:'J6U.
MW_9+H(/>[[4*A:J*?I7&HX'2AY]NM4_;'[Z=A=][=<O#K^:@J2M=4@Y98NMX
M='RX!T_F7Z*%&V\J_O77PGAO"KY<*8FFD!;@_=(8W]S0 >W/ 5_]%U!+ P04
M    " !Y-ZE:OI*!XK(%  "5#@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6SE5]]OVS80_E<(M6@3P+5E^4?2-@G@I.W6K5F#I&T>ACW0$FUQI4B%
MI.)X?_V^(V7'#N(4V]. /<0A1=[==W??'<FCA;'?72F$9W>5TNXX*;VOW_1Z
M+B]%Q5W7U$)C969LQ3VF=MYSM16\"$*5ZF5I.NY57.KDY"A\N[ G1Z;Q2FIQ
M89EKJHK;Y:E09G&<])/5ATLY+SU]Z)T<U7PNKH3_6E]8S'IK+86LA';2:&;%
M[#B9]-^<#FE_V/!-BH7;&#/R9&K,=YI\+(Z3E  ))7)/&CC^W8HSH10I HR;
M5F>R-DF"F^.5]@_!=_@RY4Z<&74M"U\>)X<)*\2,-\I?FL7/HO5G1/IRHUSX
M98NXMX_->>.\J5IA(*BDCO_Y71N'#8'#=(= U@ID 7<T%%"^XYZ?'%FS8)9V
M0QL-@JM!&N"DIJ1<>8M5"3E_<L9KZ;EB5][DWX]Z'BIIH9>WXJ=1/-LA/F#G
M1OO2L?>Z$,6V? ]0UGBR%9[3[$F%Y]QVV:#?85F:C9[0-UC[-PCZ!COTO;]I
MI%^RWR=3YRTH\,=C/D85P\=54%F\<37/Q7$"WCMA;T5R\N)9?YR^?0+@< UP
M^)3V'R?@'XBSB5*,5Z;1WC$S8Z[D $RCW%05:L"%75(S7PJ&>&C'0W$X$-GE
M5DY%P:94J*SDMP)#@;HI_@0-L> -52&5$ZN-\VR"VBSPY^^W[#"(.1D\,U7-
M];++/FMVSI<L9GG8V5QDI5 %D\!/2VRB=0/OSD%OJ>>D*#A:&E4(Z]@>22;;
MFY)]MBB%%9M:7[J(9"5W:UJ'>%U; T]ON96F<0PS^,:50Y!RU11D=$_NPT-3
MARX"!)QI-)N66!]UC@B@L; +Q75T)0G0']V0=*".]"&NZ_ !QP;6%\\.L_[!
M6\<NA?.<<)X)Z^5,YIB0?6@TMC:6!T 0!E3T8Q<]UDTU%3;@;'QIK/QK*R]G
M,2^1+I#MC]).FL8_Q$WFY58V9E)!?"%]_'PE8,FC><=,$""<"W')M_#>"<47
M,,?,5I;A<D&^PWG:'@//58=Q![)H+ZI:!6^G2_8;=P6_89^D"UF_;)1@H_%@
MU%DQ23K7< 26YDU-?HPZP\-Q)QV/=_G:U";27MP)FTL79+^@!'#,L0F[YA9C
MT(Y@KCZ?WG\FBP#7EDYMY2VY"\BYB#DLN6>Y,@Z;8.B#F-J&XC2*W@?._\)U
M^#9XE/C0 M:2">+E(R;XW(HX"ODXYW>R8C]9@P!\^G3&J#%1M!#/31GZI1SU
M.P>C46<T&N\HT@XLBE>SAOHX6ZS<!I2ZL7E)[(J![G>R<;\S.LQVZJ$(\CR/
M;A&B^RAO!_<)*U0?<_@[;TGU6'HWK7;9%^IHAEJAQE4&Y,J%*!R;65/M2-F"
MFD3@(0*));5DS_N#[B&.6:506E'G/?@U7")WRR(^5;$$(NRL<S <=-+!8%<G
M!$G@VIJ" !5)_'S4'8X/AZQ&Z0;1H/1A%-K8/( \ZJ8KR"' "XQAHI;DGH^<
MYU;)V!6HFPU25O E@F,4>CVE*)2DUC@YVN!@YZR!G@*7"K8';6C[D?]@[GC_
M/J[W'?8BY"]#%4B-9J5PP$C\[DU.)V=?KUYE^Z3TUX^?7PW2/BFJT< $Q3/0
MV5+SEEZ"O7).$-"&@SMDI. 2KGXSJJD$NPXW+8"9W H+@K.+$,7DV_7D(GEP
MUKQTV_$7-S@IPDEB$2*B"$V>O^Z^'@ZR!]%'E-"8G,B;T+YQ7(;-/XI<V^<0
M(I):(O0;+"S:3 8K\31:M\(5]!7/MOEW^K_CGS<UW79^3$&4M-9861$P\JXE
M6S\=DDB@%[Y*/5,<[P^_0KM!+_#GW]&GGW6'V>OTO\:?QVZGO8VG0B7L/#R(
MR$O<&>.K8?UU_>::Q*?&_?;X8,-5?2YQ=51B!M&T>S!*F(V/H#A! L/#8VH\
MGC%A6.+=*"QMP/K,X!K63LC ^B5Z\C=02P,$%     @ >3>I6H&F-V:: @
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M\T8:F@UNF],P1F4#R)]):78'FZ ?[ZM?4$L#!!0    ( 'DWJ5I,PUJ^LP0
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MDSUR]IFU)H]L#:14@G,EB+]86D-LP%$.@4B/AP+$PA%M&<>A#<7BIJFJG&.
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M]!U2/TC9;H 3H>VM1DD"33(_F?M^^]$@GC0-F  AI3.YSCC1EJ"\ %)"_#J
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M0!(6:&\$7?U$\,5-:().M<",5Q#'*2EV'HJZ^LVE+GSMY')#, 9).'RC"/0
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MV60D;/<<[2;>M.$)N#0>#\HPK/"")\L"V%\9X[<3-C#\)CC^!U!+ P04
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M26XA7 MM>@NH.UTY&F'64L4D,4%9 ;TBT':6$RVA-^ HCQAC()>*"*R\X?=
MEFA[CL-S;96?C#R%=A,'.[DSG?9I^O6G_=NQ2"/SAWIZ>&C<;(1V(+$FTV+X
M_"(#FX9YVGC3Q@&Z-I[&<5PV]/ZA#0HDKXWQQTUPT+^H\^]02P,$%     @
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MV3_41!<)%F#_S=^>G)Z>//TPNYJIOU]>OJ6_YT^/%>P.7N%=)VIMMFM$#I&
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M^$QD?*EE%06'CE_W^TZ_I9N-*[F@7'2>JY+DXGAZKGGA3==4R]JN->RM,)!
M%GQ@BB'1P6NL\_1MA?GA#QR\HYH+&YG/\N=?>]H^_>D>[OSPO=EWE'CAG7-7
M?%17X'W&R?WL6=1OM?IG!\*^F(P40Y<6#UVU>FF:EG) SH(N85]E.%Q%;,'>
M6\+18"#>E.<;9+&H%6[(ARGB]WNB#;PRJ)V:;W#0)?N@UO&/5Y DW6#$B5$
MGRUHA"RU>M=X6/O@:$Y_?'=T+%FKX9L[RM.VQ7.XKJ6.HE"#!RII%.,Y[1/K
M$'S<9,I@!':\778Q2/7[1$<_B/+&F/ 1GJO\U37>I )"WNCPA85'7##8L^["
MX15\K))"8)1=4]"1>JSI;4QV1=^)T.?S7.KI>9DQ?81[//\86_'$FKLO^%M.
MY++DUIP'!3=^7ZR0<[\G%MQY>K4W+.M@R]]PVV0!;^A0INU7$V)[S_Y=1]%3
M%XD.]9#]/)GD>\>^E<Q;WV"9+S1BR=D'[PE+9DV!?DJ:,/CV'74J=/1E PP
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MZ=^E;I9,U[/-X/WOZ^)>EZ9N&S]Y;:!%D9-VM+Y/EU%N^W4Y[V.8!,A[ ?S
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M+QW"30->^C_AWF*KC9-J"W]=K*TSU!Q_/Q=NAY8]C^8OS)EM18F+B&Z$1?.
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M:\NX*Y7KZEKY8_:Q&1;?X73]R>T4#[0(#DIS:]K^^Y3=_1H'6@T_-ZT/FC:
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MXG+%Z)*)W$"_?^!</=_D']BK'U2F_P-02P,$%     @ >3>I6D0*?A3I @
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M8' V0A[5=KIV8N3:-8N%--AZW+#"GP,H&X#[2RG-T\3VG_YWD_\#4$L#!!0
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MN3!7.T@;8.9G0NC7CKT]VC\+^3]02P,$%     @ >3>I6O0V?YDK"0  *EX
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M+[P(Z86G20\U4:,'T@O[JW?ZLC 0M_&^C.=U"/DN!*H,QR7?A581U)8W-7F
MH&$?^>[\HC@MXJ$F:O3 @&%_$4]?%/WD;+P;XRD=Y&# ULF XU+Q0JO@:<N;
MFCP SW!@%2_LJG.=2L!,U*,4@?FBL[2[/H_6> _&!RP.H>5%0)'1N+2\R"IF
MVO*F)@\P,QI8R]O[YT@1H":[N*>M@[SK4]3E5?PQR4J2B@?9QGE5JS?%[F#R
MW9LJ7V_/]K[/JRI?;5\N1;P016T@__Z0Y]6W-_5QX<WQ\+/_ U!+ P04
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MHM/P=ZV&;^\U>FDTLMJE(YUPCD:H:(:+P$<9?C2%;79 5=RJ,FIHX-S>&%<
M6^KIEJ.4UJ5H)KINMYN@+_3<Z.Z.-^.W'%[D]X"C'!92U#L;R"RP9J)M%H)6
M>BB<4R%'3'VY IP!4P?D_06E8KM0!KK_*TQ_ E!+ P04    " !Y-ZE:'6):
MI88$  ##%@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6S-6%U/XS@4
M_2M65EHQTD"^TY9M*T%A-$C#+@+M\K#:!Y/<-EX2NVL[+?/OUW9"TK0A,T@1
MZ@O-Q[W']US[F!-/MXP_BQ1 HI<\HV)FI5*NSVU;Q"GD6)RQ-5#U9LEXCJ6Z
MY2M;K#G@Q"3EF>TY3F3GF%!K/C7/[OA\R@J9$0IW'(DBSS'_?@D9V\XLUWI]
M<$]6J=0/[/ETC5?P /+/]1U7=W:-DI <J"",(@[+F77AGB\\1R>8B+\(;,7.
M-=)4GAA[UC<WR<QR=$6002PU!%8_&UA EFDD5<=_%:A5CZD3=Z]?T;\8\HK,
M$Q:P8-DC260ZL\862F")BTS>L^U7J B%&B]FF3!_T;:*=2P4%T*RO$I6%>2$
MEK_XI6K$3H+"Z4[PJ@1O/R%X(\&O$GQ#M*S,T+K"$L^GG&T1U]$*35^8WIAL
MQ890/8T/DJNW1.7)^>]JI9Q\8T)\0C<T9CF@-7#TD&(.Z!1=8D%BA&F"KDA6
M2$C0R15(3#(5?HJ$CA)36ZHZ-)H=5V->EF-Z;XSIHUM&92K0-4T@:>?;JOZ:
MA/=*XM+K!;S%_ SY[F?D.5[84<_BY].#GG+\NJ>^P?/?P+N@DB2Z7VJ!H@>(
M"TXD 47W)<X*Q1@M.<O1@N7K0F*SF-D276-."5T)=%?W_^]O"AC=2,C%/UU=
M+JL(NJO0^C\7:QS#S%("%\ W8,U__<6-G-^Z6C006*MA0=VPH ]]_FC$!LDI
MW@!7FP<JZ :$7FYJ+,E)K"_5XLQ5JY0BXF<D4RQ1B@5Z J"("%&H"+U.B5 [
MTM._:I- DB&US2V!R$(U\X30:L%^ZNIE66!H"M1;WV8>A'[D3^W-;I,.H[S
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MCJ+9TACO[_8O/5<A+?P$2@N@-(ZBV5*:\H+[ZO("4<;90,Z5<>B^6L<96E!
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MO(V/&R^=83F1K-#F:LHD6C4]C-%- U<!N#]C3*XGZH#:GP?_ %!+ P04
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M/NNY,2<<;M.]/"A27]JJ!A HA:DR]3J16E%X>?92-B0KS/'%A$G),G,Y!Y(
MUQW4\REC<MW0 ]0G8./_ %!+ P04    " !Y-ZE:[PV]8.@#   S$0  &0
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M;-SC&TGQ BSO_#S]B*H"'\H*?%5=T<R/%R#Z+Y97V.TU"XN67B>+\-3[0\F
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MMN(7#%UPX/NMM?1LA*D:WL3\#U!+ P04    " !Y-ZE:D#@MS40#  !<"P
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MX"=""XKX/"-+; .9X^=R?PY")T;F8".+\%( [)! *J*C!BE:8"+0&F<%(+Y
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MF#*0[Z\H%8<;]0'-KR#S?P%02P,$%     @ >3>I6G.->8QM P  N!8   T
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M31N^B-?)V4.F/BUT.J*<0Z?0&TD3MBSGRZ01@+'[.#O)<[[ZR-E,I-0DOW?
MT8#4?LX\D^Q11X-6F6H#E:[S0*5BT[;EIR3Y'5VJNIV6":ZY>X2:_VV=9U10
M27A;M.[]0Z[RBQ4'O=>27#Y5M@5;-5;[BD,7>7D,(L-C$'D4/=D_?)%!=/@:
MJYWJ@8OLO=J3_3DB_6,0V3U(D5ZUIVQM7#>VK8W5@=>#H?L-7D3X.J@S63"N
MF*AF<Q;'5#S9O6IZ12;ZM7R#7U\?TX0LN+IKP*&['G^E,5ND47/5#12BNFH]
M_@+IZ:UP_6ZB8S$1TR6-Q]54SB;ET-$#';4ZP&$;N2X/.X+Y&,R. (;%P11@
M/L8+B_,_Y=-'\S$8IJUO1?JH3Q_U,5XV9%Q^L#AVGT@?]DRC* C"$*OH>&Q5
M,,;J%H;P9V?#M($'%@<B/:_6^&KC';*[#[ UW=4A6*9X)V*9XK4&Q%XW\(@B
M^VIC<< #6P6L=R"^/0[TE-TG"&!5,6W8'8PC480AT(OV'@U#I#HA?.SK@]TE
M01!%=@0PNX(@P!"X&W$$4P :,"0(RM_!K=\CK_Z=\M;_JQ[]!5!+ P04
M" !Y-ZE:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZVV"SA$!O0[V-0&]#O8U
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M<F]P<R]A<' N>&UL4$L! A0#%     @ >3>I6A']?;+S    *P(  !$
M         ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ >3>I
M6IE<G",0!@  G"<  !,              ( !Y0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !Y-ZE:(O?"!.$%  "K'P  &
M@($F"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ >3>I
M6FK@,O(K!P  91\  !@              ("!/0X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( 'DWJ5H.X<JM?00  ,L:   8
M      " @9X5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !Y-ZE:AP$;(@0&   K&0  &               @(%1&@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ >3>I6JL=<K;V!P  XD,  !@
M             ("!BR   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( 'DWJ5I'S H_1@(  +X$   8              " @;<H  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !Y-ZE:+(O">9H'  !O
M(0  &               @($S*P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ >3>I6D1P:E3I'0  M5T  !@              ("! S,
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( 'DWJ5H9ZI)J
MG@@  %86   8              " @2)1  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !Y-ZE:'(04N(0-   :*   &0
M@('V60  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'DW
MJ5J^DH'BL@4  )4.   9              " @;%G  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ >3>I6H&F-V:: @  Z@4  !D
M         ("!FFT  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !Y-ZE:3,-:OK,$  !C"P  &0              @(%K<   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( 'DWJ5K12[C*DPD  #T;
M   9              " @55U  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ >3>I6KMCKBIP#   <Q\  !D              ("!'W\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !Y-ZE:Z'6_
M9(<%   ?#   &0              @('&BP  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( 'DWJ5H8]:L(2P,  %T'   9
M  " @821  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M>3>I6E5( Z]& @  F 4  !D              ("!!I4  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !Y-ZE:$ZV'ZT0"  "*!@  &0
M            @(&#EP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( 'DWJ5HK13MZBQL  #]9   9              " @?Z9  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ >3>I6D[ [_%-!P
M1A<  !D              ("!P+4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !Y-ZE:.N30!RD&  #1$@  &0              @(%$
MO0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( 'DWJ5J.
M1<\;L (  /X%   9              " @:3#  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ >3>I6E"<AX-# P  W 8  !D
M     ("!B\8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'DWJ5H/]\R*RP(  *<)   9              "
M@:'<  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ >3>I
M6O]'KKON!   7!D  !D              ("!H]\  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !Y-ZE:1 I^%.D"  !7"0  &0
M        @('(Y   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( 'DWJ5JSG/.DT ,  &L3   9              " @>CG  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ >3>I6C;+UO3* @  W0<
M !D              ("![^L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !Y-ZE:@I!=9X8"  !Z!@  &0              @('P[@
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( 'DWJ5K["C1%
MX (  #@(   9              " @:WQ  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ >3>I6O0V?YDK"0  *EX  !D
M ("!Q/0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !Y
M-ZE:2*9NW*0"  !\"   &0              @($F_@  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( 'DWJ5IXX?\>?@,  "82   9
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M970T,BYX;6Q02P$"% ,4    " !Y-ZE:'6):I88$  ##%@  &0
M    @(%^%0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M 'DWJ5H LT0G1P@  (E.   9              " @3L: 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ >3>I6E^@P\(= P  JPL  !D
M             ("!N2(! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !Y-ZE:\;-=HAD$   -$P  &0              @($-)@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( 'DWJ5KO#;U@Z ,
M #,1   9              " @5TJ 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ >3>I6K'"E6>-"@  ;XP  !D              ("!
M?"X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !Y-ZE:
M"N"-V5 "   ?!0  &0              @(% .0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( 'DWJ5J0."W-1 ,  %P+   9
M      " @<<[ 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ >3>I6A[546/U @  *PH  !D              ("!0C\! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !Y-ZE:-(R'R10%   1&0
M&0              @(%N0@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( 'DWJ5ISC7F,;0,  +@6   -              "  ;E' 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ >3>I6I>*NQS     $P(   L
M         ( !44L! %]R96QS+RYR96QS4$L! A0#%     @ >3>I6C%&N@L_
M!   W"(   \              ( !.DP! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( 'DWJ5J*,79?SP$  #,?   :              "  :90 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( 'DWJ5HRX8'AQP$
M !(?   3              "  :U2 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     \ #P 6Q   *54 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>209</ContextCount>
  <ElementCount>287</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Business, Presentation and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements</Role>
      <ShortName>Business, Presentation and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformation</Role>
      <ShortName>Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Fair Value Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueDisclosures</Role>
      <ShortName>Fair Value Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Net (Loss) Income per Share - Basic and Diluted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDiluted</Role>
      <ShortName>Net (Loss) Income per Share - Basic and Diluted</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Business, Presentation and Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationTables</Role>
      <ShortName>Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/BalanceSheetInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Fair Value Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueDisclosuresTables</Role>
      <ShortName>Fair Value Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/FairValueDisclosures</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/Warrants</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Net (Loss) Income per Share - Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedTables</Role>
      <ShortName>Net (Loss) Income per Share - Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDiluted</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/SegmentInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails</Role>
      <ShortName>Business, Presentation and Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Balance Sheet Information - Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Information - Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Balance Sheet Information - Maturities of Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Information - Maturities of Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Balance Sheet Information - Available-for-Sale Investments Gross Unrealized Losses and Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails</Role>
      <ShortName>Balance Sheet Information - Available-for-Sale Investments Gross Unrealized Losses and Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Balance Sheet Information - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Information - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Balance Sheet Information - Schedule of Tax and Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails</Role>
      <ShortName>Balance Sheet Information - Schedule of Tax and Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Balance Sheet Information - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Information - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Fair Value Disclosures - Assets at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails</Role>
      <ShortName>Fair Value Disclosures - Assets at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Fair Value Disclosures - Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Disclosures - Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Fair Value Disclosures - Unobservable Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails</Role>
      <ShortName>Fair Value Disclosures - Unobservable Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Fair Value Disclosures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueDisclosuresNarrativeDetails</Role>
      <ShortName>Fair Value Disclosures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&amp;D (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails</Role>
      <ShortName>Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&amp;D (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Capital Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CapitalStockDetails</Role>
      <ShortName>Capital Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/CapitalStock</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Warrants - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails</Role>
      <ShortName>Warrants - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Net (Loss) Income per Share - Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails</Role>
      <ShortName>Net (Loss) Income per Share - Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Stock-Based Compensation - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Stock-Based Compensation - Schedule of stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Commitments and Contingencies - Supplemental balance sheet information related to the leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails</Role>
      <ShortName>Commitments and Contingencies - Supplemental balance sheet information related to the leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Commitments and Contingencies - Future annual minimum lease payments under non-cancellable operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails</Role>
      <ShortName>Commitments and Contingencies - Future annual minimum lease payments under non-cancellable operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Commitments and Contingencies - Maximum obligation payments per respective agreements and estimated fair value of contingent consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails</Role>
      <ShortName>Commitments and Contingencies - Maximum obligation payments per respective agreements and estimated fair value of contingent consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="kprx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyegatepharma.com/role/SegmentInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="kprx-20250331.htm">kprx-20250331.htm</File>
    <File>kprx-20250331.xsd</File>
    <File>kprx-20250331_cal.xml</File>
    <File>kprx-20250331_def.xml</File>
    <File>kprx-20250331_lab.xml</File>
    <File>kprx-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>kprx-20250331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="610">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kprx-20250331.htm": {
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "kprx-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "kprx-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "kprx-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "kprx-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 243,
   "keyCustom": 44,
   "axisStandard": 24,
   "axisCustom": 1,
   "memberStandard": 36,
   "memberCustom": 25,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 4
   },
   "contextCount": 209,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 574,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 610,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.eyegatepharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-38",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-38",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited",
     "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements",
     "longName": "9952157 - Disclosure - Business, Presentation and Recent Accounting Pronouncements",
     "shortName": "Business, Presentation and Recent Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformation",
     "longName": "9952158 - Disclosure - Balance Sheet Information",
     "shortName": "Balance Sheet Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.eyegatepharma.com/role/FairValueDisclosures",
     "longName": "9952159 - Disclosure - Fair Value Disclosures",
     "shortName": "Fair Value Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.eyegatepharma.com/role/CapitalStock",
     "longName": "9952160 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.eyegatepharma.com/role/Warrants",
     "longName": "9952161 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "kprx:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kprx:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDiluted",
     "longName": "9952162 - Disclosure - Net (Loss) Income per Share - Basic and Diluted",
     "shortName": "Net (Loss) Income per Share - Basic and Diluted",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.eyegatepharma.com/role/StockBasedCompensation",
     "longName": "9952163 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingencies",
     "longName": "9952164 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.eyegatepharma.com/role/SegmentInformation",
     "longName": "9952165 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.eyegatepharma.com/role/SubsequentEvents",
     "longName": "9952166 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies",
     "longName": "9955511 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Policies)",
     "shortName": "Business, Presentation and Recent Accounting Pronouncements (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "kprx:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kprx:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationTables",
     "longName": "9955512 - Disclosure - Balance Sheet Information (Tables)",
     "shortName": "Balance Sheet Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.eyegatepharma.com/role/FairValueDisclosuresTables",
     "longName": "9955513 - Disclosure - Fair Value Disclosures (Tables)",
     "shortName": "Fair Value Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.eyegatepharma.com/role/WarrantsTables",
     "longName": "9955514 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedTables",
     "longName": "9955515 - Disclosure - Net (Loss) Income per Share - Basic and Diluted (Tables)",
     "shortName": "Net (Loss) Income per Share - Basic and Diluted (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.eyegatepharma.com/role/StockBasedCompensationTables",
     "longName": "9955516 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables",
     "longName": "9955517 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "kprx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kprx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.eyegatepharma.com/role/SegmentInformationTables",
     "longName": "9955518 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
     "longName": "9955519 - Disclosure - Business, Presentation and Recent Accounting Pronouncements (Details)",
     "shortName": "Business, Presentation and Recent Accounting Pronouncements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-52",
      "name": "kprx:CollaborativeArrangementNumberOfPerformanceObligations",
      "unitRef": "performance_obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9955520 - Disclosure - Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails",
     "longName": "9955521 - Disclosure - Balance Sheet Information - Short-term Investments (Details)",
     "shortName": "Balance Sheet Information - Short-term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails",
     "longName": "9955522 - Disclosure - Balance Sheet Information - Maturities of Short-term Investments (Details)",
     "shortName": "Balance Sheet Information - Maturities of Short-term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails",
     "longName": "9955523 - Disclosure - Balance Sheet Information - Available-for-Sale Investments Gross Unrealized Losses and Fair Value (Details)",
     "shortName": "Balance Sheet Information - Available-for-Sale Investments Gross Unrealized Losses and Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "unitRef": "count",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "unitRef": "count",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9955524 - Disclosure - Balance Sheet Information - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Balance Sheet Information - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "kprx:PrepaidResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "kprx:PrepaidResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails",
     "longName": "9955525 - Disclosure - Balance Sheet Information - Schedule of Tax and Other Receivables (Details)",
     "shortName": "Balance Sheet Information - Schedule of Tax and Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "kprx:ResearchTaxCreditsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfTaxAndOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "kprx:ResearchTaxCreditsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfTaxAndOtherReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails",
     "longName": "9955526 - Disclosure - Balance Sheet Information - Accrued Expenses (Details)",
     "shortName": "Balance Sheet Information - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
     "longName": "9955527 - Disclosure - Fair Value Disclosures - Assets at Fair Value (Details)",
     "shortName": "Fair Value Disclosures - Assets at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails",
     "longName": "9955528 - Disclosure - Fair Value Disclosures - Liabilities at Fair Value (Details)",
     "shortName": "Fair Value Disclosures - Liabilities at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails",
     "longName": "9955529 - Disclosure - Fair Value Disclosures - Unobservable Level 3 Inputs (Details)",
     "shortName": "Fair Value Disclosures - Unobservable Level 3 Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.eyegatepharma.com/role/FairValueDisclosuresNarrativeDetails",
     "longName": "9955530 - Disclosure - Fair Value Disclosures - Narrative (Details)",
     "shortName": "Fair Value Disclosures - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "kprx:ChangeInContingentConsiderationFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "kprx:ChangeInContingentConsiderationFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
     "longName": "9955531 - Disclosure - Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&D (Details)",
     "shortName": "Fair Value Disclosures - Estimate to Measure Contingent Consideration Unobservable Level 3 In-process R&D (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-132",
      "name": "kprx:InProcessResearchAndDevelopmentMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "kprx:InProcessResearchAndDevelopmentMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.eyegatepharma.com/role/CapitalStockDetails",
     "longName": "9955532 - Disclosure - Capital Stock (Details)",
     "shortName": "Capital Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails",
     "longName": "9955533 - Disclosure - Warrants - Schedule of Warrant Activity (Details)",
     "shortName": "Warrants - Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails",
     "longName": "9955534 - Disclosure - Net (Loss) Income per Share - Basic and Diluted (Details)",
     "shortName": "Net (Loss) Income per Share - Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "9955535 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails",
     "longName": "9955536 - Disclosure - Stock-Based Compensation - Stock-based Compensation (Details)",
     "shortName": "Stock-Based Compensation - Stock-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails",
     "longName": "9955537 - Disclosure - Stock-Based Compensation - Schedule of stock option activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails",
     "longName": "9955538 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)",
     "shortName": "Stock-Based Compensation - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-177",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-176",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "longName": "9955539 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "kprx:LesseeNumberOfOperatingLeases",
      "unitRef": "operatinglease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kprx:LesseeNumberOfOperatingLeases",
      "unitRef": "operatinglease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails",
     "longName": "9955540 - Disclosure - Commitments and Contingencies - Supplemental balance sheet information related to the leases (Details)",
     "shortName": "Commitments and Contingencies - Supplemental balance sheet information related to the leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "kprx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails",
     "longName": "9955541 - Disclosure - Commitments and Contingencies - Future annual minimum lease payments under non-cancellable operating leases (Details)",
     "shortName": "Commitments and Contingencies - Future annual minimum lease payments under non-cancellable operating leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails",
     "longName": "9955542 - Disclosure - Commitments and Contingencies - Maximum obligation payments per respective agreements and estimated fair value of contingent consideration (Details)",
     "shortName": "Commitments and Contingencies - Maximum obligation payments per respective agreements and estimated fair value of contingent consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.eyegatepharma.com/role/SegmentInformationDetails",
     "longName": "9955543 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "kprx_A12MonthLeaseAdelaideAustraliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "A12MonthLeaseAdelaideAustraliaMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adelaide Lease",
        "label": "12 Month Lease, Adelaide Australia [Member]",
        "documentation": "12 Month Lease, Adelaide Australia"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_A18MonthLeaseEncinitasCAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "A18MonthLeaseEncinitasCAMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Encinitas Lease",
        "label": "18 Month Lease, Encinitas, CA [Member]",
        "documentation": "18 Month Lease, Encinitas, CA"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_A2YearLeasePerthAndBrisbaneAustraliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "A2YearLeasePerthAndBrisbaneAustraliaMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Perth and Brisbane Lease",
        "label": "2 Year Lease Perth and Brisbane Australia [Member]",
        "documentation": "2 Year Lease Perth, Australia"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_A3Year3MonthLeaseEncinitasCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "A3Year3MonthLeaseEncinitasCaliforniaMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Encinitas Lease",
        "label": "3 Year 3 Month Lease, Encinitas California [Member]",
        "documentation": "3 Year 3 Month Lease, Encinitas California"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_A5YearLeaseViennaAustriaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "A5YearLeaseViennaAustriaMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vienna Lease",
        "label": "5 Year Lease, Vienna Austria [Member]",
        "documentation": "5 Year Lease, Vienna Austria"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts Payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r782"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Receivables",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "kprx_AccruedClinicalExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "AccruedClinicalExpensesPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Clinical Expenses",
        "label": "Accrued Clinical Expenses [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accrued clinical expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r76"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Expenses",
        "totalLabel": "Total Accrued Expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Professional Fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Other Comprehensive Loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r53",
      "r109",
      "r575",
      "r602",
      "r603",
      "r1079"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r16",
      "r455",
      "r458",
      "r519",
      "r598",
      "r599",
      "r916",
      "r917",
      "r918",
      "r971",
      "r972",
      "r973",
      "r974"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r782",
      "r1143"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r971",
      "r972",
      "r973",
      "r974",
      "r1080",
      "r1145"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to Reconcile Net (Loss) Income to Net Cash (Used in) Provided by Operating Activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r821",
      "r831",
      "r863"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r824",
      "r834",
      "r866"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r859",
      "r867",
      "r871",
      "r879"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Anti-dilutive shares excluded from the calculation of net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of land",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Backed Securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r748",
      "r783",
      "r993",
      "r998",
      "r999"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r87",
      "r105",
      "r129",
      "r130",
      "r131",
      "r169",
      "r179",
      "r196",
      "r199",
      "r240",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r445",
      "r447",
      "r497",
      "r561",
      "r562",
      "r570",
      "r650",
      "r729",
      "r730",
      "r742",
      "r782",
      "r788",
      "r789",
      "r802",
      "r1025",
      "r1026",
      "r1098"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r110",
      "r129",
      "r130",
      "r131",
      "r240",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r445",
      "r447",
      "r497",
      "r782",
      "r1025",
      "r1026",
      "r1098"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets Measured at Fair Value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r770"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r260",
      "r569"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one to five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one to five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r565"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r564"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r260",
      "r470",
      "r492",
      "r493",
      "r494",
      "r495",
      "r558",
      "r703",
      "r770",
      "r773",
      "r780",
      "r985",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Count",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]",
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_BayonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "BayonMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayon",
        "label": "Bayon [Member]",
        "documentation": "Represents information pertaining to Bayon."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Domain]",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r605",
      "r751",
      "r752",
      "r1067",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Axis]",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r605",
      "r751",
      "r752",
      "r1067",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration [Line Items]",
        "label": "Business Combination, Contingent Consideration [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r439",
      "r440",
      "r441"
     ]
    },
    "kprx_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value of Contingent Consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liabilities",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value of Contingent Consideration",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r963"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum Obligation per Agreements",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r439",
      "r472",
      "r473",
      "r474",
      "r757",
      "r759"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, measurement input, rate",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure liability in contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r439",
      "r472",
      "r473",
      "r474",
      "r757",
      "r759"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "verboseLabel": "Non-current",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails",
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r103",
      "r706"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Cash Equivalents Measured at Fair Value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash, Beginning of Period",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash, End of Period",
        "totalLabel": "Total Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r59",
      "r128"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r59"
     ]
    },
    "kprx_ChangeInContingentConsiderationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ChangeInContingentConsiderationFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "label": "Change in Contingent Consideration Fair Value",
        "documentation": "The amount of change in contingent consideration fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106",
      "r107",
      "r108",
      "r129",
      "r131",
      "r156",
      "r157",
      "r162",
      "r164",
      "r171",
      "r172",
      "r240",
      "r288",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r302",
      "r303",
      "r305",
      "r306",
      "r308",
      "r311",
      "r314",
      "r315",
      "r318",
      "r321",
      "r328",
      "r497",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r638",
      "r658",
      "r676",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r889",
      "r966",
      "r968",
      "r975"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r171",
      "r305",
      "r314",
      "r315",
      "r316",
      "r318",
      "r321",
      "r326",
      "r328",
      "r453",
      "r610",
      "r611",
      "r612",
      "r613",
      "r743",
      "r889",
      "r964",
      "r966"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails",
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132",
      "r329"
     ]
    },
    "kprx_ClassOfWarrantOrRightNumberOfAwardsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ClassOfWarrantOrRightNumberOfAwardsRollForward",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Common Shares Issuable Upon Exercise of Outstanding Warrants",
        "label": "Class Of Warrant Or Right, Number Of Awards [Roll Forward]",
        "documentation": "Class Of Warrant Or Right, Number Of Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants issued to purchase the shares (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "kprx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ClassOfWarrantOrRightThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, threshold consecutive trading days",
        "label": "Class of Warrant or Right, Threshold Consecutive Trading Days",
        "documentation": "Class of Warrant or Right, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ClassOfWarrantOrRightThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ClassOfWarrantOrRightThresholdTradingDays",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, threshold trading days",
        "label": "Class of Warrant or Right, Threshold Trading Days",
        "documentation": "Class of Warrant or Right, Threshold Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, volume weighted average price of common stock (in usd per share)",
        "label": "Class of Warrant or Right, Volume Weighted Average Price Of Common Stock",
        "documentation": "Class of Warrant or Right, Volume Weighted Average Price Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Class Of Warrant Or Right, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Term in Years",
        "label": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ClinicalTrialsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ClinicalTrialsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Trials",
        "label": "Clinical Trials Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "kprx_CollaborationCreditOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "CollaborationCreditOperatingExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Collaboration and Research Credits",
        "negatedTerseLabel": "KIO-301 Collaboration Credit",
        "label": "Collaboration Credit, Operating Expense",
        "documentation": "Collaboration Credit, Operating Expense"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_CollaborationCreditReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "CollaborationCreditReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Collaboration Credit",
        "label": "Collaboration Credit Receivable, Current",
        "documentation": "Collaboration Credit Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "kprx_CollaborativeArrangementNumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "CollaborativeArrangementNumberOfPerformanceObligations",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Collaborative Arrangement, Number Of Performance Obligations",
        "documentation": "Collaborative Arrangement, Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r78",
      "r572",
      "r637"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r281",
      "r282",
      "r699",
      "r1018",
      "r1020"
     ]
    },
    "kprx_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Line Items]",
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Table]",
        "documentation": "Commitments and Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock Reserved for Future Issuance",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794",
      "r796",
      "r797",
      "r798",
      "r799",
      "r971",
      "r972",
      "r974",
      "r1080",
      "r1142",
      "r1145"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r638"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47",
      "r638",
      "r656",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock, $0.01 Par Value: 150,000,000 shares authorized; 3,000,788 shares issued and outstanding at March\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r303",
      "r310",
      "r574",
      "r782"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (Loss) Income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r72",
      "r115",
      "r117",
      "r122",
      "r559",
      "r583"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Comprehensive (Loss) Income:",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Fair Value Estimated",
        "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure",
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083",
      "r1087"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities",
        "verboseLabel": "Corporate Debt Securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r748",
      "r750",
      "r770",
      "r783",
      "r790",
      "r1139"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r129",
      "r134",
      "r135",
      "r297",
      "r316",
      "r520",
      "r539",
      "r568",
      "r708",
      "r709",
      "r710",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r1023"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r1023"
     ]
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Credit Losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r266"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r265",
      "r736"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r265"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Count",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r1000"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Investments Gross Unrealized Losses and Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r736",
      "r1005"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationMaturitiesofShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r571"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and Amortization of Intangible Assets",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r124",
      "r169",
      "r183",
      "r199",
      "r711",
      "r729",
      "r730"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (Loss) Income per Common Share - Basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r123",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r156",
      "r162",
      "r163",
      "r164",
      "r168",
      "r301",
      "r375",
      "r388",
      "r444",
      "r467",
      "r468",
      "r560",
      "r584",
      "r719"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (Loss) Income per Common Share - Diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r123",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r162",
      "r163",
      "r164",
      "r168",
      "r301",
      "r375",
      "r388",
      "r444",
      "r467",
      "r468",
      "r560",
      "r584",
      "r719"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDiluted"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (Loss) Income per Share - Basic and Diluted",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r165",
      "r166",
      "r167"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "kprx_EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Employee and Non Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table Text Block]",
        "documentation": "Tabular disclosure of employee and non employee service share based compensation allocation of recognized period costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payroll and Benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized compensation expense related to restricted stock",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized compensation expense related to options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "kprx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r97",
      "r98",
      "r99",
      "r118",
      "r119",
      "r120",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r170",
      "r241",
      "r242",
      "r277",
      "r300",
      "r330",
      "r375",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r389",
      "r443",
      "r444",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r466",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r519",
      "r581",
      "r598",
      "r599",
      "r600",
      "r615",
      "r676"
     ]
    },
    "kprx_EquityIncentivePlan2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "EquityIncentivePlan2014Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Plan",
        "label": "Equity Incentive Plan 2014 [Member]",
        "documentation": "Two Thousand Fourteen Plan"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_EquityLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "EquityLineOfCreditMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Line Of Credit",
        "label": "Equity Line Of Credit [Member]",
        "documentation": "Equity Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r821",
      "r831",
      "r863"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r818",
      "r828",
      "r860"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "kprx_FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment Income and Fair Value Adjustments on Marketable Securities and Cash Equivalents",
        "label": "Fair Value Adjustment and Investment Income of Marketable Securities and Cash Equivalents",
        "documentation": "Fair Value Adjustment and Investment Income of Marketable Securities and Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r484",
      "r770"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r484",
      "r770"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r757",
      "r759",
      "r773"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r757",
      "r759",
      "r773"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unobservable Level 3 Inputs",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r773"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Measured on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r483",
      "r484",
      "r486",
      "r493",
      "r526",
      "r527",
      "r528",
      "r703",
      "r740",
      "r741",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r770",
      "r773",
      "r780"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r474",
      "r770",
      "r1085",
      "r1088"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r479",
      "r481",
      "r482",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r557",
      "r770",
      "r774"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r332",
      "r337",
      "r338",
      "r471",
      "r484",
      "r493",
      "r526",
      "r703",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r770",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r332",
      "r337",
      "r338",
      "r340",
      "r471",
      "r472",
      "r484",
      "r493",
      "r527",
      "r703",
      "r740",
      "r741",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r770",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r471",
      "r472",
      "r473",
      "r474",
      "r484",
      "r493",
      "r528",
      "r703",
      "r740",
      "r741",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r770",
      "r773",
      "r780"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Liabilities Measured on Recurring Basis",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r485"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r474",
      "r770",
      "r1085",
      "r1088"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r483",
      "r484",
      "r486",
      "r493",
      "r526",
      "r527",
      "r528",
      "r703",
      "r740",
      "r741",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r770",
      "r773",
      "r780"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1088"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r247",
      "r248",
      "r249",
      "r250",
      "r255",
      "r264",
      "r266",
      "r267",
      "r299",
      "r326",
      "r453",
      "r464",
      "r491",
      "r496",
      "r499",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r567",
      "r582",
      "r736",
      "r770",
      "r771",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r783",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1081",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and Administrative",
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r660"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant",
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_HoldersOwingMoreThanTenPercentageVotingRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "HoldersOwingMoreThanTenPercentageVotingRightsMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Holders Owing More Than Ten Percentage Voting Rights",
        "label": "Holders Owing More Than Ten Percentage Voting Rights [Member]",
        "documentation": "n/a."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_InProcessResearchAndDevelopmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "InProcessResearchAndDevelopmentMeasurementInput",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process R&amp;D",
        "label": "In Process Research And Development, Measurement Input",
        "documentation": "In Process Research And Development, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research and Development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-Process Research and Development",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) Income Before Income Tax Expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r82",
      "r86",
      "r561",
      "r563",
      "r579",
      "r713",
      "r715",
      "r716",
      "r723",
      "r729",
      "r977",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r449",
      "r450",
      "r451",
      "r452",
      "r476",
      "r480",
      "r485",
      "r498",
      "r499",
      "r500",
      "r595",
      "r597",
      "r661",
      "r702",
      "r703",
      "r757",
      "r758",
      "r768",
      "r769",
      "r772",
      "r780",
      "r1066",
      "r1068",
      "r1112"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r449",
      "r450",
      "r451",
      "r452",
      "r476",
      "r480",
      "r485",
      "r498",
      "r499",
      "r500",
      "r595",
      "r597",
      "r661",
      "r702",
      "r703",
      "r757",
      "r758",
      "r768",
      "r769",
      "r772",
      "r780",
      "r1066",
      "r1068",
      "r1112"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income Tax Expense",
        "terseLabel": "Income Tax Expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r95",
      "r129",
      "r150",
      "r151",
      "r169",
      "r184",
      "r199",
      "r380",
      "r381",
      "r384",
      "r586",
      "r713",
      "r715",
      "r716",
      "r756"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax receivable",
        "label": "Income Taxes Receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax Receivables",
        "totalLabel": "Total Tax Receivables",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r903"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts Payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Collaboration Receivables",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "kprx_IncreaseDecreaseInAccruedCollaborationCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "IncreaseDecreaseInAccruedCollaborationCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Collaboration Credit",
        "label": "Increase (Decrease) in Accrued Collaboration Credit",
        "documentation": "Increase (Decrease) in Accrued Collaboration Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax Receivables",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in Operating Assets and Liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r963"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other Assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "kprx_IncreaseDecreaseInRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "IncreaseDecreaseInRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of Operating Lease Right-of-Use Assets",
        "label": "Increase Decrease In Right-Of-Use Assets",
        "documentation": "Represents increase decrease right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_IncreaseDecreaseResearchTaxCreditsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "IncreaseDecreaseResearchTaxCreditsReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research Credit Receivables",
        "label": "Increase (Decrease) Research Tax Credits Receivables",
        "documentation": "Increase (Decrease) Research Tax Credits Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r274",
      "r276",
      "r705",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-Process R&amp;D",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r276",
      "r705"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r274",
      "r276",
      "r705",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r859",
      "r867",
      "r871",
      "r879"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r883"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r883"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r883"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and In-Process R&amp;D, Net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r1014",
      "r1015"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Income, Net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r767",
      "r920",
      "r979"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest Income, Net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r182",
      "r199",
      "r729",
      "r919"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r606",
      "r607",
      "r608",
      "r609",
      "r683",
      "r684"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Short-term Investments Measured at Fair Value",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083",
      "r1087",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "kprx_KIO101Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "KIO101Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KIO-101",
        "label": "KIO-101 [Member]",
        "documentation": "KIO-101"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_KIO104Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "KIO104Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KIO-104",
        "label": "KIO-104 [Member]",
        "documentation": "KIO-104"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_KIO104NetOfAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "KIO104NetOfAdjustmentMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KIO-104",
        "label": "KIO-104, Net Of Adjustment [Member]",
        "documentation": "KIO-104, Net Of Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_KIO201Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "KIO201Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KIO-201",
        "label": "KIO-201 [Member]",
        "documentation": "KIO-201"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_KIO301Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "KIO301Member",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KIO-301",
        "label": "KIO-301 [Member]",
        "documentation": "KIO-301"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r891"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r891"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r781"
     ]
    },
    "kprx_LesseeNumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "LesseeNumberOfOperatingLeases",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating leases",
        "label": "Lessee, Number Of Operating Leases",
        "documentation": "Lessee, Number Of Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Annual Minimum Lease Payments Under Non-Cancellable Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r965",
      "r970",
      "r1107"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r965",
      "r970",
      "r1107"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r965",
      "r970",
      "r1107"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r965",
      "r970",
      "r1107"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remaining months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Amounts Representing Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "kprx_LesseeOperatingLeaseMonthlyRentPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "LesseeOperatingLeaseMonthlyRentPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for rent",
        "label": "Lessee, Operating Lease, Monthly Rent Payment",
        "documentation": "Lessee, Operating Lease, Monthly Rent Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r1094"
     ]
    },
    "kprx_LesseeOperatingLeaseSecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "LesseeOperatingLeaseSecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Lessee, Operating Lease, Security Deposit",
        "documentation": "Lessee, Operating Lease, Security Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "kprx_LesseeOperatingLeaseTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination period",
        "label": "Lessee, Operating Lease, Termination Period",
        "documentation": "Lessee, Operating Lease, Termination Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r38",
      "r39",
      "r40",
      "r42",
      "r43",
      "r44",
      "r45",
      "r129",
      "r130",
      "r131",
      "r240",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r446",
      "r447",
      "r448",
      "r497",
      "r636",
      "r722",
      "r742",
      "r802",
      "r1025",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r79",
      "r577",
      "r782",
      "r788",
      "r789",
      "r964",
      "r969",
      "r1004",
      "r1093"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r102",
      "r129",
      "r130",
      "r131",
      "r240",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r446",
      "r447",
      "r448",
      "r497",
      "r782",
      "r1025",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Contingent Consideration",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r1082"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r43",
      "r44",
      "r45",
      "r129",
      "r130",
      "r131",
      "r240",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r446",
      "r447",
      "r448",
      "r497",
      "r1025",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r77",
      "r1109"
     ]
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r41",
      "r964",
      "r967",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r41",
      "r964",
      "r967",
      "r1023",
      "r1024"
     ]
    },
    "kprx_LiquidityAndCapitalResourcesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "LiquidityAndCapitalResourcesPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity And Capital Resources",
        "label": "Liquidity And Capital Resources [Policy Text Block]",
        "documentation": "Liquidity And Capital Resources"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_MaximGroupLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "MaximGroupLLCMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maxim Group LLC",
        "label": "Maxim Group LLC [Member]",
        "documentation": "Maxim Group LLC"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r283",
      "r284",
      "r285",
      "r286",
      "r341",
      "r368",
      "r369",
      "r370",
      "r376",
      "r474",
      "r555",
      "r594",
      "r596",
      "r604",
      "r628",
      "r629",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r701",
      "r735",
      "r743",
      "r753",
      "r757",
      "r759",
      "r760",
      "r773",
      "r774",
      "r778",
      "r779",
      "r785",
      "r1027",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment discount rate",
        "verboseLabel": "Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r759",
      "r760",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r472",
      "r473",
      "r474",
      "r757",
      "r759",
      "r760",
      "r773"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r757",
      "r759",
      "r760",
      "r773"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r283",
      "r284",
      "r285",
      "r286",
      "r341",
      "r368",
      "r369",
      "r370",
      "r376",
      "r474",
      "r555",
      "r594",
      "r596",
      "r604",
      "r628",
      "r629",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r701",
      "r735",
      "r743",
      "r753",
      "r757",
      "r759",
      "r760",
      "r773",
      "r774",
      "r778",
      "r785",
      "r1027",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "kprx_MultiPeriodExcessEarningsMethodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "MultiPeriodExcessEarningsMethodMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multi-Period Excess Earnings Method",
        "label": "Multi-Period Excess Earnings Method [Member]",
        "documentation": "Multi-Period Excess Earnings Method"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business, Presentation and Recent Accounting Pronouncements",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r173",
      "r720",
      "r721"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financing Activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash (Used in) Provided by Operating Activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r62"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (Loss) Income",
        "terseLabel": "Net (Loss) Income",
        "verboseLabel": "Net (Loss) Income",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r62",
      "r83",
      "r99",
      "r100",
      "r114",
      "r116",
      "r120",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r161",
      "r240",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r301",
      "r304",
      "r307",
      "r312",
      "r375",
      "r388",
      "r444",
      "r468",
      "r497",
      "r580",
      "r657",
      "r674",
      "r675",
      "r713",
      "r715",
      "r716",
      "r800",
      "r1025"
     ]
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (Loss) Income Attributable to Common Shareholders",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r164"
     ]
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (Loss) Income Attributable to Common Shareholders",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158",
      "r159",
      "r160",
      "r164"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption of Accounting Standards and Accounting Standards Pending Adoption",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r859",
      "r867"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosures of Noncash Operating and Financing Activities",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncumulativePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncumulativePreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, as Converted into Common Stock",
        "label": "Noncumulative Preferred Stock [Member]",
        "documentation": "Preferred stock upon which unpaid dividends do not accrue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income, Net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income (Expense), Net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_NumberOfGeographicSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "NumberOfGeographicSegments",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic segments",
        "label": "Number Of Geographic Segments",
        "documentation": "Number Of Geographic Segments"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_NumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "NumberOfLicenseAgreements",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of license agreements",
        "label": "Number Of License Agreements",
        "documentation": "Number Of License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r978"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Expenses:",
        "terseLabel": "Operating Expenses [Abstract]",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating (Loss) Income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r713",
      "r716",
      "r723",
      "r977",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities",
        "negatedLabel": "Less Current Portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesFutureannualminimumleasepaymentsundernoncancellableoperatingleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Operating Lease Liabilities",
        "verboseLabel": "Total",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Right-of-Use Assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Discount Rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r781"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesSupplementalbalancesheetinformationrelatedtotheleasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Remaining Lease Term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r781"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign Currency Translation Adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r72"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Loss on Marketable Securities",
        "verboseLabel": "Unrealized Loss on Marketable Securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r581"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign Currency Translation Adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r581"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (Expense) Income, Net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r767"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r1007"
     ]
    },
    "kprx_OtherTaxReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "OtherTaxReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails": {
       "parentTag": "us-gaap_IncomeTaxesReceivable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Tax Receivables",
        "label": "Other Tax Receivables, Current",
        "documentation": "Other Tax Receivables, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r823",
      "r833",
      "r865"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "kprx_PanoptesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "PanoptesMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Panoptes",
        "label": "Panoptes [Member]",
        "documentation": "Represents information pertaining to acquisition of Panoptes Pharma Ges.m.b.H."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Issuance Costs for Private Placement",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of Marketable Securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r125",
      "r208"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "kprx_PercentageOfExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "PercentageOfExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price",
        "label": "Percentage of Exercise Price",
        "documentation": "The percentage of exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "kprx_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_PreferredStockDesignatedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "PreferredStockDesignatedShares",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock designated shares (in shares)",
        "label": "Preferred Stock Designated Shares",
        "documentation": "The number of designated preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r796",
      "r797",
      "r798",
      "r799",
      "r1142",
      "r1145"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r314"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r638"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r314"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r638",
      "r656",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at March\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r303",
      "r309",
      "r573",
      "r782"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "totalLabel": "Total Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrentAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expense, Current [Abstract]",
        "label": "Prepaid Expense, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_PrepaidGeneralAndAdministrative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "PrepaidGeneralAndAdministrative",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid General and Administrative",
        "label": "Prepaid General And Administrative",
        "documentation": "Prepaid General And Administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r737",
      "r1007"
     ]
    },
    "kprx_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Research and Development",
        "label": "Prepaid Research And Development",
        "documentation": "Prepaid Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ProbabilityOfSuccessForDevelopmentPhaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ProbabilityOfSuccessForDevelopmentPhaseMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of success for next development phase",
        "label": "Probability Of Success For Development Phase [Member]",
        "documentation": "Probability Of Success For Development Phase"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ProbabilityOfSuccessForPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ProbabilityOfSuccessForPaymentMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of success for payment",
        "label": "Probability of Success for Payment [Member]",
        "documentation": "Probability of Success for Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaborators",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Proceeds from Private Placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of Marketable Securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r986"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of Marketable Securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r125",
      "r208",
      "r239"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of Warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r556",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r704",
      "r712",
      "r715",
      "r716",
      "r744",
      "r745",
      "r784",
      "r785",
      "r786",
      "r787",
      "r791",
      "r890",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r1021",
      "r1022",
      "r1111",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1140",
      "r1141"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r556",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r704",
      "r712",
      "r715",
      "r716",
      "r744",
      "r745",
      "r784",
      "r785",
      "r786",
      "r787",
      "r791",
      "r890",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r1021",
      "r1022",
      "r1111",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1140",
      "r1141"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r517",
      "r566",
      "r578",
      "r782"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r283",
      "r284",
      "r285",
      "r286",
      "r331",
      "r341",
      "r368",
      "r369",
      "r370",
      "r374",
      "r376",
      "r474",
      "r529",
      "r538",
      "r555",
      "r594",
      "r596",
      "r604",
      "r628",
      "r629",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r701",
      "r735",
      "r743",
      "r753",
      "r757",
      "r759",
      "r760",
      "r773",
      "r774",
      "r778",
      "r779",
      "r785",
      "r794",
      "r1019",
      "r1027",
      "r1085",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r283",
      "r284",
      "r285",
      "r286",
      "r331",
      "r341",
      "r368",
      "r369",
      "r370",
      "r374",
      "r376",
      "r474",
      "r529",
      "r538",
      "r555",
      "r594",
      "r596",
      "r604",
      "r628",
      "r629",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r701",
      "r735",
      "r743",
      "r753",
      "r757",
      "r759",
      "r760",
      "r773",
      "r774",
      "r778",
      "r779",
      "r785",
      "r794",
      "r1019",
      "r1027",
      "r1085",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r26"
     ]
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table]",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r818",
      "r828",
      "r860"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r129",
      "r134",
      "r135",
      "r297",
      "r316",
      "r520",
      "r539",
      "r568",
      "r708",
      "r709",
      "r710",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "kprx_ResearchAndDevelopmentAllocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ResearchAndDevelopmentAllocationAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Allocation [Axis]",
        "label": "Research and Development Allocation [Axis]",
        "documentation": "Research and Development Allocation"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ResearchAndDevelopmentAllocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ResearchAndDevelopmentAllocationDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Allocation [Domain]",
        "label": "Research and Development Allocation [Domain]",
        "documentation": "Research and Development Allocation [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development",
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r702",
      "r713",
      "r714",
      "r729",
      "r1106"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ResearchAndDevelopmentRefundsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ResearchAndDevelopmentRefundsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refunds for Research and Development",
        "label": "Research and Development, Refunds, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for refunds assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ResearchTaxCreditsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ResearchTaxCreditsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails": {
       "parentTag": "us-gaap_IncomeTaxesReceivable",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationScheduleofTaxandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credits",
        "label": "Research Tax Credits Receivable, Current",
        "documentation": "Research Tax Credits Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r819",
      "r829",
      "r861"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r820",
      "r830",
      "r862"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r827",
      "r837",
      "r869"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationCashCashEquivalentsandRestrictedCashDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Cash",
        "terseLabel": "Restricted Cash, Non-current",
        "label": "Restricted Cash and Cash Equivalent, Noncurrent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r92",
      "r128"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Deficit",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r68",
      "r576",
      "r601",
      "r603",
      "r614",
      "r639",
      "r782"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r241",
      "r242",
      "r277",
      "r300",
      "r375",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r389",
      "r443",
      "r444",
      "r454",
      "r456",
      "r457",
      "r459",
      "r466",
      "r508",
      "r509",
      "r598",
      "r600",
      "r615",
      "r1145"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Revenue",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r1074"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME",
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Revenue",
        "terseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r121",
      "r129",
      "r130",
      "r131",
      "r169",
      "r180",
      "r181",
      "r195",
      "r199",
      "r203",
      "r205",
      "r206",
      "r240",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r497",
      "r561",
      "r563",
      "r729",
      "r767",
      "r788",
      "r789",
      "r1025"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Creation of Right-of-Use Assets and Related Lease Liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r781"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Potential Common Stock Equivalents are not Included in the Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesMaximumobligationpaymentsperrespectiveagreementsandestimatedfairvalueofcontingentconsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration [Table]",
        "label": "Business Combination, Contingent Consideration [Table]",
        "documentation": "Disclosure of information about contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r439",
      "r440",
      "r441"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maximum Obligation Payments Per Respective Agreements and Estimated Fair Value of Contingent Consideration",
        "label": "Business Combination, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1073"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of of Cash and Cash Equivalents and Restricted Cash",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "kprx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the components of Prepaid expenses and Other Current Assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r1110"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "kprx_ScheduleOfShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ScheduleOfShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short term Investments",
        "label": "Schedule Of Short Term Investments [Table Text Block]",
        "documentation": "Schedule Of Short Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r66",
      "r67",
      "r68",
      "r106",
      "r107",
      "r108",
      "r171",
      "r314",
      "r315",
      "r316",
      "r318",
      "r321",
      "r326",
      "r328",
      "r453",
      "r610",
      "r611",
      "r612",
      "r613",
      "r743",
      "r889",
      "r964",
      "r966"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "kprx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Supplemental Balance Sheet Information Related To Leases",
        "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "documentation": "Schedule Of Supplemental Balance Sheet Information Related To Leases"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ScheduleOfTaxAndOtherReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ScheduleOfTaxAndOtherReceivablesTableTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Tax and Other Receivables",
        "label": "Schedule Of Tax And Other Receivables [Table Text Block]",
        "documentation": "Schedule Of Tax And Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r169",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r185",
      "r186",
      "r187",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r206",
      "r724",
      "r727",
      "r728",
      "r729",
      "r731",
      "r733",
      "r734"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Segment Expenses",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r186",
      "r187",
      "r199",
      "r729"
     ]
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherSignificantReconcilingItemLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Segment and Geographical Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r202",
      "r205",
      "r725",
      "r726",
      "r732"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Preferred Stock",
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E Preferred Stock",
        "label": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesFPreferredStockMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series F Preferred Stock",
        "label": "Series F Preferred Stock [Member]",
        "documentation": "Series F preferred stock."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r1028",
      "r1030"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Term in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised Weighted Average Exercise Price",
        "documentation": "The weighted average exercise price of Vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired In Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired In Period"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expired Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted Weighted Average Exercise Price",
        "documentation": "The weighted average exercise price of granted awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued (in shares)",
        "verboseLabel": "Awarded (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded (in usd per shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in shares)",
        "periodEndLabel": "Outstanding at end of year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in usd per share)",
        "periodEndLabel": "Outstanding at end of year (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "negatedTerseLabel": "Released (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Released (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in usd per share)",
        "periodEndLabel": "Outstanding at end of year (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price",
        "documentation": "The weighted average exercise price of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shares issuable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "kprx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Term in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in shares)",
        "periodEndLabel": "Outstanding at end of year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in usd per share)",
        "periodEndLabel": "Outstanding at end of year (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable and vested at the end of year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable and vested at end of year (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expired (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationScheduleofstockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable and vested at the end of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning of year",
        "verboseLabel": "End of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1036"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "verboseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r905"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106",
      "r107",
      "r108",
      "r129",
      "r131",
      "r156",
      "r157",
      "r162",
      "r164",
      "r171",
      "r172",
      "r240",
      "r288",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r302",
      "r303",
      "r305",
      "r306",
      "r308",
      "r311",
      "r314",
      "r315",
      "r318",
      "r321",
      "r328",
      "r497",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r638",
      "r658",
      "r676",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r889",
      "r966",
      "r968",
      "r975"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47",
      "r50",
      "r51",
      "r97",
      "r98",
      "r99",
      "r118",
      "r119",
      "r120",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r170",
      "r241",
      "r242",
      "r277",
      "r300",
      "r330",
      "r375",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r389",
      "r443",
      "r444",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r466",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r519",
      "r581",
      "r598",
      "r599",
      "r600",
      "r615",
      "r676"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r170",
      "r302",
      "r303",
      "r305",
      "r308",
      "r509",
      "r556",
      "r606",
      "r616",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r715",
      "r716",
      "r795",
      "r1144"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.eyegatepharma.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r170",
      "r207",
      "r302",
      "r303",
      "r305",
      "r308",
      "r509",
      "r556",
      "r606",
      "r616",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r715",
      "r716",
      "r795",
      "r1144"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r822",
      "r832",
      "r864"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46",
      "r47",
      "r68",
      "r610",
      "r676",
      "r690"
     ]
    },
    "kprx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock from Warrant Exercises (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "documentation": "Number of stock issued as a result of the exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46",
      "r47",
      "r68",
      "r615",
      "r676",
      "r690",
      "r801"
     ]
    },
    "kprx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock from Warrant Exercises",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "documentation": "Value of stock issued as a result of the exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r63",
      "r640",
      "r656",
      "r677",
      "r678",
      "r782",
      "r802",
      "r964",
      "r968",
      "r969",
      "r1004",
      "r1093",
      "r1145"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r313",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r330",
      "r453",
      "r465",
      "r679",
      "r681",
      "r694"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r680"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSunaudited",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Information",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1097"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "kprx_TrancheAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "TrancheAWarrantsMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A Warrants",
        "label": "Tranche A Warrants [Member]",
        "documentation": "Tranche A Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_TrancheBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "TrancheBWarrantsMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B Warrants",
        "label": "Tranche B Warrants [Member]",
        "documentation": "Tranche B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r299",
      "r326",
      "r453",
      "r464",
      "r491",
      "r496",
      "r499",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r567",
      "r582",
      "r770",
      "r771",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r783",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1081",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "kprx_UBSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "UBSMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UBS",
        "label": "UBS [Member]",
        "documentation": "UBS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationAvailableforSaleInvestmentsGrossUnrealizedLossesandFairValueDetails",
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Agency Securities",
        "verboseLabel": "Government Agency Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r746",
      "r748",
      "r1108"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/BalanceSheetInformationShorttermInvestmentsDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresAssetsatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasuries",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r746",
      "r748",
      "r750",
      "r770",
      "r1108"
     ]
    },
    "kprx_UnallocatedResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "UnallocatedResearchAndDevelopmentMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KIO-301 Collaboration Credit",
        "label": "Unallocated Research and Development [Member]",
        "documentation": "Unallocated Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "kprx_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/BusinessPresentationandRecentAccountingPronouncementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Financial Information",
        "label": "Unaudited Interim Financial Information Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for interim financial information."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r757",
      "r760",
      "r773",
      "r1086"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted cash flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r773",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/FairValueDisclosuresEstimatetoMeasureContingentConsiderationUnobservableLevel3InprocessRDDetails",
      "http://www.eyegatepharma.com/role/FairValueDisclosuresUnobservableLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r757",
      "r760",
      "r773",
      "r1086"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.eyegatepharma.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails",
      "http://www.eyegatepharma.com/role/WarrantsScheduleofWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants",
        "verboseLabel": "Common Stock Warrants, Excluding Pre-funded Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "kprx_WarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "WarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants",
        "documentation": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.eyegatepharma.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding, term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "kprx_WarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eyegatepharma.com/20250331",
     "localname": "WarrantsDisclosureTextBlock",
     "presentation": [
      "http://www.eyegatepharma.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants Disclosure [Text Block]",
        "documentation": "The entire disclosure for warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Shares Outstanding - Diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "presentation": [
      "http://www.eyegatepharma.com/role/NetLossIncomeperShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average unvested restricted common stock that has been issued and is subject to forfeiture (in shares)",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.eyegatepharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Shares Outstanding - Basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r164"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001372514-25-000044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-25-000044-xbrl.zip
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M/?YV_;#UP@Z^?(,C;W/DX=EM?/U&"9CTC3P93FP T'W$N07 H 6 C%*54EL
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M2>)2XAXQ(]\.[2TWAR_;XKJ][24U9_]-96=2%W;C^3V0DRFYV]9_HB#$4Q=
MV.X&C\9K;CF3X\.J6RV^F)-5O!6]ZU3A,%N[^E-73G3U9PG5.' 6?KI")_)]
MXIIOPJ,/K3GQ$813+I_'R8,%GN2Q1JH2DJ<4IP2//]AVK1GR%Z#*Z?':4G/G
MHYK8\1-.$G=[.:J)$0AJE4M=%NM-!O:P/-U@X9HPX9:E^_$@E@*PY[OL9C>"
ME%_K;*9T,O1-JCG@EQ,A1>X]G^J6F:6GCUXQ.S#I=*L!1=(S,W+;KI#;B?5L
MKY_C8G[R8EZ@KWALZ8ZW05";LMA0"S[3YN R3HV13Y0^\%_+?K[\ O^DW1T9
M_I/MQM]=J'$Q"9(O@=#EE[[_:9IEYLT<O!DV7MN[*E%0E?0($=HFB#U\\0T+
MEFZ]D 3QOA$8V B(1<]\1BDQL-;IQG8-UX3O"KT0+M!(0FWEX))O:77HS-@+
M;)3J"Y^@*_),/K_85CA,==K,6XGD2M-7C#[T( I7OW)<*M;G"3#[+_81E9VM
MUG53!EM?DP<#35=;?3!M5%U7^JJE&P-+_K<"ED[RTG!243(VGDBU[Q/C9]48
MP+ N#.?%> M0W<P"'U _2^I%*JVDQ6!0,"UBF0.%[\7KG2] /1,?GX*>&$?N
M@3#T<5+\R_N\:%8N'VG6(SG]/(Z7&9=9?#X""I=<1HK"W[MW#VWA_K?VP_=V
MY_K'8[?3_M83A>YM9[6 'K?'G;O;J^O;WO65 '_U[KYUK]J/\*/W"/_Y?GW[
MV!/N;N#77>?WW^Z^75T_]&B,N?E9N/[[C^[COQ@=U2/ C C?X;EA(%P#^BS,
MHYG#V)I195%0)*4N&*Z%?VB,CN)#Y!I@_H'._WB(*2].,DXF &JCP0 =8QR0
MB_2/S^FV3[9+.TQ?^IQ,^\FL45\.PM/OQ;<3U=AJU>KU.FK')'B4?#A1G#4@
MP*?EZXI64U0M\Y94DS.OKVJJ7I/KV7=6M;3ZNJ(U3K9/S9JJ*[Q/[_:I59/J
M^5K:?Y]DJ28U6 -4J];26HSU2:\UY/K:EK+KC!5M39WQVE1+:^FQC+A/K)OW
M&>_0-PJ%WX/51GP?IM%>Z)D_-RB2/9VQI\LVBQ@X/.9[+XNYMA(0H0T]1%/>
M<*A=<6_85K7KTK\[QM@.X?K9DL8THU'DH&M.Z7%%!K9IKSZIZMSH05.F,5)F
M(YWT"N;4SI90](@S2@:J6Y(-R!+_BEZ__C.RP[=-EKML/0W-9$(VC<JR2,MX
MQ=$FBS=V/N&[S&1JC[S(+4(UG0(Q.&:.@ID]/W:Z9TY\-1S#-8E@A,(5,0FN
MN!224):V"8IWWK/\N(G8;*+D7=:JS^9BN[<WB]G8C*6KRRE37**L%+0X^4S.
M/<CFWFF>>Y 3J5DE _K:DH%9>S&V$;-0J@-*5V+T<*42K!VD<+R%UZ>O75OY
MM6O.:I46;@P 0Q6;NLX5,%? ^U+ K=P*.!^06WB(<:,I-IK+*\*XCN:RRV5W
M:]E5I'W++EW,V1+E>D-4,TY$YO++Y9?+[_;+(I0-UT44(,EXN+2FBJJNB'+&
M3E/\'$4N4J<A4LK!1$H%PQ;%J;[+5@=<G%B V#F)4QYITO9M8.(6ZW6Q66^)
MS>;J/=;/U[[,SH*KN?9\9'73/OX^?Y^_O_W[IY  SM;"=&*I?C7B%6&C,7$#
MNKZFB+ W$TF(59-/LJM1L<']R?NGM.E)0JOR[T3#H<NA6U+HGA)3<L48U+5N
MT<R^9X_>M)X<2\F[;E)$3O/#?9S@9N>W!P)>5&"'I$?\9]LD]S 6SWH@IO?D
MTE;^83@1R>UDU3'VIXL-N:@#/C@(N6;@3.%,*8>Z7K_7(G/:NL&:MN8Q*/X^
M?Y^_OT4,*MU# 9086?TY_A1_ZKVG.-#X4QQH_*G3>8H#C3_%@<:?.IVG.-#X
M4QQH_*G3>8H#C3_% M!RQ?;UFI)5UC5W@E@S?N;XB9R=#X+,3R06\UF\?N8,
M$[(<NARZ)84N9PIG"F?*N3$EWTK,Q<5CC)U4W6H6<%(U!QP[@&/\9/26S@[>
M>$D7?Y^_S]_?X[+"\H6B-CS,GD>BN'ER:DX*ARZ';DFARYG"F<*9<FY,.60@
M*K$+4[.06H7Q9]NN-6,C+H<(]GB:>:M5N91%J;F\E1\':EF!NF, BT6<*I+$
M%DYYY(N_S]_G[Y_7AEJ@Z(4-CR#D 8#S,$Q.QJWAT.70+2ET.5,X4]BIGU#J
MF_F?8$Q,*R9R^X-RY5(1Y98BMG3I^(40'#A<FDO#E'U40^TFS I3PLQ0;&?W
MDY1YSWC/>,]XSU;T[!1B5>^>_OW=\,UA>O1WO8"CO^/AX)0@6%Z$*PQ/](!:
MI;'[\=^*I#)U_/<&S#O%,X8V&7:I$)OE>C9V/@9<D;03. 9\,P7%>KSU[+1M
M<\_'@2M2G<'CP+E"/EV%W-SOR6^*U#B98\'9U=E<CL]>CO5]RW$S/B)<E32Q
MU9*Y+'-9YK*\K[.-6P<ZVUB1<*VR5A?KS;HH2\4=%\[%BXL7L^*E2@<3KQ88
MOZVF*.MU+EI<M$HI6KDD:\]&J"R!/*DB=%14]=7QZO.V06G&Z!-=W '_M>SG
MRR_P3]JIF79,@FL]$C!=?NG[GZ8!)O9>BS>*3$D;4Q#(ZACC@%RD?WQ.]]NT
M7<HL^M+GD>$_V6Y*[_KR)@3T>_'MSR^V%0XO6JV:IFD(_R3WEGPXOBO7@/F?
MEJ\K6DUIJ)FWI)J<>7U54_6:7&_D:FGU=47+UU*9^M2LJ:V\WS['/K5J4J/)
M6)]DJ28U\XG+(0BE:RW&^J37&JJRMJ7LDBA%6U,3M3;YTUIZ+,,BBW7S/FT4
M?2,3Y=XG ^+[Q!*HB;%!EN1TQM[Q1B.PR@H9.#SF>R^+]90E($+;2H_SI'8%
MGNE9[;KT[^1DS_,EC6E&H\@Q0F)1>ER1@6W:FVQN=![TH(NL8Z3,KK2F5S9<
M27>:A'KTPD2<9OTV6B_>_$ROQS[<'(&RIR%YZVEH)A+Q;LD<P[2,RP(VR=[O
M7+)89C*U1^ L%Z&:3H$8'#-'P<R>'SN+<MXK8I)1G_AI1:]:0$5O/G0R'SS-
MKB]3Y0*J>669J6K>=QAWBJ'^]X9<*J1FA?D7UYQM4<4K*R=0Q?N^4BI)!>]Y
M:%=EW]6[LEJYU.L-4=:72RFX^N7JMR#UJ^P[S:I5+IM-46JNKD#G"IJ++A?=
M_**[]PJ)>N52KJMTK;ZB</GE\LOEM]#:P0WW&"Y DAM8FML06\V&J->+JQ_D
M(L5%BBV1VG [J@)$"M>PZ(JH2\OK5[@X<7%B59QR25/^%?8YA4BO7#9$66J)
MC3H/X#&].15_G[_/WV?H_5/(_F9K83JO5+\: ;$$+*0B;D#/H. ;D>^4P3FE
M72U/9JM1#ET.W9)"]Y28DLLK6K_-S?2DI.#1FQ:38QUYUTTJR&ERN(\3W.S\
M]D# B0KLD/2(_VR;Y![&XED/Q/2>7-K*/PPG(KE]+#STJUD7-4UEY#@E#D*N
M&3A3.%,.=$!>N=2U(K&FKGD0BK_/W^?OLQ"$FMG7(6FBBL]?-&M*VHKM6J#,
M+ZIP2:8ZZG#34C<((KINP1L(LVMI!<.UA#\,WS=@EA$&OC<2[GW[V0B)<.\8
M)L'91Q3PO#UX\6XP@*^[3]!" $_#E;_F\D[F-N^KUK>:[[#3.!ABI4.BG9E,
M5XWI="7#=%5;KE 5@*C.;,R.;LO!(W=G;[J=C#U]&M#-6_;>>J_L?:HZKB)4
M8[%5'%?#WY(7>BOWF4&*@@="-^MUL5YO[+T:_B3E+M<<LKAGY$8\IN[.]BQ6
ML=A4Q^W*&?%[.))V1Y*VN#WB(9"DH;*HRPU0&,LK%SF66,+2R5@#G"F<*<QH
M776##=P+U[JX6$1L-#6&M"Z/7/+W^?O\_2TBE^G>KZ#$R.K/\:?X4^\]Q8'&
MG^) XT^=SE,<:/PI%H"6RV_4IQGBF3QS1L:8 5]_91Z9IHZ31+)P_4I\TPXV
MV]>QQ"DJGET]P]#=:4 W9W956[5EX\^Q_[H^M9I6EZ1*P<H=OVM4+E6I+C;D
M_>_V>)*BERLMEKWIX3HVT^CL[EQN5BZ5IEB7EK/HY=<9YXJF%0M2#H F//&Q
MWA!U>;D C,.))3B=C%W F<*9PHSB7;&TY "*%]?TZ9JHRLN[\O%4*W^?O\_?
M9^=]'B_F3[$0+SY^!_E3I_%4P8F)K!5P;&8F;CP??KI")_)]XIIOPB,8LH%#
MUT,+TZ5E/"/!_:E3<W(Y=#ET2PI=SA3.%,Z4<V-*KHW3M?7G -&3C><.->ZZ
MIC<BB3V8FH/4&HR_UG:M&=MP:AK>DO!N\&B\WGL^O1&&OMV/0J/OD$?OUG.Q
M6[[GP'">NG@J* G"O-%15:I<ZK)8;R[OH)-[9W8.3@; ^<X63N4"I\P..'G0
MGK_/W^?OL["ST^&F'MQG*9X@>)B*VR.GYL%PZ'+HEA2ZG"F<*<S4=FGJ6I\3
MC(C8AOCF!4%N'Q"W,U-%K:Z*BL3*9AD<-%R22\.4 J-'NTFRRJ D,Q36>?]H
MO&,YO+QGO&>\9Z7OV2F$J;(/:OUJ.'0-N!$*WPW?' JJ+ J*I&B[.,4)9>/A
MX)0@6%[4=TCF<:6E.KYVQ8I:[;W]BNEK=U$8A(:+@\^:Y+7*I:;L?UEL<<P[
MQ<.6-QEVJ1";Y71JN0]<7D9K'=!:]K.4-U-0K =:ST[;UO-KVYS^5J-RJ8@M
MN2FJ]3I7R%PA[ULAUW,KY)R Q@T9&HI8U[G.WIO.YG)\]G+<V+<<TZTPZJ*D
MR:*BR5R6N2QS6=Y\O/EJE1<#^@'T^I=*=0]2C?LLJ*I85U2QH2WOM9"[8I.+
M%Q<OYL5K\?2(O8F7)J'QJXEJ<]GXY:+%1:L,HI5+LC8X5VTW@9)!H/#LJ[JH
M9Z2CN1$Z21E]HHLZTG-)9XZ5G6G')+C&(T'3Y9>^_VD:86+SM;TS54&F]@@1
MVJ;IC>"+;\ )X=8+22"$GM#Q<,."@%CX%TW;&2'\N+%=PS7ANT(OA OT\-G:
MRL$EW]+JT)FQ%] #:B]\@FMUGLGG%]L*AZGLS;R5@$6:OF+TH0=1N/J5XU*Q
ML7 T[LR_V$>4:%NMZZ8,>D>3!P--5UM]6:^KNJ[T54LW!I;\;]R!,7EI."GX
M&!M/I-KWB?&S:@Q@6!>&\V*\!8C]F=&/;+<Z2^I%*JVDQ6!0,"UBV06MYOET
M/=8%: 3BXU/0$^/(/1"&/BKOO[S/BV;E\A&52KQK-^ )4/[EDW&9Q><CH'!I
M^J(H_+U[]] 6[G]K/WQO=ZY_/'8[[6\]4>C>=E8+Z'%[W+F[O;J^[5U?"?!7
M[^Y;]ZK]"#]ZC_"?[]>WCSWA[D;HM'N_"3??[O[H"1\BUX@L&_30QUPCHA/$
M5+O0&0E&YACC@%RD?WQ.=X:Q7=I3^M+GD>$_@70E*JF^O',+_5Y\.Y&[5JM6
M5YLH>DDQ0_+A1"IK,/)/R]>;<$-K9-Z2:G+F]55-R4I-:6FYFEI]79/THCK5
MK"MKFWJG &1M"J^U]%B&71T#8I^6IKZ1H?D(BH@(W^&Y82!<@WZRIG4A<P;6
M+A29<6W>K<%AF%:*I-0W20;N7 %5<B)I>8!3XEJJNS'!B1U,U39X0L]@'Y+@
MHH ZJB)KYXJM.=A+[=Q">1\+_%Z]Q/,#UG-_7+'2,\\0V8BV9 ]T\VA+UL!8
MK.S/MS'$9I'*G4K\-05+3N26(K;TY:/I-P]39@O/W@*1:TIQ.?A9!3\KRUJT
M0I>U%(3\(C?=I/Q8N^5FZ\#[;68;+M.M:6A\[8$ !DP;_-*E&0YOX\6.$0R%
M#S\P!F>['X5[WWNVT5?HOPF%6T''MG7.R**Y(F,?Q#7>:-5P+:$]PCV*_AM?
M\ : @M!PGVR,6;2#@(2K3X5;MPYPTQF@E ISK;Z<)3#\[9!DGZA9.F=I2JUR
M6< I#.P8!QPFZ^?5S7"2<[K%DGU1;[08@1'S^ZB?0J0B&ZD/Q(K,5*=/)^QO
MQ B(\( /5KU!%:;W7;3\2:_V7GTD#QA*/M+QBL3_[;J4H'<#(&=,S=R"VP [
MN24JK67'D.\74%H$K3G5:0\0:@*$9%'5EO>#/.KN 2=H0]/ZFNI7(ZY/&(V)
M&]#IFEO*N2QENHB+4G&6B+EQCP7SFBXVY)V/(N7&,SO(66\\%P0=K,INUD5M
M=YW)#>:R&\R=H>$^$<%VA1O#]@5ZOF):@0,])VY(:]%LB_C;*_N3-G=66SM?
MHP":#@(0UK[M4O)-R3I'U38>:/D45_;%'.FZX!%'+IA&*U[Y9AM]VZ%!R+P*
MH(YUXZ  Y!8_=YAM(.ZVS?M".H]M3,HP*6&>L("E#'PZ*JV/T76?29RP2?,R
M&*R?F9IF,SH@#]\-_R>)2PU[Q(Q\BCWZ#DWDX#* 9T":>R;Q_)VR_S-: @E.
MZ3TE=]NUILR)>7,WF))_2GUX$&D_0_K<N@!+!E2Q5=_EC ?NU;!C(JV)".T3
M:0/[E5C5_Q+?RP*9.K---O>""IAV> =/OH.E<'2S2T%B$S9 3W>FD(/&G*F]
M,&.[\J*.5>I,KRE,FHWW/AD;MB5<OV)4++$ Z;E6R5&[(:_JV*D$=#EQDY#\
MB@P($-A** ]3,B7[=LF<.NX46=?$EKIS8(*;?^Q ;,/]1@Z$L3H--#3JRYL,
M,6GVY8IRL*J?.[C>KY^L#L4R3 (6.]CRYU%_48!7OEI&<"5Y!*[/E*BY):)1
MN6RJ#5'+*%7F!WZ6$D/KTXA[ 1'68>@ML26Q'\ ]"9/W@02$KE_MP,QHASLK
MU;)9($6%.A>%(:7KH_$:4W9&*/(;&WKELM'0Q59&E08/93*"I,)S;/N%%%9O
M-.IB0S_%A46L:EM@W=F9K0<)(\3Q?2 OV<'X:&!!@U(7FQG98U[04%I,;1TW
M* 94<KR(4V*E./T<K-HX9GM&L=J]Q@8H-2?9CNWB90VE<JFV1$7A%BRS(#J,
M5BT$3;@R7I1E5N+[YV"[IL$=X=YXPXF0&Z\%A5P3>N:6 8W*0%,6&QFGHG%[
MM;0PVC;JNBV.:"9+$UO-Y:.<N(6Z1VWJ1V1::L"MU,)B 0EI=Z@B;^""8E'2
M-5'1EDT,;J^6$DY;&ZP%X*D9JUBUM5PM<' TG8FM2K7K?,% '#4_"[NU2$V[
M8LE]0N,Y$L<4SBT>>N52T6119V'5#C=A#[UWPZ9 6EN'WV@55H?/K=C-XZP+
M6^/,S)'<H"W,H)U0F1(YI7'N8VF:$BU95.NGL7\J!]0.,=B"$"6OW#6GK&8M
M@TM.MMA/=!<;=[/=]$](BC;>O1J9D%+^ZQLR8T:2IL3/+45T:^NFI(ER:WGO
MP6U/X'O_- 363>,3 &*Q.TGO"W_Q-M,-11/U>E$QX/VA\!1V+<A6]/%RY2)V
MADZ&O(?S,38QR(KM6=D7NS+?P9)OV;YB*6?DFT,#UW!Z@^SM/7@<,%\"^]YX
MH_NE/'IM\\_(]DG[V; =).J-Y_>,V1T5KD@_=Q"PB5MXBPW<QS5C(V\>!F0$
M4 5:-#L!:FTPL%D_Y6!@650PLK!@]5NV<$Z!VM?W (E6<.-[(R3LW:!@]=NH
M7.J2*.U>ILPCA.Q ZAT%O!.FUFO@9LFV13I)(_B[$:9[V9VU%;P?-3RE+MU@
M(C9FZ&9BCA.LDZ7<NAF7?X)9K!2AGKE]S [4-E?/!6%MO<X^Z10Z>SK[G6S/
M;(XG*S*XBP%];J'U;2+K$YIO'UG7<4&IV&@J8E,O:JG*\=,[!5G<YX;!K=([
M[X)PK4;7Y:*M<(;2.J7)W]_8KN&:1:1USNC8<^:S)LQWL.364;;&_=7W@D!(
M+6-A *8Q_+*?C9 (]XYATG,&>&AQ:Y^V&P01*"MR-TBH.B%JGFE'82WXPX.)
M!_56-T71!A8TUJ;4,>[!4&CZ%$R5%>=F)(P3.EX0!LBK@K3K*8=QZM)&:<Z[
M 3WY,"4QI7 >I:JQ%IWA(< ":B[JFQ5=O ^>#71IG6X8T(+_UY?+_%C;7?-D
M[&L&U?SU*_%-.Z G]/UAX %=9[)-TGZ,YH2$*55S:?4&-Y5/$#J;F\KKL;.!
M4L>EY:*FZJ(NG]A.G@R&\C*3,UGQO3-?@+/WY,R$YMO%Q?6B;>GC9V7XHIO#
M967>1=\&>KM% QN*UA0;NQ]3PQ?=;&\+#P;$#-$2OGXUXU.L'S#>D1[TA?N&
M  3$I9- Z>%0#R0(?=L,27Q2*,_)%Z3V8Z[<#5*>($ON7"3QPE&-4P;@C;9K
MS5_8X?C0%BZ7ET2YL./MCS]'\,S]7M?9LP!:N7)9ET5)V64G'9[KWQI7Z"!\
M2/=9^"BD.R_@<9%[GD5.QW[;Q^K]G83P'L;A6<N[:)A.A!2=%?=8!>266MP!
M0!:59@'[7QU_EN&>R!X\$<8!K * =1$\:E%K[&POE<6;*57ES.;3CRA\)4^V
MZV)$"]RB&#P\/; @K]K^Q#6W]-&ET\U60U2;RQO(\#1"62&F-AC"6!U+V;6Z
M+K9.\LC;4U3CUW!QI0+?H_G%B"_VUST-N?1JA2&MTJ S5[,NRA+[.T\5X !Q
MJ3M7J=-:#(E=$\1.%A5=$C6YJ+,.]^ZNI3U(6-  H3KFOF4JC,3R(EQ.S]J6
M:N]V[;0MI^S:C5XT'CNT@MEPA"L[,!TOB/QX:X1;SS71I)KNI8H&5:["C@.L
MKBK\_;.,@_@D/@T"V/Z UZO>H/HC(,EID8DE[1AH1K^[J?G.;FGI)NVL@95]
M:EZ?BJ8@N1L 1"A"[OJA 5^SNFX:-KWQ_(+VTV[IN)^V)C8RSGDO;1B'R\A)
MR,CZ]$1A0K*V;J]5W XEAPE!,;^(@7=PLPY^HOMFP7\M^_GR"_R3/CT#%1.L
M'.(G$GSYI>_CRPD<^6LE>6WOFE>AO@@!>],TO1%\\0T=C%LO!$\D](2.A]9R
M0,\N<ZD/32W1Q!4!SZ47P@6Z)JRV<G#)M[0Z=&;L!38JR L?C5K[F7Q^L:UP
MF$X!,V_%6NU"FKYB]*$'4;CZE>-2L3E/@-E_L8\X:=AJ73=E< @U>3#0=+75
ME_6ZJNM*7[5T8V#)_U;E2OK2<!)B&!M/I-H'3^%GU1C L"X,Y\5X"U =S(Q^
M9+MIAYIX/M,BE5;28C HF!;QC 7S<W)\U@7,=,3'IZ GQI%[( Q]M"'^\CXO
MFI7+1[H_(?AF'30_Z+HTX_A2O!11H/C[O7OWT!;N?VL_?&]WKG\\=COM;SU1
MZ-YV5HOF<7M\>_=XW1,>[X3.W>W5]6WO^@K_ZMU]ZUZU'^''3?>V?=OIMK\)
MO4>X\/WZ]K$G?(A<([)L4$,?&1W6=\,WA[$!J,JBH$A*/4LUS(JNX3^!]-)@
MI4(#B1OV]M$>@:*^)2_"@S<RW%7]WJC;PC(Y-]196F7FI4-26JX)B==P&XV@
M"7/9E5Y808$;%Y*[06+\PYR66O.J),5.ANU&Q&J'R35L@H#E/T94^1$HL*]1
M /T( E&X]TF \3OJK<2!&D2;D)R C1/IO>^Y\'>\54&0>@E)9Q<4"=Q+OA^W
M..D7]B&C9TIE'89FO8;_1$%H#]X.*@1WX*0\V^1EI8P>K;_9L_?O-DP5POW0
M .?/)!'UKX#'7=>L"1_0RU.DS_09^K?\6?!\(1P2(;G5B8VGY.9'X<6@^U6,
MP%B"OPSA"LR=%\,GP$A_G)X "_]W!9 9]8DO*#IJ"DFK"7%/;'S+A'Y21R\(
MP000@C%!HRM\$\9S_102TPU<XF?B>.,T8@R71[B0$ZCZ7[P&_?6-,>Z_.TAZ
M'V+X$;&)<YPW'H9#PQF!&('7@5[Q&J..,?;U;-PGQ X# ?\8(WG%A))#8  0
MQD/#-8CZ0$H0)<-QW@3XA[Y"!D"/D!J\_42Z!7"Z:,V9**"4HT:G)$THC"03
MZ07?L .D+:@(.S2<VI),OZ^<Z$&D/])9K8OSE3V:F-A=-PY(P(CNP0 WW^)_
M'Z&AKXYG_IPJL"55Q02_LM7#9+A",MX9GV)FQ&6!WR/(DC'K04V,%&1ZXD*9
MLR[48#+<8.)"H1"B5";*!)#[3(0^(:XPQFUV?7K<'OV.;]%]<5[L<$A_)]/-
MV ?TVV,\Z.")N"#L%.4F"D3\+K;^PZ7]HIY;,-%M/VJ]FO!KNWT_46&H(^R$
M.=/>VE/F4/S3+F"SMAL ZFCTBTK2#3PFR%+U[_'4&($=K5<EE28ZR%/DQ$WT
MJO^L"?>1CQN)A/@:-!40P8]P#%2^)L^"-H:;H.0\P?5"E',GLD@LQ N=<JG_
MZA-ZC@==%3T9'AT6,LHA(<GD0@T 2$>$BC1)S8!M!0HXD7KXH&$ARF*F?4"^
MVO%^N/"HBSUQX.-FY/M4$T^?_4@Q8(,K KUR0?4'@>&_T2X9PL"P?63TU*:8
MAP,--38_!S.=1FS9DU'#JY$3H\B;V#<S($HH9M5F$HOI.^F$,*;564':#YR^
M8-)">J?=!9&!EBR8=]!]3_N8M@,32 C4>H,O"N05YBN*]:3Q002D>P-E6A/^
MP#XY-FC3^!6\;<UD0<?IBG:8L@B"'GIA6,!07 P),!D9/TD"NRGKIYW&#H_L
MP"$&QE.%ER%Q$V1-!3/%=AX!Q6[ E$EE"9[^#YAV],L3*9B1^O>:FN 4NOUL
M>U% "1NS*)751=:#+Z$);1=,1 >D" R)$(V(5-1^%^+O40=$4.JQ[U$34#OU
M#8>JC&!(2(@V"3 N-3[F?!6-VBX 4>"N%6]IN/F@%A18/\+,/PQQ46 7V9TI
MJ@MSZ:+QG,_P)R]3LWS>*G]G5E4VF%636%4#Y@K&YMFVY8U373+CEX#R=RW#
MMX+W)E@61I8]Y79GC6=)4>GL(-RT>U_!=@[ 4Q+:O1_T3E5J44/>&Q'AT7C%
M2>\1=+LI-#7IHU 5NB/4-@F"0;=,'YTMS(C%R 57.TB(EZ*66NH)XN%U4'LH
MV]2P?$WF!3MN,H0F9V OQA;] &UX$'X_R?/'LR!8EB$J&P"V:3OV='*;MH6Z
MP["MN&>37MG4H"4F5<^H>J, =&VZA (4R\#&5!95Q%1!3/2S$2L6GRH6:D_0
MV4 @+M6B$W*G48T,DN#'4[6/YC0T.AZ#GK=0H^-HL5?.FTA5@T_"Z<7X03/Q
M?0/\]L@.0Y(,+U4I!@)ZGKFH O]? [H.4^E<SXQ9\,\\;]GQ#$&G1@/F$IP(
M8. D67P?Z]Y<\P*=?F/VS3#X7?>)!?%:H3@RE(5PGR AU2J;!. .K!OD>JP;
M;E&B$]V@K=0-&EBD(DJY\?0$EN;$[$I4P"2[(5P#J-U@QEZ>:2"UF&/0/45V
M;)R#I,T\-%46*"\9()J;#W'Z-_I@^/I).EK$VY-.4CF>,7G['D@36C^F;_<1
ML-#FD^>CIQ\'OM_BD #5,>093>U$BTP_3^(1HB-+#<?WM,J,%IG5+S1!,545
M<FR$-!+-%5M<J9&)5M.\/GJ_I:88&UOPL/,VE? 9;?%CC"1);HAS/$@,TTR5
MA &=.87DO,UK'J  FO1 *W@8B.A$,2>H%0J/F.'4E,W0/),.4*V#.@[TQ@+/
M\5(.M5.$@42##]]LP";8>&_T#!<:R'@@@1?Y8/*O-(S4$H4;)@.D.$R&*$S&
M6)8P0SL4,I(+XD+0P *A]^=7WR3#7EBF ^#\Z]9+-:KUK*)Q"J"Y:O!VV#%\
M'Q70/T!DR*2.IC%%$BX8K"V?L@H>G..D5D]O"#9)%33"*#E^9K2/(="O/,)'
M9KZ1U6-<?B;5EI<6IUV.8X, "YA&HU$4&P97!"P].]R]SRMV%7@@<9G3M>&C
M @UFOIU\.FLHC<JEK-5KRR5^Z5AJ,W%4F#50!5JIJ0BZ*T@"-2Z=F9YQ @&8
M#1SO)8".QA/A)"*+#PXBS,%,7D7''NP,TQX;5'W_YKV09^*+@/0TYI*&"H*I
M@DW0_K<@#;QB!"(6YL2YS1 4F#G ]X0)((@&2 \2AYP&,$<N-$JCOS#,F3@*
M#=*$@D.,(!1D11@!CX9!,DM1?Y:&)I(.SD4:\D888AOE'>W^:2%?=(XE%_KJ
MD@M>/<&K)WCUQ.E63ZS.EBN9V7*5:?NT!Q^F<:"%\@&TO>U%^S17X#/;*%MI
MU#?9,NII.Q<XO]OF!G[_2E.W! 8^'<"LOYFFB@(:,1_"4^!W.M21 9-J:@)3
M=QB<?1@'F!*CN4-V0U#7)#55P(!Q,+5-LR%CL)7 HIN$Z:C51J84JTW]AL5;
MDT@^O0%N*V9$,"UDI.=^"N:0F#^I$Q^#&4.=QC,:I3-7H%OD#3J,YP!3(RR(
M#<31]&3@8')R:#S,^=&IF2,SS#B7$'OO9N)\",:(?C:);DY3+%EFVERR)#;]
MS)740(L-HP%H%8?02!"*T!$;"P;&8]][M4<TT4K3>_2Y(O,:4S]EI4CKI1;I
MV.][7/#[RB+/,U[KK,B.?0 %S:0FN6,JJ[@-5H1!.W%2)01>!>F',V(02\B3
M!QZ22UTCZF<^$==\FWEJ/G"%CIOI&$$ ,PRQ$N]DMCM8H92*;A7 7@V,.=D3
M\0F4%7H=NAI$YG"NA22P-DGCP0 QI^"E DL3(_8H6?$ZDTX'-N PGR9#PQHE
M GT@B]V.\_P+:F_2O$5EK$_>/-K&C-9+D\M(3.AZJO=P2$DX#_ZD:RT3A9"O
MCF->5=2$-A!\[).1'8U0+6& #_4.:(FX3@BZ,^D"UGB-,-7R7^I16Y_0Q31-
MGR39$QHOA0&GP5KDDSM33X#/O-G$L80H2".12$^ZCA3!*(Q(./3 C7U.?%3'
M'DQ2]G'!!K93FPNIQ#GN1$G&U /-A>=^CF*W=:K(A!\N@-:A_7\RH$'*PAG/
M?C:?;<R$0CQD,TV:^01T=H!Q@P_XWL?9L=('8)*(R],"/')FZ#DX)?Z-:F#@
M.QI*Z/O'G2A2LW8 QW;X#?HT4XJ54FRELFV56MFV'<=[H7#&*2^F@/"-LK,L
M&O<&96B=,J-0=&F(-$$NXDY(0Q[SP=2![0>Q?J"0!ON" M<.J6R"Q8(B&!#'
M$5'8[0&] ^H0]9=C_\2T0CB$KV&VD8:&X'X:A)HHRTD35'[CCJ(ZI5H0$\ @
MO6\H 9@>F"H,M#1 _<#T ?([$(A-NY8(MPEM8%(3ZZ<,WXHS1B&5)#_]<JI"
M\..TUR2<[\.D["3KH_C&BX\Y%U>PO!>71M(FJ@%UL!<]T3P-#4;6A/<Y0RF4
ME'>-L$R%JF,D W85F(,=2 8VSZ<D'3/#(JKSB4FU(.:8ICW#>24N5TKK6\P8
MZ(G>@F[&ZFE@F*'GQ_5@(^-GK&%19U,XQ,5@8:;!'A,1V(:,3-4M/&3[:>$H
M/)WLZ(YIGU3/XU2(AG%L$D^JN] @2)Y.:@-FLGI)Y^-ZKE@!(\7 3,7QI? 1
MD8=8H#8_,FHATP:J:?J:YO[CS-6"C*13-/8>"VD!18@@>Z9\0DQF#ZQ0C+7^
MXAR6X@(GLHFV27R">/:<$BH&!/(+$4%KV"9-9[9##?4Y9MK!W!ST_KRS/OF_
M,-N712G.6H/DE9(C!FE2<X&N%AH>45H6APRCHM'WDL*V&0&B&,C2" "9]0*.
M_ 'K!W1M[,#9N!4'$",M6!_%%C#]-8.#&L9$YCL'."#@@='XHCMC%\XI^F *
MER353.MHP7\F:3H?OYJ 8MX8S(6#67-[JC1GZG*IN8 ="E/MA@,E:]$;9QS6
M#)R:RQY5PJ3J#094,". L>-@!CN3J;.OHX7EHY8"-E%N+(@J3I0"6'TXBXTP
M'^*GCJT=S!:RQ@&$Q'I.2H;@5_(HG1 M@CX0)J=2$WN^6W1.C(5<2/I?K#7W
M .-T(_( >'AR[6DQ_;())V>L Y(SU@&5Q;"C\<5D^,+,^,NBN[K+%>]8R#,1
MLW:O(S2DABBD8Z1Z"S,.F,A,_,0.=!P@[0?43IN\,CM[^S%I_DNK4>.6:#B)
MUF0DKPL>W4F"HC_T/2HU,/F-;%003Q[6M$#S :Y\,G&VC$W-./(43V;@VR*X
M@U2Y4!F*(]BQO.!U5(KA6U)(1W5&++94R$AZ+DQ<M0>J=/G+H)"\J<Q-QN-/
MN1\KE_^?O7=O4ANY&H>_BHH\>6)7:5@D<;7S4H7']F82>\8_SSBI_/64@&90
M#!(KB1E//OU[SNG6#4F 0(!@.I7='4"7[M/G?L5A;X]!XN-*:#6ZGYMR@H.2
M:C-R%HRGM@A  I4#X6-&$M_9Q$&NAJQO@LL&563AO5/>6&]#EA\ @$[I#<A?
M7LL0@OH]7+UZN7@%(8(S!(P4H5G+3CR-;H5[(P#P4B= 0A%M7P#'8'C9TUOB
MOR,>NLVX*%"XMGXU,N4W\-@0G9+8] ;!#KN-';,'C_(F%J619K_F+/4,GF0E
MT &0X J1 "RC,9LA4$<1@7(JB^-;8"I95 @P)'$56$Y"/&00$+^!H#H+'"BK
MY))!+'@?G?N$5'=^W@$:@NKAAVN-9S(X>$3QHU\5<R04UQ)-G-A"$S-:H@S_
M;Y)J/1G^E^%_&?Z7X7\[4MZSBN4U7BR?GS)@9*8,-$^MY*^5M7$)%NJ@0MXP
M$S3)4##QNN68<$6=D40LZG4YFHUP]:QZ/NG)"94W)DI)!%+%R\A/AJ#\J?#=
M" W;C)1LL@>YABP\91E*&.D#7JBK134R+"P?R=Y'6NO*N0Z>'BABJX9G=7$
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M>?!"E.0A.:5"76&:'V69)3J'8P1E&"#[A#%*\G-9<!I!%P= 75C 5LNI*P/
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MV'K,5+*1PKRX"R3TSFP*7_(2K24.I35Y;BS^#? WB="I%)]C!0^-BK;S@=L
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ME@<3-BNOR]307RLNK>>Y!\2E#N%2*R\1_-BX=+EFS8.#[NX=/'/%Q)WPOQ@
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M9>!EW,:?N!$HEPS5>WBM-8$EV+YRYT^9J]P-X4E/))IO[,52 K$8$'_8SGH
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M711:P5_8KP5<"M],ECX@*KS:FRJ3F?/LD6L_'1*I*_]@+_BHY7P1;(5O%"X
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M-V\TL6X^[<.L7MU\IUWURGFCA0*H9>14SA?L"[!2+9\R$R*F2"P==)V5;W[
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MWH5E@VQ'YCF*@#"* R%H_REJU['U5?3LD>E-%2 !^\I9QAH\4&LHZG8PFEI
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M1SP74_<<E/RH /&;VC'^]_]JM%KO$#KWFG"3;,19]40<HVD=6K=P,M&_K/,
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MBRP?%*>/8(9/=$#SC['@8$#*H,5$&U)(>(RO*!'@XPG^&=8OER?(*-<TTYB
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MBT.0P\A_I"B%^1B/T/$XTIA_/@+"@BCLB2BW_!8GY&:PYD1"X4=224*&/9Y
MKK%SQ+?[ #,W#_&LX]2ZS?6PX0Z(;A5%ZLJ!MKT&:+(<(MO.@<EV6[%*>NKX
M6TS1VC?6=10^^'U.LV2C',[11*#0Q?-T;KP, );UMES&,OWCAMVIMVRGV]U[
MB\Y6^ZP.7/J2N-1IVFWP8,].UQWF^>RL6OIA<ML< $?4FKX)]+,/)G*0O#WI
M%AB@^U)QIF*[)$]Z0\4F3\1@HNF"S)<G,];<<QF%1L-N=T"[G6TX"6_%K>^I
M/>W K"^+67^J7?(9676;R"W551^?=0' 3_M%RTOZ7_Y]W>J)O)S;O,UC*;?;
M=;@$K^ 2.*=V Q$8FNL:8/N^!Q7O@RH*XNVC]!0U*255)H8F#?7B7+TXW3K5
MI\:IK.QXMC(U*VW"G'BP\ANH?KU9:YL9]8$?Q8GU9^I&B8CP$Q@$EO5K1ON*
M+'/.EQ4M:MVZN[HTNJXP190ODYY;(^_.DJMZW%?D:9>&^WR].(,WLF*Y7QJU
MSGSF0RJ.W417] WF5#5C\C'",E7XKR L_A!6+= #"YFPPN0OLI3W5/=NT" K
MX#7HKG*]120XM7-IYU7D3N$[^JFLSYE#:<5;6!WD/_Q46=!:Q4 D>\S7_.(8
MK$^B[)$JN;!S!ZN5J])T5URP\1FL"SR:&RQ:B$36DL(]&EFI_N]N M2I3 ''
M55869TW\"9;0">S-@I6,1L@>#R#!PA1_X=ZSS#+:]?*=>H8FHGHH[N9!YO2H
M34GW_6'1,FP8JWM=L[,+GR9O"6DZK8=E092^;R%J0$$2D4NFZ'U&'1)Q,%9J
MZ6<_\G[D%8S3'FPHD V#5'K6Y\K[U0LQ<E!9S78A+?/!">=L=W!:#>5%-MKO
M=BT]\T?C2!@QZD7 (LX [L?0GS ]D4C8R>=P)Q\QHLDQ?A+/,7'>S:74@3(;
M4(:M#-(^J# >L"S>H$_3H$^8)MAJB,* #%,1@4T28I_U"*Y7_TE1&>LOY<B
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M,S%?8V%L+GAM;-U]67-;.9+N>_\*C^=U4,:^5'3UA"S+U8YP60Y+-3WSQ$@
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M?QGAZKVC*9;?7O[U9?J=5:ESM83T[QM\ZZMSV E&Z62TX-)[^OGTNRN\+BC
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MPC"_&^_"E^$<1H,"CEQO5 S(>9/>)6 ^1<,<.6*1 ]&L6]NS&Z!LH@+J>:I
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MC&&F797^0^<X;J//1W(<MQ'CT>0X;@R@0=#!1Y: ZE*E/.+6:6F@X'0FP?E
MLZ^=QG3L48I;*;AWE.(V@CY,O%D?A#^B%)^BSNT#SYZBB\.P1I LF51HH65T
ML@7::6 =+K3)442<LT^V>O'_YQ:EV)@LVZA@?U&*SD>N273@4Y*EZ!P'EXF
MG$5P0@<F4_W\R&<3I;B5SOI%*6XC\ 8Q9KV""&[\[?)O:5WY<C*;HWWF=;!!
M6O1A0TD9+C,D,P-$)^Z\]\:8ZODT.^ ]BOC%76S:O2EK(]$.X%B_//OPUU_>
MGO_'AZNQN\(AISO'>I5\Z36OV9O[_-@0VWG,&BUF[02N/L$Q$,@$<-;2$E(;
MO F<1EF]_4MKCYE[IG@IG1N[[ )C9=FR/7CE-#&1"V9J!]H?C<>\C3X?\9BW
M$>/Q>\R<&B)MYCB:6&I:Z 0N<0W<\BA,,N@]5C]&.7*/>2L%]_:8MQ'T87R?
M/@A_>,Q/4>?V3M!3='$8UE!/+4^20>2>+FLODXP+;>0ITJR\K-[_XMEYS(W)
MLHT*:K<\6-PNE8WV/+^<)C325EW=%)/2JM(&IE1=)5J")0%=0HXNH2+<9,X>
M,TX??,-1.L);J6)26XX-_.#?TOREFUV\FTZ^#-'2?O'U;VBTO!F?X_;JYL/Q
MIS,<_9=%^+&?S:<HC$%"9S]Z%2&2C+:6+_F%QG((D9(H8[!"U,[TW1[E4?B\
MNUBEC173ADJW BM=SA;G.0%+T;82V872YTD"#\X0HG,(JG;(XH&#6%MK[,$X
MUFW$W:0HU:T3FI)0,P[#4?H&XL?)MM*A+A-#T3Q7) D0CJ)T='"@C?-:&9^,
MJWVMW6(<)\_$@RN_0=KAJ_1YFL*P2RW SZ.TS#@XNRQ9!?_=?7^0"3-<T8B&
M7JD9A)XC.&(L$.("V@>:N^KM'?K@VC_A#L^ 26/UU;:K[P<-OA]^NIB?9Y3+
MV6R6YJ5:B,-)YSAD)CD(S2AZ%02%$"R1.1@NN.YE83_^KN^8,2VTT:)N4PED
M?'$WH77 8\R)2@\ZJ>)Y<H[>@Q<0$Z%):^:]K5YU9RV2[YA!%554,9NXX_6+
MJQDZ([,9 O+#<8?GY61<QHYBPT\SE,MTD3Y7PH<_=?[+[.5%^?AFC(OEU1@G
MP88_>3MT?CCJY#=P)9K7H0/+;$F9%JST8'(*HHU64V\9D_W2 O:%^#OFZ_$R
MHV**<C?(7]QPVD7'W\@>;8 WXR]I\<5"\N?Y5S?]1^H21&]E6X]C448YM_GB
M1F7P \XDU1'M!<,##B6AG+WT$H*TB;-LM-7]$AKJXOK>J7Q +3=(!;YOBEP+
M;1GI<..SF83V*J' )&XO0M $WEH"C(I 2;:&.UIY\^^/[CMF96-5-DA#OH_T
MW31]=L/X:EGJ_O4?Q:!).%VZ//VE39R(B98H!M(:67HQ![2)J09I9,Z*&:1/
M[0.:IR$]AJ2P.KI_E&+5%=?@M/ ^ZK,0BD4QPVF;<"4NU_0AV>!HEJ"S+>5W
M1<F02PJ,9$3C!ZMB>W+=Q_4=46E'I53T@M<ZZ>_3+.'3+SZZ/Q8W:K> S@;6
M2DJ\(L!=\==3YF \?M+>*48S)3'U\TBV>NW)L:.QY!N4S[HOD,7^CV#3;2J[
M%+Q/(D#&;1P$Y:6-1R(0T#$7WF:66?NZHVNAG1R)6JJF05FK-=(H>^>-F;C8
M1!TWEB:G41*E0&;&G;2T@P!.(YJ&+'E6O0MC/V3?$7]V5LQ>/+C51OK.?5WL
MHMH&Z1T#KEW)?<@.'-$$G XA,J93INT=MSN@OB/2[**.O3A?"'!ZE>+M8S3#
M<G :_5 N2]"J*$&K'G=60:QD2J%1%FMGOO;!]7VQ9A>E5"S\M.'*:@GPY62$
MOSM9G,0NS+.!=\0+AQNJ#:*TG3&E1Y5 PK.0HA.$$<.?9 P_]-:3XT9;N5<L
M[-1#'F_+URLN?QUDXRV+N/IQRDO%&(*0';IY/'HFHY3.N=K16KW!G1R/VJJG
M8M&G[>.)!L)Q'IQ3P$) QE-JP5!I<6LM.<1*$VEJ5]/NC^[D([$:*:J!E[X!
MZ>+69KU@N.&)>LK!!*M!<%<*+MH 5.,698-F5-5VV+='>:IQQ[44TR*CWWU=
MI0:'?UX-IVES">U7R<\'%J>4EY&!<;S+_RH3C)0:VLP6]Y!K4[LS[I80CV:=
MJJ;UNS4!&JJL2<V(24@ISGY!N2V21![!:X(Q2C,)^ _B#3Z"28("3TKP)$H+
MIMIA6=MB/'V.M51:@PB_VWA_=?,ELNXZ;S%9NEB%T6CVT$ &VDF:0W80N2B#
MH 1<RA$W :F)I<(GTI)Y3P;^7=%Q/^H]J-4VX();M"$5T%)'7U"T98W$R>70
MN-7,2Z)"[=CX_NA.GFV-%-7@LF4#TE^&8S<.&P03!664,)"4(.)R4>1HJ>@B
MG-3HCE/\Z7ZH]0#*4W4$:BFF\0ZZJ@%TGN_6GQIXXXCEI'1S#@EP7\]@D]"0
M;<J6*Y;QOX9;Y&9D1[,J5=/Q WM@)04U]">7J>#?5I/"A1>]C:P@&2I!H!#
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M$WF_(WSV'#]B0C18K'>;NU1I*R.CH%FI$!63Q%FL/:04%&XT@FE;N]KP][T
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MRZXAK@.XNO3I ;%1.$L/> >*4JFMVDW4J:R7 U$HT41I$@FH*?7+6(Q@/5K
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M*FGAIVU(.)=":TEX!*6\0M<C.["<*H0E=4H.7<EXXBU)CL, KZ&?!KVFJR8
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MB<8D$:MW%/XN<NVWXLL3<NVWT=N!$J7[0/R1:[^C:I^0,?T4O1RJ7(/FU+I
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M3M3.LMLO&1XYX]TG%[:1]7XX@&;ZY&J\K#+RRVCR^ZKB7C+92^Z )JE Q)S
M<Y. <6X8)5Q+6?LTMS^Z_?NT=33Z.$UJJ*/!H=NM(^W.=ROI7-TLX4E%870
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M"K1R'H21$4SGRV6?:*2<^]BO@]YA\!_##M>$7?O9[ZI1X_G,ALZ!2_'!D<=
M79 X5,YUV0T-!:^\Q]7'IUR"?XPQ!YX4/8;Q8VX<%5$JNO_-K>#%&!\9NZ>1
M\V1!)2Y*X"2N#"IIX%(*%PESX6Y=H .X0ST&\F.:'!E9GMT)P<,C5Y25_X%1
MHK3%<P*L);FD6I8NNBI:TZ]BQD&'\6.2'!51*IXU'-+"]))QXDM_J%3NXJ53
MX,KVR2@GVN.28!A_-LY'@X.%]ZE,E>'XT\O)>#YU87[E1B4X_<S/NB\'SFI*
M*".021$@15&BV +H;(-)VE$G5;4#AL?0_#AH:*J_9W5]="N;HJ=,9@,=+!-)
M&M"TI./8F,%J-*NC5Y:8*#WSS^<,\@D".,(]MBZ!]W8]U9I]&T\[ZN?[_);F
M;R>SV9LQ?B=]3M.51(8!Q_=J.+K"L>V0\K/-XVME_3QY2)42?\[&\V$LKQE^
M23=U=E[_$497^/"2B5[X>#7OZ'B>5]V)WRV1WNP=1G-G>&0072ZIR<&47E .
M5'<9FH.@K';^2BWL]9* =D2T2 ! I] (R3G$&$IE/)G!Q:"!1JD5%2'$NX4B
M*V8"U1C!OM*!#L+=S4E!>U?^L60&[3CP%U_7/Z +;[>9,*LM :HD.H(\J[(3
ME39"C%)J/;_5K^@XEI6'AG/X[*3]DW1RG&1I$(:Y'MFM&OE]\#7*='H,VV'2
MG8Z&#+U(NJ,F#\,X*H5)N)59GQ=W,M9+!4QFI@P3S$EZ$DQ[)'_J&1.MOP+;
MIV%Y'5A ZXB+2$ PK]'!90&2"HHH'B-)O?K;/)\TK+KZ>3@7:POA-DBF>8T>
M\N1K2EU9D<71P77E=6]-U@8R+U4.5:3@(WY)*.[SP3%F6>UPYXU@3HP!=83>
M8-Z_3[/Y=!CF*7;05GUBO4E61P/*:U'*P&3P2B8P3G 9;+ FU*X:N1;(B;%@
M=V$W. [_;3(.5Y=7(U>&_ Z5F:;3;P$RZW"]T@085Z7#:T0O@&0#T61K)"7$
MDER9#8^".C%FU%5"B^JS-P7F5AVIDU9*^8B#- FMH4);YPDDFI@L24#.UF;%
M/1 GQH+=A-P@%/_./<*W);9O]P:X\O^5POSCY*:-W/GT92EK.AIUEO8 L29F
MT,IQQN,VIQD#YUF"8*/.$A>^1&N?&E<#?RPLV_.!YV&4W\#BW5&:9Y>E$>+
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M!]/[9%?YUVY 7T L/;\^,+:Y0NQ#A_I.]>,WA#L(_Z[Z=I!<0T6&3)..K)P
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M@Z\^:?8RL.][JAP?=^Y/$'VT$V2A#K0;E]\JOT<'3 KM<_00"4TX6FK $,^
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M[J!  <0AA1*.7"V_?$&*N@[DKV.Y:Z'<15J(_#68XT0H=04)PI6ZNV1^?N:
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M6R?4PX0(%.ML'CY7Q+'K8BF&3D1/Z84&)"@6J_5V@X N5L3T"8/()M:9#7E
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M'8PH.:C0*F;AI#&;%,-JT!GS)^)((,TVALPF7U(1\?D@G4P@50B8R@!3%K)
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MDATQ<*;XP_Z1EE]>>R/5'G=T&#OA>+Z/=L Q>))B0Y=6QCJOG5C36C]IO&]
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MO_;^YMD+QS92OSV,=N/II[\[./# 1PV>E:^_.UL)[_W);;N?;_T[ -Q:-X
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MVI&>)?#!(T#I\'W+T%8WFG0" /NT;7M_.M=QY_^A[JW#LMC6QN&ANU20!D%
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M5B$#*JZ!LV>ZK:G)0KY.0>'I]  3N PJX]:6B6:D%V$H,.IR8!NZ)BZ4Y*D
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MQNT[$#9K9:T>"@(Y998U'"L$VRDNV<>I9W^OP5G!;DW;B@.S8I+KJ\>]TI_
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MQAGU!_+U+7AWSJ<!M<E/SJ;V_I.<[/^L&Q/QA8Q)]<A)#R"TF=/Q3D6\AGP
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MCY'O=UCE_=DKC94=V"6ZU3+N7'^*3DC;J''N@JW&VVJKVJPJH!#,;BE>NR2
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M2R![+JL;'87T^=Z/\44/!C5"?MFDNUK7:Z41*O"BD"E1_+_Z?GQY]2D3>J*
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M7K[P[5SQBF#2D\V[V4AM5PQ..Y=V[+#$A?Y9XGE(2<99"$Y' C4I1$01F^R
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MHDY_V<)XX2QB:SC"F%/9S[A6=+W<B H1)K @=)D95FNLDI=&.R+N[, Q?LL
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M3*>MUV*WX+)<1B/-S6OL5E.+BKG#>9\_E RTO'^=^_#QEHV;Z9)ADD75D)S
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MZTYR\PM(!T6[I 7<6#UF0OS!#\@ 1M5A6J@E]PB.E)9J/Y7VB<*YVP&L;O6
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MLUMO+VPG.NY%70\\*G&O]>9+I3D)ZYE743\!2L.&\_:<Q!Q^>EGY7$FO-))
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MN0A56/]F-/.>*3?K:<S3X @?WT 4=7[",HB9_'@_"E3\ZW%Z4+@7K_!;-3;
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M5*;G!1PAA'YM.\P?R)1\QB*X';N?/>/$M6U"9NJAUP"';=0,OCIJ(U+Z .:
MN;V S)Z'O;&; ;TPX!:+'+.BWU45>S,A$$D_BODPP+WF6&%B#0#K#_Y&%5;;
M@=)D9&NNR_@*YR\)UZ]2LIC"MC/<9T!C+'F=TQ-(B'FO76 NW0E1>MYO]?G"
MBSJ$]& DJAL,I 0A(:O[31,'(=4R3CF6!W\::+F'H?Z)JO\6X%,XWHGI/+CF
M;-R^SS9"C]&H XC]]*1;;1'OTBS!L474%=N0%ZX! Y]]@$[9KTC,1H5O =4
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MV%9/ +JH$I@$K+XYP;_B%"MAT6;*>T'W3</>"%2X]TE0H,L/];#7P-C&6(S
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MFZ0]KK0U#2K#,[OF\G7JM^31_WPQCC-K/LZQ]DE ",RSUS1^_@.D[^//6SF
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MQGF*+$"D9<=<ZGHLZK0/;!#J\N>]$JS8BYM<<NT35]ABO8,IB? #'+P(&U!
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MT81,*<LVNV(1FM_*OBK3QM0!-#_&]P+&PE\GN#W+TPBR.\R?LN7YE+)P5GK
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M%&,TN>$ YG*VMZJ,62F]X2!"'K7(:B_RP$PM GA/EDO'5,Y<:A#-H3<J>10
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M;-[(@9N"5\BC4H@UC03(B";NG7!4-%U\>'NPV]$>TN/V5*08\6DH5UPTGCX
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M=*=<2_*@,-<(L!VBE8"SQ*]V*;-Y,3)!NO-Y(:<8@7T8J,,P3+?^V&PIL54
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MQR)/1WQ[WQ5QJ9_#9 U+SWU82@D>0MACR1Q<7AF7_ZPRC97X/69^2BIT5)7
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MV!>FI8U'S$:M!^W/; M> W58\HSE%R:G][ 2ZI#W$N)A(,770'U.H$^)3K(
MG+<-XE$P]U1OMKK>H*;<^5UM28HAOKP9#>F$4KYUU#!?MK#5PVL=,W N9Y]+
MS'W)N(*D]?:73L]M#5]-)TI?DWDEM-&K:R!S'K=Y!NISV??(&>G'1]8N.M84
MJG.BX\#146/1ONXEZM\9W++:]$0+!ZP,[M64&S14'DPD(K>G%&Z!O]F5B[ I
M5F7C2\5ZO!M*=E/[%=&YE9'-M4J)/],=\&] X3>>E*+%F(KEZ^7-%"-D_@IO
MS8=%UJ9-<H7#XMT&O#Y>0U#I-:MS]0VS-PV=[&"XCLW\:]"#?/7G'WKT"!)8
M/5V?GSJ+Q2Z/%%9_GZN;D7DJGM'WT7;2T'0Y9722F5(8CZ($]-*YI8A,F?(-
MYGTR0;AIZ)3\<,YU<'.^^:.+JT\3O$R3SOB;4S86 R.,5$].E$Y$B_(C$'+\
MY,=B)!%A.9R#L'CW03<^;G*W+^,3ZMQ4=377J><&N@EYRHYX /39HUO\P@/N
M:,L$6WVMA97]@U "<H_5C=Z#L:T07F7T_.A0.WVP9)A$JN%N1TF_R-'"^1_X
MDI!%_E.=]0*+G?O6SU^:907H3+\,)L#)-FO\!RW:K\K=#-#'#A9!#!;4^VGB
M%M#]O#Z@\AC=6HJ;R/QY<MVH8257S>AB?]Z1\9\D>NK[L_[$<UP?"$&VA?F^
M'/BMTK0(S.7[D@-5,_7(TUK'R1;X**8""FN)94J'OW/F3&[[*SS*6<C+G<Y&
MB$^87Y)_Z?HLL=@_U04XH",&U4HB'F5*T&'DGLO&;S[5%X"M07\V+UFG+OI:
M)8I.[*7+)FXS0MGQ/S(-Y>77#MQ>%<58#(+U97/O0=_0Q>7B'&R'O,U*47D$
MN ._/.FCF,7\0!-[M*B6F)CPU*TV,_;"B!O4^ B6P;E\&Y;')W?RJG!\L?.0
M2Z@.RO%D\8]Q+W;.]YNJHM^ZZ#UN_EC[NT>)5?/@:A%(]:F5[>!&EN^?X(NK
M;8B&T(GJQ"VG@@S9'-V&OYJ=\-93E]C^:G?,AB19<]$#A2S5OF$8URGD4_'>
M$]S++,&M79LV:5-)M?-#<_GFKJ,*^W(\^USJH2-EZ&\3!>?^VJAZ-989_+G@
MF(7?-#(F;CO5&*][_%72\9E>/5Q7R9ANJ\48@K!R'O9(C*8D?NZJ-_\*<2!7
M@,;-+&0#EKSY[^)GRS5^.OP3N9V<[/)XR^ ,"6\SGTXFUM-ILYA^T_"HOC;F
M9]J!:^PD0_GG<ZOZ=AD-K\:^W9B9;Q="\RO4JC5^M)&YO!XUTT]MLHVL_Z96
M84V0#+_=C_(6RA9;I49N39!F>JKFI/EL(T7*>Y;"_<;9$^O"2T!_]/67VA,?
MU#VD"MY#HBBSZ5XZ5FM4@._J0O>@2.ZYTJ>4.E:.P%5)WRL:[+7,7D:K(G[<
MIXEHMQEQ@'3\)@)CH93)^I<^QV?/_R@E,.X@X.ZN&U%,!G?Y]Q-9>F!:>:\X
M6.NFQX791@URL_"E\I0& L$E\MAX(2T5$WD+::3<K#=?^'+PX%C9!/A;;0CA
M26!)K>IYHGS"DEO 79 R24DO@3AU*7*8YDWX$AZ3'&%)P;^K]P\^R^:,"KS3
MR/7\6?]9+-C]2LD?A<JG]9+V=(1#2EE/0W7$9M5*EO6MBE!+W7O<E5[+R-(%
M5:J=/DVS5AN$W=C8OUSEWZ?H>7>!!:0;SPYT1K^M)W(%_T:_[W\52NJVB^X0
MFG37>YET"7!;?/\N9U.88)9FER5I/8NPK3QN5S(J ]ERRV  +_N_[>+ ?^GB
MKCH,!@T9SD,Q26HZCP*M[2();MM[2R ,=MJ;=V>\D+LUS]3_HR_5^8I+\PZ@
MXU,^?"'CJ>  )Q-I'6NF%(DU[:'M39 %NX<O!EOR$WT$JM$#X$M /"TPQ[[D
MROG3LJA?1355*P,?%R/JWLFG_[**$V.H=R2',M#O*HWL=A[^>A?A7Y^MJ+.J
M3$1?1%":KME(/B=54-=87*+N/N0$+G4:VXAHUO6'S*<6;QF/!HYW*1 1I=0=
M8JE[$ I4!'EQ'<//(F.R2^^GJ=O3_UXA1$QMNEH>MX >O4TMOHNX$3%"2$(H
M; !^-CG2;GU@"YV:JU +S3\W2H?FZL!9-/)@\QK;_U U[L#)H3>S%\'\O'GW
M(-)3\J/3;J;"5QJ$2<#KHW>1Q#>E*CVIU 8 ^A4&W ;H#*%\T))9XGSXSCE4
M&R'IC"Y#;I6C&:E($;BZ]8VU2[C)667SY.'$K#398LFF<QB/S?Z>@G6.[Y;?
M,,!@GFAQVAI--4_]2A,_1_3KXQ3G/.$1EX!LV>LJ@?V@4*2\Q]WV!^OQMY&.
MGK=*Z9[)>J7>VZ?[;Z+X]K]$<7K?+.YW<^MF:771G#71SA>YTP%J-\E-8M(=
M*KYORCUU^5NN_'ZB[JWS\X&@ZS7:M_(*4L/(>K<%(/)W;N\K99/XJ6AMEJ='
MP4=A7-=3F&]<_*Y^%[NW>4^UK*PNJE;@.FMZ)QP73I=99ASQH-0X_S7:1KC,
MN).'AY^5=[Q]D[,AB5\Q <I)BD0J%NL25!7R)6NIP85KK9?&]JMU]=$/WE$O
MH=[8*PW@3^?SJ71>^;JQCR9-7W'@^.N $9>2H>=W@Z95(#;V(ZON[/8:/KW5
MZFR0O62&'%^OU^I6-[-_@?I $Q&M;C;9\VT^U]C%S?+/W[.N7-@]I;'O$'[E
MPJ/&*[?.]'3)2\DR-0@[Z0%M(TE4$$C].P)S[B9.G#G&Z7C-T->@\\0##5LR
M[ZEC)X\TWP)T:P8Z<&!;9ANLH<%EQF/+NI=&95$7"%^ I\K_,77/^*Q_6^&]
M. =O8B;D6(A4#\.;AW*J:!K+!&Y_OQ"=V8CNOT><NR<?A5>#5J['?(3]#3V>
M;/.V5/,S=-?,\K/K@A64LI=ZYKPQ.+"1-V6^P8B##25<RG$44H)67K[5(ES+
MHXI'JN1?)_ 4M%]@$IVK'R'IU(B8.\I"TGG,_0(PK3?E]3JBM?\T8\;F(9/5
MN)T25?4:=,I4JC=OD6]P47B?VK&#\?# 2PYJB.NT>0LH<2@G][M6Y1#Q1S>'
MI&^@XVE\5TD7,S?Z17V&KL#UHJZAHKQ;]#\N 8@Y,QT<2ARU6LWLX>^X_TW\
M^]7L]<_X-QB8M>OK&5^K9H6TNS5<:\,E8RA!,M&$X']9UL)-16KTI#V;H-)&
M8M'JMP#VJOAP NPH-)GNW2<OW? W:IF*K(EX,R =D^+ _=V=^?B:/NZC)9!?
M88-+3W;E$7>^F=J?@%&1MF:<5@A@::L52T,Z5>KM5 -OC4T>R+WYU]4' [L6
MH'!8^+V#&H<,![H\(A@] EUCNXJDJG>F6UC,%X"$%N:$7I=&%5A0ZPE[(5]Z
MU'Q:K?1F9BK4[M/6\R9 ^4DX5XK$.] 6GAU\)J#33?6=/VYIB$R/$.J.N+/P
M\"">^S&':/G*(!TL!>>O/T".JW TE1Y97*> &F.W&0^^U2X_6!>B63!8Z2R]
ML,# \25O0@4H#14M6I^']:FU&0CY@#.!%7Z*(I/>Z^WSJXW1?(MT#_5?@?F<
M]79.]AO3$DH4&E+XXDU/4H3GVR3@P%1PMN=[AGTL^9KN&G1L0YS<@2[[+=7U
MBL[_9B'(18S$$4F /(N_[LLI&ZE]65=TNTO6*&3VJ-[G=8<\:V$"R75OCAY.
MF_U\E%:#%HB"FUO?X%>KSJ-&*)5.7A$(9N-HKL$6X=5_6@_B%*_<[W;R*6A-
M:GC1L!^13KO>&<A.T#O84&/&*6>(FMH,4K@10BH^,&:_YP$1'=6:(Y_ALMJO
M30 /$02FO+CN%S(9"K[_6M;FNC.(G'LRY4MA>$E-\0Y[_)[&P^N.H:(,I_BI
M?+XZVX*RU-IVLU^"N#: "5&L72,BL',%S29N1]'Y39/ -PSS<5EJ! L-EX 4
M(5EJ?^X;.05<<'GH5-O_1U-3H8-F48:DW'9Z$IFB7IS*-9E@JJ.LUK,51FNK
M&<E"BT2<UIRY^@01R5E\" YV*M_0^FD<Z+/^ZZ$552VZ%334/;059Z-LK")U
MZ"+!<Q7O0<I#0+>B=-[%$P796T'&[+_F^FIW1@W54SN1J9MAI@5S_=7EA9Q/
MDE$I'4D6<8Y@*K/9_J^[L"@VV+@>W2[U<1>PA<FWC\_TFKSCJWY7'/%R\/MS
M[:F4V-G:&-G!N4.0MOC7C*/T<BLSE[_2)O0/#.82$+@]30E*WQ\X4)RL4)'^
M*XU,]!IF6;WI&NH:D3'J':L#2_+"PG 9(*?X,[7;]_=&I?]"U]=_&G*N&P3G
M]Q9V62"W1\R7*O-HAWS?_//;#Q-U[^:&84D]=?U-&V]^$NOGZ>RATHN<8/>1
MUN.OZ:)3O@GS"K/3M_WY#LM_E'8-IZ<J58_S=D^#:)1>O9]3^FFZP[(&.-WE
M]+/*M'95G-J'6J8BMHP_[]LONK2 >X?E7(&O;(DI3]OB5>[I&^=9!?J 9:<U
M,KHB-$<*(CTC!C1)L-E+U/*GH]47Y O&'B?4XRN*Y_-]UL"_R:8=EB0(9O\+
M,W*?DN?3GLQ0+\S?IS>928KZ9.E$!Z>;2"E)JFSAG\*G7K[0+/I,,&E#W':>
MK;4J5KQYW(3EB$^)@TAY7RA(Q)7K"V&W9 V(+QG&QB7%)GI;9C6<)3Z@J('3
M@39A+'%ZCJ@^3^G[AU_Q2\VNS+>_.PN;?:)RR%L-^%7^$I#A].*?+MS=8N+]
M%\?6X7UG-8H?7G+A>RL=?;\$K'W]]0T%F)BX,H!+0)@;OVY*F@N 7 O0)3K?
M7E8R:%-3F=5)_!-+,\,4(6GNU*YH)[VS1I>1(6DU('+[G.!>>)<8W5" ];-"
MUX'0BC*DU4:X8X=OXS>758_"]^(_!KQ\:D( MXHY)#.</P"\JP**,OHD,X6E
MM[#:0M]H7 * KO-=/-SPJ"['9]72/U@Z(G32-!BY*5:ZIR'ON6+TDU1.0[FZ
MC\Z['%YQZS:<#+]:;P[==-QH/D+4P$56-5(*LH3MARW@WW;R[@LV_,!/EQ,*
MC1L0OH\W_*3'6_#'"9]BG,R6NL<7_TM L.!\>T3N9F9:12##MM^MG[Q8!J.%
MA0I/PM/6 V2UT!;$524E.>OO)E** HD7M4*1KQ.V[X]PM>V^#/6E\?)(0 QJ
M].>JD&+!&/MT=$<>"<! B,YQU.T;F#:@3,T^WI+H 9$ZG4[ 8F=#:>6R4<V9
M&<DE(!93/]N!C81 />2#_GC:$PKBWG:-.8I6H[#^)VE8EX ;\DK"]P=&X,6\
M?4_P$OW3@;HH54D[!JKC6R)!38-OOMV8F:9 VCXIQBY8EN:06DL%>#K?#G?'
M&<DO^/D4)O/9N98%::R1X*JO/>C]%MO"4(\.UM>5,$^ZK.G1L=HY/%4/WZH,
M%[WEO#I44.;==1-_)BD1,7B'AD[WQQ>4)J95\R4 -XYZM99-+_U6Z%EB/J_"
M/5W"*DF"$OHF_)8MC\'F_+</H0)/.E.ESAUOS[UA,-)B5VQM(;B54XW)ZPWB
M6*6AK^+34:M!DARSGC?$N.>)&AZV-."ZY!6KA;\XVO)M7"9R$%J23NNNFJD[
MMM:(SG"0E=;?J5K25?E!'6&,K\<!J1^,,(H%8'?:2-QLXKWP$X-9,VZ6W8&M
MW$W+#.%W+^X4KRQ4T)7)^'$6/TK;(M5_R^49\=1T LI9RKPB-^EC(-X]T0/M
M,25=.%YKGF^91^I.%19+9I6(PX97G=593=X.KE>5L&M+\;#FE'\'OC&J)4\)
M>ZY;%9168<N=$_Z8B3+-Y+7/(#,"-R+V!X+QS%WP$C"H<PE(%2'Y"W]FEIWD
M-.?&RS$32M5H$""%LQ?]\1)4 >2R;U$*IPD*<>5$#&RXO1-"/&1.+);>/W B
MP";LUN>)JZ]9NR7[ 8,:@,''QJ\6CSV4+J+R\)=]4@+2@G%9MFF>4T/Z4UDT
MS<A@2[9"ME)EH*5O0D6\'5WOZ]L*7F-K>FL&*1]9E#USHLM7^&S<^D)8FQU+
MJ@CDK26I$NTU<37KAV\N =Z#EX#'U;LE67XST$PQK6-X'N.;78DR_]3P*Z&S
MIG[)7!V(C"KR9L)D30!@QPG^("+.BIU',4X/-1=6U=9GDA#VJ"M6P:M9+P&=
M:JB)(9]Z?@ODZUJ*)IPFOH>'/B&0-WB)O(';;LO39ILHUCL)63CLR'A^Q:A!
M/@XI"5#,'KGW<U(8^M7+&?;E&6U,CB%URN/$$??U;BQQY$/'TB/-5"JM N:"
MT#)1*PNKF/\9J:?W:";0M4Z&OGUWY&ED;\=\HJ8D%MSWA,3%J$B. :U.LA8Z
MF?*9&/&3+0CB,8EZ+*9]H\H9?,(G0DO<IZF&5F0A3T)^$-UI2$ 5;DB41NUT
M]=+W#H7A#IOB?%.[6/G>;O#]92Q88_VPIFP.^2(SF?1B!=1FC=VJL617ME40
M@8]GM!1%";&1:@:0L<8!6 -"5^T]-I[/Q/VL,!L1>YE=-OO$G,68+2@YG.,G
MI@P^TH;:DHA=G 4K>7ZMB<\**P^_%J>T_*5Y ]5NU1;S)6!!(<G:*]*(+->[
MZZ"4IV"P=(;B?3I7.>$3"L,P89Q&Q1+BWG=,,.$/%@)=!H>7@*6CCD5>7P<[
M1L]DVQ&]'XO%H8?GX#TFM@^V>])V8JS:JO*C^Q;(?*ZE?D XJS\&ZTT9+(6B
MNZ=UH2?P0U@9[X%M=]=G\@G>VV4@F4^D&=WFNY,.M9CDN[6XZB1+):/*\0R4
M@!!"A5(;U@Q(,\1[H"UM\Q%(4JOK(JF<M@7M<-[L<\ML7N-EKER3H6D8'F"X
MEF=O2W2^N9S*RN>^/X8%)N#JYZ;&OWT=,5!!!FJP>A<+2A]0$T9R.( 01,->
M-7-."5R4#< ;2GH6YZMQ'\XK38H7_NUA37*^A!GXH8$ 2^0;4%P=IP0A83P&
M@#;%QN]9;Z:!6-ZP*T<<@!<@>R4J1OC_B('*6,JWB")58&(!XW(G:9%QQO!.
MQ=ANAXVH4ZRZC)G6[A8XOPT5T23Y<^I]A/W(>SV#Z:'^O$.4-1\!45?7AJPL
MKDWZPX="A=,C]K7T QL 0@#I];H^^A\P 6*>4H\"!T'GIQG6 D9N W'-.')5
MN$S^270MQH,%*4S(UH)E4&L"B!T%^F;UO[RN!ZX].I.:F4P)HLD@,NJP*.G!
MHF'73!)XR3']5O<B\EGO6=57[E="[4Y_O-%9G5\,\"$Z=MXA_!265Q):^R^?
MD/*=]T$5])+9,"EN-/*_@^W&%VHY)BN":L2)UD*;(6?1QY:'T =6SV:?)FNE
MK8C?V=3;DACY%S<PG3WOSPG/=E+K8DATJO#BKIP(%[8?5;?OA9BR)'EJ2+!I
MR!@0,2OI$<TY2?6HX/TD*/K1<%:%\N6N:AY.#T*O[16,@+]8#HH?BV&'UP;*
M PF,R5H$Q[#^C A__@:I*-1M,6F[_=8:?E(RM[?-O?,F9:?F".9DU4U& MHI
MT>/"02),*(C,7S!L"//>IS^N,8[:F0CK&SQ_M/[=>[%O=RLZ'M]E+VLWS2>=
MA(<XE?)N#'X-XR7D+>$NX9+%N#(+7@"&!< 0\&8M9E _:LE3S,^T-8+_@%U^
M_/4B+[\B-L#6*/GDF,[9="92J#5'%E"%<6WUN.R8/]B>?[Q8X;GHZBLL=/MJ
MI.\T+3,R&/;\8\%R#:8YNTOMC+NN$G8P[V'O'Z&Z^Y,H$"[CJ/K"@'\KHVMT
MQNF^ !D?^=O!GL3Z]PL:F_22V<H;4A[<@89I .'5EDD33K&M*06/UIZHRAW/
MBL-Z9T=YPRH,E&T_4CBQ!Z<00!%0C!1,N)O+>\>!:'C_&7OK(0 PJ^NY,.ZD
M)(-^GN\<SRTO,B*!@YW8BJT)B'#G-AH2#/YYY]6G52(_8WXW/O47%)1?'D<=
M+KL=Y6!]P\SY>:<B1FZ/_U41(G1S4UT3B3S"J/W14^(.'"P?)+Y3$Z.*)AX;
MYPF&S3]+6;3H#@^0>1<@*B9<>',40?)4X\XI]A@B#=47G%/E>LRB@D<C.ZL\
M6[XWM.%7^-0'OOQ .*@YR;:6Q$1%Z_8:I1:=_^,(-1^5_K3%*$/OW !1J#NU
MV[B$GQK\L058QDH:;M\0Z79/IZ>/9$QO)$FD)OL.[DX.UB<GG&^J>2P4@3 9
MLW(7%@_E58;I2KD]6 Y'\2?]GWQ831C?),6V#XW,*WJ3F6LV241M/]MD?G0C
M).EF^%]%"B>!AO1!<7=@=+_7JB)VLR# &"0!$$X,=)2VSZV/KX?,LSW[^ :^
MT; 4I#]3G\H=D]B@I#/H@CD9@"QSL8@))(ZXV2TYVCO9!A 7S?;Z0D^F=?ZJ
M>,%0+:[L&/Q6CO4C!JQ36M48QM%7WT1JPM#+X^_0!DS/[P7R,+PS=!,19\B^
M70)';"D12'4ZTQA,#F:XQX^N6N)>917G%>X#+RC/=EN)HB0&GA%.@00T[TL^
M.UD1I%.3,#)PU#_9/'HP&_ &TTZ/!?S@5KN5BHPX(*?J'FU&WI.T=M91Q\?W
MMA+;D1*/]^N#4Y/.6'BE]<GT5SE62]0^"+.>SRS+BZH0)F/;QG39L*[1ZNG$
M?11D.EH3C_%>'DSK]Y[J&NE^LOA-^.$AXZ+PA4TTNSIA37@BQE RZ1+*T>+&
M_[;&*G_7V&PR)U5:#^ *M68!F$>/S:S*9)WME2*?)-^>6Z:N[]H<U/*8T:=W
M463@<.K>E,#HQ"\M=RR#,MRB38(GPB0V0@83*Y:#'G%= O1.Z!T(?&FUQ-WZ
M\P27V%<E0%C>&%)F(U=I8RKO0NNHTPH!\;KE'/J,BU,>=>/>Q^K(.^1>S3ZH
MX);$'P./]6-V0B+]F#1W.D?S?DQS?E9D)_H2SK&3(JE*0VFA@(5)#"XR>9_:
M_VV)@XEH\J9H4F 1G34D;SBA:]H"3VIU+B"[)+/JU0<A=J-E\9I+ &D_H/O3
M?)>>>GJ"A.!H&:]EJS=1!_:#ZC1I3_6Y*=6 WGD5#_M]/4.F$RB7JQE34;0'
M\6[L6_@E +XW14=*Q*)'>!1>(6*C)#&[_3;V?UE7SG_W+M1  F*K&0!@N?(O
MD56>O:[V.DM;'4XR>]J%NQ*8<^1+DU"(E6 /"]:HU[ (QII8IQTKYG1].54S
MQ$,'SATU-[(Q[]SSA_C)%L]LM"WD#\5.\ ;4K=8#3Z*:O4_5?/HJWO,?]1R6
M=.IIJX%TE96H#Q.?,J! DJ<Z$A;Z?O*B$ZM#VVE;0"' 25AG107"]JA0\.&:
MF8"JQ5.J1%8?/)*OHI^V9\88]+EV[-?VN!WH9A>$QKBZ/V[['!ROH=%(*MK"
M>QM.DLF)8T9U%]*\THZ#6??KL,;'._G\V-*-32[T&1\"VCJL!#<R1._-3_WD
MQ1[0*.==E,-F^,#;DX),S8<2LK/%-M^.DJ!AZ!(4\3_8N7%,:GJ_OJ[BHG13
M>03QRTQ2$$E$2O!EI"Q4,OT@8!3 :FH9<.N /\?<6EL+WX__$XWO>4O*#0[[
M3C?,&T])C \G1D&;A[T:<V'>M"_?F\(MT:7<3,(BJ;?!9*&5PG:52?YW1,<W
M[N',B!ZS,=+BN75@Y:G@I@"T(>K>#VYZ/!RVE[C)'"%:CYIQ"HK;6,+]Y$XJ
M1_O)8<D((6,0J=IN7=UR Z02A2W;*DOUC0YZZU5;IB#G8GBP]\OMQY;\";+!
MZ:K(-X-,DN(B#-AVDSG3WBG,?6F@%:S5@HONBL2+>@T;=4MKU'WV&V<.+G=H
M.S*85FYZZ=;9[I64HC<W=+QAPE0O<=<LX4Q,6,+#E95IDPY;=4;1&T< ''^\
M:Y,4$J1>X_GZXO#LX2&5M)A(;,M@K6W)3Q>(PE<_]I,X\L\BGCFU&0F<K,QV
M7H)0G:3##8!B@BP@ 9<Q('<R_KNQPGFSM^@,E5>MY=J3</L48GW6[(;V>3O.
MN6&T!/,"CY8F8EL2 X*7H"GG7U9.<#X=\BV%)+!Y]AOXBU(\W](/)2V@NV'"
MVVW)LUM/P(^7?ADD;4CG#24#EN+^&[3B:0F:['\((?:A*5+<I,X972/C@5W;
MO@ ;RY!H<F6?V[O1CHW$<AMEN$\RO93]] J:"9\* 8@I A)+-D^/;X1\AJQ2
MB3S>^9B%5YZSI?.).B/'WE]P=$*J:105Z#$ WJ@&?(R,Q;N'[_M!.UN@3Y7G
M8_*.^*?Q+F [O*Y?,7>K:47/.;U'^9 %=Y^N%+(S.;.LO^OB'2I[6!SB&1Y#
M!#+C0XR9AG*.$O7<#B8G'K^&_6>R\:KS8M/8R'C?XEW!86<,37<R^R[V'Q"E
M8 NVD1<]*!)<RW"L@>=QBS$)49'^R5QON"=_-/IS(%U<""UA.A%^L!)2/MGZ
M30PK.VM:>F D/2M=;T#'*BACQN($3JWD^S')E=5JAIXE!D,9F]2%:5GP5>F\
M8*I@P&VDLT)7 6.@#&/9K6@5MN;W,=.A1U.S%@)>U'B<=>\4FRUXZP$ ; !F
M)X#JR@((VVG^K>E.H0,T"\4]W3/'1TY1IRT?CKQ;$,)*CZ]WPS >2PKJ* GF
M,%2%QT3[5BU7!3UABNL,Q,=F:/J[N1""-:*.%]]"C$'?5N((P6D$R->,)O?J
MEMF"5BL^1LVY4#U<.G @3E;'RN4U[_,6CBI_1V%+9&8ZKY>Q%J^LI!-'\EF(
M-0O*8=:&VZ/WLP@M?O]O7++^_!MI8UE6D5!Z9C'?Y[#ZQ^2;G$8.3%>3(O3'
M[,1U3M2=D,\W),2[D18Z:.ESAWOA"9LF0T-5QIAS)%P JA3T_#@I^S6[VJ/:
M6SVDJDS;V,:"QG[PF^=/ZWJD9"5<2+IQ!PU7N8O9>0<XQ%:W+)SUFF3OQ78;
MO+9<K:J.V]8?:+.7E.L&7]A66N&DX62.WJ?Z>#MX'A?86"D0_QE7T:>&->]3
MU>2#N ^](7JX-'Q4;7S"&6OBJ+WW@WMO)N] _7EW;U:R!2M@D2H_5F8[V2HS
MU#2Q8V)@3K&X(_BI5V>TE4' ?Z/?$O]02F6LX).@%++*G"@KVI77W99XY'S(
M(?NHFG[@$W!B,$*'E<YC."P]!"S>K'QV?_J>^O07/#:4FC8RGXGV* %<D EB
M3?AWYY11P.^Z19> DULE$UC+;'B)O)> 0[Y"G2&G6BLN^1@\"PNYJD!AAK]'
MC/D]=;5HX=QAS #R%YWFX$YCI^[&5S=F*B1'XE7",M-']KV9Q.G<57U[[U08
MBE>/NG,.PA=9'ONBMP6DQP"TE,I*M#?PPUD_[ (/=L197IW(Z%0/_3Z@5N_Q
M8ZI,0>/YU5K/$OH] 3?W!N]50[S$:H>,5$A<(&]/)T;'Y^A9,:H2/N[ #U_O
MOSV!;.V2^5!53%$:MUNI9PB\'!81; Y96Z%:"$1-V_?//.?UJ9SB$(AS'C9&
MB3NS^)8.N&&6L>!)XDFLSO=!<?W,GO(AKL+?'.[3]UUAVU:EOD=GC&2&O3_'
MB=ETCJQZ(@(GQ?1RX,NZ#\B?E;J[=JXFBP[?42CF[OI M'([W4TFNL#087<C
M#J?_:](B[LEB& .C?X&>8-1+9XF1UREQWC1OGZ>PY"4KVN%,:M:X^].789@S
M!B <!K$G2[/FN85=$N#<82F2  [LZ;HX6.KP$]EA.)]5FC4T5DR6C)WUA\"<
MVD1F16%E:6J\TE)!O_$M^I<O^_W];PX)M[=;@4LS)FPE$ONO@@33M>/W=#X,
MKERZ!+S9?-%D^&5J],$>]TA&T5FS#LG2E\P96?4^C8NS8K:N['FQA"D/L]A6
M@+"D?R9A5G@(4%-Y_J&S2)+3EB=]W(%U08'\";$%4OA'ISFHZLK!8:V,1DW;
M[:[,(IR#KE:P&H"W1P:)^7HZO_@KKII@VJ-,7-T[#?5#4Y)U1P!AC,>8G4))
MO^< LU/Y^=>C 38E_5L3+:BR1*/8'3ENG[V"BG"N6\'Z<=_M.9JR 0FUF+"X
M) !\'$3T-NC-^P-N/SE&^\*5@KBD(,)I@F\];=L<P>'WOJ;8+1S7-%Q%>'IC
M-.2$*CTA]>UH_WU3-% BQCDRZE=(5X))_&3^WHO55H=;6N%Z.E<^PK[K C_D
M,9W#V#8:C6%QJ2S>&38AB>B:MFQ]TJ/4LR:<\-I^+&73T"4(ZVW:)M4/+ D3
MC3LU3^V+= 3NEGV^42PDL@N1!SF+HCON84P+F9,$O#CT?<M<@=16)',JL9T0
M<(N.%A$*_,;ZZN5W+F,1SZGI$_@1YYNZ=$+YH,=5S:2D&.FV!N^'8?7NQKR]
M1SY7,1W[6E<T:82?DK]W?'U6^97P3D9ZWY*-42WD$B#!S?R]/=&W'__)5T2)
M4CI8B*"E"L?(4"XYH.HJ"M/C=49HCWSW+4XM<J?(7P=9K:M'!^? *>UW81@-
M!K\GYU#.G?$VA32 I*:% .LL3M'-V#)3]Q5TA<UM)V=)P.&&WZ/UM%=&M5?K
M;S&H,*,OZ1LJQ'ITL],44$6(*_X''*=)2@HSSQT&T#[_-4[AL/"#:K>Q%\CF
M)+?JN@VL1R>>&N0YQCV)G^LR_5LS<9I@QAEM)*4:RWIV5LM4-PL.7D[3+75P
M>#2'GODDQX:G?:.^XZK,LJ^P5P[I2&47L0F8&-W;^-;]MM7=R=3,U?SAW0\\
M+W1_QL^S1R#RS30 X6V(;WPM*DJ- >(-[/I-2<S\C\>?M\3 I,H"&156L1%Q
M=X%6+W5:>K':'R<K<!QNJA-(6/!Q>&1J[O;TSZ#Z@"9>KM..D(^X82NN 3(7
M[\K(@>W9%[KQU@/Y74M&WEL"&*M5_^8P6F>')K)FJL5-:@PVADS'!+];PNTE
MHU,UP@^ZS2UVIUYSM#W#4I^6&&HC"9T*T4M6E?0:_ [+RK<3*5X,=6"C)*<N
M=K?89-W / +[6^95^7Z]?197=\:3Q#22- _'6!I7?5#K-JRQ;+*E$V?>^]9:
MU;>E44![B[=/8!BGDQ!09113L-?X>C;BQ=2%\KMP^%M8E.Q5$B\.P-4%SSYG
M+\8JMXUQZY#3\B]"L1S;O,;T$A+'"%TMGKT$S&^*O?H>=5]D(Q9@NVUN(8YR
MX+-=[,9@&]5 S6X]P!B8:"&=ZYPGOF'D<'()<$J;"?A1* F,\I6,E7@7P_T+
M'BD[2EZH'M!".W-Z&*BQN,6BF%,8F.Y;"-XLH&1AVJ:)B'A\5TP/#!P8)5UB
MHES[AE&ZA3> 4(UYHRA BI(*O@FY,%\929%=M'3(P06LVC0Q3\7)]2L%/\/A
M@>HI\C!PQ>(%IS 7],4KZW.SW+W-YG#.BJ_.AEE,&_)L8QE4EP"J^_>&R7F[
MK^9(U;T6?.MA@ DP2RG-I;74#)X\::+I3V_I5S>J4YL^Y:)0APIY23CFWHFK
M;Q6OK-?)HDICKX:Q1^,[$&S<)SB<SS3D$S[K1<YT/MTG!N?\O.(NV!:SH4D$
MA1Q<P9PZQ15NFN)T&O+VH7[/Y!Z]-]_#.1F65GN%HW6,-]J=G^[<&N;4L0\!
M$X0'S<2OYC9++!]OS+D[KWSW=%<Q IG@MS\B(?1,V1JS,J$@RIR$</H0(PSI
MP^[1XO(I?Q;.!&[>&#3L_$2/08-<;FU7Z='_B;BX6X?(3QLK8M=9-M'[AD>_
M^L'!WC]0/>NM;W7$)0"?_KE^VDO%2X#QW%FG?=0IDXDPS5=]DRJ*VW'Y7/[A
M(9_(>C0\2..UI: KCK=]5K,_/,#P[\ 0+[$L1_K[5+?="!#8":(Z&J#R?_!O
MK<X?J-)7B;6TB;YP-4CQT;X]I_5L0-(?>U?]#C/!W=<+?U!(2LA+CR*Q;9:H
MLCXFQM4KA7A!UM40_I-IKE;-Z<I*Z^&-%C"8JI_3A[=/4DB"%]JY-UOGGDY-
M-5^%OROS^-QDBA,XD@MZ[RI7?>L24'(>'?$#K'L):%!E:K!S['*U><$^)!I
M2NU4Z(A?Q9N'URZ2$_&C2#@0;G$"Y35^ULO;)RE^"?@1(F>Q4+,',RQ7;(AX
M%;>-;:BLK7I/O3+>4ASXK0*H?A2%EAL*\^4:IQ!0'HSAEYJCL<'>#"$!01 .
M;-7Z]/E)]&^;(I79_^!57.=ML<(>Y<PS"HE^1N'+/743/W8Y?^AHE306:,?3
M:GQ^GG><Z<LDZQ(?C./O#7MZ%VT?-AFB)\SPNO;*60.:K/QMA'19B+=&',>5
MG45Z3NX0+(+SO '7'0[+CE3 EN@ 0.0=3[2$O,>"MZQLX+]W8^7 (5H.FE=K
MYE'0S.@M^<BF70_OV)PJR=:T27,ZX^W-%K1/-/^CS.FD.&4K^ZI(O#H:9\_3
M24GE43N=9N()8VZVJ&X81UYI<MH&5E0F-@B+I'O2O4BL4C#&_56\2F C$0HD
M/:FB"#TI)?K,RXA?6_W)8)>>B1;)3=.ZS5I+00X:](K^>Y;!;H;#&746C=&<
ME=W)HKG:95Z)N&*G=9NVG](.$UTVNSK%7P3$6:FHJ1V*CMT\[,Z3"&?@:V<;
MLW<X^V0P7/3V19X&20)XXZ;6Q5&RW[-<_-=/0/&-DP*)34T9?_"N$@YEP"B>
M=Z$["2(\O_@SHN4,H?5^8?*DY^VH^UP11+9YF4/1CV(IW>!>%Z3 5FJ0Q4<P
MTTCJH^VPK=2^%=':X\4ND!4MRD_/CSB6CG(M9M3F]F=:/9VDCX*A=YP7V75&
M:YR*;*30JO>IC!HW'<[%4,BLM5LNB83N&#X2&.2/$Y$P7^'4K#FSD8KML@FI
M0(#AC:ZE?U_=JZU:X.M6N29L(ED?T/3%1E/J5,VJ64!R?N^@$!Z=-9H/9WA=
M!U%WWN_+BTQ..R(<J++@@BG:TE##)4?G1BWN4S;=W$AX6ACH'SH3Q3?(AN4F
MN<!=26@$& &Z4V=L)(#"69=!8W4E?\\).$RG*K?LPEB?T?I\70P[D0VHV]^:
MSGVI[LYV,K_^1=$DD$9Q7JN3,:C8?F923L/5^A-]4)[W%5E@&GI,(,@49,^T
MC#?\V!=ZXU/L6(I[KH0*,*UDT(*HYQ'/+X9O<I[Z)08%&D IWY1X&X/Q/D]1
MA9@EQIK?)U!JC61@>:&479M/:!8@DF!Q []+N5)5'E*%3VM\>I\7M'88<4LP
M4_?3.3ZNR\^P98YF"7W)+2TPVUZ!QCU(M;1.F/$7TF3=>&F/P,9/.PPHS97T
M[WGE[D/Q=[@2;YR^/0V2^+<JI58&XGCK@-/!1K31%-V%>X.9NH0J$(,JBKO#
MU< $F&&)D0O8\4%M$?7)E]^,#ZAC*/L]B^N+4&-KF;&:D,N.9:)*]#(D  HY
M'VX7'&3]"%R]!SILJ)CN$:]CF6E5BWGVD3!E[:DU]DB&NL8C$&M/@C-KHH^4
MYA^H(AE_7- WF^UAR3ASB=FWRKO1G:MD #QL #6 '\NVI4$G*L*FT<M*MI%T
M@CY4?9466BT=[&%[<^?]QZY>^M<6#'B<BG+4I"YW22?9\&8FWTU*DFY7$H0%
M)"<KL_PA% *-VL7NU_9&N-UJGVMC:.&VQ>M'F(ED:F[0?XXDKGB[D1N583D7
M4U4_^C.>IS6_F;W]H1JD<WP4H^YQ6,QM*J=:6J?705EDI$\:W-F9HL[=YZ/7
MK*(/,$W\E)?CD;#GY\\ZJS\K[?>Y0:BD@O"-6Z(]8 5#>/F/"4?AKAQ<K)E:
M76W_1K4U\GQ-)E"N"?9R7WNJ5^MNXEV3UK>CX<5.6)_Z&X^_MP96E@S$6?RB
MXYZU+1RI^8F5CY)\[JG0KI2-[?W 55YZW.F,\B#'NU:"=6IG*_#-(><T:KAZ
M(CFX(-&'@TM*]P_J(>7>QH-.RXT^S@&L83>B M[8 5M<EP93AKTM6'#/Q(DF
M@Z9&A;*%AH1&#7N^CG7*I\"BP5QX[CN,;^[+5D[T#*=RRB>XEJ6FX;:I0/,
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M]X&R'*C"HQP-XM8N/1&2%\(_64@<,K2ZK+N3#5&AKBUYVM-[[8Q@D'=FJ9[
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M4(4$5,GXI1+7\6BRQ"N?Q+]+=5O##&R:L;966R;W:$PE]#3TG5,52:/E;%H
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MDN&BBF$O%$LRV"@=/^>2O'B$]PI0[SI<D$ KXE0>^X6K&2J^@U]:^'VFS+'
M7X;&5V77MUWDC9N4=I/+!0;J)1>2U]HY"&X[8CD"3>5F#,]6]Z+CXD:VID4G
M[33CT6?T>!HG1(Q7[Z"%?,M,X6OS<H3_'V):Y=-H8=VJP*QFG&;O9L\6,.]3
MUV#C5*9TL&-M\<2.AS"%8=-!RI(&@U4Y[V7J5/DV'XG*V@FN;!XL%$B5X*%Y
M W#[L99QV4ZHO/-0+-2X.U L^FV)QVYG1^?#W]<SZPC=F9B)9?&?6B"WT].L
M% (+:3L.Q?L5/S_)8A0QNN\DV+7(>@OFX#(HP9;/4\NDIT<T251Z'\2&&V+E
M+_.Q.Z*'9[BUIA@-F5XTV""YW,'3]LE/OK,5] =?MV24!<'[R96#T(JRB/>U
ME,3L2W /FA(CD^Y  X^<B)?)TZ0"62F^!K%AX4N)0NRFM:P:INR(E%4XB5B5
M<O#ND6A@W&B9MVFL[./>&P []CX%;4LQR3P>)FEUFY7R\P55<#I&, D@>&F\
MLA@X5"R/W=Z+33^U2J_:K5N9^MA&>E]0@\K<=[F,0@N>6YY]NMUL_UJW-G@9
M$^%]H$R."QN4X>6O#DQY(S*TW&XDHQ.8+/30@#9(^%%.916)X8'F56L&L=G"
MR-,BA99%]718Z- T$^MV0WFK"JJ6GU@XGCT-52B0CER[8^D&T,(0Y-J7)!RO
M1I7&E8M#4[N_['_$V?Q;"QOJ!P(-='[L%(SVQ?SZW%.O_H^TK0U_*!94]E@)
M>;+-4E0A6@GP; C5LS -'6"(8P.;]T!/ CR"]JZA'  U]QQ,0S?LRFJBQO<?
MA.Q%=1S5O<5'.+'$R IFC+EK)1$^3]M1<:EZ3Z1@7ILBL?I4*^!E1>'D>R0$
M7OWVF1$2$?1>=*ON"6$]!)H4?..45FT4I&"#.F8!\RQ=B=0$V_AD5Y,56O+.
M->NP>?7<[1<"\>R5[*\M+X6# $GLO8RC%!6'+;AH7DSJ$'<?4 :FM<*YTJMG
M4YN>O>03_?+9_?BV@K;?]>H8W05B*#[*7'GC/8]99'A,UX3D':ZW[V+(@D]U
MLF\3\<$^]'VOFF]C2@&KB:*9'B\MQC?AA(8R03)%$!ZN@>'_KR3[Y="&%>+:
MEOFFVE26R">)VE[=E9"(!A' RS9T=1DK4.TDF[ZJ1G5;-8)OS84$0@C"[_#]
M<9CR8]UJ6DOH6V6%@&/NSK:,A.^4FP$"Y]HG@VKMQ]_9!ND^#[IOB-;D=J-N
M9X'_Z'9RN*JK$>+RU9_Q]EGU/4@#U!LZ1XB++%"<<=KN1Z(B/F;KS:!;'I+&
MYL:+YJO/JY]C,.J><4M1&>&)<0-$YE>:W(NR1?;$]0QE1V-:TOZU*4!J-JUX
M1@0RX/A.6E80;16( U'Y#B/70'H-2U<)IO6DB/U#'\+P3C5+FV'4LY=5"8!O
M:4%BW1.8+7Y5/YYV ]BW^#K[/+#C!J"$\Z;R=/L&<*7_^-PNE_,&,-6-<I#^
MN2TPL1])P8Z/=T3@,L_W1;@LD]6V6/\A4>0CX/245@7FZ\RW\-!'%V 9P +)
M+!1?^T5*.M,FG;G-)%KY<S%31SGO=)GO!!;M(6F+/O??=J81U'NWR7G)(&6M
MD=QWIJ554KB*<9)[4O &TOTXT'^?;>]S.U3O A:WY<[6S^;QC&A=S5C9EJ^&
MK/K5W&H,(F2=.#J:'S>II#"CX4%VGIN<7"!%B1(8^.4<?_OR,]'V_)??DGS?
M+/W6NOM J5(;>RKS-5@XT;DUI&7%YMIM$>._R#/EX09_X%SJI>1>TR9S;<1%
M/1TV8F(INL@4Q0.4K^K9K1-+Z37(<#4G&HPJ>FPKDT+.":OT"\8NT?"U*3MF
MA5)Y*ABN[!K\F^U_%%W9O#^<0K^$[23PL^_PT<,'M>0E>)I?]P;2_1(^_M&Y
M<'J(O*N ?PA)3<#. -I-45UTXB'A^5!4&0\FV>[ZL/D-2B",S9VBB3M\G"YO
MJB6#3Y#MUY3,XH^6S+TYBBXAF19#HM H-UX$9H:Y=YG!]BA!L&=5VW&>E(-?
MX0;81R+2CR.F\S5I8(=<G^V5;-'&,'KJ/MG8#[W33)L=&>C^,6;-SJ+2/Q7>
M*T.HFP$V8R_2&;+GR>K:HHH!XR'C@JDVBOZ!-CRN_ZT,3]IP*%+$.#E34)2D
MC.L&<"_!%[WM>_[?H&@>34HZ#%<V',\#C9H8RZA2GG14CK_ZD^35FJ'D*VB$
M.C>CD>-MQ+C+[I;^L(2_]B:RL;!9ARS<H=*3MY]Z92 =!;CDYL=Z-F?T1 5\
M&/:7/0S?LO-U[3*;I?V1?K_I3VE#;6-L7K%#QMNP1GC@O8B4$8U>=B^:N4F
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MRF:7N,+.IX6K#?..64;_["LJRIJE[D9DNIGBM&E]5M\&_<^UBWP09$+>J!N
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M.FJU]3KX4"!J *&#X(49C?;D-A.=&]E;!&+"(H>&PW2!Q&,QM6-,](*R).[
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M%EO.@( @$+3?C-G3CI \G%Z'%ZW$.[JF)>RXP10K8EEI4J<TP#\&$8=I!-Q
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M/G-#=3'85$/+"@4BXGP(6=20W\<Z07B8*R4O["0S%K<DE9;:"Q6VGA$,$^R
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M!S-@!VDRH KPD![0@H<>I8UO(4;4*?-=HRO1P_Z57 PN-TMD)-M]9C%4 %
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MN3S-1C\S,1EW30SI=A7][?P2J&BQW,HO"Q*&5+R@P4Z&FE34!R!^!^2H@/H
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MC8#.Y2=@4W(!Y;+;/%'PB",M+<*(K\C4JY><,B@,E1>+8+.REC0^&Z/9WCX
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MS8-S&3S!U630?1@&!9%T2P@<,P#M2[>] 7>DPMB&@"D/Z21YM"D8R8CV. /
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MV$^3<T'#Y@>*(P2QD^$ BLJNVJ0U/YDT:3,!GY-HZ'BPV$+-,L7YC&XD_Q-
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MPUV7V_9T I #7_SOL;I"1<GCLG:O/K'T;DP2P1/#<%5J"N5K8A-<=W/.>/$
M;'V>)FB-=']QI:Y_MZHK8(7;G.F*22_^HRISH%C8#NL*L6JI.BZ+I3^5?K8H
M>PF:1L+2[44T_%S%O[C0W+]+GTD>WFF@_ FX+269SI<D-9HLHF(12,-">1LC
MZ5@2^S%\-$L*?=,@%_P2B:TG?!LK^N5?7?CTWX6'A!>8Z 457$J2J3P/[E,&
MLMX[H53'93,>]H9N]>B/IGB&90T(1 -3Z\@,.]U:3[90"GB",=A!X_C%=]]W
M_"\S!%H.=[>=!K9X;(K*98A ; \<J3S[Y>,LE/;VTNCZPX<][D!A(T RVQWE
MD)4W0$5TI&J+>Z;ZQT/2$I'V,G*>!.EE1OK/G7]M24+VGP"7JP5YC<6*^DQ.
M*2ZMH%XVH&E]_0!_[01LDJV:><.TI@;+ @:[42VO"[$2H/M._-G=6'4'G\J-
MND(<AD?E&0S!KDE2,R_T8FH,$ :'4S<XX=:0^S'W>%E\)@U*XAK@A$E>(]+C
MC.\<GTI1B9/4]/;)VB5)_$VIFVJVM^))X$?8+<N_L)87*<,"$QF$ 2$=%,)^
M'3"2X*_\Y:'63T"04/0A6E1;X</'-4M%L1N9)1U[:+/#916JY?*);W!>1AQ#
M0/H3T\J.ER^AQ0&Y\[1'HM^!WSN'QJ&1W '1<N5'\#..88-RGC$%,>DBP3A)
M]<))PZ>6.$)#%'2]MCCZT2BA#,_2'8I]&2&9G.EI.D:3B*O"-#A2?1/#W0*-
M?7#*DOP*7?=D')U%1GM$F(7Q!:E =ARXIVF6=TLC,\^L\<B:E #/_*^_TKC/
MA(]+W6G2)Y@D:%_HSU!X[EMZ>^OC<Y1F8,9R/.(H2NY4]7#:*KTU(L;N.#"6
MU26P"6HN*8'CPA>XVCD_W+^B??5HB,W%ED#73O)H\B=@7/(J#Z2H5P!YR3OT
MRG4&R^/T\"=@0.4G0.@GX-R3=CPLYPG6ZPS+V(FE-M$,&5UQG/E4R^3N3U+K
MF 1F4R.[PYA37.$2'=->[.SBMS"[J+\3:S_1WW6AG&+H*R7XAK')_508&KDN
M"KWKGBJX;CE2;TG9D4TV2#<S.@E?ER-AH,BH_PGH^PF8_@GX>OA_^YDWQ]+#
MW_"@(H+^)^#0Z7>A&,%)Q>1.-$G56)F..4;3(^7;BG** NSE6H2]-ID?_%1'
M=1\' 7;?.HS#7BO=D_>J*1L,6.GZ%'">\=__1905@1F*F)5SBD=%',5>2!Y.
M!EQ][+JD_MN3VX^'9Y*V^3.)LB8WTPV6[_%D6F/>M@XA)\+# ]+]!( .?BX
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M#(L!F^,1=IC9C60[8\''/!UTT8L0F@@V>BPIM?%03NMN7G0;7H'@7$)?PHF
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M9-O(3CLMMU3%5:?9)KIGSOF"KP<B\!U*$_9 4+7*K"GXQ@6_7:8D&E6;QX5
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M@(GLX)1\JPF:=O:_%7A%YYM-GSE'TS3R=IJ\KG3RLKGG6CC4]\_)DIIRLO@
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M!LK8T8U#18'ZPN>I.\1TKGP,=I%DPHMT^W>3<G=#P&>G%7S!E^2CWP'[41]
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MXZ*^>)'"7:PY".:EQ.K?+ +QN"W7@,M!<>#1P QMSM5;I8WN7?87D&$+WB9
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MSL /(R6\_D:'3/VJ;%R8F90C%4^D1>&Q!E\,I:1XMT&Z?/6T];3Y65Y,+G>
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M)P.@YN6?_ ?BTV,*=X WB_N+C7< !2Z.6T*G!L>97ZQ]G9>&'>/M*N<->'<
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M5 7'-P6.<M3Z_=8\><TY3?="AQUG@R=?,@E) F>"F<1\@*)6Q^!R),#,LSL
ME;=@,<OA38W]<"SSN-!3%0VSF"'[E$RRO U!;-8WRJB?O4B=VI##+&8LD#V\
M_1V\A<%#AQ3:);HJ+NB]\*5%3%Y$$+PWF@SA+3' ,AZ""WH,N>$ZPL 1DJXH
M+>8G9G^.E2=N=DGU5&=;4#F(]U?[ 1Y+=3GI"SU>ESX:^@R/ E"?+?64>?*+
M'BQ# ]P79L* <@@$4KAW:NP><6^G8KYD<_. N<'&+R"08' D!%(:#([HETOQ
M30"):1XDN5=--RD6!$>.YB]FND;JO;/:C'39=[8G&1#*+R:*#/V<DB3]Z^2
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MJU,*J^SY@NYCOP,=KNTM:1(8P"NW7!$34A64N:0L;T@61I8%E\SIB:?HV4!
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M+E3:(^)96)<K3XV*$P19+HM0#B!GA(]54Z;1,VU:>D&"X!F8LE9T"PMVG1O
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M3WZ<LO;-YVX_.86N45&B0(YP^Z<%T"WGE_L37H_"]=/QL2P:G?9[LS!VX]B
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MF.M(VKW6B8Y%83H,$5;54C;F/87YI;TP]]@3O^(U3>(%;85P9R@3L&/S=;1
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M3=U\')K LS*16!YW64I+"SH%J5N+TT3\0N&]+?V4A9SQX+NUFLF'Z_Q"(9Q
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MYU/UN(8H_2G1!<TMI3KG&,\O%*Q_9"C*.J=@,^.H_D)E0&REG@4LGP'?X7A
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M,+VHT4B<>P+_V-*T7;)?*.\"_XD:Y3/F@B&.8_&-3(<6M8.5DSZ/+TG-+>@
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M6B$VP7Z<QP60*> GNR:5:)1J<]Q6W? *D6TCNR5'?\;38.IYSA&*CX7\&RN
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M1@@Z,=G)[>+>I721'+DAD:Y*JO2Y$3:9&8UX+P5\*N_@H*FI$#,9^4YC"04
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M76;[S%)6.O&US!7CPU>"J^$A96(Y#U']<CAOZ/^[QZ0EZA4)^TS:M3_V[+Z
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MG;1Y[!5PT!$_&<Q_%)OJB,@%7$HU--RNC?-%\IH\=2R*D_3UVC%VIY>^<#4
MRNYL'+7%30MX;EAD<9&<^E<9R6LL.M1>-X8WJ+AUM<P"K4:&5\K<,G+4D\23
M(SM'N@I+NPHW.]G:5IWJ[&UL.60PO53C6CM)ZV)3M:B+L ##NCY,L^\X_+&&
M[H,+V!Y[A;TVX!+[MLR:6#H_$;FO& 5Y,B@MJP0U<U)J+ARVZ'G&HT-(**>V
M<Y?&)[_XOC/Q&);H01PF?'1H=X'S"4X0&0<.O8Y>"Y'.\9\%*L07GWXG$/:O
MJ+&%^'+QX]-W&]^_YS>@$>+*:!QHQWO,4 5^IY6%X31 1))K7\C5[[2QMI5>
MV^MI4D2D92GS",[(R!AR1*COH=2<Z2HU9X*&#N"A5W_Y'_ JHO^1/.T-:F M
MZA>4VL"!ROJO0 T<2A5W_J(6$#US/A$&F<, ,1Y0-$5)-/VOI84J'6VB[EME
MPY,QN^/SRE+RCO#9,/%KO#$%<T,= YD I7( <W] T(#6MNDI[I?E@T>DA//T
M!^H.Q@:*,ZW^A2"'%B=8^8+2C&_.I9ORA[<R3U(JF!7YC4;FHLXT$VG<H3_4
MF'Y^72N_>(^[P#'P_B#"]LN83=JIP]:SF(^?#01BDIS$KW$0"3Q1^)G$N[/L
M0H4G/<[J?RL=]T-6[.R0+\8!4M$*P\^R;+\EF]DR2F^\<_B%8N"G6!!9M@@*
M ;\_-]-H<V6)>6&*,[-Z'8V=,U3U>==OSZ0;KQ[HA*JW=N6%.18.+U.$,8S
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M,6]$KT[=ZS!CR\/DH<1&8^>1V&57%LQ9[4$T&IND:%09&6GC<XL"NC9!>Q[
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M7AP%CC_$UO/^"\4OR"=>:L._LO'_03:-_RYD4UT]Q1_D]#;@*<U8':#>9=/
M3N[M5"/'&W<=/GX0)K40ZR8D%E=914<Q^N[]I_-X46L_[S#E&=-P3G;N(J5D
M],@RC\1,R1E7YGVE9S\T4JD>BGT1 5Q:GM;NY72-:ZCDA0_C<X4WHU>1EF0:
M,&(HRVN:N;9O;'&V8YJO22NO0I0Z^.,ZBSSB9HVRA!<6"^.X7G1@;)6X>R1!
ME:"4"I_3$8QVMRI8A@?RC[Q%DP'@K^?=.1_K&*^(TICP3I/D])5/V$O0BYR;
M/V(5A!0]&^\/#WS\;[#3*CF?WTJ1DG6:%*?I0YZ97"/((UC?O3%5.Z6R$7U@
MH)!B,FX/#88M%@G!J(60P^'KSNJ?62QV#,?M@LIO\]W-D[2:FWS+PX G>; T
M*WO1:\_2\=YZ= _+*7=<[(D6QK[O5?;J#H4IC!+U?<-GHE#)X5DJT<69[K4X
MV*D]NZQL557UJ 3H6^F2KRKZLF)?B0>_9,WF[>#L?80N7YD!G7C;M.99CV;;
M$ZB1+@=9ZAJ8WE =(MD_\B>G98-'732,919##F2C%*!C.3'QQD4+BO>9S*?5
M)H_])9$W!\9B6._(DZI^7NC-HMEXGD^]3;'Q"I),D/@JOP=C@V*B??,Q2G'=
M;=;<\O;FJHA  6/;>Y TP/^A8+$"-WENQFZ3]Y!'*DG@_C+DITH;"V+?NP1?
M_'@BS]MX6J1Y0U\+GTOD74L!<>9+U+7MS8\IQFI*8/&]K2GC4AW.DU/&#\#@
M8\U&+X\]><L-@5]O2,W7AP/7_9$2;N>)?Z'8=(Z$[^VSMN*6?+QB<2PA? 8!
M#>=M^(899L+6".GVM;0J-Y_LD]OO^2':)!/L4QF>>;2;$T5E.GP^>ZN/Y;J&
MO'%=47#OK"S*&R@A),*!37-'J+>A+&H(H:U#@:OO_D[MPD+!8?S[8BO_0V,Z
MW$XJP+LRW@NRYJC+TQV_O/K(PW,6:(0KT *L8 ,3$.=+O(\<[ H@;=;]$$WG
MU*9RU@.4+F<VJA\S6S0?+\9A/89[T!EN.Z+H"FDD1,AG\@AAY1Z*3I40I %G
M>U#9W5*)%#*("=<".S@K/_I<^"D]8QIIZ<;FX*DY*0H*_OV\7?I;RI&%'M)B
M["L&XU6&T:*CWL$2/]=2MG\]]R7-_8)73B091A[Q;+1,8_QF6?]0E%+*(NV0
M[JJ@0%^,V:8>X,78^#Q&QGO3@.B1MK2YVME3Q1UUG&7)TF?DX-=(GR68Z!&*
M\4S/AB^@ZY5*I"R#@J[J%,"(W_FXVF57?PG^RI9IJ*&N(7%)E,":;XT)HA!'
MF@IM(I$G()&_E^;H_$9GRO MR.TT^(/%7*H&^KA1%S=7]ZJ?A\Q\*H3=H6=I
M=7PXP9,"7?-2$]'7.DM/:F#3</68_70:,-$5W\$RXFH_;S[ J$/*&.-D?NK<
M0YS".WD<]X: @H@@M2;N-[<@(M+$B8POG%ZOA!Z(3T"\Q.[4(1*.E),JQ'H.
MI]^?$\P<&J'EIRCX,;56@Z.IO>/FV*PG >E$1 _G VLMS4L-'+:>G*'D FHC
ME_?*WP&QERKLWV.C?K9)NW*.IXQ(_:M$_A-GST3S-3NZ5TK\M3BU)M]!N=H'
M K53EJ8DZKB@5V.SV!U@1G0B(GV=]WWLWD'6R12%F_1$@N3T\5//'-*08;L<
M-#8L6H+4<6*$0[\6;3'Z*C=AYFK$&SD%'$JUMV$*1Z'-UT<A'L'O*9YF0"/7
M52S&!<^EL/>,^3.*1YT>BW7.9ZQ=V0JLO0Q8DKS;CJS5,,\'.ZH*:&S .NN*
M.H',,.7<D'19TGN=E\](LC5*7)&^9RX4$PBJ?(BP1;P^@70D"N/)9(U[VE,5
M,1+#%%(=+8O_#NJ"[Z^Q0>2Q!&DQ+WQ@0W'8N0'XC7.KL==""#N^_+0I4QVV
M8&K 34#66>V&3S@P,3^@#EG9NYU22.<4K?$" RPYIW.0L[_ET/PX1])\H'C.
MWQ./PU0G*DEC-^(IL;-4\<*N7R?A3.IU.GCW?HPTR#AC+T #=]SEPI'WN+Q=
MO&6AVP:0S ]@KI ?#?KD[ZZO#U(P.2M_2'2K,3,SQI?>'2PIU;:Q);A'1#UW
MMB+ D?OX(<Y\TITZ9^(2$"1H=,$H<,96]O#KG]Q2BG/%@$G7[N!-X?,N\]@%
M=N"@A$/J25V6"Q3 _DO[9Z]^M2O.I5Y]<ED!%>D-583H!#2ZUN"L&M])H^?Z
M2SX!XV[78Q7_.UO!6;$W5?[V3D0U6Z]J7<DS(G_8#)H>:@V8*6V.-%&(&2R_
M2WG7U'2I$7.P=M[J]6)B@22ZGV+DH=X].XLKYRNSJ,J@@C]18%!^ RZL(*<9
M(3"GYG2ON[KOW11L/B15,3G!N<$Z25<_X>78Y((R,!*N*<&.!2(Q_$,=^ZFG
M>7>@WDB7#^G-&\273;-DF1UX77]SP H+I,ZDX8FE/6M;]UNY+\KO-U6DOE"V
M?0_:)]VJX G?ZO E"V&"U,+3$ *F&5+GY#DF$XJA^=I-9^]=I0F=6'Y!DHEE
MY&/CI$5KS_MFUJ9/J,7_WEJX,_BV(DQL\W^V%ISM? KM$D7,_[.U\ 9N[CC;
M >9G8"%5N*M-D=P1FI9Q_3MK$;8(C4_KW$U_%X924E-3P\CHN_UA,P&],'K5
M;H&?UHB.*8H*6#>H]WF,Y$Q1/8XQZ '6O[4 )CVXAO.FOS8.P;N'*\J9\L!=
M D6[M4Q5_+'RN>8$7'D4BHQ&&'04*Y&KD29W";.CV(EA=VPD>\6D'8AOF:/$
M."<9!'5K\UM.+13<#NU1W]1LX4*VZ'-2IS@3V9[^'"6DG[]7TNE\>XCY_(&A
MY2#I-<X+;:HIIBM)8/A6Z::_P=P;$AI22F*HL\7X 6R>(+75F..CGJ:GVPK$
MKRNV=Q<3,W=0*1,]X^DXY[V"?Z-H8]HA<G.KIOC3Y8M_U7KU0UY!*3DL5RE5
M9\9YJ ;>NVRO+Z9><Y5#_I08G53;HU46"I\(&XG,)'%TBZ>E6RV-9O-3?I(X
M.L'8$H[8]]\1556BF-2;&=O3E'?O;T.@-E9_AV:GCWQG9</1.?GYCC!@NR[X
M?MO4@ET1U7;="KA@>#GS0TO6/TO=]NC2Y#7;4I 717[<$47!<IR-&;?8:OK@
M#W?H"1LF!7S)]]-;\SCN=%8+V]2H4'VMH>XBOVQ@:+I=OOGI")O8@L6;9D\:
MOQF@Y,%.V(^(H8,=295R'KH5TG].)CWA@U2)>E7G;F0A6>D(@>'IYD-S2&%^
MHZ"QQYYZ+A/J%!VAGC9DNZX ;]H*2U<]P-BW'G'7WD?<Y"Z!N(.;Q6^-7\'?
M9H,:.05*E%'9J+Q)=? J\T0H4B>?U5/"K%U.^$)^E'KZ>4!CWB "UHX!3UD;
MUIZ$L:]0P%6,]X0VQX135T3WC9MCHS2R267RO5\-5&X\'(RQ7^4-)Z6<SUHQ
M!JKWP(T7Y+$% &7='KL23BDF0K6,)?.4&&QCAW1XD];ZOE)^?RAGW3\>EH"F
MN$,3&=>IGF&6,@^--RYAA+)DRR<V".^M6MWKB_IZC.=H%\>R]T[UPL@*$*1L
M"D4NN./T@RUKK;I\"0%)QA,UQ0<6]%!6P[YO=IY";[3PU;TP7^GC@D(4>YHG
MZG%\=S_5RRV ?5B41<[JSOE5JZSB#J\*4NT 5@ZB'O*9K"J,Z-FH4DU[B8T[
M/$6!$N^:V1AV2'PEQFU&[<8VXHT5K0X]H %HNMBU:><>C];=6[IO<#P20B<9
M&^F^J!D?XWF9&P2,+<\VGU%3)TT=\Y&)X660[HH'M.&3.-? MC@$7^COIY!F
MT[*\>JJ_%"+E N_BIU4(U]X%I6L*$MJ9]AKB8JRSM-J+[!&= KK%R/1B@PIR
MN1=^%6O](0V]OO5]7UWCA](/C?DZ7AIN.,*9H%[06P>K5;CQBKK39Z_3HV'_
MM8!LF76?5@8&'9#F0L=%?%E3ZS&UG7EWO6+B1NX7QYXAN&SO-];[VY($CZ\)
M*KQ7R PS 69Y(R)L"VA,Q4.!P_O06L\+#0T_X9KZIVTM8#K<TV==%6^HP7;9
M9!F#L29;B'V9JA"]K#RO/M3&-'\<S%$1W+4@AHAFD;<^OUFC68(N8=RY^FHF
MG/_Z66?D6EW5!7+M@J4MFAD6MV,4H'^$YD[^Z7@;9+)"Z^OE%1^]B)B9>.(:
M)/9K3F>:VYDK$NPH><%D(<Y"]55!4[7Y-BFDY:[&U=GH*:?@L2&P<0X,9'J;
MFW):-_E9U'RDP5(^8S"%]EZ87-?,G)VP^GF\.TC_VT/ "7\N$675R@_\QN-6
M':610-^.2=1'/5M#V%1"V+<X(X6-;S:QV<S%N(MKA/H)TD^JKBUGDV<ZO1@E
M-W+2]U0@YBD KFAE1!J='&LT!DZ)=5553<)I;KKR'DM?]VC=*ZWLMU'5*\N
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MYN(/[B?OA/S'JERS/EN:F/\?JW+")[MQC[^MRNMGHD@>U.RJP8>P3PC.SJV
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M0OHD@$.842)R<98H/K4:N//[5-"_N.OX=WFH-31U$M;52R?8#X6M0"[F)ZT
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MMOC"XJ/I].-*"1 B1$VARX)MSUD<$:W']^V089^C+>_E<?. %9*D<=._"U9
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MX'[",-CL6O;B"U 9]/L'._\&=L+;DZBI;*&6C$Z=/6&BQ,3QLU,R=M44(C&
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M00U.9/J17ZCRB?"S4 J-B=,*T@=F"&U3KY+T,W4PLT(@>PI>P:@E,;PTZ;Q
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M4 A2SQ[_S/:7<V6&',AO[^I5?)KPH;4=?T>\( #(*&V4*I?YT\AT+F0A645
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MEJ-C"S>[&-\#B41"(F_K3R7!!.T9?G!/$_O2KRBG,<O  "CXXRG%_C-2]6?
MZL2IM7%"HEH <AWK$KS .>!R;6P-M-0]U@X'?X><\[N\$:7X[=)XL=I'-CN[
MB_^M<50H*-9"&T>[Z;2"(W\4J)/<W4*7C@\)CLG$<H1*(5!1E15*^JK^NAD@
M9A=L$Z.R8A''2<:=HAQZTZO.-_@QUXH7TY4R]+ED&-5/I=VA(Y6VE9U//4[G
M!"9J\MEB?_)AZUZ"#85F!0F:V!5KO>R-U5]O02L*GKD7*5Q)[U]5X>O?JU0@
M/+"=[$]%7PEV4N/C&X060J,+KN0=$C@>J4(8+PK\8=):70E?81@SKLF<R&CB
MMKG$65B:!CNNC9'PO]]=Q#1&:O-,I#-03C-1TM-^4"9[^%R]=,V.='1BPA0[
MH@=/:VG6[%A'.I7^AC_G5CI>)A'<H99^1-6>H.4O^@]1[6\0U<Y/5 IL?DB:
M*->G)]0<6P \DSW=;?A=,C:0L)0;66:W/U +C1*ZMI,;..URG<1M\4TXV/DZ
MX11!AM@?(I0*50_+Z39E*R%5$=_/< O% W&@6=BG&-@JST(&%K>JR[6E'54Y
M:O9OKO:L0.[1UF83X$- 0873H&>HY^<SXZ74UD99A5_/#?DZ[#T_?W]$LN&T
M <&K8331-ZDT*I.?RZSO@W32\;9?_N&*_ VN",DBB<FN5G6S?0[QA!ED5,'P
M*Q](.,26?U :"YS>@9>AY88ST1*!QM%X(8TC?OT*,S.'=EX846H=3LFW;AKS
M#BL KRY=0<5\'SV%OGHW2:H#1Y/V7$O<OOV?Z?A;TT$TGRF(!-(A7UR2(J39
MK:!ZQ)Z+FN(D']YKA*-Q7YR#T^/<(:_AJ,./]TR#.PDZC,:$U38GO,4KZ3^_
MRQUM2[GZGAFV&AG[Y5U&7;92Q86QYKZ_9-A/%X#6GQ.WSAS?8S<:!:C(47)Z
M<VKI:.07;0T8!<IA&SK$I.DD#ZAVMWR , !NQIHFNCOL):VVM%2\NE!97.Y-
MDJ=7>;O5"B[G)GF4R1FB5/*A%>-PD>>O,/]L$__&-C$&^,W**N4K#T&A-N&E
M,B]UL8[%UO6\"*Y[&EOL&Y[<Q\X:Y++JH*B)9B,NG2AUK*Q7&!67S[C"B#DC
MUXWFUN2@L(CUNAY2WXW$<W(*#!96[JV4H18)RA^*:4O83V__L6Y_Q[K%.!6X
M2'O0[]Z*Z9%L<F\U1YFYFT/Y'14O,"D9M#03UNA.6L0XK+#8O\?GD"Z&-?<R
M+!7ULQFZYN$,'A86D$N4%@9-^.)&)& 8!W2;X2R@1+9M)2268T)>80Y.-9'.
MT[,0/EG_G BG_^K/U9*H3V,I$]\7I-31=YP9&0B(1(8P.)]X17&,A_:#(B[>
MX_J4R7"P+TWQCQB[8L<-Y$A2*1.MCL:2A:#31700!\#X_.-._O?=25^CEX*&
MMI2H)H&@BE"&A,BZ#OH[:-Z[(']!.*]I0]OC0P60X?!F1[44X4\*/ (NDV>1
MB5 -G(:I<_B$>-/?9PY&*72$4O6#$PO8JA:6[(0R ]A?$ Q<5JEW8:5=PE=<
MTI:<_]3ZR7(O-:!^1^32(,6SZC"M&JJ&@\/'NOF/-M?? 4GP''N2-M]+XAR:
M]EZ6G<97?^4M0=>(\S7?V'<,E=GKO030NWP><2U2BR\VOWA"QFW&FTBY/++,
MA3R($'3-PL2);%/U0?#03-LZ<0QL*6QEI+5S'\?,KFG:FX'3#E;TL9=,__4N
MZW71'\.NU(]=O_:/+?C..L(#Q[:]+LX]SW?0B 4#^E:>'0*62IN?A+OFAYXS
M??ZM0J1Y#<%H/CW)7]=.("'0@Q4Y_PYRKSA]]S!$KDFJB?TY"WRN]G-]V*$Z
M0R"D[\M D?LQSYB1PP>SF?.$.8J68?>^4I)$F>=\' Y,;K$M6!:)LI)#[3B]
MG4LY*9>J?0U0^42ABRJ!3?UX*J?^EE3XJK&JG?#*%/UGNE*V2XGFXKI )PT+
MDE;WFQ0WRJGJ/(R?DE::]'7$'EQEI^!S+%@*JGN\'^M^@J\P7_^P_7&+G9-C
M34,SZ%<I#]Q7:;^J.L!=OL]DSU\L2?<N7TSZ+UZ\=4*'T@9$B'4D?JE<X3U0
M/CJM$3:K/C.^PLAW!3SC/Q=;8^M:_R!S"2A<8^W\-O:[AG-7:$>%\Z>G/Z?A
MZO8A[_SC@_!5^PU%\4WJ^@/];R=G/]KGS,W;UKSIW_Z/]4>KG0^WK*F7_LHF
MJ>>^*O#KQA*O,.'-#XNO, TJH.8OKS"%.L><-WJA/X O-\_U_C-^C[^S^HIO
M/\<_I]C_]O!R-,$:/"]R>X71B0^H.OS,JG'O)V^IU5:!JR#PI,LL$S/>3@^M
M#XPU:XDW3/%KFXF53UF5C-CI#V<W:SSHVA2*J0"^PJ [7=>]PECE+D^]F1)@
M?T[[V0IUCS+W8AEF*288R>@^N&!,=^?D.$CFX))AFBOV%YEM2J&N\936,BM4
M$[&4,M'H;*1]0'EF>8YPC"DN\T]YA2G::!%)>IEPBUKE/$!OZ9H^_1^]S+C(
M=?VSEZ($Z\:N_^JETYU/0%7<(]?-OZHLB"8#'8X***F4NC1F9PTRX"E0&Q%B
MF2:0)&8<DC[:55/VRTE$#I=]E A.N_*!_MJ^VV(XY:VK/2[?B2Z .!;B?KIS
M9MSRQ2 Z_Z E>#^S<T)(H^?7QN56<_%&M)';,(IA;P>C4&YY?+994*PGD7HK
MMFU%C.*$_^=M ;_;S/S-7%88D\T!PR /4L8/XS5U#F6>Q6? $*6"83"1N]+F
MD^%=7?;F)BOK6QP3%=>K;R]A9(U=2]1SS*(S>5?@!Z*KX W\6.'D^[A"T=K*
MFC5CDXWU=[0=5)=WAD]]$\.B9W]TTX#LQO:D["%TH?IR2_ S7/Z$/25Q*O7'
M$N\?^#A0;JLKIW[F><9/F(S6B+>\')2%SZ0-#M>\V=VW)_XM!;8/AO+M5O0T
M5O>AXW>-GK%DR!._/*1A?CL=XX,.*##-)"*W/VJ3X,KAO9!N'%F\3 @WH7\4
M_>7RR/ ,>19]A3G:N I]<#LE^[K<Q;U$]L+HWU?["N/M,_,K(/$59H_]"9U]
MVY^S[RQNUK;?3>UE]3*GQSJIDHF^*IIP8]4SEQJW?=U+:B6D!_HV]NX63PT@
M'5V[1$!L22@41?S'4OUY\@(5/9Y9OBRMR,T5G7Z%H;0V,;3&=X_*BKK)G 32
MDM956!T1V@'LOOEJ>6#85AK6.CSIP1Y[.A5$E,7Q5J!T?N5-K9SY;A*[4_:V
MEM/NO>/@3VA*/_O7DKKLB4%)RBB9B'%<*H&/#!&,/3X?PT/7'8TNZ>/9;)\M
M*G8U9HE[8,6!*ZBM]I5Y%P4/Y%GGVR.D)J B=SXW+,]FF169O5;4*R0]A!_]
MY^5%BVWR^*/P'IRI;#1'Q(@#5! >NX(0F^S1K<5/S,G2[E0B3"$B7R'64!>X
M.4JA[9I#PBT[R:K;+#D$YC17/MN-I;)'='%WZN"[H9%]&W/[Z+TV#H:FGH.P
M4Z=(O2A8L.\ZG.RJLMHFRGA';85+9P5;!\V+-5T5VEZX5VF.V>6>3 'SBY^!
M?.A$\D4!.9R"O%"_'/T)!-U&^PK*QGSH8-',TOFCVM+K>F9+B,YA-)2',G8P
MA63:&& J194'>' 6B'A.]%\6.IT<:!KZ_@I3VM60AW+ +*-B^SNOB$SBLC.
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MCJY9BCJS8B0HZB<L1 1<XYLR7@X1*VNX4.>#D5_01!G^[A;E;A)/1RM/F_Q
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M/&N"O<DOLPW0/]/9N3E?S_(Z'8ZBW]%[)6N,FQ</1^(+<<E#;3[/@W7GY!T
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M1WN[?C@1%5<EA86Q.;9%5O><!N?;PM9=5MM1<,SP7M^H@[UAI;B$#9_'L)7
M[7!]7)O:$6-;[GE^4GUZ(7Y9[X!E!6:JP,$QZ]WYX">X=DZ%^^W3"8>F20G;
MR!H+#BN6(R)#/,.<+?7L]B??OI";AOW<Y&8KX$_5TM("L/$O6XYSS8E\U)[=
M-K@9)=9G,-9:Z;(<+QZG@H>4D/KC<+4N(5A?"IIKS5>OR2(TJZGWFN3^H'7
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M?,#6J&0M/_6&AFSNX?%ADVP\*BH<'K5\"VFK 2!DL9Z)*IE9-96AVV6 &BC
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M_D. ,7,3Q(*W*H&O/I7:'TA5Z3I:>C"@.;-0/WPN[+ASS""^QL_*?GF%FX@
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M)6#FO(6-L!-F:LN[2&A;WN^X&_D'4956?BXH#5D+QZW*RJ,2NO'XOK3906W
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M%:A80$V-,G^'//30&=S^K4YK-L5HN]Z/A"@BKE9"T-IKUZ*2V<O5?LGZRD7
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M2=>O)-/KT0F;-=":$[I80WFI;VW%\Z*ZHHU&Q,Z#GP;P+[!;6'H:X28UY4;
M\_8W2>Q&L4R.U==.GP>L-ENW#+=J^2J,TL2O4GBWRA.&LL55/K5([^[VRT[;
M#KO%U.T.>NP!U+O!][[_L1/3&?YSZ'AJU51AVXIF7SS&9%L,HO)#<:/>*XD/
M8&DINB:20*&UG,^1CONU@P"]/%G^99+? V2QP] >= 4:=<7+*6=IS=EL$]ZB
M'X1"4,M+:AY^RZD65GP#)CP' N"3"NXJ1__;9]-A[+FO=QRN@XBHTNYC2]]Z
M5#SU'R+'*:\]*;>-48DGOG"$O*?5$G@1Z>Y^E\8HJ]S4.*X5)L$W-[3F;F"B
M)SU+*S/R3D:>AZI=:7KA;&-+@9:M; 7%/V\8YS.SLT  3MSP4=<I[QL>32!M
MRE3T,MLLP=0)MWTZ-QNT1[ND,;PTL7)/</3Q3K/M6>][%+SQ :2+W1QVP-JY
M&-LG/!*NS'ZW3*OW&?F379A)03K=[%L 09ETNUO>DF:9^>=O#70+I_9D/#_)
MKB/W\Z=XN(@@YEX!C'>TJJ?Q02)C6SXX)F+>KCRT[/]G?[T!*IWKV<^-6Q/\
M6_(6&4M[QL(0-[XG%+SH'1,FKV&WZ1GA=):J_KH^'Y( N!X:/PY9!5N[]_+)
M/(IYMR6?&6730UP6<L,WDLH<>'Z5B!<Z&V$>*#]R(^Y^D7=L',J4,$V:<MY_
M/T$9V\7K0$]Z#,*6T];7&_3P8X_]R)MB9;XIE?#&BO<4>)RH;6H(1#M4@J.U
MU[/.,+]$)UAZYTF]M)C5 <L"SA<L.EB.)MH/4NJ8Q#644AEZ?+9<YI^/_&^@
MDZJDN'UBI-ZPD3>;4N7(GC#9R$H,"G9 88]D6NUX*K"FSW?7H,EK$EI=@LZ9
M3[*.)$_S%%YE'XW6 [NN<-G].QRR6?M@.Y.KLQV?BC"/\92X&U1 !0A)+;#$
M Y0@]HHC.2'BAMAHU[J2/.T'D_C)1,ALZTVNO\*0C*"^VXH/X#I@BUFD:.L[
M(Q+D=/>39[]=;WKLB#O)PN"H.%DR@120M]+L2;+2:!<BF4=U[?9)9H#:ODO;
M 4P=0O36#UGVW?=2)',4N>H5O]X @79<&[PP6Z@G4E_)4L3P0)@$XDB(NPWF
MD$?2S.-]@%?#S MN1H'!80Y0*JK."Z2I0IKQ[,*.B>]Z;;U'\1*%%^EXG7;Q
MH-9>$M<>#3>3P[<72OEW#W_0TO!G#V0FW?7R5$4.Z_D2HHB?M^.KTYB'M)FF
M'BM7(,03O/DK5)(+7G]Z*4:Z.,FLP1:."KA)3YSS]FRC/)1.FINF@SY=[[YX
M9@'Q^77O!$P2,T_:?3'7QRW9SF35MUS6%8"#<HJOL=F3 NTD(J$BAM8EG#3S
M7B-4)(LWL>)[3VTPO5T=SZS/F;2=@D490/353I]_<@]"F[\:7$M_\OBH3"06
M]6G,J)W#MA-.@.L-[<D2_85<0M=E3&<?EUN'F+\P&A]._)4NZZ(:RZWD,9!#
M_KV4[7-//,L&(2,AD!=?D&X65D-(\D9.8X5!1P10-N \2Q!<@:U9"!KMR6^\
M$"T$;"<7TA@E5EV21952DRV=;EU0TK7O5CYJ+ZYA+LLJW C,D&;V'E<50=)$
M.TJ7452F6_67[(F.B)VUL:)>?A7?17WM<OM-15>M!LUL0D-H])M/;QY\;S[_
MY7_E]J"3">>F:B.ZW[K9 [^7;_\[QZ&V6,NYNAYTR)I,RA0'PU>1QRL;]6ZC
MAD>4AZ7<^A->=,-U?D;I+%WO9S(]#/4IP6" O+GL_V<%FWAL5+=@I1G$B!OA
M'(6KD)2YZGM[# B7(8&MB6D,@Q!$KNRL!*"_.-?;@OE*XI7CD=$09C%BJ:^T
ME\=:]K5SY!,^WY/?EK^GV$JN_35I#@Y#>@MV:?1LQJ8-D"/PF8@;O?K $JXQ
M,]CN?+]=!;\]^8U+9!V1A=I'7 3;:].F! ,?@'FX6].EIQ!W2RJ(ARGBYG>;
M"Z?K@TJ9PQ)'HX^>E^4RZR2.SNCFP7).N^I&7)O=4?NJ[52:/9GPGAW^8KRC
MY,[P\2O++OAW8;->GQ%E%Z:9,.-HM0,>VNU[\=#]-L:&"Y9-4D*1U>IPABU/
MF2T?C-3[^/%J>+S$"&E5"M !;@P3EL157R[!"ZENW#_XKU8WNI[9E,D*'2NS
MC?+&,<X5!)QL/V*%,TF,#MN[\3H!J!>D$>? Y^R'_%9U&F$4[Z.W7&!5%RN^
M?]!T*!$4[<?0/VCR\PL0?:VC+IS.(+;9RM ?*U1C"NBN.DE62^ ^0C/[X1R
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M]MXN]G>1/1%;E%-\6PB4<K];ZU?)$>EX8'\)-E<?$0Y(*BU$Y5^\9>]XMP)
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MU2X,? :7L7BJ5%S/Y?HC?5U"O"E*QM'0$([%4'_.4:0]V42E#YR8JDWRV?U
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MR[S..INYXQ.FJIO(\IFRQ8M5=6:);G-)0AI;_+,3+4-A>Q*5V;6] _SG@(^
MUY65 YP6Q$]+_]8VTLF=_$ )U4P+F3E=T?_1-F*2#_@1?H+<N_0L%FX]VT/T
M5UH6O*;[M:5K/M"%&02AG0ZV$NW$4W;J#OC<=5[]*>#@FY_R8!I[.7Y]@WV6
MH'D:?4=H_D4?%">8"F13>:9 _]PF1.!!H^TW&M7I-<?L;[3=\<3S_,__D^+[
MP-A##]V='TWH\"2S(\U:A>CA=$"!*E^13.KQ6MJ^98K@D):92VRF4 $;>7LH
MJ7/O)%&G:-DWCKN:SZ6\'1:=P>;/2<SB?=(DI/@6D0)5GD0.G-W.:K3$I.&!
MS\#;524?'M.]<L45BP5[H)1Y_"X!YQ$VUE(-S)SQN^%62C;SD)<CZFQF3*SJ
MRW,X2SIE0ZZ;A0<WKW??3^M)%M-@4_++0<6EARX7ET^45V.8VI/S5&JN+:@,
M9L6<1GW&$/56;I_R!1O9991]>EK]0!2D2P&8"DB_N3SVA)"XTGNPA53B"Z]]
MPAV.D1J"MK0S%*L$B3GQ-M= BNP1SW.5:F8S:3+)8USC<DGRCD7]^C$-/<+0
M<Q:(Y'>_4BG^OFN4?3MRCDU-&:72)3CLV26;/,XV+H0:JW&E&G;>[I1<O7ZX
M\ &T  !)*R2!^C^I+DSMRP;)XB:)I5PAU,>>^<O7C/M]ZZV>,1DY;2@J,R.5
MU_VDE/=F1UU:^.*I.O1D9*\!MMI$Q0D,#/^@LS6<+\M\>6-E*XBDJW.N2WI+
M'-52U^]SF$].;.&,&<.BI^T-F,YDA*F'GW&^PT$[V"@YAR?=_U(KF-OU.2[*
M%OGUE?>H$Y2SP[PE.8*4T**REVU+TP!AZ9[KGX:?RO@'D;+W =GY5+*VJ3!(
MV&(]$NW ,Z<N94CVT&/6[Q+,92O1;3/GCXF9]+5?%I2LN7]Z[FP.6E7T>V!U
M1A/F;%XD\+'T];?EHM&%4QSZ&>-BFEF+8.T/N$_H9/0^LT"%51X?7<0[SVN]
M(:4>H \ J/WR+4]>K>4MS"H*X#/YLH(Y[Q@>E&N2'@,.P'U:_K?T'-MO$A6_
MT4Q=NY7_@I>2\BC+_1Y)YSXXK ;3>&L;'A,0Z0QBRLD5X _%[!U=Q4_&]\]S
M(FA) ]#%*<9W!?OQ1Z-251+<(.8ITX/>L!9FO^<YD46[IMSMBB@U6R6HV:5P
M]5YTL0_CB//9-2W@%/8MCJVU7C#CG2"DM;YK3#FFX:HV=3F9_V!F1\&%X(3"
M1E2RS 9V9XI]6AVZZQ,2Y3EY7.Q]2U76,>4J[PO.E2?*0-?QQ.-]_="N6C)K
MURQ,5*P5^@-OI@ 3H*2%VU-T4T1  V]A>?U5VGE$RN$H7\^]O<*77X%L)0?$
MKLZJ]D1Z!>Q!0[SS&^TFDRRA\QD\+,7D.*_*[QJBOO/]-]KL7C=A4(:4+'>>
MNWVC"73EQV=+E7.]\6D,9+UZD,.\A9VK58GC@/1/7$O"GU-'-9&=TM.'J%GJ
M@<$M&\LYOJ*),6=R0!VEI.S%H.=0[=<5)8 \=P]>'P7,;TV*M((."FYL]DOO
MW=;_13V2G=F<D?/<2HN]<1[*HA;[Q63X',;C3(@,[R&+VLKRW)9^_=_>5_]1
MK3R_L,-J@<RDR=S2R,+Y5YX"K)4+INQ]Y:!E6U\OW9R50GL3\4O#]&#67.O%
MBQH8SZ":+*ZF98B#L,]4FK=S8')?^2X>4N#XL->8OZ;%%RYZQF.KIYDB1]H&
M#:/CW]/7%8CZ1ZS?A(:K>'WAQJX1$:S!K 1#D9&1P&&NP0.[O;;N(#ZB@ITO
M=F2@;'3%?701IFNX++X_SF@-9?U@1]9'_N_)W8*;#F3!&^ (+>.ZS[HLF#QX
MKO<0IZ(GS9%7JT^YDV.>EBYHUAQ:3=9-]EG.4 ZPL5*<GK92A> UQP!P%G6F
M"&FL7:VV?;PNSG+U2?5W^=<=OG$EK>.NZ(HJEP]S7&0+,[_"NICX(!(9-4C#
M8=UH^\(EEPS.H VG6+U=3V?* ;T8:40YI%6F(0FXD-5]P1+$Z^@X1&7#;/OV
MUYJM6;(8&-RY0=H3#8H-DZ(>4O6=C,:&%[P2^>YVKLPVPC9"QS2 32#O6V0N
M@!XK),WGWP$6_Z, B\KRP^,*TQADM_3J)&5;'9BS(,^VM,91MJHJ.OHD*WO?
M+D-_;P"#@\>,&4ZK#]XW?^>E+0NHU:SA1(+]TA"9>>;VYA*1>_(%Z&Z&=/%"
M9"-3L?&2*Z3N0%7Y*ECLN=E_S:%=K?]+J<.?IALEI;29\J]$G6D4;2<;SL-[
M!^MM1A&K>O? //O9>I_'=6FZAT4584OX3$Q,WO607XON2L;;!L>KT1UBQA,A
M#=X2#A*V.A>0&&NBMEMXK>"$&BPS]S/3T(@Y@\X_[=\ZHC\)6G7BD0[[9$&Q
M6A2>2'.(1GJ.2R1@C).8>>WFZ]^>SHG.TI-8"%MWL;ZU>2$9]7J+D&B/.LIZ
MN_W*E%ZJ<;G)S&]5Y"Y5;S*4 K>:\>U<@X/8<%BCG3C>((X>$K/EF>LCY,=K
M YHXQ[;X]^]A1K;&(;P\/R1RW[MCDV6/8\4KX4#! 5Y?OTM>_3SP5;O:R;T^
M*+B9,;Q4&BY-<<H+V]*S!*K CVJCYQDSG.N K)S)5!4]":LI[IIEZ0*IZD:<
M.\[ [B]HFN41&:O3W_F_##,,7O.W=:>H!*'=JS"I$^T%=EPGN,8UI+=M*)@=
MZ[GNH[U_&?W3G9E##&.H-0%=E]^KDGE1#.D[HWZQD$-CH9[>?YU:3QQ;T]_U
M=H>%O\J?B4QB\JD0#:'L>!OY[>R*2'"]V8D)D/^@)GO/W<R&C=V-BW^S.$%"
M#ZYCU'PBA>TN$$-NR@\TTP^H_WO\[W>OGFI!7%!:0Z!YB\[8YR@ZW(_3+_?G
MK)<VXA*Q!P_CK=MU>QLAV&:4G@6-4 F,/+;3FA]&MNQ"1P;75U.92+F:!IZ4
M3Y(=/0E']%;;<1GL;QW%T]+(N2\O/BTN+-]$#6*+E[N<#J;-X1.4+M1TG)9:
M[49B\%H=9<+ME.?FA[:9+Q4;2_-XF%U#SW=', B(<C;S$_\Z+GO@]#6A\?@I
M2;'NC@?D5_2 /S3+1WH:Y5?]M#I_*:XKG7**^-%A_+G;&XY1TG<4@!>GU7SN
MC%"-XXI#W<"(<4#O]D_?K!KNV^P-M ZG1%:=Q311/4"RG#+[=')TKFITMVSA
MCR!5C?%1H1.LC]/F.14C9)J%43G&?IVOV+JP=(S2TG4'8_F&YC7>JX;T2->1
M\,R4($Z@Q.M>4<LA3<[[]$X+K<;0<B+-5E/!_QB7T\)#42[Y(U^K8QQE,&24
M06A">K$U'>UN+8\ZF0&*7N,X$KR/B^*BN[H\)L$4H9SW5-=)J.5YC4[3DRX_
M!^$TD(86#C-9G8I1!NZ+\GAS'Y!,I,.+S-G8L[)AY^MH,S<<WI8IH\%TM<H+
M*&GMJX3U"UD"K1 84J/-LZSM(^_+DR\4:I"A]GKP8\A7-0(<A12J)<&3S]@C
M[H*\_21M]2-><07T#6EZ4#FH'E=["W(!J)/KH$]U9B_$#]RQ8V7EK.AN[*9:
M:CFEKUH[C9-TX?O&5:$O6>P@3H#'^.#]DX6\V,#^(@ZZ$?PNSENM,DG"HFI>
M(5&(-I)M(+U?UV8L[MAC*(7J^C^'CMCSK?=CL/'!BA$@4$"@MF.(XHD1F1Z;
M0LB]NKD>65!\7@-KT]2R?/_96?+$*(06KIQ;P%JTH"BD+<P%MY#)><,AUO(0
M,0!A2*M^!=&,&:LH\S(-9+2'AI\Y<,S>_S"CB$=D[EC3X_'3/,NRHTW2OBX\
M_EFYIK.Y?P-PY"B;]$F2]\I:CJ!K]J?T=]]-\[%%GI@E/[0LX(>D_$;[FC9+
MZ(S;=:\;_X_2A<_K6D7S!*>7Z<1G1X:1 Y2":8<W'>SVL=>UED&X'E(_N49Y
M62<\T8B4JS:",S31*8NN8V:FP=#'+;]D[2B2'5QJ"^SN.A^K[?I[TZ8X)NY6
MO-^!7Z6#7,[5+JVZ4M.U)2][&]ED[R6/.]0I*<B6B)A6]4T7)A*MC9V-K>G:
M/7E=RP>\#IK>:\'.),<GJ?[8D<+_6 Y[XM:;>H0BBT;3%\+-0^J.\ART_)LN
MC+S(7^C8O#HR._J4U2S,:WEV7"VWR26 WO:I/?^*IIVC^5HS<]P95D5]^>;@
MFB#:@$EEJ"'81'C?GCPA%/>BJ'['?E2LM$>%76&*OO%P'-SKIZS64+\<);E@
MF[.P',E#>C%1#^QB8B2O; P$YJ<><>'T6.&+3ORL?>3R"U#'1$O+H&=-^14O
MOOD.9R+P WV=#;J1L30Z#O?&PGZ"_G :44'J98( 5."?\0W9?T0?7B>0AA@=
MXS)'_N)A'7BT$0!X$\LI2.7143M$^XW^G%:2RSV)-<ES4_4Y?I$$(<2\A,L7
MZ8O875I>,E(.I/UQ=[8A?LFD&<5( R<W,R9(<0=N_K&9QS!S<_NE^(:7STT*
M9TZ&!YFJKAL_QXWE<'_.\CAI)V6PLD#1Y^!9A(G-*)(>LI]DDCZ0_JX1TM5?
MOAY&;G_"6=N=Z=*56J0+D2:XV"5U91DD-\N@JS\WDW.9>IS"74)![*)&F?FD
M:&=:G$#H$TU=QV$LI!EE4^(N;E?!B,99]><^G8?0I/FT\%6JK;7S5+6B8^W9
M2[[KDOEZZ@!O^L)TYE\&,Y-%S=6;K93K1:%W.&J!IG'=9L:$'CF[8E3NUNEK
M1G82LMI)RR^171^ZD*F[*!Y75ZXZ&>Y7=[/Y'+1>'YF9V< 6RST1,YF7R(Q6
M_E8QUI$]D;/M'Y>$-AI^[DUQ0P.8\CT)[UEQ&<\-]T>!14-/[+KF5-Z]VJO8
M3I[9!N%:R"6/)\P'=?U&$VO"TN:<NA# 7E=JZ<D<\VZ9@GR,G".FTK>1DB\@
MS#E\2M]TSMGLSAK$8*68L%7L[I:7VX\G9VHW6L[U<LAW%WN.A=(_ ,I25%6]
M)M-\9 ;^V6GE\?Y-!>^IA1U-)D^#C9PT2<N#0ZC=&S]7<;*#$\,T ^D;-G_<
M+(Z*(PZ%@8@OWN,US%K:M0,T>LE2PH^AN</8\91].(LA5_X:ZZZ[V"6-[!W2
M !R0F?W^9+F)$&0QE^0)C2>.(LH3A^AM+_S/E%" U(OY)3\."JRC:D!&#;O0
MSOX:EA\=]8?48Q[#51*Y0%?$CA%H<#MBS'_\@KGJ']DTYT_Y("2%RR;5XHBL
MYN;@,\BTO^J2!"1U1;""1=6 TJET$UG,GG7]&ZTNAJ#5<!F*X(Z+94#D:(;(
M.:(?)6\C%1I.7&J/2D4ED6,82%7Z6"#^T*/%7$SY)X]P_G@[_=D]"OW;WVC@
MU>T$@M>?E_8OB0I&[W.L\8%UQ-CPU(9!A!Z$+G/ 2[@X_U 9*DT:Q6Q8Z!@2
MXFBIIJ)F"=S8W]]P<UFM@E4M3TTT-C4U9AX_VS3LC1SMN)S*!,Y9*2J&PKHK
M?+52FN <900$LG,'"V/AT<4M2-9/)C\G$QHVE'-=Z>KK(:[G9]!F^%YN&N>\
M]&^T#!LVB)N: 3F0I/CC.W0R?_O)'*#I^P$C.',#X7-V_8PU(D@#B;"0HB+8
M8M5?W:+?A7^T)8;'T9T-(O-AU3U0L(:OJH!)V'G)<]6!YX!X\?;QEBY_D9?H
M[2%R$R^^C940:!.)A05CQ6*%L;+R](&"TJ2,'0,!T?I4PK#=3KY@AWG:P//9
M?:\EKQ7^'*_&8PZ\W;C@!EJP%B9-:.6R[1V;9@1@3R,EQE'/E?@62&07REPM
M9#."M>&4JH8C7HX.^--_\&]KZ/]"E1_VWU;Y+2*'3R(=*&8CJ1<Y;Y]=/"=>
M+V^@J1D'DE5\;;YK*,4JK**.0NE0&.6!&0D,0QFO#[]H+R\&-4EDQ0@C@#GN
MR$=2URD(L%!7)'(D&^Q\:)2BMS/S*-%+I<JUVW#5$C0W;1)PY<QS-35V>.GX
MTCI9]AD;H =2?<)ZZQ Z#N((88H^'L(M\]YN+LNMA5VG%'NX22^ZSJ;;\N 3
M^7XFM_TQ+A8XS+_45, 2L+8;(5WGO$R&AE6DW\!9U140+//WS&N9U@JG;<$%
M9'9QZC7C#MJ\H=\&@"R_ ;'@3T*D,M3R6,S>-K&CBM>(!AZ=X^!:+PRLFR7K
M0$FN>+N>N-:PR!"&!-]ZT$*3ROJ3"$9B^7DC1UMI/!5[!_\CX FK!.6O6_(]
MH]W#6CA3E&VIP%5WW[L+]X#&("N!D <,&VFE84KX5*CVEF"$3*Q09*ZAUJ5L
MH*FF*>;/L)X>=6%&HQ>9(VI10+*1H5VH%]NPIQED:.1=+RL36$GIN^38_?>/
M/96B-Q"\GP<+G^O)+!*LZYI<HEMOW:%QEM;MYK2?5)C-;+-$S:I<JT8952LT
MM.JR=^Q_H\GYK:^+VJMSW04VB366E[>D?T)\58G4PG(_TZ@T18.\_Z$=N=*7
M^QYG;$6V\ )V3_V\W&]GDM>09135LPI\%G--F*-OP]B.%<3'T8"*,09^3"9>
M,NQR>O?->$9A3T2IKK3L'4E543Z&9$?5V.VIXCM34TNZMB0K>5AOF&"1 FP$
MB;+B9/R/>*V,OYX7SG8E(D'V]#E4@YRG" W8MJ6D8F51T3OFV8TQ722A.'QS
M:=!K;H^$7\<"NQH5>$4'YWV;A;P&RJ7TAG'>&U8*^B:EW5J(;OM02!GU,& 1
M^+@.!K22!2VU:O\2?^%BK+ 21%B$!6;'[D"XG.$F4C O^_.1RE>A6L0U%>\(
MDBL2HY>+DKUV5CO2B\@"C[*CB8Z.CK>!O /OS-&EO)CD82/,>*#M(:<7F%+A
M2J3S7\=6LZ?]-Z7J]&3D7+\1-+ES+YU4ZNW9G]D^(740)D/Q ]8,*-W:32)1
MN*'+26]W)'HXG+D3N?L1N&[55!VAVRW  L;A&EO3.1,%7RE4FJ4M0:NIP,$S
MI=-BR?BA1<X7J([/-.,.<I&*;J!=;VM\MW[*?3%+MB# ./-DK?]YPFL@5Y#2
M+_M;(1F*>7(*4J$^Q",U7NZ,E ^#WM@G(P[5 OWU-.@9B7LBXZP+,7SGI&YK
MUF>!PM//]LJL20"1VX>1]N\(Q3H:5_O%O(98.YP)$]UF%(R?6F=H%,4JR$ K
M:[##>H,9A".'G42R+3U?MBTV,E"H:T*PZQP[>E%*+.(+:<*E0YW]1B%S7Z!>
MQ]11#/PW^)UR[^:_O<PJ$Q"AP?JR)RG&73K)LR_[83%Y"I G$3Y1!F/M/OUY
M,3I !I9GVZ3+>OW-US%P;\GX7(O>O@29>RBX=K;\G/?<=<U5*EK;1U)AL%6S
MQR$6M:>C%ZCA7N6 ZEF*&C4W+PQ,<+%+\)=#G&FA=,%+B>%8918L6P-*4&CL
MVQJD;QG.//M6*W'0B 0>\? S-P.Y9OGX.U1N*[<M2^A\*C^CYJP:JYR%%V S
MUC'AU6FHE0R_;<JRGY"EBB>R;MZY7''%U\9>@@VL16>\\RQ8)VM8>M=?G%0W
M/ *O9:@?);%ACO"IOKD?G#+/V27/ BK8;'/?VK(O;FBTVXVC=]4"P^.;L4/1
MF:-CU**V D[W3=/MD"#G\S5'ZJH\Z)L@B,2, YV]DI(KB>/R=.HY(W*.+RM+
M $-KN5RO^XW.PIK#F1:Y7%V@6[+7:<4YSD0[/<1"K=7<>MC5XT*UKG5J2A:/
MN8,#H:=YDUHT]/UO9EIU"U_2>=F>^?:6:;!$CZ-A@KT/QW!C3JS1D0R#"NYI
M4BRZGBNN)E)*XAV8U9)$\,93$?S3S?G-1=[PK9@'<BCC-QK7VILPOW^UUK0<
M(@6AM858BZQ(KPG-L0PRI#!WD.N9@]6A0/A.&C5/#%!42PGS0A&@3:CJ?PY6
MO'58,/D8XVCL2*(9D@8)=W!XT?!.,"5>B&S96V[D8EL]80NXXX[S^.U+5ABL
M$L5Q]+S<S::?Y>"2J_DF+5QR T@>(KMA]O+>03A)R4W7^CA&>&.WI'7/JRW4
MVE*B+X3Y@_4JH435-8U$76'<SP2IXNM.4N_U@#%5S[PDHS$Q:_/DS?J<NK8_
M>KQPSGHU43]U$HIV6^4CCC)(9QU_NZG],1W('P;1\/VB2$R;>TS%.VGIJT>W
M1 RFA'2R. -(!WRZ.GEC.DWM=NI9JE9?M,VN_+P8(48F#BL,'WUCO'VIQ>EI
MF'3WMCO?0I=+RS;Y9G$Z!*[-QT"P\,@@!3_+:0Y^&I.\^7'\Q0X,2SE:M38Y
M.MN;:\4VC_G5C4+5F(X,77Q::YWI]$7 1 <AFF99']?V_/:KQ?/8I-[RR9[H
MZD%""0[,4]>6UHWQ<6!9;QN1BX5:^DJ[K,*S53%"4;"^G'*UD],6:>G>IIR#
MM/C!RS\^OZJ\1DW#RK/CM9_6^]?G%>=NZC3A/J>U-?8D%V&01!ZO[6$GM142
M"_8=I825KLOX9BQ; :YI@VJ.HWJ7!06Z@I0^K\HK<4U&U<M/+9'$XL5"YV %
M*'7@JHF_B;$(*ZQQ9U#NGR6*EP?-<V@]D:OI:'!A'.FJSWQD_/:;5>A<M" B
MHPCQ005(U3BV9OI5A2IC"\,5[05CWE.F>52GI=V/<9OM61C?(D_:8J>YU1A3
M&[Y6Y/9E?VMI _G"B!_1^FO\13+SA.-XHNR9+S^FA<=\KWWBQM5NKZTC/IO8
M2HBR#CQVMEM8GWL998LY9_\1W6"-WHH9L,U=T6+T12<@'V=!ENM)OSTJUL[<
MN66,!1+&)_Q]G+(N!S9]]@(:,]IVDH5X"FMG ^MW"DU-]@6^G?.[KX$VY<38
MWFWP8QQBMR75"=)FW<.,!BU874YYW9GZY+#37ABGL%2-^FI+LI:COXXXDAOU
M2L./P-RIF3=XAAVMA",MMJ:%FPNF@+%,S;J;_;05_^2#X2:F=G(@,"+ _W.#
MAJVA\83D64'TIY;;8;1@%:6 "Z;,EQ%S8B_;]XVM;'9 WGR?4W4V6QKR%$7<
MC;<#A%>^HRIVG0I@IH%S( MNF\HQI-'^"BIANP,YN#0Z*5S)W/W.-:-8VLP
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MW/ **Q@4D*H?)$&JL3TK1)#E@V:]']0I>6& 8F![;+ .-R6Q"X!;V00@1MS
M'6-#1DX1R#'06#"Y7&!^^\-ECL\5<KA5@0$ZJ?(#97XD])=L9*RG\W5E[Z<I
M0^??#2'@3[B:[KGNI$MV<Y^+57&N$#"V_82TW8,"WFNROV-[=HO[Q#6XO*@V
M1Z73"X-C]^-B$-#7#Z]EL^6BT?0QAX&-:^[@/#%80LALJ'->T4CVXF3/7T?F
M^6F\QGLG%!": / W33#B;L,OG-M[#9ZP.8\(&? 8B.*[OE?:VYE</U")(I2:
MW1N'5LS8##E]AK,K[/,)TDL1X$A>3DNJ,J+#%%]&QPPWXT@>ETE?T@]R<&:[
M$;3@7:M'E#!_O<G%P_^R3BZA^,AG&5P:X_!%DL0[Z,DX*.>J&_$TT YT3Z54
MT=*WMBU9QHJ<!-MN[$W1^07E#FXRJL)7AVGD]Y_(*[Q9+%Q:G7LZU$!+0_%V
MW4$BVOI[R_*UA-JC.FYB5V[NXL$PXO_3WG5%-=6U:4"D28?0BT  "4T0$ 14
M,!$(O830D2XE2)&NHHA "!U"+QJ0$IJTT)OT+A)J0.D=D8Z",'[?K/EFK9FY
MF'_^N?@OOO?FG+77OCAK[^<\Y]WO?IY]RKP,).Y#! 3Y%Z'8EC<M)>]J]A6^
MPDR5M/6OUNUR&HMM]7]Z(C3CZ[;?,%5O#<("[U"&%*[=,J42E@R6]]WD+56*
MK$(!]&T.STJ$[D['<;\);SBP++@C7X<A/&D/&58$I+1I10@-N*8R9>KB-R5*
M*S;;O<Y4'"$A3HD"E9_NF(VX](8SYG\<-KA06#]=[7YES2B@T44\B-R_0)_*
MK:G_H,E!!;^[Q5M0QZPV2RP]8:X#+C(^.BJA\J[K5JQ8&$D1Z?I!QV?_@EOV
M1'(RV$H9$AA->98RWEJ(MWKM+ZG/!C*9PM<(WBQ%1S?R)#JY;DC7PT[VM-Z^
M&U)! MN@D*<30N/]?%<"I3(0<:;+EHI!K<7*CZ8;SHVZ.*.C$#,1F>JCQ:4^
M"-LEUK!^^FI:?=V*>&!<Y@W/\"D-DYA/;57:3Y)5E]8\HTY8FCKVV3++."&K
M15YLLA/ZIW>FJ0ZJLS]AGQ6VO'':%BAXMK_+5GFC.T,86&;!"U<+O2128+XD
M*IAVP=M-(-1L,!ZIY8'V'<Q@YQ3J-JK8)T<(SU@?X7J786XT"RM/F>KC;:JY
M-ZP&)A.6,N-AP[41IWQJB:XLS&1U>]!Q?XXX?B)^(I(0_AM_F&!(P89_F&!(
MP>=7Y#"K+8 :6)*3S93Q;Q9VHQSE!9#G:B*!7+8/:$.^7Y?2-[J(F6#WT_7B
M?'43/6U04]I4S?&#S$(KG*DI>3&H#FTXC93OBP$V5;(3LS3J]$@W:&KY'E>,
MV_IH=PK/ZT0M/LO<5B>21;0?OQR+8,/28R,Q%\1_.UO_Y9RM@J+N1Y1C^;<K
M<3+]D5@1!4BV9LYXOV]^?*XMEK&SQVLF$$^!D%</C7J7PNL,KYV:O/9+CI S
M*&F>AK!,^5PFC':C>1UOYI 6HR$I/ET!_&(/-\C,<'8\-QO\0N--.Y"TP?%:
MK'H&=,:/G"-03M?1:9PF*V2YEC1R#G]O"I.SK@;VOAOPY$PU)5/PYI$-\Y8@
M#<=^$YU^1GR<9=_+0/W[$9\_1)14;3IZ*;':+BH(4:;;?;9.X5 ^%DPQU.[9
MO^/,Z+H,SN'.@ :1I]ZRF<@FEM63 D)T*\I8?R)J[Z5:5D;EY&MS0XIVO:$1
M3Q64HR''SNXK-5J4*!M:IJ$5=O$MZM=,E-J4;]W&@] PQ1:N%$WW<TCFKHGC
MW0VM'$:T<Y N[?+C;\65H/SW SWB(CN U%J85)Z_[>FK#/ZP4"7]%]UUUANX
MV0L;W]XJ][1#(5EL95/92T_7LYG&J);59^?^;K8$<:A"TK)?+J, 3L\DH-V&
M$ZZ=C,?7DX=C!VYMM^99@ ABP]+FLQTWJKER'8VCDR&)9M"&Q@\<FYE?:(R(
MTQQD)QDB!F]QE[D;MQ'3&Z! W0T:71O22HZ+5==[OKD>-#=T_D0UF):8PDP_
M/O.ENR4]KQM%*$WW0X9(OLMPFSW+.]<4&,9)6"8X!>0_$):<8<BS=JCW&9Q]
M+5 ?S]&J@"11G$AAH;O[J$-;FM3E)<F-B-2P.?PO\<4Z]^ZV4D)+IU>$J=5
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M <8UWXJEW_4[P)/:ZFZDLF%?1Z<SN>/ 9$!@8>Z#9WKKQUU<4HH-]X&.$BJ
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M-!E_V&S)_,R^71)2K.LCCYNRR,4_29V&7S69J?LISC0-X]!+4Y R5][\PS[
MJ<\!]##U:!(1''HZ2ZDN Y/'08JG>F41KO"6+^$&BP4&E;0YD#OZAQN6RPN8
M3C>"WAJL/0]J:_.4Z.K9"L%)'[==7N9)2C<%P]+:KDU^UC7?%)Q]7\!X'(,,
MDF-Y*VW*Z\L[]E14V6H1,Q]Z480!)<P#T*<I2"". <>)R[PDI#%%RDDD"@0G
MMD\=-8<VY#22)%30&K8J4V"@9T5.IJ]M<'DW"2X:^2.6\3%+(3D?)[TT$@VA
M!S-)5,:9+YE$0ZJ=?!*=]PS,W@T3DRZ^B'MVS=]_%S]D%;LI,\(6'$:0^&D$
M0H1=X9+%'D"0B!^)[].0N3Z.E$YUA\E,;.*V=*43QEK*SI,DK:'6IU%2,')6
M9-<S;;MB=T2=&VMB:]@P*^*;6:Z[!S'5 U_ 'RU9K%$1!^W4Z;?GLTZC$NS8
MI/&G39/;2"GMVSO6_.]5WKI_U0UZJ7,O$Y][7A@F@ =$[!-#B$#JH@B@&*6$
MQVX0TTCO8&R4YN0'7AT]IR6HFZLVAIG:[LXJ#GK6JB/M_-P1_X.3Y8XR+@;9
M:(JR6LL_&Z,W<\:9HOB'.6:J+YKJOUCB6;42=(I']O[[$\LK]EEL^SKOYS,3
MFS#, Y9Z#*107DQBH;R3A"- &.<!)<3UU?P2':(3>RD="T[#PX4C2.I: 07D
M5 V!73QT;<$.%,[/+0-_$*#T>+!I"]3%M68.%$C.;!'403@T"AKO&J;.[5TX
MWKN.3(1ON%[*.D%_+HNJ^C47QFF9_3>C'\5/;Q@O2G:'OB]"3-,0\D!L:()0
MUID+ ?(H!"Z+.<>0>%B0/*A#-9YA9H,Y)852J\@UH%Q;XHZDSC1KE=B9!C4K
M-!^J4U4ZN'!Z7#HUF\[>!%PXN&;5$;Q:3 >T"9VMM$$K/,V;7F@3QH,T1*N#
M&QR)ET@>,%V6Y9N7JYPV%]M43\./O#OU07A#TA$T97VJ]IP'OP@O@6;/&5VK
MIA:?E'W8*MD06\_ *$AL[_;>F'AFI^+'!ISO0'Q G)VS\*'G3.*I98';R\[7
M_,N:$%950L?;B\]MZKK+4>KZG +J^Q3 !!*0>DCX)"%BQ(-N0'&D'EI5H#AU
ME'7+@@RR50T3,N'6>6K8T DZJB"H$G:UC(MF!'87DB\]2%H.QB\"&&*C$YNU
MC)%9F'8<*UMQ6@UQAT.V*@/-&+W5D&LWD*OSHMG>[3TJ95F5ZH:5=0[O&U1E
M9 $]AD-.H-B+R9/T,(E!RL( \!33)**ABUVB%\<]2F?RV*W8VSH_2Z?L#UW
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MT>R0./U3V<'G)JA?W)7G?;=F?V6HO!/0LD7DQRR$) +(=9'PL!$#B, $N$G
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MQ:*4=C)<;\J",$;K*WI;.WQ3LJ?VS.TRIV_1<EE=\]-&?(&8C]PPQ<"+? ]
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ML=5J64-EZS+QW/,T&.2?C9GY3@?FQG?G6&%VXF:AR;\@27W5)H)&82)V!Y
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M/:H.6CF8W6=Y+G\0/MX+0V5=\;NN]%W-5>K[Y+P%'H[E,@(\PE( P[JM2,)
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MKMM*]RA0PQ;"GOAZUL!4<H.6N4."G=$J]^BP,[?('1+ML#7NX-/ZB7RWPH=
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M&X4N"^)0*=MBD,KD+G5-MUY?NT]1+X8VC-&P"EJ37-=U-A!:6?64A!I:',4
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MV3![8\V7%'-<B)W<F!./F&VS/Q4Y>VG.7S_('.>VU1V+"$V3V 4>)QS .(@
M)B0 +/ 3-X@H]P*DL^<^3F9BM:J)MH?+3DU6;^-] ANU7?CY$NMIV*&P%MO_
MJ0EE:;]^@LBLF_=A0?=W\B-/GQ4 VRF4?_D]JQ8P3A+.* 4H%?^!))"73)G8
MV"//]Q(8)HG/#>)A!X0FULZ:[$%##>>K)*U9HN0D5%H!L[, ,(B?:<MN&E$[
M*9C= -LAF=>(MYT4]D3X[?3S9FI[E9/BD=VA[[>,L.RY3DCF7LP"'"! .2$
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MF^3+5UG]^/3'L_X>NEL*-T_/!IMASCM(77"/9:?!1[;VCJ=@S50#9KIFRR3
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M=1CKK66:(!S%H=YSL@()*D(A=,2<"Q"NU0"MJ<[U]Z]87';$?U1KEK&S'UT
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M0H/_ TE=HHA3(L,0BRX5W1FKR'JRP?!$0R*= R8Z^NZDD$1#W.^#$0T^^]Y
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M+UH=/RV&]74I#*P--TYZ:7[5U6*9Q?7K2PM#$RJ5A"E#*I=21_U4(B9BDSC
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M3U5S\^WCO.:+I;G+\<N\E#<K^60'U'5^F/$^R,U'N%2!IK\LY?*E7G3QUCZ
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MZG:,#5FS+IBEVRP,>_%4/=+U-1NAG<*GP8$GBY]LQ.L'4%;/O[>>GU^7#1K
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MH$V5 53IR0_ZY&Q2+QI I8<^. 0)^[K.^XK?5M6'/Y_F;='[>[(V'D)UZM[
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MY_HOT:Z4WWS[;*2ARQMJW\JQ^Q(8Z\5SUYJMY$X[<2,"D^W-;<0=[M:M[G-
MLKPC2Q4(Z-GR+60EIY#F- $$9P+ K$P!3@0$60J3A#)>E*51X]6)9X<^ONJ(
M62 L'L@^;JU72F1YY-31<<&-/)#* B#273HW),@M>+9&+9.KZK%U1/HPM]L9
MJJTDV<&>-V._>LW<J8_H(XG^*NJ_//Z%_N6__N()-/*T$D;1(0]NF0X&\C2O
M>WB/9RYQB_25WZETM_Q[T?[Y:7G+&M3F^JM@8O[<3*^!C'-<%@24A>0 TE@#
M94$,$@BS)$ZD2"GJ<>#OS4-Q$]I&K^P^]ON]RVYBH1A;=37N.^J6X!A&RC2+
M6KWIQLE9]=2CGWKZ/VL4PIZ%@8;\!78V$GL*N8Q(3AH,V2CA,$RQNM?Q7%!4
MND_H9%$\S@5)"4\!U%W>[:BR N6@+$4>JQ^5,)=6!W7G:07>=[24H]O#PGG+
M@[(171F>7/G1@.51TAGA W0-&,CGZVQEA-*TAQV713XZ?3"XQ<Z:N9C//BS7
M\_5+5[*H=FVK2A?0?%/;O4T]@P63*14,4*)-&:<24%EPP,J22I*CI$R-R@8O
M$0I] MZ0[LMEHRWQJ*5N9LX7E35NRSY58&?(KM(;F[&I:".AOGI$:[[J+SNK
MO?C@24S65+S>7HVO]X=>I\\$O\C^D'!&"\;*G%"004& ^O\44 $E*(JT1 PS
MGJ=6L^<NDPQLP"U6W7HL?^"J*[,OL%\-V-GO66 ZS8".FWL6PF+2G18W(!K=
M <%7QZ$[K0 3!+HS=SH./JK?+5;JF:O?ED]SC5K5#I8U/+$__X30I2P-X:BA
MK$/(^_EC@Z3SV^>[3\/A2.;']"/*N'PX[T</=H9LJ@)_ W'-)'6?#W7ZL=,.
MB1H5[6A2U/C5CMUWO;$/\*Q820L,<09RAA.U<Y8$H#3E(",XBU/$1%%B&[BW
M$S2L#-8>]&WWN;D"Y.N4:LR^N%<*;&>9.UGW8+\\-M:=E\97-]T)"M.VT)T7
M\:AO;N12-Q,\1*S98=EH9)O?U+:[_=<_YNN'^?++4OQ3D.KV46_+_U=G\^OU
M#"O3C%&: <X*%>NRF **. 2X) G&B!&,K3;-U[,4^(O\?M-\A59+T51_*7U'
M"[5YL3-P#XHW\P?3JM/.?1@A<VUYB30S-U''\HOZS:)Q(%VMU3=E%PNQ_753
M#GL3:6DB)94_E^1/H9X\F >&)G5X_A1XZ!\]/MG-G7X5.DLK>#] [I9UZ"2"
MOQ=RSN;K68K3/$M* 7*!8P#+N  T%P0PFD,"22()+NWZWRX3M;%@IRZX <FH
MHVGG#@T4E_.$IJ7:3I=97 *E*P8HICG ,2\1C$N4$BL()K]J<XGL!DKC@91F
M]HWPJPJ[;T!/>S?O\J<3;Y/'+:6YL)[\LP'!2?VON0(._:O%G0YE5RVFN-K:
MBF6#YJ1>DS1.8)?Q8P7)=.,P$$7. *3*>2)60E!B%$M<Y#)&1FT,ETD%-GM-
MJ&F5M:A?&E?-N)'[%=@RA=+B^V_I-G)'C08<JKC&M6!1U.5-&VXU7O=_K*+[
MA]6F;L!^U55K(9;CKX1=O9:1?*/E6^-/F*Z:RTB2O>(NLSNNCY;KO?WEI^5I
MK-?ZOS?JA^L&GFYW4OEYHYGY(K=7;1'2,I*K>+J @".8*"^G]HDXA>J?I>0)
MSE%&!'<-IH-P'-A9OM/E-^Z1=9A%L@^\7UWU >)RG9:9+S?*C8V 9[?,-T6J
M/?M! /4F4W: F#T,OZ\6T@=5_UC$'Y:PXQ3=^9(LV9PL/BW5\YJ]PNV?\WJ6
M%$(6,2% BE*J8#;& +,$ IHC)#(!&<=VDW-/TPGLG;=4HQU99=Z*L.VHW#-J
M,O.T'H2W\X\N<MO/PQV7RM<,W#-4IIU[.R[JT:S;"Y>[SJ93<:Q^UA>Y)="[
M@^VGO\@@%TE: (@(!U"F>K*E5*&H3'*19IQGU,IN38@&-N(M"_HKO7NS>RY,
M/M?N^C0S<-]:LK-V#PIRF%UG+K&WL74&)">>6&>NA.-A=1;WVA<4_;/ZL.0?
M]1B/+_+#O]<OMW]4O/YKM5SS3\MWSQ7_9_5ELZ[Y\OOMDO]M^5RO>7=*85AN
MY/K\P+Y"YTN V!M1I(VB.^;IZG3^6I%E.T5 Q0C/0A? -UFX]0-91Z02D69]
M398-DHT^ OG;LH76,"]A<E;_N+^92O-V_B>LTCVV)?A0GU--E3/1R2JNKE7+
ML![KZF?9N[L/?ZJX2D=,[Y17_;ZJ7IK=N:$O.WES8$>UI1GU1 T'&9R7]K+K
MN%I0R\/U(QF]Q2 7I7$RT]-/G,P&1P4:&MCXA0Z9K7XNX!?Y;?/TM&CV)63Q
M"U'+R<2W!Z'1"[:]WE]%DU"[7S4ET/7!7#XD:8$@RT">,@VOF7% ,HZ!0(A!
M0I"*2\S!"/SQ%3I&Z0<K?I'1D-6HXS5JF(T&W$8=N]']JBW[MP%!\+A>!KFY
MUUD%RQAH,-G2<@'6_0+8C$\,NB86F<+761NWM&)0([%+0/I7VVBVTB.YZ5*;
M_G6TEP<-\'BW<S6-UE.)![&LU1>U+5S^+%18?D_^5/]:;'1$<J=+\%1@/I@6
M?;_2TWYTZ\]JL6A*GM5W0T4LVZ,C060B2YJ"N(P)@ 7/ :5JRQ'G+,5<8LD*
M85=(%XC3X-5W[:2;/>[W>P\LAWB%6C&SP[XWL IVW\9]Q>\U0C3P]_J;J9B_
MB;;L1QW_1^/1]T6(>AF"'#$&UK.G4\E07$YZD!E8U8=GGZ')A1@QOZLF.)VV
MU>VA]P]DF:2_J2L?ZJ.$[0Q"CDF:83V,L020$@@P*7.0%D)DA<S+G!MU>T[$
M[]LKG F]0&;N_PVIW>XSX*]H1@NA#VZ749)&K1PG*VFF&C[O3>F3#*2_GMLW
M-*3>F^KM!M?[(WME+O[=@M2U"F$T9$]S"DMPP;*\0* H1:%V_20%.,,,B 0Q
MG).24^:6@#^D%-H_:W+-:4J+#>50-'->2999]6M$M]PJ6TGMGC4_)Y'O5/D1
MG=?)CY\3]VQ2_.P-]CA8'5;/QWG-R$*G'#\L>3,YA9490PE3NS!62 !32(&*
MR3/ 8H)X05.:%$:6.D8DL)&^[\[AHI9PFU%5I"W&RHRJ:-Q.?0EN::(=W)65
MR%:05Y=D<H*[.OO0R:"N+HDUA+FZ>.U;"+$&W5T-_D3"XY*6L;)@B@H-4@D!
MR=,"Y#2+(404Y05Q +$-RK21G5R-?GNPE;=%O0V[;*\1=KFLPEL,NH:=J/KZ
MMQIQG='WFXRW#GG]@:.M,VH/&VN=(^I0U=,7#WU:?ML\/E8O^N"P7B_OZ4+Q
M=ONTH(M_5G9UBQ:/#+QWN_W^O6H<>EL:U^Q?1BKH-,Q(A\RM02?;2CHM JE>
M]B="W8^B=E^EY'%7'5"_=DXWK&H]%R0Z:,RMN,F"SG0E3_;"[Q5".=Q^Q;Q$
ME^GE?;MOWPA2-\E0[2^[V5&?5UVAZ\&(J.;5U6^N?G&;]_;K:J'%TD^=\9*5
MD$($(&^FE,L<X$12P"'BL2PH) ):#TU\._(%]KT]*V [V.ZDHW"8F_AV5&@S
M//'M<!VP0NSZ"8I;M(BMS%%;VM!LR[?S%;>"GQB@>/J#%*1#YVTNK,]9BF](
MNND'*KXAX<^=YKY1-B?> ?2YIV[2^2"Z:MB=D8)!3/2WFR1Z?)L0@%(>@S3G
M(LXIHD(:54R'9C1X0<#CH_+&=9-X(3WQ2*ZJZ'OC-']2N_*Z8>T\V-:T*Q?X
M"^MQ/2;_5.ZJ 5KN=^=>S8HV KR!;YVABE_[HW6)S1_CZV.H;&^?$5-ZCN#@
M^IND/D2K?<QC/0%X68M94<9Y*A(")&<20!27@!9$@J+,$$0XER)/;+SZ.+G
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M3F[ FMAD7L)5#4,GXOP,1WS#U7+5-Q"V Z>[0HMM]%PRFN.,"D *%:1 G!"
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MV7?D32U/,.3U"\#KK2S10)BHG8"Y5N+L8-E;B7:([!,"KGM>A:F UGVQ_;8
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M8SB8=2-&3=$E1:T"T-@06*&@M?TTC8?)&?=191 $'2[V;A#T_%Y6<F"2%Q3
M8F9TOA<)/@4%U@F2G7#%AM;.SR/DC/N ,@B"#A=[-PAZ<2\KTI>L$V/D$FI5
M-X.$8+PCZZH2<:E-5JW?1AXA9]QWD$$0=+C8NT'0K_>R$K#([%R R!F"$MI
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M[UX9J)",<=8#D^MDPQS YUK"54*.!"7N[*W,T0?N<[9;;[L;</;' ]I0.NG
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M.?M[YS_^T*/,_AG03]]M2DM0J$(*=?(W)RPKER!ZZX B2J^+3CR6UC>61YD
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MIN4A%5]3X4OM':0T.<>>:W*)G3<A1,UX&LR+>=)ESCN!89\RYUTTTQ/:'B^
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M;_^\MW&"28B! NJMC+!Q1Y%.PJ%D#$G<.$5TK[SM/L'?_V@=!Z*8X ?SKX%
M<Z0#\\-M%;;VDAK.<^^ RFU9P!0M0@+/27(B8NZ5&6W2P4@TG?X@PU%2+TU!
MJ0'5&E">_3@]>V&2C(D:AEC(38T0;B GHD6)<\6$5P$7?Z&YP+9?9*'40!P>
M7[-_%"B*Z<%S%59_M/-,_\_24\2>K#MNZ?1N,IZC5EHSFY+@!I$@'<IC2I#&
M,2%A.2.$8&]8Z;JU,6JE5XF8U]^SG_9^FZK<?O?""29-9 Q\+BP0YQ"S.9'@
M$),R:9N(84[L0\]!7VS$U!T+@ =IKU&X?7*&Z.UB.;F$O[OLU@9X"SLV-DG,
MNWP+^OE-82-6=$_C&L#QV/<<QM-HF4Q^%LYSD7M'$X<C7DKD32)).<5P\0;=
M9VDTV>T)K5R?^P)9^1OPQ]W,P[^Z=HA6<8(WX/H$G,#[R,_E:&V0P4PB8K7U
M2F$(<TL_;%2:AH8M]R'HVQJ%U1!U U'7UF([Z0U5%G8O11Z>A2&^A9@V(4F5
M 'YR3*PM#-FCJF+'AUX5A/2MA#U$7(W";GW]**TF1!"-A.<YKQ@HLDSJ_&@$
MQ@D[8E7IYS1/KA+V(&GWKX0]A/75[^HWE]&]R3Y1]R-3]^F[7=PDJPW6D@DK
M$-,^3^HSF6$)G'OL&+.:.O.X*>ZPFL7-GVT//4,$W:-XL0#7&S1*&XIYC;&,
M&\R15-F "PCF7,J7'DQ*#LJG7:N5U35J9(? ;"1A-#&28TM+8+36<>494@9(
MX)@R9$!!D)72N40BD%FZ-O&(CMWQVX]:<+0*B*H!B[:U19 *+R(H#\(T*,1M
M #IL#$AY[7 2EF(]?I-X"RY6"3GW[=(]A.FUW:M_7$V7DT]Q/NG"VS_S*?_6
MSF>@?:"1R^]=6%M@Y8QVCAJ49!!@X"UP2*\J/'W2UE'X7=[+K>KUN=:0,D2L
MW:@\KEP: ]YAN/++\_GUBYC7JJ25XT93D:<E@1-(\ZQ.ZPVR*402#&4DR0(5
M,IN^W4C31\WSK(A8VH#5W5.K\>;A5,:P=38)V+4#(CSHGU'1HFAHD%Y%PU*)
MLKNM&ZA7@G>\3)\"Y$@&USZR_O/].<%\;34EI5)"D($<%R(/)Z#(\!R)2**C
MXB))3'N=3/=7K2[N8R74E6!7 W)FF-P4CBI'@LWYKT#RG:K'*,><B"FN$^8\
MF=#O!OO^JO4*+,>1\S!VM5!1OS)KP46+@W=(Z]P,JP"A)AJ/=#0R4>-L\+U&
MLYU83T9MMV&8 %I S4V%<MZN-PIICCD<AX8AIWDN 6..>XJE3+W>B3BM/HR#
MA+6M#^, SM4NQW_01Z ]$\HXCB*V!O$D'1"?)[%+1@FUG&#1*Y5V@GT8AXAL
M:Q_&(?RK+?@'?00B&,:II"A*FH-P$9 -">@ M%.5N,"T1,]5BWT80P4_F'\-
M)#8+'I(?;@N5(6AB@?  3*3@8B6=>U6Q!/ K)3575(_WRF1!.AKIMV@ABU\=
M)K5CI?>S3^OB0$ !;.,[!!;W+FN?ULIK*EQ0&)%D\VQ>3I&S8!6PX%)A8AVA
M_<*I S_\8DI\!L*D>R:9-5U6_-K^F"SM],NR\_]S1"7PIF7*%>_NW62A>MNW
M_[Z:+'_=U3AZ"I%['A:[>FHRPM%L;5"(.L.=$X)17_I1QH<[./;$_N*_QW U
MC>=IQ;I7OUY/[6+=1I=,XM%@C9+/(0MW%AF7)X)3)FQRV.%^:=P#B-NQG;JV
MZ BY/S[]2K&\LJ/_>C5]=@[L6_[Z:"^OH]P\/"01(E'4-#^Y90-R7A*(5AS/
MEL!JU6NRV!Y_?].WZ^*CF%"[@ARNG?2)/Z[@G+2+>/9M'E='XV.2;BJ2A ]1
M68\H\3'?U5H(FU;3BQ7C7#F94J_ZK7TIH;X;JI<[.%[FW=@"J.T\KR+DW^;=
MU8\/'UZOXV2?O##:,:2D@VB;48P<31Y)#8&VIT)Q;GHYR!L6KYA(&D=^74%F
M-I!T6%G:\_1?N5=UMCR??YY\^[Z\+A?BS'.L(XJ6J=R!(I'6F"$7#.;1!@P\
M*^S ;-U,W2*^TL=36=ZW"J*U<EF:B 5#@2P#MO!$\_U]"LA($X-+@N-0>ESJ
MCNW4]7,*";P/C 9PO_;1]&D>WUWE*'--R<W,O>"\"CPRY/.]#S?&(9N'\GBN
M/?&6B,3[E3UL^4"#F!@BO:XP*VO#X2ML' SOV2,2DL $6V\1HR% \*@X,IJ
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MC236V#M%@O>EQQ+LV,Y+?'G@(+!TXTBN71"N&Q.%Q5PF*I /(4_>-A@9\-7
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MQ]&/E^TEQ*9R7?MYU-"M0!<7$!=^CJL'U&]O XL8Y0,^TTO(3:6^#N=AJU5
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ML"1*U<!U'(65JQ)$%>(8MFOCJBF!^\!3^)[KKH!.A&/-+PE"J3A76GB3@<
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MW-Z&?95/_/[6?::? D_C3Y#_!5!+ P04    " !Z-ZE:7HV^9RD%  "%#@
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M$J'$8@5DA<)#H<%(2%##UUS>IH(O!9B$&; 6=E3#UT,-'TNF*+GI"F:BD,J
MS.%<J@S"H/$18JF<UK>M5$%!2PZ" N#P@:DH.3P(>\&P'=;]D-G%Z4UN81*J
MVP2CA$P2N#7:B!DDG_1B(>P(BTN5HT[(.M/ <A!W"2[0U.UCC!0-W*))'*IK
M$94*C0V8Y1S.[J*$Y4L78X9:6[/T;R4YS4C'DHSKY"&E0"(B(K6J6W-*?"M1
M"3L.M<T&F7?0PG:5U8"8"+M57G- 6$&Z$5NDHFXE'X'9 AE'QBZ'_7;'JV6>
MMUV.=H4W3-5=/-N<84YYR#Q/$=470ULWZ$-;IRUFZ-*CA+;XZW:9I2F0FK U
M2]'I@@*B%:L58\[RR+XG@QR=:>N3I,K4AR\IU<ZGWH2XKITFS/?FKU#R!FUX
M6J;"8BF5+AFU%>5]IX>WK'8#YW)J1 :](*PN:M5VJV:=S<2R3+W=Z\9[J*ZI
M>B2YK2MRG)7ITN^#MK,>)^0^#^UG\_!0_'$FQ(.D-JDE@4615)Q8%+Z$HI25
M6D 5T<7P"&Q]7]%7QS70B4U3+@W5/W!!Y<<WD%RYKY&X5B1&"ZG%P^H\WJ1G
M%V'=UJNDM^H6"90N%U](WF;"2J;(%IBB67E5*C/MK?EPJV_WPR+MA:U&BIMJ
MSM%-4T>)F!K+TH Y25"!V#ZUK?Q\+M0>P.(N$L46(DUH>[QY/+? %K$CT/;P
M#A0-:!Z@:?[5#>)%A_\I03T\Z!X/:7:N_.3L^\'YKTX6QHZBC<*"RE*H!@62
MLD*+P>;'D*,N4K8:8.Z .:7AVOQ"&B.S@3VFW=@:)8+73IP_O[P^P?7[S5Z_
M9P]QADYNAF\<K\]W37>^.S+\Z5KGN-D/GE\.FN&S:]_)[)&#[&$3,9J*ZDVE
M7=DH%(QS*MU! *&KC(V]/Q!M%7=6>#<OJ8B?T.@9?*EB<VP<'G1HBW>?\);,
MY?"!YJ^A+:Y.AXSFZ7V+?%]FU@7H*I8ZFK8#Y&"#'/Y-SLC"BQ*VGR2ZGES1
MOHCVN.CFXR1!$=/THJ%F\$; I3_!6<'JE:*AA 5MK&*[OC[AU9[2?>1Z<$_3
M[UZ;:.2[#7J@A-T4;\23B]0]\:Z)@WL5MB#V2_-4Y4_N7NM/?PT\<M?/WP%0
M2P,$%     @ >C>I6@'3BF\=!0  =@X  !@   !K<')X+3(P,C4P,S,Q>&5X
M>#,R,BYH=&W%5UESVS80?N^OV,I31YJ19%)7=,4SBFQ/-&EL1U8F?>N )"AN
M A$, -I6?WT7@"3+5\_4]7@DD=CCVV\/ ./,K,3Q..,L.?YA_&.C 2<R+E<\
M-Q KS@Q/H-28+^%SPO57:#0V4E-9K!4N,P.MH-6%SU)]Q6OFUPT:P8^W=L9'
M_GE\Y)R,(YFLC\<)7@,F;RI(VKU^MQ,D<3#HI*UH,!BDK7B0=GN#J!?VHU_#
M"JF2N-?19BWXF\H*\T;&K?]AIUN8T0TF)AN&0?!3Q<D=CU.9&W*F2-G_]#8>
M63+\UC28P&4^=/%4O.IV.99"JN%!X/Y&=J61LA6*]?#51"$3K^J:Y;JAN<+4
M+VO\C1,2 N4>;SS*UZ0M,.=;U&'+0CW]Y=WL[6P![5:S=1_G?JQ,+2E<(PO2
M(K-[B&/BEZL7A3P]G2]F9[/I9#&[.(>+,[@\G<\N3F93.)N=3\ZGL\G/,#^]
MO)@OG@WH_PW@\M/\ZM/D? &+"PC[\*EYU9PVX>ITZ@(*V]W@GV3B2ZD-IFO_
M"O.$XAJV>\5_54Z=)T-;9!Q*\JTT0:+.E6F*,5?T#>]1*@:7&5,K%O/28,R$
MKL,LCYM0-:1W>-!OM8+15*X*EJ_=4SBJ0<85C]9 5B@\Y!J,M._@:RYO!$^6
M'$S&#%@+>ZKAZY&&CR53E%RQACDOI#(@<SB3:@5AT/@(J51.Z]M.JJ"@90*<
M DC@ U-Q=G@0]H)1.ZS[(;./TYO<P214-QG&&9E$O44;,X/DDUY$W(ZPM%0Y
MZHRL,PTL!WZ;882F;A]3I&C@!DWF4%WQN%1H;, L3^#T-LY8OG0QKE!K:Y;^
MK61",]*Q)-,Z>1 42$Q$"*NZ,Z?XMQ(5M^-0VVR0>0<M;%=9#8B)L%M-:@X(
M*T@W9I'@=2OY ,P.R"0V=CD<M#M>;>5YV^=H7WC+5-W%L\L9YI2'E><IIOIB
M:.L&?6B;M*4,77H4UQ9_W2XS(8#4N*U9BDX7%!"M6*T4<Y;']CT93-"9MCY)
MJA0^?$FI=C[U-L1-[31A\63^"B6OT8:GI> 62ZETR:BM*.][/;QCM1LXES/#
M5] +PFI4J[9;->MLSI>E\':O&N^ANJ'J@>2NKLCQJA1+OP_:SGJ8D+L\M)_-
MPWWQAYG@]Y+:I)8$%L=2)<0B]R44"U9J#E5$%\,#L/6GBKXZJ8'.;)IR::C^
M(>%4?LD6DBOW#1+7BL1H(36_7YW];7KV$=9MO4IZJVZ00.DR^D+R-A-64B"+
M4*!9>U4J,^VM^7"K;Y^&1=J1K4:*FVK.T4U31_&4&LO2@#E)4('8/K6M_'PN
MU!. ^6W,BQU$FM#V>/-P;H$M8D>@[>$]*!K0W$/3_*L;Q(L._Q.">GC0[8]H
M=J[]Y!SXP?FO3A;&CJ*M0D1ER56# A&LT'RX_3%*4!>"K8>8.V!.:;0Q'TEC
MY&IHCVG7MD:)X(T3Y\\O;TYP@T&S-^C90YRADYM)MHXWY[NF.]\=F>3Q6J??
M' 3/+P?-\-FU[V3VR$'VL(D8347UIM*N;!4*EB14NL, 0E<96WM_(-HJ;JWP
M?EX$3Q_1Z!E\J6)S;!P>=&B+=Y_P@0O:$ADLI([9KM:^+R.;PG.52IU,VP F
M8(,;_4VNR,*+$G6?'+J.3#/D*9SM-LD+?T:S2]5+16,'"WI[MXG:J6GW@S(W
M=O!MCG2UQSP?N:9[HLOW[TDTX]V./%3<[H+7_-'-Z8YQU[7!G0J+B/;2/%;Y
MD\O6YM/?^X[<??-W4$L! A0#%     @ >C>I6BS3VW!("0$ ? $. !$
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M &MP<G@M,C R-3 S,S%?<')E+GAM;%!+ 0(4 Q0    ( 'HWJ5KP@O#Z( <
M (T<   8              "  3,;!P!K<')X+3(P,C4P,S,Q>&5X>#,Q,2YH
M=&U02P$"% ,4    " !Z-ZE:#MV+Q10'  ")'   &               @ &)
M(@< :W!R>"TR,#(U,#,S,7AE>'@S,3(N:'1M4$L! A0#%     @ >C>I6EZ-
MOF<I!0  A0X  !@              ( !TRD' &MP<G@M,C R-3 S,S%X97AX
M,S(Q+FAT;5!+ 0(4 Q0    ( 'HWJ5H!TXIO'04  '8.   8
M  "  3(O!P!K<')X+3(P,C4P,S,Q>&5X>#,R,BYH=&U02P4&      L "P#D
) @  A30'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>kprx-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:kprx="http://www.eyegatepharma.com/20250331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="kprx-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2025-05-07</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:EquityLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kprx:EquityLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2024-06-11</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2024-06-10</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO104Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO104Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO104Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO301Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO301Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">kprx:ProbabilityOfSuccessForDevelopmentPhaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kprx:KIO301Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">kprx:MultiPeriodExcessEarningsMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kprx:MaximGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">kprx:TrancheBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoncumulativePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoncumulativePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">kprx:HoldersOwingMoreThanTenPercentageVotingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kprx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A18MonthLeaseEncinitasCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A18MonthLeaseEncinitasCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A12MonthLeaseAdelaideAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A12MonthLeaseAdelaideAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-15</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-15</startDate>
            <endDate>2023-10-15</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A2YearLeasePerthAndBrisbaneAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A2YearLeasePerthAndBrisbaneAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A3Year3MonthLeaseEncinitasCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A3Year3MonthLeaseEncinitasCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A5YearLeaseViennaAustriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:BayonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">kprx:PanoptesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">kprx:UBSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">kprx:UBSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kprx:A3Year3MonthLeaseEncinitasCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-25</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO104NetOfAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO104NetOfAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO301Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:KIO301Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="kprx:ResearchAndDevelopmentAllocationAxis">kprx:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="performance_obligation">
        <measure>kprx:performance_obligation</measure>
    </unit>
    <unit id="segment">
        <measure>kprx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="count">
        <measure>kprx:count</measure>
    </unit>
    <unit id="day">
        <measure>kprx:day</measure>
    </unit>
    <unit id="operatinglease">
        <measure>kprx:operatingLease</measure>
    </unit>
    <unit id="aud">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="licenseagreement">
        <measure>kprx:licenseAgreement</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001372514</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-57" decimals="7" id="f-330" unitRef="number">0.1111111</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-169" decimals="2" id="f-653" unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-173" decimals="2" id="f-654" unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-199" id="f-700">P3Y3M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36672</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">169 Saxony Rd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 212</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">224-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">3043857</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-31" unitRef="usd">3771024</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="0" id="f-32" unitRef="usd">3792322</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="0" id="f-33" unitRef="usd">20334831</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="0" id="f-34" unitRef="usd">22999760</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="0" id="f-35" unitRef="usd">941542</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="0" id="f-36" unitRef="usd">2042487</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="0" id="f-37" unitRef="usd">1337604</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="0" id="f-38" unitRef="usd">601197</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-3" decimals="0" id="f-39" unitRef="usd">722290</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-4" decimals="0" id="f-40" unitRef="usd">270246</us-gaap:IncomeTaxesReceivable>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="0" id="f-41" unitRef="usd">27107291</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="0" id="f-42" unitRef="usd">29706012</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="0" id="f-43" unitRef="usd">4984</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="0" id="f-44" unitRef="usd">5232</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="0" id="f-45" unitRef="usd">4081</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="0" id="f-46" unitRef="usd">4057</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="0" id="f-47" unitRef="usd">6687100</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="0" id="f-48" unitRef="usd">6687100</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="0" id="f-49" unitRef="usd">152083</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="0" id="f-50" unitRef="usd">57170</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="0" id="f-51" unitRef="usd">64323</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="0" id="f-52" unitRef="usd">24913</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="0" id="f-53" unitRef="usd">34019862</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="0" id="f-54" unitRef="usd">36484484</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="0" id="f-55" unitRef="usd">942492</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="0" id="f-56" unitRef="usd">415590</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-57" unitRef="usd">3522003</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-58" unitRef="usd">4588657</us-gaap:AccruedLiabilitiesCurrent>
    <kprx:CollaborationCreditReceivableCurrent contextRef="c-3" decimals="0" id="f-59" unitRef="usd">738584</kprx:CollaborationCreditReceivableCurrent>
    <kprx:CollaborationCreditReceivableCurrent contextRef="c-4" decimals="0" id="f-60" unitRef="usd">981111</kprx:CollaborationCreditReceivableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="0" id="f-61" unitRef="usd">71554</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="0" id="f-62" unitRef="usd">23355</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="0" id="f-63" unitRef="usd">5274633</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="0" id="f-64" unitRef="usd">6008713</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-65" unitRef="usd">4466682</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="0" id="f-66" unitRef="usd">4191490</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-3" decimals="0" id="f-67" unitRef="usd">490690</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="0" id="f-68" unitRef="usd">490690</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-69" unitRef="usd">87470</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="0" id="f-70" unitRef="usd">33815</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="0" id="f-71" unitRef="usd">5044842</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="0" id="f-72" unitRef="usd">4715995</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="0" id="f-73" unitRef="usd">10319475</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="0" id="f-74" unitRef="usd">10724708</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-75" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-76" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-77"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-79" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <kprx:PreferredStockDesignatedShares contextRef="c-5" decimals="INF" id="f-81" unitRef="shares">3750</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares contextRef="c-6" decimals="INF" id="f-82" unitRef="shares">3750</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-83" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-84" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-86" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <kprx:PreferredStockDesignatedShares contextRef="c-7" decimals="INF" id="f-87" unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares contextRef="c-8" decimals="INF" id="f-88" unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-89" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-90" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-91" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-92" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <kprx:PreferredStockDesignatedShares contextRef="c-9" decimals="INF" id="f-93" unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares contextRef="c-10" decimals="INF" id="f-94" unitRef="shares">10000</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued contextRef="c-10" decimals="INF" id="f-95" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-9" decimals="INF" id="f-96" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-97" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-10" decimals="INF" id="f-98" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <kprx:PreferredStockDesignatedShares contextRef="c-11" decimals="INF" id="f-99" unitRef="shares">20000</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="c-12"
      decimals="INF"
      id="f-100"
      unitRef="shares">20000</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-101"
      unitRef="shares">7</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-102"
      unitRef="shares">7</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-103"
      unitRef="shares">7</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-12"
      decimals="INF"
      id="f-104"
      unitRef="shares">7</us-gaap:PreferredStockSharesIssued>
    <kprx:PreferredStockDesignatedShares
      contextRef="c-13"
      decimals="INF"
      id="f-105"
      unitRef="shares">1280</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="c-14"
      decimals="INF"
      id="f-106"
      unitRef="shares">1280</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-107"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-108"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-109"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-110"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <kprx:PreferredStockDesignatedShares
      contextRef="c-15"
      decimals="INF"
      id="f-111"
      unitRef="shares">3908</kprx:PreferredStockDesignatedShares>
    <kprx:PreferredStockDesignatedShares
      contextRef="c-16"
      decimals="INF"
      id="f-112"
      unitRef="shares">3908</kprx:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-15"
      decimals="INF"
      id="f-113"
      unitRef="shares">420</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-16"
      decimals="INF"
      id="f-114"
      unitRef="shares">420</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-115"
      unitRef="shares">420</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-116"
      unitRef="shares">420</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="0" id="f-117" unitRef="usd">4</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="0" id="f-118" unitRef="usd">4</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-119"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-120"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-121" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-122" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-123" unitRef="shares">3000788</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-124" unitRef="shares">3000788</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-125" unitRef="shares">3000788</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-126" unitRef="shares">3000788</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="0" id="f-127" unitRef="usd">267679</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="0" id="f-128" unitRef="usd">267679</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="0" id="f-129" unitRef="usd">169304991</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="0" id="f-130" unitRef="usd">169156374</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="0" id="f-131" unitRef="usd">-145575102</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="0" id="f-132" unitRef="usd">-143382122</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="0" id="f-133" unitRef="usd">-297185</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="0" id="f-134" unitRef="usd">-282159</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-135" unitRef="usd">23700387</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-136" unitRef="usd">25759776</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="0" id="f-137" unitRef="usd">34019862</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="0" id="f-138" unitRef="usd">36484484</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="0" id="f-139" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-17" decimals="0" id="f-140" unitRef="usd">16000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-1" decimals="0" id="f-141" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="0" id="f-142" unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-143" unitRef="usd">1489398</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="0" id="f-144" unitRef="usd">1296441</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-145" unitRef="usd">2531887</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="0" id="f-146" unitRef="usd">1684212</us-gaap:ResearchAndDevelopmentExpense>
    <kprx:CollaborationCreditOperatingExpense contextRef="c-1" decimals="0" id="f-147" unitRef="usd">1966123</kprx:CollaborationCreditOperatingExpense>
    <kprx:CollaborationCreditOperatingExpense contextRef="c-17" decimals="0" id="f-148" unitRef="usd">190553</kprx:CollaborationCreditOperatingExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="0" id="f-149" unitRef="usd">275192</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-17" decimals="0" id="f-150" unitRef="usd">-12194</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-151" unitRef="usd">2330354</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-17" decimals="0" id="f-152" unitRef="usd">2777906</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-153" unitRef="usd">-2330354</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="0" id="f-154" unitRef="usd">13222094</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="0" id="f-155" unitRef="usd">276633</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-17" decimals="0" id="f-156" unitRef="usd">223047</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-157" unitRef="usd">-16253</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="0" id="f-158" unitRef="usd">8066</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-159" unitRef="usd">260380</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-17" decimals="0" id="f-160" unitRef="usd">231113</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="0" id="f-161" unitRef="usd">-2069974</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="0" id="f-162" unitRef="usd">13453207</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-163" unitRef="usd">123006</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="0" id="f-164" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-165" unitRef="usd">-2192980</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="0" id="f-166" unitRef="usd">13453207</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c-1" decimals="0" id="f-167" unitRef="usd">-2192980</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted contextRef="c-1" decimals="0" id="f-168" unitRef="usd">-2192980</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted contextRef="c-17" decimals="0" id="f-169" unitRef="usd">13453207</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c-17" decimals="0" id="f-170" unitRef="usd">13453207</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">4.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-173" unitRef="shares">4217007</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="0" id="f-174" unitRef="shares">2881796</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">3.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-177" unitRef="shares">4217007</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="0" id="f-178" unitRef="shares">3891722</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-179" unitRef="usd">-2192980</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="0" id="f-180" unitRef="usd">13453207</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-181" unitRef="usd">-16099</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-17" decimals="0" id="f-182" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-183" unitRef="usd">1072</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="0" id="f-184" unitRef="usd">-81573</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-185" unitRef="usd">-2208007</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="0" id="f-186" unitRef="usd">13371634</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-187"
      unitRef="shares">427</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="0" id="f-188" unitRef="usd">4</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-189"
      unitRef="shares">3000788</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="0" id="f-190" unitRef="usd">267679</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="0" id="f-191" unitRef="usd">169156374</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="0" id="f-192" unitRef="usd">-143382122</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="0" id="f-193" unitRef="usd">-282159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-194" unitRef="usd">25759776</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="0" id="f-195" unitRef="usd">148616</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="0" id="f-196" unitRef="usd">148616</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-24" decimals="0" id="f-197" unitRef="usd">-16099</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-198" unitRef="usd">-16099</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="0" id="f-199" unitRef="usd">-1072</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="0" id="f-200" unitRef="usd">-1072</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="0" id="f-201" unitRef="usd">-2192980</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-202" unitRef="usd">-2192980</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-203"
      unitRef="shares">427</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="0" id="f-204" unitRef="usd">4</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-205"
      unitRef="shares">3000788</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="0" id="f-206" unitRef="usd">267679</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="0" id="f-207" unitRef="usd">169304991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="0" id="f-208" unitRef="usd">-145575102</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="0" id="f-209" unitRef="usd">-297185</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-210" unitRef="usd">23700387</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-211"
      unitRef="shares">427</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="0" id="f-212" unitRef="usd">4</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-32"
      decimals="INF"
      id="f-213"
      unitRef="shares">856182</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="0" id="f-214" unitRef="usd">77078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="0" id="f-215" unitRef="usd">153192228</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="0" id="f-216" unitRef="usd">-146976855</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="0" id="f-217" unitRef="usd">-182801</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="0" id="f-218" unitRef="usd">6109654</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="0" id="f-219" unitRef="usd">175443</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="0" id="f-220" unitRef="usd">175443</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-38" decimals="-5" id="f-221" unitRef="usd">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-39"
      decimals="INF"
      id="f-222"
      unitRef="shares">1755556</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-39" decimals="0" id="f-223" unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-40" decimals="0" id="f-224" unitRef="usd">1516757</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="0" id="f-225" unitRef="usd">1674757</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <kprx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="c-41"
      decimals="INF"
      id="f-226"
      unitRef="shares">305617</kprx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-41" decimals="0" id="f-227" unitRef="usd">27506</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-37" decimals="0" id="f-228" unitRef="usd">156812</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <kprx:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-17" decimals="0" id="f-229" unitRef="usd">184318</kprx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="0" id="f-230" unitRef="usd">81573</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="0" id="f-231" unitRef="usd">81573</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-43" decimals="0" id="f-232" unitRef="usd">13453207</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="0" id="f-233" unitRef="usd">13453207</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-44"
      decimals="INF"
      id="f-234"
      unitRef="shares">427</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="0" id="f-235" unitRef="usd">4</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-45"
      decimals="INF"
      id="f-236"
      unitRef="shares">2917355</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="0" id="f-237" unitRef="usd">262584</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="0" id="f-238" unitRef="usd">155041241</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="0" id="f-239" unitRef="usd">-133523648</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="0" id="f-240" unitRef="usd">-264374</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="0" id="f-241" unitRef="usd">21515807</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-242" unitRef="usd">-2192980</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="0" id="f-243" unitRef="usd">13453207</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="0" id="f-244" unitRef="usd">318</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="0" id="f-245" unitRef="usd">4869</us-gaap:DepreciationDepletionAndAmortization>
    <kprx:IncreaseDecreaseInRightOfUseAssets contextRef="c-1" decimals="0" id="f-246" unitRef="usd">19290</kprx:IncreaseDecreaseInRightOfUseAssets>
    <kprx:IncreaseDecreaseInRightOfUseAssets contextRef="c-17" decimals="0" id="f-247" unitRef="usd">11343</kprx:IncreaseDecreaseInRightOfUseAssets>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-248" unitRef="usd">148616</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="0" id="f-249" unitRef="usd">175443</us-gaap:ShareBasedCompensation>
    <kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities contextRef="c-1" decimals="0" id="f-250" unitRef="usd">275192</kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities>
    <kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities contextRef="c-17" decimals="0" id="f-251" unitRef="usd">-12194</kprx:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilities>
    <kprx:FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents contextRef="c-1" decimals="0" id="f-252" unitRef="usd">23953</kprx:FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents>
    <kprx:FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents contextRef="c-17" decimals="0" id="f-253" unitRef="usd">0</kprx:FairValueAdjustmentAndInvestmentIncomeOfMarketableSecuritiesAndCashEquivalents>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="0" id="f-254" unitRef="usd">-454932</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-17" decimals="0" id="f-255" unitRef="usd">-12651</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="0" id="f-256" unitRef="usd">736407</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-17" decimals="0" id="f-257" unitRef="usd">189904</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <kprx:IncreaseDecreaseResearchTaxCreditsReceivables contextRef="c-1" decimals="0" id="f-258" unitRef="usd">668916</kprx:IncreaseDecreaseResearchTaxCreditsReceivables>
    <kprx:IncreaseDecreaseResearchTaxCreditsReceivables contextRef="c-17" decimals="0" id="f-259" unitRef="usd">-165687</kprx:IncreaseDecreaseResearchTaxCreditsReceivables>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-1" decimals="0" id="f-260" unitRef="usd">-225794</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-17" decimals="0" id="f-261" unitRef="usd">-13400</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="0" id="f-262" unitRef="usd">39226</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-17" decimals="0" id="f-263" unitRef="usd">-1112</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="0" id="f-264" unitRef="usd">1171627</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-17" decimals="0" id="f-265" unitRef="usd">124975</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="0" id="f-266" unitRef="usd">-1084242</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-17" decimals="0" id="f-267" unitRef="usd">-124391</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <kprx:IncreaseDecreaseInAccruedCollaborationCredit contextRef="c-1" decimals="0" id="f-268" unitRef="usd">-241894</kprx:IncreaseDecreaseInAccruedCollaborationCredit>
    <kprx:IncreaseDecreaseInAccruedCollaborationCredit contextRef="c-17" decimals="0" id="f-269" unitRef="usd">0</kprx:IncreaseDecreaseInAccruedCollaborationCredit>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-270" unitRef="usd">-12350</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-17" decimals="0" id="f-271" unitRef="usd">-11343</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-272" unitRef="usd">-2704199</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="0" id="f-273" unitRef="usd">13624855</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="0" id="f-274" unitRef="usd">3619218</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-17" decimals="0" id="f-275" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="0" id="f-276" unitRef="usd">80000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-17" decimals="0" id="f-277" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="0" id="f-278" unitRef="usd">6212000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-17" decimals="0" id="f-279" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-280" unitRef="usd">2672782</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="0" id="f-281" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-1" decimals="0" id="f-282" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-17" decimals="0" id="f-283" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-50" decimals="0" id="f-284" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-51" decimals="0" id="f-285" unitRef="usd">1191185</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="0" id="f-286" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-17" decimals="0" id="f-287" unitRef="usd">1438817</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-288" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="0" id="f-289" unitRef="usd">15247632</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="0" id="f-290" unitRef="usd">10143</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="0" id="f-291" unitRef="usd">-51024</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-292" unitRef="usd">-21274</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-17" decimals="0" id="f-293" unitRef="usd">28821463</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="0" id="f-294" unitRef="usd">3796379</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-36" decimals="0" id="f-295" unitRef="usd">2458951</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="0" id="f-296" unitRef="usd">3775105</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-49" decimals="0" id="f-297" unitRef="usd">31280414</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-298" unitRef="usd">114616</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-17" decimals="0" id="f-299" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-300">Business, Presentation and Recent Accounting Pronouncements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kiora Pharmaceuticals, Inc. (&#x201c;Kiora&#x201d; or the &#x201c;Company&#x201d;) was formed as a Delaware corporation on December 28, 2004. Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, Kiora has devoted substantially all its efforts to business planning, research and development, and raising capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company&#x2019;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes previously included in the Company&#x2019;s 2024 Annual Report on Form 10-K dated March 25, 2025. The balance sheet as of December&#160;31, 2024 was derived from audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for us beginning in fiscal year 2025 for the annual reporting period ending December 31, 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company adopted ASU 2023-09 on January 1, 2025. The adoption of ASU 2023-09 did not have a material effect on the condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). The guidance in ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying any relevant income statement expense captions. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. Upon adoption, ASU 2024-03 may be applied prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of ASU 2024-03 may have on its disclosures in its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2025, the Company had unrestricted Cash and Cash Equivalents of $3.8 million and Short-term Investments of $20.3 million, and an Accumulated Deficit of $145.6 million. Kiora has incurred annual losses and negative cash flows since inception, and future losses are anticipated. However, Management believes that the Company's capital resources as of March&#160;31, 2025 will be sufficient to fund the Company's planned operations for at least 12 months after the date that these unaudited condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, savings accounts, money market funds, and marketable securities with maturities of 3 months or less when acquired. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term investments primarily consist of treasuries, corporate debt securities, and government and agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive (loss) income as a component of stockholders' equity until realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive (loss) income on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on investment securities is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company&#x2019;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with FASB&#x2019;s ASC 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s balance sheet. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as deferred revenue, net of current portion. As of March&#160;31, 2025 and 2024, the Company did not have a deferred revenue balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within the Company's or a collaboration partner&#x2019;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company's estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2024, the Company entered into a strategic development and commercialization agreement ("License Agreement") with Th&#xe9;a Open Innovation ("TOI"), a sister company of the global ophthalmic specialty company Laboratoires Th&#xe9;a ("Th&#xe9;a"). Under the agreement, the Company granted TOI exclusive worldwide development and commercialization rights, excluding certain countries in Asia, to KIO-301 for the treatment of degenerative retinal diseases (the "License"). The Company concluded that the Licensing Agreement contains one material performance obligation, the License. The transaction price includes the upfront, non-refundable payment of $16.0&#160;million (the "License Access Fee"). The Company did not include any development or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;regulatory milestones in the transaction price because it is probable that changes in the estimate of receiving those milestones would result in significant reversals of cumulative revenue in future periods, due to the inherent risks and uncertainties in the drug development process. The sales-based milestones and royalties are not included in the transaction price per ASC 606-10-32-11 and ASC 606-10-55-65. There is no financing component in the License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The initial transaction price will be allocated to the one performance obligation identified (i.e., the License), which was transferred to TOI at the execution of the License Agreement and the entire $16.0&#160;million transaction price was recognized in the first quarter of 2024 upon the satisfaction of the license performance obligations. Variable components of consideration related to development and regulatory milestones, commercial milestones, and royalties will be allocated to the transaction price if and when they occur. When it is probable that including milestones in the transaction price will not result in significant reversals of cumulative revenue in future periods, the Company will recognize the revenue for the milestones immediately since the license performance obligation to which the milestones relate has already been fully satisfied when the change in estimate of the variable consideration occurs. Since the reimbursement for the development activities clearly relates to those activities and are accounted for under ASC 808, the Company will recognize those amounts that are due from TOI as contra-R&amp;amp;D expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The License Access Fee was earned at a point in time (first quarter of 2024) and, as a result, the associated contract costs specifically, sublicense fees, were expensed at the same point in time (first quarter of 2024). All further revenue sources that may lead to sublicense fee payments will not be recognized until earned. As such, sublicense fees will be expensed in the same period as the revenue of the respective milestone or royalties are earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;See Note 8 to the condensed consolidated financial statements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into a research agreement that falls under the scope of ASC 808, Collaborative Arrangements. Reimbursements from a collaboration partner are recorded as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income. Similarly, amounts that are owed to a collaboration partner are recognized as research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In-Process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records in-process R&amp;amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;amp;D project as an indefinite-lived intangible asset and evaluates this asset at least annually for impairment until the R&amp;amp;D process has been completed. Once the R&amp;amp;D process is complete, the Company amortizes the R&amp;amp;D asset over its remaining useful life. The Company performed an annual evaluation of its indefinite-lived intangible assets for impairment as of August 31, 2024 with a quantitative analysis using the Income Approach. At March&#160;31, 2025 and December&#160;31, 2024, there was $6.7 million of in-process R&amp;amp;D as part of intangible assets and in-process R&amp;amp;D, net on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Clinical Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Company&#x2019;s process of preparing the condensed consolidated financial statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#x2019;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment and three geographic areas. The Company's singular focus is developing innovative ophthalmic pharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Refunds for Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company through its subsidiaries, Kiora Pharmaceuticals GmbH and Kiora Pharmaceuticals Pty Ltd., is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the eligible incurred research and development expenses. Following the approval of a research finding by the tax authority, the Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. In situations where a new research application has not yet been approved by the tax authority, the Company records the tax receivable and reduction of expense in the period following approval. As of March&#160;31, 2025 and December&#160;31, 2024, the Company has a research and development tax receivable of $0.7&#160;million and $0.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2024, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#x201c;Amendment&#x201d;) with the Secretary of State of the State of Delaware to effect a one-for-nine ("1-for-9") reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#x2019;s stockholders at the Company&#x2019;s 2024 Annual Meeting of Stockholders held on May 1, 2024, and by the Company&#x2019;s board of directors. The amendment became effective on June&#160;11, 2024, the effective date of the reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reverse stock split proportionally adjusted all shares of the Company&#x2019;s common stock outstanding and shares of common stock underlying outstanding options and warrants immediately prior to the effective date of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all warrants, stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective date of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such warrants, stock options, and restricted stock awards, and, in the case of warrants and stock options, a proportionate increase in the exercise price of all such warrants and stock options. In addition, the number of shares reserved for issuance under the Company&#x2019;s equity compensation plans immediately prior to the effective date of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#x2019;s Restated Certificate of Incorporation, which remained at 150,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#x2019;s percentage ownership of the Company&#x2019;s common stock (except to the extent that the reverse stock split results in stockholders owning fractional shares). As a result of the reverse stock split, the number of the Company&#x2019;s outstanding shares of common stock as of June&#160;11, 2024 decreased from 26,735,116 (pre-split) shares to 2,970,545 (post-split) shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;presented reflecting the split. The Company&#x2019;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on June&#160;11, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <kprx:UnauditedInterimFinancialInformationPolicyPolicyTextBlock contextRef="c-1" id="f-301">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company&#x2019;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes previously included in the Company&#x2019;s 2024 Annual Report on Form 10-K dated March 25, 2025. The balance sheet as of December&#160;31, 2024 was derived from audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</kprx:UnauditedInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-302">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for us beginning in fiscal year 2025 for the annual reporting period ending December 31, 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company adopted ASU 2023-09 on January 1, 2025. The adoption of ASU 2023-09 did not have a material effect on the condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). The guidance in ASU 2024-03 requires new financial statement disclosures in tabular format, disaggregating information about prescribed categories underlying any relevant income statement expense captions. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. Upon adoption, ASU 2024-03 may be applied prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of ASU 2024-03 may have on its disclosures in its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <kprx:LiquidityAndCapitalResourcesPolicyTextBlock contextRef="c-1" id="f-303">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2025, the Company had unrestricted Cash and Cash Equivalents of $3.8 million and Short-term Investments of $20.3 million, and an Accumulated Deficit of $145.6 million. Kiora has incurred annual losses and negative cash flows since inception, and future losses are anticipated. However, Management believes that the Company's capital resources as of March&#160;31, 2025 will be sufficient to fund the Company's planned operations for at least 12 months after the date that these unaudited condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/div&gt;</kprx:LiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-304" unitRef="usd">3800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="-5" id="f-305" unitRef="usd">20300000</us-gaap:ShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-306" unitRef="usd">-145600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-307">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, savings accounts, money market funds, and marketable securities with maturities of 3 months or less when acquired. The carrying amounts reported in the unaudited condensed balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term investments primarily consist of treasuries, corporate debt securities, and government and agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive (loss) income as a component of stockholders' equity until realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-309">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive (loss) income on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on investment securities is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company&#x2019;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-310">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with FASB&#x2019;s ASC 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s balance sheet. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as the current portion of deferred revenue. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as deferred revenue, net of current portion. As of March&#160;31, 2025 and 2024, the Company did not have a deferred revenue balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within the Company's or a collaboration partner&#x2019;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company's estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2024, the Company entered into a strategic development and commercialization agreement ("License Agreement") with Th&#xe9;a Open Innovation ("TOI"), a sister company of the global ophthalmic specialty company Laboratoires Th&#xe9;a ("Th&#xe9;a"). Under the agreement, the Company granted TOI exclusive worldwide development and commercialization rights, excluding certain countries in Asia, to KIO-301 for the treatment of degenerative retinal diseases (the "License"). The Company concluded that the Licensing Agreement contains one material performance obligation, the License. The transaction price includes the upfront, non-refundable payment of $16.0&#160;million (the "License Access Fee"). The Company did not include any development or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;regulatory milestones in the transaction price because it is probable that changes in the estimate of receiving those milestones would result in significant reversals of cumulative revenue in future periods, due to the inherent risks and uncertainties in the drug development process. The sales-based milestones and royalties are not included in the transaction price per ASC 606-10-32-11 and ASC 606-10-55-65. There is no financing component in the License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The initial transaction price will be allocated to the one performance obligation identified (i.e., the License), which was transferred to TOI at the execution of the License Agreement and the entire $16.0&#160;million transaction price was recognized in the first quarter of 2024 upon the satisfaction of the license performance obligations. Variable components of consideration related to development and regulatory milestones, commercial milestones, and royalties will be allocated to the transaction price if and when they occur. When it is probable that including milestones in the transaction price will not result in significant reversals of cumulative revenue in future periods, the Company will recognize the revenue for the milestones immediately since the license performance obligation to which the milestones relate has already been fully satisfied when the change in estimate of the variable consideration occurs. Since the reimbursement for the development activities clearly relates to those activities and are accounted for under ASC 808, the Company will recognize those amounts that are due from TOI as contra-R&amp;amp;D expense.&lt;/span&gt;&lt;/div&gt;The License Access Fee was earned at a point in time (first quarter of 2024) and, as a result, the associated contract costs specifically, sublicense fees, were expensed at the same point in time (first quarter of 2024). All further revenue sources that may lead to sublicense fee payments will not be recognized until earned. As such, sublicense fees will be expensed in the same period as the revenue of the respective milestone or royalties are earned.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <kprx:CollaborativeArrangementNumberOfPerformanceObligations
      contextRef="c-52"
      decimals="INF"
      id="f-311"
      unitRef="performance_obligation">1</kprx:CollaborativeArrangementNumberOfPerformanceObligations>
    <us-gaap:ProceedsFromCollaborators contextRef="c-17" decimals="-5" id="f-312" unitRef="usd">16000000</us-gaap:ProceedsFromCollaborators>
    <kprx:CollaborativeArrangementNumberOfPerformanceObligations
      contextRef="c-52"
      decimals="INF"
      id="f-313"
      unitRef="performance_obligation">1</kprx:CollaborativeArrangementNumberOfPerformanceObligations>
    <us-gaap:ProceedsFromCollaborators contextRef="c-17" decimals="-5" id="f-314" unitRef="usd">16000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-315">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into a research agreement that falls under the scope of ASC 808, Collaborative Arrangements. Reimbursements from a collaboration partner are recorded as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income. Similarly, amounts that are owed to a collaboration partner are recognized as research and development expense in the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-316">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In-Process Research and Development&lt;/span&gt;&lt;/div&gt;The Company records in-process R&amp;amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&amp;amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;amp;D project as an indefinite-lived intangible asset and evaluates this asset at least annually for impairment until the R&amp;amp;D process has been completed. Once the R&amp;amp;D process is complete, the Company amortizes the R&amp;amp;D asset over its remaining useful life. The Company performed an annual evaluation of its indefinite-lived intangible assets for impairment as of August 31, 2024 with a quantitative analysis using the Income Approach.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-53" decimals="-5" id="f-317" unitRef="usd">6700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-54" decimals="-5" id="f-318" unitRef="usd">6700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <kprx:AccruedClinicalExpensesPolicyTextBlock contextRef="c-1" id="f-319">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Clinical Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Company&#x2019;s process of preparing the condensed consolidated financial statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company&#x2019;s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/div&gt;</kprx:AccruedClinicalExpensesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-320">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment and three geographic areas. The Company's singular focus is developing innovative ophthalmic pharmaceutical products.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-321"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <kprx:NumberOfGeographicSegments
      contextRef="c-1"
      decimals="INF"
      id="f-322"
      unitRef="segment">3</kprx:NumberOfGeographicSegments>
    <kprx:ResearchAndDevelopmentRefundsPolicyPolicyTextBlock contextRef="c-1" id="f-323">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Refunds for Research and Development&lt;/span&gt;&lt;/div&gt;The Company through its subsidiaries, Kiora Pharmaceuticals GmbH and Kiora Pharmaceuticals Pty Ltd., is eligible to receive certain refundable tax incentives associated with its research and development expenses in Austria and Australia. These refunds are realized in the form of a cash payment when received, following the eligible incurred research and development expenses. Following the approval of a research finding by the tax authority, the Company records the refundable payment as a tax receivable and a reduction in expense in the period in which the research and development expenses are incurred. In situations where a new research application has not yet been approved by the tax authority, the Company records the tax receivable and reduction of expense in the period following approval.</kprx:ResearchAndDevelopmentRefundsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxReceivable contextRef="c-3" decimals="-5" id="f-324" unitRef="usd">700000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable contextRef="c-4" decimals="-5" id="f-325" unitRef="usd">300000</us-gaap:IncomeTaxReceivable>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-326">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2024, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation (the &#x201c;Amendment&#x201d;) with the Secretary of State of the State of Delaware to effect a one-for-nine ("1-for-9") reverse stock split of its outstanding common stock. The Amendment was approved by the Company&#x2019;s stockholders at the Company&#x2019;s 2024 Annual Meeting of Stockholders held on May 1, 2024, and by the Company&#x2019;s board of directors. The amendment became effective on June&#160;11, 2024, the effective date of the reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reverse stock split proportionally adjusted all shares of the Company&#x2019;s common stock outstanding and shares of common stock underlying outstanding options and warrants immediately prior to the effective date of the Amendment. As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all warrants, stock options, and restricted stock awards issued by the Company and outstanding immediately prior to the effective date of the Amendment, which resulted in a proportionate decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such warrants, stock options, and restricted stock awards, and, in the case of warrants and stock options, a proportionate increase in the exercise price of all such warrants and stock options. In addition, the number of shares reserved for issuance under the Company&#x2019;s equity compensation plans immediately prior to the effective date of the Amendment was reduced proportionately. The reverse stock split did not affect the number of shares or par value of common stock authorized for issuance under the Company&#x2019;s Restated Certificate of Incorporation, which remained at 150,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No fractional shares were issued as a result of the reverse stock split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all stockholders proportionately and did not affect any stockholder&#x2019;s percentage ownership of the Company&#x2019;s common stock (except to the extent that the reverse stock split results in stockholders owning fractional shares). As a result of the reverse stock split, the number of the Company&#x2019;s outstanding shares of common stock as of June&#160;11, 2024 decreased from 26,735,116 (pre-split) shares to 2,970,545 (post-split) shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share and per share amounts in the accompanying financial statements and related footnotes have been adjusted retroactively to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented. While the number of warrants outstanding did not change, the underlying shares did and are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;presented reflecting the split. The Company&#x2019;s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on June&#160;11, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-55"
      decimals="INF"
      id="f-327"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-56" decimals="0" id="f-328" unitRef="shares">26735116</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-55" decimals="0" id="f-329" unitRef="shares">2970545</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-331">Balance Sheet Information &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of cash and cash equivalents and restricted cash is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,792,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Cash, Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,775,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,796,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current restricted cash consists of deposits with financial institutions for corporate credit cards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes short-term investments as of March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,295,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,303,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,405,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,321,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,517,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,540,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,970,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturities of the Company's short-term investments at March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,877,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,889,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,321,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,659,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,688,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,970,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the Company's available-for-sale investments' gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Count&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,052,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Count&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its investments each quarter to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. The unrealized losses in the Company&#x2019;s investments were caused by changes in interest rates resulting from changing economic conditions, and not from a decline in credit of their underlying issuers. The Company may be required to sell these investments prior to maturity to implement management strategies, however, it is not likely that the Company will sell these investments before recovery of their amortized cost basis. As such, the Company has classified these losses as temporary in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax and Other Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax and other receivables consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Tax Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,456,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,328,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of cash and cash equivalents and restricted cash is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,792,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Cash, Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,775,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,796,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-332">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of cash and cash equivalents and restricted cash is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,792,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Cash, Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,775,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,796,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-334" unitRef="usd">3771024</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="0" id="f-335" unitRef="usd">3792322</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="0" id="f-336" unitRef="usd">4081</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="0" id="f-337" unitRef="usd">4057</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="0" id="f-338" unitRef="usd">3775105</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="0" id="f-339" unitRef="usd">3796379</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <kprx:ScheduleOfShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-340">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes short-term investments as of March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,295,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,303,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,405,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,321,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,517,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,540,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,970,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kprx:ScheduleOfShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-58" decimals="0" id="f-341" unitRef="usd">395150</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-58" decimals="0" id="f-342" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-58" decimals="0" id="f-343" unitRef="usd">11</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-58" decimals="0" id="f-344" unitRef="usd">395139</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-59" decimals="0" id="f-345" unitRef="usd">15295366</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-59" decimals="0" id="f-346" unitRef="usd">10762</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-59" decimals="0" id="f-347" unitRef="usd">2292</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-59" decimals="0" id="f-348" unitRef="usd">15303836</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-60" decimals="0" id="f-349" unitRef="usd">4405847</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-60" decimals="0" id="f-350" unitRef="usd">5812</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-60" decimals="0" id="f-351" unitRef="usd">801</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-60" decimals="0" id="f-352" unitRef="usd">4410858</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-61" decimals="0" id="f-353" unitRef="usd">224846</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-61" decimals="0" id="f-354" unitRef="usd">152</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-61" decimals="0" id="f-355" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-61" decimals="0" id="f-356" unitRef="usd">224998</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="0" id="f-357" unitRef="usd">20321209</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="0" id="f-358" unitRef="usd">16726</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="0" id="f-359" unitRef="usd">3104</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="0" id="f-360" unitRef="usd">20334831</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-62" decimals="0" id="f-361" unitRef="usd">92273</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-62" decimals="0" id="f-362" unitRef="usd">40</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-62" decimals="0" id="f-363" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="0" id="f-364" unitRef="usd">92313</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-63" decimals="0" id="f-365" unitRef="usd">18517164</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-63" decimals="0" id="f-366" unitRef="usd">28008</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-63" decimals="0" id="f-367" unitRef="usd">4621</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-63" decimals="0" id="f-368" unitRef="usd">18540551</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-64" decimals="0" id="f-369" unitRef="usd">4058879</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-64" decimals="0" id="f-370" unitRef="usd">5901</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-64" decimals="0" id="f-371" unitRef="usd">2107</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-64" decimals="0" id="f-372" unitRef="usd">4062673</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-65" decimals="0" id="f-373" unitRef="usd">301844</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-65" decimals="0" id="f-374" unitRef="usd">2379</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-65" decimals="0" id="f-375" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-65" decimals="0" id="f-376" unitRef="usd">304223</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="0" id="f-377" unitRef="usd">22970160</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="0" id="f-378" unitRef="usd">36328</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="0" id="f-379" unitRef="usd">6728</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="0" id="f-380" unitRef="usd">22999760</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-381">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturities of the Company's short-term investments at March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,877,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,889,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,321,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,659,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,688,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,970,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-3" decimals="0" id="f-382" unitRef="usd">18877094</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-3" decimals="0" id="f-383" unitRef="usd">18889213</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-3" decimals="0" id="f-384" unitRef="usd">1444115</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-3" decimals="0" id="f-385" unitRef="usd">1445618</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="0" id="f-386" unitRef="usd">20321209</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="0" id="f-387" unitRef="usd">20334831</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-4" decimals="0" id="f-388" unitRef="usd">21659580</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="0" id="f-389" unitRef="usd">21688074</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-4" decimals="0" id="f-390" unitRef="usd">1310580</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-4" decimals="0" id="f-391" unitRef="usd">1311686</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="0" id="f-392" unitRef="usd">22970160</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="0" id="f-393" unitRef="usd">22999760</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-394">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the Company's available-for-sale investments' gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Count&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,052,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Count&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions contextRef="c-59" decimals="INF" id="f-395" unitRef="count">4</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-59" decimals="0" id="f-396" unitRef="usd">1943922</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-59" decimals="0" id="f-397" unitRef="usd">2292</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions contextRef="c-60" decimals="INF" id="f-398" unitRef="count">9</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-60" decimals="0" id="f-399" unitRef="usd">713852</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-60" decimals="0" id="f-400" unitRef="usd">801</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions contextRef="c-3" decimals="INF" id="f-401" unitRef="count">16</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="0" id="f-402" unitRef="usd">3052913</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-3" decimals="0" id="f-403" unitRef="usd">3104</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions contextRef="c-63" decimals="INF" id="f-404" unitRef="count">4</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-63" decimals="0" id="f-405" unitRef="usd">3369962</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-63" decimals="0" id="f-406" unitRef="usd">4621</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions contextRef="c-64" decimals="INF" id="f-407" unitRef="count">9</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-64" decimals="0" id="f-408" unitRef="usd">801149</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-64" decimals="0" id="f-409" unitRef="usd">2107</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions contextRef="c-4" decimals="INF" id="f-410" unitRef="count">13</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="0" id="f-411" unitRef="usd">4171111</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="0" id="f-412" unitRef="usd">6728</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <kprx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-413">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kprx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <kprx:PrepaidResearchAndDevelopment contextRef="c-3" decimals="0" id="f-414" unitRef="usd">728555</kprx:PrepaidResearchAndDevelopment>
    <kprx:PrepaidResearchAndDevelopment contextRef="c-4" decimals="0" id="f-415" unitRef="usd">1181699</kprx:PrepaidResearchAndDevelopment>
    <kprx:PrepaidGeneralAndAdministrative contextRef="c-3" decimals="0" id="f-416" unitRef="usd">178431</kprx:PrepaidGeneralAndAdministrative>
    <kprx:PrepaidGeneralAndAdministrative contextRef="c-4" decimals="0" id="f-417" unitRef="usd">118371</kprx:PrepaidGeneralAndAdministrative>
    <us-gaap:PrepaidInsurance contextRef="c-3" decimals="0" id="f-418" unitRef="usd">34556</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-4" decimals="0" id="f-419" unitRef="usd">96141</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-3" decimals="0" id="f-420" unitRef="usd">0</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="0" id="f-421" unitRef="usd">646276</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="0" id="f-422" unitRef="usd">941542</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="0" id="f-423" unitRef="usd">2042487</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <kprx:ScheduleOfTaxAndOtherReceivablesTableTextBlock contextRef="c-1" id="f-424">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax and other receivables consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Tax Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kprx:ScheduleOfTaxAndOtherReceivablesTableTextBlock>
    <kprx:ResearchTaxCreditsReceivableCurrent contextRef="c-3" decimals="0" id="f-425" unitRef="usd">668916</kprx:ResearchTaxCreditsReceivableCurrent>
    <kprx:ResearchTaxCreditsReceivableCurrent contextRef="c-4" decimals="0" id="f-426" unitRef="usd">223183</kprx:ResearchTaxCreditsReceivableCurrent>
    <kprx:OtherTaxReceivablesCurrent contextRef="c-3" decimals="0" id="f-427" unitRef="usd">53374</kprx:OtherTaxReceivablesCurrent>
    <kprx:OtherTaxReceivablesCurrent contextRef="c-4" decimals="0" id="f-428" unitRef="usd">47063</kprx:OtherTaxReceivablesCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-3" decimals="0" id="f-429" unitRef="usd">722290</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-4" decimals="0" id="f-430" unitRef="usd">270246</us-gaap:IncomeTaxesReceivable>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-431">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,456,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,328,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,588,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-432" unitRef="usd">653201</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-433" unitRef="usd">1169618</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="0" id="f-434" unitRef="usd">112556</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="0" id="f-435" unitRef="usd">55032</us-gaap:AccruedProfessionalFeesCurrent>
    <kprx:ClinicalTrialsCurrent contextRef="c-3" decimals="0" id="f-436" unitRef="usd">243556</kprx:ClinicalTrialsCurrent>
    <kprx:ClinicalTrialsCurrent contextRef="c-4" decimals="0" id="f-437" unitRef="usd">875072</kprx:ClinicalTrialsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-3" decimals="0" id="f-438" unitRef="usd">2456920</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-4" decimals="0" id="f-439" unitRef="usd">2328042</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-440" unitRef="usd">55770</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-441" unitRef="usd">160893</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-442" unitRef="usd">3522003</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-443" unitRef="usd">4588657</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-444">Fair Value Disclosures&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Cash Equivalents Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,970,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,303,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,303,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,305,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,509,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Cash Equivalents Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,540,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,540,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,254,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,691,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with historical acquisitions, additional consideration may be owed by the Company related to the achievement of certain milestones and such contingent consideration payments are required by U.S. GAAP to be presented at fair value. The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific milestones. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48% - 77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42% - 77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30% - 33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30% - 33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the above table is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. The change in fair value of contingent consideration of $0.3 million for the three months ended March&#160;31, 2025, was primarily driven by a decrease in the discount rate. The change in fair value of contingent consideration of $12.2 thousand for the three months ended March&#160;31, 2024 was primarily driven by an increase in the discount rate. The change in fair value of contingent consideration is recorded within operating expenses on the accompanying condensed consolidated statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records in-process R&amp;amp;D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use at estimated fair value. For in-process R&amp;amp;D projects acquired in business combinations, the Company capitalizes the in-process R&amp;amp;D project as an indefinite-lived intangible asset and evaluates this asset annually for impairment until the R&amp;amp;D process has been completed. Once the R&amp;amp;D process is complete, the Company amortizes the R&amp;amp;D asset over its remaining useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 350 allows an entity to first assess qualitative factors to determine whether events and circumstances indicate that it is more likely than not (that is, a likelihood of more than 50 percent) that an indefinite-lived intangible asset is impaired. If it is more likely than not that the asset is impaired, the entity must calculate the fair value of the asset and record an impairment charge if the carrying amount exceeds fair value. If an entity concludes that there is a less than 50 percent likelihood that the asset is impaired, no further action is required. An indefinite-lived intangible asset should be tested for impairment if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If such events or changes have occurred, a quantitative assessment is required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity bypasses the qualitative assessment or determines from its qualitative assessment that an indefinite-lived intangible asset is more likely than not impaired, a quantitative impairment test should be performed. The quantitative impairment test compares the fair value of an indefinite-lived intangible asset with the asset&#x2019;s carrying amount. If the fair value of the indefinite-lived intangible asset is less than the carrying amount, an impairment loss should be recognized in an amount equal to the difference in accordance with ASC 350-30-35-19.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values in-process R&amp;amp;D related to asset acquisitions using the Income Approach which measures the value of an asset by the present value of its future economic benefits. These benefits can include interest and principal payments, earnings, cost savings, tax deductions, or proceeds from its disposition. Value indications are developed by discounting expected cash flows at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation, and risks associated with the particular investment. The selected discount rate is generally based on rates of return available from alternative investments of similar type and quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company engaged a third-party valuation firm to complete a quantitative assessment of in-process R&amp;amp;D as of August 31, 2024, which includes the following unobservable Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multi-Period Excess Earnings Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for next development phase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17% to 36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multi-Period Excess Earnings Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for next development phase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23% to 43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company assessed qualitative factors to determine whether events and circumstances indicate impairment, and concluded that it is not more likely than not that any assets are impaired.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-445">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Cash Equivalents Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,970,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,303,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,303,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,334,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,305,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,509,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Cash Equivalents Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government Agency Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,540,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,540,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,062,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset Backed Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Short-term Investments Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,999,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets Measured at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,254,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,691,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-66" decimals="0" id="f-446" unitRef="usd">1796171</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-67" decimals="0" id="f-447" unitRef="usd">1796171</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-68" decimals="0" id="f-448" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="0" id="f-449" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-70" decimals="0" id="f-450" unitRef="usd">174611</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-71" decimals="0" id="f-451" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-72" decimals="0" id="f-452" unitRef="usd">174611</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-73" decimals="0" id="f-453" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-74" decimals="0" id="f-454" unitRef="usd">1970782</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-75" decimals="0" id="f-455" unitRef="usd">1796171</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-76" decimals="0" id="f-456" unitRef="usd">174611</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-77" decimals="0" id="f-457" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-78" decimals="0" id="f-458" unitRef="usd">395139</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-79" decimals="0" id="f-459" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-80" decimals="0" id="f-460" unitRef="usd">395139</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-81" decimals="0" id="f-461" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-82" decimals="0" id="f-462" unitRef="usd">15303836</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-83" decimals="0" id="f-463" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-84" decimals="0" id="f-464" unitRef="usd">15303836</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-85" decimals="0" id="f-465" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-86" decimals="0" id="f-466" unitRef="usd">4410858</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-87" decimals="0" id="f-467" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-88" decimals="0" id="f-468" unitRef="usd">4410858</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-89" decimals="0" id="f-469" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-90" decimals="0" id="f-470" unitRef="usd">224998</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-91" decimals="0" id="f-471" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-92" decimals="0" id="f-472" unitRef="usd">224998</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-93" decimals="0" id="f-473" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-74" decimals="0" id="f-474" unitRef="usd">20334831</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-75" decimals="0" id="f-475" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-76" decimals="0" id="f-476" unitRef="usd">20334831</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-77" decimals="0" id="f-477" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-74" decimals="0" id="f-478" unitRef="usd">22305613</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-75" decimals="0" id="f-479" unitRef="usd">1796171</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-76" decimals="0" id="f-480" unitRef="usd">20509442</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-77" decimals="0" id="f-481" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-94" decimals="0" id="f-482" unitRef="usd">562604</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-95" decimals="0" id="f-483" unitRef="usd">562604</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-96" decimals="0" id="f-484" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-97" decimals="0" id="f-485" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-98" decimals="0" id="f-486" unitRef="usd">691917</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-99" decimals="0" id="f-487" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-100" decimals="0" id="f-488" unitRef="usd">691917</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-101" decimals="0" id="f-489" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-102" decimals="0" id="f-490" unitRef="usd">1254521</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="0" id="f-491" unitRef="usd">562604</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-104" decimals="0" id="f-492" unitRef="usd">691917</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-105" decimals="0" id="f-493" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-106" decimals="0" id="f-494" unitRef="usd">92314</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-107" decimals="0" id="f-495" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-108" decimals="0" id="f-496" unitRef="usd">92314</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-109" decimals="0" id="f-497" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-110" decimals="0" id="f-498" unitRef="usd">18540550</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-111" decimals="0" id="f-499" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-112" decimals="0" id="f-500" unitRef="usd">18540550</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-113" decimals="0" id="f-501" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-114" decimals="0" id="f-502" unitRef="usd">4062673</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-115" decimals="0" id="f-503" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-116" decimals="0" id="f-504" unitRef="usd">4062673</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-117" decimals="0" id="f-505" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-118" decimals="0" id="f-506" unitRef="usd">304223</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-119" decimals="0" id="f-507" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-120" decimals="0" id="f-508" unitRef="usd">304223</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-121" decimals="0" id="f-509" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-102" decimals="0" id="f-510" unitRef="usd">22999760</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-103" decimals="0" id="f-511" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-104" decimals="0" id="f-512" unitRef="usd">22999760</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-105" decimals="0" id="f-513" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-102" decimals="0" id="f-514" unitRef="usd">24254281</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-103" decimals="0" id="f-515" unitRef="usd">562604</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-104" decimals="0" id="f-516" unitRef="usd">23691677</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-105" decimals="0" id="f-517" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-518">The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-77" decimals="0" id="f-519" unitRef="usd">4466682</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-105" decimals="0" id="f-520" unitRef="usd">4191490</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-77" decimals="0" id="f-521" unitRef="usd">4466682</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-105" decimals="0" id="f-522" unitRef="usd">4191490</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-523">After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 - 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48% - 77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42% - 77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30% - 33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30% - 33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company engaged a third-party valuation firm to complete a quantitative assessment of in-process R&amp;amp;D as of August 31, 2024, which includes the following unobservable Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multi-Period Excess Earnings Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for next development phase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17% to 36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multi-Period Excess Earnings Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success for next development phase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23% to 43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-122" decimals="3" id="f-524" unitRef="number">0.140</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-123" decimals="3" id="f-525" unitRef="number">0.151</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-124" decimals="2" id="f-526" unitRef="number">0.48</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-125" decimals="2" id="f-527" unitRef="number">0.77</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-126" decimals="2" id="f-528" unitRef="number">0.42</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-127" decimals="2" id="f-529" unitRef="number">0.77</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-128" decimals="2" id="f-530" unitRef="number">0.30</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-129" decimals="2" id="f-531" unitRef="number">0.33</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-130" decimals="2" id="f-532" unitRef="number">0.30</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-131" decimals="2" id="f-533" unitRef="number">0.33</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <kprx:ChangeInContingentConsiderationFairValue contextRef="c-3" decimals="-5" id="f-534" unitRef="usd">300000</kprx:ChangeInContingentConsiderationFairValue>
    <kprx:ChangeInContingentConsiderationFairValue contextRef="c-49" decimals="-2" id="f-535" unitRef="usd">-12200</kprx:ChangeInContingentConsiderationFairValue>
    <kprx:InProcessResearchAndDevelopmentMeasurementInput contextRef="c-132" decimals="2" id="f-536" unitRef="number">0.17</kprx:InProcessResearchAndDevelopmentMeasurementInput>
    <kprx:InProcessResearchAndDevelopmentMeasurementInput contextRef="c-133" decimals="2" id="f-537" unitRef="number">0.36</kprx:InProcessResearchAndDevelopmentMeasurementInput>
    <kprx:InProcessResearchAndDevelopmentMeasurementInput contextRef="c-134" decimals="2" id="f-538" unitRef="number">0.43</kprx:InProcessResearchAndDevelopmentMeasurementInput>
    <kprx:InProcessResearchAndDevelopmentMeasurementInput contextRef="c-135" decimals="2" id="f-539" unitRef="number">0.23</kprx:InProcessResearchAndDevelopmentMeasurementInput>
    <kprx:InProcessResearchAndDevelopmentMeasurementInput contextRef="c-136" decimals="2" id="f-540" unitRef="number">0.43</kprx:InProcessResearchAndDevelopmentMeasurementInput>
    <kprx:InProcessResearchAndDevelopmentMeasurementInput contextRef="c-137" decimals="2" id="f-541" unitRef="number">0.43</kprx:InProcessResearchAndDevelopmentMeasurementInput>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-542">Capital Stock&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All amounts of shares of common stock in the transactions described below have been adjusted to reflect post Amendment adjusted shares of common stock of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") where the Company's stockholders voted to approve various proposals including (i) adoption of a new Equity Incentive Plan, the "2024 Equity Incentive Plan", (ii) an amendment to the Company&#x2019;s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to 150,000,000, which the Company filed with the Secretary of State for the State of Delaware on May 1, 2024 and (iii) the approval, as contemplated by Nasdaq Listing Rule 5635, of the issuance of up to 5,486,066 shares of Common Stock upon the exercise of Tranche A Warrants and Tranche B Warrants issued in the private placement that closed on February 5, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2024, the Company entered into a private placement agreement with Maxim Group LLC serving as placement agent for 1,755,556 shares of common stock, pre-funded warrants to purchase up to 1,261,582 shares of common stock, and accompanying Tranche A and Tranche B warrants to purchase up to an aggregate of 5,486,066 shares of common stock. The total net proceeds from the private placement were approximately $13.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Tranche A warrants are exercisable for up to 2,743,033 shares of common stock at an exercise price of $5.4684 per share for an aggregate of up to approximately $15.0 million and will expire at the earlier of (i) 30 days following the announcement of full data (expected in 2026) from the Company's Phase 2 clinical trial (ABACUS-2) of KIO-301 in patients with retinitis pigmentosa and the daily Volume Weighted Average Price "VWAP" of the Company's common stock equaling or exceeding $9.9432 per share for 30 consecutive trading days following the announcement and (ii) five years from the date of shareholder approval of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Tranche B warrants are exercisable for up to 2,743,033 shares of common stock at an exercise price of $5.4684 per share for an aggregate of up to approximately $15.0 million and will expire at the earlier of (i) 30 days following the announcement of topline data (expected in 2026) from the planned Phase 2 trial of KIO-104 in retinal inflammation and the daily VWAP of the Company's common stock equaling or exceeding $12.4290 per share for 30 consecutive trading days following the announcement and (ii) five years from the date of shareholder approval of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-138"
      decimals="INF"
      id="f-543"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-138" decimals="0" id="f-544" unitRef="shares">5486066</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-139" decimals="0" id="f-545" unitRef="shares">1755556</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-140" decimals="0" id="f-546" unitRef="shares">1261582</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-141" decimals="0" id="f-547" unitRef="shares">5486066</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-139" decimals="-5" id="f-548" unitRef="usd">13800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-142" decimals="0" id="f-549" unitRef="shares">2743033</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-142"
      decimals="INF"
      id="f-550"
      unitRef="usdPerShare">5.4684</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-143" decimals="-5" id="f-551" unitRef="usd">15000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <kprx:ClassOfWarrantOrRightThresholdTradingDays contextRef="c-143" decimals="INF" id="f-552" unitRef="day">30</kprx:ClassOfWarrantOrRightThresholdTradingDays>
    <kprx:ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock
      contextRef="c-143"
      decimals="INF"
      id="f-553"
      unitRef="usdPerShare">9.9432</kprx:ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock>
    <kprx:ClassOfWarrantOrRightThresholdConsecutiveTradingDays contextRef="c-143" decimals="INF" id="f-554" unitRef="day">30</kprx:ClassOfWarrantOrRightThresholdConsecutiveTradingDays>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-142" id="f-555">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-144" decimals="0" id="f-556" unitRef="shares">2743033</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-144"
      decimals="INF"
      id="f-557"
      unitRef="usdPerShare">5.4684</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-145" decimals="-6" id="f-558" unitRef="usd">15000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <kprx:ClassOfWarrantOrRightThresholdTradingDays contextRef="c-145" decimals="INF" id="f-559" unitRef="day">30</kprx:ClassOfWarrantOrRightThresholdTradingDays>
    <kprx:ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock
      contextRef="c-145"
      decimals="INF"
      id="f-560"
      unitRef="usdPerShare">12.4290</kprx:ClassOfWarrantOrRightVolumeWeightedAveragePriceOfCommonStock>
    <kprx:ClassOfWarrantOrRightThresholdConsecutiveTradingDays contextRef="c-145" decimals="INF" id="f-561" unitRef="day">30</kprx:ClassOfWarrantOrRightThresholdConsecutiveTradingDays>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-144" id="f-562">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <kprx:WarrantsDisclosureTextBlock contextRef="c-1" id="f-563">Warrants&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of warrant activity for the Company&#x2019;s equity-classified warrants for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Common Shares&lt;br/&gt;Issuable Upon Exercise&lt;br/&gt;of Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,389,523&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,389,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kprx:WarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-564">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of warrant activity for the Company&#x2019;s equity-classified warrants for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Common Shares&lt;br/&gt;Issuable Upon Exercise&lt;br/&gt;of Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,389,523&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,389,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-146"
      decimals="INF"
      id="f-565"
      unitRef="shares">7389523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice
      contextRef="c-146"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">7.06</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-147" id="f-567">P5Y21D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-148"
      decimals="INF"
      id="f-568"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice
      contextRef="c-148"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">0</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-148"
      decimals="INF"
      id="f-570"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice
      contextRef="c-148"
      decimals="2"
      id="f-571"
      unitRef="usdPerShare">0</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c-148"
      decimals="INF"
      id="f-572"
      unitRef="shares">69</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice
      contextRef="c-148"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">4500</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-149"
      decimals="INF"
      id="f-574"
      unitRef="shares">7389454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice
      contextRef="c-149"
      decimals="2"
      id="f-575"
      unitRef="usdPerShare">7.02</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-148" id="f-576">P4Y9M21D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-577">Net (Loss) Income per Share - Basic and Diluted&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net (loss) income per share is computed by dividing net (loss) income available to common shareholders by the weighted-average number of common shares outstanding for the time period, which for basic net (loss) income per share, does not include the weighted-average unvested restricted common stock that has been issued and is subject to forfeiture totaling 45,363 and 24,094 shares for the three months ended March&#160;31, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net (loss) income per share as their effect would be anti-dilutive. The following is a summary of potentially dilutive securities excluded from the calculation of diluted net (loss) income per share as of March&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock Warrants, Excluding Pre-funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,872&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661,699&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,276&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,338&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,094&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred Stock, as Converted into Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,426&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570,846&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,947,783&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,872,252&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="c-1" decimals="0" id="f-578" unitRef="shares">45363</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="c-17" decimals="0" id="f-579" unitRef="shares">24094</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-580">The following is a summary of potentially dilutive securities excluded from the calculation of diluted net (loss) income per share as of March&#160;31, 2025 and 2024:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock Warrants, Excluding Pre-funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,872&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661,699&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,276&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,338&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,094&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred Stock, as Converted into Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,426&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570,846&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,947,783&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,872,252&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-150" decimals="0" id="f-581" unitRef="shares">6127872</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-151" decimals="0" id="f-582" unitRef="shares">5661699</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-152" decimals="0" id="f-583" unitRef="shares">161276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-153" decimals="0" id="f-584" unitRef="shares">89338</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-154" decimals="0" id="f-585" unitRef="shares">45363</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-155" decimals="0" id="f-586" unitRef="shares">24094</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-156" decimals="0" id="f-587" unitRef="shares">42426</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-157" decimals="0" id="f-588" unitRef="shares">42426</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-158" decimals="0" id="f-589" unitRef="shares">570846</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-159" decimals="0" id="f-590" unitRef="shares">54695</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-591" unitRef="shares">6947783</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-17" decimals="0" id="f-592" unitRef="shares">5872252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c-1" id="f-593">Stock-Based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors (the "Board") adopted the 2014 Equity Incentive Plan (the "2014 Plan") and the Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) and the Company's Stockholders approved the 2014 Plan and ESPP in February 2015. The Board subsequently adopted the 2024 Equity Incentive Plan (the "2024 Plan") and the Company's Stockholders approved the Plan in May 2024. Following adoption of the 2024 Plan, no further grants were made under the 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with the 2014 Plan, the 2024 Plan provides for the granting of stock options (incentive and nonqualified), restricted stock or other stock-based awards to employees, officers, directors, consultants, and advisors. The Board is responsible for administration of the 2024 Plan. The Company&#x2019;s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company&#x2019;s voting stock) and with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more than 10% of the Company&#x2019;s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant, or director at an exercise price per share of not less than the par value per share. In January 2025, the number of shares of common stock issuable under the 2024 Plan automatically increased by 120,031 shares pursuant to the terms of the 2024 Plan. As of March&#160;31, 2025, the maximum number of shares of Common Stock that may be issued pursuant to the 2024 Plan was 853,133 of which 570,846 shares were available for awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is presented in the same expense line items as cash compensation paid and for the three months ended March&#160;31, 2025 and 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.915%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Stock-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants time-based stock options which generally vest one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period. The fair value of time-based stock options is determined using the Black-Scholes Option Pricing Model, with such value recognized as expense over the service period, which is typically three years, net of actual forfeitures. There were no grants made during the three months ended March&#160;31, 2025 and 2024, and therefore no assumptions used to determine the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options outstanding as of March&#160;31, 2025 was $6.77. The expected term of the options granted is based on management's estimate. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized compensation expense related to the options amounted to $0.4 million as of March&#160;31, 2025 and is expected to be recognized over a weighted average period of approximately 3.44 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of stock option activity for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Remaining&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,276&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,397&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock options outstanding and exercisable as of March&#160;31, 2025 had no aggregate intrinsic value. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#x2019;s common stock for options that had exercise prices lower than $3.01, the closing price of the Company&#x2019;s stock on March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock compensation expense is recognized over the vesting period, which is typically one-third of the underlying shares on the one-year anniversary of the grant date and the remainder ratably over a 24-month period. Unamortized compensation expense related to the restricted stock awards amounted to $0.2 million as of March&#160;31, 2025 and is expected to be recognized over a weighted average period of approximately 3.53 years. The following is a summary of restricted stock activity for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Remaining&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a non-qualified ESPP, which provides for the issuance of shares of the Company&#x2019;s common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of common stock through payroll deductions at a discounted price. Six month offering periods are made at the Board&#x2019;s discretion. The ESPP provides for 32 aggregate shares of the Company&#x2019;s common stock for participants to purchase. As of March&#160;31, 2025 and 2024, the remaining shares reserved for future offerings was 23. Subsequent to the reporting period, in May 2025 the Company terminated the ESPP (Note 10).&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <kprx:PercentageOfExercisePrice contextRef="c-160" decimals="2" id="f-594" unitRef="number">1.10</kprx:PercentageOfExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-161" id="f-595">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-162" id="f-596">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-163"
      decimals="INF"
      id="f-597"
      unitRef="shares">120031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-164"
      decimals="INF"
      id="f-598"
      unitRef="shares">853133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-164"
      decimals="INF"
      id="f-599"
      unitRef="shares">570846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock contextRef="c-1" id="f-600">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is presented in the same expense line items as cash compensation paid and for the three months ended March&#160;31, 2025 and 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.915%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Stock-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kprx:EmployeeAndNonEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-165" decimals="0" id="f-601" unitRef="usd">84944</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-166" decimals="0" id="f-602" unitRef="usd">94571</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-167" decimals="0" id="f-603" unitRef="usd">63672</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-168" decimals="0" id="f-604" unitRef="usd">80872</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-1" decimals="0" id="f-605" unitRef="usd">148616</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-17" decimals="0" id="f-606" unitRef="usd">175443</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-169" id="f-607">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-170" id="f-608">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-171" id="f-609">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-610"
      unitRef="usdPerShare">6.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-611" unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-612">P3Y5M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-613">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of stock option activity for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Remaining&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,276&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,397&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-614" unitRef="shares">161303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">21.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-172" id="f-616">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-617" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-618"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-619" unitRef="shares">27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-620"
      unitRef="usdPerShare">23490</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-621" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-622"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-623" unitRef="shares">161276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-624"
      unitRef="usdPerShare">17.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-625">P8Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-3" decimals="INF" id="f-626" unitRef="shares">58397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-627"
      unitRef="usdPerShare">37.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-628">P8Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-3" decimals="INF" id="f-629" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-3" decimals="INF" id="f-630" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="c-3"
      decimals="2"
      id="f-631"
      unitRef="usdPerShare">3.01</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-173" id="f-632">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-174" id="f-633">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-175" decimals="-5" id="f-634" unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-176" id="f-635">P3Y6M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-636">The following is a summary of restricted stock activity for the three months ended March&#160;31, 2025:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average&lt;br/&gt;Remaining&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-177"
      decimals="INF"
      id="f-637"
      unitRef="shares">46697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-177"
      decimals="2"
      id="f-638"
      unitRef="usdPerShare">7.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-178" id="f-639">P2Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-176"
      decimals="INF"
      id="f-640"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-176"
      decimals="2"
      id="f-641"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-176"
      decimals="INF"
      id="f-642"
      unitRef="shares">1334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-176"
      decimals="2"
      id="f-643"
      unitRef="usdPerShare">34.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-176"
      decimals="INF"
      id="f-644"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-176"
      decimals="2"
      id="f-645"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-175"
      decimals="INF"
      id="f-646"
      unitRef="shares">45363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-175"
      decimals="2"
      id="f-647"
      unitRef="usdPerShare">6.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-176" id="f-648">P1Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod contextRef="c-179" id="f-649">P6M</kprx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-180"
      decimals="INF"
      id="f-650"
      unitRef="shares">32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-181"
      decimals="INF"
      id="f-651"
      unitRef="shares">23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-180"
      decimals="INF"
      id="f-652"
      unitRef="shares">23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-655">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to five real property operating leases for the rental of office and clinical trial space. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the Company entered into an 18-month lease for an office facility in Encinitas, California (the "Encinitas Lease"), which is now used for its corporate headquarters. The Encinitas Lease commenced in May 2022 and was amended to extend its lease term through April 30, 2025. The Company recorded a right-of use ("ROU") asset and lease liability upon lease commencement and lease amendment in May 2022 and November 2023, respectively. Monthly rent payments are approximately $3.3 thousand, and the security deposit is $12 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company entered into a 12-month lease for office space in Adelaide, Australia (the "Adelaide Lease") which expired in May 2023. Following expiration, the landlord agreed to extend the Adelaide Lease on a month-month basis, whereby the Company must provide 90-day notice of termination. The Adelaide Lease is a short-term lease which is exempt for ROU asset and lease liability reporting. Monthly rent payments are approximately A$2.2 thousand. The Adelaide lease is being used was a clinical trial site for ABACUS-2, with rent costs fully reimbursed by TOI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also entered into a lease for 910 square feet of office space in Vienna, Austria (the "Vienna Lease"). The Vienna Lease commenced on October 15, 2023 with a term of 5 years through October 14, 2028. The Company recorded a ROU asset and lease liability upon lease commencement in October 2023. Monthly rent payments are approximately &#x20ac;1.3 thousand, and the security deposit is &#x20ac;4.5 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Company entered into a lease in Perth, Australia (the "Perth Lease") and another in Brisbane, Australia (the "Brisbane Lease"). Both leases commenced in February 2025, at which time the Company recorded a ROU asset and lease liability, with a term of 2 years through January 2027. Monthly rent payments are approximately A$8.9 thousand, and the total security deposit is A$44.0 thousand. The Company has rent abatement for the first 2 months of the Brisbane Lease and for the first 3 months of the Perth Lease. The Brisbane and Perth leases are for ABACUS-2 clinical trial sites, with rent costs fully reimbursed by TOI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025, the Company entered into a new lease in Encinitas, California (the "New Encinitas Lease"). The New Encinitas Lease will commence in June 2025 with a term of 3 years and 3 months through August 31, 2028. Monthly rent payments will be approximately $8.4 thousand per month and will increase by approximately 4% each year on the anniversary of the commencement, starting in 2026. The Company has rent abatement for the first 2 months of the lease and maintains a security deposit of $9.4 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense, consisting of the reduction of the right-of-use asset and the imputed interest on the lease liability, totaled $13,845 and $20,231 for the three months ended March&#160;31, 2025 and 2024, respectively.The remaining lease terms range from less than 30 days to 3.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the leases is as follows as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual minimum lease payments under non-cancellable operating leases as of March&#160;31, 2025 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 (remaining months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Amounts Representing Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Current Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Exclusive Rights Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to six license agreements as previously disclosed in Note 12 to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes to the terms of these agreements during the three months ended March&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant Funding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the Company received grant funding of $20,000 from the Choroideremia Research Foundation in support of validating functional vision assessments for patients with profound blindness. This grant funding will aid in further validation of a suite of tests expected to be used in the upcoming ABACUS-2 Phase 2 clinical trial assessing KIO-301.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price of various acquisitions in prior periods included contingent consideration, which consisted of various cash earn-out payments upon the achievement of certain milestones. Below are the maximum obligation payments per the respective agreements and estimated fair value of contingent consideration payments remaining as of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maximum Obligation&lt;br/&gt;per Agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current Fair&lt;br/&gt;Value Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,135,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,635,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Line Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025, the Company entered into a credit line with UBS (the &#x201c;Credit Line&#x201d;) providing for a $10.0&#160;million revolving line of credit. The Credit Line bears interest at the 30-day Secured Overnight Financing Rate ("SOFR") average, plus 1.5%. The SOFR rate is variable. The Credit Line is secured by a first priority lien and security interest in the Company&#x2019;s marketable securities held in its managed investment accounts with UBS. As of March&#160;31, 2025 the line was unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, as well as governmental proceedings and investigations that are incidental to the business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#x2019;s standard practice is to cooperate with regulators and investigators in responding to inquiries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <kprx:LesseeNumberOfOperatingLeases
      contextRef="c-1"
      decimals="INF"
      id="f-656"
      unitRef="operatinglease">5</kprx:LesseeNumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-182" id="f-657">P18M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <kprx:LesseeOperatingLeaseMonthlyRentPayment contextRef="c-183" decimals="-2" id="f-658" unitRef="usd">3300</kprx:LesseeOperatingLeaseMonthlyRentPayment>
    <kprx:LesseeOperatingLeaseSecurityDeposit contextRef="c-182" decimals="-3" id="f-659" unitRef="usd">12000</kprx:LesseeOperatingLeaseSecurityDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-184" id="f-660">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <kprx:LesseeOperatingLeaseTerminationPeriod contextRef="c-185" id="f-661">P90D</kprx:LesseeOperatingLeaseTerminationPeriod>
    <kprx:LesseeOperatingLeaseMonthlyRentPayment contextRef="c-185" decimals="-2" id="f-662" unitRef="aud">2200</kprx:LesseeOperatingLeaseMonthlyRentPayment>
    <us-gaap:AreaOfLand contextRef="c-186" decimals="INF" id="f-663" unitRef="sqft">910</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-186" id="f-664">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <kprx:LesseeOperatingLeaseMonthlyRentPayment contextRef="c-187" decimals="-2" id="f-665" unitRef="eur">1300</kprx:LesseeOperatingLeaseMonthlyRentPayment>
    <kprx:LesseeOperatingLeaseSecurityDeposit contextRef="c-186" decimals="-2" id="f-666" unitRef="eur">4500</kprx:LesseeOperatingLeaseSecurityDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-188" id="f-667">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <kprx:LesseeOperatingLeaseMonthlyRentPayment contextRef="c-189" decimals="-2" id="f-668" unitRef="aud">8900</kprx:LesseeOperatingLeaseMonthlyRentPayment>
    <kprx:LesseeOperatingLeaseSecurityDeposit contextRef="c-188" decimals="-2" id="f-669" unitRef="aud">44000.0</kprx:LesseeOperatingLeaseSecurityDeposit>
    <kprx:LesseeOperatingLeaseMonthlyRentPayment contextRef="c-190" decimals="0" id="f-670" unitRef="usd">8400</kprx:LesseeOperatingLeaseMonthlyRentPayment>
    <kprx:LesseeOperatingLeaseSecurityDeposit contextRef="c-191" decimals="0" id="f-671" unitRef="usd">9400</kprx:LesseeOperatingLeaseSecurityDeposit>
    <us-gaap:LeaseCost contextRef="c-1" decimals="0" id="f-672" unitRef="usd">13845</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-17" decimals="0" id="f-673" unitRef="usd">20231</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-192" id="f-674">P30D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-193" id="f-675">P3Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <kprx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock contextRef="c-1" id="f-676">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the leases is as follows as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</kprx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-677">P2Y3M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-678" unitRef="number">0.066</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-679">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual minimum lease payments under non-cancellable operating leases as of March&#160;31, 2025 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 (remaining months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Amounts Representing Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less Current Portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="0" id="f-680" unitRef="usd">59207</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="0" id="f-681" unitRef="usd">81666</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="0" id="f-682" unitRef="usd">19714</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="0" id="f-683" unitRef="usd">11144</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="0" id="f-684" unitRef="usd">171731</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="0" id="f-685" unitRef="usd">12707</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="0" id="f-686" unitRef="usd">159024</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="0" id="f-687" unitRef="usd">71554</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-688" unitRef="usd">87470</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <kprx:NumberOfLicenseAgreements
      contextRef="c-1"
      decimals="INF"
      id="f-689"
      unitRef="licenseagreement">6</kprx:NumberOfLicenseAgreements>
    <us-gaap:Revenues contextRef="c-194" decimals="0" id="f-690" unitRef="usd">20000</us-gaap:Revenues>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="c-1" id="f-691">Below are the maximum obligation payments per the respective agreements and estimated fair value of contingent consideration payments remaining as of March&#160;31, 2025.&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maximum Obligation&lt;br/&gt;per Agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current Fair&lt;br/&gt;Value Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayon&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,135,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Panoptes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,635,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,466,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-195" decimals="0" id="f-692" unitRef="usd">7135000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="c-195" decimals="0" id="f-693" unitRef="usd">2355232</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-196" decimals="0" id="f-694" unitRef="usd">9500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="c-196" decimals="0" id="f-695" unitRef="usd">2111450</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-3" decimals="0" id="f-696" unitRef="usd">16635000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="c-3" decimals="0" id="f-697" unitRef="usd">4466682</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:LineOfCredit contextRef="c-197" decimals="-5" id="f-698" unitRef="usd">10000000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-198" decimals="3" id="f-699" unitRef="number">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-701">Segment Information&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in and reports as a single reportable segment, focused on the development of innovative ophthalmic pharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Operating Decision Maker "CODM" is our President and Chief Executive Officer. The CODM does not evaluate profitability nor evaluate performance or allocate resources below the level of the consolidated Company. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM reviews operating expenses and net (loss) income presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. These metrics serve as benchmarks to evaluate the business, measure performance, identify trends, prepare financial projections, and make strategic decisions. The CODM does not evaluate performance or allocate resources based on segment assets data; therefore, total segment assets are not presented. As part of the adoption of ASU 2023-07, the comparative prior period segment information has been disclosed herein to align with the current year&#x2019;s presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the revenue, significant expenses, and net (loss) income for the Company&#x2019;s single reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Less: Significant and Other Segment Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,489,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,296,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-104&lt;span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(149,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-201&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,101,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,018,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-301 Collaboration Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,966,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(190,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated Research and Development Expenses&lt;span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;576,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;622,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value of Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;275,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest Income, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(277,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(223,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Segment Expenses&lt;span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;123,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(2,192,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;13,453,207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-702">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the revenue, significant expenses, and net (loss) income for the Company&#x2019;s single reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Less: Significant and Other Segment Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and Administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,489,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,296,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-104&lt;span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(149,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-201&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,101,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,018,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KIO-301 Collaboration Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,966,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(190,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated Research and Development Expenses&lt;span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;576,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;622,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value of Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;275,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest Income, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(277,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(223,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other Segment Expenses&lt;span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;123,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(2,192,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;13,453,207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues contextRef="c-1" decimals="0" id="f-703" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="0" id="f-704" unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-705" unitRef="usd">1489398</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="0" id="f-706" unitRef="usd">1296441</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-200" decimals="0" id="f-707" unitRef="usd">3014</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-201" decimals="0" id="f-708" unitRef="usd">10474</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-202" decimals="0" id="f-709" unitRef="usd">-149326</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-203" decimals="0" id="f-710" unitRef="usd">1639</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-204" decimals="0" id="f-711" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-205" decimals="0" id="f-712" unitRef="usd">30875</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-206" decimals="0" id="f-713" unitRef="usd">2101850</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-207" decimals="0" id="f-714" unitRef="usd">1018847</us-gaap:ResearchAndDevelopmentExpense>
    <kprx:CollaborationCreditOperatingExpense contextRef="c-1" decimals="0" id="f-715" unitRef="usd">1966123</kprx:CollaborationCreditOperatingExpense>
    <kprx:CollaborationCreditOperatingExpense contextRef="c-17" decimals="0" id="f-716" unitRef="usd">190553</kprx:CollaborationCreditOperatingExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-208" decimals="0" id="f-717" unitRef="usd">576349</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-209" decimals="0" id="f-718" unitRef="usd">622377</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="0" id="f-719" unitRef="usd">275192</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-17" decimals="0" id="f-720" unitRef="usd">-12194</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="0" id="f-721" unitRef="usd">277321</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-17" decimals="0" id="f-722" unitRef="usd">223235</us-gaap:InvestmentIncomeInterest>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-1" decimals="0" id="f-723" unitRef="usd">16941</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-17" decimals="0" id="f-724" unitRef="usd">-7878</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-725" unitRef="usd">123006</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="0" id="f-726" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-727" unitRef="usd">-2192980</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="0" id="f-728" unitRef="usd">13453207</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-729">Subsequent Events&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2025, the Company and D&#xf4;mes Pharma, successor to SentrX Animal Care Inc., agreed to terminate the license agreement dated June 7, 2023 given the Company's decision to cease continued development of KIO-201 in combination with an antibiotic, and thereby to cease continued maintenance of all related licensed IP. D&#xf4;mes Pharma elected not to resume the prosecution and maintenance of the licensed IP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2025, the Company terminated the ESPP effective as of April 30, 2025. The Company has provided notice of the ESPP's termination to the Company's employees and ESPP participants, and there are no employee funds currently held for purchasing shares of Common Stock under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-730">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-731">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-732">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-733">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
